FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Mischke, C Verbeek, JH Job, J Morata, TC Alvesalo-Kuusi, A Neuvonen, K Clarke, S Pedlow, RI AF Mischke, Christina Verbeek, Jos H. Job, Jenny Morata, Thais C. Alvesalo-Kuusi, Anne Neuvonen, Kaisa Clarke, Simon Pedlow, Robert I. TI Occupational safety and health enforcement tools for preventing occupational diseases and injuries SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review ID INTERRUPTED TIME-SERIES; OSHA ENFORCEMENT; REGULATORY ENFORCEMENT; WORKERS-COMPENSATION; WASHINGTON-STATE; CONSTRUCTION; INSPECTIONS; IMPACT; RATES; WORKPLACE AB Background There is uncertainty as to whether and what extent occupational safety and health regulation and legislation enforcement activities, such as inspections, are effective and efficient to improve workers' health and safety. We use the term regulation to refer both to regulation and legislation. Objectives To assess the effects of occupational safety and health regulation enforcement tools for preventing occupational diseases and injuries. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (PubMed), EMBASE (embase.com), CINAHL (EBSCO), PsycINFO (Ovid), OSH update, HeinOnline, Westlaw International, EconLit and Scopus from the inception of each database until January 2013. We also checked reference lists of included articles and contacted study authors to identify additional published, unpublished and ongoing studies. Selection criteria We included randomised controlled trials (RCTs), controlled before-after studies (CBAs), interrupted time series (ITS) and econometric panel studies of firms or workplaces evaluating inspections, warnings or orders, citations or fines, prosecution or firm closure by governmental representatives and if the outcomes were injuries, diseases or exposures. In addition, we included qualitative studies of workers' or employers' attitudes or beliefs towards enforcement tools. Data collection and analysis Pairs of authors independently extracted data on the main characteristics, the risk of bias and the effects of the interventions. We expressed intervention effects as risk ratios (RR) or mean differences (MD). We recalculated other effect measures into RRs or MDs. We combined the results of similar studies in a meta-analysis. Main results We located 23 studies: two RCTs with 1414 workplaces, two CBAs with 9903 workplaces, one ITS with six outcome measurements, 12 panel studies and six qualitative studies with 310 participants. Studies evaluated the effects of inspections in general and the effects of their consequences, such as penalties. Studies on the effects of prosecution, warnings or closure were not available or were of such quality that we could not include their results. The effect was measured on injury rates, on exposure to physical workload and on compliance with regulation, with a follow-up varying from one to four years. All studies had serious limitations and therefore the quality of the evidence was low to very low. The injury rates in the control groups varied across studies from 1 to 23 injuries per 100 person-years and compliance rates varied from 40% to 75% being compliant. The effects of inspections were inconsistent in seven studies: injury rates decreased or stayed at a similar level compared to no intervention at short and medium-term follow-up. In studies that found a decrease the effect was small with a 10% decrease of the injury rate. At long-term follow-up, in one study there was a significant decrease of 23% (95% confidence interval 8% to 23%) in injury rates and in another study a substantial decrease in accident rates, both compared to no intervention. First inspections, follow-up inspections, complaint and accident inspections resulted in higher compliance rates compared to the average effect of any other type of inspections. In small firms, inspections with citations or with more penalties could result in fewer injuries or more compliance in the short term but not in the medium term. Longer inspections and more frequent inspections probably do not result in more compliance. In two studies, there was no adverse effect of inspections on firm survival, employment or sales. Qualitative studies show that there is support for enforcement among workers. However, workers doubt if the inspections are effective because inspections are rare and violations can be temporarily fixed to mislead inspectors. Authors' conclusions There is evidence that inspections decrease injuries in the long term but not in the short term. The magnitude of the effect is uncertain. There are no studies that used chemical or physical exposures as outcome. Specific, focused inspections could have larger effects than inspections in general. The effect of fines and penalties is uncertain. The quality of the evidence is low to very low and therefore these conclusions are tentative and can be easily changed by better future studies. There is an urgent need for better designed evaluations, such as pragmatic randomised trials, to establish the effects of existing and novel enforcement methods, especially on exposure and disorders. C1 [Mischke, Christina; Verbeek, Jos H.] Finnish Inst Occupat Hlth, Cochrane Occupat Safety & Hlth Review Grp, Kuopio 70101, Finland. [Job, Jenny] Safe Work Australia, Strateg Policy Branch, Canberra, ACT, Australia. [Morata, Thais C.] NIOSH, Cincinnati, OH 45226 USA. [Alvesalo-Kuusi, Anne] Univ Turku, Fac Law, Turku, Finland. [Neuvonen, Kaisa] Finnish Inst Occupat Hlth, Cochrane Occupat Safety & Hlth Review Grp, Helsinki, Finland. [Pedlow, Robert I.] Safe Work Australia, Res & Evaluat Team, Canberra, ACT, Australia. RP Mischke, C (reprint author), Finnish Inst Occupat Hlth, Cochrane Occupat Safety & Hlth Review Grp, Neulaniementie 4,POB 310, Kuopio 70101, Finland. EM christina.mischke@ttl.fi RI Verbeek, Jos/F-8382-2013 OI Verbeek, Jos/0000-0002-6537-6100 FU Finnish Institute of Occupational Health, Finland; WorkSafeBC, Canada FX Internal sources; Finnish Institute of Occupational Health, Finland.; Provided facilities and IT support for Christina Mischke and Jos Verbeek; External sources; WorkSafeBC, Canada.; Provided grant which paid for Christina Mischke's salary NR 82 TC 3 Z9 3 U1 2 U2 21 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1469-493X J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2013 IS 8 AR CD010183 DI 10.1002/14651858.CD010183.pub2 PG 89 WC Medicine, General & Internal SC General & Internal Medicine GA 211RW UT WOS:000323928900038 PM 23996220 ER PT J AU Tusting, LS Thwing, J Sinclair, D Fillinger, U Gimnig, J Bonner, KE Bottomley, C Lindsay, SW AF Tusting, Lucy S. Thwing, Julie Sinclair, David Fillinger, Ulrike Gimnig, John Bonner, Kimberly E. Bottomley, Christian Lindsay, Steven W. TI Mosquito larval source management for controlling malaria SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review ID DAR-ES-SALAAM; INSECTICIDE-TREATED NETS; THURINGIENSIS VAR. ISRAELENSIS; GROWTH-REGULATOR PYRIPROXYFEN; CONTROLLING AQUATIC STAGES; ANOPHELES-GAMBIAE; WESTERN KENYA; ENVIRONMENTAL-MANAGEMENT; SPATIAL-DISTRIBUTION; SRI-LANKA AB Background Malaria is an important cause of illness and death in people living in many parts of the world, especially sub-Saharan Africa. Long-lasting insecticide treated bed nets (LLINs) and indoor residual spraying (IRS) reduce malaria transmission by targeting the adult mosquito vector and are key components of malaria control programmes. However, mosquito numbers may also be reduced by larval source management (LSM), which targets mosquito larvae as they mature in aquatic habitats. This is conducted by permanently or temporarily reducing the availability of larval habitats (habitat modification and habitat manipulation), or by adding substances to standing water that either kill or inhibit the development of larvae (larviciding). Objectives To evaluate the effectiveness of mosquito LSM for preventing malaria. Search methods We searched the Cochrane Infectious Diseases Group Specialized Register; Cochrane Central Register of Controlled Trials (CENTRAL); MEDLINE; EMBASE; CABS Abstracts; and LILACS up to 24 October 2012. We handsearched the Tropical Diseases Bulletin from 1900 to 2010, the archives of the World Health Organization (up to 11 February 2011), and the literature database of the Armed Forces Pest Management Board (up to 2 March 2011). We also contacted colleagues in the field for relevant articles. Selection criteria We included cluster randomized controlled trials (cluster-RCTs), controlled before-and-after trials with at least one year of baseline data, and randomized cross-over trials that compared LSM with no LSM for malaria control. We excluded trials that evaluated biological control of anopheline mosquitoes with larvivorous fish. Data collection and analysis At least two authors assessed each trial for eligibility. We extracted data and at least two authors independently determined the risk of bias in the included studies. We resolved all disagreements through discussion with a third author. We analyzed the data using Review Manager 5 software. Main results We included 13 studies; four cluster-RCTs, eight controlled before-and-after trials, and one randomized cross-over trial. The included studies evaluated habitat modification (one study), habitat modification with larviciding (two studies), habitat manipulation (one study), habitat manipulation plus larviciding (two studies), or larviciding alone (seven studies) in a wide variety of habitats and countries. Malaria incidence In two cluster-RCTs undertaken in Sri Lanka, larviciding of abandoned mines, streams, irrigation ditches, and rice paddies reduced malaria incidence by around three-quarters compared to the control (RR 0.26, 95% CI 0.22 to 0.31, 20,124 participants, two trials, moderate quality evidence). In three controlled before-and-after trials in urban and rural India and rural Kenya, results were inconsistent (98,233 participants, three trials, very low quality evidence). In one trial in urban India, the removal of domestic water containers together with weekly larviciding of canals and stagnant pools reduced malaria incidence by three quarters. In one trial in rural India and one trial in rural Kenya, malaria incidence was higher at baseline in intervention areas than in controls. However dam construction in India, and larviciding of streams and swamps in Kenya, reduced malaria incidence to levels similar to the control areas. In one additional randomized cross-over trial in the flood plains of the Gambia River, where larval habitats were extensive and ill-defined, larviciding by ground teams did not result in a statistically significant reduction in malaria incidence (2039 participants, one trial). Parasite prevalence In one cluster-RCT from Sri Lanka, larviciding reduced parasite prevalence by almost 90% (RR 0.11, 95% CI 0.05 to 0.22, 2963 participants, one trial, moderate quality evidence). In five controlled before-and-after trials in Greece, India, the Philippines, and Tanzania, LSM resulted in an average reduction in parasite prevalence of around two-thirds (RR 0.32, 95% CI 0.19 to 0.55, 8041 participants, five trials, moderate quality evidence). The interventions in these five trials included dam construction to reduce larval habitats, flushing of streams, removal of domestic water containers, and larviciding. In the randomized cross-over trial in the flood plains of the Gambia River, larviciding by ground teams did not significantly reduce parasite prevalence (2039 participants, one trial). Authors' conclusions In Africa and Asia, LSM is another policy option, alongside LLINs and IRS, for reducing malaria morbidity in both urban and rural areas where a sufficient proportion of larval habitats can be targeted. Further research is needed to evaluate whether LSM is appropriate or feasible in parts of rural Africa where larval habitats are more extensive. C1 [Tusting, Lucy S.; Fillinger, Ulrike; Lindsay, Steven W.] London Sch Hyg & Trop Med, Dept Dis Control, London WC1, England. [Thwing, Julie] US Ctr Dis Control & Prevent CDC, Strateg & Appl Sci Unit, Malaria Branch, Atlanta, GA 30341 USA. [Sinclair, David] Univ Liverpool, Liverpool Sch Trop Med, Dept Clin Sci, Liverpool L3 5QA, Merseyside, England. [Gimnig, John] US Ctr Dis Control & Prevent CDC, Entomol Branch, Atlanta, GA 30341 USA. [Bonner, Kimberly E.] Princeton Univ, Woodrow Wilson Sch Publ & Int Affairs, Princeton, NJ 08544 USA. [Bottomley, Christian] London Sch Hyg & Trop Med, MRC Trop Epidemiol Grp, London WC1, England. [Lindsay, Steven W.] Univ Durham, Sch Biol & Biomed Sci, Durham, England. RP Thwing, J (reprint author), US Ctr Dis Control & Prevent CDC, Strateg & Appl Sci Unit, Malaria Branch, 4770 Buford Highway NE,Mailstop F-22, Atlanta, GA 30341 USA. EM fez3@cdc.gov OI Tusting, Lucy/0000-0002-6897-8625 FU Intramural CDC HHS [CC999999]; Medical Research Council [G0700837]; NIAID NIH HHS [R01 AI082537] NR 129 TC 10 Z9 10 U1 3 U2 35 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1469-493X J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2013 IS 8 AR CD008923 DI 10.1002/14651858.CD008923.pub2 PG 92 WC Medicine, General & Internal SC General & Internal Medicine GA 211RW UT WOS:000323928900022 PM 23986463 ER PT J AU Leitao, J Chandramohan, D Byass, P Jakob, R Bundhamcharoen, K Choprapawon, C De Savigny, D Fottrell, E Franc, E Froe, F Gewaifel, G Hodgson, A Hounton, S Kahn, K Krishnan, A Kumar, V Masanja, H Nichols, E Notzon, F Rasooly, MH Sankoh, O Spiegel, P AbouZahr, C Amexo, M Kebede, D Alley, WS Marinho, F Ali, M Loyola, E Chikersal, J Gao, J Annunziata, G Bahl, R Bartolomeus, K Boerma, T Ustun, B Chou, D Muhe, L Mathai, M AF Leitao, Jordana Chandramohan, Daniel Byass, Peter Jakob, Robert Bundhamcharoen, Kanitta Choprapawon, Chanpen De Savigny, Don Fottrell, Edward Franc, Elizabeth Froe, Frederik Gewaifel, Gihan Hodgson, Abraham Hounton, Sennen Kahn, Kathleen Krishnan, Anand Kumar, Vishwajeet Masanja, Honorati Nichols, Erin Notzon, Francis Rasooly, Mohammad Hafiz Sankoh, Osman Spiegel, Paul AbouZahr, Carla Amexo, Marc Kebede, Derege Alley, William Soumbey Marinho, Fatima Ali, Mohamed Loyola, Enrique Chikersal, Jyotsna Gao, Jun Annunziata, Giuseppe Bahl, Rajiv Bartolomeus, Kidist Boerma, Ties Ustun, Bedirhan Chou, Doris Muhe, Lulu Mathai, Matthews TI Revising the WHO verbal autopsy instrument to facilitate routine cause-of-death monitoring SO GLOBAL HEALTH ACTION LA English DT Article DE verbal autopsy; cause of death; vital registration; civil registration; vital statistics; World Health Organization; Inter VA ID DIAGNOSTIC GOLD STANDARDS; DATA-DERIVED ALGORITHMS; INTERVA MODEL; ADULT DEATHS; VALIDATION; MORTALITY; PERFORMANCE; POPULATION; MULTICENTER; ACCURACY AB Objective: Verbal autopsy (VA) is a systematic approach for determining causes of death (CoD) in populations without routine medical certification. It has mainly been used in research contexts and involved relatively lengthy interviews. Our objective here is to describe the process used to shorten, simplify, and standardise the VA process to make it feasible for application on a larger scale such as in routine civil registration and vital statistics (CRVS) systems. Methods: A literature review of existing VA instruments was undertaken. The World Health Organization (WHO) then facilitated an international consultation process to review experiences with existing VA instruments, including those from WHO, the Demographic Evaluation of Populations and their Health in Developing Countries (INDEPTH) Network, InterVA, and the Population Health Metrics Research Consortium (PHMRC). In an expert meeting, consideration was given to formulating a workable VA CoD list [with mapping to the International Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) CoD] and to the viability and utility of existing VA interview questions, with a view to undertaking systematic simplification. Findings: A revised VA CoD list was compiled enabling mapping of all ICD-10 CoD onto 62 VA cause categories, chosen on the grounds of public health significance as well as potential for ascertainment from VA. A set of 221 indicators for inclusion in the revised VA instrument was developed on the basis of accumulated experience, with appropriate skip patterns for various population sub-groups. The duration of a VA interview was reduced by about 40% with this new approach. Conclusions: The revised VA instrument resulting from this consultation process is presented here as a means of making it available for widespread use and evaluation. It is envisaged that this will be used in conjunction with automated models for assigning CoD from VA data, rather than involving physicians. C1 [Leitao, Jordana; Chandramohan, Daniel] London Sch Hyg & Trop Med, London WC1, England. [Byass, Peter] Umea Univ, Dept Publ Hlth & Clin Med, Div Epidemiol & Global Hlth, WHO Collaborating Ctr Verbal Autopsy, Umea, Sweden. [Jakob, Robert] WHO, CH-1211 Geneva, Switzerland. [Bundhamcharoen, Kanitta] WHO, CH-1211 Geneva, Switzerland. [Choprapawon, Chanpen] Minist Publ Hlth, Hlth Policy & Strateg Bur, Nonthaburi, Thailand. [De Savigny, Don] Swiss Trop & Publ Hlth Inst, Basel, Switzerland. [Fottrell, Edward] Inst Child Hlth, UCL Ctr Int Hlth & Dev, London, England. [Franc, Elizabeth] Univ Fed Minas Gerais, Fac Med, Belo Horizonte, MG, Brazil. [Froe, Frederik] Norwegian Inst Publ Hlth, Genes & Environm Div Epidemiol, Oslo, Norway. [Gewaifel, Gihan] Univ Alexandria, Fac Med, Alexandria, Egypt. [Hodgson, Abraham] Ghana Hlth Serfice, Hlth Res & Dev Div, Accra, Ghana. [Hounton, Sennen] United Nations Populat Fund UNFPA, New York, NY USA. [Kahn, Kathleen] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, MRC Wits Rural Publ Hlth & Hlth Transit Res Unit, Johannesburg, South Africa. [Krishnan, Anand] All India Inst Med Sci, Ctr Community Med, New Delhi, India. [Masanja, Honorati] Ifakara Hlth Inst, Dar Es Salaam, Tanzania. [Nichols, Erin; Notzon, Francis] Ctr Dis Control & Prevent, Int Stat Div, Hyattsville, MD USA. [Rasooly, Mohammad Hafiz] Afghanistan Minist Publ Hlth, Afghan Publ Hlth Inst, Kabul, Afghanistan. [Sankoh, Osman] INDEPTH Network, INDEPTH Network Secretariat, Accra, Ghana. [Spiegel, Paul] Off United Nations High Commissioner Refugees UNH, Publ Hlth & HIV Sect, Geneva, Switzerland. [Amexo, Marc] Hlth Metr Network, Monitoring Vital Events, Geneva, Switzerland. [Kebede, Derege; Alley, William Soumbey; Marinho, Fatima] Pan Amer Hlth Org, Washington, DC USA. [Ali, Mohamed] WHO Reg Off Eastern Mediterranean, Div Hlth Syst & Serv Dev, Cairo, Egypt. [Loyola, Enrique] WHO Reg Off Europe, Copenhagen, Denmark. [Chikersal, Jyotsna] WHO Reg Off S Eastern Reg, Evidence Based Hlth Situat & Trends Assessment, New Delhi, India. [Gao, Jun] WHO Reg Off Western Pacific, Manila, Philippines. [Annunziata, Giuseppe] WHO, Mediterranean Ctr Hlth Risk Reduct, CH-1211 Geneva, Switzerland. [Bahl, Rajiv] WHO, Dept Child & Adolescent Hlth & Dev, CH-1211 Geneva, Switzerland. [Bartolomeus, Kidist] WHO, Dept Violence & Injury Prevent & Disabil, CH-1211 Geneva, Switzerland. [Boerma, Ties] WHO, Classificat Terminol & Stand Unit, CH-1211 Geneva, Switzerland. [Ustun, Bedirhan] WHO, Dept Reprod Hlth & Res, CH-1211 Geneva, Switzerland. [Chou, Doris; Muhe, Lulu; Mathai, Matthews] WHO, CH-1211 Geneva, Switzerland. RP Jakob, R (reprint author), WHO, HSI CTS, 20 Appia, CH-1211 Geneva, Switzerland. EM jakobr@who.int OI Jakob, Robert/0000-0001-6542-7548; Byass, Peter/0000-0001-5474-4361; Krishnan, Anand/0000-0002-9173-7811; Froen Froen, Jahn Frederik/0000-0001-9390-8509 NR 41 TC 58 Z9 58 U1 1 U2 13 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1654-9880 J9 GLOBAL HEALTH ACTION JI Glob. Health Action PY 2013 VL 6 AR 21518 DI 10.3402/gha.v6i0.21518 PG 17 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 216OP UT WOS:000324293600001 PM 28141011 ER PT J AU Tsai, J Grant, AM Soucie, JM Helwig, A Yusuf, HR Boulet, SL Reyes, NL Atrash, HK AF Tsai, James Grant, Althea M. Soucie, J. Michael Helwig, Amy Yusuf, Hussain R. Boulet, Sheree L. Reyes, Nimia L. Atrash, Hani K. TI Clustering Patterns of Comorbidities Associated with In-Hospital Death in Hospitalizations of US Adults with Venous Thromboembolism SO INTERNATIONAL JOURNAL OF MEDICAL SCIENCES LA English DT Article DE Comorbidity; Clustering pattern; Elixhauser comorbidity index; Venous thromboembolism; Hospitalization; Death; Mortality ID QUALITY-OF-CARE; RISK-FACTORS; ADMINISTRATIVE DATA; PULMONARY-EMBOLISM; DISEASE; CANCER; PROPHYLAXIS; PREVENTION; GUIDELINES; DIAGNOSIS AB Background: Venous thromboembolism (VTE) is a significant source of mortality, morbidity, disability, and impaired health-related quality of life in the world. Objective: We aimed to evaluate the clustering patterns and associations of 29 comorbidities with in-hospital death among adult hospitalizations with a diagnosis of VTE in the United States by analyzing data from the 2009 Nationwide Inpatient Sample. Methods: This cross-sectional study included 153,124 adult hospitalizations with a diagnosis of VTE. Adjusted rate ratios and 95% confidence intervals (CI) for in-hospital death were generated by using multivariable log-linear regression models to measure independent associations between comorbidities and in-hospital death. Results: We estimated that 44,200 in-hospital deaths occurred in 2009 among 773,273 US adult hospitalizations with a diagnosis of VTE. Subgroups of hospitalizations with comorbidities of "congestive heart failure," "chronic pulmonary disease," " coagulopathy," "liver disease," "lymphoma," " fluid and electrolyte disorders," "metastatic cancer," "peripheral vascular disorders," " pulmonary circulation disorders," "renal failure," "solid tumor without metastasis," or "weight loss" were positively and independently associated with 1.07 (95% CI: 1.02-1.12) to 2.06 (95% CI: 1.97-2.16) times increased likelihoods of in-hospital death, when compared to those without the corresponding comorbidities. The clustering patterns of these comorbidities by 4 disease categories (i.e., "cancer," "cardiovascular/respiratory/blood," "gastrointestinal/urologic," and "nutritional/bodyweight") were associated with 2.74 to 10.28 times increased likelihoods of in-hospital death, as compared to hospitalizations without any of these comorbidities. The overall increase in the cumulative number of comorbidities corresponded to significantly elevated risks (P-trend<0.01) for in-hospital death among hospitalizations with a diagnosis of VTE. Conclusion: The presence of multiple comorbidities is ubiquitous among hospitalizations of adults with VTE and among in-hospital deaths with VTE in the United States. The findings of our study further suggest that, among hospitalizations of adults with VTE, the presence of certain comorbidities or clustering of these comorbidities significantly elevates the risk of in-hospital death. C1 [Tsai, James; Grant, Althea M.; Soucie, J. Michael; Yusuf, Hussain R.; Reyes, Nimia L.; Atrash, Hani K.] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Helwig, Amy] Agcy Healthcare Res & Qual, Ctr Qual Improvement & Patient Safety, Rockville, MD USA. [Boulet, Sheree L.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Tsai, J (reprint author), Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,Mail Stop E-64, Atlanta, GA 30333 USA. EM jxt9@cdc.gov NR 56 TC 3 Z9 3 U1 1 U2 1 PU IVYSPRING INT PUBL PI LAKE HAVEN PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA SN 1449-1907 J9 INT J MED SCI JI Int. J. Med. Sci. PY 2013 VL 10 IS 10 BP 1352 EP 1360 DI 10.7150/ijms.6714 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 218DC UT WOS:000324411800013 PM 23983596 ER PT J AU Rehmani, I Liu, FG Liu, AM AF Rehmani, Imran Liu, Fange Liu, Aimin BE Villamena, FA TI CELL SIGNALING AND TRANSCRIPTION SO MOLECULAR BASIS OF OXIDATIVE STRESS: CHEMISTRY, MECHANISMS, AND DISEASE PATHOGENESIS LA English DT Article; Book Chapter ID HYPOXIA-INDUCIBLE-FACTOR; NF-KAPPA-B; PROTEIN-KINASE-C; VASCULAR SMOOTH-MUSCLE; IRON-SULFUR CLUSTER; HYDROGEN-PEROXIDE; ESCHERICHIA-COLI; OXIDATIVE-STRESS; NADPH OXIDASE; SUPEROXIDE-DISMUTASE C1 [Rehmani, Imran] Ctr Dis Control & Prevent, ORISE, Atlanta, GA USA. [Liu, Fange] Georgia State Univ, Atlanta, GA 30303 USA. [Liu, Aimin] Georgia State Univ, Fac Chem, Atlanta, GA 30303 USA. RP Rehmani, I (reprint author), Ctr Dis Control & Prevent, ORISE, Atlanta, GA USA. NR 167 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER, W SUSSEX PO 19 8SQ, ENGLAND BN 978-0-470-57218-4 PY 2013 BP 177 EP 199 D2 10.1002/9781118355886 PG 23 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA BGS38 UT WOS:000323972400009 ER PT J AU Humblet, O Korrick, SA Williams, PL Sergeyev, O Emond, C Birnbaum, LS Burns, JS Altshul, LM Patterson, DG Turner, WE Lee, MM Revich, B Hauser, R AF Humblet, Olivier Korrick, Susan A. Williams, Paige L. Sergeyev, Oleg Emond, Claude Birnbaum, Linda S. Burns, Jane S. Altshul, Larisa M. Patterson, Donald G., Jr. Turner, Wayman E. Lee, Mary M. Revich, Boris Hauser, Russ TI Genetic Modification of the Association between Peripubertal Dioxin Exposure and Pubertal Onset in a Cohort of Russian Boys SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE children; development; gene-environment interaction; PCBs; puberty; TCDD ID ARYL-HYDROCARBON RECEPTOR; GENOME-WIDE ASSOCIATION; TOXIC EQUIVALENCY FACTORS; ENVIRONMENT INTERACTIONS; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; SERUM; AGE; MENARCHE; RAT; EXPRESSION AB BACKGROUND: Exposure to dioxins has been associated with delayed pubertal onset in both epidemiologic and animal studies. Whether genetic polymorphisms may modify this association is currently unknown. Identifying such genes could provide insight into mechanistic pathways. This is one of the first studies to assess genetic susceptibility to dioxins. OBJECTIVES: We evaluated whether common polymorphisms in genes affecting either molecular responses to dioxin exposure or pubertal onset influence the association between peripubertal serum dioxin concentration and male pubertal onset. METHODS: In this prospective cohort of Russian adolescent boys (n = 392), we assessed gene-environment interactions for 337 tagging single-nucleotide polymorphisms (SNPs) from 46 candidate genes and two intergenic regions. Dioxins were measured in the boys' serum at age 8-9 years. Pubertal onset was based on testicular volume and on genitalia staging. Statistical approaches for controlling for multiple testing were used, both with and without prescreening for marginal genetic associations. RESULTS: After accounting for multiple testing, two tag SNPs in the glucocorticoid receptor (GR/NR3C1) gene and one in the estrogen receptor-alpha (ESR1) gene were significant (q < 0.2) modifiers of the association between peripubertal serum dioxin concentration and male pubertal onset defined by genitalia staging, although not by testicular volume. The results were sensitive to whether multiple comparison adjustment was applied to all gene-environment tests or only to those with marginal genetic associations. CONCLUSIONS: Common genetic polymorphisms in the glucocorticoid receptor and estrogen receptor-alpha genes may modify the association between peripubertal serum dioxin concentration and pubertal onset. Further studies are warranted to confirm these findings. C1 [Humblet, Olivier; Korrick, Susan A.; Burns, Jane S.; Altshul, Larisa M.; Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. [Humblet, Olivier] Univ Calif San Francisco, Ctr Hlth & Community, San Francisco, CA 94143 USA. [Korrick, Susan A.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA. [Korrick, Susan A.] Harvard Univ, Sch Med, Boston, MA USA. [Williams, Paige L.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Sergeyev, Oleg] Samara State Med Univ, Dept Phys Educ & Hlth, Samara, Russia. [Sergeyev, Oleg] Chapaevsk Med Assoc, Chapaevsk, Russia. [Emond, Claude] BioSimulat Consulting Inc, Newark, DC USA. [Birnbaum, Linda S.] NIEHS, NCI, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA. [Altshul, Larisa M.] Environm Hlth & Engn Inc, Needham, MA USA. [Patterson, Donald G., Jr.] EnviroSolut Consulting Inc, Jasper, GA USA. [Turner, Wayman E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Lee, Mary M.] Univ Massachusetts, Sch Med, Dept Pediat, Pediat Endocrinol Div, Worcester, MA USA. [Lee, Mary M.] Univ Massachusetts, Sch Med, Dept Cell Biol, Pediat Endocrinol Div, Worcester, MA USA. [Revich, Boris] Russian Acad Sci, Inst Forecasting, Ctr Demog & Human Ecol, Moscow, Russia. RP Hauser, R (reprint author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, 665 Huntington Ave,Bldg 1,Room 1405, Boston, MA 02115 USA. EM rhauser@hohp.harvard.edu RI Sergeyev, Oleg/H-8854-2013 OI Sergeyev, Oleg/0000-0002-5745-3348 FU U.S. Environmental Protection Agency [EPA R82943701]; National Institute of Environmental Health Sciences (NIEHS) [ES014370, ES00002, 5T32-ES07069-28]; Robert Wood Johnson Foundation Health & Society Scholars program from NIEHS/National Human Genome Research Institute [5T32ES016645-02] FX This work was funded by grants from the U.S. Environmental Protection Agency (EPA R82943701) and the National Institute of Environmental Health Sciences (NIEHS) (ES014370, ES00002, and 5T32-ES07069-28). O.H. was supported by the Robert Wood Johnson Foundation Health & Society Scholars program and grant 5T32ES016645-02 from NIEHS/National Human Genome Research Institute. M.M.L. is a member of the University of Massachusetts Diabetes and Endocrinology Research Center (DK32520). NR 48 TC 1 Z9 1 U1 1 U2 9 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD JAN PY 2013 VL 121 IS 1 BP 111 EP 117 DI 10.1289/ehp.1205278 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 208SE UT WOS:000323698700033 PM 23060366 ER PT J AU Chevrier, J Gunier, RB Bradman, A Holland, NT Calafat, AM Eskenazi, B Harley, KG AF Chevrier, Jonathan Gunier, Robert B. Bradman, Asa Holland, Nina T. Calafat, Antonia M. Eskenazi, Brenda Harley, Kim G. TI Maternal Urinary Bisphenol A during Pregnancy and Maternal and Neonatal Thyroid Function in the CHAMACOS Study SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE bisphenol A; endocrine disruption; neonates; pregnancy; thyroid hormone ID STIMULATING HORMONE-LEVELS; UDP-GLUCURONOSYLTRANSFERASE; POLYCHLORINATED-BIPHENYLS; PRENATAL EXPOSURE; FREE-THYROXINE; FLAME RETARDANTS; SERUM THYROXINE; NATIONAL-HEALTH; WOMEN; LIVER AB BACKGROUND: Bisphenol A (BPA) is widely used in the manufacture of polycarbonate plastic bottles, food and beverage can linings, thermal receipts, and dental sealants. Animal and human studies suggest that BPA may disrupt thyroid function. Although thyroid hormones play a determinant role in human growth and brain development, no studies have investigated relations between BPA exposure and thyroid function in pregnant women or neonates. OBJECTIVE: Our goal was to evaluate whether exposure to BPA during pregnancy is related to thyroid hormone levels in pregnant women and neonates. METHODS: We measured BPA concentration in urine samples collected during the first and second half of pregnancy in 476 women participating in the CHAMACOS (Center for the Health Assessment of Mothers and Children of Salinas) study. We also measured free thyroxine (T-4), total T-4, and thyroid-stimulating hormone (TSH) in women during pregnancy, and TSH in neonates. RESULTS: Associations between the average of the two BPA measurements and maternal thyroid hormone levels were not statistically significant. Of the two BPA measurements, only the one taken closest in time to the TH measurement was significantly associated with a reduction in total T-4 (beta = -0.13 mu g/dL per log(2) unit; 95% CI: -0.25, 0.00). The average of the maternal BPA concentrations was associated with reduced TSH in boys (-9.9% per log(2) unit; 95% CI: -15.9%, -3.5%) but not in girls. Among boys, the relation was stronger when BPA was measured in the third trimester of pregnancy and decreased with time between BPA and TH measurements. CONCLUSION: Results suggest that exposure to BPA during pregnancy is related to reduced total T-4 in pregnant women and decreased TSH in male neonates. Findings may have implications for fetal and neonatal development. C1 [Chevrier, Jonathan; Gunier, Robert B.; Bradman, Asa; Holland, Nina T.; Eskenazi, Brenda; Harley, Kim G.] Univ Calif Berkeley, Sch Publ Hlth, Ctr Childrens Environm Hlth Res, Berkeley, CA 94704 USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA USA. RP Chevrier, J (reprint author), Univ Calif Berkeley, Sch Publ Hlth, CERCH, 1995 Univ Ave,Suite 265, Berkeley, CA 94704 USA. EM chevrier@berkeley.edu OI Gunier, Robert/0000-0001-5485-9919 FU U.S. Environmental Protection Agency [RD 83171001]; National Institute of Environmental Health Sciences [RC ES018792, P01 ES009605]; University of California Institute for Mexico and the United States; University of California Berkeley Center for Latino Policy Research FX This publication was supported by grants RD 83171001 from the U.S. Environmental Protection Agency and RC ES018792 and P01 ES009605 from the National Institute of Environmental Health Sciences. Additional funding was provided by the University of California Institute for Mexico and the United States and the University of California Berkeley Center for Latino Policy Research. NR 50 TC 45 Z9 46 U1 0 U2 35 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD JAN PY 2013 VL 121 IS 1 BP 138 EP 144 DI 10.1289/ehp.1205092 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 208SE UT WOS:000323698700037 PM 23052180 ER PT J AU Dube, SR Felitti, VJ Rishi, S AF Dube, Shanta R. Felitti, Vincent J. Rishi, Shobhana BE Linden, M Rutkowski, K TI Moving Beyond Childhood Adversity: Association Between Salutogenic Factors and Subjective Well-Being Among Adult Survivors of Trauma SO HURTING MEMORIES AND BENEFICIAL FORGETTING: POSTTRAUMATIC STRESS DISORDERS, BIOGRAPHICAL DEVELOPMENTS, AND SOCIAL CONFLICTS SE Elsevier Insights LA English DT Article; Book Chapter ID SELF-RATED HEALTH; HOUSEHOLD DYSFUNCTION; SOCIOECONOMIC-STATUS; SEXUAL-ABUSE; EXPERIENCES; STRESS; RISK; DETERMINANTS; COHERENCE; MORTALITY C1 [Dube, Shanta R.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30329 USA. [Felitti, Vincent J.] Kaiser Permanente, So Calif Permanente Med Grp, Dept Prevent Med, San Diego, CA USA. [Rishi, Shobhana] Calif Dept Educ, Sacramento, CA USA. RP Dube, SR (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30329 USA. NR 42 TC 2 Z9 2 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 978-0-12-398404-3 J9 ELSEV INSIGHT PY 2013 BP 139 EP 151 DI 10.1016/B978-0-12-398393-0.00012-2 PG 13 WC Psychology, Clinical SC Psychology GA BGJ14 UT WOS:000323208700013 ER PT J AU Bombard, JM Robbins, CL Dietz, PM Valderrama, AL AF Bombard, Jennifer M. Robbins, Cheryl L. Dietz, Patricia M. Valderrama, Amy L. TI Preconception Care: The Perfect Opportunity for Health Care Providers to Advise Lifestyle Changes for Hypertensive Women SO AMERICAN JOURNAL OF HEALTH PROMOTION LA English DT Article DE Female; Young Adult; Hypertension; Directive Counseling; Risk Reduction Behavior; Prevention Research ID HIGH BLOOD-PRESSURE; RECOMMENDATION STATEMENT; RISK-FACTORS; INTERVENTIONS; COMPLICATIONS; PREVENTION; PREGNANCY AB Purpose. To provide estimates for prevalence of health care provider advice offered to reproductive-aged women and to assess their association with behavior change. Design. Cross-sectional study using the 2009 Behavioral Risk Factor Surveillance System. Setting. Nineteen states/areas. Subjects. Women aged 18 to 44 years with a self-reported history of hypertension or current antihypertensive medication use (n = 2063). Measures. Self-reported hypertension; sociodemographic and health care access indicators; and provider advice and corresponding self-reported behavior change to improve diet, limit salt intake, exercise, and reduce alcohol use. Analysis. We estimated prevalence and prevalence ratios for receipt of provider advice and action to change habits. We calculated 95% confidence interval (CI) and used chi(2) tests to assess associations. Results. Overall, 9.8% of reproductive-aged women had self-reported hypertension; most reported receiving advice to change eating habits (72.9%), reduce salt intake (74.6%), and exercise (82.1%), and most reported making these changes. Only 44.7% reported receiving advice to reduce alcohol intake. Women who received provider advice were more likely to report corresponding behavior change compared to those who did not (prevalence ratios ranged from 1.3 [95% CI, 1.2-1.5, p < .05] for exercise to 1.6 [95% CI, 1.4-1.8, p < .05] for reducing alcohol use. Conclusion. Health care providers should routinely advise hypertensive reproductive-aged women about lifestyle changes to reduce blood pressure and improve pregnancy outcomes. C1 [Bombard, Jennifer M.; Robbins, Cheryl L.; Dietz, Patricia M.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA USA. [Valderrama, Amy L.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Heart Dis & Stroke Prevent, Atlanta, GA USA. RP Bombard, JM (reprint author), CDC, 4770 Buford Highway NE,Mailstop K-22, Atlanta, GA 30341 USA. EM ZWF3@cdc.gov FU Intramural CDC HHS [CC999999] NR 26 TC 1 Z9 1 U1 0 U2 5 PU AMER JOURNAL HEALTH PROMOTION INC PI TROY PA PO BOX 1254, TROY, MI 48099-1254 USA SN 0890-1171 J9 AM J HEALTH PROMOT JI Am. J. Health Promot. PD JAN-FEB PY 2013 VL 27 IS 3 SU S BP S43 EP S49 DI 10.4278/ajhp.120109-QUAN-6 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 205XY UT WOS:000323479400012 PM 23286663 ER PT J AU Remick, AP Kendrick, JS AF Remick, Arlene P. Kendrick, Juliette S. TI Breaking New Ground: The Text4baby Program SO AMERICAN JOURNAL OF HEALTH PROMOTION LA English DT Editorial Material C1 [Remick, Arlene P.] Hlth Babies Coalit, Natl Hlth Mothers, Alexandria, VA 22302 USA. [Kendrick, Juliette S.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. RP Remick, AP (reprint author), Hlth Babies Coalit, Natl Hlth Mothers, 4401 Ford Ave,Suite 300, Alexandria, VA 22302 USA. EM info@text4baby.org FU Intramural CDC HHS [CC999999] NR 0 TC 8 Z9 8 U1 0 U2 3 PU AMER JOURNAL HEALTH PROMOTION INC PI TROY PA PO BOX 1254, TROY, MI 48099-1254 USA SN 0890-1171 J9 AM J HEALTH PROMOT JI Am. J. Health Promot. PD JAN-FEB PY 2013 VL 27 IS 3 SU S BP S4 EP S6 DI 10.4278/ajhp.27.3.c2 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 205XY UT WOS:000323479400006 PM 23286662 ER PT J AU Diwakar, PK Harilal, SS LaHaye, NL Hassanein, A Kulkarni, P AF Diwakar, Prasoon K. Harilal, Sivanandan S. LaHaye, Nicole L. Hassanein, Ahmed Kulkarni, Pramod TI The influence of laser pulse duration and energy on ICP-MS signal intensity, elemental fractionation, and particle size distribution in NIR fs-LA-ICP-MS SO JOURNAL OF ANALYTICAL ATOMIC SPECTROMETRY LA English DT Article ID PLASMA-MASS SPECTROMETRY; FEMTOSECOND LASERS; UV-FEMTOSECOND; SILICATE GLASS; ABLATION; BRASS; NANOSECOND; SAMPLES; AEROSOLS; NM AB Laser parameters, typically wavelength, pulse width, irradiance, repetition rate, and pulse energy, are critical parameters which influence the laser ablation process and thereby influence the LA-ICP-MS signal. In recent times, femtosecond laser ablation has gained popularity owing to the reduction in fractionation related issues and improved analytical performance which can provide matrix-independent sampling. The advantage offered by fs-LA is due to shorter pulse duration of the laser as compared to the phonon relaxation time and heat diffusion time. Hence the thermal effects are minimized in fs-LA. Recently, fs-LA-ICP-MS demonstrated improved analytical performance as compared to ns-LA-ICP-MS, but detailed mechanisms and processes are still not clearly understood. Improvement of fs-LA-ICP-MS over ns-LA-ICP-MS elucidates the importance of laser pulse duration and related effects on the ablation process. In this study, we have investigated the influence of laser pulse width (40 fs to 0.3 ns) and energy on LA-ICP-MS signal intensity and repeatability using a brass sample. Experiments were performed in single spot ablation mode as well as rastering ablation mode to monitor the Cu/Zn ratio. The recorded ICP-MS signal was correlated with total particle counts generated during laser ablation as well as particle size distribution. Our results show the importance of pulse width effects in the fs regime that becomes more pronounced when moving fromfemtosecond to picosecond and nanosecond regimes. C1 [Diwakar, Prasoon K.; Harilal, Sivanandan S.; LaHaye, Nicole L.; Hassanein, Ahmed] Purdue Univ, Sch Nucl Engn, Ctr Mat Extreme Environm, W Lafayette, IN 47907 USA. [Kulkarni, Pramod] NIOSH, Cincinnati, OH 45213 USA. RP Diwakar, PK (reprint author), Purdue Univ, Sch Nucl Engn, Ctr Mat Extreme Environm, W Lafayette, IN 47907 USA. EM pdiwakar@purdue.edu RI Diwakar, Prasoon/E-8689-2010; Harilal, Sivanandan/B-5438-2014; OI Harilal, Sivanandan/0000-0003-2266-7976; LaHaye, Nicole/0000-0001-5047-8078 FU US Department of Energy, office of National Nuclear Security Administration [DE-NA0000463] FX This work is partially supported by US Department of Energy, office of National Nuclear Security Administration under award number DE-NA0000463. NR 45 TC 11 Z9 11 U1 4 U2 38 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 0267-9477 J9 J ANAL ATOM SPECTROM JI J. Anal. At. Spectrom. PY 2013 VL 28 IS 9 BP 1420 EP 1429 DI 10.1039/c3ja50088h PG 10 WC Chemistry, Analytical; Spectroscopy SC Chemistry; Spectroscopy GA 198KS UT WOS:000322922300008 PM 26664120 ER PT J AU Zhang, L Gwinn, M Hu, DJ AF Zhang, L. Gwinn, M. Hu, D. J. TI Viral Hepatitis C Gets Personal - The Value of Human Genomics to Public Health SO PUBLIC HEALTH GENOMICS LA English DT Review DE Hepatitis C; Host genetic predisposition to disease; IL28B polymorphism; Interferon response ID SUSTAINED VIROLOGICAL RESPONSE; VIRUS-INFECTION; GENOTYPE 1; PEGYLATED INTERFERON; UNITED-STATES; SPONTANEOUS CLEARANCE; GENETIC-VARIATION; IL28B POLYMORPHISM; RIBAVIRIN THERAPY; WIDE ASSOCIATION AB About 180 million people worldwide are chronically infected with hepatitis C virus (HCV), with 3-4 million newly infected each year. Only 15-25% of acute HCV infections clear spontaneously, and the remainder persists as chronic HCV infection. More than 350,000 people die every year from hepatitis C-related liver failure and cancer. There is currently no vaccine and the standard-of-care therapies - peg-interferon alpha (pegIFN) plus ribavirin (RBV) - are expensive and have serious side effects. Also, they may be effective in only 40-50% of patients infected with HCV genotype 1, the most common HCV genotype in the US. Interleukin 28B (IL28B) genotype was recently and convincingly associated with response to pegIFN and RBV therapy. It has emerged as a robust pretreatment predictor of sustained virological response (SVR, i.e. virologic clearance) to pegIFN and RBV as well as to new triple therapy regimens that include a direct-acting antiviral agent with pegIFN and RBV and increase SVR rates as much as 75% in patients infected with HCV genotype 1. Testing for IL28B genotype may contribute to clinical decision-making and could inform clinical guidelines and public health policies. (C) 2013 S. Karger AG, Basel C1 [Zhang, L.; Hu, D. J.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Gwinn, M.] McKing Consulting Corp, Atlanta, GA USA. RP Zhang, L (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,MS A33, Atlanta, GA 30333 USA. EM chn6@cdc.gov FU Centers for Disease Control and Prevention, Atlanta, Ga FX This study was supported by the Centers for Disease Control and Prevention, Atlanta, Ga. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 51 TC 5 Z9 5 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1662-4246 J9 PUBLIC HEALTH GENOM JI Pub. Health Genomics PY 2013 VL 16 IS 4 BP 192 EP 197 DI 10.1159/000352014 PG 6 WC Genetics & Heredity; Public, Environmental & Occupational Health SC Genetics & Heredity; Public, Environmental & Occupational Health GA 197MW UT WOS:000322856300006 PM 23859951 ER PT S AU Black, CM AF Black, Carolyn M. BE Black, CM TI Chlamydial Infection: A Clinical and Public Health Perspective Introduction SO CHLAMYDIAL INFECTION: A CLINICAL AND PUBLIC HEALTH PERSPECTIVE SE Issues in Infectious Diseases LA English DT Editorial Material; Book Chapter ID PERSISTENT CHLAMYDIAE C1 Ctr Dis Control & Prevent, Div Sci Resources, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Black, CM (reprint author), Ctr Dis Control & Prevent, Div Sci Resources, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM cblack@cdc.gov NR 12 TC 1 Z9 1 U1 0 U2 0 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 1660-1890 BN 978-3-318-02398-5 J9 ISSUES INFECT DIS JI Issues Infect. Dis. PY 2013 VL 7 BP 1 EP 8 DI 10.1159/000348748 PG 8 WC Infectious Diseases SC Infectious Diseases GA BGF20 UT WOS:000322680600001 ER PT S AU Satterwhite, CL Douglas, JM AF Satterwhite, Catherine L. Douglas, John M., Jr. BE Black, CM TI Epidemiology and Prevention and Control Programs for Chlamydia SO CHLAMYDIAL INFECTION: A CLINICAL AND PUBLIC HEALTH PERSPECTIVE SE Issues in Infectious Diseases LA English DT Article; Book Chapter ID PELVIC-INFLAMMATORY-DISEASE; SEXUALLY-TRANSMITTED INFECTIONS; TRACHOMATIS GENITAL-INFECTION; JOB-TRAINING PROGRAM; SERVICES-TASK-FORCE; UNITED-STATES; PARTNER NOTIFICATION; ECTOPIC PREGNANCY; LABORATORY TESTS; PERSONS 14 AB An estimated 2.9 million cases of Chlamydia trachomatis occur annually in the USA, and while most infections are not detected and reported, chlamydia is the most commonly reported nationally notifiable disease in the USA, with over 1.2 million cases reported in 2009. Rates of reported cases of chlamydia have increased over the past decade as a result of expanded use of more sensitive diagnostic tests and increased testing. The highest case rates are in adolescents/young adults, females and African-Americans. In contrast to increases in reported case rates, prevalence in routinely tested populations appears to be stable in some settings (e.g. women tested in family planning clinics) and declining in others (e.g. high-risk youths assessed by the National Job Training Program, the general population assessed by the National Health and Nutrition Examination Survey). Prevention and control programs rely on detection and treatment of infection to prevent complications and ongoing transmission, based primarily on recommended annual screening of young sexually active women and treatment of sex partners. Important complementary prevention components include enhancing awareness to promote adherence to recommended testing and education and risk reduction counseling to promote condom use. Enhancing the public health impact of chlamydia prevention and control requires expanding population coverage of recommended strategies, especially among the most affected populations. Copyright (C) 2013 S. Karger AG, Basel C1 Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. Ctr Dis Control & Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA USA. RP Satterwhite, CL (reprint author), Univ Kansas, Sch Med, Dept Prevent Med & Publ Hlth, 3901 Rainbow Blvd,MS 1008, Kansas City, KS 66160 USA. EM csatterwhite@kumc.edu NR 71 TC 0 Z9 0 U1 1 U2 4 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 1660-1890 BN 978-3-318-02398-5 J9 ISSUES INFECT DIS JI Issues Infect. Dis. PY 2013 VL 7 BP 9 EP 24 DI 10.1159/000348750 PG 16 WC Infectious Diseases SC Infectious Diseases GA BGF20 UT WOS:000322680600002 ER PT S AU Igietseme, JU Black, CM AF Igietseme, Joseph U. Black, Carolyn M. BE Black, CM TI Chlamydia Vaccine Development SO CHLAMYDIAL INFECTION: A CLINICAL AND PUBLIC HEALTH PERSPECTIVE SE Issues in Infectious Diseases LA English DT Article; Book Chapter ID PELVIC-INFLAMMATORY-DISEASE; SEXUALLY-TRANSMITTED-DISEASE; GENITAL-TRACT SECRETIONS; TRACHOMA VIRUS VACCINE; OUTER-MEMBRANE PROTEIN; TERM FOLLOW-UP; IFN-GAMMA; INTRANASAL IMMUNIZATION; ANTIBODY-RESPONSES; ANTIGENIC MIMICRY AB The search for a safe and efficacious human chlamydial vaccine has been ongoing for more than 5 decades. Unfortunately, the dream has yet to be realized. However, much progress has been made in defining the immunologic requirements of a potentially efficacious vaccine, which involve the induction of a strong CD4T cell-driven Th1 response, as well as an accessory antibody response that is vital for a rapid and robust memory response to reinfections. While a subunit vaccine is currently preferred to the whole organism, the vaccine antigen(s) may be a single or a multisubunit, provided it furnishes ample T and B cell epitopes to induce adequate protective immune responses without immunopathogenic responses. In addition, any subunit vaccine prospect would require a delivery vehicle and method that can together produce an effective immunomodulation to both boost the protective immunity and target immune effectors to the mucosal site of infection. Furthermore, a vaccine that confers broadly specific and long-term protective immunity against both chlamydial infection and disease is the ultimate goal; however, a vaccine that prevents only the development of serious complications (e.g. blinding trachoma, pelvic inflammatory disease, ectopic pregnancy, infertility and pneumonia) could be an acceptable short-term goal. Copyright (C) 2013 Carolyn M. Black, Atlanta, Ga. C1 [Igietseme, Joseph U.; Black, Carolyn M.] Ctr Dis Control & Prevent, Natl Ctr Emerging Zoonot & Infect Dis, Atlanta, GA 30333 USA. RP Igietseme, JU (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging Zoonot & Infect Dis, 1600 Clifton Rd NE,Mailstop G36, Atlanta, GA 30333 USA. EM Jigietseme@cdc.gov NR 99 TC 2 Z9 2 U1 0 U2 2 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 1660-1890 BN 978-3-318-02398-5 J9 ISSUES INFECT DIS JI Issues Infect. Dis. PY 2013 VL 7 BP 115 EP 130 DI 10.1159/000348762 PG 16 WC Infectious Diseases SC Infectious Diseases GA BGF20 UT WOS:000322680600008 ER PT J AU Tao, GY Hoover, KW AF Tao, Guoyu Hoover, Karen W. TI Differences in access to healthcare and utilisation of HIV and sexually transmissible infection services between men who have sex with men and men who have sex only with women: results of the 2006-10 National Survey of Family Growth in the United States SO SEXUAL HEALTH LA English DT Article ID SAME-SEX; TRANSMITTED INFECTIONS; INSURANCE COVERAGE; INDIVIDUALS; DISPARITIES; GAY; ACT AB Background: Men who have sex with men (MSM) experience disparities in access to healthcare and have specific healthcare needs. Methods: We analysed data from the 2006-10 National Survey of Family Growth (NSFG) to examine differences in access to healthcare and HIV and sexually transmissible infection (STI) related health services by MSM and non-MSM among men in the United States aged 15-44 years who have ever had sex. MSM and sexually active MSM were identified in the NSFG as men who had ever had oral or anal sex with another man, or who had sex in the past 12 months with another man, respectively. Access was measured by the type of health insurance, having a usual place for receiving healthcare and type of usual place. Results: Of men aged 15-44 years who have ever had sex, there were no significant differences between MSM and non-MSM in the three access measures. MSM were more likely than non-MSM to receive HIV counselling (22.5% v. 8.3%) and STI testing (26.2% v. 15.6%) in the past 12 months, or to ever have had HIV testing (67.8% v. 44.6%). STI testing in the past 12 months was reported by 38.7% of sexually active MSM. Conclusion: Our findings show no significant differences in access to healthcare between MSM and non-MSM. MSM were more likely to receive HIV- and STI-related preventive services than non-MSM. However, the low STI testing rate among MSM highlights the need for interventions to increase STI testing, and HIV and STI counselling for MSM. C1 [Tao, Guoyu; Hoover, Karen W.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Tao, GY (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,MS E80, Atlanta, GA 30333 USA. EM gat3@cdc.gov NR 19 TC 2 Z9 2 U1 0 U2 6 PU CSIRO PUBLISHING PI COLLINGWOOD PA 150 OXFORD ST, PO BOX 1139, COLLINGWOOD, VICTORIA 3066, AUSTRALIA SN 1448-5028 J9 SEX HEALTH JI Sex Health PY 2013 VL 10 IS 4 BP 363 EP 368 DI 10.1071/SH13017 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 193RM UT WOS:000322579200012 PM 23806743 ER PT J AU Jones, GC Crews, JE AF Jones, Gwyn C. Crews, John E. TI Health disparities among workers and nonworkers with functional limitations: implications for improving employment in the United States SO DISABILITY AND REHABILITATION LA English DT Article DE Health outcomes; International Classification of Functioning; Disability and Health ID SERIOUS MENTAL-ILLNESS; PSYCHOLOGICAL DISTRESS; SECONDARY CONDITIONS; INTERVIEW SURVEY; PUBLIC-HEALTH; DISABILITIES; ADULTS; WOMEN; PERFORMANCE; PREVENTION AB Purpose: The aim of this study was to compare workers and nonworkers who reported mild, moderate, and severe/complete functional limitations to identify disparities in 19 health and social indicators. Method: Using the International Classification of Functioning, Disability and Health as our conceptual framework, we analyzed data from the combined 2000-2008 National Health Interview Survey, comparing workers and nonworkers by severity of functional limitations, as measured by the FL12 Scale of Functional Limitation Severity. Results: Only 9.5% of people reporting moderate/severe functional limitations worked. Although not without exception, not working and severity of functional limitation were associated with poorer health outcomes, with nonworkers reporting severe/complete limitations having least optimal health. Prevalence of chronic conditions was associated with level of functional limitation severity, with the strongest associations among nonworkers. Conclusions: By focusing exclusively on people with functional limitations, we were better able to examine factors contributing to health and participation of workers and nonworkers. People who worked and had moderate or severe/complete limitations often did so while reporting poor health. With improved access to health care, health promotion activities, and other support systems, the quality of life and likelihood of work participation of people with greater functional limitations might also be improved. C1 [Crews, John E.] Ctr Dis Control & Prevent, Vis Hlth Initiat, Div Diabet Translat, Atlanta, GA 30329 USA. RP Jones, GC (reprint author), 2279 Alnwick Dr, Duluth, GA 30096 USA. EM geeceejay@bellsouth.net FU Intramural CDC HHS [CC999999] NR 53 TC 3 Z9 3 U1 4 U2 7 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0963-8288 J9 DISABIL REHABIL JI Disabil. Rehabil. PY 2013 VL 35 IS 17 BP 1479 EP 1490 DI 10.3109/09638288.2012.740137 PG 12 WC Rehabilitation SC Rehabilitation GA 186IW UT WOS:000322037800009 PM 23234295 ER PT S AU Schulte, PA Geraci, CL Hodson, LL Zumwalde, RD Kuempel, ED Murashov, V Martinez, KF Heidel, DS AF Schulte, P. A. Geraci, C. L. Hodson, L. L. Zumwalde, R. D. Kuempel, E. D. Murashov, V. Martinez, K. F. Heidel, D. S. GP IOP TI Overview of Risk Management for Engineered Nanomaterials SO NANOSAFE 2012: INTERNATIONAL CONFERENCES ON SAFE PRODUCTION AND USE OF NANOMATERIALS SE Journal of Physics Conference Series LA English DT Proceedings Paper CT 3rd International Conference on Safe Production and Use of Nanomaterials (Nanosafe) CY NOV 13-15, 2012 CL Minatec, Grenoble, FRANCE HO Minatec ID EXPOSURE-REGISTRIES; CARBON NANOTUBE; LOW-TOXICITY; IN-VITRO; NANOPARTICLES; WORKPLACE; SURVEILLANCE; WORKERS; PARTICLES; LIMITS AB Occupational exposure to engineered nanomaterials (ENMs) is considered a new and challenging occurrence. Preliminary information from laboratory studies indicates that workers exposed to some kinds of ENMs could be at risk of adverse health effects. To protect the nanomaterial workforce, a precautionary risk management approach is warranted and given the newness of ENMs and emergence of nanotechnology, a naturalistic view of risk management is useful. Employers have the primary responsibility for providing a safe and healthy workplace. This is achieved by identifying and managing risks which include recognition of hazards, assessing exposures, characterizing actual risk, and implementing measures to control those risks. Following traditional risk management models for nanomaterials is challenging because of uncertainties about the nature of hazards, issues in exposure assessment, questions about appropriate control methods, and lack of occupational exposure limits (OELs) or nano-specific regulations. In the absence of OELs specific for nanomaterials, a precautionary approach has been recommended in many countries. The precautionary approach entails minimizing exposures by using engineering controls and personal protective equipment (PPE). Generally, risk management utilizes the hierarchy of controls. Ideally, risk management for nanomaterials should be part of an enterprise-wide risk management program or system and this should include both risk control and a medical surveillance program that assesses the frequency of adverse effects among groups of workers exposed to nanomaterials. In some cases, the medical surveillance could include medical screening of individual workers to detect early signs of work-related illnesses. All medical surveillance should be used to assess the effectiveness of risk management; however, medical surveillance should be considered as a second line of defense to ensure that implemented risk management practices are effective. C1 [Schulte, P. A.; Geraci, C. L.; Hodson, L. L.; Zumwalde, R. D.; Kuempel, E. D.; Murashov, V.; Martinez, K. F.; Heidel, D. S.] NIOSH, Cincinnati, OH 45226 USA. RP Schulte, PA (reprint author), NIOSH, 4676 Columbia Pkwy,MS C14, Cincinnati, OH 45226 USA. EM PSchulte@cdc.gov NR 44 TC 3 Z9 3 U1 2 U2 21 PU IOP PUBLISHING LTD PI BRISTOL PA DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND SN 1742-6588 J9 J PHYS CONF SER PY 2013 VL 429 AR 012062 DI 10.1088/1742-6596/429/1/012062 PG 10 WC Nanoscience & Nanotechnology; Physics, Multidisciplinary SC Science & Technology - Other Topics; Physics GA BEW67 UT WOS:000318429400062 ER PT J AU Freedman, DS Ogden, CL Goodman, AB Blanck, HM AF Freedman, David S. Ogden, Cynthia L. Goodman, Alyson B. Blanck, Heidi M. TI Skinfolds and Coronary Heart Disease Risk Factors are More Strongly Associated with BMI Than with the Body Adiposity Index SO OBESITY LA English DT Article ID MASS INDEX; ADULTS; FAT; CHOLESTEROL; PREVALENCE; MORTALITY; PROGRAM; WEIGHT; TRENDS; WOMEN AB Objective: A recent, cross-sectional analysis of adults found that the hip circumference divided by height(1.5) minus 18 (the body adiposity index, BAI) was strongly correlated (r = 0.79) with percent body fat determined by dual energy X-ray absorptiometry. The BAI was proposed as a more accurate index of body fatness than BMI. We examined whether BAI was more strongly related, than was BMI and waist circumference, to skinfold thicknesses and levels of various risk factors for coronary heart disease. Design and Methods: Cross-sectional analyses of adults (n = 14,263 for skinfold thickness; n=6291 for fasting lipid levels) in the National Health and Nutrition Examination Survey (NHANES) III, 1988-1994. Results: As compared with BMI and waist circumference, we found that BAI was less strongly associated with the skinfold sum and with risk factor levels. For example, correlations with the skinfold sum were r = 0.79 (BMI) vs. r = 0.70 (BAI) among men, and r = 0.86 (BMI) vs. r = 0.79 (BAI) among women; p < 0.001 for the difference between each pair of correlations. An overall index of the 7 risk factors was also more strongly associated with BMI and waist circumference than BAI in analyses stratified by sex, race-ethnicity and age. Multivariable analyses indicated that if BMI was known, BAI provided little additional information on risk factor levels. Conclusions: Based on the observed associations with risk factor levels and skinfold thicknesses, we conclude that BAI is unlikely to be a better index of adiposity than BMI. C1 [Freedman, David S.; Goodman, Alyson B.; Blanck, Heidi M.] Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Surveys, Div Nutr & Phys Act & Obes, Atlanta, GA 30333 USA. [Ogden, Cynthia L.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Freedman, DS (reprint author), Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Surveys, Div Nutr & Phys Act & Obes, Atlanta, GA 30333 USA. EM dxf1@CDC.gov FU Intramural CDC HHS [CC999999] NR 40 TC 5 Z9 7 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 J9 OBESITY JI Obesity PD JAN PY 2013 VL 21 IS 1 BP E64 EP E70 DI 10.1002/oby.20054 PG 7 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 187AE UT WOS:000322086900009 PM 23401381 ER PT J AU Kim, SY Sappenfield, W Sharma, AJ Wilson, HG Bish, CL Salihu, HM England, LJ AF Kim, Shin Y. Sappenfield, William Sharma, Andrea J. Wilson, Hoyt G. Bish, Connie L. Salihu, Hamisu M. England, Lucinda J. TI Racial/Ethnic Differences in the Prevalence of Gestational Diabetes Mellitus and Maternal Overweight and Obesity, by Nativity, Florida, 2004-2007 SO OBESITY LA English DT Article ID SIMILAR RISK PROFILE; BODY-MASS INDEX; INSULIN-RESISTANCE; NATIONAL-HEALTH; UNITED-STATES; SHORT STATURE; WOMEN; ETHNICITY; US; PREGNANCY AB Objective: We examined the risk of gestational diabetes mellitus (GDM) among foreign-born and U.S.born mothers by race/ethnicity and BMI category. Design and Method: We used 2004-2007 linked birth certificate and maternal hospital discharge data of live, singleton deliveries in Florida to compare GDM risk among foreign-born and U.S.-born mothers by race/ethnicity and BMI category. We examined maternal BMI and controlled for maternal age, parity, and height. Results: Overall, 22.4% of the women in our study were foreign born. The relative risk (RR) of GDM among women who were overweight or obese (BMI >= 25.0 kg m(-2)) was higher than among women with normal BMI (18.5-24.9 kg m(-2)) regardless of nativity, ranging from 1.3 (95% confidence interval (CI) = 1.0, 1.9) to 3.8 (95% CI = 2.1, 7.2). Foreign-born women also had a higher GDM risk than U.S.-born women, with RR ranging from 1.1 (95% CI = 1.1, 1.2) to 2.1 (95% CI = 1.4, 3.1). This finding was independent of BMI, age, parity, and height for all racial/ethnicity groups. Conclusions: Although we found differences in age, parity, and height by nativity, these differences did not substantially reduce the increased risk of GDM among foreign-born mothers. Health practitioners should be aware of and have a better understanding of how race/ethnicity and nativity can affect women with a high risk of GDM. Although BMI is a major risk factor for GDM, it does not appear to be associated with race/ethnicity or nativity. C1 [Kim, Shin Y.; Sharma, Andrea J.; Wilson, Hoyt G.; Bish, Connie L.; England, Lucinda J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Sappenfield, William] Florida Dept Hlth, Div Family Hlth Serv, Tallahassee, FL USA. [Salihu, Hamisu M.] Univ S Florida, Dept Biostat & Epidemiol, Tampa, FL USA. RP Kim, SY (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM skim1@cdc.gov OI Sharma, Andrea/0000-0003-0385-0011 FU Intramural CDC HHS [CC999999] NR 38 TC 12 Z9 12 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 J9 OBESITY JI Obesity PD JAN PY 2013 VL 21 IS 1 BP E33 EP E40 DI 10.1002/oby.20025 PG 8 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 187AE UT WOS:000322086900005 PM 23404915 ER PT J AU Lipscomb, JC Maples-Reynolds, N Mumtaz, M AF Lipscomb, John C. Maples-Reynolds, Nikki Mumtaz, Moiz BE Fowler, BA TI Multiple Chemical Exposures and Risk Assessment SO COMPUTATIONAL TOXICOLOGY: METHODS AND APPLICATIONS FOR RISK ASSESSMENT LA English DT Article; Book Chapter ID BY-PRODUCT MIXTURES; EVALUATING SUFFICIENT SIMILARITY; EQUIVALENTS EXPERT WORKSHOP; BIOMONITORING EQUIVALENTS; INTERACTION THRESHOLDS; DBP MIXTURES; TOXICITY; TOXICOLOGY; GUIDELINES; ADDITIVITY C1 [Lipscomb, John C.] US EPA, Off Res & Dev, Natl Ctr Environm Assessment, Cincinnati, OH 45268 USA. [Maples-Reynolds, Nikki] ICF Int, Fairfax, VA USA. [Mumtaz, Moiz] Ctr Dis Control & Prevent, Dept Toxicol & Environm Med, Atlanta, GA USA. RP Lipscomb, JC (reprint author), US EPA, Off Res & Dev, Natl Ctr Environm Assessment, Cincinnati, OH 45268 USA. NR 67 TC 0 Z9 0 U1 1 U2 5 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-12-396508-0 PY 2013 BP 23 EP 44 PG 22 WC Mathematical & Computational Biology; Toxicology SC Mathematical & Computational Biology; Toxicology GA BFR29 UT WOS:000321041500004 ER PT J AU Krishnan, K McPhail, B Chiu, W White, P AF Krishnan, Kannan McPhail, Brooks Chiu, Weihsueh White, Paul BE Fowler, BA TI Modeling of Sensitive Subpopulations and Interindividual Variability in Pharmacokinetics for Health Risk Assessments SO COMPUTATIONAL TOXICOLOGY: METHODS AND APPLICATIONS FOR RISK ASSESSMENT LA English DT Article; Book Chapter ID INTRASPECIES UNCERTAINTY FACTOR; VOLATILE ORGANIC-COMPOUNDS; HUMAN-LIVER; CANCER-RISK; CARDIAC-OUTPUT; PBPK MODELS; BLOOD-FLOW; ENVIRONMENTAL TOXICANTS; TOXICOKINETIC MODELS; PRENATAL EXPOSURE C1 [Krishnan, Kannan] Univ Montreal, Montreal, PQ, Canada. [McPhail, Brooks] ATSDR CDC, DTHHS ETB, Atlanta, GA USA. [Krishnan, Kannan; Chiu, Weihsueh] US EPA, Natl Ctr Environm Assessment, Washington, DC 20460 USA. RP Krishnan, K (reprint author), Univ Montreal, Montreal, PQ, Canada. NR 95 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-12-396508-0 PY 2013 BP 45 EP 66 PG 22 WC Mathematical & Computational Biology; Toxicology SC Mathematical & Computational Biology; Toxicology GA BFR29 UT WOS:000321041500005 ER PT J AU O'Hegarty, M Pederson, LL Asman, KJ Malarcher, AM Kruger, J AF O'Hegarty, Michelle Pederson, Linda L. Asman, Katherine J. Malarcher, Ann M. Kruger, Judy TI Reactions of Adult Smokers and Former Smokers to Current US Warning Labels SO AMERICAN JOURNAL OF HEALTH BEHAVIOR LA English DT Article ID CIGARETTE PACKAGES AB Objective: To assess current and former smokers' reactions to US warning labels as a baseline for comparison to new labels. Methods: The mail-in Consumer-Styles survey was sent to a representative sample of US adult consumers in 2010 (N = 10,328). Results: Among current smokers, 51.5% (95% CI: 47.5-55.5) reported that they had 'never/rarely' seen or looked closely at the labels in the past 30 days. Current smokers (91.1%) reported that warning labels never stopped them from having a cigarette (95% CI: 89.1-93.1) and that the labels had no effect on their likelihood of quitting (75.5%; 95% CI: 71.6-79.4). Conclusions: Current warning labels do not make smokers think about the risks of smoking or have an effect on their likelihood of forgoing cigarettes or quitting. C1 [O'Hegarty, Michelle; Malarcher, Ann M.; Kruger, Judy] Ctr Dis Control & Prevent, Atlanta, GA USA. [Pederson, Linda L.; Asman, Katherine J.] Res Triangle Inst Int, Atlanta, GA USA. RP O'Hegarty, M (reprint author), Ctr Dis Control & Prevent, Atlanta, GA USA. EM mohegarty@cdc.gov NR 13 TC 1 Z9 1 U1 1 U2 2 PU PNG PUBLICATIONS PI OAK RIDGE PA 2205-K OAK RIDGE RD, #115, OAK RIDGE, NC 27310 USA SN 1945-7359 J9 AM J HEALTH BEHAV JI Am. J. Health Behav. PY 2013 VL 37 IS 5 BP 654 EP 659 DI 10.5993/AJHB.37.5.9 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 175FW UT WOS:000321217300009 PM 23985288 ER PT J AU Suzuki, R Krahn, G Small, E Peterson-Besse, J AF Suzuki, Rie Krahn, Gloria Small, Eusebius Peterson-Besse, Jana TI Multi-level Barriers to Obtaining Mammograms for Women with Mobility Limitations: Post Workshop Evaluation SO AMERICAN JOURNAL OF HEALTH BEHAVIOR LA English DT Article DE mammogram; disability; health promotion; intervention; qualitative analysis ID HEALTH-CARE ACCESS; BREAST-CANCER; PHYSICAL-DISABILITIES; PREVENTIVE SERVICES; IMPAIRMENTS; DIAGNOSIS AB Objectives: To assess the barriers and facilitators to mammogram use in middle aged women with mobility limitations who had completed an educational workshop, Promoting Access to Health Service (PATHS), on clinical preventive services. Methods: Women aged 40 to 64 with mobility impairments who reported not receiving a mammogram in the last 2 years were randomly assigned to a PATHS workshop and received follow-up monthly phone call interviews over 6 months. Results: Individual (eg, comorbidities, family responsibilities), interpersonal (eg, unclear provider communication, negative history), and environmental (eg, healthcare availability, insurance coverage, finances) factors were identified as unsolved barriers and potential facilitators (eg, reminders, physical proximity), to obtaining a mammogram. Conclusions: A multi-level intervention approach is required to promote mammogram use by women with disabilities. C1 [Suzuki, Rie] Univ Michigan, Dept Publ Hlth & Hlth Sci, Flint, MI 48503 USA. [Krahn, Gloria] Ctr Dis Control & Prevent, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Small, Eusebius] Univ Texas Arlington, Sch Social Work, Arlington, TX 76019 USA. [Peterson-Besse, Jana] Univ Pacific, Forest Grove, OR USA. RP Suzuki, R (reprint author), Univ Michigan, Dept Publ Hlth & Hlth Sci, Flint, MI 48503 USA. EM rsuzuki@umflint.edu NR 31 TC 3 Z9 3 U1 1 U2 4 PU PNG PUBLICATIONS PI OAK RIDGE PA 2205-K OAK RIDGE RD, #115, OAK RIDGE, NC 27310 USA SN 1945-7359 J9 AM J HEALTH BEHAV JI Am. J. Health Behav. PY 2013 VL 37 IS 5 BP 711 EP 718 DI 10.5993/AJHB.37.5.15 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 175FW UT WOS:000321217300015 PM 23985294 ER PT J AU Fekedulegn, D Burchfiel, CM Hartley, TA Andrew, ME Charles, LE Tinney-Zara, CA Violanti, JM AF Fekedulegn, Desta Burchfiel, Cecil M. Hartley, Tara A. Andrew, Michael E. Charles, Luenda E. Tinney-Zara, Cathy A. Violanti, John M. TI Shiftwork and Sickness Absence Among Police Officers: The BCOPS Study SO CHRONOBIOLOGY INTERNATIONAL LA English DT Article DE BMI; police officers; shiftwork; sick leave; ungrouped poisson regression ID RISK-FACTORS; METABOLIC SYNDROME; WORK FACTORS; LEAVE; EMPLOYEES; SLEEP; ASSOCIATION; POPULATION; PREDICTORS; REFERENT AB Shiftwork, regarded as a significant occupational stressor, has become increasingly prevalent across a wide range of occupations. The adverse health outcomes associated with shiftwork are well documented. Shiftwork is an integral part of law enforcement, a high-stress occupation with elevated risks of chronic disease and mortality. Sickness absence is an important source of productivity loss and may also serve as an indirect measure of workers' morbidity. Prior studies of shiftwork and sickness absenteeism have yielded varying results and the association has not been examined specifically among police officers. The objective of this study was to compare the incidence rate of sick leave (any, >= 3 consecutive days) among day-, afternoon-, and night-shift workers in a cohort of police officers and also examine the role of lifestyle factors as potential moderators of the association. Participants (N = 464) from the Buffalo Cardio-Metabolic Occupational Police Stress (BCOPS) study examined between 2004 and 2009 were used. Daily work history records that included the shift schedule, number of hours worked, and occurrence of sick leave were available for up to 15 yrs starting in 1994 to the date of the BCOPS study examination for each officer. Poisson regression analysis for ungrouped data was used to estimate incidence rates (IRs) of sick leave by shift, and comparison of IRs across shifts were made by computing incidence rate ratios (IRRs) and their 95% confidence intervals (CIs). Sick leave occurred at a higher rate on the night shift (4.37 per 10 000 person-hours) compared with either day (1.55 per 10 000 person-hours) or afternoon (1.96 per 10 000 person-hours) shifts. The association between shiftwork and sickness absence depended on body mass index (BMI). For overweight individuals (BMI >= 25 kg/m(2)), the covariate-adjusted incidence rate of sick leave (>= 1 day) was twice as large for night-shift officers compared with those working on the day (IRR = 2.29, 95% CI: 1.69-3.10) or afternoon (IRR = 1.74, 95% CI: 1.29-2.34) shift. The IR of three or more consecutive days of sick leave was 1.7 times larger for those working on night shift (IRR = 1.65, 95% CI: 1.17-2.31) and 1.5 times larger for those working on afternoon shift (IRR = 1.50, 95% CI: 1.08-2.08) compared with day shiftworkers. For subjects with normal BMI (<25 kg/m(2)), the incidence rates of sick leave did not differ significantly across shifts. In conclusion, shiftwork is independently associated with sickness absence, with officers who work the night shift having elevated incidence of sick leave. In addition, overweight officers who work the night shift may be at additional risk for sickness absence. C1 [Fekedulegn, Desta; Burchfiel, Cecil M.; Hartley, Tara A.; Andrew, Michael E.; Charles, Luenda E.; Tinney-Zara, Cathy A.] NIOSH, Biostat & Epidemiol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Violanti, John M.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Social & Prevent Med, Buffalo, NY 14260 USA. RP Fekedulegn, D (reprint author), NIOSH, HELD BEB, MS L-4050,1095 Willowdale Rd, Morgantown, WV 26505 USA. EM djf7@cdc.gov OI Tinney-Zara, Cathy/0000-0002-6529-9619 FU National Institute for Occupational Safety and Health (NIOSH) [200-2003-01580] FX This work was supported by the National Institute for Occupational Safety and Health (NIOSH), contract no. 200-2003-01580. The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health. NR 48 TC 6 Z9 6 U1 2 U2 19 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0742-0528 J9 CHRONOBIOL INT JI Chronobiol. Int. PY 2013 VL 30 IS 7 BP 930 EP 941 DI 10.3109/07420528.2013.790043 PG 12 WC Biology; Physiology SC Life Sciences & Biomedicine - Other Topics; Physiology GA 176CL UT WOS:000321280700008 PM 23808812 ER PT J AU Lopez, LM Grimes, DA Gallo, MF Stockton, LL Schulz, KF AF Lopez, Laureen M. Grimes, David A. Gallo, Maria F. Stockton, Laurie L. Schulz, Kenneth F. TI Skin patch and vaginal ring versus combined oral contraceptives for contraception SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review DE Contraceptive Devices, Female [adverse effects]; Drug Implants [adverse effects]; Consumer Satisfaction; Contraceptive Agents, Female [administration & dosage; adverse effects]; Contraceptives, Oral, Combined [administration & dosage; adverse effects]; Randomized Controlled Trials as Topic; Female; Humans; Pregnancy ID RANDOMIZED-CONTROLLED-TRIAL; 30 MU-G; COMBINED HORMONAL CONTRACEPTIVES; PHASE-3 CLINICAL-TRIAL; CYCLE CONTROL; ETHINYL ESTRADIOL; VENOUS THROMBOEMBOLISM; HEMOSTASIS VARIABLES; HEPATIC PROTEINS; EFFICACY AB Background The delivery of combination contraceptive steroids from a transdermal contraceptive patch or a contraceptive vaginal ring offers potential advantages over the traditional oral route. The transdermal patch and vaginal ring could require a lower dose due to increased bioavailability and improved user compliance. Objectives To compare the contraceptive effectiveness, cycle control, compliance (adherence), and safety of the contraceptive patch or the vaginal ring versus combination oral contraceptives (COCs). Search methods Through February 2013, we searched MEDLINE, POPLINE, CENTRAL, LILACS, ClinicalTrials.gov, and ICTRP for trials of the contraceptive patch or the vaginal ring. Earlier searches also included EMBASE. For the initial review, we contacted known researchers and manufacturers to identify other trials. Selection criteria We considered randomized controlled trials comparing a transdermal contraceptive patch or a contraceptive vaginal ring with a COC. Data collection and analysis Data were abstracted by two authors and entered into RevMan. For dichotomous variables, the Peto odds ratio (OR) with 95% confidence intervals (CI) was calculated. For continuous variables, the mean difference was computed. We also assessed the quality of evidence for this review. Main results We found 18 trials that met our inclusion criteria. Of six patch studies, five examined the marketed patch containing norelgestromin plus ethinyl estradiol (EE); one studied a patch in development that contains levonorgestrel (LNG) plus EE. Of 12 vaginal ring trials, 11 examined the same marketing ring containing etonogestrel plus EE; one studied a ring being developed that contains nesterone plus EE. Contraceptive effectiveness was not significantly different for the patch or ring versus the comparison COC. Compliance data were limited. Patch users showed better compliance than COC users in three trials. For the norelgestromin plus EE patch, ORs were 2.05 (95% CI 1.83 to 2.29) and 2.76 (95% CI 2.35 to 3.24). In the levonorgestrel plus EE patch report, patch users were less likely to have missed days of therapy (OR 0.36; 95% CI 0.25 to 0.51). Of four vaginal ring trials, one found ring users had more noncompliance (OR 3.99; 95% CI 1.87 to 8.52), while another showed more compliance with the regimen (OR 1.67; 95% CI 1.04 to 2.68). More patch users discontinued early than COC users. ORs from two meta-analyses were 1.59 (95% CI 1.26 to 2.00) and 1.56 (95% CI 1.18 to 2.06) and another trial showed OR 2.57 (95% CI 0.99 to 6.64). Patch users also had more discontinuation due to adverse events than COC users. Users of the norelgestromin-containing patch reported more breast discomfort, dysmenorrhea, nausea, and vomiting. In the levonorgestrel-containing patch trial, patch users reported less vomiting, headaches, and fatigue. Of 11 ring trials with discontinuation data, two showed the ring group discontinued less than the COC group: OR 0.32 (95% CI 0.16 to 0.66) and OR 0.52 (95% CI 0.31 to 0.88). Ring users were less likely to discontinue due to adverse events in one study (OR 0.32; 95% CI 0.15 to 0.70). Compared to the COC users, ring users had more vaginitis and leukorrhea but less vaginal dryness. Ring users also reported less nausea, acne, irritability, depression, and emotional lability than COC users. For cycle control, only one trial study showed a significant difference. Women in the patch group were less likely to have breakthrough bleeding and spotting. Seven ring studies had bleeding data; four trials showed the ring group generally had better cycle control than the COC group. Authors' conclusions Effectiveness was not significantly different for the methods compared. Pregnancy data were available from half of the patch trials but two-thirds of ring trials. The patch could lead to more discontinuation than the COC. The patch group had better compliance than the COC group. Compliance data came from half of the patch studies and one-third of the ring trials. Patch users had more side effects than the COC group. Ring users generally had fewer adverse events than COC users but more vaginal irritation and discharge. The quality of the evidence for this review was considered low for the patch and moderate for the ring. The main reasons for downgrading were lack of information on the randomization sequence generation or allocation concealment, the outcome assessment methods, high losses to follow up, and exclusions after randomization. C1 [Lopez, Laureen M.] FHI 360, Clin Sci, Res Triangle Pk, NC 27709 USA. [Grimes, David A.] Univ N Carolina, Sch Med, Chapel Hill, NC USA. [Gallo, Maria F.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. [Stockton, Laurie L.] FHI360, Hlth Serv Res, Res Triangle Pk, NC USA. [Schulz, Kenneth F.] FHI 360, Quantitat Sci, Res Triangle Pk, NC 27709 USA. [Schulz, Kenneth F.] UNC Sch Med, Res Triangle Pk, NC USA. RP Lopez, LM (reprint author), FHI 360, Clin Sci, POB 13950, Res Triangle Pk, NC 27709 USA. EM llopez@fhi360.org FU National Institute of Child Health and Human Development, USA; U.S. Agency for International Development, USA FX External sources; National Institute of Child Health and Human Development, USA.; For conducting the review: LML (2007 to 2013); DAG (2001 to 2010); MFG (2001 to 2002); LLS (2012); KFS (2001 to 2010); U.S. Agency for International Development, USA.; For conducting the review: LML (2007 to 2013); DAG (2001 to 2010); MFG (2001 to 2002); LLS (2012); KFS (2001 to 2010) NR 81 TC 6 Z9 6 U1 2 U2 16 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1469-493X J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2013 IS 4 AR CD003552 DI 10.1002/14651858.CD003552.pub4 PG 148 WC Medicine, General & Internal SC General & Internal Medicine GA 167SJ UT WOS:000320654400011 PM 23633314 ER PT J AU Wilhelmi, O de Sherbinin, A Hayden, M AF Wilhelmi, Olga de Sherbinin, Alex Hayden, Mary BE King, B Crews, KA TI Exposure to heat stress in urban environments SO ECOLOGIES AND POLITICS OF HEALTH SE Routledge Studies in Human Geography LA English DT Article; Book Chapter ID WATCH-WARNING SYSTEM; 9 FRENCH CITIES; CLIMATE-CHANGE; EXTREME HEAT; US CITIES; ADAPTIVE CAPACITY; HUMAN MORTALITY; PUBLIC-HEALTH; UNITED-STATES; WAVE C1 [Wilhelmi, Olga] Natl Ctr Atmospher Res, Boulder, CO 80307 USA. [de Sherbinin, Alex] Columbia Univ, CIESIN, Earth Inst, New York, NY 10027 USA. [Hayden, Mary] Natl Ctr Atmospher Res, Res Applicat Lab, Integrated Sci Program, Boulder, CO 80307 USA. [Hayden, Mary] Univ Colorado, Sch Publ Hlth, Boulder, CO 80309 USA. [Hayden, Mary] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. RP Wilhelmi, O (reprint author), Natl Ctr Atmospher Res, POB 3000, Boulder, CO 80307 USA. OI de Sherbinin, Alex/0000-0002-8875-4864 NR 93 TC 1 Z9 1 U1 1 U2 4 PU TAYLOR & FRANCIS LTD PI LONDON PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND BN 978-1-136-29553-9 J9 ROUTL STUD HUM GEOGR PY 2013 VL 41 BP 219 EP 238 PG 20 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA BFN81 UT WOS:000320653500013 ER PT S AU Tamin, A Rota, PA AF Tamin, A. Rota, P. A. BE Roth, JA Richt, JA Morozov, IA TI Current Status of Diagnostic Methods for Henipavirus SO VACCINES AND DIAGNOSTICS FOR TRANSBOUNDARY ANIMAL DISEASES SE Developments in Biologicals LA English DT Proceedings Paper CT Workshop on Vaccines and Diagnostics for Transboundary Animal Diseases CY SEP 17-19, 2012 CL Ames, IA SP US Dept Homeland Secur Sci & Technol Directorate, Kansas State Univ, Coll Vet Med, DHS Ctr Excellence Emerg & Zoonot Anim Dis, Iowa State Univ, Coll Vet Med, Ctr Food Secur & Publ Hlth, Inst Int Cooperat Anim Biol, Benchmark Biolabs, Boehringer Ingelheim Vetmedica Inc, Pfizer Animal Hlth, Merial Ltd, World Org Anim Hlth, Int Alliance Biol Standardizat DE Henipavirus; diagnostic; Nipah virus; Hendra virus; zoonotic diseases ID NIPAH VIRUS; HENDRA; ASSAY; ANTIBODIES; TAQMAN; CELLS AB Hendra virus (Hey) and Nipah virus (NiV) are the causative agents of emerging transboundary animal disease in pigs and horses. They also cause fatal disease in humans. NiV has a case fatality rate of 40 - 100%. In the initial NiV outbreak in Malaysia in 1999, about 1.1 million pigs had to be culled. The economic impact was estimated to be approximately US$450 million. Worldwide, HeV has caused more than 60 deaths in horses with 7 human cases and 4 deaths. Since the initial outbreak, HeV spillovers from Pteropus bats to horses and humans continue. This article presents a brief review on the currently available diagnostic methods for henipavirus infections, including advances achieved since the initial outbreak, and a gap analysis of areas needing improvement. C1 [Tamin, A.] Ctr Dis Control & Prevent, Measles Mumps Rubella & Herpes Viruses Branch, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Tamin, A (reprint author), Ctr Dis Control & Prevent, Measles Mumps Rubella & Herpes Viruses Branch, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, MS C-22, Atlanta, GA 30333 USA. EM atamin@cdc.gov NR 20 TC 1 Z9 1 U1 1 U2 11 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 1424-6074 BN 978-3-318-02365-7 J9 DEV BIOLOGICALS JI Dev. Biols PY 2013 VL 135 BP 139 EP 145 PG 7 WC Veterinary Sciences SC Veterinary Sciences GA BFV96 UT WOS:000321592800014 PM 23689891 ER PT J AU Rhodes, SD Martinez, O Song, EY Daniel, J Alonzo, J Eng, E Duck, S Downs, M Bloom, FR Allen, AB Miller, C Reboussin, B AF Rhodes, Scott D. Martinez, Omar Song, Eun-Young Daniel, Jason Alonzo, Jorge Eng, Eugenia Duck, Stacy Downs, Mario Bloom, Fred R. Allen, Alex Boeving Miller, Cindy Reboussin, Beth TI Depressive Symptoms Among Immigrant Latino Sexual Minorities SO AMERICAN JOURNAL OF HEALTH BEHAVIOR LA English DT Article DE Hispanic; Latino; MSM; gay; community-based participatory research; CBPR; respondent-driven sampling; prevalence; depression; homophobia; social support ID SUBSTANCE USE DISORDERS; SOUTH-EASTERN USA; MENTAL-HEALTH; PERCEIVED DISCRIMINATION; UNITED-STATES; BISEXUAL MEN; SELF-ESTEEM; HIV RISK; PARTICIPATORY RESEARCH; PSYCHIATRIC-DISORDERS AB Objective: To estimate the prevalence and identify correlates of depressive symptoms among immigrant Latino sexual minorities. Methods: Respondent-driven sampling (RDS) was used to estimate the prevalence of depressive symptoms, and univariate and multivariable analyses were conducted to identify correlates of depressive symptoms. Results: Unweighted and RDS-weighted prevalence estimates of depressive symptoms were 69.2% and 74.8%, respectively. In the multivariable analysis, low social support, sexual compulsivity, and high self-esteem were significantly associated with increased depressive symptoms. Conclusions: A need exists for culturally congruent mental health services for immigrant Latino sexual minorities in the southern United States. C1 [Rhodes, Scott D.; Song, Eun-Young; Alonzo, Jorge; Downs, Mario; Miller, Cindy] Wake Forest Sch Med, Dept Social Sci & Hlth Policy, Winston Salem, NC 27106 USA. [Martinez, Omar] Columbia Univ, HIV Ctr Clin & Behav Studies, New York, NY USA. [Daniel, Jason] Univ Iowa, Coll Publ Hlth, Dept Community & Behav Hlth, Iowa City, IA USA. [Eng, Eugenia] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Behav & Hlth Educ, Chapel Hill, NC USA. [Duck, Stacy] Alliance AIDS Serv Carolina, Raleigh, NC USA. [Bloom, Fred R.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Allen, Alex Boeving] Wake Forest Sch Med, Dept Pediat, Winston Salem, NC USA. [Reboussin, Beth] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA. [Reboussin, Beth] Wake Forest Sch Med, Dept Social Sci & Hlth Policy, Winston Salem, NC USA. RP Rhodes, SD (reprint author), Wake Forest Sch Med, Dept Social Sci & Hlth Policy, Winston Salem, NC 27106 USA. EM srhodes@wakehealth.edu FU NICHD NIH HHS [R21 HD049282, R21HD049282]; NIMH NIH HHS [R01MH087339, R01 MH087339]; NIMHD NIH HHS [R24 MD002774] NR 69 TC 8 Z9 8 U1 3 U2 11 PU PNG PUBLICATIONS PI OAK RIDGE PA 2205-K OAK RIDGE RD, #115, OAK RIDGE, NC 27310 USA SN 1945-7359 J9 AM J HEALTH BEHAV JI Am. J. Health Behav. PY 2013 VL 37 IS 3 BP 404 EP 413 DI 10.5993/AJHB.37.3.13 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 175ES UT WOS:000321214000013 PM 23985187 ER PT J AU Park, S Blanck, HM Sherry, B Foti, K AF Park, Sohyun Blanck, Heidi M. Sherry, Bettylou Foti, Kathryn TI Problem Behavior, Victimization, and Soda Intake in High School Students SO AMERICAN JOURNAL OF HEALTH BEHAVIOR LA English DT Article DE soda; adolescents; problem behaviors; being victimized; YRBS ID SWEETENED BEVERAGE CONSUMPTION; UNITED-STATES; INDUCED ANALGESIA; FAMILY-HISTORY; SUBSTANCE USE; SOFT DRINKS; ADOLESCENTS; RISK; ADDICTION; CHILDREN AB Objective: To examine associations of problem behaviors and victimization with nondiet soda intake among a national sample of 16,188 US high school students. Methods: We used the 2009 national Youth Risk Behavior Survey. The outcome measure was daily nondiet soda intake. Results: Smoking, having any sex partners, not always wearing a seat belt, being bullied/threatened/injured on school property, and being physically hurt by their boyfriend/girl-friend were significantly associated with daily nondiet soda intake after adjustment for age, sex, race/ethnicity, and weight status. Conclusions: Our findings suggest a need to examine why nondiet soda intake is associated with these behaviors to understand potential mechanisms. C1 [Park, Sohyun; Blanck, Heidi M.; Sherry, Bettylou; Foti, Kathryn] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Park, S (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM spark3@cdc.gov FU Intramural CDC HHS [CC999999] NR 39 TC 5 Z9 5 U1 1 U2 8 PU PNG PUBLICATIONS PI OAK RIDGE PA 2205-K OAK RIDGE RD, #115, OAK RIDGE, NC 27310 USA SN 1945-7359 J9 AM J HEALTH BEHAV JI Am. J. Health Behav. PY 2013 VL 37 IS 3 BP 414 EP 421 DI 10.5993/AJHB.37.3.14 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 175ES UT WOS:000321214000014 PM 23985188 ER PT J AU Logan, JE Walsh, S Patel, N Hall, JE AF Logan, Joseph E. Walsh, Sabrina Patel, Nimeshkumar Hall, Jeffrey E. TI Homicide-Followed-by-Suicide Incidents Involving Child Victims SO AMERICAN JOURNAL OF HEALTH BEHAVIOR LA English DT Article DE homicide-suicide; children ID INTIMATE PARTNER VIOLENCE; DEATH REPORTING SYSTEM; PATERNAL FILICIDE; MURDER-SUICIDE; ALCOHOL-USE; PARENTS; ATTITUDES; FATHERS; SEEKING; FINLAND AB Objectives: To describe homicide-followed-by-suicide incidents involving child victims Methods: Using 2003-2009 National Violent Death Reporting System data, we characterized 129 incidents based on victim and perpetrator demographic information, their relationships, the weapons/mechanisms involved, and the perpetrators' health and stress-related circumstances. Results: These incidents accounted for 188 child deaths; 69% were under 11 years old, and 58% were killed with a firearm. Approximately 76% of perpetrators were males, and 75% were parents/caregivers. Eighty-one percent of incidents with paternal perpetrators and 59% with maternal perpetrators were preceded by parental discord. Fifty-two percent of incidents with maternal perpetrators were associated with maternal psychiatric problems. Conclusions: Strategies that resolve parental conflicts rationally and facilitate detection and treatment of parental mental conditions might help prevention efforts. C1 [Logan, Joseph E.; Patel, Nimeshkumar; Hall, Jeffrey E.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. [Walsh, Sabrina] Univ Kentucky, Lexington, KY USA. RP Logan, JE (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. EM ffa3@cdc.gov FU Intramural CDC HHS [CC999999] NR 30 TC 1 Z9 1 U1 0 U2 25 PU PNG PUBLICATIONS PI OAK RIDGE PA 2205-K OAK RIDGE RD, #115, OAK RIDGE, NC 27310 USA SN 1945-7359 J9 AM J HEALTH BEHAV JI Am. J. Health Behav. PY 2013 VL 37 IS 4 BP 531 EP 542 DI 10.5993/AJHB.37.4.11 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 175FB UT WOS:000321215200011 PM 23985234 ER PT J AU Noll, J Janisko, S Mischler, SE AF Noll, James Janisko, Samuel Mischler, Steven E. TI Real-time diesel particulate monitor for underground mines SO ANALYTICAL METHODS LA English DT Article ID LIGHT-ABSORPTION MEASUREMENTS; BLACK CARBON; AMBIENT MEASUREMENTS; LUNG-CANCER; EXHAUST; DUST; OVEREXPOSURE; CALIBRATION; MORTALITY; AEROSOLS AB The standard method for determining diesel particulate matter (DPM) exposures in underground metal/nonmetal mines provides the average exposure concentration for an entire working shift, and several weeks might pass before results are obtained. The main problem with this approach is that it only indicates that an overexposure has occurred rather than providing the ability to prevent an overexposure or detect its cause. Conversely, real-time measurement would provide miners with timely information to allow engineering controls to be deployed immediately and to identify the major factors contributing to any overexposures. Toward this purpose, the National Institute for Occupational Safety and Health (NIOSH) developed a laser extinction method to measure real-time elemental carbon (EC) concentrations (EC is a DPM surrogate). To employ this method, NIOSH developed a person-wearable instrument that was commercialized in 2011. This paper evaluates this commercial instrument, including the calibration curve, limit of detection, accuracy, and potential interferences. The instrument was found to meet the NIOSH accuracy criteria and to be capable of measuring DPM concentrations at levels observed in underground mines. In addition, it was found that a submicron size selector was necessary to avoid interference from mine dust and that cigarette smoke can be an interference when sampling in enclosed cabs. C1 [Noll, James; Janisko, Samuel; Mischler, Steven E.] NIOSH, US Dept HHS, Publ Hlth Serv, Ctr Dis Control & Prevent,Pittsburgh Res Lab, Pittsburgh, PA 15236 USA. RP Noll, J (reprint author), NIOSH, US Dept HHS, Publ Hlth Serv, Ctr Dis Control & Prevent,Pittsburgh Res Lab, 626 Cochrans Mill Rd, Pittsburgh, PA 15236 USA. EM jnoll@cdc.gov; sjanisko@cdc.gov; smischler@cdc.gov NR 48 TC 5 Z9 5 U1 1 U2 17 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1759-9660 EI 1759-9679 J9 ANAL METHODS-UK JI Anal. Methods PY 2013 VL 5 IS 12 BP 2954 EP 2963 DI 10.1039/c3ay40083b PG 10 WC Chemistry, Analytical; Food Science & Technology; Spectroscopy SC Chemistry; Food Science & Technology; Spectroscopy GA 156JW UT WOS:000319819000008 ER PT S AU Galinski, MR Meyer, EVS Barnwell, JW AF Galinski, Mary R. Meyer, Esmeralda V. S. Barnwell, John W. BE Hay, SI Price, R Baird, JK TI Plasmodium vivax: Modern Strategies to Study a Persistent Parasite's Life Cycle SO ADVANCES IN PARASITOLOGY, VOL 81: EPIDEMIOLOGY OF PLASMODIUM VIVAX: HISTORY, HIATUS AND HUBRIS, PT B SE Advances in Parasitology LA English DT Review; Book Chapter ID SPOROZOITE TISSUE STAGES; HUMAN MALARIA PARASITE; CAVEOLA-VESICLE COMPLEXES; RED-BLOOD-CELLS; PRIMATE MALARIA; IN-VITRO; INFECTED ERYTHROCYTES; SIMIAN MALARIA; CYNOMOLGI-BASTIANELLII; EXOERYTHROCYTIC STAGES AB Plasmodium vivax has unique attributes to support its survival in varying ecologies and climates. These include hypnozoite forms in the liver, an invasion preference for reticulocytes, caveola-vesicle complex structures in the infected erythrocyte membrane and rapidly forming and circulating gametocytes. These characteristics make this species very different from P falciparum. Plasmodium cynomolgi and other related simian species have identical biology and can serve as informative models of P vivax infections. Plasmodium vivax and its model parasites can be grown in non-human primates (NHP), and in short-term ex vivo cultures. For P. vivax, in the absence of in vitro culture systems, these models remain highly relevant side by side with human clinical studies. While post-genomic technologies allow for greater exploration of P vivax-infected blood samples from humans, these come with restrictions. Two advantages of NHP models are that infections can be experimentally tailored to address hypotheses, including genetic manipulation. Also, systems biology approaches can capitalise on computational biology combined with set experimental infection periods and protocols, which may include multiple sampling times, different types of samples, and the broad use of "omics" technologies. Opportunities for research on vivax malaria are increasing with the use of existing and new methodological strategies in combination with modern technologies. C1 [Galinski, Mary R.; Barnwell, John W.] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA 30322 USA. [Galinski, Mary R.; Meyer, Esmeralda V. S.] Yerkes Natl Primate Res Ctr, Emory Vaccine Ctr, Atlanta, GA USA. [Barnwell, John W.] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Atlanta, GA USA. RP Galinski, MR (reprint author), Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA 30322 USA. EM Mary.Galinski@emory.edu FU NCRR NIH HHS [P51RR000165]; NIAID NIH HHS [R01AI24710]; NIH HHS [P51OD011132]; PHS HHS [HHSN272201200031C] NR 130 TC 21 Z9 21 U1 5 U2 21 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0065-308X BN 978-0-12-407826-0 J9 ADV PARASIT JI Adv.Parasitol. PY 2013 VL 81 BP 1 EP 26 DI 10.1016/B978-0-12-407826-0.00001-1 PG 26 WC Parasitology SC Parasitology GA BEV58 UT WOS:000318315900002 PM 23384620 ER PT S AU Mueller, I Galinski, MR Tsuboi, T Arevalo-Herrera, M Collins, WE King, CL AF Mueller, Ivo Galinski, Mary R. Tsuboi, Takafumi Arevalo-Herrera, Myriam Collins, William E. King, Christopher L. BE Hay, SI Price, R Baird, JK TI Natural Acquisition of Immunity to Plasmodium vivax: Epidemiological Observations and Potential Targets SO ADVANCES IN PARASITOLOGY, VOL 81: EPIDEMIOLOGY OF PLASMODIUM VIVAX: HISTORY, HIATUS AND HUBRIS, PT B SE Advances in Parasitology LA English DT Review; Book Chapter ID DUFFY-BINDING-PROTEIN; MEROZOITE SURFACE PROTEIN-1; TRANSMISSION-BLOCKING IMMUNITY; APICAL MEMBRANE ANTIGEN-1; NEW-GUINEAN CHILDREN; FALCIPARUM-INFECTED ERYTHROCYTES; MALARIA-ENDEMIC AREA; PAPUA-NEW-GUINEA; TROPHOZOITE-INDUCED INFECTIONS; CAVEOLA-VESICLE COMPLEXES AB Population studies show that individuals acquire immunity to Plasmodium vivax more quickly than Plasmodium falciparum irrespective of overall transmission intensity, resulting in the peak burden of P.vivax malaria in younger age groups. Similarly, actively induced P vivax infections in malaria therapy patients resulted in faster and generally more strain-transcending acquisition of immunity than P falciparum infections. The mechanisms behind the more rapid acquisition of immunity to P vivax are poorly understood. Natural acquired immune responses to P vivax target both pre-erythrocytic and blood-stage antigens and include humoral and cellular components. To date, only a few studies have investigated the association of these immune responses with protection, with most studies focussing on a few merozoite antigens (such as the Pv Duffy binding protein (PvDBP), the Pv reticulocyte binding proteins (PvRBPs), or the Pv merozoite surface proteins (PvMSP1, 3 & 9)) or the circumsporozoite protein (PvCSP). Naturally acquired transmission-blocking (TB) immunity (TBI) was also found in several populations. Although limited, these data support the premise that developing a multi-stage P vivax vaccine may be feasible and is worth pursuing. C1 [Mueller, Ivo] Walter Eliza Hall Inst, Infect & Immun Div, Parkville, Vic, Australia. [Mueller, Ivo] Univ Barcelona, Barcelona Ctr Int Hlth Res CRESIB, Hosp Clin, Barcelona, Spain. [Galinski, Mary R.] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA 30322 USA. [Galinski, Mary R.] Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA. [Galinski, Mary R.] Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA 30322 USA. [Tsuboi, Takafumi] Ehime Univ, Cell Free Sci & Technol Res Ctr, Matsuyama, Ehime, Japan. [Tsuboi, Takafumi] Ehime Univ, Venture Business Lab, Matsuyama, Ehime, Japan. [Arevalo-Herrera, Myriam] Caucaseco Res Ctr, Cali, Colombia. [Collins, William E.] Ctr Dis Control & Prevent, Inst Assoc, Malaria Branch, Div Parasit Dis, Atlanta, GA USA. [King, Christopher L.] Case Western Reserve Univ, Vet Affairs Med Ctr, CGHD, Cleveland, OH 44106 USA. RP Mueller, I (reprint author), Walter Eliza Hall Inst, Infect & Immun Div, Parkville, Vic, Australia. NR 347 TC 26 Z9 26 U1 3 U2 12 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0065-308X BN 978-0-12-407826-0 J9 ADV PARASIT JI Adv.Parasitol. PY 2013 VL 81 BP 77 EP 131 DI 10.1016/B978-0-12-407826-0.00003-5 PG 55 WC Parasitology SC Parasitology GA BEV58 UT WOS:000318315900004 PM 23384622 ER PT J AU Hamner, HC Tinker, SC Berry, RJ Mulinare, J AF Hamner, Heather C. Tinker, Sarah C. Berry, R. J. Mulinare, Joe TI Modeling fortification of corn masa flour with folic acid: the potential impact on exceeding the tolerable upper intake level for folic acid, NHANES 2001-2008 SO FOOD & NUTRITION RESEARCH LA English DT Article DE Folic acid; fortification; corn masa flour; tolerable upper intake level ID NEURAL-TUBE DEFECTS; NUTRITION EXAMINATION SURVEY; UNITED-STATES; INTAKE DISTRIBUTIONS; NATIONAL-HEALTH; SPINA-BIFIDA; PREVENTION; PREVALENCE; FOLATE; CHILDREN AB Background: The Institute of Medicine set a tolerable upper intake level (UL) for usual daily total folic acid intake (1,000 mu g). Less than 3% of US adults currently exceed the UL. Objective: The objective of this study was to determine if folic acid fortification of corn masa flour would increase the percentage of the US population who exceed the UL. Design: We used dietary intake data from NHANES 2001-2008 to estimate the percentage of adults and children who would exceed the UL if corn masa flour were fortified at 140 mu g of folic acid/100 g. Results: In 2001-2008, 2.5% of the US adult population (aged >= 19 years) exceeded the UL, which could increase to 2.6% if fortification of corn masa flour occurred. With corn masa flour fortification, percentage point increases were small and not statistically significant for US adults exceeding the UL regardless of supplement use, sex, race/ethnicity, or age. Children aged 1-8 years, specifically supplement users, were the most likely to exceed their age-specific UL. With fortification of corn masa flour, there were no statistically significant increases in the percentage of US children who were exceeding their age-specific UL, and the percentage point increases were small. Conclusions: Our results suggest that fortification of corn masa flour would not significantly increase the percentage of individuals who would exceed the UL. Supplement use was the main factor related to exceeding the UL with or without fortification of corn masa flour and within all strata of sex, race/ethnicity, and age group. C1 [Hamner, Heather C.; Tinker, Sarah C.; Berry, R. J.; Mulinare, Joe] Ctr Dis Control & Prevent CDC, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Hamner, HC (reprint author), Ctr Dis Control & Prevent CDC, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,Mail Stop E-86, Atlanta, GA 30333 USA. EM hfc2@cdc.gov OI Berry, Robert/0000-0002-7162-5046 NR 39 TC 0 Z9 0 U1 2 U2 7 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1654-6628 J9 FOOD NUTR RES JI Food Nutr. Res. PY 2013 VL 57 AR 57 DI 10.3402/fnr.v57i0.19146 PG 13 WC Food Science & Technology; Nutrition & Dietetics SC Food Science & Technology; Nutrition & Dietetics GA 148QL UT WOS:000319261000001 ER PT J AU Liu, X Qi, Q Xiao, G Li, JY Luo, HBR Ye, KQ AF Liu, Xia Qi, Qi Xiao, Ge Li, Jingyu Luo, Hongbo R. Ye, Keqiang TI O-Methylated Metabolite of 7,8-Dihydroxyflavone Activates TrkB Receptor and Displays Antidepressant Activity SO PHARMACOLOGY LA English DT Article DE TrkB agonist; Brain-derived neurotrophic factor; Synthetic derivatives; Antidepressant; Neurogenesis ID ADULT HIPPOCAMPAL NEUROGENESIS; TAIL SUSPENSION TEST; SIGNAL-TRANSDUCTION; BDNF; METHYLTRANSFERASE; INHIBITORS; POTENT; BRAIN; RAT; DEPRESSION AB 7,8-Dihydroxyflavone (7,8-DHF) acts as a TrkB receptor-specific agonist. It mimics the physiological actions of brain-derived neurotrophic factor (BDNF) and demonstrates remarkable therapeutic efficacy in animal models of various neurological diseases. Nonetheless, its in vivo pharmacokinetic profiles and metabolism remain unclear. Here we report that 7,8-DHF and its O-methylated metabolites distribute in mouse brain after oral administration. Both hydroxy groups can be mono-methylated, and the mono-methylated metabolites activate TrkB in vitro and in vivo. Blocking methylation, using COMT inhibitors, diminishes the agonistic effect of TrkB activation by 7,8-DHF or 4'-dimethylamino-7,8-DHF, supporting the contribution of the methylated metabolite to TrkB activation in mouse brain. Moreover, we have synthesized several methylated metabolite derivatives, and they also potently activate the TrkB receptor and reduce immobility in both forced swim test and tail suspension test, indicating that these methylated metabolites may possess antidepressant activity. Hence, our data demonstrate that 7,8-DHF is orally bioavailable and can penetrate the brain-blood barrier. The O-methylated metabolites are implicated in TrkB receptor activation in the brain. Copyright (C) 2013 S. Karger AG, Basel C1 [Liu, Xia; Qi, Qi; Ye, Keqiang] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA. [Xiao, Ge] Ctr Dis Control & Prevent, Atlanta, GA USA. [Li, Jingyu; Luo, Hongbo R.] Harvard Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA USA. [Li, Jingyu; Luo, Hongbo R.] Childrens Hosp, Boston, MA 02115 USA. RP Ye, KQ (reprint author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA. EM kye@emory.edu RI Qi, Qi/J-3508-2013 OI Qi, Qi/0000-0003-4460-0713 FU National Institute of Health [RO1 DC010204] FX This work was supported by grants from the National Institute of Health RO1 DC010204 to K. Ye. The authors are grateful to Dr. Obianyo in the lab of Dr. Ye and to Dr. Harish Joshi for critically reading the manuscript. NR 30 TC 14 Z9 14 U1 3 U2 8 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0031-7012 J9 PHARMACOLOGY JI Pharmacology PY 2013 VL 91 IS 3-4 BP 185 EP 200 DI 10.1159/000346920 PG 16 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 146JD UT WOS:000319086500010 PM 23445871 ER PT J AU Prosser, LA Payne, K Rusinak, D Shi, P Messonnier, M AF Prosser, Lisa A. Payne, Katherine Rusinak, Donna Shi, Ping Messonnier, Mark TI Using a Discrete Choice Experiment to Elicit Time Trade-Off and Willingness-to-Pay Amounts for Influenza Health-Related Quality of Life at Different Ages SO PHARMACOECONOMICS LA English DT Article ID CONTINGENT VALUATION; CONJOINT-ANALYSIS; DECISION-MAKING; COST-UTILITY; PREFERENCES; VALUES; CHILDREN; STATES AB Background Recent research suggests that values for health-related quality of life may vary with the age of the patient. Traditional health state valuation questions and discrete choice experiments are two approaches that could be used to value health. Objective To measure whether public values for health vary with the age of the affected individual. Methods A discrete choice experiment was administered via the Internet in December 2007 to measure preferences for different attributes of influenza-related health-related quality of life: age of hypothetical affected individual (range 1-85 years), length of episode (days of illness), severity of illness (workdays lost) and time trade-off or willingness-to-pay amounts. Each respondent answered identical choice questions for a hypothetical family member and for himself/herself. Data on sociodemographic characteristics and influenza illness experience were also collected. Respondents were US adults randomly sampled from an Internet survey panel (n = 1,012). The relative value of attributes was estimated using generalized estimating equations and controlling for sociodemographic characteristics and illness experience. Marginal time traded and marginal willingness to pay using discrete choice and traditional time trade-off or willingness-to-pay questions were compared. Results Respondents preferred shorter influenza episodes but did not significantly prefer fewer workdays lost if episode length was held constant. Respondents were more likely to choose to avert uncomplicated illness in children and less likely to choose to avert uncomplicated illness in working-age adults. Marginal time trade-off and willingness-to-pay amounts elicited using discrete choice questions were larger than those elicited using direct valuation questions. Conclusions Approaches that assume values for health-related quality of life do not vary with the age of a patient may bias economic analyses that use these values. If patient age could affect valuations, then age should be included in the valuation exercise. Additional research should evaluate the effect of patient age on values for other conditions. C1 [Prosser, Lisa A.] Univ Michigan Hlth Syst, Dept Pediat & Communicable Dis, Child Hlth Evaluat & Res Unit, Div Gen Pediat, Ann Arbor, MI 48109 USA. [Prosser, Lisa A.; Rusinak, Donna; Shi, Ping] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA 02115 USA. [Prosser, Lisa A.; Rusinak, Donna; Shi, Ping] Harvard Univ, Pilgrim Hlth Care Inst, Boston, MA 02115 USA. [Payne, Katherine] Univ Manchester, Inst Populat Hlth, Manchester Ctr Hlth Econ, Manchester, Lancs, England. [Messonnier, Mark] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Prosser, LA (reprint author), Univ Michigan Hlth Syst, Dept Pediat & Communicable Dis, Child Hlth Evaluat & Res Unit, Div Gen Pediat, 300 N Ingalls St,Room 6E14,SPC 5456, Ann Arbor, MI 48109 USA. EM lisapros@med.umich.edu OI Payne, Katherine/0000-0002-3938-4350 FU Harvard-CDC Joint Initiative in Vaccine Economics; RCUK FX Funding for this project was provided from the Harvard-CDC Joint Initiative in Vaccine Economics. Dr. Payne was also funded in part by an RCUK academic fellowship. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the CDC. NR 27 TC 4 Z9 4 U1 0 U2 7 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 1170-7690 J9 PHARMACOECONOMICS JI Pharmacoeconomics PY 2013 VL 31 IS 4 BP 305 EP 315 DI 10.1007/s40273-013-0029-6 PG 11 WC Economics; Health Care Sciences & Services; Health Policy & Services; Pharmacology & Pharmacy SC Business & Economics; Health Care Sciences & Services; Pharmacology & Pharmacy GA 138TX UT WOS:000318534000005 PM 23512145 ER PT J AU Gray, J Dantas-Torres, F Estrada-Pena, A Levin, M AF Gray, Jeremy Dantas-Torres, Filipe Estrada-Pena, Agustin Levin, Michael TI Systematics and ecology of the brown dog tick, Rhipicephalus sanguineus SO TICKS AND TICK-BORNE DISEASES LA English DT Review DE Rhipicephalus sanguineus; Brown dog tick; Taxonomy; Ecology; Climate ID MEDITERRANEAN SPOTTED-FEVER; IXODES-RICINUS ACARI; DOMESTIC DOGS; RICKETTSIA-CONORII; SOUTH-AMERICA; SEASONAL DYNAMICS; MINAS-GERAIS; LIFE-CYCLES; GUINEA-PIGS; IXODIDAE AB Rhipicephalus sanguineus, the brown dog tick, kennel tick, or pan-tropical dog tick, is probably the most widespread ixodid tick, colonising both human and canine dwellings. It is of great significance in both human and veterinary medicine as a vector of several important pathogens and can also cause clinical illness in heavy infestations of dogs. However, there are still significant taxonomic uncertainties, and it is probable that some records of this tick refer to other species. Most past reviews have been broad-ranging or have focused on the pathogens that R. sanguineus transmits, and relatively few have considered its biology in detail or the issues around its true identity. The present review has paid most attention to the taxonomy of R. sanguineus and to the ecological factors that influence tick survival and distribution, particularly in a climate change context. It is evident that more research is required on the systematics of the R. sanguineus species complex, in order to elucidate the epidemiology and prevention of the diseases that it transmits, and to provide the relevant biological data required for development of predictive models of future tick distribution in a climate change scenario. (c) 2013 Elsevier GmbH. All rights reserved. C1 [Gray, Jeremy] Univ Coll Dublin, UCD Sch Biol & Environm Sci, Dublin 4, Ireland. [Dantas-Torres, Filipe] Fundacao Oswaldo Cruz, Aggeu Magalhaes Res Ctr, Dept Immunol, BR-50670420 Recife, PE, Brazil. [Dantas-Torres, Filipe] Univ Bari, Fac Vet Med, Dept Vet Med, I-70010 Valenzano, Italy. [Estrada-Pena, Agustin] Fac Vet, Dept Parasitol, Zaragoza 50013, Spain. [Levin, Michael] Ctr Dis Control & Prevent, Med Entomol Lab, Rickettsial Zoonoses Branch, DVBD, Atlanta, GA 30333 USA. RP Gray, J (reprint author), Univ Coll Dublin, UCD Sch Biol & Environm Sci, Dublin 4, Ireland. EM jeremy.gray@ucd.ie RI Dantas-Torres, Filipe/G-1617-2012; OI Estrada Pena, Agustin/0000-0001-7483-046X FU Ministry of Science and Technology of Spain; [AGL2009-10797] FX Parts of this work were supported by the project AGL2009-10797, funded by the Ministry of Science and Technology of Spain. NR 98 TC 42 Z9 46 U1 1 U2 29 PU ELSEVIER GMBH, URBAN & FISCHER VERLAG PI JENA PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY SN 1877-959X EI 1877-9603 J9 TICKS TICK-BORNE DIS JI Ticks Tick-Borne Dis. PY 2013 VL 4 IS 3 BP 171 EP 180 DI 10.1016/j.ttbdis.2012.12.003 PG 10 WC Infectious Diseases; Microbiology; Parasitology SC Infectious Diseases; Microbiology; Parasitology GA 136VN UT WOS:000318391600001 PM 23415851 ER PT J AU Manopaiboon, C Prybylski, D Subhachaturas, W Tanpradech, S Suksripanich, O Siangphoe, U Johnston, LG Akarasewi, P Anand, A Fox, KK Whitehead, SJ AF Manopaiboon, C. Prybylski, D. Subhachaturas, W. Tanpradech, S. Suksripanich, O. Siangphoe, U. Johnston, L. G. Akarasewi, P. Anand, A. Fox, K. K. Whitehead, S. J. TI Unexpectedly high HIV prevalence among female sex workers in Bangkok, Thailand in a respondent-driven sampling survey SO INTERNATIONAL JOURNAL OF STD & AIDS LA English DT Article DE female sex workers; HIV; prevalence; sexually transmitted infection; epidemiology; Asia ID HIDDEN POPULATIONS; RISK BEHAVIORS; SURVEILLANCE; INFECTION; VIRUS; MODEL AB The pattern of sex work in Thailand has shifted substantially over the last two decades from direct commercial establishments to indirect venues and non-venue-based settings. This respondent-driven sampling survey was conducted in Bangkok in 2007 among female sex workers (FSW) in non-venue-based settings to pilot a new approach to surveillance among this hidden population. Fifteen initial participants recruited 707 consenting participants who completed a behavioural questionnaire, and provided oral fluid for HIV testing, and urine for sexually transmitted infection (STI) testing. Overall HIV prevalence was 20.2% (95% confidence interval [CI] 16.3-24.7). Three-quarters of women were street-based (75.8%, 95% Cl 69.9-81.1) who had an especially high HIV prevalence (22.7%, 95% CI 18.2-28.4); about 10 times higher than that found in routine sentinel surveillance among venue-based FSW (2.5%). STI prevalence (Chlamydia trachomatis and Neisseria gonorrhoeae) was 8.7% (95% Cl 6.4-10.8) and 1.0% (95% Cl 0.2-1.9), respectively. Lower price per sex act and a current STI infection were independently associated with HIV infection (P < 0.05). High HIV prevalence found among FSW participating in the survey, particularly non-venue-based FSW, identifies need for further prevention efforts. In addition, it identifies a higher-risk segment of FSW not reached through routine sentinel surveillance but accessible through this survey method. C1 [Manopaiboon, C.; Prybylski, D.; Tanpradech, S.; Suksripanich, O.; Siangphoe, U.; Akarasewi, P.; Fox, K. K.; Whitehead, S. J.] Minist Publ Hlth, Thailand MOPH US CDC Collaborat, Thailand Asia Reg Off, Global AIDS Program, Nonthabhuri, Thailand. [Subhachaturas, W.] Bangkok Metropolitan Adm, Bangkok, Thailand. [Johnston, L. G.] Univ Calif San Francisco, Global Hlth Sci, San Francisco, CA 94143 USA. [Prybylski, D.; Anand, A.; Fox, K. K.; Whitehead, S. J.] US Ctr Dis Control & Prevent, Atlanta, GA USA. RP Manopaiboon, C (reprint author), Minist Publ Hlth, Thailand MOPH US CDC Collaborat, Thailand Asia Reg Off, Global AIDS Program, Nonthabhuri, Thailand. EM ChomnadM@th.cdc.gov FU Intramural CDC HHS [CC999999] NR 28 TC 10 Z9 10 U1 0 U2 4 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 0956-4624 J9 INT J STD AIDS JI Int. J. STD AIDS PD JAN PY 2013 VL 24 IS 1 BP 34 EP 38 DI 10.1177/0956462412472300 PG 5 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 134IJ UT WOS:000318203300005 PM 23512512 ER PT J AU Nahar, N Uddin, M Sarkar, RA Gurley, ES Khan, MSU Hossain, MJ Sultana, R Luby, SP AF Nahar, Nazmun Uddin, Main Sarkar, Rouha Anamika Gurley, Emily S. Khan, M. Salah Uddin Hossain, M. Jahangir Sultana, Rebeca Luby, Stephen P. TI Exploring pig raising in Bangladesh: implications for public health interventions SO VETERINARIA ITALIANA LA English DT Article DE Bangladesh; Discrimination; Pig-human interactions; Pig raisers; Public health; Social stigma; Zoonoses ID NEGLECTED TROPICAL DISEASES; QUALITY-OF-LIFE; NIPAH VIRUS; JAPANESE ENCEPHALITIS; INFECTIOUS-DISEASE; INFLUENZA-VIRUSES; FARMING COMMUNITY; PERCEIVED STIGMA; RURAL BANGLADESH; RISK-FACTORS AB Pigs are intermediate hosts and potential reservoirs of a number of pathogens that can infect humans. The objectives of this manuscript are to understand pig raising patterns in Bangladesh, interactions between pigs and humans, social stigma and discrimination that pig raisers experience and to explore the implications of these findings for public health interventions. The study team conducted an exploratory qualitative study by interviewing backyard pig raisers and nomadic herders (n = 34), observing daily interactions between pigs and humans (n = 18) and drawing seasonal diagrams (n = 6) with herders to understand the reasons for movement of nomadic herds. Pig raisers had regular close interaction with pigs. They often touched, caressed and fed their pigs which exposed them to pigs' saliva and feces. Herders took their pigs close to human settlements for scavenging. Other domestic animals and poultry shared food and sleeping and scavenging places with pigs. Since pigs are taboo in Islam, a majority of Muslims rejected pig raising and stigmatized pig raisers. This study identified several potential ways for pigs to transmit infectious agents to humans in Bangladesh. Poverty and stigmatization of pig raisers make it difficult to implement health interventions to reduce the risk of such transmissions. Interventions that offer social support to reduce stigma and highlight economic benefits of disease control might interest of pig raisers in accepting interventions targeting pig borne zoonoses. C1 [Nahar, Nazmun; Uddin, Main; Sarkar, Rouha Anamika; Gurley, Emily S.; Khan, M. Salah Uddin; Hossain, M. Jahangir; Sultana, Rebeca; Luby, Stephen P.] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh. [Luby, Stephen P.] Ctr Dis Control & Prevent CDC, Atlanta, GA 30333 USA. RP Nahar, N (reprint author), Int Ctr Diarrhoeal Dis Res, GPO Box 128, Dhaka 1000, Bangladesh. EM nahar.nazmun@yahoo.com RI Gurley, Emily/B-7903-2010 OI Gurley, Emily/0000-0002-8648-9403 FU Centers for Disease Control and Prevention (CDC) [5-U01-CI000298-03] FX This study was funded by the Centers for Disease Control and Prevention (CDC), CoAg Grant Number was: 5-U01-CI000298-03. NR 51 TC 5 Z9 5 U1 0 U2 10 PU IST ZOOPROFILATTICO SPERIMENTALE ABRUZZO & MOLISE G CAPORALE-IZS A&M PI TERAMO PA CAMPO BOARIO, TERAMO, 64100, ITALY SN 0505-401X J9 VET ITAL JI Vet. Ital. PD JAN-MAR PY 2013 VL 49 IS 1 BP 7 EP 17 PG 11 WC Veterinary Sciences SC Veterinary Sciences GA 130YV UT WOS:000317957400002 PM 23564585 ER PT J AU Mabery, MJ Gibbs-Scharf, L Bara, D AF Mabery, Mamie Jennings Gibbs-Scharf, Lynn Bara, Debra TI Communities of practice foster collaboration across public health SO JOURNAL OF KNOWLEDGE MANAGEMENT LA English DT Article DE Collaboration; Communities of practice; Informatics; Public health; Social capital; United States of America; Critical success factors AB Purpose - The complexity and responsibilities of public health make collaboration across multiple levels of government critical. The Centers for Disease Control and Prevention (CDC) effectively uses communities of practice (CoPs) to bring its staff together with partners to share, learn, and address public health problems. This paper aims to focus on CoPs. Design/methodology/approach - The paper assesses the value of CoPs to individual members, their organizations, and their public health domains; assesses whether the CoP Program has improved CDC's relationship with participants in various CoPs; and identifies barriers to participation or success factors that could be applied to the development of new CoPs. Responses from a random sample of active CoP members were analyzed using qualitative data analysis software to identify themes and answer research questions. Findings - The results reveal clear benefits to individual members, their organizations, and public health disciplines including daily work efficiencies, expanded infrastructure, and enhanced relationships between CDC and its public health partners. Research limitations/implications - This qualitative research analyzed a small number of communities of practice spanning their launch through year 2; further study of a larger sample of public health CoPs, including sustainability factors, would build on this case study's implications. Practical implications - Public health practitioners seeking a collaborative approach to problem solving will find in this study some useful lessons learned from CDC; readers will be introduced to CDC's CoP Resource Kit and a public health collaboration portal, phConnect. Originality/value - Well-facilitated, member-driven, and highly participative CoPs are valuable tools for fostering collaboration essential to improving the public health system, and should be used more broadly across public health. C1 [Mabery, Mamie Jennings; Gibbs-Scharf, Lynn] Ctr Dis Control & Prevent, Off State Tribal Local & Terr Support, Atlanta, GA USA. [Bara, Debra] Publ Hlth Informat Inst, Task Force Global Hlth, Decatur, GA USA. RP Mabery, MJ (reprint author), Ctr Dis Control & Prevent, Off State Tribal Local & Terr Support, Atlanta, GA USA. EM mmabery@cdc.gov NR 16 TC 2 Z9 2 U1 6 U2 26 PU EMERALD GROUP PUBLISHING LIMITED PI BINGLEY PA HOWARD HOUSE, WAGON LANE, BINGLEY BD16 1WA, W YORKSHIRE, ENGLAND SN 1367-3270 J9 J KNOWL MANAG JI J. Knowl. Manag. PY 2013 VL 17 IS 2 BP 226 EP 236 DI 10.1108/13673271311315187 PG 11 WC Information Science & Library Science; Management SC Information Science & Library Science; Business & Economics GA 128VY UT WOS:000317799000005 ER PT J AU Wyatt, SW Brady, KT Maynard, WR AF Wyatt, Stephen W. Brady, Kevin T. Maynard, W. Ryan BE Holsinger, JW TI Partnerships in Public Health Working Together for a Mutual Benefit SO CONTEMPORARY PUBLIC HEALTH: PRINCIPLES, PRACTICE, AND POLICY LA English DT Article; Book Chapter ID COMMUNITY; COLLABORATION C1 [Wyatt, Stephen W.] Univ Kentucky, Coll Publ Hlth, Lexington, KY 40506 USA. [Wyatt, Stephen W.] US PHS, Washington, DC USA. [Wyatt, Stephen W.; Brady, Kevin T.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Brady, Kevin T.] CDC Fdn, Atlanta, GA USA. RP Wyatt, SW (reprint author), Univ Kentucky, Coll Publ Hlth, Lexington, KY 40506 USA. NR 12 TC 0 Z9 0 U1 0 U2 0 PU UNIV PRESS KENTUCKY PI LEXINGTON PA 102 LAFFERTY HALL, UNIVERSITY OF KENTUCKY, LEXINGTON, KY 40506 USA BN 978-0-8131-4124-4 PY 2013 BP 193 EP 204 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA BDZ13 UT WOS:000315694300012 ER PT J AU King, CC Ellington, SR Kourtis, AP AF King, Caroline C. Ellington, Sascha R. Kourtis, Athena P. TI The Role of Co-Infections in Mother-to-Child Transmission of HIV SO CURRENT HIV RESEARCH LA English DT Article DE Co-infections; HIV; infections; infant; mother-to-child transmission ID HUMAN-IMMUNODEFICIENCY-VIRUS; HERPES-SIMPLEX-VIRUS; HEPATITIS-C-VIRUS; PLACEBO-CONTROLLED TRIAL; RANDOMIZED CONTROLLED-TRIAL; PLASMODIUM-FALCIPARUM MALARIA; MATERNAL-INFANT TRANSMISSION; INFECTED PREGNANT-WOMEN; FEMALE GENITAL-TRACT; CONGENITAL CYTOMEGALOVIRUS-INFECTION AB In HIV-infected women, co-infections that target the placenta, fetal membranes, genital tract, and breast tissue, as well as systemic maternal and infant infections, have been shown to increase the risk for mother-to-child transmission of HIV (MTCT). Active co-infection stimulates the release of cytokines and inflammatory agents that enhance HIV replication locally or systemically and increase tissue permeability, which weakens natural defenses to MTCT. Many maternal or infant co-infections can affect MTCT of HIV, and particular ones, such as genital tract infection with herpes simplex virus, or systemic infections such as hepatitis B, can have substantial epidemiologic impact on MTCT. Screening and treatment for co-infections that can make infants susceptible to MTCT in utero, peripartum, or postpartum can help reduce the incidence of HIV infection among infants and improve the health of mothers and infants worldwide. C1 [King, Caroline C.; Ellington, Sascha R.; Kourtis, Athena P.] Ctr Dis Control & Prevent, Div Reprod Hlth, NCCDPHP, Atlanta, GA 30341 USA. RP King, CC (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, NCCDPHP, 4770 Buford Highway,NE,MS-K34, Atlanta, GA 30341 USA. EM ccking@cdc.gov FU Intramural CDC HHS [CC999999] NR 260 TC 8 Z9 8 U1 0 U2 7 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1570-162X J9 CURR HIV RES JI Curr. HIV Res. PD JAN PY 2013 VL 11 IS 1 BP 10 EP 23 PG 14 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 119LF UT WOS:000317098100003 PM 23305198 ER PT J AU Hueffer, K Parkinson, AJ Gerlach, R Berner, J AF Hueffer, Karsten Parkinson, Alan J. Gerlach, Robert Berner, James TI Zoonotic infections in Alaska: disease prevalence, potential impact of climate change and recommended actions for earlier disease detection, research, prevention and control SO INTERNATIONAL JOURNAL OF CIRCUMPOLAR HEALTH LA English DT Review DE Zoonotic infections; climate change; gaps in knowledge; recommendations; US Arctic ID TOXOPLASMA-GONDII; ECHINOCOCCUS-MULTILOCULARIS; SEROLOGIC SURVEY; MOLECULAR CHARACTERIZATION; SARCOCYSTIS-NEURONA; MARINE MAMMALS; GRIZZLY BEARS; BRUCELLA; CRYPTOSPORIDIUM; TRICHINELLA AB Over the last 60 years, Alaska's mean annual temperature has increased by 1.6 degrees C, more than twice the rate of the rest of the United States. As a result, climate change impacts are more pronounced here than in other regions of the United States. Warmer temperatures may allow some infected host animals to survive winters in larger numbers, increase their population and expand their range of habitation thus increasing the opportunity for transmission of infection to humans. Subsistence hunting and gathering activities may place rural residents of Alaska at a greater risk of acquiring zoonotic infections than urban residents. Known zoonotic diseases that occur in Alaska include brucellosis, toxoplasmosis, trichinellosis, giardiasis/cryptosporidiosis, echinococcosis, rabies and tularemia. Actions for early disease detection, research and prevention and control include: (1) determining baseline levels of infection and disease in both humans and host animals; (2) conducting more research to understand the ecology of infection in the Arctic environment; (3) improving active and passive surveillance systems for infection and disease in humans and animals; (4) improving outreach, education and communication on climate-sensitive infectious diseases at the community, health and animal care provider levels; and (5) improving coordination between public health and animal health agencies, universities and tribal health organisations. C1 [Hueffer, Karsten] Univ Alaska Fairbanks, Dept Biol & Wildlife, Inst Arctic Biol, Fairbanks, AK USA. [Parkinson, Alan J.] Ctr Dis Control & Prevent, Arctic Invest Program, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK 99516 USA. [Gerlach, Robert] Alaska Div Environm Hlth, Off State Veterinarian, Anchorage, AK USA. [Berner, James] Alaska Native Tribal Hlth Consortium, Community Hlth Serv, Anchorage, AK USA. RP Parkinson, AJ (reprint author), Ctr Dis Control & Prevent, Arctic Invest Program, Anchorage, AK 99516 USA. EM ajp1@cdc.gov FU National Center for Research Resources [5P20RR016466-12]; National Institute of General Medical Sciences from the National Institutes of Health [8 P20 GM103395-12] FX This project was supported by grants from the National Center for Research Resources (5P20RR016466-12) and the National Institute of General Medical Sciences (8 P20 GM103395-12) from the National Institutes of Health. NR 62 TC 13 Z9 15 U1 5 U2 56 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1239-9736 EI 2242-3982 J9 INT J CIRCUMPOL HEAL JI Int. J. Circumpolar Health PY 2013 VL 72 AR 19562 DI 10.3402/ijch.v72i0.19562 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 118UG UT WOS:000317050700001 ER PT J AU Van Zee, J Black, WC Levin, M Goddard, J Smith, J Piesman, J AF Van Zee, Janice Black, William C. Levin, Michael Goddard, Jerome Smith, Joshua Piesman, Joseph TI High SNP density in the blacklegged tick, Ixodes scapularis, the principal vector of Lyme disease spirochetes SO TICKS AND TICK-BORNE DISEASES LA English DT Article DE Ixodes scapularis; SNPs; Haplotypes; Lyme disease ID SINGLE-NUCLEOTIDE POLYMORPHISMS; SOUTHERN CATTLE TICK; BORRELIA-BURGDORFERI; ANOPHELES-GAMBIAE; UNITED-STATES; HUMAN GENOME; HARD TICK; POPULATION-STRUCTURE; TANDEM REPEATS; ACARI IXODIDAE AB Single-nucleotide polymorphisms (SNPs) are the most widespread type of sequence variation in genomes. SNP density and distribution varies among different organisms and genes. Here, we report the first estimates of SNP distribution and density in the genome of the blacklegged tick (Ixodes scapularis), an important vector of the pathogens causing Lyme disease, human granulocytic anaplasmosis and human babesiosis in North America. We sampled 10 individuals from each of 4 collections from New Jersey, Virginia, Georgia, and Mississippi and analyzed the sequences of 9 nuclear genes and the mitochondrial 16S gene. SNPs are extremely abundant (one SNP per every 14 bases). This is the second highest density so far reported in any eukaryotic organism. Population genetic analyses based either on haplotype frequencies or the 372 SNPs in these 9 genes showed that the 40 ticks formed 3 genetic groups. In agreement with earlier population genetic studies, northern ticks from New Jersey and Virginia formed a homogeneous group with low genetic diversity, whereas southern ticks from Georgia and Mississippi consisted of 2 separate groups, each with high genetic diversity. (C) 2012 Elsevier GmbH. All rights reserved. C1 [Van Zee, Janice; Piesman, Joseph] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. [Black, William C.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA. [Levin, Michael] Ctr Dis Control & Prevent, Div Vector Borne Dis, Atlanta, GA USA. [Goddard, Jerome] Mississippi State Univ, Dept Biochem Mol Biol Entomol & Plant Pathol, Mississippi State, MS 39762 USA. [Smith, Joshua] Fairfax Cty Hlth Dept, Fairfax Co, VA USA. RP Van Zee, J (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM vbx3@cdc.gov FU American Society of Microbiology; Centers for Disease Control and Prevention postdoctoral fellowship program FX We thank Jorge Arias for organizing tick collections in Fairfax County, Virginia. Special thanks to the staff at Mississippi State University for providing L scapularis ticks. We also thank Andrias Hojgaard for lab support and Gabrielle Dietrich for maintenance of tick colonies. Thanks to Ben Beard and Ron Rosenberg for reviewing the manuscript. This work was supported by American Society of Microbiology and Centers for Disease Control and Prevention postdoctoral fellowship program. NR 56 TC 11 Z9 11 U1 1 U2 22 PU ELSEVIER GMBH, URBAN & FISCHER VERLAG PI JENA PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY SN 1877-959X J9 TICKS TICK-BORNE DIS JI Ticks Tick-Borne Dis. PY 2013 VL 4 IS 1-2 BP 63 EP 71 DI 10.1016/j.ttbdis.2012.07.005 PG 9 WC Infectious Diseases; Microbiology; Parasitology SC Infectious Diseases; Microbiology; Parasitology GA 111KA UT WOS:000316519000009 PM 23219364 ER PT J AU Ullmann, AJ Dolan, MC Sackal, CA Fikrig, E Piesman, J Zeidner, NS AF Ullmann, A. J. Dolan, M. C. Sackal, C. A. Fikrig, E. Piesman, J. Zeidner, N. S. TI Immunization with adenoviral-vectored tick salivary gland proteins (SALPs) in a murine model of Lyme borreliosis SO TICKS AND TICK-BORNE DISEASES LA English DT Article DE Tick salivary proteins; Anti-tick vaccine; Ixodes scapularis; Adenovirus ID IXODES-SCAPULARIS; DISEASE AGENT; BURGDORFERI; HOST; MICE; MODULATION; IMMUNITY AB Prior exposure of vertebrate hosts to tick salivary proteins can induce specific immunity to tick infestation, as well as affording protection against tick-transmitted Borrelia burgdorferi infection in the mammalian host. Vaccination using an adenovirus expression system to deliver 4 tick salivary proteins (Ad-Salps) derived from Ixodes scapularis, Salp15, Salp25A, Salp25D, and [sac, was explored. Results indicate that vaccination with tick salivary proteins in an adenoviral vector can be used to modulate a Th1 response in the host and partially control spirochete load in immunized mice after infected tick challenge. Published by Elsevier GmbH. C1 [Ullmann, A. J.; Dolan, M. C.; Sackal, C. A.; Piesman, J.; Zeidner, N. S.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Bacterial Dis Branch, Ft Collins, CO 80521 USA. [Fikrig, E.] Yale Univ, Sch Med, Infect Dis Sect, New Haven, CT 06520 USA. RP Ullmann, AJ (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Bacterial Dis Branch, 3156 Rampart Rd, Ft Collins, CO 80521 USA. EM aff1@cdc.gov FU NIAID NIH HHS [R37 AI049200] NR 17 TC 5 Z9 5 U1 0 U2 7 PU ELSEVIER GMBH, URBAN & FISCHER VERLAG PI JENA PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY SN 1877-959X J9 TICKS TICK-BORNE DIS JI Ticks Tick-Borne Dis. PY 2013 VL 4 IS 1-2 BP 160 EP 163 DI 10.1016/j.ttbdis.2012.08.006 PG 4 WC Infectious Diseases; Microbiology; Parasitology SC Infectious Diseases; Microbiology; Parasitology GA 111KA UT WOS:000316519000025 PM 23141105 ER PT J AU Steiner, LJ Burgess-Limerick, R Eiter, B Porter, W Matty, T AF Steiner, Lisa J. Burgess-Limerick, Robin Eiter, Brianna Porter, William Matty, Tim TI Visual feedback system to reduce errors while operating roof bolting machines SO JOURNAL OF SAFETY RESEARCH LA English DT Article; Proceedings Paper CT 5th National Occupational Injury Research Symposium (NOIRS) CY OCT, 2011 CL Natl Inst Occupat Safety & Hlth (NIOSH), Morgantown, WV SP Natl Safety Council, Liberty Mutual Res Inst Safety HO Natl Inst Occupat Safety & Hlth (NIOSH) DE Mining; Control compatibility; Equipment design; Situational awareness; Visual feedback system ID MINING EQUIPMENT; AWARENESS AB Problem: Operators of roof bolting machines in underground coal mines do so in confined spaces and in very close proximity to the moving equipment. Errors in the operation of these machines can have serious consequences, and the design of the equipment interface has a critical role in reducing the probability of such errors. Methods: An experiment was conducted to explore coding and directional compatibility on actual roof bolting equipment and to determine the feasibility of a visual feedback system to alert operators of critical movements and to also alert other workers in close proximity to the equipment to the pending movement of the machine. The quantitative results of the study confirmed the potential for both selection errors and direction errors to be made, particularly during training. Results: Subjective data confirmed a potential benefit of providing visual feedback of the intended operations and movements of the equipment. Impact: This research may influence the design of these and other similar control systems to provide evidence for the use of warning systems to improve operator situational awareness. National Safety Council and Elsevier Ltd. All rights reserved. C1 [Steiner, Lisa J.; Eiter, Brianna; Porter, William; Matty, Tim] NIOSH, CDC, Off Min Safety & Hlth Res, Pittsburgh, PA USA. [Steiner, Lisa J.] NIOSH, Human Factors Branch, OMSHR, Pittsburgh, PA USA. [Burgess-Limerick, Robin] Univ Queensland, Minerals Ind Safety & Hlth Ctr, Sustainable Minerals Inst, Brisbane, Qld 4072, Australia. RP Steiner, LJ (reprint author), NIOSH, CDC, Off Min Safety & Hlth Res, Pittsburgh, PA USA. EM steinercpe@hotmail.com FU Intramural CDC HHS [CC999999] NR 23 TC 1 Z9 1 U1 1 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-4375 J9 J SAFETY RES JI J. Saf. Res. PY 2013 VL 44 IS 1 SI SI BP 37 EP 44 DI 10.1016/j.jsr.2012.06.003 PG 8 WC Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation SC Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation GA 110ER UT WOS:000316425900007 PM 23398703 ER PT J AU Pollack, KM Yee, N Canham-Chervak, M Rossen, L Bachynski, KE Baker, SP AF Pollack, Keshia M. Yee, Nathan Canham-Chervak, Michelle Rossen, Lauren Bachynski, Kathleen E. Baker, Susan P. TI Narrative text analysis to identify technologies to prevent motor vehicle crashes: Examples from military vehicles SO JOURNAL OF SAFETY RESEARCH LA English DT Article; Proceedings Paper CT 5th National Occupational Injury Research Symposium (NOIRS) CY OCT, 2011 CL Natl Inst Occupat Safety & Hlth (NIOSH), Morgantown, WV SP Natl Safety Council, Liberty Mutual Res Inst Safety HO Natl Inst Occupat Safety & Hlth (NIOSH) DE Narrative text analysis; Motor vehicle; Technology; US Army; Occupational injury ID INJURIES AB Introduction: The purpose of this research is to describe the leading circumstances of military vehicle crashes to guide prioritization and implementation of crash avoidance and/or warning technologies. Methods: A descriptive study using narrative text analysis on 3,944 military vehicle crash narratives. Crash data on drivers, from 2001 to 2006, were assembled from the U.S. Army Combat Readiness/Safety Center. Reviewers collected information on the circumstances of crashes and determined if vehicle technology could have prevented the crash. Results: Nearly 98% of the crashes were nonfatal; 63% occurred in the U.S. and 24% in Iraq. Among crash events where the direction of the impact was recorded, 32% were to the front of the vehicle and 16% involved a vehicle being rear-ended. Rollovers were mentioned in 20% of the narratives. Technology was determined to have the potential to prevent 26% of the crashes, with the forward collision warning system, rear end collision avoidance, emergency brake assistance, and rollover stability control system likely to have the greatest impacts. Conclusions: Some technologies available for civilian vehicles may prevent certain military crash circumstances. Impact on Industry: The results of this research are significant in light of ongoing global military operations that rely on military vehicles. Improving the preventive technology featured on military vehicles may be an effective strategy to reduce the occurrence of military crashes. (C) 2013 National Safety Council and Elsevier Ltd. All rights reserved. C1 [Pollack, Keshia M.; Baker, Susan P.] Johns Hopkins Ctr Injury Res & Policy, Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA. [Yee, Nathan] Univ Calif, Sch Med, Berkeley, CA USA. [Canham-Chervak, Michelle] USA, Injury Prevent Program, Aberdeen Proving Ground, MD 21010 USA. [Rossen, Lauren] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Bachynski, Kathleen E.] Columbia Univ, Mailman Sch Publ Hlth, Dept Sociomed Sci, New York, NY 10032 USA. RP Pollack, KM (reprint author), Johns Hopkins Univ, 624 N Broadway,Room 557, Baltimore, MD 21205 USA. EM kpollack@jhsph.edu FU NCIPC CDC HHS [5R49CE001507] NR 18 TC 3 Z9 3 U1 0 U2 9 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-4375 J9 J SAFETY RES JI J. Saf. Res. PY 2013 VL 44 IS 1 SI SI BP 45 EP 49 DI 10.1016/j.jsr.2012.10.013 PG 5 WC Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation SC Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation GA 110ER UT WOS:000316425900008 PM 23398704 ER PT J AU Lincoln, JM O'Connor, MB Retzer, KD Hill, RD Teske, TD Woodward, CC Lucas, DL Somervell, PD Burton, JT Mode, NA Husberg, BJ Conway, GA AF Lincoln, Jennifer M. O'Connor, Mary B. Retzer, Kyla D. Hill, Ryan D. Teske, Theodore D. Woodward, Chelsea C. Lucas, Devin L. Somervell, Philip D. Burton, Jason T. Mode, Nicolle A. Husberg, Brad J. Conway, George A. TI Occupational Fatalities in Alaska: Two Decades of Progress, 1990-1999 and 2000-2009 SO JOURNAL OF SAFETY RESEARCH LA English DT Article; Proceedings Paper CT 5th National Occupational Injury Research Symposium (NOIRS) CY OCT, 2011 CL Natl Inst Occupat Safety & Hlth (NIOSH), Morgantown, WV SP Natl Safety Council, Liberty Mutual Res Inst Safety HO Natl Inst Occupat Safety & Hlth (NIOSH) DE Injury surveillance; Commercial fishing; Drowning prevention; Aviation safety; Oil and gas AB Introduction: Alaska had the highest work-related fatality rate of any state during 1980-1989. The National Institute for Occupational Safety and Health established the Alaska Field Station (AFS) to address this problem. Methods: AFS established surveillance systems to provide scientific assessments of occupational hazards. Interventions were developed in collaboration with partners and evaluated. Results: During 2000-2009, Alaska experienced a 42.5% decline in work-related fatalities over the previous decade of 1990-1999. In 2009, the workplace fatality rate for Alaska was 5.6/100,000 workers. Commercial pilot deaths were reduced by 50% and Bering Sea crab fishing death rates were reduced by 60%. Building on this success, AFS established national programs to improve safety in the commercial fishing and oil and gas extraction industries. Impact on Industry: A focused, epidemiological approach to reducing fatalities in high-risk occupations is effective. Ongoing commitment to this type of approach will assist in continued success in Alaska and elsewhere. (C) 2013 National Safety Council and Elsevier Ltd. All rights reserved. C1 [Lincoln, Jennifer M.; O'Connor, Mary B.; Retzer, Kyla D.; Teske, Theodore D.; Woodward, Chelsea C.; Lucas, Devin L.; Somervell, Philip D.; Burton, Jason T.; Husberg, Brad J.; Conway, George A.] NIOSH, Ctr Dis Control & Prevent, Alaska Pacif Off, Anchorage, AK 99508 USA. [Hill, Ryan D.] NIOSH, Ctr Dis Control & Prevent, Western States Off, Denver Fed Ctr, Lakewood, CO 80225 USA. [Mode, Nicolle A.] Nicolle Mode & Associates, Pleasanton, CA 94566 USA. RP Lincoln, JM (reprint author), 4230 Univ Dr,Suite 310, Anchorage, AK 99508 USA. EM JLincoln@cdc.gov; MBOConnor@cdc.gov; KRetzer@cdc.gov; RDHill1@cdc.gov; TTeske@cdc.gov; CWoodward@cdc.gov; DLucas@cdc.gov; PSomervell@cdc.gov; JBurton1@cdc.gov; NMode@cdc.gov; BHusberg@cdc.gov; GConway@cdc.gov OI Lucas, Devin/0000-0002-4401-5883 NR 23 TC 1 Z9 1 U1 0 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-4375 J9 J SAFETY RES JI J. Saf. Res. PY 2013 VL 44 IS 1 SI SI BP 105 EP 110 DI 10.1016/j.jsr.2012.08.023 PG 6 WC Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation SC Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation GA 110ER UT WOS:000316425900015 PM 23398711 ER PT J AU Park, RM Bhattacharya, A AF Park, Robert M. Bhattacharya, Anasua TI Uncompensated consequences of workplace injuries and illness: Long-term disability and early termination SO JOURNAL OF SAFETY RESEARCH LA English DT Article; Proceedings Paper CT 5th National Occupational Injury Research Symposium (NOIRS) CY OCT, 2011 CL Natl Inst Occupat Safety & Hlth (NIOSH), Morgantown, WV SP Natl Safety Council, Liberty Mutual Res Inst Safety HO Natl Inst Occupat Safety & Hlth (NIOSH) DE workers' compensation; health insurance; occupational disease ID WORKERS-COMPENSATION BENEFITS; HEALTH-CARE COSTS; OCCUPATIONAL-DISEASE; WASHINGTON-STATE; CUMULATIVE TRAUMA; BACK DISORDERS; AUTO INDUSTRY; SURVEILLANCE; INSURANCE; EARNINGS AB Problem: Costs related to early retirement, termination, or long-term disability could fall outside workers' compensation (WC). Method: Statistical models examined early retirement, long-term disability status, or early termination related to WC claims. Results: The WC-associated early-termination rate ratio was 1.20 (95% CI=1.14-1.28) for hourly nonunion employees, 1.05 (95% CI=0.97-1.13) for hourly union employees, and 3.43 (95% CI=3.11-3.79) for salaried nonunion employees. In the manufacturing-durable sector the WC-associated rate ratio was 1.58 (95% CI=1.42-1.76) for hourly nonunion employees and 1.23 (95% CI=1.10-1.38) for union hourly employees. In contrast, in transportation-utilities-communications, the rate ratio was 0.52 (95% CI=0.46-0.59) for hourly nonunion and 1.22 (95% CI=1.08-1.38) for union hourly employees. Discussion: Uncompensated costs of workplace injuries and illnesses may result from adverse events previously compensated by WC. In some workplaces reduced termination rates with prior WC suggests added costs to employers. Summary: Conditions leading to WC claims have cost implications related to early - or delayed - removal from the workforce. Impact on industry: Additional costs from work-related injury or illness that are not covered by workers compensation may result from the effect of continuing impairment on the subsequent early termination (or prolonging) of employment. These costs would accrue to both employers and employees and are not generally included in global estimates of the burden of workplace injuries and illnesses. (C) 2013 National Safety Council and Elsevier Ltd. All rights reserved. C1 [Park, Robert M.] NIOSH, Risk Evaluat Branch, Cincinnati, OH 45226 USA. [Bhattacharya, Anasua] NIOSH, Cincinnati, OH 45226 USA. RP Park, RM (reprint author), NIOSH, Ctr Dis Control & Prevent, Educ & Informat Div, MS C-15,4676 Columbia Pkwy, Cincinnati, OH 45226 USA. EM rhp9@cdc.gov NR 25 TC 2 Z9 2 U1 0 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-4375 J9 J SAFETY RES JI J. Saf. Res. PY 2013 VL 44 IS 1 SI SI BP 119 EP 124 DI 10.1016/j.jsr.2012.08.019 PG 6 WC Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation SC Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation GA 110ER UT WOS:000316425900017 PM 23398713 ER PT J AU Park, S Blanck, HM Sherry, B Jones, SE Pan, LP AF Park, Sohyun Blanck, Heidi M. Sherry, Bettylou Jones, Sherry Everett Pan, Liping TI Regular-Soda Intake Independent of Weight Status Is Associated with Asthma among US High School Students SO JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS LA English DT Article DE Soda; Adolescents; Asthma; Youth Risk Behavior Survey (YRBS) ID SUGAR-SWEETENED BEVERAGES; UNITED-STATES; CHILDHOOD OBESITY; PHYSICAL-ACTIVITY; SULFUR-DIOXIDE; CHILDREN; ADOLESCENTS; CONSUMPTION; FOODS; SURVEILLANCE AB Limited research shows an inconclusive association between soda intake and asthma, potentially attributable to certain preservatives in sodas. This cross-sectional study examined the association between regular (nondiet)-soda intake and current asthma among a nationally representative sample of high school students. Analysis was based on the 2009 national Youth Risk Behavior Survey and included 15,960 students (grades 9 through 12) with data for both regular-soda intake and current asthma status. The outcome measure was current asthma (ie, told by doctor/nurse that they had asthma and still have asthma). The main exposure variable was regular-soda intake (ie, drank a can/bottle/glass of soda during the 7 days before the survey). Multivariable logistic regression was used to estimate the adjusted odds ratios for regular-soda intake with current asthma after controlling for age, sex, race/ethnicity, weight status, and current cigarette use. Overall, 10.8% of students had current asthma. In addition, 9.7% of students who did not drink regular soda had current asthma, and 14.7% of students who drank regular soda three or more times per day had current asthma. Compared with those who did not drink regular soda, odds of having current asthma were higher among students who drank regular soda two times per day (adjusted odds ratio=1.28; 95% CI 1.02 to 1.62) and three or more times per day (adjusted odds ratio=1.64; 95% CI 1.25 to 2.16). The association between high regular-soda intake and current asthma suggests efforts to reduce regular-soda intake among youth might have benefits beyond improving diet quality. However, this association needs additional research, such as a longitudinal examination. J Acad Nutr Diet. 2013;113:106-111. C1 [Park, Sohyun; Blanck, Heidi M.; Sherry, Bettylou; Pan, Liping] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Jones, Sherry Everett] Ctr Dis Control & Prevent, Div Adolescent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30341 USA. [Jones, Sherry Everett] Ctr Dis Control & Prevent, Sch Hlth, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30341 USA. RP Park, S (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Mailstop K26,4770 Buford Highway NE, Atlanta, GA 30341 USA. EM spark3@cdc.gov FU Intramural CDC HHS [CC999999] NR 38 TC 12 Z9 12 U1 1 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 2212-2672 J9 J ACAD NUTR DIET JI J. Acad. Nutr. Diet. PD JAN PY 2013 VL 113 IS 1 BP 106 EP 111 DI 10.1016/j.jand.2012.09.020 PG 6 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 107SZ UT WOS:000316242400011 PM 23260727 ER PT J AU Park, S Onufrak, S Blanck, HM Sherry, B AF Park, Sohyun Onufrak, Stephen Blanck, Heidi M. Sherry, Bettylou TI Characteristics Associated with Consumption of Sports and Energy Drinks among US Adults: National Health Interview Survey, 2010 SO JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS LA English DT Article DE Sports drinks; Energy drinks; Sugar-sweetened beverages; Behaviors; Adults ID SWEETENED BEVERAGE CONSUMPTION; COLLEGE-STUDENTS; BODY-WEIGHT; ADOLESCENTS; DIETARY; RISK; PATTERNS; CHILDREN; OBESITY; SAFETY AB Sales of sports and energy drinks have increased dramatically, but there is limited information on regular consumers of sports and energy drinks. Characteristics associated with sports and energy drink intake were examined among a sample representing the civilian noninstitutionalized US adult population. The 2010 National Health Interview Survey data for 25,492 adults (18 years of age or older; 48% males) were used. Nationwide, 31.3% of adults were sports and energy drink consumers during the past 7 days, with 21.5% consuming sports and energy drinks one or more times per week and 11.5% consuming sports and energy drinks three or more times per week. Based on multivariable logistic regression, younger adults, males, non-Hispanic blacks and Hispanics, not-married individuals, adults with higher family income, those who lived in the South or West, adults who engaged in leisure-time physical activity, current smokers, and individuals whose satisfaction with their social activities/relationships was excellent had significantly higher odds for drinking sports and energy drinks one or more times per week. In this model, the factor most strongly associated with weekly sports and energy. drink consumption was age (odds ratio [OR]=10.70 for 18- to 24-year-olds, OR=6.40 for 25- to 39-year-olds, OR=3.17 for 40- to 59-year-olds vs 60 years or older). Lower odds for consuming sports and energy drinks one or more times per week were associated with other/multiracial (OR=0.80 vs non-Hispanic white) and obesity (OR=0.87 vs underweight/normal weight). Separate modeling of the association between other beverage intake and sports and energy drink intake showed that higher intake of regular soda, sweetened coffee/tea drinks, fruit drinks, milk, 100% fruit juice, and alcohol were significantly associated with greater odds for drinking sports and energy drinks one or more times per week. These findings can help medical care providers and public health officials identify adults most in need of encouragement to reduce sports and energy drink intake and increase healthier beverage intake. J Acad Nutr Diet. 2013;113:112-119. C1 [Park, Sohyun; Onufrak, Stephen; Blanck, Heidi M.; Sherry, Bettylou] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Park, S (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,Mailstop K26, Atlanta, GA 30341 USA. EM spark3@cdc.gov FU Intramural CDC HHS [CC999999] NR 37 TC 15 Z9 15 U1 1 U2 54 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 2212-2672 J9 J ACAD NUTR DIET JI J. Acad. Nutr. Diet. PD JAN PY 2013 VL 113 IS 1 BP 112 EP 119 DI 10.1016/j.jand.2012.09.019 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 107SZ UT WOS:000316242400012 PM 23260728 ER PT J AU Shulman, ST Long, SS AF Shulman, Stanford T. Long, Sarah S. TI A Conversation with Sarah S. Long, MD SO PEDIATRIC ANNALS LA English DT Editorial Material C1 [Long, Sarah S.] NIH, Res Advisory Comm, Bethesda, MD USA. [Long, Sarah S.] Ctr Dis Control & Prevent, Res Advisory Comm, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0090-4481 J9 PEDIATR ANN JI Pediatr. Annu. PD JAN PY 2013 VL 42 IS 1 BP 40 EP 40 DI 10.3928/00904481-20121221-18 PG 1 WC Pediatrics SC Pediatrics GA 107VC UT WOS:000316247900022 ER PT J AU Haaland, RE Johnson, JA Tang, J AF Haaland, R. E. Johnson, J. A. Tang, J. TI Recent Advances in Research of HIV Infection: Implications of Viral and Host Genetics on Treatment and Prevention SO PUBLIC HEALTH GENOMICS LA English DT Article DE AIDS; Antiretroviral drug resistance; Human immunodeficiency virus; Immunogenetics; Transmission ID IMMUNODEFICIENCY-VIRUS TYPE-1; DRUG-RESISTANCE MUTATIONS; TREATMENT-NAIVE PATIENTS; HLA-B; TRIAL; DETERMINANTS; POPULATIONS; RESPONSES; VARIANTS; EFFICACY AB The genetic diversity among human immunodeficiency virus (HIV) subtypes as well as the variability of viral sequences found in HIV-infected individuals presents a number of difficult obstacles for the development of universally effective HIV treatment and prevention methods. Here, we present a brief summary of recent developments in the analysis of viral genetics and human genomics to provide insight into future methods for HIV treatment and prevention. Recent studies have mined viral sequences found in newly infected individuals to identify common features of all transmitted viruses that could provide potential targets for HIV vaccine development. Analysis of human immunogenetics has identified specific alleles associated with reduced virus loads in HIV-infected individuals providing valuable information that may influence individual responses to treatment and prevention methods. Increased sensitivity of antiretroviral drug resistance testing has improved the detection of hidden drug resistant virus but also highlighted the potential for drug resistant viruses to reduce the effectiveness of clinical treatment regimens. The rapidly expanding amount of data generated by studies of viral genetics and human immunogenetics will provide valuable information to guide the design of new strategies to improve clinical treatment and enhance HIV vaccine development. Copyright (C) 2013 S. Karger AG, Basel C1 [Haaland, R. E.; Johnson, J. A.] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Tang, J.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. RP Haaland, RE (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,M-S A-25, Atlanta, GA 30333 USA. EM hyw9@cdc.gov OI Tang, Jianming/0000-0003-0137-7486 NR 36 TC 3 Z9 3 U1 0 U2 13 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1662-4246 J9 PUBLIC HEALTH GENOM JI Pub. Health Genomics PY 2013 VL 16 IS 1-2 BP 31 EP 36 DI 10.1159/000345935 PG 6 WC Genetics & Heredity; Public, Environmental & Occupational Health SC Genetics & Heredity; Public, Environmental & Occupational Health GA 107VE UT WOS:000316248100006 PM 23548715 ER PT J AU Lucchi, NW Oberstaller, J Kissinger, JC Udhayakumar, V AF Lucchi, N. W. Oberstaller, J. Kissinger, J. C. Udhayakumar, V. TI Malaria Diagnostics and Surveillance in the Post-Genomic Era SO PUBLIC HEALTH GENOMICS LA English DT Article DE Bioinformatics; Diagnosis; Genome; Malaria; Molecular tools ID PLASMODIUM-FALCIPARUM; PARASITE; REGION; AMPLIFICATION; RESISTANCE; SEQUENCE; KNOWLESI; TESTS; BLOOD; VIVAX AB Genome sequences are available for 3 human-infecting malaria parasites, Plasmodium falciparum, P. vivax and P. knowlesi, and population genomics data are available for many endemic regions. This review summarizes how genomic data have been used to develop new, species-specific molecular targets for better malaria diagnosis. The combination of bioinformatics and genomics has been used to identify new sequence targets suitable for diagnostic applications and assess their viability within the context of global Plasmodium sequence variation. The selection criteria maximized the sensitivity and specificity of the novel targets. At least one target from each species was found to be suitable for molecular diagnosis of malaria with some advantages over existing molecular methods. The promise of using genome sequence data to develop sensitive, genus-or species-specific diagnostic methods for other pathogens of public health interest is strong. This undertaking together with what we envision as the future of malaria diagnosis in the 'omic' era is discussed. Copyright (C) 2013 S. Karger AG, Basel C1 [Lucchi, N. W.; Udhayakumar, V.] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. [Oberstaller, J.; Kissinger, J. C.] Univ Georgia, Dept Genet, Athens, GA 30602 USA. [Oberstaller, J.; Kissinger, J. C.] Univ Georgia, Ctr Trop & Emerging Global Dis, Athens, GA 30602 USA. [Kissinger, J. C.] Univ Georgia, Inst Bioinformat, Athens, GA 30602 USA. RP Udhayakumar, V (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Mail Stop D-67, Atlanta, GA 30333 USA. EM vxu0@cdc.gov RI Kissinger, Jessica/E-9610-2010 OI Kissinger, Jessica/0000-0002-6413-1101 FU Intramural CDC HHS [CC999999] NR 32 TC 3 Z9 3 U1 3 U2 8 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1662-4246 J9 PUBLIC HEALTH GENOM JI Pub. Health Genomics PY 2013 VL 16 IS 1-2 BP 37 EP 43 DI 10.1159/000345607 PG 7 WC Genetics & Heredity; Public, Environmental & Occupational Health SC Genetics & Heredity; Public, Environmental & Occupational Health GA 107VE UT WOS:000316248100007 PM 23548716 ER PT J AU King, EM Filep, S Smith, B Platts-Mills, T Hamilton, RG Schmechel, D Sordillo, JE Milton, D van Ree, R Krop, EJM Heederik, DJJ Metwali, N Thorne, PS Zeldin, DC Sever, ML Calatroni, A Arbes, SJ Mitchell, HE Chapman, MD AF King, Eva M. Filep, Stephanie Smith, Bryan Platts-Mills, Thomas Hamilton, Robert G. Schmechel, Detlef Sordillo, Joanne E. Milton, Donald van Ree, Ronald Krop, Esmeralda J. M. Heederik, Dick J. J. Metwali, Nervana Thorne, Peter S. Zeldin, Darryl C. Sever, Michelle L. Calatroni, Agustin Arbes, Samuel J., Jr. Mitchell, Herman E. Chapman, Martin D. TI A multi-center ring trial of allergen analysis using fluorescent multiplex array technology SO JOURNAL OF IMMUNOLOGICAL METHODS LA English DT Article DE Allergen measurement; Asthma; Indoor air quality; Immunoassay; Multiplex array; Occupational health ID INNER-CITY CHILDREN; 1ST NATIONAL-SURVEY; DUST MITE ALLERGEN; MOUSE ALLERGEN; BIRTH COHORT; CAT ALLERGEN; ASTHMA; EXPOSURE; SENSITIZATION; LEAD AB Background: Consistent Consistent performance of allergen assays is essential to ensure reproducibility of exposure assessments for investigations of asthma and occupational allergic disease. This study evaluated intra- and inter-laboratory reproducibility of a fluorescent multiplex array, which simultaneously measures eight indoor allergens in a single reaction well. Methods: A multi-center study was performed in nine laboratories in the US and Europe to determine the inter-laboratory variability of an 8-plex array for dust mite, cat, dog, rat, mouse and cockroach allergens. Aliquots of 151 dust extract samples were sent to participating centers and analyzed by each laboratory on three separate occasions. Agreement within and between laboratories was calculated by the concordance correlation coefficient (CCC). Results: Results were obtained for over 32,000 individual allergen measurements. Levels covered a wide range for all allergens from below the lower limit of detection (LLOD.=0.1-9.8 ng/ml) to higher than 6800 ng/ml for all allergens except Mus m 1, which was up to 1700 ng/ml. Results were reproducible within as well as between laboratories. Within laboratories, 94% of CCC were >= 0.90, and 80% of intra-laboratory results fell within a 10% coefficient of variance (CV%). Results between laboratories also showed highly significant positive correlations for all allergens (similar to 0.95, p<0.001). Overall means of results were comparable, and inter-laboratory CV% for all allergens except Rat n 1 ranged between 17.6% and 26.6%. C1 [King, Eva M.; Filep, Stephanie; Smith, Bryan; Chapman, Martin D.] INDOOR Biotechnol Inc, Charlottesville, VA 22903 USA. [Platts-Mills, Thomas] Univ Virginia, Div Allergy, Charlottesville, VA USA. [Hamilton, Robert G.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Schmechel, Detlef] CDC, NIOSH, Morgantown, WV USA. [Sordillo, Joanne E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Lab,Dept Med, Boston, MA 02115 USA. [van Ree, Ronald] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol & Otorhinolaryngol, NL-1105 AZ Amsterdam, Netherlands. [Krop, Esmeralda J. M.; Heederik, Dick J. J.] Univ Utrecht, Inst Risk Assessment Sci, Div Environm Epidemiol, NL-3508 TC Utrecht, Netherlands. [Metwali, Nervana; Thorne, Peter S.] Univ Iowa, Dept Occupat & Environm Hlth, Iowa City, IA USA. [Zeldin, Darryl C.] NIEHS, Div Intramural Res, NIH, Res Triangle Pk, NC 27709 USA. [Sever, Michelle L.; Calatroni, Agustin; Arbes, Samuel J., Jr.; Mitchell, Herman E.] Rho Inc, Chapel Hill, NC USA. [Milton, Donald] Univ Maryland, Maryland Inst Appl Environm Hlth, College Pk, MD 20742 USA. RP King, EM (reprint author), INDOOR Biotechnol Inc, 1216 Harris St, Charlottesville, VA 22903 USA. EM eking@inbio.com RI Milton, Donald/G-3286-2010; OI Milton, Donald/0000-0002-0550-7834; Sever, Michelle/0000-0002-2435-1214 FU U.S. National Institutes of Health Small Business Innovation and Research (SBIR) Phase II Award from the National Institute of Environmental Health Sciences [ES55545C]; Intramural Research Program of the NIH, National Institute of Environmental Health Sciences FX This study was supported in part by U.S. National Institutes of Health Small Business Innovation and Research (SBIR) Phase II Award ES55545C from the National Institute of Environmental Health Sciences, by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences, and by internal funds of all participating centers. Indoor Biotechnologies provided all reagents for use in the study and also provided travel and accommodation support for technician training. NR 36 TC 16 Z9 16 U1 0 U2 24 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0022-1759 J9 J IMMUNOL METHODS JI J. Immunol. Methods PD JAN PY 2013 VL 387 IS 1-2 BP 89 EP 95 DI 10.1016/j.jim.2012.09.015 PG 7 WC Biochemical Research Methods; Immunology SC Biochemistry & Molecular Biology; Immunology GA 101AB UT WOS:000315746200010 PM 23085532 ER PT J AU Alriksson-Schmidt, AI Thibadeau, JK Swanson, ME Marcus, D Carris, KL Siffel, C Ward, E AF Alriksson-Schmidt, Ann I. Thibadeau, Judy K. Swanson, Mark E. Marcus, David Carris, Kari L. Siffel, Csaba Ward, Elisabeth TI The Natural History of Spina Bifida in Children Pilot Project: Research Protocol SO JOURNAL OF MEDICAL INTERNET RESEARCH LA English DT Article DE spina bifida; musculoskeletal disorder; health; children; follow-up ID YOUNG-ADULTS; HYDROCEPHALUS; LEVEL; DISABILITIES; PREVALENCE; MANAGEMENT; DEFECTS; LESION AB Background: Population-based empirical information to inform health care professionals working with children with spina bifida currently is lacking. Spina bifida is a highly complex condition that not only affects mobility but many additional aspects of life. We have developed a pilot project that focuses on a broad range of domains: surgeries, development and learning, nutrition and physical growth, mobility and functioning, general health, and family demographics. Specifically, we will: (1) explore the feasibility of identifying and recruiting participants using different recruitment sources, (2) test a multidisciplinary module to collect the data, (3) determine the utility of different methods of retrieving the data, and (4) summarize descriptive information on living with spina bifida. Objective: The overall objective of the project was to provide information for a future multistate prospective study on the natural history of spina bifida. Methods: Families with a child 3 to 6 years of age with a diagnosis of spina bifida were eligible for enrollment. Eligible families were identified through a US population-based tracking system for birth defects and from a local spina bifida clinic. Results: This is an ongoing project with first results expected in 2013. Conclusions: This project, and the planned multistate follow-up project, will provide information both to health care professionals experienced in providing care to patients with spina bifida, and to those who have yet to work with this population. The long-term purpose of this project is to increase the knowledge about growing up with spina bifida and to guide health care practices by prospectively studying a cohort of children born with this condition. (JMIR Res Protoc 2013; 2(1): e2) doi:10.2196/resprot.2209 C1 [Alriksson-Schmidt, Ann I.] Lund Univ, Dept Orthoped, SE-22185 Lund, Sweden. [Thibadeau, Judy K.; Swanson, Mark E.; Siffel, Csaba] Ctr Dis Control & Prevent, Atlanta, GA USA. [Marcus, David] Childrens Healthcare Atlanta, Dept Neuropsychol, Atlanta, GA USA. [Carris, Kari L.] Univ Chicago, NORC, Chicago, IL 60637 USA. [Ward, Elisabeth] Carter Consulting Inc, CDC, Atlanta, GA USA. RP Alriksson-Schmidt, AI (reprint author), Lund Univ, Dept Orthoped, Klin Gatan 22, SE-22185 Lund, Sweden. EM ann.alriksson-schmidt@med.lu.se OI Alriksson-Schmidt, Ann/0000-0001-9430-263X FU Centers for Disease Control and Prevention FX We would like to thank Dr. Vincent A. Campbell for his willingness to share his expertise during the development of the project. The current project was funded by the Centers for Disease Control and Prevention. AS (Principal Investigator) and JT have made substantial contributions to conception, design, and are responsible for drafting the manuscript, MS has made substantial contributions to the conception and the design, DM has made substantial contributions to the design, KC has made substantial contributions to the conception and the design and CS and EW have made substantial contributions to the design. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 39 TC 0 Z9 0 U1 1 U2 8 PU JMIR PUBLICATIONS, INC PI TORONTO PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA SN 1438-8871 J9 J MED INTERNET RES JI J. Med. Internet Res. PD JAN PY 2013 VL 15 IS 1 AR e2 DI 10.2196/resprot.2209 PG 9 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA 092IF UT WOS:000315113200003 ER PT B AU Coronado, VG McGuire, LC Faul, M Sugerman, DE Pearson, WS AF Coronado, Victor G. McGuire, Lisa C. Faul, Mark Sugerman, David E. Pearson, William S. BE Zasler, ND Katz, DI Zafonte, RD TI Traumatic Brain Injury Epidemiology and Public Health Issues SO BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION LA English DT Article; Book Chapter ID LONG-TERM DISABILITY; GLASGOW COMA SCALE; UNITED-STATES; HEAD-INJURY; HIGH-SCHOOL; RISK-FACTORS; FOOTBALL PLAYERS; FOLLOW-UP; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION C1 [Coronado, Victor G.; McGuire, Lisa C.] Ctr Dis Control & Prevent, Div Injury Response, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. [Faul, Mark] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Sugerman, David E.] Ctr Dis Control & Prevent, Div Injury Response, LCDR US Publ Hlth Serv, Atlanta, GA USA. [Pearson, William S.] Ctr Dis Control & Prevent, Div Injury Response, Atlanta, GA USA. RP Coronado, VG (reprint author), Ctr Dis Control & Prevent, Div Injury Response, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. NR 117 TC 5 Z9 5 U1 3 U2 5 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-936287-27-7 PY 2013 BP 84 EP 100 PG 17 WC Clinical Neurology SC Neurosciences & Neurology GA BDJ25 UT WOS:000313536100008 ER PT J AU Lee, EK Pietz, F Benecke, B Mason, J Burel, G AF Lee, Eva K. Pietz, Ferdinand Benecke, Bernard Mason, Jacquelyn Burel, Greg TI Advancing Public Health and Medical Preparedness with Operations Research SO INTERFACES LA English DT Article DE public health emergency preparedness; national health security; optimization; simulation; mass dispensing; decision support ID EMERGENCY RESPONSE; MITIGATION STRATEGIES; PANDEMIC INFLUENZA; ANTHRAX ATTACK; MODEL; OUTBREAKS AB Planning for a catastrophe involving a disease outbreak with the potential for mass casualties is a significant challenge for emergency managers. Public health experts at the US Centers for Disease Control and Prevention (CDC) teamed with operations researchers to address important aspects of mass dispensing: medical supply distribution, locations of dispensing facilities, optimal facility staffing and resource allocation, routing of the population, and dispensing methods. Simulation-optimization technology was integrated into a decision support and data management suite, RealOpt (c), for tactical and strategic operational planning. RealOpt has enabled the CDC to provide modern tools that support dynamic planning for emergencies and that establish a knowledge data bank to provide feedback about the deployment of various techniques. The RealOpt suite now has a US user base of over 6,500 public health and emergency directors covering all states, plus many international users. RealOpt has been applied in hundreds of drills and dispensing events, including anthrax preparedness, and for seasonal flu and H1N1 vaccination events. C1 [Lee, Eva K.] Georgia Inst Technol, Ctr Operat Res Med & HealthCare, NSF I, IUCRC Ctr Hlth Org Transformat,Sch Ind & Syst Eng, Atlanta, GA 30332 USA. [Pietz, Ferdinand; Burel, Greg] Ctr Dis Control & Prevent, Atlanta, GA 30322 USA. [Benecke, Bernard] Ctr Dis Control & Prevent, Guatemala City, Guatemala. [Mason, Jacquelyn] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30322 USA. RP Lee, EK (reprint author), Georgia Inst Technol, Ctr Operat Res Med & HealthCare, NSF I, IUCRC Ctr Hlth Org Transformat,Sch Ind & Syst Eng, Atlanta, GA 30332 USA. EM eva.lee@gatech.edu; eoj3@cdc.gov; bbenecke@gt.cdc.gov; zao4@cdc.gov; wbu1@cdc.gov FU National Science Foundation (NSF); NSF; CDC grant; US Defense Threat Reduction Agency; two U19 Center from the National Institutes of Health, National Institute of Allergy and Infectious Diseases (a cooperative center for translational research on human immunology, biodefense, and human immune profiling) [U19 AI 057266, U19 AI090023-01]; Whitaker Foundation FX Our work has been supported by the following grants: a National Science Foundation (NSF) grant for theoretical OR advances; a special NSF grant for Japan's radiological events; a CDC grant for public health preparedness response; a classified grant from the US Defense Threat Reduction Agency for tactical and operational capabilities in protecting soldiers from weapons of mass destruction; and two U19 Center grants [U19 AI 057266, U19 AI090023-01] from the National Institutes of Health, National Institute of Allergy and Infectious Diseases (a cooperative center for translational research on human immunology, biodefense, and human immune profiling).; Eva K. Lee is a professor in the H. Milton Stewart School of Industrial and Systems Engineering at Georgia Institute of Technology, and Director of the Center for Operations Research in Medicine and HealthCare, a center established through funds from the National Science Foundation (NSF) and the Whitaker Foundation. The center focuses on biomedicine, public health, and defense, advancing domains from basic science to translational medical research; intelligent, quality, and cost-effective delivery; and medical preparedness and protection of critical infrastructures. She is also the co-director of the Center for Health Organization Transformation, an NSF Industry/University Cooperative Research Center. In this role, she partners with hospital leaders to develop novel transformational strategies in delivery, quality, safety, operations efficiency, information management, change management, and organizational learning. She also served as the Senior Health Systems Professor for the US Department of Veterans Affairs from 2009-2011. NR 45 TC 3 Z9 3 U1 1 U2 19 PU INFORMS PI HANOVER PA 7240 PARKWAY DR, STE 310, HANOVER, MD 21076-1344 USA SN 0092-2102 J9 INTERFACES JI Interfaces PD JAN-FEB PY 2013 VL 43 IS 1 SI SI BP 79 EP 98 DI 10.1287/inte.2013.0676 PG 20 WC Management; Operations Research & Management Science SC Business & Economics; Operations Research & Management Science GA 087WA UT WOS:000314793900007 ER PT J AU Ko, JY Dietz, PM Conrey, EJ Rodgers, L Shellhaas, C Farr, SL Robbins, CL AF Ko, Jean Y. Dietz, Patricia M. Conrey, Elizabeth J. Rodgers, Loren Shellhaas, Cynthia Farr, Sherry L. Robbins, Cheryl L. TI Gestational Diabetes Mellitus and Postpartum Care Practices of Nurse-Midwives SO JOURNAL OF MIDWIFERY & WOMENS HEALTH LA English DT Article DE gestational diabetes mellitus; glucose tolerance test; postpartum care; nurse-midwives; women's health ID GLUCOSE-INTOLERANCE; WOMEN; PREVALENCE; PREGNANCY; RISK AB Introduction: Postpartum screening for glucose intolerance among women with recent histories of gestational diabetes mellitus (GDM) is important for identifying women with continued glucose intolerance after birth, yet screening rates are suboptimal. In a thorough review of the literature, we found no studies of screening practices among certified nurse-midwives (CNMs). The objectives of our study were to estimate the prevalence of postpartum screening for abnormal glucose tolerance and related care by CNMs for women with recent histories of GDM and to identify strategies for improvement. Methods: From October through December 2010, the Ohio Department of Health sent a survey by mail and Internet to all licensed CNMs practicing in Ohio. We calculated prevalence estimates for knowledge, attitudes, clinical practices, and behaviors related to postpartum diabetes screening. Chi-square statistics were used to assess differences in self-reported clinical behaviors by frequency of postpartum screening. Results: Of the 146 CNMs who provided postpartum care and responded to the survey (62.2% response rate), 50.4% reported screening women with GDM-affected pregnancies for abnormal glucose tolerance at the postpartum visit. Of CNMs who screened postpartum, only 48.4% used fasting blood sugar or the 2-hour oral glucose tolerance test. Although 86.2% of all responding CNMs reported that they inform women with recent histories of GDM of their increased risk for type 2 diabetes mellitus, only 63.1% counseled these women to exercise regularly and 23.3% reported referring overweight/obese women to a diet support group or other nutrition counseling. CNMs reported that identification of community resources for lifestyle interventions and additional training in postpartum screening guidelines may help to improve postpartum care. Discussion: CNMs in Ohio reported suboptimal levels of postpartum diabetes testing and use of a recommended postpartum test. Providing CNMs with additional training and identifying community resources to support needed lifestyle behavior change may improve care for women with recent GDM-affected pregnancies. C1 [Ko, Jean Y.; Rodgers, Loren] Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30341 USA. [Ko, Jean Y.; Dietz, Patricia M.; Conrey, Elizabeth J.; Farr, Sherry L.; Robbins, Cheryl L.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. [Conrey, Elizabeth J.; Rodgers, Loren; Shellhaas, Cynthia] Ohio Dept Hlth, Columbus, OH 43266 USA. [Shellhaas, Cynthia] Ohio State Univ, Coll Med, Div Maternal Fetal Med, Columbus, OH 43210 USA. RP Ko, JY (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy,Mailstop K-22, Atlanta, GA 30341 USA. EM JeanKo@cdc.gov RI Shellhaas, Cynthia/E-4077-2011 FU Intramural CDC HHS [CC999999] NR 26 TC 8 Z9 8 U1 5 U2 26 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-9523 J9 J MIDWIFERY WOM HEAL JI J. Midwifery Women Health PD JAN-FEB PY 2013 VL 58 IS 1 BP 33 EP 40 DI 10.1111/j.1542-2011.2012.00261.x PG 8 WC Nursing SC Nursing GA 083NU UT WOS:000314472100005 PM 23317376 ER PT J AU Salzer, JS Carroll, DS Rwego, IB Li, Y Falendysz, EA Shisler, JL Karem, KL Damon, IK Gillespie, TR AF Salzer, Johanna S. Carroll, Darin S. Rwego, Innocent B. Li, Yu Falendysz, Elizabeth A. Shisler, Joanna L. Karem, Kevin L. Damon, Inger K. Gillespie, Thomas R. TI SEROLOGIC EVIDENCE FOR CIRCULATING ORTHOPOXVIRUSES IN PERIDOMESTIC RODENTS FROM RURAL UGANDA SO JOURNAL OF WILDLIFE DISEASES LA English DT Article DE ELISA; monkeypox; Orthopoxvirus; poxvirus; Rattus; rodent; Uganda; Western blot ID MONKEYPOX VIRUS; ANIMAL-MODEL; INFECTION; TRANSMISSION; POXVIRUS; SMALLPOX; AFRICA; ZAIRE; ASSAY AB The prevalence of orthopoxviruses (OPXV) among wildlife, including monkeypox virus (MPXV), remains largely unknown. Outbreaks of human monkeypox in central Africa have been associated with hunting, butchering, and consuming infected forest animals, primarily rodents and primates. Monkeypox cases have not been reported in east Africa, where human contact with wildlife is more limited. Whether this lack of human disease is due to the absence of MPXV in rodents is unknown. However, testing of wildlife beyond the known geographic distribution of human cases of monkeypox has rarely been conducted, limiting our knowledge of the natural distribution of MPXV and other OPXV. To improve our understanding of the natural distribution of OPXV in Africa and related risks to public health, we conducted a serosurvey of peridomestic rodents (Rattus rattus) in and around traditional dwellings in Kabarole District, Uganda, from May 2008 to July 2008. We tested for OPXV antibody in areas free of human monkeypox. Sera from 41% of the R. rattus individuals sampled reacted to OPXV-specific proteins from multiple, purified OPXV samples, but did not react by enzyme-linked immunosorbent assay. The specific OPXV could not be identified because poxvirus DNA was undetectable in corresponding tissues. We conclude that an OPXV or a similar poxvirus is circulating among wild rodents in Uganda. With the known geographic range of OPXV in rodents now increased, factors that dictate OPXV prevalence and disease will be identified. C1 [Salzer, Johanna S.; Gillespie, Thomas R.] Emory Univ, Program Populat Biol Ecol & Evolut, Atlanta, GA 30322 USA. [Salzer, Johanna S.; Carroll, Darin S.; Li, Yu; Karem, Kevin L.; Damon, Inger K.] Ctr Dis Control & Prevent, Poxvirus Program, Poxvirus & Rabies Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Salzer, Johanna S.; Rwego, Innocent B.; Gillespie, Thomas R.] Emory Univ, Dept Environm Studies, Atlanta, GA 30322 USA. [Rwego, Innocent B.] Makerere Univ, Coll Nat Sci, Dept Biol, Kampala, Uganda. [Falendysz, Elizabeth A.] Univ Wisconsin, Coll Vet Med, Madison, WI 53706 USA. [Shisler, Joanna L.] Univ Illinois, Coll Med, Dept Microbiol, Urbana, IL 61801 USA. [Gillespie, Thomas R.] Emory Univ, Dept Environm Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Salzer, JS (reprint author), Emory Univ, Program Populat Biol Ecol & Evolut, Atlanta, GA 30322 USA. EM JSalzer@cdc.gov RI Rwego, Innocent/I-5049-2013 OI Rwego, Innocent/0000-0003-1274-7788 FU Centers for Disease Control and Prevention (CDC); University of Illinois Earth and Society Initiative; University of Illinois Center for Zoonoses Research; National Institutes of Health [T35 2006]; U.S. Department of Energy; CDC FX This work was primarily supported by program funds from the Centers for Disease Control and Prevention (CDC) in addition to support by the University of Illinois Earth and Society Initiative, The University of Illinois Center for Zoonoses Research, and the National Institutes of Health grant T35 2006. This research was supported in part by the appointment of Johanna Salzer to the Research Participation Program at CDC administered by the Oak Ridge Institute for Science and Education (ORISE) through an interagency agreement between the U.S. Department of Energy and the CDC. We thank the Uganda Wildlife Authority and Uganda National Council of Science and Technology for permission to conduct this research. We thank R. Ryan Lash for his cartographic contributions to Figure 1. We thank Anna Czekala, Abigail Mathewson, Clement Nyikiriza, Charles Kyalisima, Derek Meyer, Michele Madonia, and Dennis Twinomugisha for assistance in the field. We thank all the members of the Poxvirus Program at the CDC for continued guidance and assistance in the laboratory. The views expressed in this article are solely those of the authors and do not represent those of the CDC, the U.S. Government, or any other entity with which the authors may be affiliated. NR 26 TC 5 Z9 5 U1 0 U2 9 PU WILDLIFE DISEASE ASSOC, INC PI LAWRENCE PA 810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA SN 0090-3558 J9 J WILDLIFE DIS JI J. Wildl. Dis. PD JAN PY 2013 VL 49 IS 1 BP 125 EP 131 DI 10.7589/2012-04-100 PG 7 WC Veterinary Sciences SC Veterinary Sciences GA 070UM UT WOS:000313538100013 PM 23307378 ER PT J AU Amman, BR Manangan, AP Flietstra, TD Calisher, CH Carroll, DS Wagoner, KD Mills, JN AF Amman, Brian R. Manangan, Arie P. Flietstra, Timothy D. Calisher, Charles H. Carroll, Darin S. Wagoner, Kent D. Mills, James N. TI ASSOCIATION BETWEEN MOVEMENT AND SIN NOMBRE VIRUS (BUNYAVIRIDAE: HANTAVIRUS) INFECTION IN NORTH AMERICAN DEERMICE (PEROMYSCUS MANICULATUS) IN COLORADO SO JOURNAL OF WILDLIFE DISEASES LA English DT Article DE Deermouse; fitness; hantavirus; mark-recapture; minimum convex polygon; movement; Peromyscus maniculatus; Sin Nombre virus ID SOUTHWESTERN UNITED-STATES; CREEK CANAL VIRUS; GENETIC IDENTIFICATION; RODENT POPULATIONS; PULMONARY SYNDROME; ETIOLOGIC AGENT; NATURAL-HISTORY; LONG-TERM; MICE; ANTIBODY AB Capture data from long-term, mark-recapture studies were used to evaluate movements of North American deermice (Peromyscus maniculatus) on mark-recapture webs in Colorado with respect to Sin Nombre virus (SNV) infection status, age, sex, and trapping site. Latitude and longitude coordinates for each capture during the approximately 12-yr study were used to produce an individual minimum convex polygon (MCP) area representing the movements (not home range) of an individual mouse over time. These MCP areas were compared by SNV infection status (as determined by the presence of antibody), age, and sex. Antibody-negative deermice had significantly larger mean MCP areas than did antibody-positive mice. No differences in MCP area were found between male and female mice (either positive or negative). The smaller MCP areas of antibody-positive mice correspond to decreased movement by SNV-infected deermice on the trapping webs. These findings may indicate that SNV has a negative effect on movement, perhaps by reducing the health of infected deermice. C1 [Amman, Brian R.; Flietstra, Timothy D.; Mills, James N.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathogenesis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Manangan, Arie P.] Ctr Dis Control & Prevent, Climate & Hlth Program, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Calisher, Charles H.] Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Microbiol Immunol & Pathol, Arthropod Borne & Infect Dis Lab, Ft Collins, CO 80523 USA. [Carroll, Darin S.] Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Div Viral & Rickettsial Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Wagoner, Kent D.] Univ Tennessee, Off Inst Res & Assessment, Knoxville, TN 37996 USA. RP Amman, BR (reprint author), Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathogenesis, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM bamman@cdc.gov FU U.S. Centers for Disease Control and Prevention, Viral Special Pathogens Branch, Atlanta, Georgia [U50/ccu809862-03] FX We thank the field crews for their efforts over the many years of this study and the Viral Special Pathogens Branch Diagnostic Laboratory for providing reagents and sample testing. We also thank Richard Douglass, Jon Towner, and Rachel Wilson for content and editorial comments. Funding for this work was provided by the U.S. Centers for Disease Control and Prevention, Viral Special Pathogens Branch, Atlanta, Georgia, under cooperative agreement U50/ccu809862-03. NR 50 TC 6 Z9 6 U1 3 U2 22 PU WILDLIFE DISEASE ASSOC, INC PI LAWRENCE PA 810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA SN 0090-3558 J9 J WILDLIFE DIS JI J. Wildl. Dis. PD JAN PY 2013 VL 49 IS 1 BP 132 EP 142 DI 10.7589/2012-02-041 PG 11 WC Veterinary Sciences SC Veterinary Sciences GA 070UM UT WOS:000313538100014 PM 23307379 ER PT J AU Collier, SA Hlavsa, MC Piercefield, EW Beach, MJ AF Collier, Sarah A. Hlavsa, Michele C. Piercefield, Emily W. Beach, Michael J. TI Antimicrobial and Analgesic Prescribing Patterns for Acute Otitis Externa, 2004-2010 SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article DE otitis externa; outpatient visits; antibiotics; antimicrobial resistance; opioids; prescribing patterns ID CLINICAL-PRACTICE GUIDELINE; ACCURACY AB Objective. Acute otitis externa (AOE) is a common but preventable ear condition. Clinical guidelines issued in 2006 recommended topical treatments for uncomplicated AOE, but systemic antimicrobials appear to be commonly prescribed. The objective of this analysis was to describe pre- and postguideline prescribing patterns by clinician specialty and antimicrobial type and assess trends over time. Study Design. Retrospective longitudinal analysis of a large insurance database. Setting. Outpatient departments in the United States. Methods. Initial outpatient visits in 2004 to 2010 for AOE (excluding visits with complicating conditions) were extracted from an insurance database. Prescription drug claims were linked and categorized by clinician specialty and antimicrobial type. Results. The analysis included 907,261 initial outpatient visits. Use of systemic antimicrobials declined by 4.9% (95% confidence interval [CI], 4.1%, 5.7%) from 36.5% of initial visits in 2004 to 32.1% in 2010. Use of systemic antimicrobials varied by specialty. Systemic antimicrobials were prescribed in 47.1% of 2010 emergency department (ED) visits (-6.9% from 2004, 95% CI -12.3, -1.5), 25.9% of otolaryngologist visits (-1.6%, 95% CI -5.6, 2.4), and 20.4% of pediatrician visits (-6.6%, 95% CI -8.8, -4.4). Penicillins were prescribed most frequently (42.3% of systemic prescriptions in 2010), followed by cephalosporins (19.8%), erythromycin/macrolides (17.4%), and quinolones (11.1%). Opioids were prescribed in 26.4% of ED visits and 9% of outpatient visits. Conclusions. Use of systemic antimicrobials declined over time, but one-third of 2010 visits resulted in systemic antimicrobials, despite exclusion of visits with complicating factors. Use of systemic antimicrobials varied by specialty. Further educational efforts and outreach to other specialties might be warranted. C1 [Collier, Sarah A.; Hlavsa, Michele C.; Piercefield, Emily W.; Beach, Michael J.] Ctr Dis Control & Prevent, Natl Ctr Enter & Zoonot Infect Dis, Waterborne Dis Prevent Branch, Atlanta, GA 30333 USA. RP Collier, SA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Mailstop C-09,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM scollier@cdc.gov FU Intramural CDC HHS [CC999999] NR 22 TC 6 Z9 6 U1 0 U2 1 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD JAN PY 2013 VL 148 IS 1 BP 128 EP 134 DI 10.1177/0194599812467000 PG 7 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 092SJ UT WOS:000315142000020 PM 23131826 ER PT J AU Nevin-Woods, C Morita, J Birkhead, G Almquist, J Babcock, H Bednarczyk, R Beigi, R Berlinger, N Bleser, W Borwegen, W Brewer, K Diniega, B Duchin, J Gordon, J Grabowsky, M Groom, A Harriman, K Hart-Malloy, R Hilliard, J Hughes, N Jacobs, A Lewin, C Longmire, A Ludlow, C Martinello, R Piacentino, J Poland, G Ryan, S Rothholz, M Stewart, A Sokas, R Swift, M Tan, L Weissman, D Wharton, M Wu, L Yee, T Zalen, J AF Nevin-Woods, Christine Morita, Julie Birkhead, Guthrie Almquist, Jon Babcock, Hilary Bednarczyk, Robert Beigi, Richard Berlinger, Nancy Bleser, William Borwegen, William Brewer, Katherine Diniega, Benedict Duchin, Jeffrey Gordon, Jennifer Grabowsky, Mark Groom, Amy Harriman, Kathleen Hart-Malloy, Rachel Hilliard, Jennifer Hughes, Nancy Jacobs, Anna Lewin, Clement Longmire, Atkinson Ludlow, Charlene Martinello, Richard Piacentino, John Poland, Gregory Ryan, Shane Rothholz, Mitchel Stewart, Alexandra Sokas, Rosemary Swift, Melanie Tan, Litjen Weissman, David Wharton, Melinda Wu, Lauren Yee, Ted Zalen, Janice CA Natl Vaccine Advisory Comm TI Strategies to Achieve the Healthy People 2020 Annual Influenza Vaccine Coverage Goal for Health-Care Personnel: Recommendations from the National Vaccine Advisory Committee SO PUBLIC HEALTH REPORTS LA English DT Article ID LONG-TERM-CARE; RESPIRATORY SYNCYTIAL VIRUS; IMMUNIZATION PRACTICES ACIP; RANDOMIZED CONTROLLED-TRIAL; UNITED-STATES; PREGNANT-WOMEN; INSTITUTIONAL REQUIREMENTS; PANDEMIC INFLUENZA; ELDERLY-PEOPLE; A H1N1 C1 [Nevin-Woods, Christine] Pueblo Colorado City Cty Hlth Dept, Pueblo, CO USA. [Morita, Julie] Chicago Dept Publ Hlth, Chicago, IL USA. [Birkhead, Guthrie; Bednarczyk, Robert; Hart-Malloy, Rachel] New York State Dept Hlth, Albany, NY 12237 USA. [Stewart, Alexandra] George Washington Univ, Med Ctr, Sch Publ Hlth & Hlth Policy, Washington, DC 20052 USA. [Tan, Litjen] Amer Med Assoc, Chicago, IL 60610 USA. [Wharton, Melinda] CDC, Atlanta, GA 30333 USA. RP Nevin-Woods, C (reprint author), Pueblo Colorado City Cty Hlth Dept, Pueblo, CO USA. NR 78 TC 0 Z9 0 U1 0 U2 5 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD JAN-FEB PY 2013 VL 128 IS 1 BP 7 EP 25 PG 19 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 079SU UT WOS:000314193300003 ER PT J AU Bradley, H Leichliter, JS Gift, TL AF Bradley, Heather Leichliter, Jami S. Gift, Thomas L. TI Does discussing sexually transmissible infections or HIV with a parent increase condom use among young women using other contraceptive methods? SO SEXUAL HEALTH LA English DT Article DE birth control; oral contraceptive pill; United States ID UNITED-STATES; ADOLESCENT COMMUNICATION; PREVALENCE; BEHAVIORS; PATTERNS; FEMALES; SAMPLE AB Background: Young people may be more likely to use condoms if they discuss sexual risks with their parents. However, no previous study has examined whether discussing sexual risks with a parent is differently associated with condom use among women using and not using other contraceptive methods. Methods: Using weighted data from the 2006-2008 National Survey of Family Growth, we examined condom use at last sex among 1206 sexually active unmarried women aged 15-24 years. Using logistic regression, we examined the association between condom use and discussing sexually transmissible infections (STIs) with parents before the age of 18 years, adjusted for women's characteristics (age, ethnicity, income and condom use at first sex). We estimated the predicted probability of condom use by whether women discussed STIs with parents, stratified by use of other contraceptive methods. Results: Overall, 53% of women used condoms at last sex. Among 564 women using other contraceptives, 42% used condoms, versus 64% of 642 women not using other contraceptive methods (P < 0.01). After adjustment for covariates, the predicted probability of condom use among women using other contraceptives was 47% among women who discussed STIs with their parents (v. 31% of those not discussing STIs; P < 0.01). Among women not using other contraceptives, the predicted probability of condom use remained 64% regardless of whether they discussed STIs with their parents. Conclusions: Young women who use other contraceptive methods are less likely to use condoms, but discussing STIs with parents is associated with increased condom use among these women. C1 [Bradley, Heather; Leichliter, Jami S.; Gift, Thomas L.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div STD Prevent, Atlanta, GA 30333 USA. RP Bradley, H (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div STD Prevent, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM iyk5@cdc.gov NR 28 TC 1 Z9 1 U1 3 U2 9 PU CSIRO PUBLISHING PI COLLINGWOOD PA 150 OXFORD ST, PO BOX 1139, COLLINGWOOD, VICTORIA 3066, AUSTRALIA SN 1448-5028 J9 SEX HEALTH JI Sex Health PY 2013 VL 10 IS 1 BP 82 EP 90 DI 10.1071/SH12091 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 089RC UT WOS:000314926700012 PM 23257013 ER PT J AU Asfaw, A Mark, C Pana-Cryan, R AF Asfaw, Abay Mark, Christopher Pana-Cryan, Regina TI Profitability and occupational injuries in U.S. underground coal mines SO ACCIDENT ANALYSIS AND PREVENTION LA English DT Article DE Underground mines; Profitability; Injury; Negative binomial; Panel data ID SAFETY PAY; ACCIDENTS AB Background: Coal plays a crucial role in the U.S. economy yet underground coal mining continues to be one of the most dangerous occupations in the country. In addition, there are large variations in both profitability and the incidence of occupational injuries across mines. Objective: The objective of this study was to examine the association between profitability and the incidence rate of occupational injuries in U.S. underground coal mines between 1992 and 2008. Data and method: We used mine-specific data on annual hours worked, geographic location, and the number of occupational injuries suffered annually from the employment and accident/injury databases of the Mine Safety and Health Administration, and mine-specific data on annual revenue from coal sales, mine age, workforce union status, and mining method from the U.S. Energy Information Administration. A total of 5669 mine-year observations (number of mines x number of years) were included in our analysis. We used a negative binomial random effects model that was appropriate for analyzing panel (combined time-series and cross-sectional) injury data that were non-negative and discrete. The dependent variable, occupational injury, was measured in three different and non-mutually exclusive ways: all reported fatal and nonfatal injuries, reported nonfatal injuries with lost workdays, and the 'most serious' (i.e. sum of fatal and serious nonfatal) injuries reported. The total number of hours worked in each mine and year examined was used as an exposure variable. Profitability, the main explanatory variable, was approximated by revenue per hour worked. Our model included mine age, workforce union status, mining method, and geographic location as additional control variables. Results: After controlling for other variables, a 10% increase in real total revenue per hour worked was associated with 0.9%, 1.1%. and 1.6% decrease, respectively, in the incidence rates of all reported injuries, reported injuries with lost workdays, and the most serious injuries reported. Conclusion: We found an inverse relationship between profitability and each of the three indicators of occupational injuries we used. These results might be partially due to factors that affect both profitability and safety, such as management or engineering practices, and partially due to lower investments in safety by less profitable mines, which could imply that some financially stressed mines might be so focused on survival that they forgo investing in safety. Published by Elsevier Ltd. C1 [Asfaw, Abay; Pana-Cryan, Regina] NIOSH, Ctr Dis Control & Prevent CDC, Washington, DC USA. [Mark, Christopher] Coal Mine Safety & Hlth Mine Safety & Hlth Adm MS, Pittsburgh, PA USA. RP Asfaw, A (reprint author), NIOSH, Ctr Dis Control & Prevent CDC, Washington, DC USA. EM hqp0@cdc.gov FU Intramural CDC HHS [CC999999] NR 50 TC 14 Z9 14 U1 3 U2 26 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0001-4575 J9 ACCIDENT ANAL PREV JI Accid. Anal. Prev. PD JAN PY 2013 VL 50 BP 778 EP 786 DI 10.1016/j.aap.2012.07.002 PG 9 WC Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation SC Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation GA 079SD UT WOS:000314191600089 PM 22884379 ER PT J AU Yu, BR Zhang, XJ Wang, GJ AF Yu, Baorong Zhang, Xiaojuan Wang, Guijing TI Full Coverage for Hypertension Drugs in Rural Communities in China SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID MEDICATION ADHERENCE; CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; GLOBAL BURDEN; HOSPITALIZATION COSTS; LIAONING PROVINCE; HEART-FAILURE; ADULTS; PREVALENCE; AWARENESS AB Background: The control rate for hypertension is unacceptably low worldwide, and poor adherence to medication is a primary reason. Objectives: To evaluate the impact of full coverage for hypertension drugs on adherence to medication, medical costs, and hypertension control in Shandong Province, China. Methods: In November 2009, we interviewed 110 hypertensive patients who had been participating in a free medication program since May 2008 and 241 hypertensive patients who were not participating. We used a 1:1 propensity-score matching technique to obtain matched samples of 102 program participants (intervention) and 102 nonparticipants (control). We used univariate analysis to compare patient drug-taking behaviors, medical costs, and hypertension control between the 2 groups. Results: All intervention patients took >1 drugs for hypertension control and 93% of them took >3 such drugs, 15 control patients (15%) did not take any, and only 39% took 3 or more (P <.001). Three-fourths (75%) of the intervention patients took the prescribed drugs regularly, whereas 66% of the control group (P = .034) did so. Participation in the program was associated with lower annual out-of-pocket medical costs both overall and for outpatient services (P < .001 for both). Conclusions: Low-income rural residents in China receiving free drugs had enhanced medication adherence and reduced total medical costs. Providing hypertension drugs at no charge may be a promising strategy for preventing costly cardiovascular events associated with hypertension in China and other parts of the world with growing rates of cardiovascular disease. (Am J Manag Care. 2013;19(1):e22-e29) C1 [Yu, Baorong] Univ Int Business & Econ, Sch Insurance & Econ, Beijing, Peoples R China. [Zhang, Xiaojuan] Chinese Acad Med Sci, Inst Med Informat, Beijing 100730, Peoples R China. [Wang, Guijing] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30341 USA. RP Wang, GJ (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, 4770 Buford Hwy, Atlanta, GA 30341 USA. EM gbw9@cdc.gov FU Intramural CDC HHS [CC999999] NR 37 TC 5 Z9 5 U1 0 U2 8 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD JAN PY 2013 VL 19 IS 1 BP E22 EP E27 PG 6 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 085NN UT WOS:000314621600012 PM 23379776 ER PT J AU Rossen, LM Milsom, VA Middleton, KR Daniels, MJ Perri, MG AF Rossen, Lauren M. Milsom, Vanessa A. Middleton, Kathryn R. Daniels, Michael J. Perri, Michael G. TI Benefits and risks of weight-loss treatment for older, obese women SO CLINICAL INTERVENTIONS IN AGING LA English DT Article DE lifestyle intervention; adverse events; metabolic risk factors ID BODY-MASS INDEX; LIFE-STYLE MODIFICATION; EXTENDED-CARE PROGRAMS; BEHAVIORAL TREATMENT; RANDOMIZED-TRIAL; BLOOD-PRESSURE; FOLLOW-UP; ADULTS; MORTALITY; OVERWEIGHT AB Background: A key issue in the treatment of obesity in older adults is whether the health benefits of weight loss outweigh the potential risks with respect to musculoskeletal injury. Objective: To compare change in weight, improvements in metabolic risk factors, and reported musculoskeletal adverse events in middle-aged (50-59 years) and older (65-74 years), obese women. Materials and methods: Participants completed an initial 6-month lifestyle intervention for weight loss, comprised of weekly group sessions, followed by 12 months of extended care with biweekly contacts. Weight and fasting blood samples were assessed at baseline, month 6, and month 18; data regarding adverse events were collected throughout the duration of the study. Results: Both middle-aged (n = 162) and older (n = 56) women achieved significant weight reductions from baseline to month 6 (10.1 +/- 0.68 kg and 9.3 +/- 0.76 kg, respectively) and maintained a large proportion of their losses at month 18 (7.6 +/- 0.87 kg and 7.6 +/- 1.3 kg, respectively); there were no significant differences between the two groups with respect to weight change. Older women further experienced significant reductions in systolic blood pressure, HbA(1c), and C-reactive protein from baseline to month 6 and maintained these improvements at month 18. Despite potential safety concerns, we found that older women were no more likely to experience musculoskeletal adverse events during the intervention as compared with their middle-aged counterparts. Conclusion: These results suggest that older, obese women can experience significant health benefits from lifestyle treatment for obesity, including weight loss and improvements in disease risk factors. Further investigation of the impact of weight loss on additional health-related parameters and risks (eg, body composition, muscular strength, physical functioning, and injuries) in older adults is needed. C1 [Rossen, Lauren M.; Milsom, Vanessa A.; Middleton, Kathryn R.; Perri, Michael G.] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL 32610 USA. [Rossen, Lauren M.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Milsom, Vanessa A.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Middleton, Kathryn R.] Brown Univ, Dept Psychiat & Human Behav, Weight Control & Diabet Res Ctr, Warren Alpert Med Sch, Providence, RI 02912 USA. [Middleton, Kathryn R.] Miriam Hosp, Providence, RI 02906 USA. [Daniels, Michael J.] Univ Florida, Dept Stat, Gainesville, FL 32610 USA. [Daniels, Michael J.] Univ Texas Austin, Div Stat & Sci Computat, Austin, TX 78712 USA. [Perri, Michael G.] Univ Florida, Coll Publ Hlth & Hlth Profess, Gainesville, FL 32610 USA. RP Perri, MG (reprint author), Univ Florida, Coll Publ Hlth & Hlth Profess, POB 100185, Gainesville, FL 32610 USA. EM mperri@phhp.ufl.edu RI Middleton, Kathryn/D-2551-2013 OI Middleton, Kathryn/0000-0002-7225-649X FU National Heart, Lung and Blood Institute [R18HL73326]; University of Florida FX This research was supported by grant R18HL73326 from the National Heart, Lung and Blood Institute. Publication of this article was funded in part by the University of Florida Open Access Publishing Fund. NR 43 TC 4 Z9 4 U1 2 U2 19 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1176-9092 J9 CLIN INTERV AGING JI Clin. Interv. Aging PY 2013 VL 8 BP 157 EP 165 DI 10.2147/CIA.S38155 PG 9 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 088OB UT WOS:000314843400001 PM 23430455 ER PT J AU Pihoker, C Badaru, A Anderson, A Morgan, T Dolan, L Dabelea, D Imperatore, G Linder, B Marcovina, S Mayer-Davis, E Reynolds, K Klingensmith, GJ AF Pihoker, Catherine Badaru, Angela Anderson, Andrea Morgan, Timothy Dolan, Lawrence Dabelea, Dana Imperatore, Giuseppina Linder, Barbara Marcovina, Santica Mayer-Davis, Elizabeth Reynolds, Kristi Klingensmith, Georgeanna J. CA SEARCH Diabet Youth Study Grp TI Insulin Regimens and Clinical Outcomes in a Type 1 Diabetes Cohort The SEARCH for Diabetes in Youth study SO DIABETES CARE LA English DT Article ID CHILDREN; COMPLICATIONS; ADOLESCENTS; FREQUENCY; CARE AB OBJECTIVE-To examine the patterns and associations of insulin regimens and change in regimens with clinical outcomes in a diverse population of children with recently diagnosed type 1 diabetes. RESEARCH DESIGN AND METHODS-The study sample consisted of youth with type 1 diabetes who completed a baseline SEARCH for Diabetes in Youth study visit after being newly diagnosed and at least one follow-up visit. Demographic, diabetes self-management, physical, and laboratory measures were collected at study visits. Insulin regimens and change in regimen compared with the initial visit were categorized as more intensive (MI), no change (NC), or less intensive (LI). We examined relationships between insulin regimens, change in regimen, and outcomes including A1C and fasting C-peptide. RESULTS-Of the 1,606 participants with a mean follow-up of 36 months, 51.7% changed to an MI regimen, 44.7% had NC, and 3.6% changed to an LI regimen. Participants who were younger, non-Hispanic white, and from families of higher income and parental education and who had private health insurance were more likely to be in MI or NC groups. Those in MI and NC groups had lower baseline A1C (P = 0.028) and smaller increase in A1C over time than LI (P < 0.01). Younger age, continuous subcutaneous insulin pump therapy, and change to MI were associated with higher probability of achieving target A1C levels. CONCLUSIONS-Insulin regimens were intensified over time in over half of participants but varied by sociodemographic domains. As more intensive regimens were associated with better outcomes, early intensification of management may improve outcomes in all children with diabetes. Although intensification of insulin regimen is preferred, choice of insulin regimen must be individualized based on the child and family's ability to comply with the prescribed plan. Diabetes Care 36: 27-33, 2013 C1 [Pihoker, Catherine; Badaru, Angela] Univ Washington, Dept Pediat, Seattle, WA 98195 USA. [Anderson, Andrea; Morgan, Timothy] Wake Forest Univ, Bowman Gray Sch Med, Dept Biostat, Winston Salem, NC USA. [Dolan, Lawrence] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati Childrens Hosp, Cincinnati, OH USA. [Dabelea, Dana] Univ Colorado Denver, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA. [Imperatore, Giuseppina] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Linder, Barbara] NIDDKD, NIH, Bethesda, MD 20892 USA. [Marcovina, Santica] Univ Washington, Dept Med, Seattle, WA USA. [Mayer-Davis, Elizabeth] Univ N Carolina, Dept Nutr, Chapel Hill, NC USA. [Mayer-Davis, Elizabeth] Univ N Carolina, Dept Med, Chapel Hill, NC USA. [Reynolds, Kristi] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA USA. [Klingensmith, Georgeanna J.] Univ Colorado Denver, Sch Med, Barbara Davis Ctr, Aurora, CO USA. [Klingensmith, Georgeanna J.] Univ Colorado Denver, Sch Med, Dept Pediat, Aurora, CO USA. RP Pihoker, C (reprint author), Univ Washington, Dept Pediat, Seattle, WA 98195 USA. EM catherine.pihoker@seattlechildrens.org FU Centers for Disease Control and Prevention [00097, DP-05-069, DP-10-001]; National Institute of Diabetes and Digestive and Kidney Diseases; Kaiser Permanente Southern California [U48/CCU919219, U01 DP000246, U18DP002714]; University of Colorado Denver [U48/CCU819241-3, U01 DP000247, U18DP000247-06A1]; Kuakini Medical Center [U58CCU919256, U01 DP000245]; Children's Hospital Medical Center (Cincinnati) [U48/CCU519239, U01 DP000248, 1U18DP002709]; University of North Carolina at Chapel Hill [U48/CCU419249, U01 DP000254, U18DP002708-01]; University of Washington School of Medicine [U58/CCU019235-4, U01 DP000244, U18DP002710-01]; Wake Forest University School of Medicine [U48/CCU919219, U01 DP000250, 200-2010-35171]; National Institutes of Health/National Center for Research Resources [UL1RR029882]; Children's Hospital and Regional Medical Center [M01RR00037]; Colorado Pediatric General Clinical Research Center [M01 RR00069]; Barbara Davis Center at the University of Colorado at Denver [DERC NIH P30 DK57516]; Institutional Clinical and Translational Science Award, National Institutes of Health/National Center for Research Resources, at the University of Cincinnati [1UL1RR026314-01] FX SEARCH for Diabetes in Youth is funded by the Centers for Disease Control and Prevention (PA nos. 00097, DP-05-069, and DP-10-001) and supported by the National Institute of Diabetes and Digestive and Kidney Diseases. Site contract nos. are as follows: Kaiser Permanente Southern California (U48/CCU919219, U01 DP000246, and U18DP002714), University of Colorado Denver (U48/CCU819241-3, U01 DP000247, and U18DP000247-06A1), Kuakini Medical Center (U58CCU919256 and U01 DP000245), Children's Hospital Medical Center (Cincinnati) (U48/CCU519239, U01 DP000248, and 1U18DP002709), University of North Carolina at Chapel Hill (U48/CCU419249, U01 DP000254, and U18DP002708-01), University of Washington School of Medicine (U58/CCU019235-4, U01 DP000244, and U18DP002710-01), and Wake Forest University School of Medicine (U48/CCU919219, U01 DP000250, and 200-2010-35171). The authors acknowledge the involvement of general clinical research centers at the South Carolina Clinical & Translational Research Institute, Medical University of South Carolina (National Institutes of Health/National Center for Research Resources Grant UL1RR029882); Children's Hospital and Regional Medical Center (Grant M01RR00037); Colorado Pediatric General Clinical Research Center (Grant M01 RR00069) and the Barbara Davis Center at the University of Colorado at Denver (DERC NIH P30 DK57516); and the Institutional Clinical and Translational Science Award, National Institutes of Health/National Center for Research Resources, at the University of Cincinnati (grant 1UL1RR026314-01). NR 15 TC 18 Z9 19 U1 0 U2 4 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD JAN PY 2013 VL 36 IS 1 BP 27 EP 33 DI 10.2337/dc12-0720 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 083LP UT WOS:000314465700027 PM 22961571 ER PT J AU Saydah, SH Imperatore, G Beckles, GL AF Saydah, Sharon H. Imperatore, Giuseppina Beckles, Gloria L. TI Socioeconomic Status and Mortality Contribution of health care access and psychological distress among US adults with diagnosed diabetes SO DIABETES CARE LA English DT Article ID ALL-CAUSE MORTALITY; EDUCATIONAL-LEVEL; RISK-FACTORS; LIFE-COURSE; FOLLOW-UP; POSITION; INEQUALITIES; ASSOCIATION; DEPRESSION; BEHAVIORS AB OBJECTIVE-Although several studies have examined the association between socioeconomic status (SES) and mortality in the general population, few have investigated this relationship among people with diabetes. This study sought to determine how risk of mortality associated with measures of SES among adults with diagnosed diabetes is mitigated by association with demographics, comorbidities, diabetes treatment, psychological distress, or health care access and utilization. RESEARCH DESIGN AND METHODS-The study included 6,177 adults aged 25 years or older with diagnosed diabetes who participated in the National Health Interview Surveys (1997-2003) linked to mortality data (follow-up through 2006). SES was measured by education attained, financial wealth (either stocks/dividends or home ownership), and income-to-poverty ratio. RESULTS-In unadjusted analysis, risk of death was significantly greater for people with lower levels of education and income-to-poverty ratio than for those at the highest levels. After adjusting for demographics, comorbidities, diabetes treatment and duration, health care access, and psychological distress variables, the association with greater risk of death remained significant only for people with the lowest level of education (relative hazard 1.52 [95% CI 1.04-2.23]). After multivariate adjustment, the risk of death was significantly greater for people without certain measures of financial wealth (e. g., stocks, home ownership) (1.56 [1.07-2.27]) than for those with them. CONCLUSIONS-The findings suggest that after adjustments for demographics, health care access, and psychological distress, the level of education attained and financial wealth remain strong predictors of mortality risk among adults with diabetes. Diabetes Care 36: 49-55, 2013 C1 [Saydah, Sharon H.; Imperatore, Giuseppina; Beckles, Gloria L.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30329 USA. RP Saydah, SH (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30329 USA. EM ssaydah@cdc.gov NR 40 TC 33 Z9 33 U1 2 U2 10 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD JAN PY 2013 VL 36 IS 1 BP 49 EP 55 DI 10.2337/dc11-1864 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 083LP UT WOS:000314465700030 PM 22933434 ER PT J AU Hoerger, TJ Schillie, S Wittenborn, JS Bradley, CL Zhou, FJ Byrd, K Murphy, TV AF Hoerger, Thomas J. Schillie, Sarah Wittenborn, John S. Bradley, Christina L. Zhou, Fangjun Byrd, Kathy Murphy, Trudy V. TI Cost-Effectiveness of Hepatitis B Vaccination in Adults With Diagnosed Diabetes SO DIABETES CARE LA English DT Article ID PREVENT HERPES-ZOSTER; VIRUS-INFECTION; UNITED-STATES; POSTHERPETIC NEURALGIA; ECONOMIC-ANALYSIS; OLDER-ADULTS; DISEASE AB OBJECTIVE-To examine the cost-effectiveness of a hepatitis B vaccination program for unvaccinated adults with diagnosed diabetes in the U. S. RESEARCH DESIGN AND METHODS-We used a cost-effectiveness simulation model to estimate the cost-effectiveness of vaccinating adults 20-59 years of age with diagnosed diabetes not previously vaccinated for or infected by hepatitis B virus (HBV). The model estimated acute and chronic HBV infections, complications, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. Data sources included surveillance data, epidemiological studies, and vaccine prices. RESULTS-With a 10% uptake rate, the intervention will vaccinate 528,047 people and prevent 4,271 acute and 256 chronic hepatitis B infections. Net health care costs will increase by $91.4 million, and 1,218 QALYs will be gained, producing a cost-effectiveness ratio of $75,094 per QALY gained. Results are most sensitive to age, the discount rate, the hepatitis B incidence ratio for people with diabetes, and hepatitis B infection rates. Cost-effectiveness ratios rise with age at vaccination; an alternative intervention that vaccinates adults with diabetes 60 years of age or older had a cost-effectiveness ratio of $2.7 million per QALY. CONCLUSIONS-Hepatitis B vaccination for adults with diabetes 20-59 years of age is modestly cost-effective. Vaccinating older adults with diabetes is not cost-effective. The study did not consider hepatitis outbreak investigation costs, and limited information exists on hepatitis progression among older adults with diabetes. Partly based on these results, the Advisory Committee on Immunization Practices recently recommended hepatitis B vaccination for people 20-59 years of age with diagnosed diabetes. Diabetes Care 36: 63-69, 2013 C1 [Hoerger, Thomas J.; Bradley, Christina L.] RTI Int, Res Triangle Pk, NC 27709 USA. [Schillie, Sarah; Zhou, Fangjun; Byrd, Kathy; Murphy, Trudy V.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Wittenborn, John S.] Univ Chicago, NORC, Atlanta, GA USA. RP Hoerger, TJ (reprint author), RTI Int, Res Triangle Pk, NC 27709 USA. EM tjh@rti.org FU CDC [200-2009-30991 TO3] FX This study was supported by the CDC (contract 200-2009-30991 TO3). NR 27 TC 14 Z9 15 U1 0 U2 8 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD JAN PY 2013 VL 36 IS 1 BP 63 EP 69 DI 10.2337/dc12-0759 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 083LP UT WOS:000314465700032 PM 22933435 ER PT J AU Culwell, KR Curtis, KM AF Culwell, Kelly R. Curtis, Kathryn M. TI Contraception for women with systemic lupus erythematosus SO JOURNAL OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE LA English DT Editorial Material ID ANTIPHOSPHOLIPID ANTIBODIES; ORAL-CONTRACEPTIVES; VENOUS THROMBOSIS; RISK; MENORRHAGIA; SAFETY; COHORT C1 [Culwell, Kelly R.] Univ Calif Davis, Dept Obstet & Gynecol, Sacramento, CA 95819 USA. [Curtis, Kathryn M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. RP Culwell, KR (reprint author), Univ Calif Davis, Dept Obstet & Gynecol, 4860 Y St, Sacramento, CA 95819 USA. EM Kelly.culwell@ucdmc.ucdavis.edu NR 21 TC 3 Z9 3 U1 0 U2 3 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1471-1893 J9 J FAM PLAN REPROD H JI J. Fam. Plan. Reprod. Health Care PD JAN PY 2013 VL 39 IS 1 BP 9 EP 11 DI 10.1136/jfprhc-2012-100437 PG 3 WC Family Studies; Obstetrics & Gynecology; Social Sciences, Biomedical SC Family Studies; Obstetrics & Gynecology; Biomedical Social Sciences GA 080QY UT WOS:000314259600003 PM 23104972 ER PT J AU Power, ML Wilson, EK Hogan, SO Loft, JD Williams, JL Mersereau, PW Schulkin, J AF Power, Michael L. Wilson, Ellen K. Hogan, Sean O. Loft, John D. Williams, Jennifer L. Mersereau, Patricia W. Schulkin, Jay TI Patterns of Preconception, Prenatal and Postnatal Care for Diabetic Women by Obstetrician-Gynecologists SO JOURNAL OF REPRODUCTIVE MEDICINE LA English DT Article DE clinical care; diabetes; pregnancy ID AMBULATORY RESEARCH NETWORK; OUTPATIENT OBSTETRICS; MELLITUS; PREGNANCY; PREVALENCE; DISPARITIES; OBESITY; MOTHERS; TRENDS; RISK AB OBJECTIVE: To assess barriers to and quality of care received by diabetic pregnant women from obstetrician-gynecologists. STUDY DESIGN: A questionnaire was mailed to 1,000 representative practicing Fellows of the American College of Obstetricians and Gynecologists; 74 did not treat pregnant patients and 510 (55.1%) returned completed surveys. Respondents were divided into 3 groups: maternal-fetal medicine specialists, physicians with high minority/low insurance patient populations, and physicians with low minority/high insurance patient populations. RESULTS: Reported preconception and prenatal care was generally consistent with guidelines. Regarding gestational diabetes mellitus patients the 3 physician groups differed in assessing postpartum glycemic status, counseling about lifestyle changes, and counseling patients to consult a doctor before their next pregnancy. Patient demographics and perceived barriers to care were similar between maternal-fetal medicine specialists and physicians with high minority/low insurance patient populations. These two physician groups were more likely to agree that lack of educational materials, arranging specialist referrals, patient compliance with recommendations, and patients' ability to afford healthful food were barriers to quality care. CONCLUSION: According to physician self-report, pregnant diabetic patients with access to an obstetrician receive quality care regardless of insurance status. Postpartum care is more variable. Physicians with high minority/low insurance patient populations may lack access to resources. (J Reprod Med 2013;58:7-14) C1 Amer Coll Obstetricians & Gynecologists, Washington, DC 20024 USA. RTI Int, Chicago, IL USA. Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. SciMetrika LLC, Atlanta, GA USA. RP Power, ML (reprint author), Amer Coll Obstetricians & Gynecologists, Dept Res, 409 12th St SW,POB 96920, Washington, DC 20024 USA. EM mpower@acog.org FU National Center on Birth Defects and Developmental Disabilities in the Centers for Disease Control and Prevention; RTI International; American College of Obstetricians and Gynecologists; American College of Obstetricians and Gynecologists from the Maternal and Child Health Bureau; Health Resources and Services Administration; Department of Health and Human Services; [UA6MC19010] FX Research funded through a cooperative agreement among the National Center on Birth Defects and Developmental Disabilities in the Centers for Disease Control and Prevention, RTI International, and the American College of Obstetricians and Gynecologists, and by cooperative agreement UA6MC19010 with the American College of Obstetricians and Gynecologists from the Maternal and Child Health Bureau, Health Resources and Services Administration, Department of Health and Human Services. NR 25 TC 4 Z9 4 U1 0 U2 8 PU SCI PRINTERS & PUBL INC PI ST LOUIS PA PO DRAWER 12425 8342 OLIVE BLVD, ST LOUIS, MO 63132 USA SN 0024-7758 J9 J REPROD MED JI J. Reprod. Med. PD JAN-FEB PY 2013 VL 58 IS 1-2 BP 7 EP 14 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 084TN UT WOS:000314562100003 PM 23447912 ER PT J AU Karras, NA Weeres, M Sessions, W Xu, XY DeFor, T Young, JAH Stefanski, H Brunstein, C Cooley, S Miller, JS Blazar, BR Wagner, JE Verneris, MR AF Karras, Nicole A. Weeres, Matthew Sessions, Wendy Xu, Xiyan DeFor, Todd Young, Jo-Anne H. Stefanski, Heather Brunstein, Claudio Cooley, Sarah Miller, Jeffrey S. Blazar, Bruce R. Wagner, John E. Verneris, Michael R. TI A Randomized Trial of One versus Two Doses of Influenza Vaccine after Allogeneic Transplantation SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE BMT; UCB transplantation; Vaccine; Influenza ID RESPIRATORY VIRUS-INFECTIONS; STEM-CELL TRANSPLANTATION; CORD BLOOD TRANSPLANTATION; MARROW-TRANSPLANTATION; ANTIBODY-RESPONSE; ADULT RECIPIENTS; TRACT INFECTIONS; T-LYMPHOCYTES; EXPRESSION; EXPERIENCE AB Influenza infection after allogeneic hematopoietic cell transplantation (allo-HCT) can result in severe complications. The effectiveness of the annual vaccine depends on age, immune competence, and the antigenic potential of the 3 strains included. We hypothesized that a second vaccine dose, the standard of care for vaccine-naive children, might improve post hematopoietic cell transplantation (HCT) immune responses. Patients > 60 days post-HCT were randomized to receive either 1 (n = 33) or 2 (n = 32) influenza vaccine doses separated by 1 month. The primary endpoint was whether 2 vaccinations induced superior immunity; however, we found no difference. Secondary endpoints were to identify variables associated with responses. Both hemagglutination inhibition (HI; P < .005) and ELISpot responses (P = .03) were greater for patients vaccinated >= 1 year posttransplantation. Umbilical cord blood (UCB) recipients showed less IFN-gamma responses (P < .001). Interestingly, there was a positive correlation between the total number of CD19(+) cells before vaccination and seroconversion (P = .01) and an inverse correlation for IFN-gamma responses (P = .05). Variables not associated with vaccine responses included prevaccine CD4(+) cell counts (total, naive, or memory), steroid usage at vaccination, age, or conditioning intensity. Time from transplantation to vaccination and absolute CD19(+) cell counts were the strongest predictors of vaccine responses. Methods to improve influenza vaccine responses after allo-HCT are needed. (C) 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved. C1 [Karras, Nicole A.; Weeres, Matthew; Stefanski, Heather; Blazar, Bruce R.; Wagner, John E.; Verneris, Michael R.] Univ Minnesota, Dept Pediat, Div Hematol Oncol & Blood & Marrow Transplantat, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA. [Sessions, Wendy; Xu, Xiyan] Ctr Dis Control, Atlanta, GA 30333 USA. [DeFor, Todd] Univ Minnesota, Masonic Canc Ctr, Biostat Core, Minneapolis, MN 55455 USA. [Young, Jo-Anne H.] Univ Minnesota, Dept Med, Div Infect Dis, Minneapolis, MN 55455 USA. [Brunstein, Claudio; Cooley, Sarah; Miller, Jeffrey S.] Univ Minnesota, Hematol Oncol & Transplantat Dept Med, Minneapolis, MN 55455 USA. RP Verneris, MR (reprint author), Univ Minnesota, Dept Pediat, Div Hematol Oncol & Blood & Marrow Transplantat, Dept Lab Med & Pathol, 660 CCRB,425 E River Rd, Minneapolis, MN 55455 USA. EM verneris@umn.edu RI Young, Jo-Anne/G-2617-2013; OI Young, Jo-Anne/0000-0003-4182-341X; Miller, Jeffrey S/0000-0002-0339-4944 FU NCI NIH HHS [R01 CA072669, P01 CA065493]; NIAID NIH HHS [R01 AI034495]; NICHD NIH HHS [K12 HD068322] NR 33 TC 6 Z9 6 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD JAN PY 2013 VL 19 IS 1 BP 109 EP 116 DI 10.1016/j.bbmt.2012.08.015 PG 8 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 076ZP UT WOS:000313998000017 PM 22940056 ER PT J AU Gryder, BE Nelson, CW Shepard, SS AF Gryder, Berkley E. Nelson, Chase W. Shepard, Samuel S. TI Biosemiotic Entropy of the Genome: Mutations and Epigenetic Imbalances Resulting in Cancer SO ENTROPY LA English DT Article DE genetics; epigenetics; semiotics; cancer; biosemiotic entropy; homeostasis; gene mutations; population genetics; chromatin architecture; encode ID ANDROGEN RECEPTOR; PROSTATE-CANCER; HISTONE MODIFICATIONS; LETHAL MUTAGENESIS; NONCODING RNA; HUMAN-DISEASE; DNA-REPAIR; JUNK DNA; THERAPY; EVOLUTION AB Biosemiotic entropy involves the deterioration of biological sign systems. The genome is a coded sign system that is connected to phenotypic outputs through the interpretive functions of the tRNA/ribosome machinery. This symbolic sign system (semiosis) at the core of all biology has been termed "biosemiosis". Layers of biosemiosis and cellular information management are analogous in varying degrees to the semiotics of computer programming, spoken, and written human languages. Biosemiotic entropy-an error or deviation from a healthy state-results from errors in copying functional information (mutations) and errors in the appropriate context or quantity of gene expression (epigenetic imbalance). The concept of biosemiotic entropy is a deeply imbedded assumption in the study of cancer biology. Cells have a homeostatic, preprogrammed, ideal or healthy state that is rooted in genomics, strictly orchestrated by epigenetic regulation, and maintained by DNA repair mechanisms. Cancer is an eminent illustration of biosemiotic entropy, in which the corrosion of genetic information via substitutions, deletions, insertions, fusions, and aberrant regulation results in malignant phenotypes. However, little attention has been given to explicitly outlining the paradigm of biosemiotic entropy in the context of cancer. Herein we distill semiotic theory (from the familiar and well understood spheres of human language and computer code) to draw analogies useful for understanding the operation of biological semiosis at the genetic level. We propose that the myriad checkpoints, error correcting mechanisms, and immunities are all systems whose primary role is to defend against the constant pressure of biosemiotic entropy, which malignancy must shut down in order to achieve advanced stages. In lieu of the narrower tumor suppressor/oncogene model, characterization of oncogenesis into the biosemiotic framework of sign, index, or object entropy may allow for more effective explanatory hypotheses for cancer diagnosis, with consequence in improving profiling and bettering therapeutic outcomes. C1 [Gryder, Berkley E.] Georgia Inst Technol, Sch Chem & Biochem, Parker H Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA. [Nelson, Chase W.] Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA. [Shepard, Samuel S.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. RP Gryder, BE (reprint author), Georgia Inst Technol, Sch Chem & Biochem, Parker H Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA. EM berkley.gryder@gatech.edu; nelsoncw@email.sc.edu; vfn4@cdc.gov FU Center for Drug Design, Development and Delivery (CD4); University of South Carolina; U.S. Department of Energy; CDC FX We thank the editors and reviewers for their guidance and very helpful comments. We also thank John C. Sanford and Robert W. Carter for their valuable comments and conversations throughout the development of this manuscript, and we thank the editors of Entropy for the opportunity to publish this work. B.E. Gryder is thankful for support by the Georgia Tech GAANN fellowship from the Center for Drug Design, Development and Delivery (CD4). C.W. Nelson is grateful for support from a teaching assistantship and Presidential Fellowship from the University of South Carolina. S.S. Shepard is supported by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and CDC. This review was co-authored by S.S. Shepard in his private capacity. No official support or endorsement by the Centers for Disease Control and Prevention, Department of Health and Human Services is intended, nor should be inferred. NR 101 TC 4 Z9 4 U1 4 U2 23 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 1099-4300 J9 ENTROPY-SWITZ JI Entropy PD JAN PY 2013 VL 15 IS 1 BP 234 EP 261 DI 10.3390/e15010234 PG 28 WC Physics, Multidisciplinary SC Physics GA 077IV UT WOS:000314022000013 ER PT J AU O'Leary, A Wolitski, RJ AF O'Leary, Ann Wolitski, Richard J. TI Disclosure, sex and moral agency: A response to Groves, Maman and Moodley SO GLOBAL PUBLIC HEALTH LA English DT Letter ID HIV C1 [O'Leary, Ann; Wolitski, Richard J.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30329 USA. RP O'Leary, A (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30329 USA. EM aoleary@cdc.gov NR 4 TC 0 Z9 0 U1 0 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1744-1692 J9 GLOB PUBLIC HEALTH JI Glob. Public Health PD JAN 1 PY 2013 VL 8 IS 1 BP 120 EP 122 DI 10.1080/17441692.2012.760640 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 081VY UT WOS:000314351700009 PM 23356347 ER PT J AU Sommers, BD Buchmueller, T Decker, SL Carey, C Kronick, R AF Sommers, Benjamin D. Buchmueller, Thomas Decker, Sandra L. Carey, Colleen Kronick, Richard TI The Affordable Care Act Has Led To Significant Gains In Health Insurance And Access To Care For Young Adults SO HEALTH AFFAIRS LA English DT Article ID COVERAGE; WORK AB The Affordable Care Act enables young adults to remain as dependents on their parents' health insurance until age twenty-six, and recent evidence suggests that as many as three million young adults have gained coverage as a result. However, there has been no evidence yet on the policy's effect on access to care, and questions remain about the coverage impact on important subgroups. Using data from two nationally representative surveys, comparing young adults who gained access to dependent coverage to a control group (adults ages 26-34) who were not affected by the new policy, we found sizable coverage gains for adults ages 19-25. The gains continued to grow throughout 2011 (up 6.7 percentage points from September 2010 to September 2011), with the largest gains seen in unmarried adults, nonstudents, and men. Analysis of the timing of the policy impact suggested that early gains in coverage were greatest for people in worse health. We found strong evidence of increased access to care because of the law, with significant reductions in the number of young adults who delayed getting care and in those who did not receive needed care because of cost. C1 [Sommers, Benjamin D.] US Dept HHS, Off Assistant Secretary Planning & Evaluat, Washington, DC 20201 USA. [Sommers, Benjamin D.] Harvard Univ, Sch Publ Hlth, Sch Med, Boston, MA 02115 USA. [Sommers, Benjamin D.] Harvard Univ, Brigham & Womens Hosp, Boston, MA 02115 USA. [Buchmueller, Thomas] Univ Michigan, Stephen M Ross Sch Business, Ann Arbor, MI 48109 USA. [Buchmueller, Thomas] Univ Michigan, Dept Hlth Management & Policy, Ann Arbor, MI 48109 USA. [Buchmueller, Thomas; Decker, Sandra L.] Natl Bur Econ Res, Cambridge, MA 02138 USA. [Decker, Sandra L.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Decker, Sandra L.] NYU, Sch Publ Serv, New York, NY 10003 USA. [Carey, Colleen] Johns Hopkins Univ, Dept Econ, Baltimore, MD 21218 USA. [Kronick, Richard] Univ Calif San Diego, La Jolla, CA 92093 USA. RP Sommers, BD (reprint author), US Dept HHS, Off Assistant Secretary Planning & Evaluat, Washington, DC 20201 USA. EM bsommers@hsph.harvard.edu NR 20 TC 87 Z9 87 U1 2 U2 19 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD JAN PY 2013 VL 32 IS 1 BP 165 EP 174 DI 10.1377/hlthaff.2012.0552 PG 10 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 077KH UT WOS:000314026100021 PM 23255048 ER PT J AU Kim, JH Williams, WJ Coca, A Yokota, M AF Kim, Jung-Hyun Williams, W. Jon Coca, Aitor Yokota, Miyo TI Application of thermoregulatory modeling to predict core and skin temperatures in firefighters SO INTERNATIONAL JOURNAL OF INDUSTRIAL ERGONOMICS LA English DT Article DE Real-time modeling; Heat stress; Core temperature; Skin temperature; Protective clothing ID HEART-RATE; OXYGEN-UPTAKE; RESPONSES; EXERCISE; WORK; CONSTANT; KINETICS; STRESS; BODY; VALIDATION AB The purpose of the study was to compare body temperature responses from subjects who exercised while wearing firefighter clothing to predictive data from a real-time thermoregulatory model that had been initially developed and validated for use in the military. Data from two firefighter studies, firefighter study I (FFS1: 7 males and 3 females, continuous treadmill exercise at 50% VO2max, 25 degrees C, 50% RH) and firefighter study 2 (FFS2: 6 males, intermittent treadmill exercise at 75% VO2max, 35 degrees C, 50% RH), were utilized for the thermoregulatory modeling and comparison. The results showed that prediction error (RMSD) of the model for core and skin temperatures was 0.33 and 0.65 degrees C in FFSI and 0.39 and 0.86 degrees C in FFS2, respectively. While the real-time thermoregulatory model tested in the present study showed the potential for providing a means for reasonably accurate prediction of body. temperature responses in firefighters, further development on the model's metabolism algorithms to include adjustments for protective clothing, options to facilitate external work, inclusions of cooling effects are suggested. Relevance to industry: Firefighters exposed to thermal extremes experience physiological strain, but direct monitoring of physiological variables is not always practical. Thermoregulatory models can simulate the thermal responses reasonably accurately by applying known thermo-physiological mechanisms together with heat loss mechanisms related to clothing and environment in an effort to improve firefighter safety. Published by Elsevier B.V. C1 [Kim, Jung-Hyun; Williams, W. Jon; Coca, Aitor] NIOSH, NPPTL, CDC, Pittsburgh, PA 15236 USA. RP Yokota, M (reprint author), USARIEM, Biophys & Biomed Modeling Div, Bldg 42,Kansas St, Natick, MA 01760 USA. EM aun7@cdc.gov; miyo.yokota@us.army.mil NR 33 TC 7 Z9 7 U1 0 U2 25 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0169-8141 J9 INT J IND ERGONOM JI Int. J. Ind. Ergon. PD JAN PY 2013 VL 43 IS 1 BP 115 EP 120 DI 10.1016/j.ergon.2012.11.011 PG 6 WC Engineering, Industrial; Ergonomics SC Engineering GA 083CU UT WOS:000314441100013 ER PT J AU O'Sullivan, A Willoughby, RE Mishchuk, D Alcarraz, B Cabezas-Sanchez, C Condori, RE David, D Encarnacion, R Fatteh, N Fernandez, J Franka, R Hedderwick, S McCaughey, C Ondrush, J Paez-Martinez, A Rupprecht, C Velasco-Villa, A Slupsky, CM AF O'Sullivan, Aifric Willoughby, Rodney E. Mishchuk, Darya Alcarraz, Brisa Cabezas-Sanchez, Cesar Condori, Rene Edgar David, Dan Encarnacion, Rafael Fatteh, Naaz Fernandez, Josefina Franka, Richard Hedderwick, Sara McCaughey, Conall Ondrush, Joanne Paez-Martinez, Andres Rupprecht, Charles Velasco-Villa, Andres Slupsky, Carolyn M. TI Metabolomics of Cerebrospinal Fluid from Humans Treated for Rabies SO JOURNAL OF PROTEOME RESEARCH LA English DT Article DE rabies; metabolomics; NMR spectroscopy; cerebrospinal fluid ID MAGNETIC-RESONANCE SPECTROSCOPY; POSITRON-EMISSION-TOMOGRAPHY; TRAUMATIC BRAIN-INJURY; QUINOLINIC ACID; KYNURENINE PATHWAY; N-ACETYLASPARTATE; CANAVAN-DISEASE; DIAGNOSIS; METABOLISM; VIRUS AB Rabies is a rapidly progressive lyssavirus encephalitis that is statistically 100% fatal. There are no clinically effective antiviral drugs for rabies. An immunologically naive teenager survived rabies in 2004 through improvised supportive care; since then, 5 additional survivors have been associated with use of the so-called Milwaukee Protocol (MP). The MP applies critical care focused on the altered metabolic and physiologic states associated with rabies. The aim of this study was to examine the metabolic profile of cerebrospinal fluid (CSF) from rabies patients during clinical progression of rabies encephalitis in survivors and nonsurvivors and to compare these samples with control CSF samples. Unsupervised clustering algorithms distinguished three stages of rabies disease and identified several metabolites that differentiated rabies survivors from those who subsequently died, in particular, metabolites related to energy metabolism and cell volume control. Moreover, for those patients who survived, the trajectory of their metabolic profile tracked toward the control profile and away from the rabies profile. NMR metabolomics of human rabies CSF provide new insights into the mechanisms of rabies pathogenesis, which may guide future therapy of this disease. C1 [O'Sullivan, Aifric; Mishchuk, Darya; Slupsky, Carolyn M.] Univ Calif Davis, Dept Food Sci & Technol, Davis, CA 95616 USA. [Slupsky, Carolyn M.] Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA. [Willoughby, Rodney E.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Alcarraz, Brisa] Hosp Nacl Cayetano Heredia, Lima, Peru. [Cabezas-Sanchez, Cesar; Condori, Rene Edgar] Inst Nacl Salud, Lima, Peru. [David, Dan] Kimron Vet Inst, Bet Dagan, Israel. [Encarnacion, Rafael; Fernandez, Josefina] Hosp Robert Reid Cabral, Santo Domingo, Dominican Rep. [Fatteh, Naaz; Ondrush, Joanne] INOVA Fairfax Hosp, Fairfax, VA USA. [Franka, Richard; Rupprecht, Charles; Velasco-Villa, Andres] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hedderwick, Sara; McCaughey, Conall] Belfast HSC Trust, Royal Hosp, Belfast, Antrim, North Ireland. [Paez-Martinez, Andres] Inst Nacl Salud, Bogota, Colombia. RP Slupsky, CM (reprint author), Univ Calif Davis, Dept Food Sci & Technol, Davis, CA 95616 USA. EM cslupsky@ucdavis.edu OI PAEZ MARTINEZ, ANDRES/0000-0001-7316-3706 FU Zach Jones Foundation FX This work was supported by the Zach Jones Foundation. The authors thank all of the patients and patients' families that were involved in this study. We gratefully acknowledge A. Jansen (Medical College of Wisconsin), J. Blanton, F. Jackson, I. Kuzmin, N. Kuzmina, X. Ma, M. Niezgoda, L. Orciari, O. Urazova, and P. Yager (CDC) for laboratory support and J. Rubin (Centro Medico La Paz, Equatorial Guinea), Y. Caicedo (Hospital Universidad del Valle, Columbia), A. Roy-Berman (Children's Hospital & Research Center, Oakland, CA), C. Glaser (California Department of Public Health, Richmond, CA), Y. Oba (University of Missouri), G. Arroyo Sanchez (Hospital Nacional Cayetano Heredia, Lima, Peru), and S. Lo (Children's Hospital of Wisconsin) for providing CSF samples. NR 62 TC 14 Z9 15 U1 4 U2 33 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1535-3893 J9 J PROTEOME RES JI J. Proteome Res. PD JAN PY 2013 VL 12 IS 1 BP 481 EP 490 DI 10.1021/pr3009176 PG 10 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 065NX UT WOS:000313156300048 PM 23163834 ER PT J AU Mainous, AG Diaz, VA Knoll, ME Hulihan, MM Grant, AM Wright, RU AF Mainous, Arch G., III Diaz, Vanessa A. Knoll, Michele E. Hulihan, Mary M. Grant, Althea M. Wright, Robert U. TI Transferrin Saturation and Hospital Length of Stay and Mortality in Medicare Beneficiaries SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE transferrin saturation; National Health and Nutrition Examination Survey; Medicare; mortality ID HEREDITARY HEMOCHROMATOSIS; AMERICAN-COLLEGE; UNITED-STATES; DIETARY IRON; RISK; PREVALENCE; PHYSICIANS; STORES AB Objectives To evaluate in a large, nationally representative cohort the association between high serum transferrin saturation (TS) and hospital length of stay and mortality in older adults. Design Prospective cohort. Setting Longitudinal analyses of the Third National Health and Nutrition Examination Survey linked to Medicare claims from 1991 through 2006. Participants Medicare beneficiaries aged 65 and older at baseline. Measurements Transferrin saturation collected on each participant at baseline was characterized as <20.0%, 20.0% to 54.9%, and 55.0% and greater. Length of stay in the hospital and death in the hospital were primary outcomes. Analyses were adjusted for age, sex, race and ethnicity, education, and severity of illness. Results Individuals hospitalized during the study period (79.4%) with high (odds ratio (OR) = 2.54, 95% confidence interval (CI) = 1.056.12) or low (OR = 1.31, 95% CI = 1.071.62) TS had a significantly greater risk of death than those with moderate TS. Individuals with high TS had longer average length of stay per hospitalization (11.1 days, (standard error, SE 1.7 days), P = .01) than those with moderate TS (8.4 (0.3) days). Individuals with high TS also had more hospital days per year (8.6 (2.0) days, P = .04) than those with moderate TS (6.7 (0.5) days). Conclusion High TS is associated with longer length of stay and death in the hospital (unweighted N = 3,847, weighted N = 28,395,464). C1 [Mainous, Arch G., III; Diaz, Vanessa A.; Knoll, Michele E.; Wright, Robert U.] Med Univ S Carolina, Dept Family Med, Charleston, SC 29425 USA. [Hulihan, Mary M.; Grant, Althea M.] Ctr Dis Control & Prevent, Div Blood Disorders, Atlanta, GA USA. RP Mainous, AG (reprint author), Med Univ S Carolina, Dept Family Med, 295 Calhoun St, Charleston, SC 29425 USA. EM mainouag@musc.edu OI Mainous, Arch/0000-0002-2535-7685 FU CDC [MM1144] FX Funded in part by a cooperative agreement (MM1144) from the CDC. NR 31 TC 8 Z9 8 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JAN PY 2013 VL 61 IS 1 BP 132 EP 136 DI 10.1111/jgs.12044 PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 073AM UT WOS:000313715600023 PM 23205743 ER PT J AU Boonsilp, S Thaipadungpanit, J Amornchai, P Wuthiekanun, V Bailey, MS Holden, MTG Zhang, CC Jiang, XG Koizumi, N Taylor, K Galloway, R Hoffmaster, AR Craig, S Smythe, LD Hartskeerl, RA Day, NP Chantratita, N Feil, EJ Aanensen, DM Spratt, BG Peacock, SJ AF Boonsilp, Siriphan Thaipadungpanit, Janjira Amornchai, Premjit Wuthiekanun, Vanaporn Bailey, Mark S. Holden, Matthew T. G. Zhang, Cuicai Jiang, Xiugao Koizumi, Nobuo Taylor, Kyle Galloway, Renee Hoffmaster, Alex R. Craig, Scott Smythe, Lee D. Hartskeerl, Rudy A. Day, Nicholas P. Chantratita, Narisara Feil, Edward J. Aanensen, David M. Spratt, Brian G. Peacock, Sharon J. TI A Single Multilocus Sequence Typing (MLST) Scheme for Seven Pathogenic Leptospira Species SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID SP NOV.; MAXIMUM-LIKELIHOOD; GENETIC DIVERSITY; INTERROGANS; HUMANS; EPIDEMIOLOGY; RELATEDNESS; FEATURES; EBURST AB Background: The available Leptospira multilocus sequence typing (MLST) scheme supported by a MLST website is limited to L. interrogans and L. kirschneri. Our aim was to broaden the utility of this scheme to incorporate a total of seven pathogenic species. Methodology and Findings: We modified the existing scheme by replacing one of the seven MLST loci (fadD was changed to caiB), as the former gene did not appear to be present in some pathogenic species. Comparison of the original and modified schemes using data for L. interrogans and L. kirschneri demonstrated that the discriminatory power of the two schemes was not significantly different. The modified scheme was used to further characterize 325 isolates (L. alexanderi [n = 5], L. borgpetersenii [n = 34], L. interrogans [n = 222], L. kirschneri [n = 29], L. noguchii [n = 9], L. santarosai [n = 10], and L. weilii [n = 16]). Phylogenetic analysis using concatenated sequences of the 7 loci demonstrated that each species corresponded to a discrete clade, and that no strains were misclassified at the species level. Comparison between genotype and serovar was possible for 254 isolates. Of the 31 sequence types (STs) represented by at least two isolates, 18 STs included isolates assigned to two or three different serovars. Conversely, 14 serovars were identified that contained between 2 to 10 different STs. New observations were made on the global phylogeography of Leptospira spp., and the utility of MLST in making associations between human disease and specific maintenance hosts was demonstrated. Conclusion: The new MLST scheme, supported by an updated MLST website, allows the characterization and species assignment of isolates of the seven major pathogenic species associated with leptospirosis. C1 [Boonsilp, Siriphan; Thaipadungpanit, Janjira; Amornchai, Premjit; Wuthiekanun, Vanaporn; Day, Nicholas P.; Chantratita, Narisara; Peacock, Sharon J.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand. [Boonsilp, Siriphan; Chantratita, Narisara; Peacock, Sharon J.] Mahidol Univ, Fac Trop Med, Dept Microbiol & Immunol, Bangkok, Thailand. [Bailey, Mark S.] Birmingham Heartlands Hosp, Dept Infect & Trop Med, Birmingham, W Midlands, England. [Holden, Matthew T. G.] Wellcome Trust Sanger Inst, Cambridge, England. [Zhang, Cuicai; Jiang, Xiugao] Chinese Ctr Dis Control & Prevent, Dept Leptospirosis, Natl Inst Communicable Dis Control & Prevent, Beijing, Peoples R China. [Koizumi, Nobuo] Natl Inst Infect Dis, Dept Bacteriol, Tokyo, Japan. [Taylor, Kyle] Hokkaido Univ, Grad Sch Vet Med, Lab Wildlife Biol & Med, Sapporo, Hokkaido, Japan. [Galloway, Renee; Hoffmaster, Alex R.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Craig, Scott; Smythe, Lee D.] Queensland Hlth, Hlth Serv Support Agcy, WHO FAO OIE Collaborating Ctr Reference & Res Lep, Queensland Hlth Forens Serv, Brisbane, Qld, Australia. [Craig, Scott; Smythe, Lee D.] Queensland Hlth, Hlth Serv Support Agcy, WHO FAO OIE Collaborating Ctr Reference & Res Lep, Queensland Hlth Sci Serv, Brisbane, Qld, Australia. [Hartskeerl, Rudy A.] Royal Trop Inst, KIT Biomed Res, WHO FAO OIE, NL-1105 AZ Amsterdam, Netherlands. [Hartskeerl, Rudy A.] Royal Trop Inst, KIT Biomed Res, Natl Leptospirosis Reference Ctr, NL-1105 AZ Amsterdam, Netherlands. [Day, Nicholas P.] Univ Oxford, Nuffield Dept Clin Med, Churchill Hosp, Ctr Trop Med, Oxford, England. [Feil, Edward J.] Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England. [Aanensen, David M.; Spratt, Brian G.] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London, England. [Peacock, Sharon J.] Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England. RP Boonsilp, S (reprint author), Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand. EM janjira@tropmedres.ac RI Bailey, Mark/D-3854-2013; Holden, Matthew/K-6449-2014; OI Bailey, Mark/0000-0003-4840-5093; Holden, Matthew/0000-0002-4958-2166; Taylor, Kyle/0000-0002-9289-3664 FU Wellcome Trust [089472]; NIHR Cambridge Biomedical Research Centre FX This study was funded by the Wellcome Trust. BGS and DMA were funded by Wellcome Trust grant 089472. SJP receives support from the NIHR Cambridge Biomedical Research Centre. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 35 TC 34 Z9 36 U1 0 U2 18 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD JAN PY 2013 VL 7 IS 1 AR e1954 DI 10.1371/journal.pntd.0001954 PG 10 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 081ZB UT WOS:000314360200005 PM 23359622 ER PT J AU Saxton-Shaw, KD Ledermann, JP Borland, EM Stovall, JL Mossel, EC Singh, AJ Wilusz, J Powers, AM AF Saxton-Shaw, Kali D. Ledermann, Jeremy P. Borland, Erin M. Stovall, Janae L. Mossel, Eric C. Singh, Amber J. Wilusz, Jeffrey Powers, Ann M. TI O'nyong nyong Virus Molecular Determinants of Unique Vector Specificity Reside in Non-Structural Protein 3 SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID EQUINE ENCEPHALITIS-VIRUS; CHIKUNGUNYA-VIRUS; ANOPHELES-GAMBIAE; IN-VITRO; NSP3; REPLICATION; INFECTION; PHOSPHORYLATION; VIRULENCE; FEVER AB O'nyong nyong virus (ONNV) and Chikungunya virus (CHIKV) are two closely related alphaviruses with very different infection patterns in the mosquito, Anopheles gambiae. ONNV is the only alphavirus transmitted by anopheline mosquitoes, but specific molecular determinants of infection of this unique vector specificity remain unidentified. Fifteen distinct chimeric viruses were constructed to evaluate both structural and non-structural regions of the genome and infection patterns were determined through artificial infectious feeds in An. gambiae with each of these chimeras. Only one region, non-structural protein 3 (nsP3), was sufficient to up-regulate infection to rates similar to those seen with parental ONNV. When ONNV non-structural protein 3 (nsP3) replaced nsP3 from CHIKV virus in one of the chimeric viruses, infection rates in An. gambiae went from 0% to 63.5%. No other single gene or viral region addition was able to restore infection rates. Thus, we have shown that a non-structural genome element involved in viral replication is a major element involved in ONNV's unique vector specificity. C1 [Saxton-Shaw, Kali D.; Ledermann, Jeremy P.; Borland, Erin M.; Stovall, Janae L.; Mossel, Eric C.; Singh, Amber J.; Powers, Ann M.] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Ft Collins, CO USA. [Mossel, Eric C.; Wilusz, Jeffrey] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA. RP Saxton-Shaw, KD (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Ft Collins, CO USA. EM APowers@cdc.gov FU Centers for Disease Control and Prevention (CDC); National Institutes of Health (NIH) [AI47877] FX This work was funded by the Centers for Disease Control and Prevention (CDC) and in part by National Institutes of Health (NIH) grant AI47877. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 41 TC 21 Z9 22 U1 0 U2 11 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD JAN PY 2013 VL 7 IS 1 AR e1931 DI 10.1371/journal.pntd.0001931 PG 9 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 081ZB UT WOS:000314360200003 PM 23359824 ER PT J AU Noe, RS Schnall, AH Wolkin, AF Podgornik, MN Wood, AD Spears, J Stanley, SAR AF Noe, Rebecca S. Schnall, Amy H. Wolkin, Amy F. Podgornik, Michelle N. Wood, April D. Spears, Jeanne Stanley, Sharon A. R. TI Disaster-Related Injuries and Illnesses Treated by American Red Cross Disaster Health Services During Hurricanes Gustav and Ike SO SOUTHERN MEDICAL JOURNAL LA English DT Article DE American Red Cross; disasters; Hurricane Ike; postdisaster surveillance; shelter ID HOUSTON; KATRINA; TEXAS AB Objective: To describe the injuries and illnesses treated by the American Red Cross (Red Cross) during Hurricanes Gustav and Ike disaster relief operations reported on a new Aggregate Morbidity Report Form. Methods: From August 28 to October 18, 2008, 119 Red Cross field service locations in Louisiana, Mississippi, Tennessee, and Texas addressed the healthcare needs of people affected by the hurricanes. From these locations, individual client visit data were retrospectively collated per site onto new 24-hour Aggregate Morbidity Report Forms. Results: A total of 3863 clients were treated. Of the clients, 48% were girls and women and 44% were boys and men; 61% were 19 to 64 years old. Ninety-eight percent of the visits occurred in shelters. The reasons for half of the visits were acute illness and symptoms (eg, pain) and 16% were for routine follow-up care. The majority (65%) of the 2516 visits required treatment at a field location, although 34%, or 1296 visits, required a referral, including 543 healthcare facility transfers. Conclusions: During the hurricanes, a substantial number of displaced evacuees sought care for acute and routine healthcare needs. The capacity of the Red Cross to address the immediate and ongoing health needs of sheltered clients for an extended period of time is a critical resource for local public health agencies, which are often overwhelmed during a disaster. This article highlights the important role that this humanitarian organization fills, to decrease surge to local healthcare systems and to monitor health effects following a disaster. The Aggregate Morbidity Report Form has the potential to assist greatly in this role, and thus its utility for real-time reporting should be evaluated further. C1 [Noe, Rebecca S.] Ctr Dis Control & Prevent, Div Environm Hazards & Hlth Effects, Chamblee, GA 30341 USA. Amer Red Cross, Washington, DC 20006 USA. RP Noe, RS (reprint author), Ctr Dis Control & Prevent, Div Environm Hazards & Hlth Effects, 4770 Buford Hwy,Mailstop F-57, Chamblee, GA 30341 USA. EM rhn9@cdc.gov FU Intramural CDC HHS [CC999999] NR 24 TC 5 Z9 5 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0038-4348 J9 SOUTH MED J JI South.Med.J. PD JAN PY 2013 VL 106 IS 1 BP 102 EP 108 DI 10.1097/SMJ.0b013e31827c9e1f PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 068EW UT WOS:000313349400021 PM 23263323 ER PT J AU Jia, HM Zack, MM Thompson, WW AF Jia, Haomiao Zack, Matthew M. Thompson, William W. TI The Effects of Diabetes, Hypertension, Asthma, Heart Disease, and Stroke on Quality-Adjusted Life Expectancy SO VALUE IN HEALTH LA English DT Article DE chronic diseases; health-related quality of life (HRQOL); life expectancy; quality-adjusted life expectancy (QALE) ID UNITED-STATES; SMOKING; HEALTH; POPULATION; MORTALITY; OBESITY; SURVEILLANCE; BURDEN; TRENDS; DEATH AB Objective: Quality-adjusted life expectancy (QALE) is a summary measure that combines mortality and health-related quality of life across different stages of life. The objective of this study was to estimate QALE loss due to five chronic diseases diabetes mellitus, hypertension, asthma, heart disease, and stroke. Methods: Health-related quality of life scores were from the 1993-2009 Behavioral Risk Factor Surveillance System. Using age-specific deaths from the Compressed Mortality File, this study constructed life tables to calculate losses in life expectancy and QALE due to each of the five diseases from 1993 through 2009 and for 50 US states and the District of Columbia. Results: In 2009, the individual-level QALE loss for diabetic people, compared with nondiabetic people, was 11.1 years; for those with hypertension, 6.3 years; for those with asthma, 7.0 years; for those with heart disease, 10.3 years; and for those with stroke, 12.4 years. At the population level, diabetes, hypertension, asthma, heart disease, and stroke contributed 1.9, 2.2, 0.8, 1.2, and 0.8 years of population QALE loss at age 18 years, respectively. Conclusions: Persons with each of the five diseases had significantly lower life expectancy and QALE. Because the prevalence of diabetes and hypertension has increased significantly in the United States in the last two decades, the burdens of these two conditions, measured by population QALE losses, had increased 83% and 29% from 1993 to 2009, respectively. Also, by examining changes in population QALE loss at different ages, policymakers can identify age groups most affected by particular diseases and develop the most cost-effective interventions by focusing on these groups. C1 [Jia, Haomiao] Columbia Univ, Dept Biostat, Mailman Sch Publ Hlth, New York, NY 10032 USA. [Jia, Haomiao] Columbia Univ, Sch Nursing, New York, NY 10032 USA. [Zack, Matthew M.; Thompson, William W.] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Jia, HM (reprint author), Columbia Univ, Dept Biostat, Mailman Sch Publ Hlth, 617 W 168th St, New York, NY 10032 USA. EM hj2198@columbia.edu FU Centers for Disease Control and Prevention [200-2010-M-35363] FX This study (H.J.) was supported by a Centers for Disease Control and Prevention contract (no. 200-2010-M-35363). The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 33 TC 15 Z9 15 U1 2 U2 18 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 J9 VALUE HEALTH JI Value Health PD JAN-FEB PY 2013 VL 16 IS 1 BP 140 EP 147 DI 10.1016/j.jval.2012.08.2208 PG 8 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 077WN UT WOS:000314060200017 PM 23337225 ER PT J AU Vivolo-Kantor, AM DeGue, S DiLillo, D Cuadra, LE AF Vivolo-Kantor, Alana M. DeGue, Sarah DiLillo, David Cuadra, Lorraine E. TI The Mediating Effect of Hostility Toward Women on the Relationship Between Childhood Emotional Abuse and Sexual Violence Perpetration SO VIOLENCE AND VICTIMS LA English DT Article DE psychological abuse; rape; sexual violence; child maltreatment; sexual coercion ID RISK-FACTORS; LONG-TERM; ASSAULT PERPETRATION; MALTREATED CHILDREN; EXPERIENCES SURVEY; COLLEGE-STUDENTS; CONFLUENCE MODEL; COMMUNITY SAMPLE; NATIONAL SAMPLE; YOUNG ADULTHOOD AB Some evidence suggests that childhood emotional abuse (CEA) may serve as a risk factor for sexual violence (SV) perpetration; however, little is known about the mechanisms by which CEA may influence SV. This study examined the relationship between CEA and SV by assessing the mediating role of hostility toward women (HTW) in a sample of adjudicated adult males (N = 360). Approximately 1 in 5 participants was classified as sexually violent based on self-reported behavior and/or criminal records. Results indicated that CEA significantly predicted HTW and SV, and HTW significantly predicted SV. As hypothesized, the relationship between CEA and SV was no longer significant after controlling for HTW, supporting the role of HTW as a mediator between CEA and SV. Efforts that aim to prevent CEA or that address early aggressive attitudes or behavior toward women may have a positive impact on preventing or reducing SV. C1 [Vivolo-Kantor, Alana M.; DeGue, Sarah] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. [DiLillo, David] Univ Nebraska Lincoln, Lincoln, NE USA. [Cuadra, Lorraine E.] Los Angeles Cty Dept Mental Hlth, Jail Mental Hlth Serv, Los Angeles, CA USA. RP Vivolo-Kantor, AM (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE, Atlanta, GA 30341 USA. EM AVivoloKantor@cdc.gov NR 67 TC 0 Z9 0 U1 4 U2 19 PU SPRINGER PUBLISHING CO PI NEW YORK PA 11 WEST 42ND STREET, NEW YORK, NY 10036 USA SN 0886-6708 J9 VIOLENCE VICTIMS JI Violence Vict. PY 2013 VL 28 IS 1 BP 178 EP 191 DI 10.1891/0886-6708.28.1.178 PG 14 WC Criminology & Penology SC Criminology & Penology GA 082VS UT WOS:000314421200011 PM 23520839 ER PT J AU Medley, A Ackers, M Amolloh, M Owuor, P Muttai, H Audi, B Sewe, M Laserson, K AF Medley, Amy Ackers, Marta Amolloh, Manase Owuor, Patrick Muttai, Helen Audi, Beryl Sewe, Manquins Laserson, Kayla TI Early Uptake of HIV Clinical Care After Testing HIV-Positive During Home-Based Testing and Counseling in Western Kenya SO AIDS AND BEHAVIOR LA English DT Article DE HIV/AIDS; HIV testing and counseling; Antiretroviral therapy; Kenya ID SUB-SAHARAN AFRICA; RESOURCE-LIMITED SETTINGS; ANTIRETROVIRAL THERAPY; SOUTH-AFRICA; FOLLOW-UP; MORTALITY; STRATEGIES; OUTCOMES; TRANSMISSION; PREVENTION AB Home-based HIV testing and counseling (HBTC) has the potential to increase access to HIV testing. However, the extent to which HBTC programs successfully link HIV-positive individuals into clinical care remains unclear. To determine factors associated with early enrollment in HIV clinical care, adult residents (aged a parts per thousand yen13 years) in the Health and Demographic Surveillance System in Kisumu, Kenya were offered HBTC. All HIV-positive residents were referred to nearby HIV clinical care centers. Two to four months after HBTC, peer educators conducted home visits to consenting HIV-positive residents. Overall, 9,895 (82 %) of 12,035 residents accepted HBTC; 1,087 (11 %) were HIV-positive; and 737 (68 %) received home visits. Of those receiving home visits, 42 % reported HIV care attendance. Factors associated with care attendance included: having disclosed, living with someone attending HIV care, and wanting to seek care after diagnosis. Residents who reported their current health as excellent or who doubted their HBTC result were less likely to report care attendance. While findings indicate that HBTC was well-received in this setting, less than half of HIV-positive individuals reported current care attendance. Identification of effective strategies to increase early enrollment and retention in HIV clinical care is critical and will require coordination between testing and treatment program staff and systems. C1 [Medley, Amy; Ackers, Marta] US Ctr Dis Control & Prevent CDC, Atlanta, GA 30333 USA. [Amolloh, Manase; Owuor, Patrick; Audi, Beryl; Sewe, Manquins; Laserson, Kayla] Kenya Med Res Inst KEMRI, Nairobi, Kenya. [Muttai, Helen; Laserson, Kayla] US Ctr Dis Control & Prevent CDC Kenya, Nairobi, Kenya. RP Medley, A (reprint author), US Ctr Dis Control & Prevent CDC, MS E04,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM igm8@cdc.gov FU NCPDCID CDC HHS [5U19CI000323-05] NR 33 TC 15 Z9 15 U1 0 U2 10 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS Behav. PD JAN PY 2013 VL 17 IS 1 BP 224 EP 234 DI 10.1007/s10461-012-0344-5 PG 11 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 073HL UT WOS:000313734000023 PM 23076720 ER PT J AU O'Leary, ST Parashar, UD Crane, LA Allison, MA Stokley, S Beaty, BL Brtnikova, M Hurley, LP Kempe, A AF O'Leary, Sean T. Parashar, Umesh D. Crane, Lori A. Allison, Mandy A. Stokley, Shannon Beaty, Brenda L. Brtnikova, Michaela Hurley, Laura P. Kempe, Allison TI Adoption of Rotavirus Vaccine by U.S. Physicians Progress and Challenges SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID PNEUMOCOCCAL CONJUGATE VACCINE; UNITED-STATES; GASTROENTERITIS; REDUCTION; CHILDREN; PEDIATRICIANS; IMMUNIZATION; EFFICACY; INFANTS; SAFETY AB Background: Pentavalent rotavirus vaccine (RV5) was recommended for routine use in 2006 followed by monovalent rotavirus vaccine (RV1) in 2008. Purpose: To describe, among a U. S. sample of pediatricians (n = 289 respondents) and family medicine physicians (n = 243 respondents), (1) current practices regarding rotavirus vaccine (RV) and barriers to use with comparison to a 2007 survey and (2) knowledge of recent safety concerns regarding RV1 and their impact on its use. Methods: A mail and Internet survey was conducted with the physicians, from November 2010 to January 2011; analyses were conducted March-September 2011. Results: Response rates were 70% (289/410) for pediatricians and 61% (243/401) for family medicine physicians; routine administration of RV was reported by 95% of pediatricians and 65% of family medicine physicians (2007: 85% and 45%). Almost all barriers to use of RV had decreased compared to 2007. For pediatricians and family medicine physicians, respectively, 94% and 70% were aware of the temporary suspension of RV1 due to presence of porcine circovirus; 49% and 45%, respectively, were aware of the addition to RV1 labeling regarding a possible increased risk of intussusception. Among physicians aware of the safety issues, <5% reported stopping giving RV as a result. After reading information about porcine circovirus, 35% of pediatricians and 59% of family medicine physicians reported it had increased their own concerns about the safety of RV; and 31% and 60%, respectively, reported this regarding intussusception. Conclusions: The acceptance of RV has increased, and barriers to use have decreased. Among physicians, recent safety questions about RV1 have not affected use of RV, although they have raised safety concerns. (Am J Prev Med 2013;44(1):56-62) (C) 2013 Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [O'Leary, Sean T.; Allison, Mandy A.; Kempe, Allison] Univ Colorado, Dept Pediat, Aurora, CO 80045 USA. [Beaty, Brenda L.; Kempe, Allison] Univ Colorado, Colorado Hlth Outcomes Program, Aurora, CO 80045 USA. [Crane, Lori A.] Univ Colorado, Colorado Sch Publ Hlth, Aurora, CO 80045 USA. [O'Leary, Sean T.; Crane, Lori A.; Allison, Mandy A.; Beaty, Brenda L.; Brtnikova, Michaela; Hurley, Laura P.; Kempe, Allison] Childrens Hosp Colorado, Childrens Outcomes Res Program, Aurora, CO USA. [Hurley, Laura P.] Denver Hlth, Div Gen Internal Med, Denver, CO USA. [Parashar, Umesh D.; Stokley, Shannon] CDC, Immunizat Serv Div, Atlanta, GA 30333 USA. RP O'Leary, ST (reprint author), Univ Colorado, Dept Pediat, Mail Stop F443,13199 E Montview Blvd,Suite 300, Aurora, CO 80045 USA. EM sean.o'leary@childrenscolorado.org FU CDC PEP through the Association of American Medical Colleges, Washington DC [MM-1040-08/08] FX This investigation was funded by a grant from the CDC PEP (MM-1040-08/08) through the Association of American Medical Colleges, Washington DC. The authors thank Lynn Olson, PhD, and Karen O'Connor from the Department of Research, AAP, Herbert Young, MD, and Bellinda Schoof, MHA, at the AAFP, and the leaders of the AAP and AAFP for collaborating in the establishment of the sentinel networks in pediatrics and family medicine. The authors also thank all pediatricians and family medicine physicians in the networks for participating in and responding to this survey. NR 26 TC 2 Z9 2 U1 1 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD JAN PY 2013 VL 44 IS 1 BP 56 EP 62 DI 10.1016/j.amepre.2012.10.001 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 071FQ UT WOS:000313574700008 PM 23253650 ER PT J AU Lubelczyk, C Mutebi, JP Robinson, S Elias, SP Smith, LB Juris, SA Foss, K Lichtenwalner, A Shively, KJ Hoenig, DE Webber, L Sears, S Smith, RP AF Lubelczyk, Charles Mutebi, John-Paul Robinson, Sara Elias, Susan P. Smith, Leticia B. Juris, Sherrie A. Foss, Kimberly Lichtenwalner, Anne Shively, Kirk J. Hoenig, Donald E. Webber, Lori Sears, Stephen Smith, Robert P., Jr. TI An Epizootic of Eastern Equine Encephalitis Virus, Maine, USA in 2009: Outbreak Description and Entomological Studies SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID ENCEPHALOMYELITIS VIRUS; MASSACHUSETTS; TRANSMISSION; MOSQUITOS; MICHIGAN; DISEASE; BIRDS; HOSTS AB From July to September, 2009, an outbreak of eastern equine encephalitis virus (EEEv) occurred in five counties in Maine. The virus was isolated from 15 horses, 1 llama, and pheasants in three separate captive flocks. One wild turkey, screened before translocation, also showed exposure to the virus in January 2010. Two pools of Culiseta melanura (Coquillett) tested positive for EEEv during routine seasonal surveillance in York County in September, but none of the mosquitoes collected during rapid response surveys tested positive. There were more Cs. melanura in July, August, and September 2009 than in preceding (2006-08) and subsequent (2010-11) years. August and September Cs. melanura abundances were correlated with July rainfall, and abundance of all species combined was correlated with total rainfall for the meteorological summer. This outbreak represents a substantial expansion of the range of EEEv activity in northern New England. C1 [Lubelczyk, Charles; Elias, Susan P.; Smith, Leticia B.; Smith, Robert P., Jr.] Maine Med Ctr, Res Inst, Vector Borne Dis Lab, Portland, ME 04106 USA. [Mutebi, John-Paul] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Ft Collins, CO USA. [Robinson, Sara; Sears, Stephen] Maine Ctr Dis Control, Augusta, ME USA. [Juris, Sherrie A.] Atlantic Pest Solut, Surveillance, Arundel, ME USA. [Foss, Kimberly] SWAMP Inc, Surveillance, Kittery, ME USA. [Lichtenwalner, Anne] Univ Maine Cooperat Extens, Dept Vet & Anim Sci, Orono, ME USA. [Shively, Kirk J.] Wildlife Serv, USDA, Anim Plant Hlth Inspect Serv, Augusta, ME USA. [Hoenig, Donald E.] Maine Dept Agr, Augusta, ME USA. [Webber, Lori] Maine Hlth & Environm Testing Lab, Augusta, ME USA. RP Lubelczyk, C (reprint author), Maine Med Ctr, Res Inst, Vector Borne Dis Lab, 75 John Roberts Rd,Suite 9B, Portland, ME 04106 USA. EM lubelc@mmc.org; jmutebi@cdc.gov; sara.robinson@maine.gov; eliass@mmc.org; leticia.smith@maine.edu; sjuris@atlanticpestsolutions.net; kfoss81@roadrunner.com; anne.lichtenwalner@maine.edu; Kirk.J.Shively@aphis.usda.gov; Donald.E.Hoenig@maine.gov; lori.webber@maine.gov; stephen.sears@maine.gov; smithr@mmc.org FU Maine Centers for Disease Control; Maine Medical Center Research Institute FX Funding for this project was supplied through the Maine Centers for Disease Control and the Maine Medical Center Research Institute. NR 40 TC 6 Z9 6 U1 1 U2 20 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JAN PY 2013 VL 88 IS 1 BP 95 EP 102 DI 10.4269/ajtmh.2012.11-0358 PG 8 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 073QL UT WOS:000313757500015 PM 23208877 ER PT J AU Berl, E Eisen, RJ MacMillan, K Swope, BN Saxton-Shaw, KD Graham, AC Turmel, JP Mutebi, JP AF Berl, Erica Eisen, Rebecca J. MacMillan, Katherine Swope, Bethany N. Saxton-Shaw, Kali D. Graham, Alan C. Turmel, Jon P. Mutebi, John-Paul TI Serological Evidence for Eastern Equine Encephalitis Virus Activity in White-Tailed Deer, Odocoileus virginianus, in Vermont, 2010 SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID MASSACHUSETTS; TRANSMISSION; OUTBREAK; VECTORS AB Serum samples from 489 free-ranging white-tailed deer (Odocoileus virginianus) were screened for antibodies against the Eastern equine encephalitis virus (EEEV) using plaque reduction neutralization tests (PRNTs). EEEV antibodies were detected in 10.2% of serum samples. This is the first evidence that EEEV is present in Vermont. Serum was collected from deer in all 14 counties in the state, and positive EEEV sera were found in 12 (85%) of 14 counties, suggesting statewide EEEV activity in Vermont. Analysis of the spatial distribution of PRNT-positive samples revealed a random distribution of EEEV throughout the state. The results indicate widespread EEEV activity in Vermont and suggest that EEEV is not a recent introduction to the state but that EEEV activity has not been detected until now. C1 [Berl, Erica] Vermont Dept Hlth, Burlington, VT 05401 USA. [Eisen, Rebecca J.; MacMillan, Katherine; Mutebi, John-Paul] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. [Saxton-Shaw, Kali D.] Ctr Dis Control & Prevent, Entomol Ecol Act Arboviral Dis Branch, Ft Collins, CO USA. [Graham, Alan C.; Turmel, Jon P.] Vermont Agcy Agr Food & Markets, Waterbury, VT USA. RP Berl, E (reprint author), Vermont Dept Hlth, 108 Cherry St, Burlington, VT 05401 USA. EM Erica.berl@state.vt.us; dyn2@cdc.gov; iky4@cdc.gov; bethany.swope+CDC@gmail.com; KSaxtonShaw@cdc.gov; Alan.graham@state.vt.us; Jon.turmel@state.vt.us; jmutebi@cdc.gov FU Centers for Disease Control and Prevention; Vermont Department of Health; Vermont Agency of Agriculture, Farm and Markets FX The work done in this study was supported by the Centers for Disease Control and Prevention, the Vermont Department of Health, and the Vermont Agency of Agriculture, Farm and Markets. NR 26 TC 7 Z9 7 U1 0 U2 10 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JAN PY 2013 VL 88 IS 1 BP 103 EP 107 DI 10.4269/ajtmh.2012.12-0236 PG 5 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 073QL UT WOS:000313757500016 PM 23208886 ER PT J AU Kading, RC Reiche, ASG Morales-Betoulle, ME Komar, N AF Kading, Rebekah C. Gonzalez Reiche, Ana Silvia Eugenia Morales-Betoulle, Maria Komar, Nicholas TI Host Selection of Potential West Nile Virus Vectors in Puerto Barrios, Guatemala, 2007 SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID BLOOD-FEEDING BEHAVIOR; CULEX-QUINQUEFASCIATUS; DIPTERA-CULICIDAE; CYTOCHROME-B; MOSQUITOS; PATTERNS; IDENTIFICATION; TRANSMISSION; COUNTY; MEXICO AB The selection of vertebrate hosts by Culex mosquitoes relative to West Nile virus (WNV) transmission in neotropical countries such as Guatemala is not described. This study determined the feeding patterns of Cx. quinquefasciatus and Cx. nigripalpus and estimated the relative contribution of two common and frequently infected wild bird species, Turdus grayi and Quiscalus mexicanus, to WNV transmission. Engorged mosquitoes were collected from rural and urban habitats after the dry and wet seasons in the Department of Izabal in 2007. Host selection by Cx. nigripalpus varied significantly between urban and rural habitats. Both Cx. quinquefasciatus and Cx. nigripalpus fed predominantly on chickens and other domestic animals. Blood meals from wild birds were rare, accounting for 1.1% of blood meals identified from Cx. quinquefasciatus and 6.5% of blood meals from Cx. nigripalpus. Transmission of WNV by these two mosquito species may be dampened by extensive feeding on reservoir-incompetent hosts. C1 [Kading, Rebekah C.; Komar, Nicholas] Ctr Dis Control & Prevent, Div Vector Borne Dis, Arbovirus Dis Branch, Ft Collins, CO 80521 USA. Univ Valle Guatemala, Ctr Estudios Salud, Guatemala City, Guatemala. RP Kading, RC (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Arbovirus Dis Branch, 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM fxk7@cdc.gov; agonzalez@ces.uvg.edu.gt; maria.morales.ctr.gt@med.navy.mil; nck6@cdc.gov RI Kading, Rebekah/E-5633-2017 OI Kading, Rebekah/0000-0002-4996-915X FU Centers for Disease Control and Prevention [U50/CCU021236-01]; Universidad de Valle del Guatemala [U50/CCU021236-01]; Robert E. Shope International Fellowship in Infectious Diseases award FX This research was funded by the Centers for Disease Control and Prevention, Cooperative Agreement U50/CCU021236-01 between the Centers for Disease Control and Prevention and the Universidad de Valle del Guatemala, and a Robert E. Shope International Fellowship in Infectious Diseases award. NR 51 TC 3 Z9 3 U1 0 U2 17 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JAN PY 2013 VL 88 IS 1 BP 108 EP 115 DI 10.4269/ajtmh.2012.12-0223 PG 8 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 073QL UT WOS:000313757500017 PM 23208881 ER PT J AU Morales-Betoulle, ME Komar, N Panella, NA Alvarez, D Lopez, MR Betoulle, JL Sosa, SM Muller, ML Kilpatrick, AM Lanciotti, RS Johnson, BW Powers, AM Cordon-Rosales, C AF Morales-Betoulle, Maria E. Komar, Nicholas Panella, Nicholas A. Alvarez, Danilo Lopez, Maria R. Betoulle, Jean-Luc Sosa, Silvia M. Mueller, Maria L. Kilpatrick, A. Marm Lanciotti, Robert S. Johnson, Barbara W. Powers, Ann M. Cordon-Rosales, Celia CA Arbovirus Ecology Work Grp TI West Nile Virus Ecology in a Tropical Ecosystem in Guatemala SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID SEROLOGIC EVIDENCE; PUERTO-RICO; AVIAN HOSTS; TRANSMISSION; MOSQUITOS; MEXICO; BIRDS; FLAVIVIRUS; CALIFORNIA; INFECTION AB West Nile virus ecology has yet to be rigorously investigated in the Caribbean Basin. We identified a transmission focus in Puerto Barrios, Guatemala, and established systematic monitoring of avian abundance and infection, seroconversions in domestic poultry, and viral infections in mosquitoes. West Nile virus transmission was detected annually between May and October from 2005 to 2008. High temperature and low rainfall enhanced the probability of chicken seroconversions, which occurred in both urban and rural sites. West Nile virus was isolated from Culex quinquefasciatus and to a lesser extent, from Culex mollis/Culex inflictus, but not from the most abundant Culex mosquito, Culex nigripalpus. A calculation that combined avian abundance, seroprevalence, and vertebrate reservoir competence suggested that great-tailed grackle (Quiscalus mexicanus) is the major amplifying host in this ecosystem. West Nile virus transmission reached moderate levels in sentinel chickens during 2007, but less than that observed during outbreaks of human disease attributed to West Nile virus in the United States. C1 [Morales-Betoulle, Maria E.; Alvarez, Danilo; Lopez, Maria R.; Sosa, Silvia M.; Mueller, Maria L.; Cordon-Rosales, Celia] Univ Valle Guatemala, Ctr Hlth Studies, Guatemala City, Guatemala. [Komar, Nicholas] CDC, Arbovirus Dis Branch, NCEZID, DVBD, Ft Collins, CO 80521 USA. [Kilpatrick, A. Marm] Univ Calif Santa Cruz, Santa Cruz, CA 95064 USA. Fdn Mario Dary, Guatemala City, Guatemala. [Betoulle, Jean-Luc] Fdn Ecodesarrollo, Off Director, Guatemala City, Guatemala. RP Komar, N (reprint author), CDC, Arbovirus Dis Branch, NCEZID, DVBD, 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM me_morales@hotmail.com; nck6@cdc.gov; nap4@cdc.gov; dalvarez@ces.uvg.edu.gt; mlopez@ces.uvg.edu.gt; betoullejeanluc@gmail.com; ssosa@ces.uvg.edu.gt; mmuller@ces.uvg.edu.gt; akp7@cdc.gov; rsl2@cdc.gov; bfj9@cdc.gov; akilpatr@ucsc.edu; ccordon@ces.uvg.edu.gt RI Kading, Rebekah/E-5633-2017 OI Kading, Rebekah/0000-0002-4996-915X FU Centers for Disease Control and Prevention [1U01/GH000028, U50/CCU021236-01, 3U51/GH000011-02]; Consejo Nacional de Ciencia y Tecnologia (CONCYT) de Guatemala [FD19-03]; Fondo de Ciencia y Tecnologia (FODECYT) de Guatemala [03-2007]; National Science Foundation [EF-0914866]; National Institutes of Health [1R01AI090159-01]; CDC FX Field and laboratory support was provided by Susan Beckett, Aquiles Garcia, Juan Garcia, Rosmery Garcia, Oscar de Leon, Luis Lopez, Melvin Marcos, Ramon Medrano, Claudia Paiz, Jorge Paniagua, Ana Lucia Ramirez, Jose Roberto Ramirez, Alfonso Salam, Odeth Solorzano, Jason Velez, and Martin Williams. John Roehrig, Roger Nasci, Lyle Peterson, and Robert Klein provided institutional support and approved internal funding from CDC. Property owner permission at field sites was provided by the Naval Military Base at Puerto Barrios and private homeowners. Logistical support was provided by Astri Alvarado, Laura Hall, Silvana Recinos, Carmen Yoc, the Fundacion Mario Dary, and the Fundacion para el Ecodesarrollo.; This research was supported by the Centers for Disease Control and Prevention cooperative agreements #1U01/GH000028, #U50/CCU021236-01, and #3U51/GH000011-02, Consejo Nacional de Ciencia y Tecnologia (CONCYT) de Guatemala grant #FD19-03, and Fondo de Ciencia y Tecnologia (FODECYT) de Guatemala grant #03-2007. Dr. Kilpatrick's salary was partly supported by grants from the National Science Foundation, EF-0914866, and the National Institutes of Health, 1R01AI090159-01. NR 55 TC 8 Z9 8 U1 0 U2 16 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JAN PY 2013 VL 88 IS 1 BP 116 EP 126 DI 10.4269/ajtmh.2012.12-0276 PG 11 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 073QL UT WOS:000313757500018 PM 23149586 ER PT J AU Foote, EM Gieraltowski, L Ayers, T Sadumah, I Faith, SH Silk, BJ Cohen, AL Were, V Hughes, JM Quick, RE AF Foote, Eric M. Gieraltowski, Laura Ayers, Tracy Sadumah, Ibrahim Faith, Sitnah Hamidah Silk, Benjamin J. Cohen, Adam L. Were, Vincent Hughes, James M. Quick, Robert E. TI Impact of Locally-Produced, Ceramic Cookstoves on Respiratory Disease in Children in Rural Western Kenya SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID SOLID-FUEL USE; INTEGRATED MANAGEMENT; CHILDHOOD PNEUMONIA; AIR-POLLUTION; HEALTH; GUATEMALA; MORTALITY; ILLNESS; INDOOR AB Household air pollution is a risk factor for pneumonia, the leading cause of death among children < 5 years of age. From 2008 to 2010, a Kenyan organization sold similar to 2,500 ceramic cookstoves (upesi jiko) that produce less visible household smoke than 3-stone firepits. During a year-long observational study, we made 25 biweekly visits to 200 homes to determine stove use and observe signs of acute respiratory infection in children < 3 years of age. Reported stove use included 3-stone firepit only (81.8%), upesi jiko only (15.7%), and both (2.3%). Lower, but not statistically significant, percentages of children in upesi jiko-using households than 3-stone firepit-using households had observed cough (1.3% versus 2.9%, rate ratio [RR] 0.48, 95% confidence interval [CI]: 0.22-1.03), pneumonia (0.9% versus 1.7%, RR 0.60, 95% CI: 0.24-1.48), and severe pneumonia (0.3% versus 0.6%, RR 0.66, 95% CI: 0.17-2.62). Upesi jiko use did not result in significantly lower pneumonia rates. Further research on the health impact of improved cookstoves is warranted. C1 [Hughes, James M.] Emory Univ, Sch Med, Atlanta, GA USA. [Gieraltowski, Laura; Ayers, Tracy; Silk, Benjamin J.; Quick, Robert E.] Ctr Dis Control & Prevent, Div Waterborne Foodborne & Enter Dis, Atlanta, GA 30333 USA. [Sadumah, Ibrahim; Faith, Sitnah Hamidah] Safe Water & AIDS Project, Kisumu, Kenya. [Cohen, Adam L.] Ctr Dis Control & Prevent S Africa, Influenza Program, Pretoria, South Africa. [Were, Vincent] Kenya Govt Med Res Ctr, Kisumu, Kenya. RP Quick, RE (reprint author), Ctr Dis Control & Prevent, Div Waterborne Foodborne & Enter Dis, Mailstop C09, Atlanta, GA 30333 USA. EM efooter@gmail.com; lax2@cdc.gov; eyk6@cdc.gov; sirahimah@yahoo.com; sitnahfaith@yahoo.com; bsilk@cdc.gov; cohena@sa.cdc.gov; vwere@ke.cdc.gov; jmhughe@emory.edu; rxq1@cdc.gov OI Ayers, Tracy/0000-0003-4140-3263 FU Clinical and Translational Science Award program, National Institutes of Health, National Center for Research Resources and National Center for Advancing Translational Sciences [UL1 TR000454, TL1 TR000456]; Infectious Disease Society of America; Emory University's Global Health Institute; United States Agency for International Development FX This work was supported by PHS Grant (UL1 TR000454, and TL1 TR000456) from the Clinical and Translational Science Award program, National Institutes of Health, National Center for Research Resources and National Center for Advancing Translational Sciences; Infectious Disease Society of America; Emory University's Global Health Institute; and the United States Agency for International Development. NR 19 TC 2 Z9 2 U1 1 U2 15 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JAN PY 2013 VL 88 IS 1 BP 132 EP 137 DI 10.4269/ajtmh.2012.12-0496 PG 6 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 073QL UT WOS:000313757500020 PM 23243108 ER PT J AU Mosites, E Carpenter, LR McElroy, K Lancaster, MJ Ngo, TH McQuiston, J Wiedeman, C Dunn, JR AF Mosites, Emily Carpenter, L. Rand McElroy, Kristina Lancaster, Mary J. Ngo, Tue H. McQuiston, Jennifer Wiedeman, Caleb Dunn, John R. TI Knowledge, Attitudes, and Practices Regarding Rocky Mountain Spotted Fever among Healthcare Providers, Tennessee, 2009 SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID UNITED-STATES; RISK-FACTORS; DOXYCYCLINE; FEATURES; DISEASE AB Tennessee has a high incidence of Rocky Mountain spotted fever (RMSF), the most severe tick-borne rickettsial illness in the United States. Some regions in Tennessee have reported increased illness severity and death. Healthcare providers in all regions of Tennessee were surveyed to assess knowledge, attitudes, and perceptions regarding RMSF. Providers were sent a questionnaire regarding knowledge of treatment, diagnosis, and public health reporting awareness. Responses were compared by region of practice within the state, specialty, and degree. A high proportion of respondents were unaware that doxycycline is the treatment of choice in children <= 8 years of age. Physicians practicing in emergency medicine, internal medicine, and family medicine; and nurse practitioners, physician assistants, and providers practicing for < 20 years demonstrated less knowledge regarding RMSF. The gaps in knowledge identified between specialties, designations, and years of experience can help target education regarding RMSF. C1 [Wiedeman, Caleb] Tennessee Dept Hlth, Dept Hlth Communicable & Environm Dis & Emergency, Communicable Serv, Communicable & Environm Dis Sect, Nashville, TN 37243 USA. [McQuiston, Jennifer] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Atlanta, GA USA. Tennessee Dept Hlth, W Tennessee Reg Off, Jackson, TN USA. Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. RP Wiedeman, C (reprint author), Tennessee Dept Hlth, Dept Hlth Communicable & Environm Dis & Emergency, Communicable Serv, Communicable & Environm Dis Sect, 425 5th Ave N, Nashville, TN 37243 USA. EM emosites@uw.edu; l.rand.carpenter@tn.gov; k.mcelroy.dvm@gmail.com; Mary.Lancaster@pnnl.gov; ngoth@musc.edu; fzh7@cdc.gov; caleb.wiedeman@tn.gov; john.dunn@tn.gov RI Lancaster, Mary/A-5065-2015 OI Lancaster, Mary/0000-0002-2530-7004 FU Centers for Disease Control; Tennessee Department of Health FX This study was supported by a Prevention Emerging Infections Program grant from the Centers for Disease Control and the Tennessee Department of Health. NR 14 TC 7 Z9 8 U1 0 U2 12 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JAN PY 2013 VL 88 IS 1 BP 162 EP 166 DI 10.4269/ajtmh.2012.12-0126 PG 5 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 073QL UT WOS:000313757500025 PM 23243110 ER PT J AU Edupuganti, S Eidex, RB Keyserling, H Akondy, RS Lanciotti, R Orenstein, W del Rio, C Pan, Y Querec, T Lipman, H Barrett, A Ahmed, R Teuwen, D Cetron, M Mulligan, MJ AF Edupuganti, Srilatha Eidex, Rachel B. Keyserling, Harry Akondy, Rama S. Lanciotti, Robert Orenstein, Walter del Rio, Carlos Pan, Yi Querec, Troy Lipman, Harvey Barrett, Alan Ahmed, Rafi Teuwen, Dirk Cetron, Martin Mulligan, Mark J. CA YF-Ig Study Team TI A Randomized, Double-Blind, Controlled Trial of the 17D Yellow Fever Virus Vaccine Given in Combination with Immune Globulin or Placebo: Comparative Viremia and Immunogenicity SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID VISCEROTROPIC DISEASE; ADVANCED AGE; RISK-FACTOR; RESPONSES; ANTIBODY; STRAIN; SAFETY; SERUM AB We evaluated whether coadministration of the yellow fever (YF) virus vaccine with human immunoglobulin (Ig) that contained YF virus-neutralizing antibodies would reduce post-vaccination viremia without compromising immunogenicity and thus, potentially mitigate YF vaccine-associated adverse events. We randomized 80 participants to receive either YF vaccine and Ig or YF vaccine and saline placebo. Participants were followed for 91 days for safety and assessments of viremia and immunogenicity. There were no differences found between the two groups in the proportion of vaccinated participants who developed viremia, seroconversion, cluster of differentiation (CD)-8(+) and CD4(+) T-cell responses, and cytokine responses. These results argue against one putative explanation for the increased reporting of YF vaccine side effects in recent years (i.e., a change in travel clinic practice after 1996 when hepatitis A prophylaxis with vaccine replaced routine use of pre-travel Ig, thus potentially removing an incidental YF vaccine-attenuating effect of anti-YF virus antibodies present in Ig) (ClinicalTrials.gov identifier: NCT00254826). C1 Emory Univ, Dept Med, Sch Med, Atlanta, GA USA. [Querec, Troy; Cetron, Martin] Ctr Dis Control & Prevent, Atlanta, GA USA. Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA. Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA. [Lanciotti, Robert] Ctr Dis Control & Prevent, Ft Collins, CO USA. [del Rio, Carlos] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Sch Med, Atlanta, GA 30322 USA. Emory Univ, Rollins Sch Publ Hlth, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA. [Barrett, Alan] Univ Texas Med Branch, Sealy Ctr Vaccine Dev, Galveston, TX 77555 USA. Sanofi Pasteur, Swiftwater, PA USA. RP Mulligan, MJ (reprint author), Emory Vaccine Ctr, Hope Clin, 603 Church St, Decatur, GA 30030 USA. EM sedupug@emory.edu; eidexr@sa.cdc.gov; hkeyser@emory.edu; rakondy@emory.edu; rs12@cdc.gov; worenst@emory.edu; cdelrio@emory.edu; jnu5@cdc.gov; tquerec@cdc.gov; abarrett@utmb.edu; rahmed@emory.edu; dirk.teuwen@ucb.com; mzc4@cdc.gov; mark.mulligan@emory.edu RI del Rio, Carlos/B-3763-2012; OI del Rio, Carlos/0000-0002-0153-3517; Akondy, Rama/0000-0003-4737-5240; Frew, Paula/0000-0002-3078-9124; Easley, Kirk/0000-0003-4419-2617 FU Sanofi Pasteur FX This work was supported by a grant from Sanofi Pasteur. This work was facilitated by the Center for AIDS Research (CFAR) at Emory University (P30 AI050409). NR 31 TC 10 Z9 10 U1 1 U2 9 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JAN PY 2013 VL 88 IS 1 BP 172 EP 177 DI 10.4269/ajtmh.2012.12-0179 PG 6 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 073QL UT WOS:000313757500027 PM 23208880 ER PT J AU Ryan, TJ Beaucham, C AF Ryan, Timothy J. Beaucham, Catherine TI Dominant microbial volatile organic compounds in 23 US homes SO CHEMOSPHERE LA English DT Article DE Bioaerosol; IAQ; Indicators; Moisture; Mold; MVOCs ID COMPOUNDS MVOCS; AIR FILTERS; FUNGI; MOLD; METABOLITES; MYCOTOXINS; HOUSES; INDICATORS; BUILDINGS; PATTERNS AB Associating Microbial Volatile Organic Compounds (MVOCs) with the species producing them may open the path to more rapid and reliable chemical methods to detect mold problems, especially for mold hidden in wall cavities or small enclosed spaces. This study associated the dominant MVOCs in a convenience sample of 23 homes with the mold species present. Three semi-quantitative predictors of mold growth ("MOW scores") were assessed in the homes through a comparison of basement to main floor areas. MVOC samples were collected and analyzed by GC/MS. Aerotek N-6 samplers were co-located with the MVOC samplers to collect bioaerosols. Concentration and prevalence data for 19 definitive MVOCs were compared with the bioaerosol data. Mold predictor scores were elevated in basement locations as compared with main floor areas. Of the 23 mold genera identified, the predominant genera (ranked occurrences) were Cladosporium, Penicillium, Basidiomycetes, and Aspergilli. The MVOCs 2-octen-1-ol, 3-octenone, 2-heptanone, 1-octen-3-ol, and 1-butanol showed the highest average concentrations (11-37 mu g m(-3)), but no single MVOC was significantly elevated in basement locations as compared with main floor living areas in these non-problematic homes. Using a less conservative one-tail test of significance, average 2-octen-1-ol concentrations in basements were higher (p < 0.040), and both 3-octenone and 1-octen-3-ol were elevated (p < 0.095). Differences in MVOC occurrence were greatest between homes, with MVOCs found in basement locations typically detected in living areas at similar concentrations and frequencies. Based on these findings, the C-8 MVOCs show promise as gross indicators of fungal growth related to the most frequently found mold genera. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Ryan, Timothy J.] Ohio Univ, W Grover Ctr 357, Athens, OH 45701 USA. [Beaucham, Catherine] NIOSH, Cincinnati, OH 45226 USA. RP Ryan, TJ (reprint author), Ohio Univ, W Grover Ctr 357, Athens, OH 45701 USA. EM ryant@ohio.edu; cbeaucham@cdc.gov FU Ohio University Research Committee FX The authors wish to thank Jennifer Sirko and Roy Nalazek for their proofing and review of this manuscript. This study was supported by a Grant from the Ohio University Research Committee. NR 41 TC 6 Z9 6 U1 5 U2 36 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0045-6535 J9 CHEMOSPHERE JI Chemosphere PD JAN PY 2013 VL 90 IS 3 BP 977 EP 985 DI 10.1016/j.chemosphere.2012.06.066 PG 9 WC Environmental Sciences SC Environmental Sciences & Ecology GA 063EJ UT WOS:000312978700013 PM 22892356 ER PT J AU Rottinghaus, E Bile, E Modukanele, M Maruping, M Mine, M Nkengasong, J Yang, CF AF Rottinghaus, Erin Bile, Ebi Modukanele, Mosetsanagape Maruping, Maruping Mine, Madisa Nkengasong, John Yang, Chunfu TI Comparison of Ahlstrom Grade 226, Munktell TFN, and Whatman 903 Filter Papers for Dried Blood Spot Specimen Collection and Subsequent HIV-1 Load and Drug Resistance Genotyping Analysis SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID VIRAL LOAD; ANTIRETROVIRAL TREATMENT; WHOLE-BLOOD; ASSAY; SURVEILLANCE; PREVENTION; THERAPY; PLASMA AB Dried blood spots (DBS) collected onto filter paper have eased the difficulty of blood collection in resource-limited settings. Currently, Whatman 903 (W-903) filter paper is the only filter paper that has been used for HIV load and HIV drug resistance (HIVDR) testing. We therefore evaluated two additional commercially available filter papers, Ahlstrom grade 226 (A-226) and Munktell TFN (M-TFN), for viral load (VL) testing and HIVDR genotyping using W-903 filter paper as a comparison group. DBS specimens were generated from 344 adult patients on antiretroviral therapy (ART) in Botswana. The VL was measured with NucliSENS EasyQ HIV-1 v2.0, and genotyping was performed for those specimens with a detectable VL (>= 2.90 log(10) copies/ml) using an in-house method. Bland-Altman analysis revealed a strong concordance in quantitative VL analysis between W-903 and A-226 (bias = -0.034 +/- 0.246 log(10) copies/ml [mean difference +/- standard deviation]) and W-903 and M-TFN (bias = -0.028 +/- 0.186 log(10) copies/ml) filter papers, while qualitative VL analysis for virological failure determination, defined as a VL of >= 3.00 log(10) copies/ml, showed low sensitivities for A-266 (71.54%) and M-TFN (65.71%) filter papers compared to W-903 filter paper. DBS collected on M-TFN filter paper had the highest genotyping efficiency (100%) compared to W-903 and A-226 filter papers (91.7%) and appeared more sensitive in detecting major HIVDR mutations. DBS collected on A-226 and M-TFN filter papers performed similarly to DBS collected on W-903 filter paper for quantitative VL analysis and HIVDR detection. Together, the encouraging genotyping results and the variability observed in determining virological failure from this small pilot study warrant further investigation of A-226 and M-TFN filter papers as specimen collection devices for HIVDR monitoring surveys. C1 [Rottinghaus, Erin; Nkengasong, John; Yang, Chunfu] Ctr Dis Control & Prevent, Div Global HIV AIDS, Int Lab Branch, Atlanta, GA 30333 USA. [Bile, Ebi; Modukanele, Mosetsanagape; Maruping, Maruping] CDC Botswana, Gaborone, Botswana. [Mine, Madisa] Botswana Minist Hlth, Gaborone, Botswana. RP Yang, CF (reprint author), Ctr Dis Control & Prevent, Div Global HIV AIDS, Int Lab Branch, Atlanta, GA 30333 USA. EM CYang1@cdc.gov RI Yang, Chunfu/G-6890-2013 FU American Public Health Laboratory (APHL); U.S. Centers for Disease Control and Prevention (CDC); President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention FX Erin Rottinghaus was the recipient of a 2009-2011 Emerging Infectious Disease (EID) fellowship sponsored by American Public Health Laboratory (APHL) and the U.S. Centers for Disease Control and Prevention (CDC). This research has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention. NR 26 TC 7 Z9 8 U1 0 U2 8 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD JAN PY 2013 VL 51 IS 1 BP 55 EP 60 DI 10.1128/JCM.02002-12 PG 6 WC Microbiology SC Microbiology GA 078NF UT WOS:000314105100009 PM 23077127 ER PT J AU Jay-Russell, MT Mandrell, RE Yuan, J Bates, A Manalac, R Mohle-Boetani, J Kimura, A Lidgard, J Miller, WG AF Jay-Russell, Michele T. Mandrell, Robert E. Yuan, Jean Bates, Anna Manalac, Rosa Mohle-Boetani, Janet Kimura, Akiko Lidgard, Janice Miller, William G. TI Using Major Outer Membrane Protein Typing as an Epidemiological Tool To Investigate Outbreaks Caused by Milk-Borne Campylobacter jejuni Isolates in California SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID UNITED-STATES; SEQUENCE; UPSALIENSIS; CONSUMPTION; COLI; LARI; IDENTIFICATION; POLYMORPHISM; HELVETICUS; PATHOGENS AB We describe using major outer membrane protein (MOMP) typing as a screen to compare the Campylobacter jejuni porA gene sequences of clinical outbreak strains from human stool with the porA sequences of dairy farm strains isolated during two milk-borne campylobacteriosis outbreak investigations in California. The genetic relatedness of clinical and environmental strains with identical or closely related porA sequences was confirmed by multilocus sequence typing and pulsed-field gel electrophoresis analysis. The first outbreak involved 1,644 C. jejuni infections at 11 state correctional facilities and was associated with consumption of pasteurized milk supplied by an on-site dairy (dairy A) at a prison in the central valley. The second outbreak involved eight confirmed and three suspect C. jejuni cases linked to consumption of commercial raw milk and raw chocolate colostrum at another central valley dairy (dairy B). Both dairies bottled fluid milk on the farm and distributed the finished product to off-site locations. Altogether, C. jejuni was isolated from 7 of 15 (46.7%) bovine fecal, 12 of 20 (60%) flush alley water, and 1 of 20 (5%) lagoon samples collected on dairy A. At dairy B, C. jejuni was cultured from 9 of 26 (34.6%) bovine fecal samples. Environmental strains indistinguishable from the clinical outbreak strains were found in five flush alley water samples (dairy A) and four bovine fecal samples (dairy B). The findings demonstrate that MOMP typing is a useful tool to triage environmental isolates prior to conducting more labor-intensive molecular typing methods. C1 [Jay-Russell, Michele T.; Manalac, Rosa] Univ Calif Davis, Davis, CA 95616 USA. [Jay-Russell, Michele T.; Yuan, Jean; Mohle-Boetani, Janet; Kimura, Akiko; Lidgard, Janice] Calif Dept Publ Hlth, Richmond, CA USA. [Mandrell, Robert E.; Bates, Anna; Miller, William G.] ARS, Dept Agr, Western Reg Res Ctr, Albany, CA USA. [Yuan, Jean] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. RP Jay-Russell, MT (reprint author), Univ Calif Davis, Davis, CA 95616 USA. EM mjay@ucdavis.edu FU USDA/ARS Current Research Information System (CRIS) [5325-42000-045-00D] FX This work was supported by funds from USDA/ARS Current Research Information System (CRIS) project no. 5325-42000-045-00D. NR 35 TC 7 Z9 7 U1 1 U2 18 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD JAN PY 2013 VL 51 IS 1 BP 195 EP 201 DI 10.1128/JCM.01845-12 PG 7 WC Microbiology SC Microbiology GA 078NF UT WOS:000314105100032 PM 23115263 ER PT J AU Kato, CY Chung, IH Robinson, LK Austin, AL Dasch, GA Massung, RF AF Kato, Cecilia Y. Chung, Ida H. Robinson, Lauren K. Austin, Amy L. Dasch, Gregory A. Massung, Robert F. TI Assessment of Real-Time PCR Assay for Detection of Rickettsia spp. and Rickettsia rickettsii in Banked Clinical Samples SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID MOUNTAIN-SPOTTED-FEVER; NEWLY RECOGNIZED CAUSE; UNITED-STATES; PROTEIN ROMPA; IDENTIFICATION; ARIZONA; GENE; DNA AB Two novel real-time PCR assays were developed for the detection of Rickettsia spp. One assay detects all tested Rickettsia spp.; the other is specific for Rickettsia rickettsii. Evaluation using DNA from human blood and tissue samples showed both assays to be more sensitive than nested PCR assays currently in use at the CDC. C1 [Kato, Cecilia Y.; Chung, Ida H.; Robinson, Lauren K.; Austin, Amy L.; Dasch, Gregory A.; Massung, Robert F.] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Atlanta, GA USA. [Austin, Amy L.] Lab Preparedness & Response Branch, Atlanta, GA USA. RP Kato, CY (reprint author), Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Atlanta, GA USA. EM ckato@cdc.gov OI Dasch, Gregory/0000-0001-6090-1810 NR 21 TC 24 Z9 27 U1 0 U2 8 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD JAN PY 2013 VL 51 IS 1 BP 314 EP 317 DI 10.1128/JCM.01723-12 PG 4 WC Microbiology SC Microbiology GA 078NF UT WOS:000314105100055 PM 23135935 ER PT J AU Benitez, AJ Winchell, JM AF Benitez, Alvaro J. Winchell, Jonas M. TI Clinical Application of a Multiplex Real-Time PCR Assay for Simultaneous Detection of Legionella Species, Legionella pneumophila, and Legionella pneumophila Serogroup 1 SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID GENUS LEGIONELLA; SCHEME AB We developed a single-tube multiplex real-time PCR assay capable of simultaneously detecting and discriminating Legionella spp., Legionella pneumophila, and Legionella pneumophila serogroup 1 in primary specimens. Evaluation of 21 clinical specimens and 115 clinical isolates demonstrated this assay to be a rapid, high-throughput diagnostic test with 100% specificity that may aid during legionellosis outbreaks and epidemiologic investigations. C1 [Benitez, Alvaro J.; Winchell, Jonas M.] Ctr Dis Control & Prevent, Resp Dis Branch, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Winchell, JM (reprint author), Ctr Dis Control & Prevent, Resp Dis Branch, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM jwinchell@cdc.gov NR 18 TC 18 Z9 20 U1 2 U2 11 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD JAN PY 2013 VL 51 IS 1 BP 348 EP 351 DI 10.1128/JCM.02510-12 PG 4 WC Microbiology SC Microbiology GA 078NF UT WOS:000314105100064 PM 23135949 ER PT J AU Henderson, JT Saraiya, M Martinez, G Harper, CC Sawaya, GF AF Henderson, Jillian T. Saraiya, Mona Martinez, Gladys Harper, Cynthia C. Sawaya, George F. TI Changes to cervical cancer prevention guidelines: Effects on screening among US women ages 15-29 SO PREVENTIVE MEDICINE LA English DT Article DE Cervical cancer screening; Clinical recommendations; Guideline-consistent; Adolescents; Young adults; National surveillance ID HEALTH-CARE ACCESS; UNITED-STATES; YOUNG-WOMEN; BEHAVIORAL-MODEL; SELF-REPORTS; PAP-SMEAR; METAANALYSIS; ADOLESCENT; NEOPLASIA; SERVICES AB Objective. A shift toward later initiation of cervical cancer screening for women began in 2002. We generated national estimates of screening prevalence rates and guideline-consistent screening among US. women ages 15-29 before and after the first evidence-based recommendations for reduced cervical cancer screening. Method. We used National Survey of Family Growth data to compare self-reported cervical cancer screening in 2002 and 2006-2008, stratified by age (15-17, 18-20, 21-29) and sexual activity. We also assessed receipt of guideline-consistent screening by selected demographic variables. Results. Among females ages 15-17, the proportion screened decreased from 23% to 12%, and screening was significantly more likely to be guideline-consistent. Among females ages 18-20, 24% were screened too early in 2006-2008, but among those not yet sexually active, screening declined to 8%, appropriately reflecting new guidelines. In multivariable analysis, private health insurance, pregnancy, and hormonal contraceptive use were associated with guideline-consistent screening among sexually-active women. Conclusion. Fewer adolescents were being screened before sexual initiation, representing newer guidelines. However, sexually-active young adult women also should have later screening initiation. Factors related to health care access contribute to receipt of screening. Monitoring and provider education are needed to improve guideline-consistent screening, as newer guidelines call for less screening. (C) 2012 Elsevier Inc. All rights reserved. C1 [Henderson, Jillian T.; Harper, Cynthia C.; Sawaya, George F.] Univ Calif San Francisco, Bixby Ctr Global Reprod Hlth, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94118 USA. [Saraiya, Mona] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Martinez, Gladys] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Div Vital Stat, Reprod Stat Branch, Hyattsville, MD 20782 USA. RP Henderson, JT (reprint author), Univ Calif San Francisco, Bixby Ctr Global Reprod Hlth, Dept Obstet Gynecol & Reprod Sci, 3333 Calif St,Suite 335, San Francisco, CA 94118 USA. EM HendersonJ@obgyn.ucsf.edu; MSaraiya@cdc.gov; Gmm7@cdc.gov; Harperc@obgyn.ucsf.edu; Sawayag@obgyn.ucsf.edu FU NIH/NICHD [K01HD054495]; CDC FX Support for Dr. Henderson's effort on this project was provided by an NIH/NICHD Mentored Research Scientist Development Award in Population Research (K01HD054495) and resources from NIH/NCRR/OD UCSF-CTSI (KL2 RR024130). Dr. Sawaya was supported in part by an interagency personnel agreement with CDC. The contents of the paper are solely the responsibility of the authors and do not necessarily represent the official views of the NIH or the Centers for Disease Control and Prevention. NR 35 TC 7 Z9 7 U1 0 U2 7 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 J9 PREV MED JI Prev. Med. PD JAN PY 2013 VL 56 IS 1 BP 25 EP 29 DI 10.1016/j.ypmed.2012.10.025 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 077AN UT WOS:000314000400005 PM 23137444 ER PT J AU Davila, EP Quintero, MA Orrego, ML Ford, ES Walke, H Arenas, MM Pratt, M AF Davila, E. P. Quintero, M. A. Orrego, M. L. Ford, E. S. Walke, H. Arenas, M. M. Pratt, M. TI Prevalence and risk factors for metabolic syndrome in Medellin and surrounding municipalities, Colombia, 2008-2010 SO PREVENTIVE MEDICINE LA English DT Article DE Metabolic syndrome X; Abdominal obesity; Colombia; Latin America ID ACUTE MYOCARDIAL-INFARCTION; BODY-FAT DISTRIBUTION; ABDOMINAL OBESITY; BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; LATIN-AMERICA; POPULATION; ADULTS; HEALTH; ASSOCIATION AB Objective. We assessed the prevalence of and risk factors for metabolic syndrome (MetS) among adults 25-64 years of age froth Medellin and surrounding municipalities, Colombia. Method. We used 2008-2010 data from the Antioquia STEPwise approach to Surveillance (STEPS), a multi-stage complex cross-sectional survey designed according to World Health Organization guidelines. The revised 2005 International Diabetes Federation definition of MetS was used. Results. There were a total of 3000 participants. Of these, 21.4% had high blood pressure (HBP) and 64% had abdominal obesity (AO). In the subsample with serum data (n=943), 19.8% had high fasting serum glucose, 43.9% had high triglycerides (HTG), and 56.6% had low HDL cholesterol (L-HDL). Among those with data to define MetS (n=901), 41% had MetS. Older age was associated with MetS and all components except L-HDL Female sex [odds ratio (OR)=2.85, 95% confidence interval (CI): 2.20-3.70], being married (OR=1.40, CI: 1.09-1.82), and high physical activity (OR=0.59, CI: 0.39-0.91) were associated with AO, smoking with HTG (OR=1.76, CI: 1.16-2.67) and L-HDL (OR=1.67, CI: 1.10-2.51) and rural residence with HBP (OR=3.42, CI: 1.83-6.37) and L-HDL (OR=1.18, CI: 1.10-2.51). Conclusion. The prevalence of MetS and AO was high in this Colombian region. Targeted strategies for promoting healthy behaviors are needed. (C) 2012 Elsevier Inc. All rights reserved. C1 [Davila, E. P.; Walke, H.] Ctr Dis Control & Prevent, Div Publ Hlth Syst & Workforce Dev, Ctr Global Hlth, Atlanta, GA 30333 USA. [Quintero, M. A.; Orrego, M. L.; Arenas, M. M.] Indeportes Antioquia, Inst Dept Deportes Antioquia, Sect Estadio, Medellin, Colombia. [Ford, E. S.; Pratt, M.] Ctr Dis Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Off Noncommunicable Dis Injury & Environm Hlth, Atlanta, GA 30333 USA. RP Davila, EP (reprint author), Ctr Dis Control & Prevent, Div Publ Hlth Syst & Workforce Dev, Ctr Global Hlth, 1600 Clifton Rd,MS E93, Atlanta, GA 30333 USA. EM epdavila@ucsd.edu NR 40 TC 3 Z9 7 U1 0 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 J9 PREV MED JI Prev. Med. PD JAN PY 2013 VL 56 IS 1 BP 30 EP 34 DI 10.1016/j.ypmed.2012.10.027 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 077AN UT WOS:000314000400006 PM 23142534 ER PT J AU Krieg, EF AF Krieg, Edward F., Jr. TI The Relationships Between Pesticide Metabolites and Neurobehavioral Test Performance in the Third National Health and Nutrition Examination Survey SO ARCHIVES OF ENVIRONMENTAL & OCCUPATIONAL HEALTH LA English DT Article DE neurobehavioral tests; NHANES III; pesticide metabolites ID 2,4-DICHLOROPHENOXYACETIC ACID 2,4-D; NEURO-BEHAVIORAL TOXICITY; LONG-TERM EXPOSURE; BRAIN ACETYLCHOLINESTERASE; NEUROMUSCULAR-JUNCTION; DELAYED NEUROTOXICITY; CHLORPYRIFOS OXON; METHYL PARATHION; REFERENCE RANGE; RAT-BRAIN AB Regression analysis was used to estimate and test for relationships between urinary pesticide metabolites and neurobehavioral test performance in adults, 20 to 59 years old, participating in the third National Health and Nutrition Examination Survey. The 12 pesticide metabolites included 2 naphthols, 8 phenols, a phenoxyacetic acid, and a pyridinol. The 3 neurobehavioral tests included in the survey were simple reaction time, symbol-digit substitution, and serial digit learning. As the 2,4-dichlorophenol, 2,5-dichlorophenol, and the pentachlorophenol concentrations increased, performance on the serial digit learning test improved. As the 2,5-dichlorophenol concentration increased, performance on the symbol-digit substitution test improved. At low concentrations, the parent compounds of these metabolites may act at acetylcholine and ?-aminobutyric acid synapses in the central nervous system to improve neurobehavioral test performance. C1 NIOSH, Robert A Taft Labs, Cincinnati, OH 45226 USA. RP Krieg, EF (reprint author), NIOSH, Robert A Taft Labs, 4676 Columbia Pkwy,MS C-22, Cincinnati, OH 45226 USA. EM erk3@cdc.gov NR 82 TC 4 Z9 4 U1 1 U2 16 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1933-8244 EI 2154-4700 J9 ARCH ENVIRON OCCUP H JI Arch. Environ. Occup. Health PD JAN 1 PY 2013 VL 68 IS 1 BP 39 EP 46 DI 10.1080/19338244.2011.633125 PG 8 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 071SQ UT WOS:000313614900006 PM 23298423 ER PT J AU Dunn, KH Shulman, S Stock, AL Naeher, LP AF Dunn, K. H. Shulman, S. Stock, A. L. Naeher, L. P. TI Personal Carbon Monoxide Exposures Among Firefighters at Prescribed Forest Burns in the Southeastern United States SO ARCHIVES OF ENVIRONMENTAL & OCCUPATIONAL HEALTH LA English DT Article DE carbon monoxide; exposure assessment; prescribed burns; wildland; firefighter ID WILDLAND FIREFIGHTERS; PULMONARY-FUNCTION; SMOKE EXPOSURE; LUNG-FUNCTION; RESPIRATORY SYMPTOMS; FIRE FIGHTERS AB Exposure to combustion products from wildland fires causes respiratory irritation and decreased lung function among firefighters. The authors evaluated carbon monoxide (CO) exposures of a group of wildland firefighters who conducted prescribed burns in the southeastern United States of America. A total of 149 person-days of samples were collected using data logging CO monitors. A questionnaire was administered to collect data on job tasks and self-reported smoke exposure. Overall, the highest exposures were seen amongst firefighters assigned to holding and mop-up tasks (geometric mean [GM]: 2.6 ppm), whereas the lowest were associated with lighting and jobs such as burn boss (GM: 1.6 and 0.3 ppm, respectively). The self-reported smoke exposure showed a significant linear trend with increasing CO exposure. The numbers of acres burned or burn duration, however, were not good predictors of exposure. C1 [Dunn, K. H.; Shulman, S.] NIOSH, Cincinnati, OH 45226 USA. [Stock, A. L.] Ctr Dis Control, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Naeher, L. P.] Univ Georgia, Dept Environm Hlth Sci, Coll Publ Hlth, Athens, GA 30602 USA. RP Naeher, LP (reprint author), Univ Georgia, Dept Environm Hlth Sci, Coll Publ Hlth, 206 Environm Hlth Sci Bldg, Athens, GA 30602 USA. EM LNaeher@uga.edu RI Dunn, Kevin/I-2195-2012 FU Department of Energy Savannah River Operations Office through the US Forest Service Savannah River [DE-AI09-00SR22188] FX Funding and support was provided by the Department of Energy Savannah River Operations Office through the US Forest Service Savannah River under Interagency Agreement DE-AI09-00SR22188. The authors gratefully acknowledge Jeff Prevey, Paul Linse, Mark Frizzell, John Blake, Gary Achtemeier, Dan Shea, Chris Hobson, Jason Demas, and the firefighters for support and participation in this study. The findings and conclusions in this manuscript are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. Mention of company names or products does not constitute endorsement by the Centers for Disease Control and Prevention. NR 19 TC 1 Z9 1 U1 0 U2 15 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1933-8244 J9 ARCH ENVIRON OCCUP H JI Arch. Environ. Occup. Health PD JAN 1 PY 2013 VL 68 IS 1 BP 55 EP 59 DI 10.1080/19338244.2011.633126 PG 5 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 071SQ UT WOS:000313614900008 PM 23298425 ER PT J AU Williams, MM Armbruster, CR Arduino, MJ AF Williams, Margaret M. Armbruster, Catherine R. Arduino, Matthew J. TI Plumbing of hospital premises is a reservoir for opportunistically pathogenic microorganisms: a review SO BIOFOULING LA English DT Review DE healthcare-associated infection; biofilm; potable water; premise plumbing; opportunistic pathogen ID INTENSIVE-CARE-UNIT; WATER DISTRIBUTION-SYSTEMS; RESISTANT PSEUDOMONAS-AERUGINOSA; RAPIDLY GROWING MYCOBACTERIA; CONTAMINATED ICE MACHINE; PLATE-COUNT BACTERIA; DRINKING-WATER; TAP-WATER; LEGIONELLA-PNEUMOPHILA; NONTUBERCULOUS MYCOBACTERIA AB Several bacterial species that are natural inhabitants of potable water distribution system biofilms are opportunistic pathogens important to sensitive patients in healthcare facilities. Waterborne healthcare-associated infections (HAI) may occur during the many uses of potable water in the healthcare environment. Prevention of infection is made more challenging by lack of data on infection rate and gaps in understanding of the ecology, virulence, and infectious dose of these opportunistic pathogens. Some healthcare facilities have been successful in reducing infections by following current water safety guidelines. This review describes several infections, and remediation steps that have been implemented to reduce waterborne HAIs. C1 [Williams, Margaret M.; Arduino, Matthew J.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30329 USA. [Armbruster, Catherine R.] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA. RP Williams, MM (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30329 USA. EM MWilliams7@cdc.gov NR 146 TC 25 Z9 27 U1 3 U2 54 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0892-7014 J9 BIOFOULING JI Biofouling PY 2013 VL 29 IS 2 BP 147 EP 162 DI 10.1080/08927014.2012.757308 PG 16 WC Biotechnology & Applied Microbiology; Marine & Freshwater Biology SC Biotechnology & Applied Microbiology; Marine & Freshwater Biology GA 073HA UT WOS:000313732900004 PM 23327332 ER PT J AU Polen, KND Rasmussen, SA Riehle-Colarusso, T Reefhuis, J AF Polen, Kara N. D. Rasmussen, Sonja A. Riehle-Colarusso, Tiffany Reefhuis, Jennita CA Natl Birth Defects Prevention Stud TI Association between reported venlafaxine use in early pregnancy and birth defects, national birth defects prevention study, 1997-2007 SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE venlafaxine; birth defects; pregnancy; antidepressants; epidemiology ID SEROTONIN-REUPTAKE INHIBITORS; NOREPINEPHRINE TRANSPORTER EXPRESSION; CONGENITAL HEART-DISEASE; CRANIAL NEURAL CREST; MATERNAL USE; RECALL BIAS; MALFORMATIONS; DEPRESSION; PAROXETINE; EXPOSURE AB BACKGROUND Few epidemiologic studies have investigated the use of venlafaxine (Effexor XR capsules, Product Monograph, Wyeth, Montreal, Canada), an antidepressant used to treat major depression and anxiety disorders in adults, during pregnancy. Our objective was to determine whether use of venlafaxine during pregnancy is associated with specific birth defects. METHODS We used data from the National Birth Defects Prevention Study (NBDPS), a population-based, case-control study in the United States. Our analysis included mothers with pregnancies affected by one of 30 selected birth defects (cases) and babies without birth defects (controls) with estimated dates of delivery between 1997 and 2007. Exposure was any reported use of venlafaxine from 1 month preconception through the third month of pregnancy. We calculated adjusted odds ratios (aORs) and 95% Fisher Exact confidence intervals (CIs) for 24 birth defect groups for which at least 400 case mothers were interviewed. Our adjusted analyses controlled for maternal age and race/ethnicity. RESULTS Among the 27,045 NBDPS participants who met inclusion criteria, 0.17% (14/8002) of control mothers and 0.40% (77/19,043) of case mothers reported any use of venlafaxine from 1 month preconception through the third month of pregnancy. Statistically significant associations were found for anencephaly, atrial septal defect (ASD) secundum, or ASD not otherwise specified, coarctation of the aorta, cleft palate, and gastroschisis. CONCLUSIONS Our data suggest associations between periconceptional use of venlafaxine and some birth defects. However, sample sizes were small, CIs were wide, and additional studies are needed to confirm these results. Birth Defects Research (Part A), 2013. (c) 2012 Wiley Periodicals, Inc. C1 [Polen, Kara N. D.; Rasmussen, Sonja A.; Riehle-Colarusso, Tiffany; Reefhuis, Jennita; Natl Birth Defects Prevention Stud] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Polen, KND (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS E-86, Atlanta, GA 30333 USA. EM Kpolen@cdc.gov FU Centers for Disease Control and Prevention [PA 96043, PA 02081, FOA DD09-001] FX This work was supported through cooperative agreements under PA 96043, PA 02081, and FOA DD09-001 from the Centers for Disease Control and Prevention to the Centers for Birth Defects Research and Prevention participating in the National Birth Defects Prevention Study NR 55 TC 23 Z9 23 U1 1 U2 18 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD JAN PY 2013 VL 97 IS 1 BP 28 EP 35 DI 10.1002/bdra.23096 PG 8 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 071LZ UT WOS:000313595600004 PM 23281074 ER PT J AU Thibadeau, JK Ward, EA Soe, MM Liu, TB Swanson, M Sawin, KJ Freeman, KA Castillo, H Rauen, K Schechter, MS AF Thibadeau, Judy K. Ward, Elisabeth A. Soe, Minn M. Liu, Tiebin Swanson, Mark Sawin, Kathleen J. Freeman, Kurt A. Castillo, Heidi Rauen, Karen Schechter, Michael S. TI Testing the feasibility of a National Spina Bifida Patient Registry SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE spina bifida; registry; quality improvement; spina bifida clinic; research ID CYSTIC-FIBROSIS; MYELOMENINGOCELE AB BACKGROUND The purpose of this study was to describe the development and early implementation of a national spina bifida (SB) patient registry, the goal of which is to monitor the health status, clinical care, and outcomes of people with SB by collecting and analyzing patient data from comprehensive SB clinics. METHODS Using a web-based, SB-specific electronic medical record, 10 SB clinics collected health-related information for patients diagnosed with myelomeningocele, lipomyelomeningocele, fatty filum, or meningocele. This information was compiled and de-identified for transmission to the Centers for Disease Control and Prevention (CDC) for quality control and analysis. RESULTS A total of 2070 patients were enrolled from 2009 through 2011: 84.9% were younger than 18 years of age; 1095 were women; 64.2% were non-Hispanic white; 6.5% were non-Hispanic black or African American; and 24.2% were Hispanic or Latino. Myelomeningocele was the most common diagnosis (81.5%). CONCLUSIONS The creation of a National Spina Bifida Patient Registry partnership between the CDC and SB clinics has been feasible. Through planned longitudinal data collection and the inclusion of additional clinics, the data generated by the registry will become more robust and representative of the population of patients attending SB clinics in the United States and will allow for the investigation of patient outcomes. Birth Defects Research (Part A), 2013. (c) 2012 Wiley Periodicals, Inc. C1 [Thibadeau, Judy K.; Ward, Elisabeth A.; Soe, Minn M.; Liu, Tiebin; Swanson, Mark] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Sawin, Kathleen J.] Univ Wisconsin, Childrens Hosp Wisconsin, Res Chair Nursing Children, Coll Nursing, Milwaukee, WI 53201 USA. [Freeman, Kurt A.] Oregon Hlth & Sci Univ, Inst Dev & Disabil, Portland, OR 97201 USA. [Castillo, Heidi] Univ Cincinnati, Med Ctr, Coll Med, Div Dev & Behav Pediat,Cincinnati Childrens Hosp, Cincinnati, OH 45267 USA. [Schechter, Michael S.] Emory Univ, Sch Med, Dept Pediat, Childrens Hosp Atlanta, Atlanta, GA USA. RP Thibadeau, JK (reprint author), 1600 Clifton Rd,MS E-88, Atlanta, GA 30333 USA. EM csn2@cdc.gov FU National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia [1UO1DDD000744.01] FX The National Spina Bifida Patient Registry is funded by the National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia, grant # 1UO1DDD000744.01 NR 15 TC 11 Z9 11 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD JAN PY 2013 VL 97 IS 1 BP 36 EP 41 DI 10.1002/bdra.23094 PG 6 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 071LZ UT WOS:000313595600005 PM 23125114 ER PT J AU Agopian, AJ Tinker, SC Lupo, PJ Canfield, MA Mitchell, LE AF Agopian, A. J. Tinker, Sarah C. Lupo, Philip J. Canfield, Mark A. Mitchell, Laura E. CA Natl Birth Defects Prevention Stud TI Proportion of neural tube defects attributable to known risk factors SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE spina bifida; neural tube; anencephaly; congenital abnormalities; attributable fraction ID STRUCTURAL BIRTH-DEFECTS; SPINA-BIFIDA; PREVENTION; FRACTIONS; EPIDEMIOLOGY AB BACKGROUND Recognized risk factors for neural tube defects (NTDs) poorly predict population-level NTD risk. However, the proportion of NTDs that can be attributed to these risk factors is uncertain. METHODS To determine the proportion of NTD cases that is attributable to known or suspected risk factors (i.e., female infant sex, family history of NTDs, and maternal Hispanic ethnicity, obesity, pregestational diabetes, gestational diabetes, low dietary folate intake, lack of folic acid supplementation, anticonvulsant use, and hot tub or sauna use), we estimated the adjusted population attributable fraction (aAF) for each factor, using the method of Eide and Geffler and data from the National Birth Defects Prevention Study. RESULTS Our analyses of these data indicate that the proportion of cases of spina bifida and anencephaly that can be attributed to known risk factors is 28% and 44%, respectively. For spina bifida, the factor with the greatest attributable fraction was maternal obesity (aAF, 10%), whereas for anencephaly it was Hispanic ethnicity (aAF, 15%). CONCLUSION Our analyses indicate that known risk factors account for <50% of NTD cases. Hence, the majority of NTD cases are attributable to, as yet, unidentified factors. These findings highlight the need for continued research to identify genetic and additional nongenetic risk factors for NTDs. Further, these findings suggest that strategies that aim to reduce the risk of NTDs associated with maternal Hispanic ethnicity and obesity may have the greatest impact on the population prevalence of these conditions. Birth Defects Research (Part A), 2013. (c) 2012 Wiley Periodicals, Inc. C1 [Agopian, A. J.; Lupo, Philip J.; Mitchell, Laura E.] Univ Texas Sch Publ Hlth, Ctr Human Genet, Div Epidemiol Human Genet & Environm Sci, Houston, TX 77030 USA. [Tinker, Sarah C.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Canfield, Mark A.] Texas Dept State Hlth Serv, Birth Defects Epidemiol & Surveillance Branch, Austin, TX USA. RP Mitchell, LE (reprint author), Univ Texas Sch Publ Hlth, Ctr Human Genet, Div Epidemiol Human Genet & Environm Sci, 1200 Herman Pressler Dr, Houston, TX 77030 USA. EM laura.e.mitchell@uth.tmc.edu OI Lupo, Philip/0000-0003-0978-5863 FU Texas Center for Birth Defects Research and Prevention from the Centers for Disease Control and Prevention [5U01DD000494-03]; Texas Department of State Health Services FX This project was partially supported by the Texas Center for Birth Defects Research and Prevention, under a cooperative agreement (#5U01DD000494-03) from the Centers for Disease Control and Prevention with the Texas Department of State Health Services NR 17 TC 20 Z9 21 U1 0 U2 20 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD JAN PY 2013 VL 97 IS 1 BP 42 EP 46 DI 10.1002/bdra.23100 PG 5 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 071LZ UT WOS:000313595600006 PM 23427344 ER PT J AU Van Bennekom, CM Mitchell, AA Moore, CA Werler, MM AF Van Bennekom, Carla M. Mitchell, Allen A. Moore, Cynthia A. Werler, Martha M. CA Natl Birth Defects Prevention Stud TI Vasoactive exposures during pregnancy and risk of microtia SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE birth defect; microtia; anotia; ear; epidemiology; diabetes mellitus; pregnancy; medication ID VASCULAR DISRUPTION DEFECTS; BIRTH-DEFECTS; EPIDEMIOLOGIC FEATURES; HEMIFACIAL MICROSOMIA; CONGENITAL-ANOMALIES; DIABETES-MELLITUS; MALFORMATIONS; RUBELLA; ANOTIA; WOMEN AB BACKGROUND Little is known about the etiology of nonsyndromic microtia. This study investigated the hypothesis that microtia is caused by vascular disruption. METHODS The study analyzed data from the population-based National Birth Defects Prevention Study (NBDPS) for deliveries between 1997 and 2005. Four hundred eleven nonsyndromic cases of microtia, with or without additional defects, were compared to 6560 nonmalformed infants with respect to maternal exposures to vasoactive medications and smoking during the periconceptional period and conditions that have previously been associated with vascular events (multiple gestation, maternal history of type 1, type 2, or gestational diabetes, and hypertension). Odds ratios (ORs) were estimated with multivariable models, controlling for the effects of race/ethnicity, education, periconceptional folic acid use, and study center. RESULTS Risk estimates for vasoactive medications and smoking were not meaningfully increased. Maternal type 1/2 diabetes was diagnosed before or during the index pregnancy in 4% and 1% of cases, respectively, compared to 1% and 0.05% of controls; the adjusted OR for these two groups combined was 7.2 (95% confidence interval [CI], 3.913.1). Gestational diabetes was observed for 9% of cases and 6% of controls; the OR was moderately elevated (OR, 1.4; 95% CI, 0.92.0). ORs were also increased for multiple gestations (OR, 2.5; 95% CI, 1.54.2) and pre-existing hypertension (OR, 1.6; 95% CI, 1.02.5). CONCLUSIONS Because ORs were only elevated for diabetes and not for vasoactive exposures or other potential vascular events, findings suggest that some microtia occurrences may be part of the diabetic embryopathy rather than manifestations of vascular disruption. Birth Defects Research (Part A), 2013. (c) 2012 Wiley Periodicals, Inc. C1 [Van Bennekom, Carla M.; Mitchell, Allen A.] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA. [Moore, Cynthia A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Van Bennekom, CM (reprint author), Boston Univ, Slone Epidemiol Ctr, 1010 Commonwealth Ave, Boston, MA 02215 USA. EM cvanben@bu.edu OI Mitchell, Allen/0000-0003-0950-6799; Werler, Martha/0000-0003-3392-6814 FU Centers for Disease Control and Prevention [U01DD000493] FX This study was supported by a grant from the Centers for Disease Control and Prevention (U01DD000493). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention NR 50 TC 4 Z9 4 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD JAN PY 2013 VL 97 IS 1 BP 53 EP 59 DI 10.1002/bdra.23101 PG 7 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 071LZ UT WOS:000313595600008 PM 23180593 ER PT J AU Ioannidis, JPA Schully, SD Lam, TK Khoury, MJ AF Ioannidis, John P. A. Schully, Sheri D. Lam, Tram Kim Khoury, Muin J. TI Knowledge Integration in Cancer: Current Landscape and Future Prospects SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID GENOME-WIDE ASSOCIATION; OUTCOME REPORTING BIAS; SYSTEMATIC METAANALYSES; REPRODUCIBLE RESEARCH; GENETIC EPIDEMIOLOGY; CUMULATIVE EVIDENCE; EMPIRICAL-EVIDENCE; CONTROLLED-TRIALS; HUMAN-DISEASES; GUIDELINES AB Knowledge integration includes knowledge management, synthesis, and translation processes. It aims to maximize the use of collected scientific information and accelerate translation of discoveries into individual and population health benefits. Accumulated evidence in cancer epidemiology constitutes a large share of the 2.7 million articles on cancer in PubMed. We examine the landscape of knowledge integration in cancer epidemiology. Past approaches have mostly used retrospective efforts of knowledge management and traditional systematic reviews and meta-analyses. Systematic searches identify 2,332 meta-analyses, about half of which are on genetics and epigenetics. Meta-analyses represent 1:89-1:1162 of published articles in various cancer subfields. Recently, there are more collaborative meta-analyses with individual-level data, including those with prospective collection of measurements [e.g., genotypes in genome-wide association studies (GWAS)]; this may help increase the reliability of inferences in the field. However, most meta-analyses are still done retrospectively with published information. There is also a flurry of candidate gene meta-analyses with spuriously prevalent "positive" results. Prospective design of large research agendas, registration of datasets, and public availability of data and analyses may improve our ability to identify knowledge gaps, maximize and accelerate translational progress or-at a minimum-recognize dead ends in a more timely fashion. Cancer Epidemiol Biomarkers Prev; 22(1); 3-10. (c) 2012 AACR. C1 [Ioannidis, John P. A.; Schully, Sheri D.; Lam, Tram Kim; Khoury, Muin J.] NCI, Knowledge Integrat Team, Epidemiol & Genom Res Program, Div Canc Control & Populat Sci,NIH, Bethesda, MD 20892 USA. [Ioannidis, John P. A.] Stanford Univ, Stanford Prevent Res Ctr, Sch Med, Dept Med, Stanford, CA 94305 USA. [Ioannidis, John P. A.] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA. [Ioannidis, John P. A.] Stanford Univ, Dept Stat, Sch Humanities & Sci, Stanford, CA 94305 USA. [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA. RP Ioannidis, JPA (reprint author), Stanford Univ, Stanford Prevent Res Ctr, Sch Med, Dept Med, 1265 Welch Rd,MSOB X306, Stanford, CA 94305 USA. EM jioannid@stanford.edu FU Intramural CDC HHS [CC999999] NR 55 TC 9 Z9 9 U1 1 U2 24 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD JAN PY 2013 VL 22 IS 1 BP 3 EP 10 DI 10.1158/1055-9965.EPI-12-1144 PG 8 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 070SS UT WOS:000313531900001 PM 23093546 ER PT J AU Miller, JW Sabatino, SA Thompson, TD Breen, N White, MC Ryerson, AB Taplin, S Ballard-Barbash, R AF Miller, Jacqueline W. Sabatino, Susan A. Thompson, Trevor D. Breen, Nancy White, Mary C. Ryerson, A. Blythe Taplin, Stephen Ballard-Barbash, Rachel TI Breast MRI Use Uncommon among U.S. Women SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID CANCER; MAMMOGRAPHY; RISK; SENSITIVITY; ULTRASOUND AB Background: The goal of breast cancer screening is to reduce breast cancer mortality. Mammography is the standard screening method for detecting breast cancer early. Breast MRI is recommended to be used in conjunction with mammography for screening subsets of women at high risk for breast cancer. We offer the first study to provide national estimates of breast MM use among women in the United States. Methods: We analyzed data from women who responded to questions about having a breast MRI on the 2010 National Health Interview Survey. We assessed report of having a breast MRI and reasons for it by socio-demographic characteristics and access to health care and computed five-year and lifetime breast cancer risk using the Gail model. Results: Among 11,222 women who responded, almost 5% reported ever having a breast MRI and 2% reported having an MM within the 2 years preceding the survey. Less than half of the women who reported having a breast MRI were at increased risk. Approximately 60% of women reported having the breast MRI for diagnostic reasons. Women who ever had a breast MRI were more likely to be older, Black, and insured and to report a usual source of health care as compared with women who reported no MRI. Conclusions: Breast MRI use may be underused or overused in certain subgroups of women. Impact: As access to health care improves, the use of breast MRI and the appropriateness of its use for breast cancer detection will be important to monitor. Cancer Epidemiol Biomarkers Prev; 22(1); 159-66. (C) 2012 AACR. C1 [Miller, Jacqueline W.; Sabatino, Susan A.; Thompson, Trevor D.; White, Mary C.; Ryerson, A. Blythe] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Breen, Nancy; Taplin, Stephen; Ballard-Barbash, Rachel] NCI, Div Canc Control & Populat Sci, NIH, Bethesda, MD 20892 USA. RP Miller, JW (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,Mailstop K-57, Atlanta, GA 30341 USA. EM JMiller5@cdc.gov RI White, Mary /C-9242-2012 OI White, Mary /0000-0002-9826-3962 FU Intramural NIH HHS [Z99 CA999999] NR 26 TC 2 Z9 2 U1 1 U2 7 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD JAN PY 2013 VL 22 IS 1 BP 159 EP 166 DI 10.1158/1055-9965.EPI-12-0967 PG 8 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 070SS UT WOS:000313531900020 PM 23155135 ER PT J AU Kazzi, ZN Miller, CW AF Kazzi, Z. N. Miller, C. W. TI The role of toxicologists and poison centers during and after a nuclear power plant emergency SO CLINICAL TOXICOLOGY LA English DT Article C1 [Kazzi, Z. N.; Miller, C. W.] Ctr Dis Control & Prevent, Radiat Studies Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Kazzi, Z. N.] Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA. RP Kazzi, ZN (reprint author), Ctr Dis Control & Prevent, Radiat Studies Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, 4770 Buford Highway,NE MS-F59, Atlanta, GA 30341 USA. EM zkazzi@cdc.gov NR 3 TC 0 Z9 1 U1 0 U2 4 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 1556-3650 J9 CLIN TOXICOL JI Clin. Toxicol. PD JAN PY 2013 VL 51 IS 1 BP 1 EP 2 DI 10.3109/15563650.2012.757319 PG 2 WC Toxicology SC Toxicology GA 072HU UT WOS:000313661700001 PM 23311539 ER PT J AU Law, RK Schier, JG Martin, CA Olivares, DE Thomas, RG Bronstein, AC Chang, AS AF Law, Royal K. Schier, Josh G. Martin, Colleen A. Olivares, Dagny E. Thomas, Richard G. Bronstein, Alvin C. Chang, Arthur S. TI National surveillance for radiological exposures and intentional potassium iodide and iodine product ingestions in the United States associated with the 2011 Japan radiological incident SO CLINICAL TOXICOLOGY LA English DT Article DE National; Poison Data System; Poison; Centers; Radiation ID ILLNESS AB Background. In March of 2011, an earthquake struck Japan causing a tsunami that resulted in a radiological release from the damaged Fukushima Daiichi nuclear power plant. Surveillance for potential radiological and any iodine/iodide product exposures was initiated on the National Poison Data System (NPDS) to target public health messaging needs within the United States (US). Our objectives are to describe self-reported exposures to radiation, potassium iodide (KI) and other iodine/iodide products which occurred during the US federal response and discuss its public health impact. Methods. All calls to poison centers associated with the Japan incident were identified from March 11, 2011 to April 18, 2011 in NPDS. Exposure, demographic and health outcome information were collected. Calls about reported radiation exposures and KI or other iodine/iodide product ingestions were then categorized with regard to exposure likelihood based on follow-up information obtained from the PC where each call originated. Reported exposures were subsequently classified as probable exposures (high likelihood of exposure), probable non-exposures (low likelihood of exposure), and suspect exposure (unknown likelihood of exposure). Results. We identified 400 calls to PCs associated with the incident, with 340 information requests (no exposure reported) and 60 reported exposures. The majority (n = 194; 57%) of the information requests mentioned one or more substances. Radiation was inquired about most frequently (n = 88; 45%), followed by KI (n = 86; 44%) and other iodine/iodide products (n = 47; 24%). Of the 60 reported exposures, KI was reported most frequently (n = 25; 42%), followed by radiation (n = 22; 37%) and other iodine/iodide products (n = 13; 22%). Among reported KI exposures, most were classified as probable exposures (n = 24; 96%); one was a probable non-exposure. Among reported other iodine/iodide product exposures, most were probable exposures (n = 10, 77%) and the rest were suspect exposures (n = 3; 23%). The reported radiation exposures were classified as suspect exposures (n = 16, 73%) or probable non-exposures (n = 6; 27%). No radiation exposures were classified as probable exposures. A small number of the probable exposures to KI and other iodide/iodine products reported adverse signs or symptoms (n = 9; 26%). The majority of probable exposures had no adverse outcomes (n = 28; 82%). These data identified a potential public health information gap regarding KI and other iodine/iodide products which was then addressed through public health messaging activities. Conclusion. During the Japan incident response, surveillance activities using NPDS identified KI and other iodine/iodide products as potential public health concerns within the US, which guided CDC's public health messaging and communication activities. Regional PCs can provide timely and additional information during a public health emergency to enhance data collected from surveillance activities, which in turn can be used to inform public health decision-making. C1 [Law, Royal K.] CDC, Agcy Toxic Subst & Dis Registry, Natl Ctr Environm Hlth, CDC NCEH EHHE HSB MS F 57, Atlanta, GA 30341 USA. [Olivares, Dagny E.] CDC, Off Publ Hlth Preparedness & Response, Atlanta, GA 30341 USA. [Thomas, Richard G.; Bronstein, Alvin C.] Amer Assoc Poison Control Ctr, Alexandria, VA USA. RP Law, RK (reprint author), CDC, Agcy Toxic Subst & Dis Registry, Natl Ctr Environm Hlth, CDC NCEH EHHE HSB MS F 57, 4770 Buford Highway NE, Atlanta, GA 30341 USA. EM Rlaw@cdc.gov RI Schier, Joshua/F-9861-2013 FU Intramural CDC HHS [CC999999] NR 6 TC 4 Z9 4 U1 0 U2 15 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 1556-3650 J9 CLIN TOXICOL JI Clin. Toxicol. PD JAN PY 2013 VL 51 IS 1 BP 41 EP 46 DI 10.3109/15563650.2012.732701 PG 6 WC Toxicology SC Toxicology GA 072HU UT WOS:000313661700007 PM 23043524 ER PT J AU Tudiver, F Click, IA Ward, P Basden, JA AF Tudiver, Fred Click, Ivy A. Ward, Patricia Basden, Jeri Ann TI Evaluation of a Quality Improvement Curriculum for Family Medicine Residents SO FAMILY MEDICINE LA English DT Article ID PROPOSALS; TRAINEES AB BACKGROUND AND OBJECTIVES: East Tennessee State University's (ETSU) Department of Family Medicine initiated Quality Improvement (QI) training in its three residency programs in 2008. The purpose of the project was to develop, implement, and assess a formal curriculum and experiential learning process to train family medicine residents in QI knowledge and skills. METHODS: Family medicine faculty members received training in QI theory and design. Rising second-year residents received a day-long workshop on the basics of QI principles. Residents worked in teams to develop and implement QI projects. Self-assessed QI proficiency was measured prior to and immediately following the workshop. QI knowledge was assessed with the Quality Improvement Knowledge Application Tool (QIKAT) at baseline and following project completion. RESULTS: Two groups of residents (n=37) received training and completed at least 1 year on their projects. Analyses revealed that residents' self-assessed QI proficiency improved after receiving a day-long training workshop and was consistent for both groups of resident training. Application of QI knowledge as assessed by the QIKAT did not improve following QI project participation in resident Group 1 but did improve in resident Group 2. CONCLUSIONS: A formal QI curriculum was successfully developed and implemented into three family medicine residency programs. Residents' QI knowledge and skills improved following training and experience conducting QI projects. Faculty and resident commitment to the program and competing time demands proved challenging to the introduction of QI training. Future studies should assess residents' sustained learning and translating QI residency experiences into practice. (Fam Med 2013;45(1):19-25.) C1 [Tudiver, Fred; Click, Ivy A.; Basden, Jeri Ann] E Tennessee State Univ, Dept Family Med, Quillen Coll Med, Johnson City, TN 37614 USA. [Ward, Patricia] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, DB Consulting, Atlanta, GA USA. RP Tudiver, F (reprint author), E Tennessee State Univ, Dept Family Med, Quillen Coll Med, Box 70621, Johnson City, TN 37614 USA. EM tudiverf@etsu.edu FU US Department of Health and Human Services, Health Resources and Services Administration, Primary Care Medical Education Branch [D58HP10320] FX Financial support was received from the US Department of Health and Human Services, Health Resources and Services Administration, Primary Care Medical Education Branch, Grant number: D58HP10320. Parts of this work were presented at the 2009 North American Primary Care Research Group Annual Meeting, Montreal; the 2010 Society of Teachers of Family Medicine Annual Spring Conference, Vancouver; the 2010 Family Medicine Forum, Vancouver; and the 2011 Family Medicine Forum, Montreal. NR 16 TC 9 Z9 9 U1 1 U2 4 PU SOC TEACHERS FAMILY MEDICINE PI LEAWOOD PA 11400 TOMAHAWK CREEK PARKWAY, STE 540, LEAWOOD, KS 66207 USA SN 0742-3225 J9 FAM MED JI Fam. Med. PD JAN PY 2013 VL 45 IS 1 BP 19 EP 25 PG 7 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA 069SR UT WOS:000313457900004 PM 23334963 ER PT J AU Fullerton, KE Mahon, BE AF Fullerton, Kathleen E. Mahon, Barbara E. TI Case-Control Studies of Sporadic Enteric Infections Complement Information from Outbreak Investigations SO FOODBORNE PATHOGENS AND DISEASE LA English DT Letter ID UNITED-STATES; CAMPYLOBACTER INFECTION; RISK-FACTORS C1 [Fullerton, Kathleen E.; Mahon, Barbara E.] Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30329 USA. RP Fullerton, KE (reprint author), Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd NE,MS C-09, Atlanta, GA 30329 USA. EM kfullerton@cdc.gov FU Intramural CDC HHS [CC999999] NR 10 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1535-3141 J9 FOODBORNE PATHOG DIS JI Foodborne Pathog. Dis. PD JAN PY 2013 VL 10 IS 1 BP 97 EP 98 DI 10.1089/fpd.2012.1412 PG 2 WC Food Science & Technology SC Food Science & Technology GA 071CJ UT WOS:000313563000015 PM 23210922 ER PT J AU Lukwago, L Nanyunja, M Ndayimirije, N Wamala, J Malimbo, M Mbabazi, W Gasasira, A Nabukenya, IN Musenero, M Alemu, W Perry, H Nsubuga, P Talisuna, A AF Lukwago, Luswa Nanyunja, Miriam Ndayimirije, Nestor Wamala, Joseph Malimbo, Mugaga Mbabazi, William Gasasira, Anne Nabukenya, Immaculate N. Musenero, Monica Alemu, Wondimagegnehu Perry, Helen Nsubuga, Peter Talisuna, Ambrose TI The implementation of Integrated Disease Surveillance and Response in Uganda: a review of progress and challenges between 2001 and 2007 SO HEALTH POLICY AND PLANNING LA English DT Article DE Integrated disease surveillance and response; surveillance indicators; epidemic preparedness and response; infectious disease surveillance; Uganda AB Methods We used a monitoring framework recommended by World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC)-Atlanta to evaluate performance of the IDSR core indicators at the national level from 2001 to 2007. To determine the performance of IDSR at district and health facility levels over a 5-year period, we compared the evaluation results of a 2004 surveillance survey with findings from a baseline assessment in 2000. We also examined national-level funding for IDSR implementation during 2000-07. Results Our findings show improvements in the performance of IDSR, including: (1) improved reporting at the district level (49% in 2001; 85% in 2007); (2) an increase and then decrease in timeliness of reporting from districts to central level; and (3) an increase in analysed data at the local level (from 10% to 47% analysing at least one target disease, P < 0.01). The case fatality rate (CFR) for two target priority diseases (cholera and meningococcal meningitis) decreased during IDSR implementation (cholera: from 7% to 2%; meningitis: from 16% to 4%), most likely due to improved outbreak response. A comparison before and after implementation showed increased funding for IDSR from government and development partners. However, funding support decreased ten-fold from the government budget of 2000/01 through to 2007/08. Per capita input for disease surveillance activities increased from US$0.0046 in 1996-99 to US$0.0215 in 2000-07. Conclusion Implementation of IDSR was associated with improved surveillance and response efforts. However, decreased budgetary support from the government may be eroding these gains. Renewed efforts from government and other stakeholders are necessary to sustain and expand progress achieved through implementation of IDSR. C1 [Lukwago, Luswa; Wamala, Joseph; Malimbo, Mugaga; Gasasira, Anne; Nabukenya, Immaculate N.; Musenero, Monica; Talisuna, Ambrose] Uganda Minist Hlth, Kampala, Uganda. [Lukwago, Luswa] Makerere Univ, Sch Publ Hlth, Kampala, Uganda. [Nanyunja, Miriam; Mbabazi, William] World Hlth Org, Country Off Uganda, Kampala, Uganda. [Ndayimirije, Nestor] World Hlth Org, Intercountry Communicable Dis Surveillance Team, Kampala, Uganda. [Alemu, Wondimagegnehu] World Hlth Org, Reg Off Africa, Brazzaville, Congo. [Perry, Helen; Nsubuga, Peter] Ctr Dis Control, Atlanta, GA 30333 USA. RP Lukwago, L (reprint author), Minist Hlth, Epidemiol Surveillance Div, POB 7272, Kampala, Uganda. EM luswal@yahoo.com FU Government of Uganda; World Health Organization (WHO); US Centers for Disease Control and Prevention (CDC); USAID African Bureau; Rockefeller Foundation; Ministry of health; CDC; World Health Organization (WHO) Country Office; WHO Regional Headquarters in Africa (AFRO); WHO Headquarters in Geneva; USAID; IDSR in general in Uganda FX The implementation of IDSR, the performance monitoring and evaluation were funded by the Government of Uganda, World Health Organization (WHO), US Centers for Disease Control and Prevention (CDC), USAID African Bureau and the Rockefeller Foundation. The review of the data and writing of this manuscript was supported financially by the Ministry of health, WHO and CDC. WHO and CDC funded a writing workshop where the authors started writing the manuscript. They also provided technical support for data analysis and interpretation, and contributed to the writing of the manuscript. Pre-submission review and clearance was also done by CDC-Atlanta.; Several individuals, institutions and organizations provided technical guidance and logistical support in establishing IDSR in Uganda. In addition some participated in this study through data collection and by providing meaningful discussions during the proposal and result presentations in the different meetings. We gratefully acknowledge the Ministry of Health in Uganda, specifically Dr Sam Zaramba, Director General; Dr Sam Okware, Commissioner of Community Health; and Dr Dennis K W Lwamafa, Commissioner for National Disease Control. We also acknowledge the support and guidance of the World Health Organization (WHO) Country Office, the WHO Regional Headquarters in Africa (AFRO), and the WHO Headquarters in Geneva particularly Dr Stella Chungong and Dr Idrissa Sow. We deeply appreciate the funding and support from USAID, in particular, Ms Mary Harvey (USAID), Rockefeller Foundation, and technical support from Dr Sambe Duale (Africa 2010, Tulane University). Many colleagues from CDC-Atlanta and CDC-Uganda contributed technical and logistical support to Uganda's IDSR program especially Dr Mark White. Several organizations supported IDSR in general in Uganda and this study in particular, including Makerere University School of Public Health, the Africa Field Epidemiology Network (AFENET), UNICEF, African Medical and Research Foundation (AMREF), and the Uganda Virus Research Institute (UVRI). NR 22 TC 8 Z9 8 U1 0 U2 10 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0268-1080 J9 HEALTH POLICY PLANN JI Health Policy Plan. PD JAN PY 2013 VL 28 IS 1 BP 30 EP 40 DI 10.1093/heapol/czs022 PG 11 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 072FQ UT WOS:000313655100004 PM 22669899 ER PT J AU Chai, SJ Mattingly, DC Varma, JK AF Chai, Shua J. Mattingly, Daniel C. Varma, Jay K. TI Protecting health care workers from tuberculosis in China: a review of policy and practice in China and the United States SO HEALTH POLICY AND PLANNING LA English DT Review DE Occupational tuberculosis; health policy; China; United States ID MULTIDRUG-RESISTANT TUBERCULOSIS; INFECTION-CONTROL PROGRAMS; HOSPITALS; OUTBREAK; TRANSMISSION; DISEASE AB We reviewed the development and content of tuberculosis infection control policies in the United States and China. Sources included published academic literature, Chinese Ministry of Health policies, US government agency reports, legal databases, personal observations of hospitals, review of internet discussion sites, and discussions with HCWs and health care and law experts. In the United States, slow acceptance of the tuberculosis problem in HCWs resulted in decades of inaction. Tuberculosis infection control policies, based mostly on expert opinion, were implemented only after tuberculosis resurged in the 1980s. Effective evidence-based policies were developed only after multiple cycles of policy implementation, evaluation and revision. These policies have now substantially reduced occupational tuberculosis. In China, tuberculosis has not been formally recognized as an occupational disease, and data regarding the burden in HCWs are sparse. Vagueness of current labour laws and suboptimal alignment of infection control authority and expertise result in varied and sometimes absent protection of HCWs against tuberculosis. Formal evaluations of occupational tuberculosis policies have not been reported. By collecting data on its current HCW tuberculosis burden and infection control practices, refining policies, continually evaluating its policies based on accumulated evidence and rapidly identifying unsuspected tuberculosis cases, China can develop a more comprehensive strategy to ensure the health of HCWs and reduce transmission of tuberculosis and multidrug-resistant tuberculosis. C1 [Chai, Shua J.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Mattingly, Daniel C.] Univ Calif Berkeley, Berkeley, CA 94720 USA. [Varma, Jay K.] US Ctr Dis Control & Prevent, Beijing, Peoples R China. RP Varma, JK (reprint author), New York City Dept Hlth & Mental Hyg, 125 Worth St, New York, NY 10013 USA. EM jvarma@health.nyc.gov NR 56 TC 12 Z9 12 U1 0 U2 15 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0268-1080 J9 HEALTH POLICY PLANN JI Health Policy Plan. PD JAN PY 2013 VL 28 IS 1 BP 100 EP 109 DI 10.1093/heapol/czs029 PG 10 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 072FQ UT WOS:000313655100010 PM 22427258 ER PT J AU Syamlal, G Schleiff, PL Mazurek, JM Doney, B Greskevitch, M AF Syamlal, Girija Schleiff, Patricia L. Mazurek, Jacek M. Doney, Brent Greskevitch, Mark TI Respirator Use Among US Farm Operators: Evidence from the 2006 Farm and Ranch Safety Survey SO JOURNAL OF AGROMEDICINE LA English DT Article DE Agriculture worker; farm operator; occupational exposure; respirator ID PROTECTIVE EQUIPMENT USE; ORGANIC DUST EXPOSURE; AGRICULTURAL HEALTH; PESTICIDE USE; PREDICTORS; SYMPTOMS; ILLNESS AB The objective of this study was to estimate the national prevalence of respirator use among primary farm operators in the United States. The authors analyzed the 2006 Farm and Ranch Safety Survey data collected for 12,278 actively farming primary farm operators. Weighted prevalence and adjusted prevalence ratios (PRs) of respirator use were calculated by farm operator characteristics, farm characteristics, and selected exposures/hazards. Of the estimated 2.1 million farm operators, 37.2% used a respirator on their farm. Respirator use prevalence was significantly higher among operators aged 1634 years than those aged =65 years (46.9% vs. 30.0%; PR = 1.6); male than female operators (39.0% vs. 24.4%; PR = 1.6); operators managing crop farms than operators managing livestock farms (40.9% vs. 33.7%; PR = 1.2); and operators managing farms with value of sales =$100,000 than operators managing farms with value of sales =$9999 (57.4% vs. 31.4%; PR = 1.8). Of the operators who used a respirator, 69.9% used while working in a dusty environment, 22.6% used while applying/handling pesticides, and 30.4% used while doing other farm-related activities. These results show that an estimated one third of operators used respirators in 2006, and respirator use is most frequent among operators working in a dusty environment. Additional research identifying specific exposures for which respirators or dust masks are used, barriers to respirator or dust mask use, motivators for wearing respirators, and opportunities to increase the use of respiratory protection among farm operators, particularly on smaller farms, is needed. C1 [Syamlal, Girija; Schleiff, Patricia L.; Mazurek, Jacek M.; Doney, Brent; Greskevitch, Mark] NIOSH, Div Resp Dis Studies, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. RP Syamlal, G (reprint author), NIOSH, Div Resp Dis Studies, Ctr Dis Control & Prevent, 1095 Willowdale Rd,Mail Stop HG 900-2, Morgantown, WV 26505 USA. EM gsyamlal@cdc.gov FU Centers for Disease Control and Prevention FX This study was supported by the Centers for Disease Control and Prevention. The authors thank Mr. Larry A Layne and Dr. Kimberly Faulkner from the National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, for their thoughtful comments. NR 35 TC 4 Z9 4 U1 0 U2 9 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1059-924X EI 1545-0813 J9 J AGROMEDICINE JI J. Agromedicine PD JAN 1 PY 2013 VL 18 IS 1 BP 27 EP 38 DI 10.1080/1059924X.2012.743379 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 069DH UT WOS:000313414900007 PM 23301888 ER PT J AU Traynor, S Kearney, G Olson, D Hilliard, A Palcic, J Pawlowicz, M AF Traynor, Sharleen Kearney, Greg Olson, David Hilliard, Aaron Palcic, Jason Pawlowicz, Marek TI Fish Consumption Patterns and Mercury Exposure Levels Among Women of Childbearing Age in Duval County, Florida SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Article ID HAIR MERCURY; BLOOD AB Consumption of fish containing methylmercury can pose serious health concerns including neurotoxic effects in adults and toxicity to the fetuses of mothers exposed during pregnancy In the study described in this article, the authors examined fish consumption patterns and measured hair mercury levels of women of childbearing age in a coastal county in Florida. Women from the community participated in a risk factor assessment survey (N = 703). Hair samples (It = 698) were collected and analyzed for mercury The authors identified 74.8% below detection limit; 25.2% had detectable limits of mercury, while 7% exceeded 1 mu g/g. Hair mercury levels increased with fish consumption and age. Race, income, and education levels were also associated with increased hair mercury levels. Women of Asian/Pacific Islander origin had the highest levels. Although reported fish consumption exceeded the recommendations for women of childbearing age, the study population had lower mercury levels than other comparative studies in Florida and at national levels. C1 [Traynor, Sharleen] Mayo Clin, Jacksonville, FL 32224 USA. [Kearney, Greg] E Carolina Univ, Brody Sch Med, Dept Publ Hlth, Greenville, NC 27834 USA. [Olson, David] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Kearney, G (reprint author), E Carolina Univ, Brody Sch Med, Dept Publ Hlth, 600 Moye Blvd,MS 660, Greenville, NC 27834 USA. EM Kearneyg@ecu.edu FU Duval County Health Department; Florida Department of Health Jacksonville Laboratory; Florida Department of Health, Division of Environmental Health, Environmental Public Health Tracking Program from the Centers for Disease Control and Prevention (CDC) [5 U38 EH000177-02] FX The authors would like to thank the participants involved, the Duval County Health Department, and the Florida Department of Health Jacksonville Laboratory for their support on this project. This publication was supported by the Florida Department of Health, Division of Environmental Health, Environmental Public Health Tracking Program under Grant/Cooperative Agreement Number 5 U38 EH000177-02 from the Centers for Disease Control and Prevention (CDC). The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the CDC. NR 26 TC 11 Z9 12 U1 0 U2 23 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD JAN-FEB PY 2013 VL 75 IS 6 SI SI BP 8 EP 15 PG 8 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 069UN UT WOS:000313462700002 PM 23397644 ER PT J AU Belay, B Allen, J Williams, N Dooyema, C Foltz, J AF Belay, Brook Allen, Jessica Williams, Nancy Dooyema, Carrie Foltz, Jennifer TI Promoting Women's Health in Hospitals: A Focus on Breastfeeding and Lactation Support for Employees and Patients SO JOURNAL OF WOMENS HEALTH LA English DT Article ID RISK; DURATION AB Hospitals often are one of the largest employers in communities, and nationwide, they employ more than 6.3 million employees. Hospitals also serve tens of millions of inpatients annually. Hospitals, therefore, can be leaders in worksite wellness and promoting breastfeeding and lactation support for new mothers. By adopting model standards and practices that promote breastfeeding, hospitals can influence women's health. This article focuses on the efforts of the Centers for Disease Control and Prevention's Division of Nutrition, Physical Activity, and Obesity to promote breastfeeding and lactation support for hospital employees and patients. C1 [Belay, Brook; Allen, Jessica; Williams, Nancy; Dooyema, Carrie; Foltz, Jennifer] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Belay, B (reprint author), Ctr Dis Control & Prevent, Div Nutr & Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,MSK 24, Atlanta, GA 30341 USA. EM bbelay@cdc.gov FU Intramural CDC HHS [CC999999] NR 24 TC 0 Z9 0 U1 1 U2 6 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD JAN PY 2013 VL 22 IS 1 BP 1 EP 4 DI 10.1089/jwh.2012.4040 PG 4 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 071HE UT WOS:000313580800001 PM 23215865 ER PT J AU Natarajan, G Shankaran, S McDonald, SA Das, A Ehrenkranz, RA Goldberg, RN Stoll, BJ Tyson, JE Higgins, RD Schendel, D Hougaard, DM Skogstrand, K Thorsen, P Carlo, WA AF Natarajan, Girija Shankaran, Seetha McDonald, Scott A. Das, Abhik Ehrenkranz, Richard A. Goldberg, Ronald N. Stoll, Barbara J. Tyson, Jon E. Higgins, Rosemary D. Schendel, Diana Hougaard, David M. Skogstrand, Kristin Thorsen, Poul Carlo, Waldemar A. TI Association Between Blood Spot Transforming Growth Factor-beta and Patent Ductus Arteriosus in Extremely Low-Birth Weight Infants SO PEDIATRIC CARDIOLOGY LA English DT Article DE Transforming growth factor; Patent ductus arteriosus; Preterm; Neonate ID EXPRESSION; CELLS; MIGRATION; CYTOKINES AB Permanent ductal closure involves anatomic remodeling, in which transforming growth factor (TGF)-beta appears to play a role. Our objective was to evaluate the relationship, if any, between blood spot TGF-beta on day 3 and day 7 of life and patent ductus arteriosus (PDA) in extremely low birth weight (ELBW) infants. Prospective observational study involving ELBW infants (n = 968) in the National Institute of Child Health and Human Development Neonatal Research Network who had TGF-beta measured on filter paper spot blood samples using a Luminex assay. Infants with a PDA (n = 493) were significantly more immature, had lower birth weights, and had higher rates of respiratory distress syndrome than those without PDA (n = 475). TGF-beta on days 3 and 7 of life, respectively, were significantly lower among neonates with PDA (median 1,177 pg/ml [range 642-1,896]; median 1,386 pg/ml [range 868-1,913]) compared with others without PDA (median 1,334 pg/ml [range 760-2,064]; median 1,712 pg/ml [range 1,014-2,518 pg/ml]). The significant difference persisted when death or PDA was considered a composite outcome. TGF-beta levels were not significantly different among subgroups of infants with PDA who were not treated (n = 51) versus those who were treated medically (n = 283) or by surgical ligation (n = 159). TGF-beta was not a significant predictor of death or PDA (day 3 odds ratio [OR] 0.99, 95 % confidence interval [CI] 0.83-1.17; day 7 OR 0.88, 95 % CI 0.74-1.04) on adjusted analyses. Our results suggest that blood spot TGF-beta alone is unlikely to be a reliable biomarker of a clinically significant PDA or its responsiveness to treatment. C1 [Natarajan, Girija; Shankaran, Seetha] Wayne State Univ, Sch Med, Dept Pediat, Detroit, MI 48201 USA. [McDonald, Scott A.] RTI Int, Dept Stat & Epidemiol, Durham, NC USA. [Das, Abhik] RTI Int, Dept Stat & Epidemiol, Rockville, MD USA. [Ehrenkranz, Richard A.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA. [Goldberg, Ronald N.] Duke Univ, Dept Pediat, Durham, NC 27706 USA. [Stoll, Barbara J.] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA. [Tyson, Jon E.] Univ Texas Med Sch Houston, Dept Pediat, Houston, TX USA. [Higgins, Rosemary D.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA. [Schendel, Diana] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Hougaard, David M.; Skogstrand, Kristin] Statens Serum Inst, Sect Neonatal Screening & Hormones, Dept Clin Biochem & Immunol, DK-2300 Copenhagen, Denmark. [Thorsen, Poul] Lillebaelt Hosp, Dept Obstet & Gynecol, Kolding, Denmark. [Thorsen, Poul] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Carlo, Waldemar A.] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL USA. RP Natarajan, G (reprint author), Wayne State Univ, Sch Med, Dept Pediat, Detroit, MI 48201 USA. EM gnatara@med.wayne.edu OI Skogstrand, Kristin/0000-0002-0026-3711 FU Eunice Kennedy Shriver National Institute of Child Health and Human Development; Department of Health and Human Services [U10 HD21385, U10 HD40689, U10 HD 27871, U10 HD21373, U10 HD36790, U10 HD40461, U10 HD34216, U10 HD21397, U10 HD27904, U10 HD40492, U10 HD27856, U10 HD40521, U10 HD27853, U10 HD27880, U10 HD27851, R03 HD054420]; National Institutes of Health [GCRC M01 RR 08084, M01 RR 00125, M01 RR 00750, M01 RR 00070, M01 RR 0039-43, M01 RR 00039, 5 M01 RR00044]; National Institutes of Health; Centers for Disease Control and Prevention FX Supported by grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the Department of Health and Human Services (Grants No. U10 HD21385, U10 HD40689, U10 HD 27871, U10 HD21373, U10 HD36790, U10 HD40461, U10 HD34216, U10 HD21397, U10 HD27904, U10 HD40492, U10 HD27856, U10 HD40521, U10 HD27853, U10 HD27880, U10 HD27851, and R03 HD054420) and from the National Institutes of Health (Grants No. GCRC M01 RR 08084, M01 RR 00125, M01 RR 00750, M01 RR 00070, M01 RR 0039-43, M01 RR 00039, and 5 M01 RR00044). The National Institutes of Health, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the Centers for Disease Control and Prevention provided grant support for recruitment for 1999 through 2001 and data analysis for the Neonatal Research Network's Cytokines Study. The funding agencies provided overall oversight for study conduct, but all data analyses and interpretation were independent of the funding agencies. Data collected at participating NRN sites were transmitted to RTI International, the data-coordinating center (DCC) for the NRN, which stored, managed, and analyzed the data for this study. On behalf of the network, Abhik Das (DCC PI) and Scott A. McDonald (DCC statistician) had full access to all of the data in the study and take responsibility for the integrity of the data and accuracy of the data analysis. We are indebted to our medical and nursing colleagues as well as the infants and their parents who agreed to take part in this study. NR 15 TC 0 Z9 0 U1 1 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0172-0643 J9 PEDIATR CARDIOL JI Pediatr. Cardiol. PD JAN PY 2013 VL 34 IS 1 BP 149 EP 154 DI 10.1007/s00246-012-0404-7 PG 6 WC Cardiac & Cardiovascular Systems; Pediatrics SC Cardiovascular System & Cardiology; Pediatrics GA 070PB UT WOS:000313520600020 PM 22684193 ER PT J AU Oster, ME Colarusso, T Glidewell, J AF Oster, Matthew E. Colarusso, Tiffany Glidewell, Jill TI Screening for Critical Congenital Heart Disease: A Matter of Sensitivity SO PEDIATRIC CARDIOLOGY LA English DT Letter ID PULSE OXIMETRY C1 [Oster, Matthew E.] Emory Univ, Sibley Heart Ctr Cardiol, Childrens Healthcare Atlanta, Atlanta, GA 30341 USA. [Oster, Matthew E.; Colarusso, Tiffany; Glidewell, Jill] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Oster, ME (reprint author), Emory Univ, Sibley Heart Ctr Cardiol, Childrens Healthcare Atlanta, 2835 Brandywine Rd,Ste 300, Atlanta, GA 30341 USA. EM osterm@kidsheart.com FU Intramural CDC HHS [CC999999] NR 4 TC 3 Z9 3 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0172-0643 J9 PEDIATR CARDIOL JI Pediatr. Cardiol. PD JAN PY 2013 VL 34 IS 1 BP 203 EP 204 DI 10.1007/s00246-012-0582-3 PG 2 WC Cardiac & Cardiovascular Systems; Pediatrics SC Cardiovascular System & Cardiology; Pediatrics GA 070PB UT WOS:000313520600031 PM 23179425 ER PT J AU Kuhn, JH Bao, YM Bavari, S Becker, S Bradfute, S Brister, JR Bukreyev, AA Chandran, K Davey, RA Dolnik, O Dye, JM Enterlein, S Hensley, LE Honko, AN Jahrling, PB Johnson, KM Kobinger, G Leroy, EM Lever, MS Muhlberger, E Netesov, SV Olinger, GG Palacios, G Patterson, JL Paweska, JT Pitt, L Radoshitzky, SR Saphire, EO Smither, SJ Swanepoel, R Towner, JS van der Groen, G Volchkov, VE Wahl-Jensen, V Warren, TK Weidmann, M Nichol, ST AF Kuhn, Jens H. Bao, Yiming Bavari, Sina Becker, Stephan Bradfute, Steven Brister, J. Rodney Bukreyev, Alexander A. Chandran, Kartik Davey, Robert A. Dolnik, Olga Dye, John M. Enterlein, Sven Hensley, Lisa E. Honko, Anna N. Jahrling, Peter B. Johnson, Karl M. Kobinger, Gary Leroy, Eric M. Lever, Mark S. Muehlberger, Elke Netesov, Sergey V. Olinger, Gene G. Palacios, Gustavo Patterson, Jean L. Paweska, Janusz T. Pitt, Louise Radoshitzky, Sheli R. Saphire, Erica Ollmann Smither, Sophie J. Swanepoel, Robert Towner, Jonathan S. van der Groen, Guido Volchkov, Viktor E. Wahl-Jensen, Victoria Warren, Travis K. Weidmann, Manfred Nichol, Stuart T. TI Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae SO ARCHIVES OF VIROLOGY LA English DT Article ID TAXONOMY; NAMES; IDENTIFICATION; VIROLOGISTS; EBOLAVIRUS; PROPOSAL AB The task of international expert groups is to recommend the classification and naming of viruses. The International Committee on Taxonomy of Viruses Filoviridae Study Group and other experts have recently established an almost consistent classification and nomenclature for filoviruses. Here, further guidelines are suggested to include their natural genetic variants. First, this term is defined. Second, a template for full-length virus names (such as "Ebola virus H.sapiens-tc/COD/1995/Kikwit-9510621") is proposed. These names contain information on the identity of the virus (e.g., Ebola virus), isolation host (e.g., members of the species Homo sapiens), sampling location (e.g., Democratic Republic of the Congo (COD)), sampling year, genetic variant (e.g., Kikwit), and isolate (e.g., 9510621). Suffixes are proposed for individual names that clarify whether a given genetic variant has been characterized based on passage zero material (-wt), has been passaged in tissue/cell culture (-tc), is known from consensus sequence fragments only (-frag), or does (most likely) not exist anymore (-hist). We suggest that these comprehensive names are to be used specifically in the methods section of publications. Suitable abbreviations, also proposed here, could then be used throughout the text, while the full names could be used again in phylograms, tables, or figures if the contained information aids the interpretation of presented data. The proposed system is very similar to the well-known influenzavirus nomenclature and the nomenclature recently proposed for rotaviruses. If applied consistently, it would considerably simplify retrieval of sequence data from electronic databases and be a first important step toward a viral genome annotation standard as sought by the National Center for Biotechnology Information (NCBI). Furthermore, adoption of this nomenclature would increase the general understanding of filovirus-related publications and presentations and improve figures such as phylograms, alignments, and diagrams. Most importantly, it would counter the increasing confusion in genetic variant naming due to the identification of ever more sequences through technological breakthroughs in high-throughput sequencing and environmental sampling. C1 [Kuhn, Jens H.; Jahrling, Peter B.; Wahl-Jensen, Victoria] NIAID, Integrated Res Facil Ft Detrick IRF Frederick, Div Clin Res DCR, NIH, Frederick, MD USA. [Bao, Yiming; Brister, J. Rodney] Natl Lib Med, Informat Engn Branch, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD USA. [Bavari, Sina; Dye, John M.; Honko, Anna N.; Olinger, Gene G.; Palacios, Gustavo; Pitt, Louise; Radoshitzky, Sheli R.; Warren, Travis K.] USA, Med Res Inst Infect Dis, Frederick, MD USA. [Becker, Stephan; Dolnik, Olga] Univ Marburg, Inst Virol, D-35032 Marburg, Germany. [Bradfute, Steven] Univ New Mexico, Albuquerque, NM 87131 USA. [Bukreyev, Alexander A.] Univ Texas Med Branch, Galveston Natl Lab, Galveston, TX 77555 USA. [Chandran, Kartik] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USA. [Davey, Robert A.; Patterson, Jean L.] Texas Biomed Res Inst, Dept Virol & Immunol, San Antonio, TX USA. [Enterlein, Sven] Integrated BioTherapeut Inc, Gaithersburg, MD USA. [Hensley, Lisa E.] Fed Drug Adm, Med Countermeasure Initiat, Silver Spring, MD USA. [Kobinger, Gary] Publ Hlth Agcy Canada, Natl Microbiol Lab, Special Pathogens Program, Winnipeg, MB, Canada. [Leroy, Eric M.] Ctr Int Rech Med Franceville, Franceville, Gabon. [Lever, Mark S.; Smither, Sophie J.] Dstl, Dept Biomed Sci, Porton Down, Salisbury, Wilts, England. [Muehlberger, Elke] Univ Sch Med, Natl Emerging Infect Dis Lab, Boston, MA USA. [Netesov, Sergey V.] Novosibirsk State Univ, Novosibirsk 630090, Novosibirsk Obl, Russia. [Paweska, Janusz T.] Natl Hlth Lab Serv, Natl Inst Communicable Dis, Ctr Emerging & Zoonot Dis, Johannesburg, Gauteng, South Africa. [Saphire, Erica Ollmann] Scripps Res Inst, Dept Immunol & Microbial Sci, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA. [Swanepoel, Robert] Univ Pretoria, Zoonoses Res Unit, ZA-0002 Pretoria, South Africa. [Towner, Jonathan S.; Nichol, Stuart T.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [van der Groen, Guido] Prins Leopold Inst Trop Geneeskunde, Antwerp, Belgium. [Volchkov, Viktor E.] Univ Lyon, Lab Filovirus, Ecole Normale Super Lyon, INSERM,U758,UCB Lyon 1, Lyon, France. [Weidmann, Manfred] Univ Med Gottingen, Abt Virol, Gottingen, Germany. RP Kuhn, JH (reprint author), NIAID, Integrated Res Facil Ft Detrick IRF Frederick, Div Clin Res DCR, NIH, B-8200 Res Plaza, Frederick, MD USA. EM kuhnjens@mail.nih.gov; stn1@cdc.gov RI LEROY, Eric/I-4347-2016; Netesov, Sergey/A-3751-2013; Volchkov, Viktor/M-7846-2014; Kuhn, Jens H./B-7615-2011; Becker, Stephan/A-1065-2010; Palacios, Gustavo/I-7773-2015; Weidmann, Manfred/G-1817-2015; OI Honko, Anna/0000-0001-9165-148X; LEROY, Eric/0000-0003-0022-0890; Muhlberger, Elke/0000-0003-3547-9376; Netesov, Sergey/0000-0002-7786-2464; Volchkov, Viktor/0000-0001-7896-8706; Kuhn, Jens H./0000-0002-7800-6045; Becker, Stephan/0000-0002-2794-5659; Palacios, Gustavo/0000-0001-5062-1938; Weidmann, Manfred/0000-0002-7063-7491; Olinger, Gene/0000-0001-7338-0292 FU Joint Science and Technology Office for Chem Bio Defense [TMTI0048_09_RD_T]; NIAID [HHSN272200200016I]; NIH, National Library of Medicine FX The content of this publication does not necessarily reflect the views or policies of the US Department of the Army, the US Department of Defense or the US Department of Health and Human Services or of the institutions and companies affiliated with the authors. This work was funded in part by the Joint Science and Technology Office for Chem Bio Defense (proposal #TMTI0048_09_RD_T to SB). JHK and VWJ performed this work as employees of Tunnell Consulting, Inc., a subcontractor to Battelle Memorial Institute under its prime contract with NIAID, under Contract No. HHSN272200200016I. This research was also supported in part by the Intramural Research Program of the NIH, National Library of Medicine (YB and JRB). NR 36 TC 49 Z9 50 U1 2 U2 32 PU SPRINGER WIEN PI WIEN PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA SN 0304-8608 EI 1432-8798 J9 ARCH VIROL JI Arch. Virol. PD JAN PY 2013 VL 158 IS 1 BP 301 EP 311 DI 10.1007/s00705-012-1454-0 PG 11 WC Virology SC Virology GA 067KY UT WOS:000313294200042 PM 23001720 ER PT J AU Hall, MW Geyer, SM Guo, CY Panoskaltsis-Mortari, A Jouvet, P Ferdinands, J Shay, DK Nateri, J Greathouse, K Sullivan, R Tran, T Keisling, S Randolph, AG AF Hall, Mark W. Geyer, Susan M. Guo, Chao-Yu Panoskaltsis-Mortari, Angela Jouvet, Philippe Ferdinands, Jill Shay, David K. Nateri, Jyotsna Greathouse, Kristin Sullivan, Ryan Tram Tran Keisling, Shannon Randolph, Adrienne G. CA Pediat Acute Lung Injury Sepsis TI Innate Immune Function and Mortality in Critically Ill Children With Influenza: A Multicenter Study SO CRITICAL CARE MEDICINE LA English DT Article DE cytokine; immunity; immunoparalysis; influenza; pediatric; Staphylococcus aureus ID COLONY-STIMULATING FACTOR; LEUKOCYTE ANTIGEN-DR; EXTRACORPOREAL MEMBRANE-OXYGENATION; RESPIRATORY-FAILURE SECONDARY; ORGAN DYSFUNCTION SYNDROME; SEVERE PANDEMIC INFLUENZA; H1N1 2009 INFECTION; IFN-GAMMA TREATMENT; VIRUS-INFECTION; MONOCYTE DEACTIVATION AB Objective: To prospectively evaluate relationships among serum cytokine levels, innate immune responsiveness, and mortality in a multicenter cohort of critically ill children with influenza infection. Design: Prospective, multicenter, observational study. Setting: Fifteen pediatric ICUs among members of the Pediatric Acute Lung Injury and Sepsis Investigators network Patients: Patients <= 18 yrs old admitted to a PICU with community-acquired influenza infection. A control group of outpatient children was also evaluated. Interventions: ICU patients underwent sampling within 72 hrs of ICU admission for measurement of a panel of 31 serum cytokine levels and quantification of whole blood ex vivo lipopolysaccharide-stimulated tumor necrosis factor-alpha production capacity using a standardized stimulation protocol. Outpatient control subjects also underwent measurement of tumor necrosis factor-alpha production capacity. Measurements and Main Results: Fifty-two patients (44 survivors, eight deaths) were sampled. High levels of serum cytokines (granulocyte macrophage colony-stimulating factor, interleukin-6, interleukin-8, interferon-inducible protein-10, monocyte chemotactic protein-1, and macrophage inflammatory protein-1 alpha) were associated with mortality (p < 0.0016 for each comparison) as was the presence of secondary infection with Staphylococcus aureus (p = 0.007), particularly methicillin-resistant S. aureus (p < 0.0001). Nonsurvivors were immunosuppressed with leukopenia and markedly reduced tumor necrosis factor-alpha production capacity compared with outpatient control subjects (n = 21, p < 0.0001) and to ICU survivors (p < 0.0001). This association remained after controlling for multiple covariables. A tumor necrosis factor-alpha response <250 pg/mL was highly predictive of death and longer duration of ICU stay (p < 0.0001). Patients with S. aureus coinfection demonstrated the greatest degree of immunosuppression (p < 0.0001). Conclusions: High serum levels of cytokines can coexist with marked innate immune suppression in children with critical influenza. Severe, early innate immune suppression is highly associated with both S. aureus coinfection and mortality in this population. Multicenter innate immune function testing is feasible and can identify these high-risk children. (Crit Care Med 2013; 41:224-236) C1 [Hall, Mark W.] Ohio State Univ, Coll Med, Dept Pediat, Nationwide Childrens Hosp, Columbus, OH 43210 USA. [Hall, Mark W.; Nateri, Jyotsna; Greathouse, Kristin] Nationwide Childrens Hosp, Res Inst, Columbus, OH USA. [Geyer, Susan M.] Ohio State Univ, Coll Med, Div Hematol, Columbus, OH 43210 USA. [Panoskaltsis-Mortari, Angela] Univ Minnesota, Dept Pediat Bone Marrow Transplantat Pulm & Crit, Minneapolis, MN USA. [Jouvet, Philippe] St Justines Childrens Hosp, Montreal, PQ, Canada. [Ferdinands, Jill; Shay, David K.] Ctr Dis Control & Prevent, Div Influenza, Atlanta, GA USA. [Randolph, Adrienne G.] Harvard Univ, Sch Med, Boston, MA USA. [Sullivan, Ryan; Tram Tran; Keisling, Shannon; Randolph, Adrienne G.] Boston Childrens Hosp, Dept Anesthesia Perioperat & Pain Med, Boston, MA USA. [Guo, Chao-Yu] Boston Childrens Hosp, Clin Res Program, Boston, MA USA. RP Hall, MW (reprint author), Ohio State Univ, Coll Med, Dept Pediat, Nationwide Childrens Hosp, Columbus, OH 43210 USA. EM Mark.Hall@NationwideChil-drens.org RI Hall, Mark/E-3193-2011; OI Jouvet, Philippe/0000-0001-5684-3398; Randolph, Adrienne/0000-0002-3084-3071 FU Centers for Disease Control and Prevention, Atlanta, GA; America's Health Insurance Plans Foundation; Health Respiratory Research Network of the Fonds de Recherche en Sante du Quebec; National Institutes of Health [AI084011]; Research Institute at Nationwide Children's Hospital FX Supported, in part, by the Centers for Disease Control and Prevention, Atlanta, GA; America's Health Insurance Plans Foundation; the Health Respiratory Research Network of the Fonds de Recherche en Sante du Quebec; the National Institutes of Health (AI084011); and the Research Institute at Nationwide Children's Hospital. This work represents the findings of the authors and not necessarily the views of the Centers for Disease Control and Prevention or the National Institutes of Health. NR 54 TC 34 Z9 35 U1 1 U2 14 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD JAN PY 2013 VL 41 IS 1 BP 224 EP 236 DI 10.1097/CCM.0b013e318267633c PG 13 WC Critical Care Medicine SC General & Internal Medicine GA 065LR UT WOS:000313150300025 PM 23222256 ER PT J AU Veenstra, DL Piper, M Haddow, JE Pauker, SG Klein, R Richards, CS Tunis, SR Djulbegovic, B Marrone, M Lin, JS Berg, AO Calonge, N AF Veenstra, David L. Piper, Margaret Haddow, James E. Pauker, Stephen G. Klein, Roger Richards, Carolyn Sue Tunis, Sean R. Djulbegovic, Benjamin Marrone, Michael Lin, Jennifer S. Berg, Alfred O. Calonge, Ned CA EGAPP Working Grp TI Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update SO GENETICS IN MEDICINE LA English DT Article DE evidence-based medicine/methods; evidence-based medicine/standards; genetics; genomics/methods; genomics/standards; medical/methods ID SERVICES TASK-FORCE; PUBLIC-HEALTH; SYSTEMATIC REVIEWS; PRINCIPLES; QUALITY; DISEASE AB To provide an update on recent revisions to Evaluation of Genomic Applications in Practice and Prevention (EGAPP) methods designed to improve efficiency, and an assessment of the implications of whole genome sequencing for evidence-based recommendation development. Improvements to the EGAPP approach include automated searches for horizon scanning, a quantitative ranking process for topic prioritization, and the development of a staged evidence review and evaluation process. The staged process entails (i) triaging tests with minimal evidence of clinical validity, (ii) using and updating existing reviews, (iii) evaluating clinical validity prior to analytic validity or clinical utility, (iv) using decision modeling to assess potential clinical utility when direct evidence is not available. EGAPP experience to date suggests the following approaches will be critical for the development of evidence based recommendations in the whole genome sequencing era: (i) use of triage approaches and frameworks to improve efficiency, (ii) development of evidence thresholds that consider the value of further research, (iii) incorporation of patient preferences, and (iv) engagement of diverse stakeholders. The rapid advances in genomics present a significant challenge to traditional evidence based medicine, but also an opportunity for innovative approaches to recommendation development. Genet Med 2013:15(1):14-24 C1 [Veenstra, David L.] Univ Washington, Inst Publ Hlth Genet, Dept Pharm, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA. [Piper, Margaret] Blue Cross & Blue Shield Assoc, Technol Evaluat Ctr, Chicago, IL USA. [Haddow, James E.] Brown Univ, Warren Alpert Med Sch, Dept Pathol & Lab Med, Providence, RI 02912 USA. [Pauker, Stephen G.] Tufts Med Ctr, Dept Med, Div Clin Decis Making Informat & Telemed, Boston, MA USA. [Klein, Roger] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Coll Med, Blood Ctr Wisconsin, Milwaukee, WI USA. [Richards, Carolyn Sue] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA. [Tunis, Sean R.] Ctr Med Technol Policy, Baltimore, MD USA. [Djulbegovic, Benjamin] Univ S Florida, Coll Med, Ctr Evidence Based Med & Hlth Outcomes, Tampa, FL 33612 USA. [Djulbegovic, Benjamin] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Med, Tampa, FL 33612 USA. [Djulbegovic, Benjamin] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Hlth Outcomes & Behav, Tampa, FL 33612 USA. [Djulbegovic, Benjamin] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Hematol, Tampa, FL 33612 USA. [Marrone, Michael] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA. [Marrone, Michael] McKing Consulting, Atlanta, GA USA. [Lin, Jennifer S.] Kaiser Permanente NW, Ctr Hlth Res, Portland, OR USA. [Berg, Alfred O.] Univ Washington, Dept Family Med, Seattle, WA 98195 USA. [Calonge, Ned] Colorado Trust, Denver, CO USA. RP Veenstra, DL (reprint author), Univ Washington, Inst Publ Hlth Genet, Dept Pharm, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA. EM veenstra@uw.edu RI Djulbegovic, Benjamin/I-3661-2012; OI Djulbegovic, Benjamin/0000-0003-0671-1447; Piper, Margaret/0000-0002-6231-9653 FU National Institutes of Health [P50HG003374, RC2CA148570, U01GM092676, U01HG006507]; Centers for Disease Control and Prevention [U18GD000005]; Novartis; Office of Public Health Genomics of the Centers for Disease Control and Prevention [1U18GD000076-01] FX David Veenstra reports that he was a consultant for Medco, Novartis Molecular Diagnostics, and Genentech, and is supported by the following genomics-related research grants: P50HG003374, RC2CA148570, U01GM092676, and U01HG006507 from the National Institutes of Health and U18GD000005 from the Centers for Disease Control and Prevention. Stephen Pauker reports that a research study of his was supported by a fund from Novartis to Tufts Medical Center. Sean Tunis has no personal conflicts of interest to disclose. The Center for Medical Technology Policy receives funding from several sources, listed at http://www.cmtpnet.org/about/funding-sources/. The other authors declare no conflict of interest.; Funding for this work was received from the Office of Public Health Genomics of the Centers for Disease Control and Prevention (grant 1U18GD000076-01). NR 37 TC 28 Z9 28 U1 1 U2 8 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 J9 GENET MED JI Genet. Med. PD JAN PY 2013 VL 15 IS 1 BP 14 EP 24 DI 10.1038/gim.2012.106 PG 11 WC Genetics & Heredity SC Genetics & Heredity GA 069TV UT WOS:000313460900002 PM 22955111 ER PT J AU Zhu, JL Hasle, H Correa, A Schendel, D Friedman, JM Olsen, J Rasmussen, SA AF Zhu, Jin Liang Hasle, Henrik Correa, Adolfo Schendel, Diana Friedman, J. M. Olsen, Jorn Rasmussen, Sonja A. TI Survival among people with Down syndrome: a nationwide population-based study in Denmark SO GENETICS IN MEDICINE LA English DT Article DE congenital heart defects; Down syndrome; mortality; mosaic trisomy 21; survival ID TURNER-SYNDROME; LIFE EXPECTANCY; MORTALITY; INDIVIDUALS; REGISTER; ABNORMALITIES; TRISOMY-21; CHILDREN; INFANTS; CANCER AB Purpose: Several studies have shown substantially longer survival among persons with Down syndrome in recent decades. We examined survival patterns among Danish persons with Down syndrome by karyotype. Methods: A-national cohort of 3,530 persons with Down syndrome identified from the Danish Cytogenetic Register and a reference cohort of persons without Down syndrome randomly selected from the general population were followed from 1 April 1968 to 15 January 2009 by linkages to the Register of Causes of Death and the Civil Registration System. Results: Overall, persons with Down syndrome had higher mortality than the reference cohort but to a lesser degree for persons with, mosaic trisomy 21 than for persons with standard trisomy 21 or with Robertsonian translocations (hazard ratio 4.98 (95% confidence interval 3.51-7.08), 8.94 (8.32-9.60), and 10.23 (7.50-13.97), respectively). Among persons with Down syndrome born after April 1968, more recent birth cohorts had lower mortality rates than older birth cohorts, which was largely due to declining mortality among persons with Down syndrome who also had congenital heart defects. Conclusion: Recent birth cohorts of persons with Down syndrome experienced declining mortality, likely due to treatment for congenital heart defects, and persons with mosaic trisomy 21 had better survival than persons with other Down syndrome karyotypes. Genet Med 2013:15(1):64-69 C1 [Zhu, Jin Liang; Olsen, Jorn] Univ Aarhus, Epidemiol Sect, Dept Publ Hlth, Aarhus, Denmark. [Hasle, Henrik] Aarhus Univ Hosp, Dept Pediat, DK-8000 Aarhus, Denmark. [Correa, Adolfo; Schendel, Diana; Rasmussen, Sonja A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Friedman, J. M.] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada. RP Zhu, JL (reprint author), Univ Aarhus, Epidemiol Sect, Dept Publ Hlth, Aarhus, Denmark. EM zjl@soci.au.dk OI Friedman, Jan/0000-0002-7482-9570; Hasle, Henrik/0000-0003-3976-9231 FU US Centers for Disease Control and Prevention [5 U10 DD000230-06] FX The study was supported by a cooperative agreement from the US Centers for Disease Control and Prevention (#5 U10 DD000230-06). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. We thank Claus Svaeke from University of Aarhus and Jan Hansen from the Danish Cytogenetic Registry for data arrangement. NR 33 TC 16 Z9 17 U1 0 U2 15 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 J9 GENET MED JI Genet. Med. PD JAN PY 2013 VL 15 IS 1 BP 64 EP 69 DI 10.1038/gim.2012.93 PG 6 WC Genetics & Heredity SC Genetics & Heredity GA 069TV UT WOS:000313460900007 PM 22878506 ER PT J AU Marrone, MT Venkataramanan, V Goodman, M Hill, AC Jereb, JA Mase, SR AF Marrone, M. T. Venkataramanan, V. Goodman, M. Hill, A. C. Jereb, J. A. Mase, S. R. TI Surgical interventions for drug-resistant tuberculosis: a systematic review and meta-analysis SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Review DE tuberculosis; multidrug-resistant; extensively drug-resistant; surgical procedures; operative; meta-analysis ID HIV-INFECTED PATIENTS; MULTIDRUG-RESISTANT; PULMONARY TUBERCULOSIS; TREATMENT OUTCOMES; FOLLOW-UP; RESECTION; SURGERY; PREDICTORS; EXPERIENCE; MORTALITY AB BACKGROUND: With the emergence of multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB), surgery, which had been replaced by short-course chemotherapy, is again being considered a viable treatment option. OBJECTIVE: To assess the literature on the effectiveness of surgical interventions in the treatment of drug-resistant TB. METHODS: Medline, EMBASE, and PubMed were searched from 1975 to April 2012 in addition to hand searching reference lists, and the International Journal of Tuberculosis and Lung Disease. Potentially relevant studies were assessed according to pre-defined eligibility criteria: MDR- and XDR-TB patients undergoing surgical and non-surgical treatment. Treatment outcomes were extracted according to internationally accepted definitions and included in meta-analyses using random effects models. RESULTS: Summary meta-analysis of 24 comparison studies revealed a significant association between surgery and successful treatment compared to non-surgical interventions (OR 2.24, 95%CI 1.68-2.97). A meta-analysis from 23 single-arm studies demonstrated that respectively 92% (95%CI 88.1-95) and 87% (95%CI 83-91) of surgical patients achieved successful short- and long-term outcomes. Subgroup analyses showed that favorable surgical outcomes were associated with increased drug resistance in studies reporting surgical and non-surgical treatment outcomes. CONCLUSIONS: While the results suggest that surgical intervention is associated with successful treatment outcomes in patients with drug-resistant TB, there is insufficient evidence to recommend surgery plus chemotherapy over chemotherapy alone, to evaluate the potential harm from surgery and to determine the optimal conditions for surgery. Controlled studies are needed to better assess the effectiveness of surgery and to investigate other contextual issues. C1 [Marrone, M. T.; Venkataramanan, V.; Jereb, J. A.; Mase, S. R.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. [Marrone, M. T.; Goodman, M.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Hill, A. C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Mase, SR (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, Mailstop E-10,1600 Clifton Rd, Atlanta, GA 30333 USA. EM smase@cdc.gov NR 74 TC 18 Z9 19 U1 0 U2 8 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD JAN PY 2013 VL 17 IS 1 BP 6 EP 16 DI 10.5588/ijtld.12.0198 PG 11 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 066NN UT WOS:000313227600005 PM 23232000 ER PT J AU Jones, RT Vetter, SM Montenieiri, J Holmes, J Bernhardt, SA Gage, KL AF Jones, Ryan T. Vetter, Sara M. Montenieiri, John Holmes, Jennifer Bernhardt, Scott A. Gage, Kenneth L. TI Yersinia pestis infection and laboratory conditions alter flea-associated bacterial communities SO ISME JOURNAL LA English DT Article DE Bartonella; experimental infection; plague ID DIVERSITY; VECTORS; PLAGUE AB We collected Oropsylla montana from rock squirrels, Spermophilus varigatus, and infected a subset of collected fleas with Yersinia pestis, the etiological agent of plague. We used bar-tagged DNA pyrosequencing to characterize bacterial communities of wild, uninfected controls and infected fleas. Bacterial communities within Y. pestis-infected fleas were substantially more similar to one another than communities within wild or control fleas, suggesting that infection alters the bacterial community in a directed manner such that specific bacterial lineages are severely reduced in abundance or entirely eliminated from the community. Laboratory conditions also significantly altered flea-associated bacterial communities relative to wild communities, but much less so than Y. pestis infection. The abundance of Firmicutes decreased considerably in infected fleas, and Bacteroidetes were almost completely eliminated from both the control and infected fleas. Bartonella and Wolbachia were unaffected or responded positively to Y. pestis infection. The ISME Journal (2013) 7, 224-228; doi: 10.1038/ismej.2012.95; published online 16 August 2012 C1 [Jones, Ryan T.; Vetter, Sara M.; Montenieiri, John; Holmes, Jennifer; Bernhardt, Scott A.; Gage, Kenneth L.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. RP Jones, RT (reprint author), Univ Sydney, Fac Agr & Environm, Dept Environm Sci, Biomed Bldg, Eveleigh, NSW 2015, Australia. EM DrRyanJones@gmail.com NR 20 TC 5 Z9 5 U1 1 U2 18 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1751-7362 J9 ISME J JI ISME J. PD JAN PY 2013 VL 7 IS 1 BP 224 EP 228 DI 10.1038/ismej.2012.95 PG 5 WC Ecology; Microbiology SC Environmental Sciences & Ecology; Microbiology GA 066QT UT WOS:000313236000020 PM 22895162 ER PT J AU Miller, JS Bilder, D Farley, M Coon, H Pinborough-Zimmerman, J Jenson, W Rice, CE Fombonne, E Pingree, CB Ritvo, E Ritvo, RA McMahon, WM AF Miller, Judith S. Bilder, Deborah Farley, Megan Coon, Hilary Pinborough-Zimmerman, Judith Jenson, William Rice, Catherine E. Fombonne, Eric Pingree, Carmen B. Ritvo, Edward Ritvo, Riva-Ariella McMahon, William M. TI Autism Spectrum Disorder Reclassified: A Second Look at the 1980s Utah/UCLA Autism Epidemiologic Study SO JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS LA English DT Article DE Autism; Epidemiology; Prevalence; Diagnostic criteria; Intellectual disability ID DIAGNOSTIC SUBSTITUTION; PREVALENCE TRENDS; SPECIAL-EDUCATION; MINNESOTA AB The purpose of the present study was to re-examine diagnostic data from a state-wide autism prevalence study (n = 489) conducted in the 1980s to investigate the impact of broader diagnostic criteria on autism spectrum disorder (ASD) case status. Sixty-four (59 %) of the 108 originally "Diagnosed Not Autistic" met the current ASD case definition. The average IQ estimate in the newly identified group (IQ = 35.58; SD = 23.01) was significantly lower than in the original group (IQ = 56.19 SD = 21.21; t = 5.75; p < .0001). Today's diagnostic criteria applied to participants ascertained in the 1980s identified more cases of autism with intellectual disability. The current analysis puts this historic work into context and highlights differences in ascertainment between epidemiological studies performed decades ago and those of today. C1 [Miller, Judith S.; Bilder, Deborah; Farley, Megan; Coon, Hilary; Pinborough-Zimmerman, Judith; McMahon, William M.] Univ Utah, Dept Psychiat, Salt Lake City, UT 84108 USA. [Coon, Hilary; McMahon, William M.] Univ Utah, Inst Brain, Salt Lake City, UT 84108 USA. [Jenson, William] Univ Utah, Dept Educ Psychol, Salt Lake City, UT 84108 USA. [Rice, Catherine E.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Fombonne, Eric] McGill Univ, Dept Psychiat, Montreal Childrens Hosp, Montreal, PQ H3Z 1P2, Canada. [Pingree, Carmen B.] Carmen B Pingree Ctr Children Autism, Salt Lake City, UT 84108 USA. [Ritvo, Edward] Univ Calif Los Angeles, Los Angeles, CA 90095 USA. [Ritvo, Riva-Ariella] Yale Univ, Sch Med, New Haven, CT USA. RP Bilder, D (reprint author), Univ Utah, Dept Psychiat, 650 Komas Dr,Suite 206, Salt Lake City, UT 84108 USA. EM deborah.bilder@hsc.utah.edu RI Rice, Catherine/D-6305-2016; OI Coon, Hilary/0000-0002-8877-5446 FU Intramural CDC HHS [CC999999] NR 28 TC 12 Z9 12 U1 3 U2 19 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0162-3257 J9 J AUTISM DEV DISORD JI J. Autism Dev. Disord. PD JAN PY 2013 VL 43 IS 1 BP 200 EP 210 DI 10.1007/s10803-012-1566-0 PG 11 WC Psychology, Developmental SC Psychology GA 064KL UT WOS:000313073700019 PM 22696195 ER PT J AU Haggstrom, DA Klabunde, CN Smith, JL Yuan, G AF Haggstrom, David A. Klabunde, Carrie N. Smith, Judith Lee Yuan, Gigi TI Variation in Primary Care Physicians' Colorectal Cancer Screening Recommendations by Patient Age and Comorbidity SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE cancer screening; health services; colorectal cancer; primary care physicians ID TASK-FORCE; QUALITY; VIGNETTES; IMPACT AB Screening patterns among primary care physicians (PCPs) may be influenced by patient age and comorbidity. Colorectal cancer (CRC) screening has little benefit among patients with limited life expectancy. To characterize the extent to which PCPs modify their recommendations for CRC screening based upon patients' increasing age and/or worsening comorbidity Cross-sectional, nationally representative survey. The study comprised primary care physicians (n = 1,266) including general internal medicine, family practice, and obstetrics-gynecology physicians. Physician CRC screening recommendations among patients of varying age and comorbidity were measured based upon clinical vignettes. Independent variables in adjusted models included physician and practice characteristics. For an 80-year-old patient with unresectable non-small cell lung cancer (NSCLC), 25 % of PCPs recommended CRC screening. For an 80-year-old patient with ischemic cardiomyopathy (New York Heart Association, Class II), 71 % of PCPs recommended CRC screening. PCPs were more likely to recommend fecal occult blood testing than colonoscopy as the preferred screening modality for a healthy 80-year-old, compared to healthy 50- or 65-year-old patients (19 % vs. 5 % vs. 2 % p < 0.001). For an 80-year-old with unresectable NSCLC, PCPs who were an obstetrics-gynecology physician were more likely to recommend CRC screening, while those with a full electronic medical record were less likely to recommend screening. PCPs consider comorbidity when screening older patients for CRC and may change the screening modality from colonoscopy to FOBT. However, a sizable proportion of PCPs would recommend screening for patients with advanced cancer who would not benefit. Understanding the mechanisms underlying these patterns will facilitate the design of future medical education and policy interventions to reduce unnecessary care. C1 [Haggstrom, David A.] Richard L Roudebush VA Med Ctr, VA Hlth Serv Res, Indianapolis, IN 46202 USA. [Haggstrom, David A.] Richard L Roudebush VA Med Ctr, Dev Ctr Excellence Implementing Evidence Based Pr, Indianapolis, IN 46202 USA. [Haggstrom, David A.] Indiana Univ Sch Med, Dept Med, Div Gen Internal Med & Geriatr, Indianapolis, IN USA. [Haggstrom, David A.] Regenstrief Inst Inc, IU Ctr Hlth Serv & Outcomes Res, Indianapolis, IN USA. [Klabunde, Carrie N.] NCI, Hlth Serv & Econ Branch, Appl Res Program, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. [Smith, Judith Lee] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. [Yuan, Gigi] Informat Management Serv Inc, Silver Spring, MD USA. RP Haggstrom, DA (reprint author), Richard L Roudebush VA Med Ctr, VA Hlth Serv Res, 1481 W 10th St 11H, Indianapolis, IN 46202 USA. EM dahaggst@iupui.edu FU National Cancer Institute [N02-PC-51308]; Agency for Healthcare Research and Quality [Y3-PC-5019-01, Y3-PC-5019-02]; Centers for Disease Control and Prevention [Y3-PC-6017-01]; VA HSR&D Career Development Award [CD207016-2] FX Funding support for this study was provided by the National Cancer Institute (contract number N02-PC-51308), the Agency for Healthcare Research and Quality (inter-agency agreement numbers Y3-PC-5019-01 and Y3-PC-5019-02), and the Centers for Disease Control and Prevention (inter-agency agreement number Y3-PC-6017-01). Dr. Haggstrom is the recipient of VA HSR&D Career Development Award CD207016-2. NR 21 TC 10 Z9 10 U1 0 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2013 VL 28 IS 1 BP 18 EP 24 DI 10.1007/s11606-012-2093-6 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 066GL UT WOS:000313208500006 PM 22653380 ER PT J AU Koh, HK Baur, C Brach, C Harris, LM Rowden, JN AF Koh, Howard K. Baur, Cynthia Brach, Cindy Harris, Linda M. Rowden, Jessica N. TI Toward a Systems Approach to Health Literacy Research SO JOURNAL OF HEALTH COMMUNICATION LA English DT Editorial Material ID CARE; COMMUNICATION; TRIAL C1 [Koh, Howard K.] US Dept HHS, Off Assistant Secretary Hlth, Washington, DC 20201 USA. [Baur, Cynthia] Ctr Dis Control & Prevent, Off Associate Director Commun, Atlanta, GA USA. [Brach, Cindy] Agcy Healthcare Res & Qual, Rockville, MD USA. [Rowden, Jessica N.] US Dept HHS, Web Commun Hlth Commun & eHlth Div, Off Dis Prevent & Hlth Promot, Off Assistant Secretary Hlth, Rockville, MD 20852 USA. RP Rowden, JN (reprint author), US Dept HHS, Web Commun Hlth Commun & eHlth Div, Off Dis Prevent & Hlth Promot, Off Assistant Secretary Hlth, 1101 Wootton Pkwy, Rockville, MD 20852 USA. EM jessica.rowden@hhs.gov FU Intramural AHRQ HHS [HS999999] NR 21 TC 3 Z9 3 U1 0 U2 18 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1081-0730 J9 J HEALTH COMMUN JI J. Health Commun. PD JAN 1 PY 2013 VL 18 IS 1 BP 1 EP 5 DI 10.1080/10810730.2013.759029 PG 5 WC Communication; Information Science & Library Science SC Communication; Information Science & Library Science GA 069DR UT WOS:000313416000001 PM 23305507 ER PT J AU Fazili, Z Pfeiffer, CM AF Fazili, Zia Pfeiffer, Christine M. TI Accounting for an Isobaric Interference Allows Correct Determination of Folate Vitamers in Serum by Isotope Dilution-Liquid Chromatography-Tandem MS SO JOURNAL OF NUTRITION LA English DT Article ID MASS-SPECTROMETRY; 5-METHYLTETRAHYDROFOLIC ACID; DEGRADATION-PRODUCTS; ANALYTICAL RECOVERY; HUMAN PLASMA; QUANTIFICATION; CATABOLITES; BIOMARKERS; METABOLISM; ASSAYS AB Mild and prolonged oxidative degradation of 5-methyltetrahydrofolate (5-methylTHF) leads to the biologically inactive pyrazino-s-triazine derivative of 4 alpha-hydroxy-5-methylTHF (MeFox). MeFox and the biologically active 5-formyltetrahydrofolate (5-formyITHF) are isobaric compounds that behave similarly during chromatographic and mass separation, making coelution and misidentification likely. Our published routine liquid chromatography-tandem MS (LC-MS/MS) method did not discern between 5-formyITHF and MeFox, measuring the sum of these compounds at a mass to charge ratio (m/z) of 474-327 as 5-formyITHF. We modified this method to separate MeFox and 5-formyITHF by either chromatography or unique mass transitions and then applied the 2 methods to serum specimens to determine typical concentrations of these compounds. The 2 unique transitions (m/z. 5-formyITHF, 474-299; MeFox, 474-284) showed good sensitivity [limit of detection (nmol/L): 5-formyITHF, 0.21; MeFox, 0.34], selectivity (no interfering peaks), spiking recovery (mean +/- SD: 5-formyITHF, 103 +/- 3.4%; MeFox, 94 +/- 10%), and low imprecision (CV: 5-formyITHF, 3.9% at 2.4 nmol/L; MeFox, 5.1% at 2.9 nmol/L). The mass separation method detected 5-formyITHF in the same specimens as the chromatographic separation method. Analysis of several thousand serum specimens showed that the majority (similar to 85%) contained MeFox at <3 nmol/L but no detectable 5-formyITHF concentrations, some (similar to 14%) contained 5-formyITHF at <0.5 nmol/L, and a few specimens contained 5-formyITHF at >1 nmol/L and MeFox at >10 nmol/L. In summary, serum can contain 5-formyITHF high enough to contribute to total folate and contains MeFox that will bias total folate if not appropriately separated. Including measurements of MeFox and 5-formyITHF along with the other folate vitamers will enhance assessments of the association between biologically active folate and health effects. J. Nutr. 143: 108-113, 2013. C1 [Fazili, Zia; Pfeiffer, Christine M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. RP Pfeiffer, CM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. EM CPfeiffer@cdc.gov FU Intramural CDC HHS [CC999999] NR 22 TC 8 Z9 8 U1 0 U2 17 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3166 J9 J NUTR JI J. Nutr. PD JAN PY 2013 VL 143 IS 1 BP 108 EP 113 DI 10.3945/jn.112.166769 PG 6 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 065MV UT WOS:000313153500016 PM 23173171 ER PT J AU Nagel, MA Russman, AN Feit, H Traktinskiy, I Khmeleva, N Schmid, DS Skarf, B Gilden, D AF Nagel, Maria A. Russman, Andrew N. Feit, Howard Traktinskiy, Igor Khmeleva, Nelly Schmid, D. Scott Skarf, Barry Gilden, Don TI VZV ISCHEMIC OPTIC NEUROPATHY AND SUBCLINICAL TEMPORAL ARTERY INFECTION WITHOUT RASH SO NEUROLOGY LA English DT Editorial Material ID VARICELLA-ZOSTER-VIRUS; GIANT-CELL ARTERITIS; BIOPSY SPECIMENS C1 [Nagel, Maria A.; Traktinskiy, Igor; Khmeleva, Nelly; Gilden, Don] Univ Colorado, Sch Med, Dept Neurol, Aurora, CO USA. [Gilden, Don] Univ Colorado, Sch Med, Dept Microbiol, Aurora, CO USA. [Russman, Andrew N.; Feit, Howard; Skarf, Barry] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA. [Schmid, D. Scott] Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA USA. RP Gilden, D (reprint author), Univ Colorado, Sch Med, Dept Neurol, Aurora, CO USA. EM don.gilden@ucdenver.edu FU NIA NIH HHS [P01 AG032958, AG032958, AG006127]; NINDS NIH HHS [K08 NS067070, NS067070] NR 7 TC 18 Z9 20 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD JAN PY 2013 VL 80 IS 2 BP 220 EP 222 DI 10.1212/WNL.0b013e31827b92d1 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 068DM UT WOS:000313344700021 PM 23255829 ER PT J AU Colton, L Kosoy, M AF Colton, L. Kosoy, M. TI Experimental infection of laboratory mice with two Bartonella tribocorum strains from wild Mus species: a homologous host-bacteria model system at the genus level SO PARASITOLOGY LA English DT Article DE Bartonella tribocorum; dose response; bacteremia; urine; Rattus; Mus ID IXODES-RICINUS; COMB-NOV; RODENTS; HENSELAE; TRANSMISSION; SPECIFICITY; GRAHAMII; PATTERNS; QUINTANA; POPULATIONS AB To date no experimental infection studies have been conducted in laboratory mice using Mus spp. bartonella strains. Therefore we designed a study to evaluate the in vivo infection characteristics of 2 Bartonella tribocorum strains from wild Mus spp. in laboratory mice with the aim of developing a mouse model that reproduces characteristics of naturally acquired bartonella infections in rodents. Groups of outbred CD1 female mice were subcutaneously inoculated with low doses of 2 mouse bartonella strains (10, 100, and 1000 bacteria/mouse). Blood was collected weekly for 27 weeks to evaluate bacteraemia kinetics in infected mice. Mouse urine collected during weeks 3-6 post-inoculation was also tested for viable bacteria to determine whether urine might serve as a source of bacterial transmission. Mice were susceptible to infection with both strains. Bacteraemias in mice lasted up to 25 weeks, sometimes with abacteraemic intervals, and achieved levels up to 107 cfu/ml of blood. Temporal lags in bacteraemia onset of up to 19 weeks in length were noted at different inoculum doses. No viable bacteria were detected in mouse urine. Bacteraemic mice displayed characteristics of infection similar to those observed in natural rodent hosts during longitudinal field studies. This mouse model of persistent bacteraemia should be suitable for a variety of experimental uses. C1 [Colton, L.; Kosoy, M.] Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Ft Collins, CO 80521 USA. RP Colton, L (reprint author), DVBD NCEZID CDC, 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM ant6@cdc.gov NR 34 TC 0 Z9 0 U1 1 U2 7 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0031-1820 J9 PARASITOLOGY JI Parasitology PD JAN PY 2013 VL 140 IS 1 BP 61 EP 68 DI 10.1017/S0031182012001333 PG 8 WC Parasitology SC Parasitology GA 066XS UT WOS:000313256200006 PM 22938938 ER PT J AU Raymond, JS Kennedy, C Brown, MJ AF Raymond, Jaime S. Kennedy, Chinaro Brown, Mary Jean TI Blood Lead Level Analysis Among Refugee Children Resettled in New Hampshire and Rhode Island SO PUBLIC HEALTH NURSING LA English DT Article DE blood lead; children; recommendations; refugee ID NATIONAL-HEALTH; NHANES AB Objective To examine the association between refugee status and elevated blood lead levels (EBLLs) among children living in two U.S. cities and to assess the effect of the Centers for Disease Control and Prevention recommendations for BLL testing of newly emigrated refugee children for EBLLs. Design and Sample A longitudinal study was conducted of 1,007 refugee children and 953 nonrefugee children living, when blood testing occurred, in the same buildings in Manchester, New Hampshire and Providence, Rhode Island. Measures Surveillance and blood lead data were collected from both sites, including demographic information, BLLs, sample type, refugee status, and age of housing. Results Refugee children living in Manchester were statistically significantly more likely to have an EBLL compared with nonrefugee children even after controlling for potential confounders. We did not find this association in Providence. Compared with before enactment, the mean time of refugee children to fall below 10 mu g/dL was significantly shorter after the recommendations to test newly emigrated children were enacted. Conclusions Refugee children living in Manchester were significantly more likely to have an EBLL compared with nonrefugee children. And among refugee children, we found a statistically significant difference in the mean days to BLL decline <10 mu g/dL before and after recommendations to test newly emigrated children. C1 [Raymond, Jaime S.; Kennedy, Chinaro; Brown, Mary Jean] Ctr Dis Control & Prevent, Div Emergency & Environm Hlth Serv, Natl Ctr Environm Hlth, Hlth Homes & Lead Poisoning Prevent Branch, Atlanta, GA 30341 USA. RP Raymond, JS (reprint author), Ctr Dis Control & Prevent, Div Emergency & Environm Hlth Serv, Natl Ctr Environm Hlth, Hlth Homes & Lead Poisoning Prevent Branch, 4770 Buford Hwy,MS F-60, Atlanta, GA 30341 USA. EM jraymond@cdc.gov NR 14 TC 2 Z9 2 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0737-1209 J9 PUBLIC HEALTH NURS JI Public Health Nurs. PD JAN PY 2013 VL 30 IS 1 BP 70 EP 79 DI 10.1111/phn.12007 PG 10 WC Public, Environmental & Occupational Health; Nursing SC Public, Environmental & Occupational Health; Nursing GA 066ZL UT WOS:000313261000010 PM 23294389 ER PT J AU Granade, TC Nguyen, S Kuehl, DS Parekh, BS AF Granade, Timothy C. Shon Nguyen Kuehl, Debra S. Parekh, Bharat S. TI Development of a Novel Rapid HIV Test for Simultaneous Detection of Recent or Long-Term HIV Type 1 Infection Using a Single Testing Device SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Article ID CAPTURE ENZYME-IMMUNOASSAY; SUBTYPE-E INFECTION; COLLOIDAL GOLD; AVIDITY INDEX; ASSAY; SEROCONVERSION; SURVEILLANCE; ANTIBODIES; STRATEGY; THAILAND AB Laboratory assays for the detection of recent HIV infection for HIV incidence surveillance are essential to HIV prevention efforts worldwide because they can identify populations with a high incidence and allow targeting of resources and monitoring of incidence trends over time. This study describes the development of a novel rapid HIV-1 incidence-prevalence (I-P) test that can be used for the simultaneous detection and discrimination of prevalent (long-term) or incident (recent) HIV infections using a single device. A lateral flow assay was developed that uses a multisubtype recombinant gp41 protein applied at two concentrations of antigen (high and low). Prevalent and incident HIV-1 infections can be distinguished based on differential antibody binding at the two antigen concentrations. High level/high avidity antibodies present in prevalent infections bind to and are detected at both antigen concentrations while low level/low avidity antibodies present in recent HIV infections are detected only at the higher antigen concentration line. A total of 205 HIV-positive specimens with known status (recent = 105, long-term = 100), including 57 specimens from seroconversion panels, were tested by the rapid I-P assay and the results were compared to the HIV-1 BED capture enzyme immunoassay (CEIA). There was a 95.1% agreement of final classification (recent or long-term) with the BED assay (kappa = 0.910) (mean recency period = 162 days) and a high correlation between the intensity score of the low antigen line with the BED OD-n (Pearson correlation = 0.89). The new rapid I-P test has great potential to simplify HIV surveillance efforts by simultaneously providing information on both HIV prevalence and incidence using a single, rapid test device. C1 [Granade, Timothy C.] Ctr Dis Control & Prevent, Div HIV AIDS, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30329 USA. [Shon Nguyen; Parekh, Bharat S.] Ctr Dis Control & Prevent, Div HIV AIDS, Ctr Global Hlth, Atlanta, GA 30329 USA. [Kuehl, Debra S.] Ctr Dis Control & Prevent, Div Lab Sci & Stand, Lab Sci Policy & Practice Program Off, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30329 USA. RP Granade, TC (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS, Natl Ctr HIV Hepatitis STD & TB Prevent, 1600 Clifton Rd,Mailstop A-25, Atlanta, GA 30329 USA. EM tgranade@cdc.gov; bparekh@cdc.gov NR 30 TC 6 Z9 6 U1 1 U2 12 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD JAN PY 2013 VL 29 IS 1 BP 61 EP 67 DI 10.1089/aid.2012.0121 PG 7 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 063YA UT WOS:000313036800011 PM 23281586 ER PT J AU Kim, JH Benson, SM Roberge, RJ AF Kim, Jung-Hyun Benson, Stacey M. Roberge, Raymond J. TI Pulmonary and heart rate responses to wearing N95 filtering facepiece respirators SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE N95 filtering facepiece respirators; Pulmonary effects; Heart rate; Exhalation valve ID HEALTH-CARE WORKERS; SURGICAL MASK; PHYSIOLOGICAL IMPACT; SATURATION AB Background: Filtering facepiece respirators are the most common respirator worn by US health care and industrial workers, yet little is known on the physiologic impact of wearing this protective equipment. Methods: Twenty young, healthy subjects exercised on a treadmill at a low-moderate (5.6 km/h) work rate while wearing 4 different models of N95 filtering facepiece respirators for 1 hour each, 2 models of which were equipped with exhalation valves, while being monitored for physiologic variables. Results: Compared with controls, respirator use was associated with mean 1 hour increases in heart rate (range, 5.7-10.6 beats per minute, P < .001), respiratory rate (range, 1.4-2.4 breaths per minute, P < .05), and transcutaneous carbon dioxide (range, 1.7-3.0 mm Hg, P < .001). No significant differences in oxygen saturation between controls and respirators were noted (P > .05). Conclusion: The pulmonary and heart rate responses to wearing a filtering facepiece respirator for 1 hour at a low-moderate work rate are relatively small and should generally be well tolerated by healthy persons. Published by Elsevier Inc. on behalf of the Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Kim, Jung-Hyun; Benson, Stacey M.; Roberge, Raymond J.] NIOSH, Natl Personal Protect Technol Lab, Ctr Dis Control & Prevent, Pittsburgh, PA 15236 USA. RP Roberge, RJ (reprint author), NIOSH, Natl Personal Protect Technol Lab, Ctr Dis Control & Prevent, 626 Cochrans Mill Rd, Pittsburgh, PA 15236 USA. EM dtn0@cdc.gov NR 26 TC 7 Z9 7 U1 0 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD JAN PY 2013 VL 41 IS 1 BP 24 EP 27 DI 10.1016/j.ajic.2012.02.037 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 063FC UT WOS:000312980600006 PM 22944510 ER PT J AU Nabukera, SK Romitti, PA Caspers, KM Street, N Cunniff, C Mathews, KD Fox, DJ Puzhankara, S Ciafaloni, E James, KA Su, Y AF Nabukera, Sarah K. Romitti, Paul A. Caspers, Kristin M. Street, Natalie Cunniff, Christopher Mathews, Katherine D. Fox, Deborah J. Puzhankara, Soman Ciafaloni, Emma James, Katherine A. Su, Yin CA MD STARnet TI Reproductive patterns among mothers of males diagnosed with Duchenne or Becker muscular dystrophy SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A LA English DT Article DE Becker muscular dystrophy; Duchenne muscular dystrophy; live birth; pregnancy ID NETWORK MD STARNET; SURVEILLANCE TRACKING; DECISION-MAKING; KNOWLEDGE; IMPACT; STATES AB Diagnosis of a child with Duchenne or Becker muscular dystrophy (DBMD) may impact future maternal reproductive choice; however, little is known about the reproductive patterns of mothers with a male child diagnosed with DBMD. Using population-based surveillance data collected by the muscular dystrophy surveillance, tracking, and research network, the proportion of mothers who conceived and delivered a live birth following the diagnosis of DBMD in an affected male child and factors associated with such reproductive choice were identified. To accomplish this, maternal demographic data were linked to birth certificate data to construct the reproductive history for 239 mothers. Univariable and bivariable analyses were conducted to determine the proportion of mothers delivering a live birth and associated factors. By the time of the current study, 96 (40.2%) of the 239 mothers had at least one live birth following delivery of their oldest affected male child; 53 (22.2%) of these mothers had a live birth before and 43 (18.0%) had a live birth after DBMD diagnosis of a male child. Mothers with a live birth after diagnosis were significantly younger at diagnosis of the oldest affected male child (26.2?+/-?4.2 years vs. 31.5?+/-?5.5 years), and were less likely to be white non-Hispanic compared to those with no live birth after diagnosis. These results suggest that about one in five mothers deliver a live birth subsequent to DBMD diagnosis in a male child. Maternal age and race/ethnicity were associated with this reproductive choice. (c) 2012 Wiley Periodicals, Inc. C1 [Nabukera, Sarah K.; Romitti, Paul A.; Caspers, Kristin M.; Puzhankara, Soman] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA 52242 USA. [Street, Natalie] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Cunniff, Christopher] Univ Arizona, Coll Med, Dept Pediat, Tucson, AZ USA. [Mathews, Katherine D.] Univ Iowa, Carver Coll Med, Dept Pediat, Iowa City, IA 52242 USA. [Mathews, Katherine D.] Univ Iowa, Carver Coll Med, Dept Neurol, Iowa City, IA 52242 USA. [Fox, Deborah J.; Su, Yin] New York State Dept Hlth, Ctr Environm Hlth, Bur Environm & Occupat Epidemiol, Congenital Malformat Registry, Troy, NY USA. [Ciafaloni, Emma] Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14642 USA. [James, Katherine A.] Colorado Dept Publ Hlth & Environm, Div Dis Control & Environm Epidemiol, Denver, CO USA. RP Romitti, PA (reprint author), Univ Iowa, Coll Publ Hlth, Dept Epidemiol, S416 CPHB,105 River St, Iowa City, IA 52242 USA. EM paul-romitti@uiowa.edu FU Centers for Disease Control and Prevention [U01DD000189, U01DD000831] FX Grant sponsor: Centers for Disease Control and Prevention; Grant numbers: U01DD000189, U01DD000831. NR 29 TC 2 Z9 2 U1 0 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4825 J9 AM J MED GENET A JI Am. J. Med. Genet. A PD JAN PY 2013 VL 161A IS 1 BP 70 EP 75 DI 10.1002/ajmg.a.35682 PG 6 WC Genetics & Heredity SC Genetics & Heredity GA 062RO UT WOS:000312939200012 PM 23239595 ER PT J AU Thompson, ND Yeh, LLL Magill, SS Ostroff, SM Fridkin, SK AF Thompson, Nicola D. Yeh, Lan Lan L. Magill, Shelley S. Ostroff, Stephen M. Fridkin, Scott K. TI Investigating Systematic Misclassification of Central Line-Associated Bloodstream Infection (CLABSI) to Secondary Bloodstream Infection During Health Care-Associated Infection Reporting SO AMERICAN JOURNAL OF MEDICAL QUALITY LA English DT Article DE health care-associated infections; central line-associated bloodstream infections; surveillance; public reporting AB Central line-associated bloodstream infection (CLABSI) rates are an important measure of health care quality. However, reputational or financial risks associated with public reporting and disclosure of hospital CLABSI rates may introduce reporting biases, including intentional underreporting. To assess systematic case misclassification of CLABSI to secondary bloodstream infection (BSI; ie, intentional underreporting of CLABSI), the authors assessed data reported to the National Healthcare Safety Network by hospitals in Pennsylvania, the only state in which both CLABSI and secondary BSI reporting are mandatory. CLABSI rates decreased over the 2-year analysis period, but the authors found no evidence of increasing secondary BSI rates, suggesting that systematic case misclassification is not widespread. C1 [Thompson, Nicola D.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Yeh, Lan Lan L.; Ostroff, Stephen M.] Penn Dept Hlth, Harrisburg, PA 17108 USA. RP Thompson, ND (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A-24, Atlanta, GA 30333 USA. EM ndthompson@cdc.gov NR 11 TC 7 Z9 7 U1 0 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1062-8606 J9 AM J MED QUAL JI Am. J. Med. Qual. PD JAN-FEB PY 2013 VL 28 IS 1 BP 56 EP 59 DI 10.1177/1062860612442565 PG 4 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 063LW UT WOS:000313001500008 PM 22679125 ER PT J AU Campbell, JD Herbst, JH Koppenhaver, RT Smith, DK AF Campbell, James D. Herbst, Jeffrey H. Koppenhaver, Robert T. Smith, Dawn K. TI Antiretroviral Prophylaxis for Sexual and Injection Drug Use Acquisition of HIV SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID GAY PRIDE EVENTS; HIGH-RISK MEN; PREEXPOSURE PROPHYLAXIS; UNITED-STATES; COST-EFFECTIVENESS; BISEXUAL MEN; LIMITED KNOWLEDGE; INTERIM GUIDANCE; HEALTH-CARE; PREVENTION AB During the past few years, much has been learned about pre-exposure prophylaxis (PrEP) of HIV from studies conducted in the U.S. and elsewhere. A review and summary was conducted of articles and reports published through August 2012 on the safety and efficacy of PrEP in humans; U.S.-based studies assessing PrEP knowledge, attitudes, and use among at-risk populations and healthcare providers; and models of the cost effectiveness of PrEP. PrEP is generally safe and effective and may be cost effective in a targeted population. Awareness and interest in PrEP are increasing. PrEP is an important new addition to HIV prevention services, but continued study is warranted. (Am J Prev Med 2013;44(1S2):S63-S69) (C) 2013 American Journal of Preventive Medicine C1 [Campbell, James D.] CDC Uganda, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Div HIV AIDS Prevent, Entebbe, Uganda. [Herbst, Jeffrey H.; Koppenhaver, Robert T.; Smith, Dawn K.] CDC, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. RP Campbell, JD (reprint author), Univ Maryland, Sch Med, Dept Pediat, Div Infect Dis & Trop Pediat,Ctr Vaccine Dev, HSF1 Room 480,685 W Baltimore St, Baltimore, MD 21201 USA. EM jcampbel@medicine.umaryland.edu FU CDC through the Association for Prevention Teaching and Research (CDCAPTR) [11-NCHHSTP-01] FX Publication of this article was supported by the CDC through the Association for Prevention Teaching and Research (CDCAPTR) Cooperative Agreement number 11-NCHHSTP-01. NR 43 TC 18 Z9 18 U1 2 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD JAN PY 2013 VL 44 IS 1 SU 2 BP S63 EP S69 DI 10.1016/j.amepre.2012.09.045 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 056YL UT WOS:000312528000002 PM 23253764 ER PT J AU Culp, L Caucci, L AF Culp, Lindsay Caucci, Lisa TI State Adolescent Consent Laws and Implications for HIV Pre-Exposure Prophylaxis SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review AB Background: Recent large clinical trials have found that pre-exposure prophylaxis (PrEP) reduced HIV infection among men who have sex with men (MSM), but efforts to provide clinical care to minors, including young MSM, may be complicated by a lack of clarity regarding parental consent requirements with respect to medical services. Purpose: The goal of this paper was to analyze law related to a minor's ability to consent to medical care, including HIV diagnostic testing and treatment, and its implications for PrEP. Methods: Analysis was performed in 2012 on laws current as of December 31, 2011. Public Health Law Program staff collected all statutes and regulations pertaining to an adolescent's ability to consent to HIV diagnostic testing and treatment and sexually transmitted infection (STI) diagnostic testing, treatment, and prevention. Results: No state expressly prohibits minors' access to PrEP or other HIV prevention methods. All jurisdictions expressly allow some minors to consent to medical care for the diagnosis or treatment of STIs, but only eight jurisdictions allow consent to preventive or prophylactic services. Thirty-four states either expressly allow minors to consent to HIV services or allow consent to STI or communicable disease services and classify HIV as an STI or communicable disease. Seventeen jurisdictions allow minors to consent to STI testing and treatment, but they do not have an express HIV provision nor classify HIV as an STI or communicable disease. Conclusions: Minors' access to PrEP without parental consent is unclear, and further analysis is needed to evaluate how state law may relate to the provision of clinical interventions for the prevention of HIV infection. (Am J Prev Med 2013;44(1S2):S119-S124) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Culp, Lindsay] CDC, Publ Hlth Law Program, Off Tribal Local & Territorial Support, Atlanta, GA 30341 USA. [Caucci, Lisa] Oak Ridge Inst Sci & Educ, Atlanta, GA USA. RP Culp, L (reprint author), CDC, Publ Hlth Law Program, Off Tribal Local & Territorial Support, 4770 Buford Highway,MS E-70, Atlanta, GA 30341 USA. EM lculp@cdc.gov FU CDC through the Association for Prevention Teaching and Research (CDC-APTR) [11-NCHHSTP-01] FX Publication of this article was supported by the CDC through the Association for Prevention Teaching and Research (CDC-APTR) Cooperative Agreement number 11-NCHHSTP-01. NR 11 TC 9 Z9 9 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD JAN PY 2013 VL 44 IS 1 SU 2 BP S119 EP S124 DI 10.1016/j.amepre.2012.09.044 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 056YL UT WOS:000312528000011 PM 23253751 ER PT J AU Dearing, JW Smith, DK Larson, RS Estabrooks, CA AF Dearing, James W. Smith, Dawn K. Larson, R. Sam Estabrooks, Carole A. TI Designing for Diffusion of a Biomedical Intervention SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID PREEXPOSURE PROPHYLAXIS; OPINION LEADERS; HIV PREVENTION; RESEARCH DISSEMINATION; HEALTH INNOVATIONS; PRIMARY-CARE; FRAMEWORK; BARRIERS; COMMUNICATION; STRATEGIES C1 [Dearing, James W.] Kaiser Permanente, Ctr Hlth Educ Disseminat & Implementat Res, Denver, CO 80231 USA. [Larson, R. Sam] Diffus Associates, Denver, CO USA. [Smith, Dawn K.] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Estabrooks, Carole A.] Univ Alberta, Fac Nursing, Edmonton, AB, Canada. RP Dearing, JW (reprint author), Kaiser Permanente, Ctr Hlth Educ Disseminat & Implementat Res, 10065 E Harvard Ave,Suite 300, Denver, CO 80231 USA. EM james.w.dearing@kp.org OI Estabrooks, Carole/0000-0002-4753-6510 FU CDC through the Association for Prevention Teaching and Research (CDCAPTR) [11-NCHHSTP-01]; CDC; University of Alberta FX Publication of this article was supported by the CDC through the Association for Prevention Teaching and Research (CDCAPTR) Cooperative Agreement number 11-NCHHSTP-01.; JWD, DKS, and RSL's work on this article was supported by the CDC. CAE's work on this article was supported by the University of Alberta. The authors have no commercial conflicts of interest regarding pre-exposure prophylaxis. NR 45 TC 10 Z9 10 U1 1 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD JAN PY 2013 VL 44 IS 1 SU 2 BP S70 EP S76 DI 10.1016/j.amepre.2012.09.038 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 056YL UT WOS:000312528000003 PM 23253765 ER PT J AU Koenig, LJ Lyles, C Smith, DK AF Koenig, Linda J. Lyles, Cynthia Smith, Dawn K. TI Adherence to Antiretroviral Medications for HIV Pre-Exposure Prophylaxis Lessons Learned from Trials and Treatment Studies SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; OF-THE-LITERATURE; THERAPY ADHERENCE; IMPROVE ADHERENCE; TREATMENT OUTCOMES; INFECTED PATIENTS; INTERIM GUIDANCE; DRUG-THERAPY; VIRAL LOAD; CARE C1 [Koenig, Linda J.; Lyles, Cynthia; Smith, Dawn K.] CDC, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. RP Koenig, LJ (reprint author), CDC, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd,MS D21, Atlanta, GA 30333 USA. EM lkoenig@cdc.gov FU CDC through the Association for Prevention Teaching and Research (CDC-APTR) [11-NCHHSTP-01] FX Publication of this article was supported by the CDC through the Association for Prevention Teaching and Research (CDC-APTR) Cooperative Agreement number 11-NCHHSTP-01. NR 76 TC 31 Z9 31 U1 3 U2 22 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD JAN PY 2013 VL 44 IS 1 SU 2 BP S91 EP S98 DI 10.1016/j.amepre.2012.09.047 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 056YL UT WOS:000312528000007 PM 23253769 ER PT J AU Smith, DK Beltrami, J AF Smith, Dawn K. Beltrami, John TI A Proposed Framework to Monitor Daily Oral Antiretroviral Pre-Exposure Prophylaxis in the US SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID HIV-INFECTION; UNITED-STATES; SURVEILLANCE SYSTEM; INTERIM GUIDANCE; PREVENTION; HEALTH; MEN; INTERVENTIONS; HIV/AIDS; EVALUATE C1 [Smith, Dawn K.; Beltrami, John] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. RP Smith, DK (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd,MS E-45, Atlanta, GA 30333 USA. EM dsmith1@cdc.gov FU CDC through the Association for Prevention Teaching and Research (CDC-APTR) [11-NCHHSTP-01] FX Publication of this article was supported by the CDC through the Association for Prevention Teaching and Research (CDC-APTR) Cooperative Agreement number 11-NCHHSTP-01. NR 30 TC 3 Z9 3 U1 2 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD JAN PY 2013 VL 44 IS 1 SU 2 BP S141 EP S146 DI 10.1016/j.amepre.2012.09.040 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 056YL UT WOS:000312528000016 PM 23253756 ER PT J AU Smith, DK Dearing, JW Sanchez, T Goldschmidt, RH AF Smith, Dawn K. Dearing, James W. Sanchez, Travis Goldschmidt, Ronald H. TI Introducing Wicked Issues for HIV Pre-Exposure Prophylaxis Implementation in the US SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID PUBLIC-HEALTH; CARE; INTEGRATION; CHALLENGES; IMPACT; IF C1 [Smith, Dawn K.] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Sanchez, Travis] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. [Dearing, James W.] Kaiser Permanente Inst Hlth Res, Ctr Hlth Educ Disseminat & Implementat Res, Denver, CO USA. [Goldschmidt, Ronald H.] Univ Calif San Francisco, San Francisco Gen Hosp, Natl HIV AIDS Clinicians Consultat Ctr, Dept Family & Community Med, San Francisco, CA USA. RP Smith, DK (reprint author), CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd,MS E-45, Atlanta, GA 30333 USA. EM dsmith1@cdc.gov OI sanchez, travis/0000-0003-1133-4762 FU CDC through the Association for Prevention Teaching and Research (CDC-APTR) [11-NCHHSTP-01] FX Publication of this article was supported by the CDC through the Association for Prevention Teaching and Research (CDC-APTR) Cooperative Agreement number 11-NCHHSTP-01. NR 36 TC 5 Z9 5 U1 0 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD JAN PY 2013 VL 44 IS 1 SU 2 BP S59 EP S62 DI 10.1016/j.amepre.2012.09.057 PG 4 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 056YL UT WOS:000312528000001 PM 23253763 ER PT J AU Tohme, RA Xing, J Liao, YL Holmberg, SD AF Tohme, Rania A. Xing, Jian Liao, Youlian Holmberg, Scott D. TI Hepatitis C Testing, Infection, and Linkage to Care Among Racial and Ethnic Minorities in the United States, 2009-2010 SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID VIRUS-INFECTION; TREATMENT ELIGIBILITY; ASIAN-AMERICANS; RISK-FACTORS; OUTCOMES; IDENTIFICATION; PREVALENCE; MANAGEMENT; MORBIDITY; MORTALITY AB Objectives. We estimated rates and determinants of hepatitis C virus (HCV) testing, infection, and linkage to care among US racial/ethnic minorities. Methods. We analyzed the Racial and Ethnic Approaches to Community Health Across the US Risk Factor Survey conducted in 2009-2010 (n = 53896 minority adults). Results. Overall, 19% of respondents were tested for HCV. Only 60% of those reporting a risk factor were tested, with much lower rates among Asians reporting injection drug use (40%). Odds of HCV testing decreased with age and increased with higher education. Of those tested, 8.3% reported HCV infection. Respondents with income of $75000 or more were less likely to report HCV infection than those with income less than $25000. College-educated non-Hispanic Blacks and Asians had lower odds of HCV infection than those who did not finish high school. Of those infected, 44.4% were currently being followed by a physician, and 41.9% had taken HCV medications. Conclusions. HCV testing and linkage to care among racial/ethnic minorities are suboptimal, particularly among those reporting HCV risk factors. Socioeconomic factors were significant determinants of HCV testing, infection, and access to care. Future HCV testing and prevention activities should be directed toward racial/ethnic minorities, particularly those of low socioeconomic status. (Am J Public Health. 2013;103:112-119. doi:10.2105/AJPH.2012.300858) C1 [Tohme, Rania A.; Xing, Jian; Holmberg, Scott D.] Ctr Dis Control & Prevent CDC, Div Viral Hepatitis, Atlanta, GA USA. [Liao, Youlian] CDC, Div Adult & Community Hlth, Atlanta, GA 30333 USA. RP Tohme, RA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A-04, Atlanta, GA 30333 USA. EM rtohme@cdc.gov NR 30 TC 20 Z9 20 U1 0 U2 7 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD JAN PY 2013 VL 103 IS 1 BP 112 EP 119 DI 10.2105/AJPH.2012.300858 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 062NZ UT WOS:000312927900024 PM 23153151 ER PT J AU An, Q Prejean, J Harrison, KM Fang, XM AF An, Qian Prejean, Joseph Harrison, Kathleen McDavid Fang, Xiangming TI Association Between Community Socioeconomic Position and HIV Diagnosis Rate Among Adults and Adolescents in the United States, 2005 to 2009 SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID DISPARITIES GEOCODING PROJECT; NEW-YORK-CITY; BREAST-CANCER; AIDS INCIDENCE; SAN-FRANCISCO; MORTALITY; INCOME; AREA; HEALTH; STAGE AB Objectives. We examined the association between socioeconomic position (SEP) and HIV diagnosis rates in the United States and whether racial/ethnic disparities in diagnosis rates persist after control for SEP. Methods. We used cases of HIV infection among persons aged 13 years and older, diagnosed 2005 through 2009 in 37 states and reported to national HIV surveillance through June 2010, and US Census data, to examine associations between county-level SEP measures and 5-year average annual HIV diagnosis rates overall and among race/ethnicity sex groups. Results. The HIV diagnosis rate was significantly higher for individuals in the low-SEP tertile than for those in the high-SEP tertile (rate ratios for low- vs high-SEP tertiles range = 1.68-3.38) except for White males and Hispanic females. The SEP disparities were larger for minorities than for Whites. Racial disparities persisted after we controlled for SEP, urbanicity, and percentage of population aged 20 to 50 years, and were high in the low-SEP tertile for males and in low- and high-SEP tertiles for females. Conclusions. Findings support continued prioritization of HIV testing, prevention, and treatment to persons in economically deprived areas, and Blacks of all SEP levels. (Am J Public Health. 2013;103:120-126. doi:10.2105/AJPH.2012. 300853) C1 [An, Qian; Prejean, Joseph; Harrison, Kathleen McDavid] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Fang, Xiangming] China Agr Univ, Coll Econ & Management, Beijing 100094, Peoples R China. RP An, Q (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,Mailstop E-47, Atlanta, GA 30333 USA. EM fei8@cdc.gov RI Fang, Xiangming/O-1653-2014 OI Fang, Xiangming/0000-0001-9922-8977 NR 36 TC 10 Z9 10 U1 1 U2 17 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD JAN PY 2013 VL 103 IS 1 BP 120 EP 126 DI 10.2105/AJPH.2012.300853 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 062NZ UT WOS:000312927900025 PM 23153140 ER PT J AU Gray, KM Tang, T Shouse, L Li, JM Mermin, J Hall, HI AF Gray, Kristen Mahle Tang, Tian Shouse, Luke Li, Jianmin Mermin, Jonathan Hall, H. Irene TI Using the HIV Surveillance System to Monitor the National HIV/AIDS Strategy SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; MEDICAL-CARE; HETEROSEXUAL TRANSMISSION; INFECTED PERSONS; VIRAL LOAD; FAILURE; RISK; INTERVENTION; PREVENTION; MANAGEMENT AB Objectives. To report on indicators of the National HIV/AIDS Strategy, we analyzed data collected through the national HIV surveillance system. Methods. We analyzed data from adults and adolescents aged 13 years or older diagnosed with HIV in 13 US jurisdictions that have laboratory reporting of CD4+ T-lymphocyte (CD4) and viral load (VL) test results and enter CD4 and VL test results into the national surveillance system. Results. Of 4899 people diagnosed in 2009, 81.7% had at least 1 CD4 or VL test performed within 3 months of diagnosis. A higher proportion of Whites (86.2%) than Blacks (78.4%) and Hispanics (82.6%) had a CD4 or VL test. Of 53 642 people diagnosed through 2008 and living with HIV at the end of 2009 who had a VL test, 69.4% had a most recent VL of 200 copies per milliliter or less. The proportion of people with suppressed VLs differed among Blacks (60.2%), Hispanics (70.3%), and Whites (77.4%) and among people aged 13 to 24 years (44.3%) compared with people aged 65 years or older (84.2%). Of men who have sex with men, 74.2% had a suppressed VL. Conclusions. The findings highlight disparities in access to and success of care. (Am J Public Health. 2013;103:141-147. doi:10.2105/AJPH.2012.300859) C1 [Gray, Kristen Mahle; Shouse, Luke; Li, Jianmin; Mermin, Jonathan; Hall, H. Irene] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA. [Tang, Tian] ICF Int, Atlanta, GA USA. RP Gray, KM (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, MS E-47,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM blo9@cdc.gov NR 32 TC 11 Z9 11 U1 6 U2 19 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD JAN PY 2013 VL 103 IS 1 BP 141 EP 147 DI 10.2105/AJPH.2012.300859 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 062NZ UT WOS:000312927900028 ER PT J AU Bennett, NM Whitney, CG Moore, M Pilishvili, T Dooling, KL AF Bennett, Nancy M. Whitney, Cynthia G. Moore, Matt Pilishvili, Tamara Dooling, Kathleen L. TI Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults With Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP) SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article ID HIV-INFECTED ADULTS; TRIAL; PREVENTION; DISEASE C1 [Dooling, Kathleen L.] CDC, Atlanta, GA 30333 USA. EM tdp4@cdc.gov NR 16 TC 4 Z9 4 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JAN PY 2013 VL 13 IS 1 BP 232 EP 235 DI 10.1111/ajt.12073 PG 4 WC Surgery; Transplantation SC Surgery; Transplantation GA 062SD UT WOS:000312941200030 ER PT J AU Kramarow, E Lubitz, J Francis, R AF Kramarow, Ellen Lubitz, James Francis, Robert, Jr. TI Trends in the coronary heart disease risk profile of middle-aged adults SO ANNALS OF EPIDEMIOLOGY LA English DT Article DE Aging; Coronary heart disease; Mortality; Risk factors ID OBESITY EPIDEMIC; OLDER AMERICANS; NATIONAL-HEALTH; SECULAR TRENDS; US POPULATION; UNITED-STATES; DISABILITY; MORTALITY; PREVENTION; PREDICTION AB Purpose: To examine recent trends in the coronary heart disease (CHD) risk profiles of the population aged 45 to 64 in the United States. Methods: Data from the National Health and Nutrition Examination Surveys (NHANES) from 2 time periods (1988-1994 and 2005-2008) are used to estimate the CHD risk functions derived from the Framingham Heart Study. The risk functions take account of levels of blood pressure (systolic and diastolic), total and high-density lipoprotein serum cholesterol, diabetes (doctor diagnosed or based on fasting glucose), and smoking status to estimate the 10-year risk of myocardial infarction or coronary death. We estimate the risk functions by gender, race, and age group (45-54 and 55-64). Results: The CHD risk profile of middle-aged adults has improved over time. For example, the mean 10-year risk of heart attack or CHD death among persons 55 to 64 years has declined from 7.1% to 5.2%. Declines are seen among both men and women and among non-Hispanic Blacks and non-Hispanic whites. Conclusions: Despite increases in diabetes and obesity, the CHD risk profile of middle-aged adults improved during the period from 1988-1994 to 2005-2008. Published by Elsevier Inc. C1 [Kramarow, Ellen; Francis, Robert, Jr.] Ctr Dis Control & Prevent, Aging & Chron Dis Stat Branch, Off Anal & Epidemiol, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Kramarow, E (reprint author), Ctr Dis Control & Prevent, Aging & Chron Dis Stat Branch, Off Anal & Epidemiol, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 6332, Hyattsville, MD 20782 USA. EM ekramarow@cdc.gov NR 36 TC 4 Z9 5 U1 0 U2 23 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD JAN PY 2013 VL 23 IS 1 BP 31 EP 34 DI 10.1016/j.annepidem.2012.10.004 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 058IY UT WOS:000312628500006 PM 23176783 ER PT J AU Bryant, KA Van Schooneveld, TC Thapa, I Bastola, D Williams, LO Safranek, TJ Hinrichs, SH Rupp, ME Fey, PD AF Bryant, Kendall A. Van Schooneveld, Trevor C. Thapa, Ishwor Bastola, Dhundy Williams, Laurina O. Safranek, Thomas J. Hinrichs, Steven H. Rupp, Mark E. Fey, Paul D. TI KPC-4 Is Encoded within a Truncated Tn4401 in an IncL/M Plasmid, pNE1280, Isolated from Enterobacter cloacae and Serratia marcescens SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID HYDROLYZING BETA-LACTAMASE; KLEBSIELLA-PNEUMONIAE; ESCHERICHIA-COLI; BLA(KPC) GENE; EPIDEMIOLOGY; SEQUENCE; SALMONELLA; EMERGENCE; VARIANTS; STRAIN AB We describe the transfer of bla(KPC-4) from Enterobacter cloacae to Serratia marcescens in a single patient. DNA sequencing revealed that KPC-4 was encoded on an IncL/M plasmid, pNE1280, closely related to pCTX-M360. Further analysis found that KPC-4 was encoded within a novel Tn4401 element (Tn4401f) containing a truncated tnpA and lacking tnpR, ISKpn7 left, and Tn4401 IRL-1, which are conserved in other Tn4401 transposons. This study highlights the continued evolution of Tn4401 transposons and movement to multiple plasmid backbones that results in acquisition by multiple species of Gram-negative bacilli. C1 [Bryant, Kendall A.; Hinrichs, Steven H.; Fey, Paul D.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA. [Van Schooneveld, Trevor C.; Rupp, Mark E.; Fey, Paul D.] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE USA. [Thapa, Ishwor; Bastola, Dhundy] Univ Nebraska Omaha, Coll Informat Sci & Technol, Omaha, NE USA. [Williams, Laurina O.] Ctr Dis Control & Prevent, Div Lab Sci & Stand, Atlanta, GA USA. [Safranek, Thomas J.] Nebraska Dept Hlth & Human Serv, Lincoln, NE USA. RP Fey, PD (reprint author), Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA. EM pfey@unmc.edu FU Division of Laboratory Science and Standards, CDC [CI 723775]; National Center for Research Resources (NCRR) [1S10RR027754-01]; Nebraska Research Network in Functional Genomics [NE-INBRE P20 RR16469]; Molecular Biology of Neurosensory Systems CoBRE [2P20RR018788-06]; Nebraska Research Initiative FX This project was supported by the Division of Laboratory Science and Standards, CDC, project CI 723775. The UNMC Next Generation Sequencing Core received support from National Center for Research Resources (NCRR) grants entitled UNMC SIG Supporting Next-Generation DNA Sequencing Technology 1S10RR027754-01, the Nebraska Research Network in Functional Genomics NE-INBRE P20 RR16469, the Molecular Biology of Neurosensory Systems CoBRE 2P20RR018788-06, and the Nebraska Research Initiative. We also acknowledge the software and hardware resources provided by the University of Nebraska at Omaha Bioinformatics Core Facility, which is supported by the Nebraska Research Network in Functional Genomics (NE-INBRE P20 RR16469). NR 32 TC 19 Z9 19 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD JAN PY 2013 VL 57 IS 1 BP 37 EP 41 DI 10.1128/AAC.01062-12 PG 5 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 062XS UT WOS:000312958400005 PM 23070154 ER PT J AU Zhu, WM Clark, N Patel, JB AF Zhu, Wenming Clark, Nancye Patel, Jean B. TI pSK41-Like Plasmid Is Necessary for Inc18-Like vanA Plasmid Transfer from Enterococcus faecalis to Staphylococcus aureus In Vitro SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID COAGULASE-NEGATIVE STAPHYLOCOCCI; HORIZONTAL GENE-TRANSFER; GRAM-POSITIVE BACTERIA; MULTIRESISTANCE PLASMIDS; GENTAMICIN-RESISTANCE; STRAINS; PIP501; MOBILIZATION; SYSTEM; DNA AB Vancomycin-resistant Staphylococcus aureus (VRSA) is thought to result from the in vivo conjugative transfer of a vanA plasmid from an Enterococcus sp. to S. aureus. We studied bacterial isolates from VRSA cases that occurred in the United States to identify microbiological factors which may contribute to this plasmid transfer. First, vancomycin-susceptible, methicillin-resistant S. aureus (MRSA) isolates from five VRSA cases were tested for their ability to accept foreign DNA by conjugation in mating experiments with Enterococcus faecalis JH2-2 containing pAM378, a pheromone-response conjugative plasmid. All of the MRSA isolates accepted the plasmid DNA with similar transfer efficiencies (similar to 10(-7)/donor CFU) except for one isolate, MRSA8, for which conjugation was not successful. The MRSA isolates were also tested as recipients in mating experiments between an E. faecalis isolate with an Inc18-like vanA plasmid that was isolated from a VRSA case patient. Conjugative transfer was successful for 3/5 MRSA isolates. Successful MRSA recipients carried a pSK41-like plasmid, a staphylococcal conjugative plasmid, whereas the two unsuccessful MRSA recipients did not carry pSK41. The transfer of a pSK41-like plasmid from a successful MRSA recipient to the two unsuccessful recipients resulted in conjugal transfer of the Inc18-like vanA plasmid from E. faecalis at a frequency of 10(-7)/recipient CFU. In addition, conjugal transfer could be achieved for pSK41-negative MRSA in the presence of a cell-free culture filtrate from S. aureus carrying a pSK41-like plasmid at a frequency of 10(-8)/recipient CFU. These results indicated that a pSK41-like plasmid can facilitate the transfer of an Inc18-like vanA plasmid from E. faecalis to S. aureus, possibly via an extracellular factor produced by pSK41-carrying isolates. C1 [Zhu, Wenming; Clark, Nancye; Patel, Jean B.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. RP Zhu, WM (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. EM waz7@cdc.gov NR 41 TC 22 Z9 22 U1 0 U2 10 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD JAN PY 2013 VL 57 IS 1 BP 212 EP 219 DI 10.1128/AAC.01587-12 PG 8 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 062XS UT WOS:000312958400026 PM 23089754 ER PT J AU Lee, J Song, J Hootman, JM Semanik, PA Chang, RW Sharma, L van Horn, L Bathon, JM Eaton, CB Hochberg, MC Jackson, R Kwoh, CK Mysiw, WJ Nevitt, M Dunlop, DD AF Lee, Jungwha Song, Jing Hootman, Jennifer M. Semanik, Pamela A. Chang, Rowland W. Sharma, Leena van Horn, Linda Bathon, Joan M. Eaton, Charles B. Hochberg, Marc C. Jackson, Rebecca Kwoh, C. Kent Mysiw, W. Jerry Nevitt, Michael Dunlop, Dorothy D. TI Obesity and other modifiable factors for physical inactivity measured by accelerometer in adults with knee osteoarthritis SO ARTHRITIS CARE & RESEARCH LA English DT Article ID UNITED-STATES; OLDER-ADULTS; US ADULTS; ENERGY-EXPENDITURE; RANDOMIZED-TRIAL; ARTHRITIS; POPULATION; EXERCISE; DIET; VALIDATION AB Objective To investigate the public health impact of obesity and other modifiable risk factors related to physical inactivity in adults with knee osteoarthritis (OA). Methods The frequency of inactivity as defined by the US Department of Health and Human Services was assessed from objective accelerometer monitoring of 1,089 participants (ages 4984 years) with radiographic knee OA during the Osteoarthritis Initiative 48-month visit (20082010). The relationship between modifiable factors (weight status, dietary fat, fiber, smoking, depressive symptoms, knee function, knee pain, and knee confidence) with inactivity was assessed using odds ratios (ORs) and attributable fractions (AFs), controlling for descriptive factors (age, sex, race, education, lives alone, employment, frequent knee symptoms, and comorbidity). Results Almost half (48.9%) of participants with knee OA were inactive. Being overweight (OR 1.8, 95% confidence interval [95% CI] 1.22.5) or obese (OR 3.9, 95% CI 2.65.7), having inadequate dietary fiber intake (OR 1.6, 95% CI 1.22.2), severe knee dysfunction (OR 1.9, 95% CI 1.32.8), and severe pain (OR 1.7, 95% CI 1.12.5) were significantly related to inactivity, controlling for descriptive factors. Modifiable factors with significant average AFs were being overweight or obese (AF 23.8%, 95% CI 10.538.6%) and inadequate dietary fiber (AF 12.1%, 95% CI 0.124.5%), controlling for all factors. Conclusion Being obese or overweight, the quality of the diet, severe pain, and severe dysfunction are significantly associated with physical inactivity in adults with knee OA. All components should be considered in designing physical activity interventions that target arthritis populations with low activity levels. C1 [Lee, Jungwha; Song, Jing; Semanik, Pamela A.; Chang, Rowland W.; Sharma, Leena; van Horn, Linda; Dunlop, Dorothy D.] Northwestern Univ, Chicago, IL 60611 USA. [Hootman, Jennifer M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Bathon, Joan M.] Columbia Univ, New York, NY USA. [Eaton, Charles B.] Brown Univ, Pawtucket, RI USA. [Hochberg, Marc C.] Univ Maryland, Baltimore, MD 21201 USA. [Jackson, Rebecca; Mysiw, W. Jerry] Ohio State Univ, Columbus, OH 43210 USA. [Kwoh, C. Kent] Univ Pittsburgh, Pittsburgh, PA USA. [Nevitt, Michael] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Lee, J (reprint author), Northwestern Univ, 680 N Lake Shore Dr,Suite 1400, Chicago, IL 60611 USA. EM jungwha-lee@northwestern.edu RI Mysiw, Walter/E-3724-2011 FU National Institute for Arthritis and Musculoskeletal Diseases [P60-AR48098, R01-AR055287, R01-AR054155, R21-AR059412]; Falk Medical Research Trust; NIH [N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, N01-AR-2-2262]; Merck Research Laboratories; Novartis Pharmaceuticals; GlaxoSmithKline; Pfizer; Foundation for the NIH FX Supported in part by the National Institute for Arthritis and Musculoskeletal Diseases (grants P60-AR48098, R01-AR055287, R01-AR054155, and R21-AR059412) and the Falk Medical Research Trust. The Osteoarthritis Initiative (OAI) is a public-private partnership comprised of 5 contracts (N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, and N01-AR-2-2262) funded by the NIH and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories, Novartis Pharmaceuticals, GlaxoSmithKline, and Pfizer. Private sector funding for the OAI is managed by the Foundation for the NIH. NR 61 TC 23 Z9 23 U1 1 U2 32 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X J9 ARTHRIT CARE RES JI Arthritis Care Res. PD JAN PY 2013 VL 65 IS 1 BP 53 EP 61 DI 10.1002/acr.21754 PG 9 WC Rheumatology SC Rheumatology GA 062RR UT WOS:000312939700008 PM 22674911 ER PT J AU Zhu, AZX Binnington, MJ Renner, CC Lanier, AP Hatsukami, DK Stepanov, I Watson, CH Sosnoff, CS Benowitz, NL Tyndale, RF AF Zhu, Andy Z. X. Binnington, Matthew J. Renner, Caroline C. Lanier, Anne P. Hatsukami, Dorothy K. Stepanov, Irina Watson, Clifford H. Sosnoff, Connie S. Benowitz, Neal L. Tyndale, Rachel F. TI Alaska Native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco-specific nitrosamine exposure and lower tobacco-specific nitrosamine bioactivation SO CARCINOGENESIS LA English DT Article ID NICOTINE METABOLITE RATIO; AMERICAN LIGHT SMOKERS; BLACK-AFRICAN DESCENT; LUNG-CANCER RISK; CIGARETTE SMOKERS; TRANSDERMAL NICOTINE; GENETIC-VARIABILITY; SMOKING-CESSATION; ETHNIC VARIATION; URINARY LEVELS AB Nicotine, the psychoactive ingredient in tobacco, is metabolically inactivated by CYP2A6 to cotinine. CYP2A6 also activates procarcinogenic tobacco-specific nitrosamines (TSNA). Genetic variation in CYP2A6 is known to alter smoking quantity and lung cancer risk in heavy smokers. Our objective was to investigate how CYP2A6 activity influences tobacco consumption and procarcinogen levels in light smokers and smokeless tobacco users. Cigarette smokers (n = 141), commercial smokeless tobacco users (n = 73) and iqmik users (n = 20) were recruited in a cross-sectional study of Alaska Native people. The participants' CYP2A6 activity was measured by both endophenotype and genotype, and their tobacco and procarcinogen exposure biomarker levels were also measured. Smokers, smokeless tobacco users and iqmik users with lower CYP2A6 activity had lower urinary total nicotine equivalents (TNE) and (methylnitrosamino)-1-(3)pyridyl-1-butanol (NNAL) levels (a biomarker of TSNA exposure). Levels of N-nitrosonornicotine (NNN), a TSNA metabolically bioactivated by CYP2A6, were higher in smokers with lower CYP2A6 activities. Light smokers and smokeless tobacco users with lower CYP2A6 activity reduce their tobacco consumption in ways (e.g. inhaling less deeply) that are not reflected by self-report indicators. Tobacco users with lower CYP2A6 activity are exposed to lower procarcinogen levels (lower NNAL levels) and have lower procarcinogen bioactivation (as indicated by the higher urinary NNN levels suggesting reduced clearance), which is consistent with a lower risk of developing smoking-related cancers. This study demonstrates the importance of CYP2A6 in the regulation of tobacco consumption behaviors, procarcinogen exposure and metabolism in both light smokers and smokeless tobacco users. C1 [Zhu, Andy Z. X.; Binnington, Matthew J.; Tyndale, Rachel F.] Univ Toronto, Dept Psychiat, Ctr Addict & Mental Hlth, Toronto, ON M5S 1A8, Canada. [Zhu, Andy Z. X.; Binnington, Matthew J.; Tyndale, Rachel F.] Univ Toronto, Dept Pharmacol, Ctr Addict & Mental Hlth, Toronto, ON M5S 1A8, Canada. [Zhu, Andy Z. X.; Binnington, Matthew J.; Tyndale, Rachel F.] Univ Toronto, Dept Toxicol, Ctr Addict & Mental Hlth, Toronto, ON M5S 1A8, Canada. [Renner, Caroline C.; Lanier, Anne P.] Alaska Native Med Ctr, Anchorage, AK USA. [Hatsukami, Dorothy K.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA. [Stepanov, Irina] Univ Minnesota, Div Environm Hlth Sci, Minneapolis, MN USA. [Stepanov, Irina] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA. [Watson, Clifford H.; Sosnoff, Connie S.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Benowitz, Neal L.] Univ Calif San Francisco, Dept Med, Div Clin Pharmacol, San Francisco, CA USA. [Benowitz, Neal L.] Univ Calif San Francisco, Dept Bioengn, Div Clin Pharmacol, San Francisco, CA 94143 USA. [Benowitz, Neal L.] Univ Calif San Francisco, Dept Therapeut Sci, Div Clin Pharmacol, San Francisco, CA 94143 USA. RP Tyndale, RF (reprint author), Univ Toronto, Dept Psychiat, Ctr Addict & Mental Hlth, 100 Coll St, Toronto, ON M5S 1A8, Canada. EM r.tyndale@utoronto.ca OI Stepanov, Irina/0000-0001-5140-8944 FU Indian Health Service; National Institute on Drug Abuse; National Cancer Institute [NARCH III U26IHS300012, HHSN261200700462P, CA114609]; National Institute on Drug Abuse [DA012353]; National Institutes of Health [DA012353, DA020830]; Canada Research Chair; Canadian Institutes of Health Research [MOP86471]; Ontario Graduate Scholarship; Centre for Addiction and Mental Health (CAMH); CAMH foundation; Canada Foundation for Innovation [20289, 16014]; Ontario Ministry of Research and Innovation; Nabi Biopharmaceuticals FX Indian Health Service with the National Institute on Drug Abuse and National Cancer Institute (NARCH III U26IHS300012); National Cancer Institute (HHSN261200700462P and CA114609); National Institute on Drug Abuse (DA012353); National Institutes of Health (DA020830 and DA012353); Canada Research Chair (for R. F. T.); Canadian Institutes of Health Research (MOP86471); Ontario Graduate Scholarship (for A.Z.Z.); Centre for Addiction and Mental Health (CAMH) and the CAMH foundation; Canada Foundation for Innovation (20289 and 16014); Ontario Ministry of Research and Innovation.; N.L.B. has been a paid consultant to pharmaceutical companies that market medications for smoking cessation treatment, and has served as a paid expert witness in litigation against tobacco companies. R. F. T. has participated in 1 day advisory meetings for Novartis and McNeil. D. K. H. has received grant funding from Nabi Biopharmaceuticals to conduct a clinical trial. NR 48 TC 17 Z9 18 U1 0 U2 15 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0143-3334 J9 CARCINOGENESIS JI Carcinogenesis PD JAN PY 2013 VL 34 IS 1 BP 93 EP 101 DI 10.1093/carcin/bgs306 PG 9 WC Oncology SC Oncology GA 065DQ UT WOS:000313128600012 PM 23027621 ER PT J AU Feikin, DR Njenga, MK Bigogo, G Aura, B Gikunju, S Balish, A Katz, MA Erdman, D Breiman, RF AF Feikin, Daniel R. Njenga, M. Kariuki Bigogo, Godfrey Aura, Barrack Gikunju, Stella Balish, Amanda Katz, Mark A. Erdman, Dean Breiman, Robert F. TI Additional Diagnostic Yield of Adding Serology to PCR in Diagnosing Viral Acute Respiratory Infections in Kenyan Patients 5 Years of Age and Older SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID COMMUNITY-ACQUIRED PNEUMONIA; REQUIRING HOSPITALIZATION; ADULTS; ETIOLOGY; THAILAND; VIRUS AB The role of serology in the setting of PCR-based diagnosis of acute respiratory infections (ARIs) is unclear. We found that acute- and convalescent-phase paired-sample serologic testing increased the diagnostic yield of naso/oropharyngeal swabs for influenza virus, respiratory syncytial virus (RSV), human metapneumovirus, adenovirus, and parainfluenza viruses beyond PCR by 0.4% to 10.7%. Although still limited for clinical use, serology, along with PCR, can maximize etiologic diagnosis in epidemiologic studies. C1 [Feikin, Daniel R.; Njenga, M. Kariuki; Bigogo, Godfrey; Aura, Barrack; Gikunju, Stella; Katz, Mark A.; Breiman, Robert F.] Ctr Dis Control & Prevent Publ Hlth & Res Collabo, Kenya Med Res Inst, Kisumu, Kenya. [Balish, Amanda; Erdman, Dean] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. EM dfeikin@jhsph.edu NR 16 TC 9 Z9 9 U1 1 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 EI 1556-679X J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD JAN PY 2013 VL 20 IS 1 BP 113 EP 114 DI 10.1128/CVI.00325-12 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 064HI UT WOS:000313064400017 PM 23114699 ER PT J AU Wormser, GP Schriefer, M Aguero-Rosenfeld, ME Levin, A Steere, AC Nadelman, RB Nowakowski, J Marques, A Johnson, BJB Dumler, JS AF Wormser, Gary P. Schriefer, Martin Aguero-Rosenfeld, Maria E. Levin, Andrew Steere, Allen C. Nadelman, Robert B. Nowakowski, John Marques, Adriana Johnson, Barbara J. B. Dumler, J. Stephen TI Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE LA English DT Article DE Lyme disease; Borrelia burgdorferi; Serology; C6 ELISA ID LINKED-IMMUNOSORBENT-ASSAY; IMMUNODOMINANT CONSERVED REGION; BORRELIA-BURGDORFERI; ANTIBODY-RESPONSES; SERODIAGNOSIS; RECOMBINANT; VLSE; ANTIGENS; DIAGNOSIS; PROTEIN AB For the diagnosis of Lyme disease, the 2-tier serologic testing protocol for Lyme disease has a number of shortcomings including low sensitivity in early disease; increased cost, time, and labor; and subjectivity in the interpretation of immunoblots. In this study, the diagnostic accuracy of a single-tier commercial C6 ELISA kit was compared with 2-tier testing. The results showed that the C6 ELISA was significantly more sensitive than 2-tier testing with sensitivities of 66.5% (95% confidence interval [CI] 61.7-71.1) and 35.2% (95% CI 30.6-40.1), respectively (P < 0.001) in 403 sera from patients with erythema migrans. The C6 ELISA had sensitivity statistically comparable to 2-tier testing in sera from Lyme disease patients with early neurologic manifestations (88.6% versus 77.3%, P = 0.13) or arthritis (98.3% versus 95.6%, P = 0.38). The specificities of C6 ELISA and 2-tier testing in over 2200 blood donors, patients with other conditions, and Lyme disease vaccine recipients were found to be 98.9% and 99.5%, respectively (P < 0.05, 95% CI surrounding the 0.6 percentage point difference of 0.04 to 1.15). In conclusion, using a reference standard of 2-tier testing, the C6 ELISA as a single-step serodiagnostic test provided increased sensitivity in early Lyme disease with comparable sensitivity in later manifestations of Lyme disease. The C6 ELISA had slightly decreased specificity. Future studies should evaluate the performance of the C6 ELISA compared with 2-tier testing in routine clinical practice. (C) 2013 Elsevier Inc. All rights reserved. C1 [Wormser, Gary P.; Nadelman, Robert B.; Nowakowski, John] New York Med Coll, Div Infect Dis, Valhalla, NY 10595 USA. [Schriefer, Martin; Johnson, Barbara J. B.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Ft Collins, CO 80521 USA. [Aguero-Rosenfeld, Maria E.] New York Univ Langone Med Ctr, Dept Pathol, New York, NY 10016 USA. [Levin, Andrew] Immunetics Inc, Boston, MA 02210 USA. [Steere, Allen C.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA. [Marques, Adriana] NIAID, NIH, Bethesda, MD 20892 USA. [Dumler, J. Stephen] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA. RP Wormser, GP (reprint author), New York Med Coll, Div Infect Dis, Valhalla, NY 10595 USA. EM gary_wormser@nymc.edu FU National Institute of Allergy and Infectious Diseases (NIAID) [R43 AI051926]; Intramural Research Program of the National Institute of Health (NIH) FX This work was supported by Public Health Service Grant R43 AI051926 from the National Institute of Allergy and Infectious Diseases (NIAID). It was also supported in part by the Intramural Research Program of the National Institute of Health (NIH). NR 45 TC 39 Z9 39 U1 1 U2 22 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0732-8893 J9 DIAGN MICR INFEC DIS JI Diagn. Microbiol. Infect. Dis. PD JAN PY 2013 VL 75 IS 1 BP 9 EP 15 DI 10.1016/j.diagmicrobio.2012.09.003 PG 7 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 059CY UT WOS:000312683200003 PM 23062467 ER PT J AU Herremans, T Hogema, BM Nabuurs, M Peeters, M Wegdam-Blans, M Schneeberger, P Nijhuis, C Notermans, DW Galama, J Horrevorts, A van Loo, IHM Vlaminckx, B Zaaijer, HL Koopmans, MP Berkhout, H Socolovschi, C Raoult, D Stenos, J Nicholson, W Bijlmer, H AF Herremans, Tineke Hogema, Boris M. Nabuurs, Marrigje Peeters, Marcel Wegdam-Blans, Marjolijn Schneeberger, Peter Nijhuis, Carla Notermans, Daan W. Galama, Joep Horrevorts, Anton van Loo, Inge H. M. Vlaminckx, Bart Zaaijer, Hans L. Koopmans, Marion P. Berkhout, Hanneke Socolovschi, Cristina Raoult, Didier Stenos, John Nicholson, William Bijlmer, Henk TI Comparison of the performance of IFA, CFA, and ELISA assays for the serodiagnosis of acute Q fever by quality assessment SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE LA English DT Article DE Coxiella burnetii; Q fever; Serology; Quality assessment ID COXIELLA-BURNETII INFECTION; LINKED-IMMUNOSORBENT-ASSAY; DIAGNOSIS; SEROLOGY; ANTIBODY AB The indirect immunofluorescence assay (IFA) is considered the reference method for diagnosing Q fever, but serology is also performed by complement fixation assay (CFA) or enzyme-linked immunosorbent assay (ELISA). However, comparability between these assays is not clear, and therefore a quality assessment was performed. A total of 25 serum samples from negative controls, Q fever patients, and a serial diluted high-positive sample were analyzed in 10 Dutch laboratories. Six laboratories performed CFA, 5 performed IFA, and 5 performed ELISAs. Three international reference laboratories from Australia, France, and the USA also participated in this study. Qualitative values between laboratories using the same methods were within close range, and all 3 methods correctly identified acute Q fever patients. The IFA, ELISA, and CFA are all suitable serodiagnostic assays to diagnose acute Q fever, but the IFA remains an important tool in the follow-up of patients and in identifying patients at risk for developing chronic Q fever. (C) 2013 Elsevier Inc. All rights reserved. C1 [Herremans, Tineke; Nijhuis, Carla; Notermans, Daan W.; Koopmans, Marion P.; Bijlmer, Henk] Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, NL-3720 BA Bilthoven, Netherlands. [Hogema, Boris M.; Zaaijer, Hans L.] Sanquin Blood Supply Fdn, Dept Blood Borne Infect, Amsterdam, Netherlands. [Nabuurs, Marrigje; Galama, Joep] UMCN, Nijmegen, Netherlands. [Nabuurs, Marrigje; Horrevorts, Anton; Berkhout, Hanneke] Canisius Wilhelmina Hosp, Nijmegen, Netherlands. [Peeters, Marcel] St Elizabeth Hosp, Tilburg, Netherlands. [Wegdam-Blans, Marjolijn] PAMM, Veldhoven, Netherlands. [Schneeberger, Peter] Jeroen Bosch Hosp, Den Bosch, Netherlands. [van Loo, Inge H. M.] CAPRHI, MUMC, Maastricht, Netherlands. [Vlaminckx, Bart] St Antonius Hosp, Nieuwegein, Netherlands. [Berkhout, Hanneke] Viecuri Med Ctr, Venlo, Netherlands. [Socolovschi, Cristina; Raoult, Didier] Unite Rickettsies, Marseille, France. [Stenos, John] Australian Rickettsial Reference Lab, Geelong, Vic, Australia. [Nicholson, William] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Atlanta, GA USA. RP Herremans, T (reprint author), Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, NL-3720 BA Bilthoven, Netherlands. EM tineke.herremans@rivm.nl NR 17 TC 9 Z9 10 U1 2 U2 18 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0732-8893 J9 DIAGN MICR INFEC DIS JI Diagn. Microbiol. Infect. Dis. PD JAN PY 2013 VL 75 IS 1 BP 16 EP 21 DI 10.1016/j.diagmicrobio.2012.09.001 PG 6 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 059CY UT WOS:000312683200004 PM 23041450 ER PT J AU Robinson, LR Bitsko, RH Schieve, LA Visser, SN AF Robinson, Lara R. Bitsko, Rebecca H. Schieve, Laura A. Visser, Susanna N. TI Tourette syndrome, parenting aggravation, and the contribution of co-occurring conditions among a nationally representative sample SO DISABILITY AND HEALTH JOURNAL LA English DT Article DE Tourette syndrome; Family functioning; Mental; emotional; behavioral conditions ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; CHILD MALTREATMENT; DISRUPTIVE BEHAVIOR; RANDOMIZED-TRIAL; UNITED-STATES; STRESS; HEALTH; FAMILY; ASSOCIATIONS; SYMPTOMS AB Background: Previous research suggests that parents of a child with Tourette Syndrome (TS) have lower self-concepts, higher caregiver burden, and more difficulties with home activities. However, the contributions of TS and mental, emotional, or behavioral (MEB) conditions to family functioning are difficult to identify from previous research due to relatively small TS sample sizes and high rates of co-occurring conditions within samples of children with TS. Objective: The current study hypothesized that families of children with TS would report significantly more family functioning difficulties (more parenting aggravation, more difficulty with coping with the child's care, less parent-child communication, and less consistent family routines). Specifically, co-occurring conditions would contribute substantially to reported parenting aggravation. Method: Parent-reported data from the 2007 National Survey of Children's Health were analyzed, including whether the child had been diagnosed with TS or an MEB. Weighted analyses were restricted to US children 6-17 years of age (n = 64,034) and adjusted for child age, sex, race and ethnicity. Results: Parents of children with TS were more likely to fall into the high parenting aggravation index category compared with parents of children without TS (aPR = 3.8, 95% CI: 2.2-6.6). Controlling for the co-occurring MEB conditions attenuated the relations between TS and parenting aggravation; however, a significant effect for TS remained in some cases. Conclusion: Parents of children with TS may face significant challenges in raising their children, leading to increased parenting aggravation; these challenges appear to be primarily associated with the presence of co-occurring MEB conditions. Published by Elsevier Inc. C1 [Robinson, Lara R.; Bitsko, Rebecca H.; Visser, Susanna N.] Ctr Dis Control & Prevent, Child Dev Studies Team, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Schieve, Laura A.] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Robinson, LR (reprint author), Ctr Dis Control & Prevent, Child Dev Studies Team, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. EM lrobinson1@cdc.gov FU Intramural CDC HHS [CC999999] NR 56 TC 6 Z9 6 U1 7 U2 17 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-6574 J9 DISABIL HEALTH J JI Disabil. Health J. PD JAN PY 2013 VL 6 IS 1 BP 26 EP 35 DI 10.1016/j.dhjo.2012.10.002 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health; Rehabilitation SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Rehabilitation GA 064LF UT WOS:000313075700005 PM 23260608 ER PT J AU Okomo-Adhiambo, M Sheu, TG Gubareva, LV AF Okomo-Adhiambo, Margaret Sheu, Tiffany G. Gubareva, Larisa V. TI Assays for monitoring susceptibility of influenza viruses to neuraminidase inhibitors SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Review DE Functional analysis; genetic analysis; influenza antiviral susceptibility; neuraminidase inhibitors ID H1N1 2009 VIRUS; H275Y OSELTAMIVIR-RESISTANT; UNITED-STATES; DRUG-RESISTANCE; A VIRUSES; MOLECULAR MARKERS; A(H1N1) VIRUSES; SURVEILLANCE; WORLDWIDE; MUTATION AB Please cite this paper as: Okomo-Adhiambo et al. (2012) Assays for monitoring susceptibility of influenza viruses to neuraminidase inhibitors. Influenza and Other Respiratory Viruses 7(Suppl. 1), 4449. Close monitoring of drug susceptibility among human influenza viruses was necessitated by widespread resistance to M2 inhibitors in influenza H1N1 (pre-pandemic and 2009 pandemic) and H3N2 viruses, and of oseltamivir resistance in pre-pandemic H1N1 viruses. The FDA-approved neuraminidase (NA) inhibitors (NAIs), oseltamivir and zanamivir, as well as investigational NAIs, peramivir and laninamivir, are currently the principal treatment options for managing influenza infection. However, there are challenges associated with assessing virus susceptibility to this class of drugs. Traditional cell culturebased assays are not reliable for phenotypic testing of NAI susceptibility due to complexity in interpretation. Two types of laboratory assays are currently available for monitoring NAI susceptibility, phenotypic such as the neuraminidase inhibition (NI) assay and genotypic. The NI assays requirement for propagated virus lengthens testing turnaround; therefore, the need for timely detection of molecular markers associated with NAI resistance (e.g., H275Y in H1N1) has spurred the development of rapid, high-throughput assays, such as real-time RT-PCR and pyrosequencing. The high sensitivity of genotypic assays allows testing of clinical specimens thus eliminating the need for virus propagation in cell culture. The NI assays are especially valuable when a novel virus emerges or a new NAI becomes available. Modifications continue to be introduced into NI assays, including optimization and data analysis criteria. The optimal assay of choice for monitoring influenza drug susceptibility varies widely depending on the needs of laboratories (e.g., surveillance purposes, clinical settings). Optimally, it is desirable to combine functional and genetic analyses of virus isolates and, when possible, the respective clinical specimens. C1 [Okomo-Adhiambo, Margaret; Sheu, Tiffany G.; Gubareva, Larisa V.] Ctr Dis Control & Prevent, Virus Surveillance & Diag Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Gubareva, LV (reprint author), Ctr Dis Control & Prevent, Virus Surveillance & Diag Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Mail Stop G-16,1600 Clifton Rd, Atlanta, GA 30333 USA. EM lgubareva@cdc.gov NR 51 TC 21 Z9 21 U1 0 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD JAN PY 2013 VL 7 SU 1 SI SI BP 44 EP 49 DI 10.1111/irv.12051 PG 6 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA 062TI UT WOS:000312945000007 PM 23279896 ER PT J AU Pan, LP Sherry, B Park, S Blanck, HM AF Pan, Liping Sherry, Bettylou Park, Sohyun Blanck, Heidi M. TI The Association of Obesity and School Absenteeism Attributed to Illness or Injury Among Adolescents in the United States, 2009 SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE Body mass index; Obesity; School absenteeism; School attendance; Adolescents ID BODY-MASS INDEX; CHILDHOOD OVERWEIGHT; US CHILDREN; NUTRITION EXAMINATION; AMERICAN ADOLESCENTS; ACADEMIC-PERFORMANCE; SCIENTIFIC STATEMENT; METABOLIC SYNDROME; REPORTED WEIGHT; NATIONAL-HEALTH AB Purpose: School attendance can impact academic performance. Childhood obesity-related physical and psychosocial consequences are potentially associated with school absenteeism. Thus, we examined the association between school absenteeism attributed to illness or injury and obesity among adolescents aged 12-17 years. Methods: We used a weighted sample of 3,470 U. S. adolescents from the 2009 National Health Interview Survey. School absenteeism was measured from the parent-reported number of sick days taken in the preceding 12 months. Body mass index was calculated from parent-reported weight and height. Weight status was classified based on the sex-specific body mass index-for-age percentile defined by the CDC growth charts. Poisson regression was conducted to examine the association between school absenteeism and weight status, controlling for selected sociodemographic characteristics and disease status. Results: The mean number of annual sick days was 3.9 days overall; 3.4 days among normal-weight, 4.4 days among overweight, and 4.5 days among obese adolescents. Obese adolescents had a higher proportion of missing >= 4 days of school per year than adolescents of normal weight. Our multivariate analyses found that compared with adolescents of normal weight, overweight and obese adolescents had greater than one-third more sick days annually (rate ratio = 1.36 for overweight and 1.37 for obese adolescents). Conclusions: Overweight and obese adolescents had 36% and 37% more sick days, respectively, than adolescents of normal weight. The results suggest another potential aspect of obesity prevention and reduction efforts among children and families is to improve children's school attendance. Published by Elsevier Inc. on behalf of Society for Adolescent Health and Medicine. C1 [Pan, Liping; Sherry, Bettylou; Park, Sohyun; Blanck, Heidi M.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Pan, LP (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,Mail Stop K-26, Atlanta, GA 30341 USA. EM Lpan@cdc.gov FU Intramural CDC HHS [CC999999] NR 34 TC 9 Z9 9 U1 1 U2 29 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD JAN PY 2013 VL 52 IS 1 BP 64 EP 69 DI 10.1016/j.jadohealth.2012.04.003 PG 6 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 061LU UT WOS:000312850500009 PM 23260836 ER PT J AU Lee, RD Walters, ML Hall, JE Basile, KC AF Lee, Rosalyn D. Walters, Mikel L. Hall, Jeffrey E. Basile, Kathleen C. TI Behavioral and Attitudinal Factors Differentiating Male Intimate Partner Violence Perpetrators With and Without a History of Childhood Family Violence SO JOURNAL OF FAMILY VIOLENCE LA English DT Article DE Child maltreatment; Witnessing intimate partner violence; Perpetrators of intimate partner violence; Family violence; Violence prevention; Behavior; Attitudes ID ADULT MENTAL-HEALTH; OF-ORIGIN VIOLENCE; DOMESTIC VIOLENCE; ANTISOCIAL-BEHAVIOR; PHYSICAL ABUSE; ALCOHOL-USE; MALTREATMENT; AGGRESSION; CONFLICT; ADOLESCENT AB This study utilized a sample of men (N = 340) charged with assault against a female partner to assess differences among IPV perpetrators with and without a history of childhood family violence on factors such as angry, controlling and violent behaviors, substance use related behaviors, and attitudes towards women. Over two-thirds of the sample reported childhood exposure to maltreatment or witnessing IPV. Chi-square analyses and t-tests indicated significant differences between perpetrators with and without a history of family violence on eight of eleven measures. Findings suggest perpetrators with a family violence history more strongly endorse ideas that present women and feminine attributes in a negative light. This research demonstrates that while exposure to family violence during childhood is not necessary for IPV to occur, its presence may be a marker for more severe attitudinal and behavioral problems. Findings highlight the need for primary prevention efforts and can inform secondary prevention strategies. C1 [Lee, Rosalyn D.; Walters, Mikel L.; Basile, Kathleen C.] US Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Violence Prevent, Atlanta, GA 30341 USA. [Hall, Jeffrey E.] US Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Violence Prevent, Atlanta, GA 30341 USA. RP Lee, RD (reprint author), US Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Violence Prevent, 4770 Buford Highway NE,MS F-64, Atlanta, GA 30341 USA. EM rdl3@cdc.gov NR 48 TC 2 Z9 3 U1 2 U2 42 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0885-7482 J9 J FAM VIOLENCE JI J. Fam. Violence PD JAN PY 2013 VL 28 IS 1 BP 85 EP 94 DI 10.1007/s10896-012-9475-8 PG 10 WC Psychology, Clinical; Family Studies SC Psychology; Family Studies GA 061WI UT WOS:000312880500009 ER PT J AU Chan-Tack, KM Gao, A Himaya, AC Thompson, EG Singer, ME Uyeki, TM Birnkrant, DB AF Chan-Tack, Kirk M. Gao, Arlene Himaya, Amalia C. Thompson, Elizabeth G. Singer, Mary E. Uyeki, Timothy M. Birnkrant, Debra B. TI Clinical Experience With Intravenous Zanamivir Under an Emergency Investigational New Drug Program in the United States SO JOURNAL OF INFECTIOUS DISEASES LA English DT Letter ID CRITICALLY-ILL PATIENTS; 2009 H1N1 INFLUENZA C1 [Chan-Tack, Kirk M.; Gao, Arlene; Himaya, Amalia C.; Thompson, Elizabeth G.; Singer, Mary E.; Birnkrant, Debra B.] US FDA, Div Antiviral Prod, Ctr Drug Evaluat & Res, Silver Spring, MD USA. [Uyeki, Timothy M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Chan-Tack, KM (reprint author), 10903 New Hampshire Ave,Bldg 22,Room 6337, Silver Spring, MD 20993 USA. EM kirk.chan-tack@fda.hhs.gov NR 8 TC 9 Z9 9 U1 2 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD JAN 1 PY 2013 VL 207 IS 1 BP 196 EP 198 DI 10.1093/infdis/jis637 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 057ZU UT WOS:000312604200024 PM 23089591 ER PT J AU Maahs, DM Dabelea, D D'Agostino, RB Andrews, JS Shah, AS Crimmins, N Mayer-Davis, EJ Marcovina, S Imperatore, G Wadwa, RP Daniels, SR Reynolds, K Hamman, RF Dolan, LM AF Maahs, David M. Dabelea, Dana D'Agostino, Ralph B., Jr. Andrews, Jeannette S. Shah, Amy S. Crimmins, Nancy Mayer-Davis, Elizabeth J. Marcovina, Santica Imperatore, Giuseppina Wadwa, R. Paul Daniels, Steven R. Reynolds, Kristi Hamman, Richard F. Dolan, Lawrence M. CA SEARCH Diabet Youth Study TI Glucose Control Predicts 2-Year Change in Lipid Profile in Youth with Type 1 Diabetes SO JOURNAL OF PEDIATRICS LA English DT Article ID CARDIOVASCULAR RISK-FACTORS; COMPLICATIONS TRIAL; INSULIN-RESISTANCE; LIPOPROTEIN LEVELS; YOUNG-ADULTS; WEIGHT-GAIN; ASSOCIATION; CHOLESTEROL; CHILDREN; ATHEROSCLEROSIS AB Objective To test the hypothesis that a change in glycated hemoglobin (A1c) over a follow-up interval of approximately 2 years would be associated with concomitant changes in fasting lipids in individuals with type 1 diabetes (T1D). Study design All subjects with T1D diagnosed in 2002-2005 in the SEARCH for Diabetes in Youth study with at least 2 study visits similar to 12 and similar to 24 months after an initial visit were included (age at initial visit, 10.6 +/- 4.1 years; 48% female; diabetes duration, 10 +/- 7 months; 76% non-Hispanic white; A1c = 7.7% +/- 1.4%). Longitudinal mixed models were fit to examine the relationship between change in A1c and change in lipid levels (total cholesterol [TC], high-density lipoprotein-cholesterol [HDL-c], low-density lipoprotein-cholesterol [LDL-c], log triglycerides [TG], and non-HDL-c) with adjustment for possible confounders. Results Change in A1c over time was significantly associated with changes in TC, HDL-c, LDL-c, TG, and non-HDL-c over the range of A1c values. For example, for a person with an A1c of 10% and then a 2% decrease in A1c 2 years later (to 8%), the model predicted concomitant changes in TC (-0.29 mmol/L, -11.4 mg/dL), HDL-c (0.03 mmol/L, 1.3 mg/dL), LDL-c (-0.23 mmol/L, -9.0 mg/dL), and non-HDL-c (-0.32 mmol/L, -12.4 mg/dL) and an 8.5% decrease in TG (mmol/L). Conclusions Improved glucose control over a 2-year follow-up was associated with a more favorable lipid profile but may be insufficient to normalize lipids in dyslipidemic T1D youth needing to decrease lipids to goal. (J Pediatr 2013;162:101-7). C1 [Maahs, David M.; Wadwa, R. Paul] Univ Colorado Denver, Barbara Davis Ctr Diabet, Aurora, CO 80045 USA. [Maahs, David M.; Dabelea, Dana; Hamman, Richard F.] Univ Colorado Denver, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO 80045 USA. [Maahs, David M.; Daniels, Steven R.] Childrens Hosp Colorado, Aurora, CO USA. [D'Agostino, Ralph B., Jr.; Andrews, Jeannette S.] Wake Forest Sch Med, Winston Salem, NC USA. [Shah, Amy S.; Crimmins, Nancy; Dolan, Lawrence M.] Univ Cincinnati, Coll Med, Med Ctr, Cincinnati Childrens Hosp, Cincinnati, OH USA. [Mayer-Davis, Elizabeth J.] Univ N Carolina, Sch Med, Chapel Hill, NC USA. [Marcovina, Santica] NW Lipid Res Lab, Seattle, WA USA. [Imperatore, Giuseppina] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Reynolds, Kristi] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA USA. RP Maahs, DM (reprint author), Univ Colorado Denver, Barbara Davis Ctr Diabet, POB 6511,Mail Stop A140, Aurora, CO 80045 USA. EM David.Maahs@ucdenver.edu RI Dagostino Jr, Ralph/C-4060-2017 OI Dagostino Jr, Ralph/0000-0002-3550-8395 FU Merck FX The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention and the National Institute of Diabetes and Digestive and Kidney Diseases. D.M. and R.W. received a research grant from Merck for a clinical trial of lipid-lowering medications in youth with type 1 diabetes. The other authors declare no conflicts of interest. NR 30 TC 24 Z9 24 U1 0 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 J9 J PEDIATR-US JI J. Pediatr. PD JAN PY 2013 VL 162 IS 1 BP 101 EP U127 DI 10.1016/j.jpeds.2012.06.006 PG 8 WC Pediatrics SC Pediatrics GA 062JK UT WOS:000312915900024 PM 22795314 ER PT J AU Taylor, CA Holman, RC Callinan, LS Zaki, SR Blau, DM AF Taylor, Christopher A. Holman, Robert C. Callinan, Laura S. Zaki, Sherif R. Blau, Dianna M. TI Unexplained Death due to Possible Infectious Diseases in Infants-United States, 2006 SO JOURNAL OF PEDIATRICS LA English DT Article ID SURVEILLANCE; MORTALITY; PARADOX; AUTOPSY AB Objectives To quantify and examine factors related to unexplained death due to possible infectious causes (UDPIC) in infants and to analyze the associations between these factors in unexplained deaths and infants with fatal and nonfatal outcomes. Study design Infant deaths meeting the International Classification of Diseases, Tenth Revision code inclusion and exclusion criteria for UDPIC were selected from the 2006 US Linked Birth and Infant Death data set. Two control groups of surviving and nonsurviving infants were selected and compared with the infants with UDPIC using a case-control study design with multivariate logistic regression models stratified by birth weight category. Comparisons with infants with identified infectious causes of death were also made. Results During 2006, 3570 infant deaths (12.5% of all US infant deaths) were categorized as a UDPIC. The highest rates for these unexplained infants deaths were found in blacks and American Indians/Alaska Natives. Infants of black mothers were more likely to experience UDPIC. Birth weight was a significant effect modifier in these models. Conclusions Many factors may contribute to an infant's death being classified as a UDPIC, including race and marital status. Other factors, such as Hispanic ethnicity and maternal age, also may play a role. Infant characteristics, such as birth weight, may be related to factors that influence the decision not to conduct a postmortem examination in infant death cases. Additional research is needed to determine the true extent of infectious disease and its relationship to UDPIC in infants. (J Pediatr 2013;162:195-201). C1 [Taylor, Christopher A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Appl Sci, Sci Educ & Prof Dev Program Off,Off Surveillance, Atlanta, GA 30341 USA. [Taylor, Christopher A.; Zaki, Sherif R.; Blau, Dianna M.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30341 USA. [Holman, Robert C.; Callinan, Laura S.] Ctr Dis Control & Prevent, Prion & Publ Hlth Off, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30341 USA. RP Taylor, CA (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Appl Sci, Sci Educ & Prof Dev Program Off,Off Surveillance, 4770 Buford Hwy,MS F-62, Atlanta, GA 30341 USA. EM CATaylor1@cdc.gov RI Taylor, Christopher/D-2067-2013 OI Taylor, Christopher/0000-0002-0937-5461 FU Centers for Disease Control and Prevention (CDC) FX Funded by the Centers for Disease Control and Prevention (CDC). The findings and conclusions in the report are those of the authors and do not necessarily represent the official position of the CDC. The authors declare no conflicts of interest. NR 22 TC 1 Z9 1 U1 1 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 J9 J PEDIATR-US JI J. Pediatr. PD JAN PY 2013 VL 162 IS 1 BP 195 EP U236 DI 10.1016/j.jpeds.2012.06.039 PG 10 WC Pediatrics SC Pediatrics GA 062JK UT WOS:000312915900042 PM 22835880 ER PT J AU Chen, LH Barnett, ED Wilson, ME MacLeod, W Yanni, EA Ooi, W Karchmer, AW Kogelman, L Marano, N Hamer, DH AF Chen, Lin H. Barnett, Elizabeth D. Wilson, Mary E. MacLeod, William Yanni, Emad A. Ooi, Winnie Karchmer, Adolf W. Kogelman, Laura Marano, Nina Hamer, Davidson H. TI Hepatitis B Screening in US Travelers Seen at the Boston Area Travel Medicine Network SO JOURNAL OF TRAVEL MEDICINE LA English DT Article ID UNITED-STATES; COST-EFFECTIVENESS; VIRUS INFECTION; SAN-FRANCISCO; LIVER-CANCER; ADULTS; RECOMMENDATIONS; CALIFORNIA; ISLANDERS; IMMUNITY AB Background Persons born in countries with hepatitis B surface antigen (HBsAg) prevalence =2% have increased risk for unrecognized hepatitis B virus (HBV) infection. Testing at pre-travel consultations is a strategy to identify previously undiagnosed HBV infections. Using records of travelers seen at the Boston Area Travel Medicine Network (BATMN) sites, we assessed how these travel clinics currently assess HBV status, describe test results, and describe characteristics of those tested and immunized for HBV. Methods Demographic data and trip information were collected for all travelers seen at the BATMN sites from June 2008 through July 2010. Proportions of those tested for HBV were determined, and differences between those tested and not tested were analyzed. Results Among 13,732 travelers enrolled during the study period, 2,134 (16%) were born in HBV-risk countries (HBsAg prevalence =2%); 532/2134 (25%) had previous HBV test results and 230 (11%) had tests performed at the travel clinic visit. Past results showed that 33/453 (7.3%) were HBV-infected (HBsAg+), 252/481 (52.4%) were immune (anti-HBs+, HBsAg), 164/303 (54.1%) were susceptible (anti-HBs, HBsAg, anti-HBc), and 38/314 (12.1%) had possible HBV exposure (anti-HBc+, HBsAg, anti-HBs). Among 230 travelers tested during the travel clinic visit, 7/213 (3.3%) were HBV-infected, 95/218 (43.6%) were immune, 106/179 (59.2%) were susceptible, and 10/182 (5.5%) had possible HBV exposure. Conclusion The travel clinic offers an opportunity to capture, identify, and educate infected persons unaware of their infection, educate those with known results, and initiate preventive action (eg, vaccination) for those still susceptible. C1 [Chen, Lin H.] Mt Auburn Hosp, Travel Med Ctr, Cambridge, MA 02238 USA. [Chen, Lin H.] Harvard Univ, Sch Med, Fac Med, Boston, MA USA. [Barnett, Elizabeth D.] Boston Univ Sch Med, Dept Pediat, Boston, MA USA. [Barnett, Elizabeth D.] Boston Med Ctr, Int Clin, Boston, MA USA. [Wilson, Mary E.] Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA. [MacLeod, William; Hamer, Davidson H.] Boston Univ, Ctr Global Hlth & Dev, Boston, MA 02215 USA. [MacLeod, William; Hamer, Davidson H.] Boston Univ Sch Publ Hlth, Dept Int Hlth, Boston, MA USA. [Yanni, Emad A.; Marano, Nina] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Karchmer, Adolf W.] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA. [Ooi, Winnie] Lahey Clin Med Ctr, Burlington, MA 01803 USA. [Kogelman, Laura] Tufts Med Ctr, Div Geog Med & Infect Dis, Boston, MA USA. [Hamer, Davidson H.] Boston Univ Sch Med, Dept Med, Infect Dis Sect, Boston, MA USA. RP Chen, LH (reprint author), Mt Auburn Hosp, Travel Med Ctr, 330 Mt Auburn St, Cambridge, MA 02238 USA. EM lchen@hms.harvard.edu OI MacLeod, William/0000-0001-8003-8874; Barnett, Elizabeth/0000-0003-4822-5949; Hamer, Davidson/0000-0002-4700-1495 FU [1 U19CI000508-01] FX We thank Erika Gleva, Christine Benoit, Rebecca Dufur, Deborah Gannon, and Manveen Bhussar for their assistance with data collection and entry. This research was funded by a cooperative agreement (1 U19CI000508-01) between the CDC and Boston Medical Center. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. NR 24 TC 5 Z9 5 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1195-1982 EI 1708-8305 J9 J TRAVEL MED JI J. Travel Med. PD JAN-FEB PY 2013 VL 20 IS 1 BP 29 EP 36 DI 10.1111/jtm.12002 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 061YW UT WOS:000312887200006 PM 23279228 ER PT J AU Taylor, CA Blau, DM DiAngelo, CR Shieh, WJ Zaki, SR Arguin, PM AF Taylor, Christopher A. Blau, Dianna M. DiAngelo, Constance R. Shieh, Wun-Ju Zaki, Sherif R. Arguin, Paul M. TI Malaria Diagnosed by Autopsy in a Young Traveler Returning From Uganda: Limitations of Surveillance SO JOURNAL OF TRAVEL MEDICINE LA English DT Article ID UNITED-STATES; DEATHS AB Fatal infectious disease acquired during international travel is less likely to be captured through existing surveillance when diagnosis is delayed or missed, especially as autopsy rates decline. Death of a young girl owing to malaria demonstrates needs for increased examination of travel-related deaths through postmortem investigation, autopsy, and expanded surveillance. C1 [Taylor, Christopher A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Appl Sci, Sci Educ & Profess Dev Program Off, Atlanta, GA 30341 USA. [Taylor, Christopher A.; Blau, Dianna M.; Shieh, Wun-Ju; Zaki, Sherif R.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [DiAngelo, Constance R.] Off Chief Med Examiner No Dist, Virginia Dept Hlth, Manassas, VA USA. [Arguin, Paul M.] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. RP Taylor, CA (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Appl Sci, Sci Educ & Profess Dev Program Off, 4770 Buford Hwy,MS F-62, Atlanta, GA 30341 USA. EM CATaylor1@cdc.gov RI Taylor, Christopher/D-2067-2013 OI Taylor, Christopher/0000-0002-0937-5461 FU Intramural CDC HHS [CC999999] NR 10 TC 1 Z9 1 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1195-1982 J9 J TRAVEL MED JI J. Travel Med. PD JAN-FEB PY 2013 VL 20 IS 1 BP 47 EP 49 DI 10.1111/j.1708-8305.2012.00672.x PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 061YW UT WOS:000312887200009 PM 23279231 ER PT J AU Townsend, MB MacNeil, A Reynolds, MG Hughes, CM Olson, VA Damon, IK Karem, KL AF Townsend, Michael B. MacNeil, Adam Reynolds, Mary G. Hughes, Christine M. Olson, Victoria A. Damon, Inger K. Karem, Kevin L. TI Evaluation of the Tetracore Orthopox BioThreat (R) antigen detection assay using laboratory grown orthopoxviruses and rash illness clinical specimens SO JOURNAL OF VIROLOGICAL METHODS LA English DT Article DE Monkeypox; Orthopoxvirus; BioThreat; Diagnostic; Rapid ID VARICELLA-ZOSTER-VIRUS; HUMAN MONKEYPOX; VACCINIA-VIRUS; INFECTION; CONGO; PCR; OUTBREAK; IDENTIFICATION; PARTICLES; STRAINS AB The commercially available Orthopox BioThreat (R) Alert assay for orthopoxvirus (OPV) detection is piloted. This antibody-based lateral-flow assay labels and captures OPV viral agents to detect their presence. Serial dilutions of cultured Vaccinia virus (VACV) and Monkeypox virus (MPXV) were used to evaluate the sensitivity of the Tetracore assay by visual and quantitative determinations; specificity was assessed using a small but diverse set of diagnostically relevant blinded samples from viral lesions submitted for routine OPV diagnostic testing. The BioThreat (R) Alert assay reproducibly detected samples at concentrations of 10(7) pfu/ml for VACV and MPXV and positively identified samples containing 10(6) pfu/ml in 4 of 7 independent experiments. The assay correctly identified 9 of 11 OPV clinical samples and had only one false positive when testing 11 non-OPV samples. Results suggest applicability for use of the BioThreat (R) Alert assay as a rapid screening assay and point of care diagnosis for suspect human monkeypox cases. (C) 2012 Elsevier B.V. All rights reserved. C1 [Townsend, Michael B.; Reynolds, Mary G.; Hughes, Christine M.; Olson, Victoria A.; Damon, Inger K.; Karem, Kevin L.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Poxvirus & Rabies Branch, Atlanta, GA 30333 USA. [MacNeil, Adam] Ctr Dis Control & Prevent, Global Immunizat Div, CGH, Atlanta, GA 30333 USA. RP Townsend, MB (reprint author), Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Poxvirus & Rabies Branch, 1600 Clifton Rd NE,Mailstop G-06, Atlanta, GA 30333 USA. EM gbu3@cdc.gov NR 31 TC 8 Z9 8 U1 0 U2 10 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-0934 EI 1879-0984 J9 J VIROL METHODS JI J. Virol. Methods PD JAN PY 2013 VL 187 IS 1 BP 37 EP 42 DI 10.1016/j.jviromet.2012.08.023 PG 6 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Virology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Virology GA 058BR UT WOS:000312609600007 PM 22981983 ER PT J AU Townsend, MB Keckler, MS Patel, N Davies, DH Felgner, P Damon, IK Karem, KL AF Townsend, M. B. Keckler, M. S. Patel, N. Davies, D. H. Felgner, P. Damon, I. K. Karem, K. L. TI Humoral Immunity to Smallpox Vaccines and Monkeypox Virus Challenge: Proteomic Assessment and Clinical Correlations SO JOURNAL OF VIROLOGY LA English DT Article ID HUMAN-ANTIBODY RESPONSES; OPEN READING FRAME; POXVIRUS INFECTION; CYNOMYS-LUDOVICIANUS; PROTECTIVE IMMUNITY; ENVELOPE PROTEIN; MATURE VIRION; ANIMAL-MODEL; VACCINATION; IMMUNOGENICITY AB Despite the eradication of smallpox, orthopoxviruses (OPV) remain public health concerns. Efforts to develop new therapeutics and vaccines for smallpox continue through their evaluation in animal models despite limited understanding of the specific correlates of protective immunity. Recent monkeypox virus challenge studies have established the black-tailed prairie dog (Cynomys ludovicianus) as a model of human systemic OPV infections. In this study, we assess the induction of humoral immunity in humans and prairie dogs receiving Dryvax, Acam2000, or Imvamune vaccine and characterize the proteomic profile of immune recognition using enzyme-linked immunosorbent assays (ELISA), neutralization assays, and protein microarrays. We confirm anticipated similarities of antigenic protein targets of smallpox vaccine-induced responses in humans and prairie dogs and identify several differences. Subsequent monkeypox virus intranasal infection of vaccinated prairie dogs resulted in a significant boost in humoral immunity characterized by a shift in reactivity of increased intensity to a broader range of OPV proteins. This work provides evidence of similarities between the vaccine responses in prairie dogs and humans that enhance the value of the prairie dog model system as an OPV vaccination model and offers novel findings that form a framework for examining the humoral immune response induced by systemic orthopoxvirus infection. C1 [Townsend, M. B.; Keckler, M. S.; Patel, N.; Damon, I. K.; Karem, K. L.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Poxvirus & Rabies Branch, Atlanta, GA 30333 USA. [Davies, D. H.; Felgner, P.] Univ Calif Irvine, Dept Med, Div Infect Dis, Irvine, CA 92717 USA. [Davies, D. H.; Felgner, P.] Antigen Discovery Inc, Irvine, CA USA. RP Townsend, MB (reprint author), Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Poxvirus & Rabies Branch, Atlanta, GA 30333 USA. EM gbu3@cdc.gov FU Centers for Disease Control and Prevention FX This work was supported by program funds from the Centers for Disease Control and Prevention. NR 71 TC 7 Z9 7 U1 0 U2 22 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD JAN PY 2013 VL 87 IS 2 BP 900 EP 911 DI 10.1128/JVI.02089-12 PG 12 WC Virology SC Virology GA 062QF UT WOS:000312934400020 PM 23135728 ER PT J AU McNulty, S Flint, M Nichol, ST Spiropoulou, CF AF McNulty, Shannon Flint, Mike Nichol, Stuart T. Spiropoulou, Christina F. TI Host mTORC1 Signaling Regulates Andes Virus Replication SO JOURNAL OF VIROLOGY LA English DT Article ID HANTAVIRUS PULMONARY SYNDROME; SUPPORT IMPROVES SURVIVAL; ENDOTHELIAL GROWTH-FACTOR; PROTEIN S6 KINASE; CARDIOPULMONARY SYNDROME; 3-KINASE/AKT PATHWAY; NUCLEOCAPSID PROTEIN; MAMMALIAN PROTEIN; RNA-SYNTHESIS; AMINO-ACIDS AB Hantavirus pulmonary syndrome (HPS) is a severe respiratory disease characterized by pulmonary edema, with fatality rates of 35 to 45%. Disease occurs following infection with pathogenic New World hantaviruses, such as Andes virus (ANDV), which targets lung microvascular endothelial cells. During replication, the virus scavenges 5'-m(7)G caps from cellular mRNA to ensure efficient translation of viral proteins by the host cell cap-dependent translation machinery. In cells, the mammalian target of rapamycin (mTOR) regulates the activity of host cap-dependent translation by integrating amino acid, energy, and oxygen availability signals. Since there is no approved pharmacological treatment for HPS, we investigated whether inhibitors of the mTOR pathway could reduce hantavirus infection. Here, we demonstrate that treatment with the FDA-approved rapamycin analogue temsirolimus (CCI-779) blocks ANDV protein expression and virion release but not entry into primary human microvascular endothelial cells. This effect was specific to viral proteins, as temsirolimus treatment did not block host protein synthesis. We confirmed that temsirolimus targeted host mTOR complex 1 (mTORC1) and not a viral protein, as knockdown of mTORC1 and mTORC1 activators but not mTOR complex 2 components reduced ANDV replication. Additionally, primary fibroblasts from a patient with tuberous sclerosis exhibited increased mTORC1 activity and increased ANDV protein expression, which were blocked following temsirolimus treatment. Finally, we show that ANDV glycoprotein Gn colocalized with mTOR and lysosomes in infected cells. Together, these data demonstrate that mTORC1 signaling regulates ANDV replication and suggest that the hantavirus Gn protein may modulate mTOR and lysosomal signaling during infection, thus bypassing the cellular regulation of translation. C1 [McNulty, Shannon; Flint, Mike; Nichol, Stuart T.; Spiropoulou, Christina F.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Atlanta, GA USA. RP Spiropoulou, CF (reprint author), Berry Coll, Sch Math & Nat Sci, Rome, GA USA. EM ccs8@cdc.gov OI Flint, Michael/0000-0002-5373-787X FU ASM/CDC Program in Infectious Disease and Public Health Microbiology postdoctoral fellowship grant; CDC core funding FX This work was supported by an ASM/CDC Program in Infectious Disease and Public Health Microbiology postdoctoral fellowship grant to S. M. Additional financial support was provided from CDC core funding. NR 71 TC 12 Z9 12 U1 0 U2 10 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD JAN PY 2013 VL 87 IS 2 BP 912 EP 922 DI 10.1128/JVI.02415-12 PG 11 WC Virology SC Virology GA 062QF UT WOS:000312934400021 PM 23135723 ER PT J AU Houser, KV Katz, JM Tumpey, TM AF Houser, Katherine V. Katz, Jacqueline M. Tumpey, Terrence M. TI Seasonal Trivalent Inactivated Influenza Vaccine Does Not Protect against Newly Emerging Variants of Influenza A (H3N2v) Virus in Ferrets SO JOURNAL OF VIROLOGY LA English DT Article ID UNITED-STATES; SWINE; INFECTION; EMERGENCE; ANTIBODY; HUMANS; ADULTS AB The recent increase in human cases of influenza A H3N2 variant virus [A(H3N2)v] highlights the need to assess whether seasonal influenza vaccination provides cross-protection against A(H3N2) v virus. Our data demonstrate that the 2011-2012 trivalent inactivated influenza vaccine (TIV) protected ferrets against homologous H3N2 virus challenge but provided minimal to no protection against A(H3N2) v virus. The complete absence of specific hemagglutination inhibition antibody response to A(H3N2) v is consistent with the poor cross-protection observed among TIV-immune animals. C1 [Houser, Katherine V.; Katz, Jacqueline M.; Tumpey, Terrence M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Houser, Katherine V.] Emory Univ, Grad Program Immunol & Mol Pathogenesis, Grad Div Biol & Biomed Sci, Atlanta, GA 30322 USA. RP Tumpey, TM (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM tft9@cdc.gov FU Oak Ridge Institute for Science and Education, Oak Ridge, TN FX K.V.H. received financial support for this work from the Oak Ridge Institute for Science and Education, Oak Ridge, TN. NR 18 TC 18 Z9 18 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD JAN PY 2013 VL 87 IS 2 BP 1261 EP 1263 DI 10.1128/JVI.02625-12 PG 3 WC Virology SC Virology GA 062QF UT WOS:000312934400053 PM 23115290 ER PT J AU Miller, DB O'Callaghan, JP AF Miller, Diane B. O'Callaghan, James P. TI Personalized medicine in major depressive disorder - Opportunities and pitfalls SO METABOLISM-CLINICAL AND EXPERIMENTAL LA English DT Article DE Biomarkers; Genome; Genetics; Metabolism ID PRIMARY-CARE; ANTIDEPRESSANT RESPONSE; MOOD DISORDERS; PHARMACOGENETICS; BIOMARKERS; DIAGNOSIS; REMISSION; 5-HTTLPR AB The sequencing of the human genome in the early days of this millennium was greeted with great fanfare as this accomplishment was expected to revolutionize medicine and result in individualized treatments based on the genetic make-up of the patient. The ultimate promise of personalized medicine would be fulfilled with the identification of disease biomarkers that would be widely available for use in diagnosis and treatment. Progress, however, has been slow in providing disease biomarkers or approved diagnostic tests. This is true for major depressive disorder (MDD), despite its prevalence in the general population and the widespread acceptance of its biological basis. Studies using strategies like genome-wide association and candidate gene analyses have identified a number of possible biomarkers of MDD, including serum levels of neurotrophic factors, inflammatory cytokines and HPA axis hormones, but none have proven sufficiently powerful for clinical use. The lack of biologically based tests available for use in identifying patients with MDD is a significant impediment to personalized and more effective treatment, because it means diagnosis continues to be driven by subjective symptoms. While genetic studies of MDD have not yet led to diagnostic and treatment biomarkers, progress in determining the role of the genome in drug metabolism heralds the first effort in personalized prescribing for the antidepressants. The FDA suggested and approved genotyping tests for common variants of drug metabolism genes, such as the cytochrome p450s. By using these tests a physician can select an appropriate antidepressant for a given patient, as differences in clearance, half-life, and peak blood concentrations are controlled by genetic variability in drug metabolism. Personalization in drug choice can be achieved because these tests: (1) identify responders and non-responders; (2) provide alerts to possible adverse drug events; and (3) help optimize dose. Improved ways of diagnosing and prescribing effective treatments for MDD are needed, as the available methods are inadequate and symptom based. In the foreseeable future, further interrogation of the genome may serve as the basis for development of new personalized medicine strategies for diagnosis and treatment of MDD. Published by Elsevier Inc. C1 [Miller, Diane B.; O'Callaghan, James P.] NIOSH, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. RP Miller, DB (reprint author), NIOSH, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. EM dum6@cdc.gov; jdo5@cdc.gov RI O'Callaghan, James/O-2958-2013; Miller, Diane/O-2927-2013 FU College International de Recherche Servier (CIRS) FX Publication of this article was supported by the College International de Recherche Servier (CIRS). NR 37 TC 13 Z9 16 U1 2 U2 30 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0026-0495 J9 METABOLISM JI Metab.-Clin. Exp. PD JAN PY 2013 VL 62 IS 1 SU 1 BP S34 EP S39 DI 10.1016/j.metabol.2012.08.021 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 056PZ UT WOS:000312504700009 PM 23021040 ER PT J AU Irving, SA Kieke, BA Donahue, JG Mascola, MA Baggs, J DeStefano, F Cheetham, TC Jackson, LA Naleway, AL Glanz, JM Nordin, JD Belongia, EA AF Irving, Stephanie A. Kieke, Burney A. Donahue, James G. Mascola, Maria A. Baggs, James DeStefano, Frank Cheetham, T. Craig Jackson, Lisa A. Naleway, Allison L. Glanz, Jason M. Nordin, James D. Belongia, Edward A. CA Vaccine Safety Datalink TI Trivalent Inactivated Influenza Vaccine and Spontaneous Abortion SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID PREGNANT-WOMEN; ANTIBODY-RESPONSE; IMMUNIZATION; SAFETY; IMMUNOGENICITY; OUTCOMES; INFANTS; COHORT; RISK AB OBJECTIVE: To estimate the association between spontaneous abortion and influenza vaccine receipt with a case-control study utilizing data from six health care organizations in the Vaccine Safety Datalink. METHODS: Women aged 18-44 years with spontaneous abortion during the autumn of 2005 or 2006 were identified using International Classification of Diseases, 9th Revision, Clinical Modification codes. Cases of spontaneous abortion at 5-16 weeks of gestation were confirmed by medical record review; date of fetal demise was based on ultrasound information when available. Control group individuals with a live birth were individually matched to case group individuals by health care organization and date of last menstrual period (LMP). The primary exposure of interest was influenza vaccination during the 28 days preceding the date of spontaneous abortion of the matched pair. Conditional logistic regression models adjusted for maternal age, health care utilization, maternal diabetes, and parity. RESULTS: Our final analysis included 243 women with spontaneous abortion and 243 matched control group women; 82% of women with spontaneous abortion had ultrasound confirmation of fetal demise. Using clinical diagnosis and ultrasound data, the mean gestational age at fetal demise was 7.8 weeks. Mean ages at LMP of case group women and control group women were 31.7 and 29.3 years, respectively (P<.001). Sixteen women with spontaneous abortion (7%) and 15 (6%) matched control group women received influenza vaccine within the 28-day exposure window. There was no association between spontaneous abortion and influenza vaccination in the 28-day exposure window (adjusted matched odds ratio 1.23, 95% confidence interval 0.53-2.89; P=.63). CONCLUSION: There was no statistically significant increase in the risk of pregnancy loss in the 4 weeks after seasonal inactivated influenza vaccination. (Obstet Gynecol 2013;121:159-65) DOI: http://10.1097/AOG.0b013e318279f56f C1 [Belongia, Edward A.] Marshfield Clin Fdn Med Res & Educ, Epidemiol Res Ctr, Marshfield, WI 54449 USA. Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA USA. Kaiser Permanente So Calif, Downey, CA USA. Grp Hlth Res Inst, Seattle, WA USA. Kaiser Permanente NW, Portland, OR USA. Kaiser Permanente Colorado, Denver, CO USA. HealthPartners Res Fdn, Minneapolis, MN USA. RP Belongia, EA (reprint author), Marshfield Clin Fdn Med Res & Educ, Epidemiol Res Ctr, 1000 N Oak Ave,ML2, Marshfield, WI 54449 USA. EM belongia.edward@marshfieldclinic.org OI Irving, Stephanie/0000-0001-7437-6797; Baggs, James/0000-0003-0757-4683; Naleway, Allison/0000-0001-5747-4643 FU America's Health Insurance Plans (AHIP) from the Centers for Disease Control and Prevention (CDC) [200-2002-00732]; Medimmune, LLC.; Merck; Sanofi Pasteur; Novartis; Glaxo Smith Kline; Pfizer FX Funded through a subcontract with America's Health Insurance Plans (AHIP) under contract 200-2002-00732, from the Centers for Disease Control and Prevention (CDC).; Stephanie A. Irving, Burney A. Kieke, James G. Donahue, and Edward A. Belongia have received unrelated research support from Medimmune, LLC. T. Craig Cheetham has received unrelated research support from Merck. Lisa A. Jackson has received unrelated research support from Sanofi Pasteur, Novartis, Glaxo Smith Kline, and Pfizer, as well as travel expenses from Pfizer. The other authors did not report any potential conflicts of interest. NR 28 TC 28 Z9 29 U1 1 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD JAN PY 2013 VL 121 IS 1 BP 159 EP 165 DI 10.1097/AOG.0b013e318279f56f PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 060LN UT WOS:000312779500023 PM 23262941 ER PT J AU Daniels, RD Bertke, S Waters, KM Schubauer-Berigan, MK AF Daniels, Robert D. Bertke, Stephen Waters, Kathleen M. Schubauer-Berigan, Mary K. TI Risk of leukaemia mortality from exposure to ionising radiation in US nuclear workers: a pooled case-control study SO OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID LINEAR-NO-THRESHOLD; CHRONIC LYMPHOCYTIC-LEUKEMIA; PORTSMOUTH-NAVAL-SHIPYARD; LOW-DOSE RADIATION; MEDICAL X-RAYS; CANCER-MORTALITY; OCCUPATIONAL COHORT; INDUSTRY WORKERS; FACILITIES; UNCERTAINTY AB Objective To follow-up on earlier studies of the leukaemogenicity of occupational ionising radiation exposure. Methods We conducted a nested case-control analysis of leukaemia mortality in a pooled cohort of US nuclear workers followed through 2005. Each case was matched to four controls on attained age. Exposures were estimated from available records. General relative risk models were used to estimate the excess relative risk (ERR) of leukaemia, excluding chronic lymphocytic (CLL), acute myeloid leukaemia, chronic myeloid leukaemia and CLL while controlling for potential confounders. Preferred exposure lags and time-windows of risks were calculated using joint maximum likelihood. Dose-response was also examined using linear, linear-quadratic, categorical and restricted cubic spline models. Results There were 369 leukaemia deaths in 105 245 US nuclear workers. The adjusted ERR for non-CLL leukaemia was 0.09 (95% CI -0.17 to 0.65) per 100 mGy. Elevated non-CLL risks were observed from exposures occurring 6-14 years prior to attained age of cases (ERR per 100 mGy=1.9; 95% CI <0 to 8.0). Lagged models indicated non-linearity of risk at very low (<10 mGy) and high (>100 mGy) doses, which contributed to the imprecision of results in linear models. Similar risk attenuation was not evident in time-windows- based models. Conclusions Risk estimates were in reasonable agreement with previous estimates, with the temporality of non-CLL leukaemia risk as a dominant factor in dose-response analyses. Future research should focus on methods that improve evaluations of the dose-response, particularly in the low-dose range. C1 [Daniels, Robert D.; Bertke, Stephen; Waters, Kathleen M.; Schubauer-Berigan, Mary K.] NIOSH, DSHEFS, Industrywide Studies Branch IWSB, Cincinnati, OH 45226 USA. RP Daniels, RD (reprint author), NIOSH, DSHEFS, Industrywide Studies Branch IWSB, 4676 Columbia Pkwy,Mailstop R-13, Cincinnati, OH 45226 USA. EM rtd2@cdc.gov RI Schubauer-Berigan, Mary/B-3149-2009 OI Schubauer-Berigan, Mary/0000-0002-5175-924X FU National Institute for Occupational Safety and Health (NIOSH) under National Occupational Research Agenda (NORA); DOE FX This research was funded by the National Institute for Occupational Safety and Health (NIOSH) following competitive award as an intramural research project under the National Occupational Research Agenda (NORA), and made possible through the cooperation and support of the DOE and their employees and contractors. NR 48 TC 11 Z9 11 U1 1 U2 16 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1351-0711 J9 OCCUP ENVIRON MED JI Occup. Environ. Med. PD JAN PY 2013 VL 70 IS 1 BP 41 EP 48 DI 10.1136/oemed-2012-100906 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 057SM UT WOS:000312584300008 PM 23000827 ER PT J AU Desai, R Cortese, MM Meltzer, MI Shankar, M Tate, JE Yen, C Patel, MM Parashar, UD AF Desai, Rishi Cortese, Margaret M. Meltzer, Martin I. Shankar, Manjunath Tate, Jacqueline E. Yen, Catherine Patel, Manish M. Parashar, Umesh D. TI Potential Intussusception Risk Versus Benefits of Rotavirus Vaccination in the United States SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE rotavirus; vaccine; United States; risk; intussusception ID DISCHARGE DATA; US CHILDREN; PENTAVALENT; GASTROENTERITIS; INFANTS; SAFETY; HOSPITALIZATIONS; REDUCTION; EFFICACY AB Background: International data show a low-level increased risk of intussusception associated with rotavirus vaccination. Although US data have not documented a risk, we assumed a risk similar to international settings and compared potential vaccine-associated intussusception cases with benefits of prevention of rotavirus gastroenteritis by a fully implemented US rotavirus vaccine program. Methods: To calculate excess intussusception cases, we used national data on vaccine coverage and baseline intussusception rates, and assumed a vaccine-associated intussusception relative risk of 5.3 (95% confidence interval [CI]: 3.0-9.3) in the first week after the first vaccine dose, the risk seen in international settings. We used postlicensure vaccine effectiveness data to calculate rotavirus disease burden averted. Results: For a US birth cohort of 4.3 million infants, vaccine-associated intussusception could cause an excess 0.2 (range: 0.1-0.3) deaths, 45 (range: 21-86) hospitalizations and 13 (range: 6-25) cases managed in short-stay or emergency department settings. Vaccination would avert 14 (95% CI: 10-19) rotavirus-associated deaths, 53,444 (95% CI: 37,622-72,882) hospitalizations and 169,949 (95% CI: 118,161-238,630) emergency department visits. Summary benefit-risk ratios for death and hospitalization are 71: 1 and 1093: 1, respectively. Conclusions: The burden of severe rotavirus disease averted due to vaccination compared with the vaccine-associated intussusception events offers a side-by-side analysis of the benefits and potential risks. If an intussusception risk similar to that seen internationally exists in the United States, it is substantially exceeded by the benefits of rotavirus disease burden averted by vaccination. C1 [Desai, Rishi; Cortese, Margaret M.; Meltzer, Martin I.; Shankar, Manjunath; Tate, Jacqueline E.; Yen, Catherine; Patel, Manish M.; Parashar, Umesh D.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Desai, R (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS-A34, Atlanta, GA 30333 USA. EM rdesai1@cdc.gov NR 28 TC 24 Z9 24 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD JAN PY 2013 VL 32 IS 1 BP 1 EP 7 DI 10.1097/INF.0b013e318270362c PG 7 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 062FC UT WOS:000312903600008 PM 22929172 ER PT J AU Loharikar, A Vawter, S Warren, K Deasy, M Moll, M Sandt, C Gilhousen, R Villamil, E Rhorer, A Briere, E Schwensohn, C Trees, E Lafon, P Adams, JK Le, B Behravesh, CB AF Loharikar, Anagha Vawter, Shannon Warren, Kim Deasy, Marshall, III Moll, Maria Sandt, Carol Gilhousen, Renee Villamil, Elizabeth Rhorer, Andrew Briere, Elizabeth Schwensohn, Colin Trees, Eija Lafon, Patricia Adams, Jennifer Kincaid Le, Brenda Behravesh, Casey Barton TI Outbreak of Human Salmonella Typhimurium Infections Linked to Contact With Baby Poultry From a Single Agricultural Feed Store Chain and Mail-order Hatchery, 2009 SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE Salmonella; baby poultry; outbreak; children ID UNITED-STATES; PULSENET AB Background: Over 30 outbreaks of human salmonellosis linked to contact with live poultry from mail-order hatcheries were reported to Centers for Disease Control and Prevention between 1990 and 2010. In May 2009, we investigated an outbreak of human Salmonella Typhimurium infections, primarily affecting children. Methods: A case was defined as a person with the outbreak strain of Salmonella Typhimurium, as determined by pulsed-field gel electrophoresis and multiple-locus variable-number tandem repeat analysis, in a Pennsylvania or New York resident with illness onset between May 1 and September 1, 2009. We conducted a case-control study to examine the relationship between illness and live poultry contact. Controls were age-matched and geographically-matched. Traceback and environmental investigations were conducted. Results: We identified 36 case-patients in Pennsylvania and New York; 36% were children aged <= 5 years. Case-patients were more likely than controls to report live baby poultry contact (matched odds ratio [mOR]: 17.0; 95% confidence interval [CI]: 2.7-710.5), contact with chicks (mOR: 14.0; 95% CI: 2.1-592.0), ducklings (mOR: 8.0; 95% CI: 1.1-355.0) and visiting agricultural feed stores (mOR: 6.0; 95% CI: 1.3-55.2). Most (83%) visited agricultural Feed Store Chain Y, a national agricultural feed store chain, which received poultry from Hatchery C, which is supplied by multiple egg sources. Salmonella Typhimurium was isolated from a source duck flock, but had a different pulsed-field gel electrophoresis pattern than the outbreak strain. Conclusions: Live baby poultry remain an important source of human salmonellosis, particularly among children. Preventing these infections requires comprehensive interventions at hatcheries and agricultural feed stores; pediatricians should inform patients of risks associated with live poultry contact. C1 [Loharikar, Anagha; Briere, Elizabeth] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Vawter, Shannon] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. [Warren, Kim] NE Dist Off, Penn Dept Hlth, Wilkes Barre, PA USA. [Deasy, Marshall, III; Moll, Maria; Gilhousen, Renee] Penn Dept Hlth, Harrisburg, PA 17108 USA. [Sandt, Carol] Penn Dept Hlth, Exton, PA USA. [Villamil, Elizabeth] New York State Dept Hlth, Albany, NY USA. [Rhorer, Andrew] Ctr Dis Control & Prevent, United States Dept Agr Anim & Plant Hlth Inspect, Serv Natl Poultry Improvement Plan, Atlanta, GA 30333 USA. [Schwensohn, Colin; Behravesh, Casey Barton] Ctr Dis Control & Prevent, Outbreak Response & Prevent Branch, Atlanta, GA 30333 USA. [Trees, Eija; Lafon, Patricia; Adams, Jennifer Kincaid] Ctr Dis Control & Prevent, Enter Dis Lab Branch, Atlanta, GA 30333 USA. [Le, Brenda] Ctr Dis Control & Prevent, Biostat Off, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. RP Loharikar, A (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, 1600 Clifton Rd NE,Mailstop A38, Atlanta, GA 30333 USA. EM anagha.loharikar@gmail.com NR 15 TC 10 Z9 10 U1 0 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD JAN PY 2013 VL 32 IS 1 BP 8 EP 12 DI 10.1097/INF.0b013e3182755e28 PG 5 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 062FC UT WOS:000312903600009 PM 23014358 ER PT J AU Feikin, DR Njenga, MK Bigogo, G Aura, B Aol, G Audi, A Jagero, G Muluare, PO Gikunju, S Nderitu, L Winchell, JM Schneider, E Erdman, DD Oberste, MS Katz, MA Breiman, RF AF Feikin, Daniel R. Njenga, M. Kariuki Bigogo, Godfrey Aura, Barrack Aol, George Audi, Allan Jagero, Geoffrey Muluare, Peter O. Gikunju, Stella Nderitu, Leonard Winchell, Jonas M. Schneider, Eileen Erdman, Dean D. Oberste, M. Steven Katz, Mark A. Breiman, Robert F. TI Viral and Bacterial Causes of Severe Acute Respiratory Illness Among Children Aged Less Than 5 Years in a High Malaria Prevalence Area of Western Kenya, 2007-2010 SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE pneumonia; severe acute respiratory illness; respiratory viruses; Africa; Kenya; Streptococcus pneumoniae ID REAL-TIME PCR; PNEUMOCOCCAL CONJUGATE VACCINE; SYNCYTIAL VIRUS-INFECTION; HOSPITALIZED CHILDREN; YOUNG-CHILDREN; DEVELOPING-COUNTRIES; PNEUMONIA ETIOLOGY; TRACT INFECTIONS; MORTALITY; DISEASE AB Background: Few comprehensive data exist on the etiology of severe acute respiratory illness (SARI) among African children. Methods: From March 1, 2007 to February 28, 2010, we collected blood for culture and nasopharyngeal and oropharyngeal swabs for real-time quantitative polymerase chain reaction for 10 viruses and 3 atypical bacteria among children aged <5 years with SARI, defined as World Health Organization-classified severe or very severe pneumonia or oxygen saturation <90%, who visited a clinic in rural western Kenya. We collected swabs from controls without febrile or respiratory symptoms. We calculated odds ratios for infection among cases, adjusting for age and season in logistic regression. We calculated SARI incidence, adjusting for healthcare seeking for SARI in the community. Results: Two thousand nine hundred seventy-three SARI cases were identified (54% inpatient, 46% outpatient), yielding an adjusted incidence of 56 cases per 100 person-years. A pathogen was detected in 3.3% of non-contaminated blood cultures; non-typhi Salmonella (1.9%) and Streptococcus pneumoniae (0.7%) predominated. A pathogen was detected in 84% of nasopharyngeal/oropharyngeal specimens, the most common being rhino/enterovirus (50%), respiratory syncytial virus (RSV, 22%), adenovirus (16%) and influenza viruses (8%). Only RSV and influenza viruses were found more commonly among cases than controls (odds ratio 2.9, 95% confidence interval: 1.3-6.7 and odds ratio 4.8, 95% confidence interval: 1.1-21, respectively). Incidence of RSV, influenza viruses and S. pneumoniae were 7.1, 5.8 and 0.04 cases per 100 person-years, respectively. Conclusions: Among Kenyan children with SARI, RSV and influenza virus are the most likely viral causes and pneumococcus the most likely bacterial cause. Contemporaneous controls are important for interpreting upper respiratory tract specimens. C1 [Feikin, Daniel R.; Njenga, M. Kariuki; Bigogo, Godfrey; Aura, Barrack; Aol, George; Audi, Allan; Jagero, Geoffrey; Muluare, Peter O.; Gikunju, Stella; Nderitu, Leonard; Katz, Mark A.; Breiman, Robert F.] Kenya Govt Med Res Ctr, Ctr Dis Control & Prevent, Publ Hlth & Res Collaborat, Kisumu, Kenya. [Winchell, Jonas M.; Schneider, Eileen; Erdman, Dean D.; Oberste, M. Steven; Katz, Mark A.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Feikin, DR (reprint author), Johns Hopkins Sch Publ Hlth, 615 N Wolfe St,Suite 600, Baltimore, MD 21205 USA. EM dfeikin@jhsph.edu FU core funding of the International Emerging Infections Program of Centers for Disease Control and Prevention, Atlanta, GA FX The funding for this project is from core funding of the International Emerging Infections Program of Centers for Disease Control and Prevention, Atlanta, GA. The authors have no other funding or conflicts of interest to disclose. NR 53 TC 31 Z9 31 U1 0 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD JAN PY 2013 VL 32 IS 1 BP E14 EP E19 DI 10.1097/INF.0b013e31826fd39b PG 6 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 062FC UT WOS:000312903600003 PM 22914561 ER PT J AU Kucik, JE Shin, M Siffel, C Marengo, L Correa, A AF Kucik, James E. Shin, Mikyong Siffel, Csaba Marengo, Lisa Correa, Adolfo CA Congenital Anomaly Multistate TI Trends in Survival Among Children With Down Syndrome in 10 Regions of the United States SO PEDIATRICS LA English DT Article DE Down syndrome; survival; mortality; congenital heart defects; epidemiology; low birth weight; population-based; racial disparities ID CONGENITAL HEART-DEFECTS; PRENATAL-DIAGNOSIS; BIRTH-DEFECTS; METROPOLITAN ATLANTA; PARENTAL DECISIONS; INFANTS BORN; POPULATION; PREVALENCE; MORTALITY; DEATH AB OBJECTIVE: This study examined changes in survival among children with Down syndrome (DS) by race/ethnicity in 10 regions of the United States. A retrospective cohort study was conducted on 16 506 infants with DS delivered during 1983-2003 and identified by 10 US birth defects monitoring programs. Kaplan-Meier survival probabilities were estimated by select demographic and clinical characteristics. Adjusted hazard ratios (aHR) were estimated for maternal and infant characteristics by using Cox proportional hazard models. RESULTS: The overall 1-month and 1-, 5-, and 20-year survival probabilities were 98%, 93%, 91%, and 88%, respectively. Over the study period, neonatal survival did not improve appreciably, but survival at all other ages improved modestly. Infants of very low birth weight had 24 times the risk of dying in the neonatal period compared with infants of normal birth weight (aHR 23.8; 95% confidence interval [CI] 18.4-30.7). Presence of a heart defect increased the risk of death in the postneonatal period nearly fivefold (aHR 4.6; 95% CI 3.9-5.4) and continued to be one of the most significant predictors of mortality through to age 20. The postneonatal aHR among non-Hispanic blacks was 1.4 (95% CI 1.2-1.8) compared with non-Hispanic whites and remained elevated by age 10 (2.0; 95% CI 1.0-4.0). CONCLUSIONS: The survival of children born with DS has improved and racial disparities in infant survival have narrowed. However, compared with non-Hispanic white children, non-Hispanic black children have lower survival beyond infancy. Congenital heart defects are a significant risk factor for mortality through age twenty. Pediatrics 2013;131:e27-e36 C1 [Kucik, James E.; Shin, Mikyong; Siffel, Csaba; Correa, Adolfo] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Shin, Mikyong] Ctr Dis Control & Prevent, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Shin, Mikyong] Res Triangle Inst Int, Atlanta, GA USA. [Marengo, Lisa] Texas Dept State Hlth Serv, Austin, TX USA. [Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA. RP Kucik, JE (reprint author), Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS E-86, Atlanta, GA 30333 USA. EM jkucik@cdc.gov FU Canadian Institutes of Health Research [PCR101415, MOP 97962]; Intramural CDC HHS [CC999999] NR 40 TC 18 Z9 20 U1 0 U2 5 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD JAN PY 2013 VL 131 IS 1 BP E27 EP E36 DI 10.1542/peds.2012-1616 PG 10 WC Pediatrics SC Pediatrics GA 063PO UT WOS:000313012400004 PM 23248222 ER PT J AU Anderson, JL Apostoaei, AI Thomas, BA AF Anderson, Jeri L. Apostoaei, A. Iulian Thomas, Brian A. TI Estimation of internal exposure to uranium with uncertainty from urinalysis data using the InDEP computer code SO RADIATION PROTECTION DOSIMETRY LA English DT Article ID RESPIRATORY-TRACT MODEL; PARAMETER UNCERTAINTIES; DOSE COEFFICIENTS; CANCER-RISK; WORKERS; MORTALITY; RADIONUCLIDES; VARIABILITY; RELIABILITY; PLUTONIUM AB The National Institute for Occupational Safety and Health (NIOSH) is currently studying mortality in a cohort of 6409 workers at a former uranium processing facility. As part of this study, over 220 000 urine samples were used to reconstruct organ doses due to internal exposure to uranium. Most of the available computational programs designed for analysis of bioassay data handle a single case at a time, and thus require a significant outlay of time and resources for the exposure assessment of a large cohort. NIOSH is currently supporting the development of a computer program, InDEP (Internal Dose Evaluation Program), to facilitate internal radiation exposure assessment as part of epidemiological studies of both uranium- and plutonium-exposed cohorts. A novel feature of InDEP is its batch processing capability which allows for the evaluation of multiple study subjects simultaneously. InDEP analyses bioassay data and derives intakes and organ doses with uncertainty estimates using least-squares regression techniques or using the Bayes' Theorem as applied to internal dosimetry (Bayesian method). This paper describes the application of the current version of InDEP to formulate assumptions about the characteristics of exposure at the study facility that were used in a detailed retrospective intake and organ dose assessment of the cohort. C1 [Anderson, Jeri L.] NIOSH, DSHEFS, Cincinnati, OH 45226 USA. [Apostoaei, A. Iulian; Thomas, Brian A.] SENES Oak Ridge Inc, Ctr Risk Anal, Oak Ridge, TN 37830 USA. RP Anderson, JL (reprint author), NIOSH, DSHEFS, Cincinnati, OH 45226 USA. EM jlanderson@cdc.gov FU DOE; U.S. Department of Energy (DOE); U.S. Department of Health and Human Services (DHHS) FX This work was made possible by the cooperation and support of the DOE and its employees and contractors.; This work was supported through an agreement between the U.S. Department of Energy (DOE) and the U.S. Department of Health and Human Services (DHHS). NR 30 TC 2 Z9 2 U1 0 U2 7 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0144-8420 J9 RADIAT PROT DOSIM JI Radiat. Prot. Dosim. PD JAN PY 2013 VL 153 IS 1 BP 64 EP 73 DI 10.1093/rpd/ncs097 PG 10 WC Environmental Sciences; Public, Environmental & Occupational Health; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging GA 061WV UT WOS:000312881800006 PM 22683620 ER PT J AU Schieb, LJ Mobley, LR George, M Casper, M AF Schieb, Linda J. Mobley, Lee R. George, Mary Casper, Michele TI Tracking Stroke Hospitalization Clusters Over Time and Associations With County-Level Socioeconomic and Healthcare Characteristics SO STROKE LA English DT Article DE acute stroke; epidemiology; geography; hospitalization; Medicare; risk factors ID BRAIN ATTACK SURVEILLANCE; UNITED-STATES; GEOGRAPHIC-DISTRIBUTION; NORTHERN MANHATTAN; ISCHEMIC-STROKE; RISK-FACTORS; RECURRENT STROKE; MORTALITY; NEIGHBORHOOD; DISEASE AB Background and Purpose-This study evaluated clustering of stroke hospitalization rates, patterns of the clustering over time, and associations with community-level characteristics. Methods-We used Medicare hospital claims data from 1995-1996 to 2005-2006 with a principal discharge diagnosis of stroke to calculate county-level stroke hospitalization rates. We identified statistically significant clusters of high- and low-rate counties by using local indicators of spatial association, tracked cluster status over time, and assessed associations between cluster status and county-level socioeconomic and healthcare profiles. Results-Clearly defined clusters of counties with high-and low-stroke hospitalization rates were identified in each time. Approximately 75% of counties maintained their cluster status from 1995-1996 to 2005-2006. In addition, 243 counties transitioned into high-rate clusters, and 148 transitioned out of high-rate clusters. Persistently high-rate clusters were located primarily in the Southeast, whereas persistently low-rate clusters occurred mostly in New England and in the West. In general, persistently low-rate counties had the most favorable socioeconomic and healthcare profiles, followed by counties that transitioned out of or into high-rate clusters. Persistently high-rate counties experienced the least favorable socioeconomic and healthcare profiles. Conclusions-The persistence of clusters of high-and low-stroke hospitalization rates during a 10-year period suggests that the underlying causes of stroke in these areas have also persisted. The associations found between cluster status (persistently high, transitional, persistently low) and socioeconomic and healthcare profiles shed new light on the contributions of community-level characteristics to geographic disparities in stroke hospitalizations. (Stroke. 2013;44:146-152.) C1 [Schieb, Linda J.; George, Mary; Casper, Michele] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30341 USA. [Mobley, Lee R.] Arizona State Univ, Tempe, AZ USA. RP Schieb, LJ (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, 4770 Buford Highway NE,MS F-72, Atlanta, GA 30341 USA. EM lschieb@cdc.gov FU Intramural CDC HHS [CC999999] NR 45 TC 6 Z9 6 U1 1 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD JAN PY 2013 VL 44 IS 1 BP 146 EP U255 DI 10.1161/STROKEAHA.112.669705 PG 11 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 061XP UT WOS:000312883800025 PM 23192758 ER PT J AU Regan, AK Promoff, G Dube, SR Arrazola, R AF Regan, Annette K. Promoff, Gabbi Dube, Shanta R. Arrazola, Rene TI Electronic nicotine delivery systems: adult use and awareness of the 'e-cigarette' in the USA SO TOBACCO CONTROL LA English DT Article ID SMOKING AB Background Electronic nicotine delivery systems (ENDS), also referred to as electronic cigarettes or e-cigarettes, were introduced into the US market in 2007. Despite concerns regarding the long-term health impact of this product, there is little known about awareness and use of ENDS among adults in the USA. Methods A consumer-based mail-in survey (ConsumerStyles) was completed by 10587 adults (>= 18 years) in 2009 and 10328 adults in 2010. Data from these surveys were used to monitor awareness, ever use and past month use of ENDS from 2009 to 2010 and to assess demographic characteristics and tobacco use of ENDS users. Results In this US sample, awareness of ENDS doubled from 16.4% in 2009 to 32.2% in 2010 and ever use more than quadrupled from 2009 (0.6%) to 2010 (2.7%). Ever use of ENDS was most common among women and those with lower education, although these were not the groups who had heard of ENDS most often. Current smokers and tobacco users were most likely to try ENDS. However, current smokers who had tried ENDS did not say they planned to quit smoking more often than smokers who had never tried them. Conclusions Given the large increase in awareness and ever use of ENDS during this 1-year period and the unknown impact of ENDS use on cigarette smoking behaviours and long-term health, continued monitoring of these products is needed. C1 [Regan, Annette K.; Promoff, Gabbi; Dube, Shanta R.; Arrazola, Rene] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Promoff, G (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,MS K50, Atlanta, GA 30341 USA. EM gpromoff@cdc.gov OI Regan, Annette/0000-0002-3879-6193 NR 24 TC 209 Z9 211 U1 3 U2 62 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0964-4563 J9 TOB CONTROL JI Tob. Control PD JAN PY 2013 VL 22 IS 1 BP 19 EP 23 DI 10.1136/tobaccocontrol-2011-050044 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 056JA UT WOS:000312483100014 PM 22034071 ER PT J AU Zendejas-Ruiz, IR Gupte, AA Schain, DC Chung, WK Kulkarni, RD Eckhoff, DE Tallaj, JA Lea, AS White, C Casey, MJ da Silva, AJ Paddock, CD Blau, DM Zaki, SR Roy, SL Visvesvara, GS Hocevar, SN Mbaey, CM Baddley, JW AF Zendejas-Ruiz, Ivan R. Gupte, Asmita A. Schain, Denise C. Chung, Won K. Kulkarni, Rupak D. Eckhoff, Devin E. Tallaj, Jose A. Lea, Alfred S. White, Clinton, Jr. Casey, Michael J. da Silva, Alexandre J. Paddock, Christopher D. Blau, Dianna M. Zaki, Sherif R. Roy, Sharon L. Visvesvara, Govinda S. Hocevar, Susan N. Mbaey, Chukwuma M. Baddley, John W. TI Balamuthia mandrillaris: An Emerging Pathogen in Transplantation SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT 13th Annual State of the Art Winter Symposium of the American-Society-of-Transplant-Surgeons (ASTS) Held in Conjunction with the NATCO Symposium for Advanced Transplant Professionals CY JAN 31-FEB 03, 2013 CL Miami, FL SP Amer Soc Transplant Surg (ASTS), NATCO C1 [Zendejas-Ruiz, Ivan R.; Gupte, Asmita A.; Schain, Denise C.; Kulkarni, Rupak D.; Casey, Michael J.] Univ Florida, Gainesville, FL 32610 USA. [Eckhoff, Devin E.; Tallaj, Jose A.; Baddley, John W.] Univ Alabama Birmingham, Birmingham, AL USA. [Chung, Won K.; Lea, Alfred S.; White, Clinton, Jr.] Univ Texas Med Branch, Galveston, TX USA. [da Silva, Alexandre J.; Paddock, Christopher D.; Blau, Dianna M.; Zaki, Sherif R.; Roy, Sharon L.; Visvesvara, Govinda S.; Hocevar, Susan N.; Mbaey, Chukwuma M.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 2 Z9 2 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JAN PY 2013 VL 13 SU 2 SI SI BP 98 EP 98 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 057CT UT WOS:000312540200136 ER PT J AU Gaul, LK Farag, NH Shim, T Kingsley, MA Silk, BJ Hyytia-Trees, E AF Gaul, Linda Knudson Farag, Noha H. Shim, Trudi Kingsley, Monica A. Silk, Benjamin J. Hyytia-Trees, Eija TI Hospital-Acquired Listeriosis Outbreak Caused by Contaminated Diced Celery-Texas, 2010 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE listeriosis; disease outbreak; hospital infections; food contamination; immunocompromised patient ID FRESH PRODUCE; MONOCYTOGENES INFECTION; UNITED-STATES; ELECTROPHORESIS; CLUSTER AB Background. Listeria monocytogenes causes often-fatal infections affecting mainly immunocompromised persons. Sources of hospital-acquired listeriosis outbreaks can be difficult to identify. We investigated a listeriosis outbreak spanning 7 months and involving 5 hospitals. Methods. Outbreak-related cases were identified by pulsed-field gel electrophoresis (PFGE) and confirmed by multiple-locus variable-number tandem-repeat analysis (MLVA). We conducted patient interviews, medical records reviews, and hospital food source evaluations. Food and environmental specimens were collected at a hospital (hospital A) where 6 patients had been admitted before listeriosis onset; these specimens were tested by culture, polymerase chain reaction (PCR), and PFGE. We collected and tested food and environmental samples at the implicated processing facility. Results. Ten outbreak-related patients were immunocompromised by >= 1 underlying conditions or treatments; 5 died. All patients had been admitted to or visited an acute-care hospital during their possible incubation periods. The outbreak strain of L. monocytogenes was isolated from chicken salad and its diced celery ingredient at hospital A, and in 19 of >200 swabs of multiple surfaces and in 8 of 11 diced celery products at the processing plant. PCR testing detected Listeria in only 3 of 10 environmental and food samples from which it was isolated by culturing. The facility was closed, products were recalled, and the outbreak ended. Conclusions. Contaminated diced celery caused a baffling, lengthy outbreak of hospital-acquired listeriosis. PCR testing often failed to detect the pathogen, suggesting its reliability should be further evaluated. Listeriosis risk should be considered in fresh produce selections for immunocompromised patients. C1 [Gaul, Linda Knudson] Texas Dept State Hlth Serv, Emerging & Acute Infect Dis Branch, Austin, TX 78756 USA. [Farag, Noha H.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Shim, Trudi] Texas Dept State Hlth Serv, San Antonio, TX USA. [Silk, Benjamin J.] Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Atlanta, GA USA. [Hyytia-Trees, Eija] Ctr Dis Control & Prevent, Enter Dis Lab Branch, Atlanta, GA USA. RP Gaul, LK (reprint author), Texas Dept State Hlth Serv, Emerging & Acute Infect Dis Branch, 1100 W 49th St, Austin, TX 78756 USA. EM linda.gaul@dshs.state.tx.us NR 30 TC 34 Z9 34 U1 2 U2 20 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2013 VL 56 IS 1 BP 20 EP 26 DI 10.1093/cid/cis817 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 058AE UT WOS:000312605500007 PM 22997210 ER PT J AU McDonald, LC Arduino, M AF McDonald, L. Clifford Arduino, Matthew TI Climbing the Evidentiary Hierarchy for Environmental Infection Control SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material ID HYDROGEN-PEROXIDE VAPOR; PRIOR ROOM OCCUPANTS; INTENSIVE-CARE-UNIT; CLOSTRIDIUM-DIFFICILE; DECONTAMINATION; RISK; CONTAMINATION; ACQUISITION C1 [McDonald, L. Clifford; Arduino, Matthew] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. RP McDonald, LC (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS07, Atlanta, GA 30333 USA. EM cmcdonald1@cdc.gov NR 11 TC 15 Z9 15 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2013 VL 56 IS 1 BP 36 EP 39 DI 10.1093/cid/cis845 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 058AE UT WOS:000312605500009 PM 23042965 ER PT J AU Moorman, AC Gordon, SC Rupp, LB Spradling, PR Teshale, EH Lu, M Nerenz, DR Nakasato, CC Boscarino, JA Henkle, EM Oja-Tebbe, NJ Xing, J Ward, JW Holmberg, SD AF Moorman, Anne C. Gordon, Stuart C. Rupp, Loralee B. Spradling, Philip R. Teshale, Eyasu H. Lu, Mei Nerenz, David R. Nakasato, Cynthia C. Boscarino, Joseph A. Henkle, Emily M. Oja-Tebbe, Nancy J. Xing, Jian Ward, John W. Holmberg, Scott D. CA Chronic Hepatitis Cohort Study Inv TI Baseline Characteristics and Mortality Among People in Care for Chronic Viral Hepatitis: The Chronic Hepatitis Cohort Study SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE HBV; HCV; cohort ID C VIRUS-INFECTION; UNITED-STATES; PREVALENCE AB Background. The Chronic Hepatitis Cohort Study (CHeCS), a dynamic prospective, longitudinal, observational cohort study, was created to assess the clinical impact of chronic viral hepatitis in the United States. This report describes the cohort selection process, baseline demographics, and insurance, biopsy, hospitalization, and mortality rates. Methods. Electronic health records of >1.6 million adult patients seen from January 2006 through December 2010 at 4 integrated healthcare systems in Detroit, Michigan; Danville, Pennsylvania; Portland, Oregon; and Honolulu, Hawaii were collected and analyzed. Results. Of 2202 patients with chronic hepatitis B virus (HBV) infection, 50% were aged 44-63 years, 57% male, 58% Asian/Pacific Islander, and 13% black; and 5.1% had Medicaid, 16.5% Medicare, and 76.3% private insurance. During 2001-2010, 22.3% had a liver biopsy and 37.9% were hospitalized. For the 8810 patients with chronic hepatitis C virus (HCV) infection, 75% were aged 44-63 years, 60% male, 23% black; and 12% had Medicaid, 23% Medicare, and 62% private insurance. During 2001-2010, 38.4% had a liver biopsy and 44.3% were hospitalized. Among persons in care, 9% of persons with HBV and 14% of persons with HCV infection, mainly those born during 1945-1964, died during the 2006-2010 five-year period. Conclusions. Baseline demographic, hospitalization, and mortality data from CHeCS highlight the substantial US health burden from chronic viral hepatitis, particularly among persons born during 1945-1964. C1 [Moorman, Anne C.; Spradling, Philip R.; Teshale, Eyasu H.; Xing, Jian; Ward, John W.; Holmberg, Scott D.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Gordon, Stuart C.; Rupp, Loralee B.; Lu, Mei; Nerenz, David R.; Henkle, Emily M.; Oja-Tebbe, Nancy J.] Henry Ford Hlth Syst, Detroit, MI USA. [Nakasato, Cynthia C.] Kaiser Permanente Hawaii, Honolulu, HI USA. [Boscarino, Joseph A.] Geisinger Hlth Syst, Danville, PA USA. Kaiser Permanente NW, Ctr Hlth Res, Portland, OR USA. RP Moorman, AC (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV Hepatitis STD & TB Prevent, Mailstop G37,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM amoorman@cdc.gov FU CDC Foundation; Abbott Laboratories; Abbott Pharmaceuticals; Anadys Pharmaceuticals; Bristol-Myers Squibb; Conatus; Eiger Biopharmaceuticals; Exalenz BioScience; Gilead Pharmaceuticals; GlaxoSmithKline; GlobeImmune; Intercept Pharmaceuticals; Merck; Roche Pharmaceuticals; Tibotec; Vertex Pharmaceuticals; Zymogenetics FX CHeCS was funded by the CDC Foundation, which received grants from Abbott Laboratories; Genentech, a member of the Roche Group; Janssen Pharmaceutical Companies of Johnson & Johnson; and Vertex Pharmaceuticals.; S. C. G. has received grant/research support from Abbott Pharmaceuticals, Anadys Pharmaceuticals, Bristol-Myers Squibb, Conatus, Eiger Biopharmaceuticals, Exalenz BioScience, Gilead Pharmaceuticals, GlaxoSmithKline, GlobeImmune, Intercept Pharmaceuticals, Merck, Roche Pharmaceuticals, Tibotec, Vertex Pharmaceuticals, and Zymogenetics; has served as a consultant for Achillion, Bristol-Myers Squibb, CVS Caremark, Gilead Pharmaceuticals, Merck, Salix Pharmaceuticals, Johnson & Johnson, and Vertex; has served on the data monitoring board for Tibotec; and has served as a speaker for Bayer, Gilead, Roche, Merck, and Vertex. J. A. B. has consulted for Pfizer and Janssen. All other authors report no potential conflicts. NR 13 TC 70 Z9 70 U1 1 U2 13 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2013 VL 56 IS 1 BP 40 EP 50 DI 10.1093/cid/cis815 PG 11 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 058AE UT WOS:000312605500010 PM 22990852 ER PT J AU Hoover, KW Tao, GY Nye, MB Body, BA AF Hoover, Karen W. Tao, Guoyu Nye, Melinda B. Body, Barbara A. TI Suboptimal Adherence to Repeat Testing Recommendations for Men and Women With Positive Chlamydia Tests in the United States, 2008-2010 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE chlamydia; testing; retesting; positivity ID SEXUALLY-TRANSMITTED-DISEASES; PELVIC-INFLAMMATORY-DISEASE; TRACHOMATIS INFECTION; YOUNG-WOMEN; PERSISTENT; GUIDELINES; GONORRHEA; THERAPY; CLINICS; COHORT AB Background. Chlamydia is prevalent among young persons in the United States. Infected persons have a high prevalence of infection several months later, most likely from reinfection. Retesting of all men and women with a positive test is recommended 3 months after treatment. A test-of-cure is recommended for pregnant women 3-4 weeks after treatment. Methods. We analyzed 2008-2010 chlamydia testing data from a large US laboratory to estimate test positivity by patient demographic characteristics and diagnoses, and patterns of repeat testing of men and nonpregnant women with a positive test and tests-of-cures of pregnant women with a positive test. Results. During the study period, 7.0% of 0.40 million tests performed in men and 4.0% of 2.92 million tests performed in women were positive. Among young women, positivity rates were highest among those aged 15-19 years, ranging from 8.5% to 10.0%. Retesting rates of persons with a positive test were suboptimal, with 22.3% of men and 38.0% of nonpregnant women retested. Although 60.1% of pregnant women with a positive test were retested, only 22.0% received a test-of-cure within the 4-week recommended time frame. Repeat tests were positive in 15.9% of men, 14.2% of nonpregnant women, and 15.4% of pregnant women. Conclusions. Analyses of laboratory testing data provided important insights into chlamydia testing, retesting, and positivity among a diverse US population of men and women. Too few persons were retested as recommended, and interventions are needed to increase both healthcare provider and patient adherence to recommendations for retesting men and women with positive tests. C1 [Hoover, Karen W.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div STD Prevent, Atlanta, GA 30333 USA. [Nye, Melinda B.; Body, Barbara A.] Lab Corp Amer Holdings, Burlington, NC USA. RP Hoover, KW (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div STD Prevent, 1600 Clifton Rd NE,MS E-80, Atlanta, GA 30333 USA. EM khoover@cdc.gov FU Centers for Disease Control and Prevention FX This work was supported by the Centers for Disease Control and Prevention. NR 34 TC 17 Z9 18 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2013 VL 56 IS 1 BP 51 EP 57 DI 10.1093/cid/cis771 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 058AE UT WOS:000312605500011 PM 23074316 ER PT J AU Hudgens, MG Taha, TE Omer, SB Jamieson, DJ Lee, H Mofenson, LM Chasela, C Kourtis, AP Kumwenda, N Ruff, A Bedri, A Jackson, JB Musoke, P Bollinger, RC Gupte, N Thigpen, MC Taylor, A van der Horst, C AF Hudgens, Michael G. Taha, Taha E. Omer, Saad B. Jamieson, Denise J. Lee, Hana Mofenson, Lynne M. Chasela, Charles Kourtis, Athena P. Kumwenda, Newton Ruff, Andrea Bedri, Abubaker Jackson, J. Brooks Musoke, Philippa Bollinger, Robert C. Gupte, Nikhil Thigpen, Michael C. Taylor, Allan van der Horst, Charles TI Pooled Individual Data Analysis of 5 Randomized Trials of Infant Nevirapine Prophylaxis to Prevent Breast-Milk HIV-1 Transmission SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE breast milk; HIV; nevirapine ID TO-CHILD TRANSMISSION; DOSE NEVIRAPINE; MORTALITY; BOTSWANA; MOTHERS; ZIDOVUDINE; INFECTION; PREGNANCY; DIARRHEA; BORN AB Background. In resource-limited settings, mothers infected with human immunodeficiency virus type 1 (HIV-1) face a difficult choice: breastfeed their infants but risk transmitting HIV-1 or not breastfeed their infants and risk the infants dying of other infectious diseases or malnutrition. Recent results from observational studies and randomized clinical trials indicate daily administration of nevirapine to the infant can prevent breast-milk HIV-1 transmission. Methods. Data from 5396 mother-infant pairs who participated in 5 randomized trials where the infant was HIV-1 negative at birth were pooled to estimate the efficacy of infant nevirapine prophylaxis to prevent breast-milk HIV-1 transmission. Four daily regimens were compared: nevirapine for 6 weeks, 14 weeks, or 28 weeks, or nevirapine plus zidovudine for 14 weeks. Results. The estimated 28-week risk of HIV-1 transmission was 5.8% (95% confidence interval [CI], 4.3%-7.9%) for the 6-week nevirapine regimen, 3.7% (95% CI, 2.5%-5.4%) for the 14-week nevirapine regimen, 4.8% (95% CI, 3.5%-6.7%) for the 14-week nevirapine plus zidovudine regimen, and 1.8% (95% CI, 1.0%-3.1%) for the 28-week nevirapine regimen (log-rank test for trend, P<.001). Cox regression models with nevirapine as a time-varying covariate, stratified by trial site and adjusted for maternal CD4 cell count and infant birth weight, indicated that nevirapine reduces the rate of HIV-1 infection by 71% (95% CI, 58%-80%; P<.001) and reduces the rate of HIV infection or death by 58% (95% CI, 45%-69%; P<.001). Conclusions. Extended prophylaxis with nevirapine or with nevirapine and zidovudine significantly reduces postnatal HIV-1 infection. Longer duration of prophylaxis results in a greater reduction in the risk of infection. C1 [Hudgens, Michael G.; Lee, Hana; van der Horst, Charles] Univ N Carolina, Chapel Hill, NC 27599 USA. [Taha, Taha E.; Kumwenda, Newton; Ruff, Andrea; Jackson, J. Brooks; Bollinger, Robert C.; Gupte, Nikhil] Johns Hopkins Univ, Baltimore, MD USA. [Omer, Saad B.] Emory Univ, Atlanta, GA 30322 USA. [Jamieson, Denise J.; Kourtis, Athena P.; Thigpen, Michael C.; Taylor, Allan] Ctr Dis Control & Prevent, Atlanta, GA USA. [Mofenson, Lynne M.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Rockville, MD USA. [Chasela, Charles] Univ N Carolina Project, Lilongwe, Malawi. [Bedri, Abubaker] Univ Addis Ababa, Addis Ababa, Ethiopia. [Musoke, Philippa] Makerere Univ Johns Hopkins Univ Res Collaborat, Kampala, Uganda. [Musoke, Philippa] Makerere Univ, Kampala, Uganda. RP Hudgens, MG (reprint author), Univ N Carolina, CB 7420,McGavran Greenberg Hall, Chapel Hill, NC 27599 USA. EM mhudgens@bios.unc.edu OI Mofenson, Lynne/0000-0002-2818-9808 FU Prevention Research Centers Special Interest Project of the CDC [SIP 13-01 U48-CCU409660-09, SIP 26-04 U48-DP000059-01, SIP 22-09 U48-DP001944]; National Institute of Allergy and Infectious Diseases (NIAID); University of North Carolina Center for AIDS Research [P30-AI50410]; NIH Fogarty AIDS International Training and Research Program (DHHS/NIH/FIC) [5-D43 TW001039, 5-R24 TW007988]; Abbott Laboratories; GlaxoSmithKline; Boehringer Ingelheim; Roche Pharmaceuticals; Bristol-Myers Squibb; Elizabeth Glaser Pediatric AIDS Foundation; United Nations Children's Fund; World Food Program; Malawi Ministry of Health and Population; Johnson Johnson; US Agency for International Development; NIH, NIAID [R01AI45462, R01AI3857601A, R01AI34235]; NIH Fogarty International Center NIH Program of International Training [D43-TW0000]; CDC [5 U50 PS022061-05, U50/CC0222061]; Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH; NIH FX The Breastfeeding, Antiretrovirals and Nutrition (BAN) study was supported by the Prevention Research Centers Special Interest Project of the CDC (SIP 13-01 U48-CCU409660-09, SIP 26-04 U48-DP000059-01, and SIP 22-09 U48-DP001944), the National Institute of Allergy and Infectious Diseases (NIAID), the University of North Carolina Center for AIDS Research (P30-AI50410), the NIH Fogarty AIDS International Training and Research Program (DHHS/NIH/FIC 5-D43 TW001039 and 5-R24 TW007988), Abbott Laboratories, GlaxoSmithKline, Boehringer Ingelheim, Roche Pharmaceuticals, Bristol-Myers Squibb, the Elizabeth Glaser Pediatric AIDS Foundation, the United Nations Children's Fund, the World Food Program, the Malawi Ministry of Health and Population, Johnson & Johnson, and the US Agency for International Development. The SWEN study was supported by grants from the NIH, NIAID (R01AI45462, R01AI3857601A, R01AI34235) and the NIH Fogarty International Center NIH Program of International Training Grants in Epidemiology Related to AIDS (D43-TW0000). The PEPI study was supported by a Cooperative Agreement (5 U50 PS022061-05; award U50/CC0222061) from the CDC and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH. The CDC and NIH were sponsors of the studies included in this pooled analysis.; During the follow-up phase of the BAN study, the University of North Carolina received cash grants from GlaxoSmithKline and Abbott Laboratories to conduct pharmacokinetic and resistance analysis substudies. In addition, GlaxoSmithKline, Abbott Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, and Roche Pharmaceuticals provided the study drugs. All authors: No reported conflicts. NR 22 TC 11 Z9 11 U1 1 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2013 VL 56 IS 1 BP 131 EP 139 DI 10.1093/cid/cis808 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 058AE UT WOS:000312605500025 PM 22997212 ER PT J AU von Karsa, L Patnick, J Segnan, N Atkin, W Halloran, S Lansdorp-Vogelaar, I Malila, N Minozzi, S Moss, S Quirke, P Steele, RJ Vieth, M Aabakken, L Altenhofen, L Ancelle-Park, R Antoljak, N Anttila, A Armaroli, P Arrossi, S Austoker, J Banzi, R Bellisario, C Blom, J Brenner, H Bretthauer, M Cancela, MC Costamagna, G Cuzick, J Dai, M Daniel, J Dekker, E Delicata, N Ducarroz, S Erfkamp, H Espinas, JA Faivre, J Wood, LF Flugelman, A Frkovic-Grazio, S Geller, B Giordano, L Grazzini, G Green, J Hamashima, C Herrmann, C Hewitson, P Hoff, G Holten, I Jover, R Kaminski, MF Kuipers, EJ Kurtinaitis, J Lambert, R Launoy, G Lee, W Leicester, R Leja, M Lieberman, D Lignini, T Lucas, E Lynge, E Madai, S Marinho, J Zakotnik, JM Minoli, G Monk, C Morais, A Muwonge, R Nadel, M Neamtiu, L Tuser, MP Pignone, M Pox, C Primic-Zakelj, M Psaila, J Rabeneck, L Ransohoff, D Rasmussen, M Regula, J Ren, J Rennert, G Rey, J Riddell, RH Risio, M Rodrigues, V Saito, H Sauvaget, C Scharpantgen, A Schmiegel, W Senore, C Siddiqi, M Sighoko, D Smith, R Smith, S Suchanek, S Suonio, E Tong, W Tornberg, S Van Cutsem, E Vignatelli, L Villain, P Voti, L Watanabe, H Watson, J Winawer, S Young, G Zaksas, V Zappa, M Valori, R AF von Karsa, L. Patnick, J. Segnan, N. Atkin, W. Halloran, S. Lansdorp-Vogelaar, I. Malila, N. Minozzi, S. Moss, S. Quirke, P. Steele, R. J. Vieth, M. Aabakken, L. Altenhofen, L. Ancelle-Park, R. Antoljak, N. Anttila, A. Armaroli, P. Arrossi, S. Austoker, J. Banzi, R. Bellisario, C. Blom, J. Brenner, H. Bretthauer, M. Cancela, M. Camargo Costamagna, G. Cuzick, J. Dai, M. Daniel, J. Dekker, E. Delicata, N. Ducarroz, S. Erfkamp, H. Espinas, J. A. Faivre, J. Wood, L. Faulds Flugelman, A. Frkovic-Grazio, S. Geller, B. Giordano, L. Grazzini, G. Green, J. Hamashima, C. Herrmann, C. Hewitson, P. Hoff, G. Holten, I. Jover, R. Kaminski, M. F. Kuipers, E. J. Kurtinaitis, J. Lambert, R. Launoy, G. Lee, W. Leicester, R. Leja, M. Lieberman, D. Lignini, T. Lucas, E. Lynge, E. Madai, S. Marinho, J. Zakotnik, J. Maucec Minoli, G. Monk, C. Morais, A. Muwonge, R. Nadel, M. Neamtiu, L. Tuser, M. Peris Pignone, M. Pox, C. Primic-Zakelj, M. Psaila, J. Rabeneck, L. Ransohoff, D. Rasmussen, M. Regula, J. Ren, J. Rennert, G. Rey, J. Riddell, R. H. Risio, M. Rodrigues, V. Saito, H. Sauvaget, C. Scharpantgen, A. Schmiegel, W. Senore, C. Siddiqi, M. Sighoko, D. Smith, R. Smith, S. Suchanek, S. Suonio, E. Tong, W. Tornberg, S. Van Cutsem, E. Vignatelli, L. Villain, P. Voti, L. Watanabe, H. Watson, J. Winawer, S. Young, G. Zaksas, V. Zappa, M. Valori, R. TI European guidelines for quality assurance in colorectal cancer screening and diagnosis: Overview and introduction to the full Supplement publication SO ENDOSCOPY LA English DT Article ID FECAL-OCCULT-BLOOD; CLINICAL-PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIAL; PREVENTIVE SERVICES; AMERICAN-COLLEGE; COLONOSCOPY; RECOMMENDATIONS; SURVEILLANCE; PREVALENCE; NEOPLASMS AB Population-based screening for early detection and treatment of colorectal cancer (CRC) and precursor lesions, using evidence-based methods, can be effective in populations with a significant burden of the disease provided the services are of high quality. Multidisciplinary, evidence-based guidelines for quality assurance in CRC screening and diagnosis have been developed by experts in a project co-financed by the European Union. The 450-page guidelines were published in book format by the European Commission in 2010. They include 10 chapters and over 250 recommendations, individually graded according to the strength of the recommendation and the supporting evidence. Adoption of the recommendations can improve and maintain the quality and effectiveness of an entire screening process, including identification and invitation of the target population, diagnosis and management of the disease and appropriate surveillance in people with detected lesions. To make the principles, recommendations and standards in the guidelines known to a wider professional and scientific community and to facilitate their use in the scientific literature, the original content is presented in journal format in an open-access Supplement of Endoscopy. The editors have prepared the present overview to inform readers of the comprehensive scope and content of the guidelines. C1 [von Karsa, L.] Int Agcy Res Canc, Qual Assurance Grp, Early Detect & Prevent Sect, F-69372 Lyon 08, France. [Patnick, J.] NHS Canc Screening Programmes Sheffield, Sheffield, S Yorkshire, England. [Patnick, J.] Univ Oxford, Canc Screening Res Unit, Canc Epidemiol Unit, Oxford, England. [Segnan, N.; Minozzi, S.; Armaroli, P.; Bellisario, C.; Giordano, L.; Senore, C.] AO Citta Salute & Sci Torino, CPO Piemonte, Turin, Italy. [Atkin, W.] Univ London Imperial Coll Sci Technol & Med, London, England. [Halloran, S.] Royal Surrey Cty Hosp NHS Fdn Trust, Bowel Canc Screening So Programme Hub, Guildford, Surrey, England. [Halloran, S.] Univ Surrey, Guildford GU2 5XH, Surrey, England. [Lansdorp-Vogelaar, I.; Kuipers, E. J.] Erasmus MC, Rotterdam, Netherlands. [Malila, N.; Anttila, A.] Finnish Canc Registry, FIN-00170 Helsinki, Finland. [Moss, S.] Royal Canc Hosp, Inst Canc Res, Sutton, Surrey, England. [Quirke, P.] St James Univ Hosp, Leeds Inst Mol Med, Leeds LS9 7TF, W Yorkshire, England. [Steele, R. J.] Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland. [Vieth, M.] Klinikum Bayreuth, Inst Pathol, Bayreuth, Germany. [Aabakken, L.] Stavanger Univ Hosp, Dept Med Gastroenterol, Stavanger, Norway. [Altenhofen, L.] Cent Res Inst Ambulatory Hlth Care, Berlin, Germany. [Ancelle-Park, R.] Direct Gen Sante, Paris, France. [Antoljak, N.] Croatian Natl Inst Publ Hlth, Zagreb, Croatia. [Antoljak, N.] Univ Zagreb, Sch Med, Zagreb 41001, Croatia. [Arrossi, S.] Consejo Nacl Invest Cient & Tecn, CEDES, RA-1033 Buenos Aires, DF, Argentina. [Banzi, R.] Mario Negri Inst Pharmacol Res, Milan, Italy. [Blom, J.] Karolinska Inst, Stockholm, Sweden. [Brenner, H.] German Canc Res Ctr, D-6900 Heidelberg, Germany. [Bretthauer, M.] Univ Oslo, Inst Hlth & Soc, Oslo, Norway. [Cancela, M. Camargo] Natl Canc Registry, Cork, Ireland. [Cancela, M. Camargo; Daniel, J.; Herrmann, C.; Ren, J.; Sighoko, D.; Voti, L.] Int Agcy Res Canc, F-69372 Lyon, France. [Costamagna, G.] A Gemelli Univ Hosp, Rome, Italy. [Cuzick, J.] Queen Mary Univ London, Wolfson Inst Prevent Med, London, England. [Dai, M.] Chinese Acad Med Sci, Canc Inst & Hosp, Beijing 100730, Peoples R China. [Daniel, J.; Smith, R.] Amer Canc Soc, Atlanta, GA 30329 USA. [Dekker, E.] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands. [Delicata, N.; Psaila, J.] Minist Hlth Elderly & Community Care, Natl Hlth Screening Serv, Valletta, Malta. [Erfkamp, H.] Univ Appl Sci FH Joanneum, Graz, Austria. [Espinas, J. A.] Catalan Canc Strategy, Lhospitalet De Llobregat, Spain. [Faivre, J.] Univ Dijon, Digest Canc Registry Burgundy, INSERM, U866, F-21004 Dijon, France. [Wood, L. Faulds] Lynns Bowel Canc Campaign, Twickenham, England. [Flugelman, A.; Rennert, G.] Natl Israeli Breast & Colorectal Canc Detect, Haifa, Israel. [Frkovic-Grazio, S.] Univ Med Ctr Ljubljana, Dept Gynecol Pathol & Cytol, Ljubljana, Slovenia. [Geller, B.] Univ Vermont, Burlington, VT USA. [Grazzini, G.; Zappa, M.] Canc Prevent & Res Inst ISPO, Florence, Italy. [Hamashima, C.; Saito, H.] Natl Canc Ctr, Tokyo 104, Japan. [Herrmann, C.] Canc League Eastern Switzerland, St Gallen, Switzerland. [Hoff, G.] Canc Registry Norway, Oslo, Norway. [Hoff, G.] Telemark Hosp, Skien, Norway. [Holten, I.] Danish Canc Soc, Copenhagen, Denmark. [Jover, R.] Hosp Gen Univ Alicante, Alicante, Spain. [Kaminski, M. F.; Regula, J.] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland. [Kaminski, M. F.; Regula, J.] Med Ctr Postgrad Educ, Warsaw, Poland. [Kurtinaitis, J.] Lithuanian Canc Registry, Vilnius, Lithuania. [Launoy, G.] CHU Caen, INSERM, U1086, UCBN, Caen, France. [Lee, W.] Catholic Univ Korea, Coll Med, Seoul, South Korea. [Faivre, J.] CHU, Dijon, France. [Leicester, R.] St George Hosp, London, England. [Leja, M.] Univ Latvia, Riga, Latvia. [Lieberman, D.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Lynge, E.] Univ Copenhagen, Copenhagen, Denmark. [Madai, S.] MaMMa Healthcare Inst, Budapest, Hungary. [Marinho, J.] Hlth Adm Cent Reg Portugal, Aveiro, Portugal. [Zakotnik, J. Maucec] Natl Publ Hlth Inst, Ljubljana, Slovenia. [Minoli, G.] Valduce Hosp, Gastroenterol Unit, Como, Italy. [Monk, C.] GlaxoSmithKline Pharma Europe, London, England. [Morais, A.] Reg Hlth Adm, Coimbra, Portugal. [Nadel, M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Neamtiu, L.] Prof Dr Ion Chiricuta, Cluj Napoca, Romania. [Tuser, M. Peris] Catalan Inst Oncol, Lhospitalet De Llobregat, Spain. [Pignone, M.; Ransohoff, D.] Univ N Carolina, Chapel Hill, NC USA. [Pox, C.; Schmiegel, W.] Ruhr Univ Bochum, Bochum, Germany. [Primic-Zakelj, M.] Inst Oncol Ljubljana, Epidemiol & Canc Registry, Ljubljana, Slovenia. [Rabeneck, L.] Univ Toronto, Toronto, ON, Canada. [Rabeneck, L.] Canc Care Ontario, Toronto, ON, Canada. [Rasmussen, M.] Bispebjerg Hosp, Dept Dermatol, Copenhagen, Denmark. [Rey, J.] Inst Arnault Tzanck, St Laurent Du Var, France. [Riddell, R. H.] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada. [Risio, M.] Inst Canc Res & Treatment, Candiolo Torino, Italy. [Rodrigues, V.] Univ Coimbra, Fac Med, Coimbra, Portugal. [Scharpantgen, A.] Minist Hlth, Luxembourg, Luxembourg. [Siddiqi, M.] Canc Fdn India, Kolkata, India. [Sighoko, D.] Univ Chicago, Dept Med, Hematol Oncol Sect, Ctr Clin Canc Genet,Global Hlth, Chicago, IL 60637 USA. [Smith, S.] Univ Hosp Coventry & Warwickshire NHS Trust, Coventry, W Midlands, England. [Suchanek, S.] Charles Univ Prague, Prague, Czech Republic. [Suchanek, S.] Mil Univ Hosp, Prague, Czech Republic. [Tornberg, S.] Stockholm Gotland Reg Canc Ctr, Dept Canc Screening, Stockholm, Sweden. [Van Cutsem, E.] Katholieke Univ Leuven, Louvain, Belgium. [Vignatelli, L.] Agenzia Sanit & Sociale Reg Reg Emilia Romagna, Bologna, Italy. [Voti, L.] Univ Miami, Miami, FL USA. [Watanabe, H.] Niigata Univ, Niigata, Japan. [Winawer, S.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Young, G.] Flinders Univ S Australia, Gastrointestinal Serv, Adelaide, SA 5001, Australia. [Zaksas, V.] State Patient Fund, Vilnius, Lithuania. [Valori, R.] NHS Endoscopy, Leicester, Leics, England. RP von Karsa, L (reprint author), Int Agcy Res Canc, Qual Assurance Grp, Early Detect & Prevent Sect, 150 Cours Albert Thomas, F-69372 Lyon 08, France. EM karsal@iarc.fr RI De Camargo Cancela, Marianna/D-4053-2015; launoy, Guy/K-7372-2015; Muwonge, Richard/P-6375-2015; Grazzini, Grazia/K-8503-2016; Riddell, Robert/J-5557-2016; Brenner, Hermann/B-4627-2017; Suchanek, Stepan/E-1143-2017; OI Sauvaget, Catherine/0000-0002-8053-4963; Armaroli, Paola/0000-0001-8965-4307; Watson, Joanna/0000-0002-2532-2423; Senore, Carlo/0000-0003-1023-7477; Vignatelli, Luca/0000-0002-9051-7091; Grazzini, Grazia/0000-0002-9713-3007; Brenner, Hermann/0000-0002-6129-1572; Suchanek, Stepan/0000-0003-3659-0252; Pignone, Michael/0000-0002-6657-7342; Atkin, Wendy/0000-0001-9073-9658; Lynge, Elsebeth/0000-0003-4785-5236; Segnan, Nereo/0000-0002-4730-5384; Quirke, Philip/0000-0002-3597-5444 FU European Union through the EU Public Health Programme [2005317]; Oxford University Cancer Screening Research Unit; Cancer Epidemiology Unit; University of Oxford, Oxford, United Kingdom; Unit of Cancer Epidemiology; Centre for Cancer Epidemiology and Prevention; CPO Piemonte; AO Citta della Salute e della Scienza di Torino, Turin, Italy; Public Association for Healthy People, Budapest, Hungary; European Cancer Patient Coalition (ECPC), Utrecht, Netherlands; Quality Assurance and Screening Groups; Section of Early Detection and Prevention, International Agency for Research on Cancer, Lyon, France; Public Affairs Committee of the United European Gastroenterology Federation; American Cancer Society; Division of Cancer Prevention and Control at the Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America; Eiken Chemicals; Olympus; Falk; Roche FX The activities described in this publication were co-funded by the European Union through the EU Public Health Programme (grant agreement no. 2005317: Development of European Guidelines for Quality Assurance of Colorectal Cancer Screening). Co-funding in the framework of the grant agreement was also provided by the following partner institutions: Oxford University Cancer Screening Research Unit, Cancer Epidemiology Unit, University of Oxford, Oxford, United Kingdom; Unit of Cancer Epidemiology, Centre for Cancer Epidemiology and Prevention, CPO Piemonte, AO Citta della Salute e della Scienza di Torino, Turin, Italy; Public Association for Healthy People, Budapest, Hungary; European Cancer Patient Coalition (ECPC), Utrecht, Netherlands; Quality Assurance and Screening Groups, Section of Early Detection and Prevention, International Agency for Research on Cancer, Lyon, France. Additional financial support was received from the Public Affairs Committee of the United European Gastroenterology Federation, and from a cooperative agreement between the American Cancer Society and the Division of Cancer Prevention and Control at the Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.; Dr. Wendy Atkin has received significant non-monetary research support from Eiken Chemicals for reagents and machine lease for processing immunochemical faecal occult blood tests. The support is ongoing and will total less than pound 80 000. Dr Hermann Brenner is employed by The German Cancer Research Center (DKFZ) that has received significant research support from Eiken Chemicals (less than 40 000(sic)) for previously and currently running studies on colorectal cancer detection. The following companies have provided the DKFZ with faecal occult blood tests free of charge for previously and currently running evaluation studies: ulti med, Ahrensburg, Germany; DIMA, Gottingen, Germany; Beckman Coulter, Krefeld, Germany; CAREdiagnostica, Voerde, Germany; Preventis, Bensheim, Germany; Quidel, San Diego, California. The total value of the non-monetary support is less than 100 000(sic). The German Cancer Research Center (DKFZ) has received significant research support from Epigenomics (less than 125 000(sic)). Dr Michael Bretthauer's research unit at the Oslo University Hospital has received research grants and non-monetary research support of less than 25 000(sic) from the companies Olympus and Falk. Dr David Liebermann has served on the advisory board of Exact Sciences. He received less than 3000(sic) for this activity to date. Dr Christian Pox has received lecture honoraria and travel support of less than 9000(sic) from the following manufacturers of pharmaceuticals, diagnostics, medical equipment and other health products: Dr Falk Pharma, Hitachi and Roche. He has also received consultancy fees of 1500(sic) for attending an Advisory Board Meeting of the Abbot company, a broad-based health care manufacturer, and 2100(sic) from the AQUA Institute, Germany, a private entity dedicated to quality assurance research and implementation that is mandated by the Federal Committee of the German Statutory Health Insurance System to implement a nationwide quality assurance scheme. Dr Wolff Schmiegel is the holder of one patent and the co-holder of three patents covering technologies related to screening and diagnosis of colorectal tumours. He is also co-holder of a patent covering substances potentially suitable for prevention and treatment of colorectal polyps. He has received consultancy fees of less than 2000(sic) from Astra Zeneca and consultancy fees, lecture honoraria and travel support totalling less than 16 000(sic) from Roche. He has also received lecture honoraria from Abbott, Pfizer and Falk. The Medical Faculty of the Ruhr University in Germany where he works has received institutional research funding of less than 160 000(sic) from Roche and the pharmaceutical manufacturer Sanofi Aventis for studies in colorectal cancer screening and diagnosis. Dr Schmiegel is the sole shareholder (25 000(sic)) of Medmotive GmbH, a holding that until 2010 controlled 25% of the companyWestdeutsches Darm-CentrumGmbH with a capital investment of 25 000(sic). The aim of these companies is to develop and coordinate a quality-assured network in colorectal oncology through such activities as consulting, development of therapeutic standards, specialized training and lobbying key stakeholders. Dr Schmiegel has received consultancy fees of less than 15 000(sic) from Amgen, Apceth, Astra Zeneca, Merck and Roche. Dr Nereo Segnan has received consultancy fees of less than 1500(sic) from Roche Diagnostics Ltd for his participation at an Advisory Board Meeting on CRC screening.; Dr Graeme Young has received consultancy fees (less than 10 000(sic)) from Quidel Corporation, a manufacturer of diagnostic products. Eiken Chemicals has provided Flinders University where he works with faecal occult blood tests free of charge for studies (total value less than 10 000(sic)). NR 71 TC 79 Z9 80 U1 5 U2 36 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0013-726X EI 1438-8812 J9 ENDOSCOPY JI Endoscopy PD JAN PY 2013 VL 45 IS 1 BP 51 EP 59 DI 10.1055/s-0032-1325997 PG 9 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 057HI UT WOS:000312553400009 ER PT J AU Hoover, JB Tao, GY Heffelfinger, JD AF Hoover, Jonathan B. Tao, Guoyu Heffelfinger, James D. TI Monitoring HIV Testing at Visits to Emergency Departments in the United States: Very-Low Rate of HIV Testing SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article; Proceedings Paper CT 19th International AIDS Conference CY JUL 22-27, 2012 CL Washington, DC SP Int AIDS Soc DE HIV screening; HIV testing; routine HIV screening; emergency department ID SAFETY-NET; RECOMMENDATIONS; PREVENTION; INFECTION; ADULTS AB Background: Early diagnosis and treatment of HIV infection result in improved clinical outcomes and decreased transmission, yet many infected persons are unaware of their infection or are diagnosed late. The Centers for Disease Control and Prevention recommends routine opt-out testing of all persons aged 13-64 years in high prevalence settings. Study Objective: To describe methods to estimate HIV testing rates at visits to emergency departments (EDs) for monitoring adherence to recommendations for opt-out testing. Methods: We analyzed data from the 2009 National Hospital Ambulatory Medical Care Survey. In 2009, 2 questions were added to the survey about HIV status and testing. We estimated the frequency of HIV testing at ED visits made by persons aged 13-64 years not known to be HIV infected. Results: In 2009, 90.5 million visits were made to EDs, including 60.0% by whites, 24.5% by blacks, and 12.1% by Hispanics and 38.4% by privately insured, 25.7% by Medicaid insured, and 21.4% by uninsured persons. Among 89.9 million visits by patients not known to be HIV infected, HIV testing was performed at only 0.2% of visits. Among 3.4 million visits made by persons in whom targeted testing is recommended-those with increased risk for HIV and other sexually transmitted diseases or pregnancy-only 2.3% were tested for HIV. Conclusions: National Hospital Ambulatory Medical Care Survey can be a useful tool to monitor trends in HIV testing in US EDs. A high proportion of visits to EDs in the United States were made by uninsured and Medicaid insured persons, and routine HIV testing was a rare event during ED visits. C1 [Hoover, Jonathan B.; Tao, Guoyu; Heffelfinger, James D.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Hoover, JB (reprint author), Univ Maryland, Dept Emergency Med, 110 S Paca St,6th Floor,Suite 200, Baltimore, MD 21201 USA. EM jhoover@umem.org NR 27 TC 16 Z9 16 U1 1 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD JAN 1 PY 2013 VL 62 IS 1 BP 90 EP 94 DI 10.1097/QAI.0b013e3182742933 PG 5 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 058PG UT WOS:000312645400020 PM 23018376 ER PT J AU Silva, LK Backer, LC Ashley, DL Gordon, SM Brinkman, MC Nuckols, JR Wilkes, CR Blount, BC AF Silva, Lalith K. Backer, Lorraine C. Ashley, David L. Gordon, Sydney M. Brinkman, Marielle C. Nuckols, John R. Wilkes, Charles R. Blount, Benjamin C. TI The influence of physicochemical properties on the internal dose of trihalomethanes in humans following a controlled showering exposure SO JOURNAL OF EXPOSURE SCIENCE AND ENVIRONMENTAL EPIDEMIOLOGY LA English DT Article DE trihalomethane exposure; water disinfection by-products; human blood; showering; partition coefficients; Henry's law constants ID DISINFECTION BY-PRODUCTS; WATER-USE ACTIVITIES; DRINKING-WATER; TAP WATER; BUTYL ETHER; BLOOD; CANCER; AIR; CHLORINATION; TEMPERATURE AB Although disinfection of domestic water supply is crucial for protecting public health from waterborne diseases, this process forms potentially harmful by-products, such as trihalomethanes (THMs). We evaluated the influence of physicochemical properties of four THMs (chloroform, bromodichloromethane, dibromochloromethane, and bromoform) on the internal dose after showering. One hundred volunteers showered for 10 min in a controlled setting with fixed water flow, air flow, and temperature. We measured THMs in shower water, shower air, bathroom air, and blood samples collected at various time intervals. The geometric mean (GM) for total THM concentration in shower water was 96.2 mu g/l. The GM of total THM in air increased from 5.8 mu g/m(3) pre shower to 351 mu g/m(3) during showering. Similarly, the GM of total-blood THM concentration increased from 16.5 ng/l pre shower to 299 ng/l at 10 min post shower. THM levels were significantly correlated between different matrices (e.g. dibromochloromethane levels) in water and air (r=0.941); blood and water (r=0.845); and blood and air (r=0.831). The slopes of best-fit lines for THM levels in water vs air and blood vs air increased with increasing partition coefficient of water/air and blood/air. The slope of the correlation plot of THM levels in water vs air decreased in a linear (r=0.995) fashion with increasing Henry's law constant. The physicochemical properties (volatility, partition coefficients, and Henry's law constant) are useful parameters for predicting THM movement between matrices and understanding THM exposure during showering. Journal of Exposure Science and Environmental Epidemiology (2013) 23, 39-45; doi:10.1038/jes.2012.80; published online 25 July 2012 C1 [Silva, Lalith K.; Ashley, David L.; Blount, Benjamin C.] Ctr Dis Control & Prevent, Div Sci Lab, Atlanta, GA USA. [Backer, Lorraine C.] Ctr Dis Control & Prevent, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA USA. [Gordon, Sydney M.; Brinkman, Marielle C.] Battelle Mem Inst, Columbus, OH 43201 USA. [Nuckols, John R.] Colorado State Univ, Dept Environm & Radiol Hlth Sci, Ft Collins, CO 80523 USA. [Wilkes, Charles R.] Wilkes Technol, Bethesda, MD USA. RP Silva, LK (reprint author), CDC, Div Sci Lab, Natl Ctr Environm Hlth, 4770 Buford Highway NE,Mail Stop F47, Atlanta, GA 30341 USA. EM zox1@cdc.gov NR 33 TC 5 Z9 6 U1 4 U2 19 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1559-0631 J9 J EXPO SCI ENV EPID JI J. Expo. Sci. Environ. Epidemiol. PD JAN-FEB PY 2013 VL 23 IS 1 BP 39 EP 45 DI 10.1038/jes.2012.80 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 057QE UT WOS:000312577300006 PM 22829048 ER PT J AU Oberste, MS Feeroz, MM Maher, K Nix, WA Engel, GA Hasan, KM Begum, S Oh, G Chowdhury, AH Pallansch, MA Jones-Engel, L AF Oberste, M. Steven Feeroz, Mohammed M. Maher, Kaija Nix, W. Allan Engel, Gregory A. Hasan, Kamrul M. Begum, Sajeda Oh, Gunwha Chowdhury, Anwarul H. Pallansch, Mark A. Jones-Engel, Lisa TI Characterizing the Picornavirus Landscape among Synanthropic Nonhuman Primates in Bangladesh, 2007 to 2008 SO JOURNAL OF VIROLOGY LA English DT Article ID REAL-TIME PCR; CLINICAL SPECIMENS; SIMIAN PICORNAVIRUSES; IDENTIFICATION; ENTEROVIRUSES; MONKEYS; TRANSMISSION; COXSACKIEVIRUS; VIRUSES; PAPIO AB The term synanthropic describes organisms that thrive in human-altered habitats. Where synanthropic nonhuman primates (NHP) share an ecological niche with humans, cross-species transmission of infectious agents can occur. In Bangladesh, synanthropic NHP are found in villages, densely populated cities, religious sites, and protected forest areas. NHP are also kept as performing monkeys and pets. To investigate possible transmission of enteric picornaviruses between humans and NHP, we collected fecal specimens from five NHP taxa at16 locations in Bangladesh during five field sessions, from January 2007 to June 2008. Specimens were screened using real-time PCR assays for the genera Enterovirus, Parechovirus, and Sapelovirus; PCR-positive samples were typed by VP1 sequencing. To compare picornavirus diversity between humans and NHP, the same assays were applied to 211 human stool specimens collected in Bangladesh in 2007 to 2008 for acute flaccid paralysis surveillance. Picornaviruses were detected in 78 of 677 (11.5%) NHP fecal samples. Twenty distinct human enterovirus (EV) serotypes, two bovine EV types, six human parechovirus serotypes, and one virus related to Ljungan virus were identified. Twenty-five additional enteroviruses and eight parechoviruses could not be typed. Comparison of the picornavirus serotypes detected in NHP specimens with those detected in human specimens revealed considerable overlap. Strikingly, no known simian enteroviruses were detected among these NHP populations. In conclusion, enteroviruses and parechoviruses may be transmitted between humans and synanthropic NHP in Bangladesh, but the directionality of transmission is unknown. These findings may have important implications for the health of both human and NHP populations. C1 [Oberste, M. Steven; Maher, Kaija; Nix, W. Allan; Pallansch, Mark A.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Feeroz, Mohammed M.; Hasan, Kamrul M.; Begum, Sajeda] Jahangirnagar Univ, Dhaka, Bangladesh. [Engel, Gregory A.; Oh, Gunwha; Jones-Engel, Lisa] Univ Washington, Seattle, WA 98195 USA. [Engel, Gregory A.; Oh, Gunwha; Jones-Engel, Lisa] Washington Natl Primate Res Ctr, Seattle, WA USA. [Chowdhury, Anwarul H.] Minist Hlth, Natl Polio & Measles Lab, Dhaka, Bangladesh. RP Oberste, MS (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM soberste@cdc.gov OI Jones-Engel, Lisa/0000-0001-6912-494X FU [NIH-NIAID R03AI064865]; [NIH-NCRR P51 RR 00166] FX This work was partially supported by grants NIH-NIAID R03AI064865 and NIH-NCRR P51 RR 00166. NR 55 TC 30 Z9 30 U1 0 U2 12 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD JAN PY 2013 VL 87 IS 1 BP 558 EP 571 DI 10.1128/JVI.00837-12 PG 14 WC Virology SC Virology GA 055ZB UT WOS:000312455500050 PM 23097448 ER PT J AU Oberste, MS Feeroz, MM Maher, K Nix, WA Engel, GA Begum, S Hasan, KM Oh, G Pallansch, MA Jones-Engel, L AF Oberste, M. Steven Feeroz, Mohammed M. Maher, Kaija Nix, W. Allan Engel, Gregory A. Begum, Sajeda Hasan, Kamrul M. Oh, Gunwha Pallansch, Mark A. Jones-Engel, Lisa TI Naturally Acquired Picornavirus Infections in Primates at the Dhaka Zoo SO JOURNAL OF VIROLOGY LA English DT Article ID CLINICAL SPECIMENS; IDENTIFICATION; PCR; COXSACKIEVIRUS; ENTEROVIRUSES; REPRESENT; SEQUENCES; SEROTYPE AB The conditions in densely populated Bangladesh favor picornavirus transmission, resulting in a high rate of infection in the human population. Data suggest that nonhuman primates (NHP) may play a role in the maintenance and transmission of diverse picornaviruses in Bangladesh. At the Dhaka Zoo, multiple NHP species are caged in close proximity. Their proximity to other species and to humans, both zoo workers and visitors, provides the potential for cross-species transmission. To investigate possible interspecies and intraspecies transmission of picornaviruses among NHP, we collected fecal specimens from nine NHP taxa at the Dhaka Zoo at three time points, August 2007, January 2008, and June 2008. Specimens were screened using real-time PCR for the genera Enterovirus, Parechovirus, and Sapelovirus, and positive samples were typed by VP1 sequencing. Fifty-two picornaviruses comprising 10 distinct serotypes were detected in 83 fecal samples. Four of these serotypes, simian virus 19 (SV19), baboon enterovirus (BaEV), enterovirus 112 (EV112), and EV115, have been solely associated with infection in NHP. EV112, EV115, and SV19 accounted for 88% of all picornaviruses detected. Over 80% of samples from cages housing rhesus macaques, olive baboons, or hamadryas baboons were positive for a picornavirus, while no picornaviruses were detected in samples from capped langurs or vervet monkeys. In contrast to our findings among synanthropic NHP in Bangladesh where 100% of the picornaviruses detected were of human serotypes, in the zoo population, only 15% of picornaviruses detected in NHP were of human origin. Specific serotypes tended to persist over time, suggesting either persistent infection of individuals or cycles of reinfection. C1 [Oberste, M. Steven; Maher, Kaija; Nix, W. Allan; Pallansch, Mark A.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Feeroz, Mohammed M.; Begum, Sajeda; Hasan, Kamrul M.] Jahangirnagar Univ, Dhaka, Bangladesh. [Engel, Gregory A.; Oh, Gunwha; Jones-Engel, Lisa] Univ Washington, Seattle, WA 98195 USA. [Engel, Gregory A.; Oh, Gunwha; Jones-Engel, Lisa] Washington Natl Primate Res Ctr, Seattle, WA 98195 USA. RP Oberste, MS (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM soberste@cdc.gov OI Jones-Engel, Lisa/0000-0001-6912-494X FU [NIH-NIAID R03AI064865]; [NIH-NCRR P51 RR 00166] FX This work was partially supported by grants NIH-NIAID R03AI064865 and NIH-NCRR P51 RR 00166. NR 23 TC 10 Z9 10 U1 0 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD JAN PY 2013 VL 87 IS 1 BP 572 EP 580 DI 10.1128/JVI.00838-12 PG 9 WC Virology SC Virology GA 055ZB UT WOS:000312455500051 PM 23097447 ER PT J AU Tahara, M Ito, Y Brindley, MA Ma, XM He, JL Xu, ST Fukuhara, H Sakai, K Komase, K Rota, PA Plemper, RK Maenaka, K Takeda, M AF Tahara, Maino Ito, Yuri Brindley, Melinda A. Ma, Xuemin He, Jilan Xu, Songtao Fukuhara, Hideo Sakai, Kouji Komase, Katsuhiro Rota, Paul A. Plemper, Richard K. Maenaka, Katsumi Takeda, Makoto TI Functional and Structural Characterization of Neutralizing Epitopes of Measles Virus Hemagglutinin Protein SO JOURNAL OF VIROLOGY LA English DT Article ID CURRENT WILD-TYPE; B-CELL RESPONSE; MONOCLONAL-ANTIBODIES; GENETIC-VARIABILITY; MEMBRANE-FUSION; CULTURED-CELLS; CLONED CDNA; RECEPTOR; SLAM; CD46 AB Effective vaccination programs have dramatically reduced the number of measles-related deaths globally. Although all the available data suggest that measles eradication is biologically feasible, a structural and biochemical basis for the single serotype nature of measles virus (MV) remains to be provided. The hemagglutinin (H) protein, which binds to two discrete proteinaceous receptors, is the major neutralizing target. Monoclonal antibodies (MAbs) recognizing distinct epitopes on the H protein were characterized using recombinant MVs encoding the H gene from different MV genotypes. The effects of various mutations on neutralization by MAbs and virus fitness were also analyzed, identifying the location of five epitopes on the H protein structure. Our data in the present study demonstrated that the H protein of MV possesses at least two conserved effective neutralizing epitopes. One, which is a previously recognized epitope, is located near the receptor-binding site (RBS), and thus MAbs that recognize this epitope blocked the receptor binding of the H protein, whereas the other epitope is located at the position distant from the RBS. Thus, a MAb that recognizes this epitope did not inhibit the receptor binding of the H protein, rather interfered with the hemagglutinin-fusion (H-F) interaction. This epitope was suggested to play a key role for formation of a higher order of an H-F protein oligomeric structure. Our data also identified one nonconserved effective neutralizing epitope. The epitope has been masked by an N-linked sugar modification in some genotype MV strains. These data would contribute to our understanding of the antigenicity of MV and support the global elimination program of measles. C1 [Tahara, Maino; Ma, Xuemin; He, Jilan; Xu, Songtao; Sakai, Kouji; Komase, Katsuhiro; Takeda, Makoto] Natl Inst Infect Dis, Dept Virol 3, Tokyo, Japan. [Ito, Yuri; Fukuhara, Hideo; Maenaka, Katsumi] Hokkaido Univ, Fac Pharmaceut Sci, Lab Biomol Sci, Sapporo, Hokkaido 060, Japan. [Brindley, Melinda A.; Plemper, Richard K.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA. [Rota, Paul A.] Ctr Dis Control & Prevent, Measles Mumps Rubella & Herpesviruses Lab Branch, Div Viral Dis, Atlanta, GA USA. RP Tahara, M (reprint author), Natl Inst Infect Dis, Dept Virol 3, Tokyo, Japan. EM maino@nih.go.jp FU Ministry of Education, Culture, Sports, Science and Technology; Ministry of Health, Labor and Welfare of Japan; Takeda Science Foundation; Public Health Service from the NIH/NIAID [AI083402] FX This work was supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Health, Labor and Welfare of Japan and by a grant from The Takeda Science Foundation (to M.T.). The work of M. A. B. and R. K. P. was supported in part by Public Health Service grant AI083402 from the NIH/NIAID (to R.K.P.). NR 53 TC 19 Z9 20 U1 1 U2 9 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD JAN PY 2013 VL 87 IS 1 BP 666 EP 675 DI 10.1128/JVI.02033-12 PG 10 WC Virology SC Virology GA 055ZB UT WOS:000312455500059 PM 23115278 ER PT J AU Lauck, M Sibley, SD Hyeroba, D Tumukunde, A Weny, G Chapman, CA Ting, N Switzer, WM Kuhn, JH Friedrich, TC O'Connor, DH Goldberg, TL AF Lauck, Michael Sibley, Samuel D. Hyeroba, David Tumukunde, Alex Weny, Geoffrey Chapman, Colin A. Ting, Nelson Switzer, William M. Kuhn, Jens H. Friedrich, Thomas C. O'Connor, David H. Goldberg, Tony L. TI Exceptional Simian Hemorrhagic Fever Virus Diversity in a Wild African Primate Community SO JOURNAL OF VIROLOGY LA English DT Article ID PHYLOGENETIC ANALYSIS; ALIGNMENT; EVOLUTION; SEQUENCE; MONKEYS AB Simian hemorrhagic fever virus (SHFV) is an arterivirus that causes severe disease in captive macaques. We describe two new SHFV variants subclinically infecting wild African red-tailed guenons (Cercopithecus ascanius). Both variants are highly divergent from the prototype virus and variants infecting sympatric red colobus (Procolobus rufomitratus). All known SHFV variants are monophyletic and share three open reading frames not present in other arteriviruses. Our data suggest a need to modify the current arterivirus classification. C1 [Sibley, Samuel D.; Friedrich, Thomas C.; Goldberg, Tony L.] Univ Wisconsin, Dept Pathobiol Sci, Madison, WI 53706 USA. [Lauck, Michael; O'Connor, David H.] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA. [Hyeroba, David; Tumukunde, Alex; Weny, Geoffrey; Chapman, Colin A.; Goldberg, Tony L.] Makerere Univ, Kampala, Uganda. [Chapman, Colin A.] McGill Univ, Dept Anthropol, Montreal, PQ, Canada. [Chapman, Colin A.] McGill Univ, Sch Environm, Montreal, PQ, Canada. [Ting, Nelson] Univ Oregon, Dept Anthropol, Eugene, OR 97403 USA. [Ting, Nelson] Univ Oregon, Inst Ecol & Evolut, Eugene, OR 97403 USA. [Switzer, William M.] Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Div HIV AIDS Prevent, Branch Lab, Atlanta, GA USA. [Kuhn, Jens H.] NIAID, Integrated Res Facil Ft Detrick, NIH, Frederick, MD USA. [Friedrich, Thomas C.; O'Connor, David H.; Goldberg, Tony L.] Wisconsin Natl Primate Res Ctr, Madison, WI USA. RP Goldberg, TL (reprint author), Univ Wisconsin, Dept Pathobiol Sci, Madison, WI 53706 USA. EM tgoldberg@vetmed.wisc.edu RI Kuhn, Jens H./B-7615-2011; OI Kuhn, Jens H./0000-0002-7800-6045; Sibley, Samuel/0000-0002-6754-3187; o'connor, david/0000-0003-2139-470X; Friedrich, Thomas/0000-0001-9831-6895 FU NIH grant as part of the joint NIH-NSF Ecology of Infectious Disease program [TW009237]; UK Economic and Social Research Council; University of Wisconsin School of Medicine and Public Health from The Wisconsin Partnership Program through the Wisconsin Center for Infectious Disease (WisCID); NIAID [HHSN272200200016I] FX This work was funded by NIH grant TW009237 as part of the joint NIH-NSF Ecology of Infectious Disease program and the UK Economic and Social Research Council, and by the University of Wisconsin School of Medicine and Public Health from The Wisconsin Partnership Program through the Wisconsin Center for Infectious Disease (WisCID). J.H.K. performed this work as an employee of Tunnell Consulting, Inc., a subcontractor to Battelle Memorial Institute under its prime contract with NIAID, under contract no. HHSN272200200016I. NR 26 TC 32 Z9 33 U1 0 U2 13 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD JAN PY 2013 VL 87 IS 1 BP 688 EP 691 DI 10.1128/JVI.02433-12 PG 4 WC Virology SC Virology GA 055ZB UT WOS:000312455500062 PM 23077302 ER PT J AU Rietmeijer, CA Aral, SO Blanchard, JF Schachter, J AF Rietmeijer, Cornelis A. Aral, Sevgi O. Blanchard, James F. Schachter, Julius TI New in the Journal: "The Real World of STD Prevention" SO SEXUALLY TRANSMITTED DISEASES LA English DT Editorial Material C1 [Rietmeijer, Cornelis A.] Univ Colorado, Colorado Sch Publ Hlth, Denver, CO 80218 USA. [Aral, Sevgi O.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Blanchard, James F.] Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB R3T 2N2, Canada. [Schachter, Julius] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA. RP Rietmeijer, CA (reprint author), Univ Colorado, Colorado Sch Publ Hlth, 533 Marion St, Denver, CO 80218 USA. EM kees@rietmeijer.us NR 2 TC 0 Z9 0 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD JAN PY 2013 VL 40 IS 1 BP 1 EP 2 DI 10.1097/OLQ.0b013e31827e6117 PG 2 WC Infectious Diseases SC Infectious Diseases GA 057IX UT WOS:000312557700001 PM 23250296 ER PT J AU Bernstein, KT Stephens, SC Strona, FV Kohn, RP Philip, SS AF Bernstein, Kyle T. Stephens, Sally C. Strona, Frank V. Kohn, Robert P. Philip, Susan S. TI Epidemiologic Characteristics of an Ongoing Syphilis Epidemic Among Men Who Have Sex With Men, San Francisco SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID NETWORK STRUCTURE; PHASE; PREVENTION AB Background: Since 2001, San Francisco has experienced a sustained syphilis epidemic that has been nearly exclusively limited to men who have sex with men. We examined the characteristics associated with changes in the syphilis epidemic in San Francisco. Methods: All primary and secondary (P&S) syphilis cases reported to the San Francisco Department of Public Health between 2001 and 2011 were examined using joinpoint analysis to identify periods within the broader epidemic. Characteristics of the index cases were compared across the periods using W 2 statistics and t tests. Results: Three distinct periods were identified, an acute increase, decline, and then period of resurgence. In the most recent period of resurgence, compared with earlier periods, patients with P&S syphilis were more likely to have a prior syphilis infection, were older, were more likely to meet partners online, and were more likely to have a partner from outside San Francisco. Conclusions: In an analysis of 11 years of P&S syphilis data, several factors were associated with declines or resurgences. Innovative prevention measures are needed to reduce syphilis morbidity among men who have sex with men. C1 [Bernstein, Kyle T.] San Francisco Dept Publ Hlth, STD Prevent & Control Serv, San Francisco, CA 94103 USA. [Bernstein, Kyle T.] Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol, Berkeley, CA 94720 USA. [Strona, Frank V.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Bernstein, KT (reprint author), San Francisco Dept Publ Hlth, STD Prevent & Control Serv, 1360 Mission St,Suite 401, San Francisco, CA 94103 USA. EM kyle.bernstein@sfdph.org FU Comprehensive STD Prevention Projects, Centers for Disease Control and Prevention [1H25PS001354-01] FX Supported (in part) by the Comprehensive STD Prevention Projects (1H25PS001354-01), Centers for Disease Control and Prevention. NR 22 TC 17 Z9 17 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD JAN PY 2013 VL 40 IS 1 BP 11 EP 17 DI 10.1097/OLQ.0b013e31827763ea PG 7 WC Infectious Diseases SC Infectious Diseases GA 057IX UT WOS:000312557700003 PM 23254114 ER PT J AU Xu, FJ Stoner, BP Taylor, SN Mena, L Martin, DH Powell, S Markowitz, LE AF Xu, Fujie Stoner, Bradley P. Taylor, Stephanie N. Mena, Leandro Martin, David H. Powell, Suzanne Markowitz, Lauri E. TI "Testing-Only" Visits: An Assessment of Missed Diagnoses in Clients Attending Sexually Transmitted Disease Clinics SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID TRICHOMONAS-VAGINALIS INFECTION; HUMAN-IMMUNODEFICIENCY-VIRUS; NEISSERIA-GONORRHOEAE; CHLAMYDIA-TRACHOMATIS; UNITED-STATES; WOMEN; SWABS; SPECIMENS; ACQUISITION; PREVALENCE AB Background: At sexually transmitted disease (STD) clinics, advances in testing technology coupled with increasing demands and diminishing resources have promoted the use of testing-only visits (clinic visits with testing for STDs but no full examination) to meet increasing demands for STD services. Objectives: The aims of the present study were to estimate the prevalence of STD diagnoses that could become "missed diagnoses" if patients would use testing-only visits and to examine patient characteristics associated with these potential missed diagnoses. Methods: We conducted a self-administered survey of STD-related symptoms and sexual risk behaviors in patients seeking routine clinical care at 3 STD clinics. Medical charts were abstracted to estimate the prevalence of viral STDs, trichomoniasis, and other diagnoses from standard clinical services that could become missed diagnoses. Results: Of 2582 patients included, the median age was 24 years and 50% were women. In women, overall, 3.2% were diagnosed as having a viral STD; 9.6%, trichomoniasis; and 41.0%, vulvovaginal candidiasis or symptomatic bacterial vaginosis. The prevalence of these potential missed diagnoses varied by patient characteristics, but in women who reported no symptoms, the prevalence of trichomoniasis was still 6.3%. In men, 19.3% received a diagnosis of urethritis but tested negative for both gonorrhea and chlamydia; this prevalence varied from 15.7% in those who reported no symptoms to 32.6% in those who reported malodor. Conclusions: A high proportion of STD clients received diagnoses from standard care visits that would be missed by testing-only visits. When patients, even those asymptomatic, use testing-only visits, missed diagnoses of STDs or related genital tract conditions can be substantial. The potential disadvantages of testing-only visits should be weighed against the advantages of such visits. C1 [Xu, Fujie; Powell, Suzanne; Markowitz, Lauri E.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. [Stoner, Bradley P.] Washington Univ, Dept Anthropol, St Louis, MO 63130 USA. [Stoner, Bradley P.] Washington Univ, Dept Internal Med, St Louis, MO USA. [Taylor, Stephanie N.; Martin, David H.] Louisiana State Univ, Hlth Sci Ctr, Infect Dis Sect, Sch Med, New Orleans, LA USA. [Mena, Leandro] Univ Mississippi, Med Ctr, Mississippi State Dept Hlth, Crossroads Clin, Jackson, MS 39216 USA. RP Xu, FJ (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM FAX1@CDC.GOV NR 22 TC 8 Z9 8 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD JAN PY 2013 VL 40 IS 1 BP 64 EP 69 DI 10.1097/OLQ.0b013e31826f32f3 PG 6 WC Infectious Diseases SC Infectious Diseases GA 057IX UT WOS:000312557700014 PM 23254118 ER PT J AU Hall, RM Achutan, C Sollberger, R McCleery, RE Rodriguez, M AF Hall, Ronald M. Achutan, Chandran Sollberger, Ron McCleery, Robert E. Rodriguez, Manuel TI Exposure Assessment for Roofers Exposed to Silica during Installation of Roof Tiles SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE LA English DT Article ID PULMONARY TUBERCULOSIS; CONSTRUCTION-INDUSTRY; CRYSTALLINE SILICA; DUST EXPOSURE; LUNG-CANCER; GOLD MINERS; RISK; QUARTZ; RESPIRATOR; DISEASES C1 [Hall, Ronald M.; Achutan, Chandran; Sollberger, Ron; McCleery, Robert E.; Rodriguez, Manuel] NIOSH, Cincinnati, OH 45226 USA. RP Hall, RM (reprint author), NIOSH, 4676 Columbia Pkwy, Cincinnati, OH 45226 USA. EM RMHall@cdc.gov FU Intramural CDC HHS [CC999999] NR 25 TC 3 Z9 3 U1 0 U2 5 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1545-9624 J9 J OCCUP ENVIRON HYG JI J. Occup. Environ. Hyg. PD JAN 1 PY 2013 VL 10 IS 1 BP D6 EP D10 DI 10.1080/15459624.2012.739439 PG 5 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 055TG UT WOS:000312439900002 PM 23186147 ER PT J AU Pereira, TA Xie, GH Choi, SS Syn, WK Voieta, I Lu, JY Chan, IS Swiderska, M Amaral, KB Antunes, CM Secor, WE Witek, RP Lambertucci, JR Pereira, FL Diehl, AM AF Pereira, Thiago A. Xie, Guanhua Choi, Steve S. Syn, Wing-Kin Voieta, Izabela Lu, Jiuyi Chan, Isaac S. Swiderska, Marzena Amaral, Kirsten B. Antunes, Carlos M. Secor, William E. Witek, Rafal P. Lambertucci, Jose R. Pereira, Fausto L. Diehl, Anna Mae TI Macrophage-derived hedgehog ligands promotes fibrogenic and angiogenic responses in human schistosomiasis mansoni SO LIVER INTERNATIONAL LA English DT Article DE alternative activation of macrophages; fibrosis; hedgehog pathway; schistosomiasis mansoni; vascular remodelling ID SONIC HEDGEHOG; ENDOTHELIAL-CELLS; ACTIVATION; CIRRHOSIS; VIABILITY; FIBROSIS; PATHWAY; DISEASE; GROWTH; FORM AB Background Schistosomiasis mansoni is a major cause of portal fibrosis and portal hypertension. The Hedgehog pathway regulates fibrogenic repair in some types of liver injury. Aims Determine if Hedgehog pathway activation occurs during fibrosis progression in schistosomiasis and to determine if macrophage-related mechanisms are involved. Methods Immunohistochemistry was used to characterize the cells that generate and respond to Hedgehog ligands in 28 liver biopsies from patients with different grades of schistosomiasis fibrosis staged by ultrasound. Cultured macrophages (RAW264.7 and primary rat Kupffer cells) and primary rat liver sinusoidal endothelial cells (LSEC) were treated with schistosome egg antigen (SEA) and evaluated using qRT-PCR. Inhibition of the Hedgehog pathway was used to investigate its role in alternative activation of macrophages (M2) and vascular tube formation. Results Patients with schistosomiasis expressed more ligands (Shh and Ihh) and target genes (Patched and Gli2) than healthy individuals. Activated LSEC and myofibroblasts were Hedgehog responsive [Gli2(+)] and accumulated in parallel with fibrosis stage (P < 0.05). Double IHC for Ihh/CD68 showed that Ihh(+) cells were macrophages. In vitro studies demonstrated that SEA-stimulated macrophages to express Ihh and Shh mRNA (P < 0.05). Conditioned media from such macrophages induced luciferase production by Shh-LightII cells (P < 0.001) and Hedgehog inhibitors blocked this effect (P < 0.001). SEA-treated macrophages also up-regulated their own expression of M2 markers, and Hh pathway inhibitors abrogated this response (P < 0.01). Inhibition of the Hedgehog pathway in LSEC blocked SEA-induced migration and tube formation. Conclusion SEA stimulates liver macrophages to produce Hh ligands, which promote alternative activation of macrophages, fibrogenesis and vascular remodelling in schistosomiasis. C1 [Pereira, Thiago A.; Xie, Guanhua; Choi, Steve S.; Syn, Wing-Kin; Lu, Jiuyi; Chan, Isaac S.; Swiderska, Marzena; Diehl, Anna Mae] Duke Univ, Med Ctr, Dept Med, Div Gastroenterol, Durham, NC 27710 USA. [Pereira, Thiago A.] Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Salvador, BA, Brazil. [Choi, Steve S.] Durham Vet Affairs Med Ctr, Dept Med, Gastroenterol Sect, Durham, NC USA. [Syn, Wing-Kin] Fdn Liver Res, Inst Hepatol, London, England. [Voieta, Izabela; Antunes, Carlos M.; Lambertucci, Jose R.] Univ Fed Minas Gerais, Fac Med, Belo Horizonte, MG, Brazil. [Amaral, Kirsten B.; Secor, William E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Witek, Rafal P.] Life Technol, Durham, NC USA. [Pereira, Fausto L.] Univ Fed Espirito Santo, Ctr Ciencias Saude, Nucleo Doencas Infecciosas, Vitoria, ES, Brazil. RP Diehl, AM (reprint author), Duke Univ, Med Ctr, Dept Med, Div Gastroenterol, Snyderman Bldg,GSRB 1,595 LaSalle St,Suite 1073, Durham, NC 27710 USA. EM diehl004@mc.duke.edu RI Xie, Guanhua/B-8162-2012; de Almeida Pereira, Thiago/E-3092-2013 FU NIH [R01 DK077794, 5K08 DK080980]; CNPq; Capes; CNPq fellowship from the Brazilian government FX This research was funded by NIH grant R01 DK077794 awarded to A. M. D., 5K08 DK080980 awarded to S. S. C., CNPq grant awarded to F. L. P. and Capes and CNPq fellowship from the Brazilian government awarded to T. A. P. We thank Professor Virginia Hora Rios Leite from the Pathology Department of the Medical School of the Federal University of Minas Gerais for sending us some of the samples analysed here. NR 37 TC 16 Z9 16 U1 0 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1478-3223 J9 LIVER INT JI Liver Int. PD JAN PY 2013 VL 33 IS 1 BP 149 EP 161 DI 10.1111/liv.12016 PG 13 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 053VK UT WOS:000312302800020 PM 23121638 ER PT J AU Nayak, AP Green, BJ Beezhold, DH AF Nayak, Ajay P. Green, Brett J. Beezhold, Donald H. TI Fungal hemolysins SO MEDICAL MYCOLOGY LA English DT Review DE fungi; hemolysins; aegerolysins ID LOW-DENSITY-LIPOPROTEIN; MUSHROOM PLEUROTUS-OSTREATUS; PORE-FORMING TOXINS; STACHYBOTRYS-CHARTARUM STRAINS; VIBRIO-VULNIFICUS HEMOLYSIN; LINKED-IMMUNOSORBENT-ASSAY; COLLOID-OSMOTIC LYSIS; ASPERGILLUS-FUMIGATUS; ASP-HEMOLYSIN; EDIBLE MUSHROOM AB Hemolysins are a class of proteins defined by their ability to lyse red cells but have been described to exhibit pleiotropic functions. These proteins have been extensively studied in bacteria and more recently in fungi. Within the last decade, a number of studies have characterized fungal hemolysins and revealed a fascinating yet diverse group of proteins. The purpose of this review is to provide a synopsis of the known fungal hemolysins with an emphasis on those belonging to the aegerolysin protein family. New insight and perspective into fungal hemolysins in biotechnology and health are additionally presented. C1 [Nayak, Ajay P.; Green, Brett J.; Beezhold, Donald H.] NIOSH, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Nayak, Ajay P.] W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA. RP Nayak, AP (reprint author), NIOSH, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, 1095 Willowdale Rd, Morgantown, WV 26505 USA. EM fyg1@cdc.gov FU National Institute of Environmental Health Sciences [Y1-ES0001-06] FX The findings and the conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health. This work was supported in part by an InterAgency agreement with the National Institute of Environmental Health Sciences (Y1-ES0001-06). NR 170 TC 13 Z9 14 U1 0 U2 28 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1369-3786 J9 MED MYCOL JI Med. Mycol. PD JAN PY 2013 VL 51 IS 1 BP 1 EP 16 DI 10.3109/13693786.2012.698025 PG 16 WC Infectious Diseases; Mycology; Veterinary Sciences SC Infectious Diseases; Mycology; Veterinary Sciences GA 052UG UT WOS:000312223400001 PM 22769586 ER PT J AU Farr, SL Dietz, PM Rizzo, JH Vesco, KK Callaghan, WM Bruce, FC Bulkley, JE Hornbrook, MC Berg, CJ AF Farr, Sherry L. Dietz, Patricia M. Rizzo, Joanne H. Vesco, Kimberly K. Callaghan, William M. Bruce, F. Carol Bulkley, Joanna E. Hornbrook, Mark C. Berg, Cynthia J. TI Health Care Utilisation in the First Year of Life Among Infants of Mothers With Perinatal Depression or Anxiety SO PAEDIATRIC AND PERINATAL EPIDEMIOLOGY LA English DT Article DE depression; anxiety; pregnancy; postpartum; immunisations; infant; emergency medical services ID MATERNAL DEPRESSION; DISORDERS; SYMPTOMS; POSTPARTUM; PREGNANCY; SERVICES AB Background: Limited information is available on associations between maternal depression and anxiety and infant health care utilisation. Methods: We analysed data from 24 263 infants born between 1998 and 2007 who themselves and their mothers were continuously enrolled for the infant's first year in Kaiser Permanente Northwest. We used maternal depression and anxiety diagnoses during pregnancy and postpartum to categorise infants into two depression and anxiety groups and examined effect modification by timing of diagnosis (pregnancy only, postpartum only, pregnancy and postpartum). Using generalised estimating equations in multivariable log-linear regression, we estimated adjusted risk ratios (RR) between maternal depression and anxiety and well baby visits (<5 and =5), up to date immunisations (yes/no), sick/emergency visits (<6 and =6) and infant hospitalisation (any/none). Results: Infants of mothers with perinatal depression or anxiety were as likely to attend well baby visits and receive immunisations as their counterparts (RR = 1.0 for all). Compared with no depression or anxiety, infants of mothers with prenatal and postpartum depression or anxiety, or postpartum depression or anxiety only were 1.1 to 1.2 times more likely to have =6 sick/emergency visits. Infants of mothers with postpartum depression only had marginally increased risk of hospitalisation (RR = 1.2 [95% confidence interval 1.0, 1.4]); 70% of diagnoses occurred after the infant's hospitalisation. Conclusions: An understanding of the temporality of the associations between maternal depression and anxiety and infant acute care is needed and will guide strategies to decrease maternal mental illness and improve infant care for this population. C1 [Farr, Sherry L.; Dietz, Patricia M.; Callaghan, William M.; Bruce, F. Carol; Berg, Cynthia J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. [Rizzo, Joanne H.; Vesco, Kimberly K.; Bulkley, Joanna E.; Hornbrook, Mark C.] Kaiser Permanente NW, Ctr Hlth Res, Portland, OR USA. RP Farr, SL (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Highway,MS K-22, Atlanta, GA 30341 USA. EM sfarr@cdc.gov FU Intramural CDC HHS [CC999999] NR 20 TC 8 Z9 8 U1 2 U2 20 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-5022 J9 PAEDIATR PERINAT EP JI Paediatr. Perinat. Epidemiol. PD JAN PY 2013 VL 27 IS 1 BP 81 EP 88 DI 10.1111/ppe.12012 PG 8 WC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics SC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics GA 051QU UT WOS:000312142900014 PM 23215715 ER PT J AU Bertelsen, RJ Longnecker, MP Lovik, M Calafat, AM Carlsen, KH London, SJ Carlsen, KCL AF Bertelsen, R. J. Longnecker, M. P. Lovik, M. Calafat, A. M. Carlsen, K-H. London, S. J. Carlsen, K. C. Lodrup TI Triclosan exposure and allergic sensitization in Norwegian children SO ALLERGY LA English DT Article DE allergy; antibacterial; asthma; rhinitis; triclosan ID URINARY CONCENTRATIONS; CARE PRODUCTS; TOXICITY; PHENOLS; ASTHMA; LIMIT AB Background Exposure to the synthetic antimicrobial chemical, triclosan, used in personal care products, has been hypothesized to lead to allergic disease. We investigated whether triclosan exposure was associated with allergic sensitization and symptoms in 10-year-old Norwegian children. Methods Urinary concentrations of triclosan were measured in one first morning void from 623 children, collected during 20012004. Logistic regression models, controlling for urine specific gravity, parental allergic disease, maternal education, and household income, were fitted for allergic sensitization (either skin prick test positivity or serum-specific IgE = 0.35 kU/l to at least one of 15 evaluated inhalant and food allergens), current rhinitis, and current asthma (questionnaire and exercise challenge test). Results The adjusted odds ratio (aOR) for allergic sensitization among those in the fourth quartile of triclosan concentration was 2.0 [95% confidence interval (CI): 1.1, 3.4] compared with the reference group (= 5 years: temperature >= 38 degrees C, difficulty breathing, and cough or sore throat) and influenza-like illness (ILI) (all ages: temperature >= 38 degrees C and cough or sore throat). Overall, 4800 persons aged >= 2 months were tested for influenza; 416 (9%) had laboratory-confirmed influenza infections. The symptom combination of cough with fever (subjective or measured >= 38 degrees C) had high sensitivity [87.0%, 95% confidence interval (CI) 83.3-88.9], and ILI had high specificity (70.0%, 95% CI 68.6-71.3). The case definition combining cough and any fever is a simple, sensitive case definition for influenza in hospitalized persons of all age groups, whereas the ILI case definition is the most specific. The SARI case definition did not maximize sensitivity or specificity. C1 [Murray, E. L.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. RP Katz, MA (reprint author), Ctr Dis Control & Prevent Haiti, Unit 3400,Box 68, Dpo, AA 34060 USA. EM katzm@ht.cdc.gov FU Centers for Disease Control and Prevention FX We thank Lilian Waiboci, Ph.D., and Muthoni Junghae, Ph.D., from the KEMRI/CDC International Emerging Infections Program (IEIP) laboratory, and the KEMRI/CDC influenza IEIP laboratory staff for performing the influenza testing, Sheila Ogwang, B.S., and Sophie Ongalo, B.S., from KEMRI/CDC for entering and managing the data, the field staff in Siaya and Bondo districts for collecting the data, and David Shay, M.D., from the Influenza Division of CDC, Atlanta, for his input during the early phases of this project. This work was supported by the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 21 TC 6 Z9 6 U1 1 U2 6 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD JAN PY 2013 VL 141 IS 1 BP 212 EP 222 DI 10.1017/S095026881200043X PG 11 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 050FD UT WOS:000312037600026 PM 22417876 ER PT J AU Sievert, DM Ricks, P Edwards, JR Schneider, A Patel, J Srinivasan, A Kallen, A Limbago, B Fridkin, S AF Sievert, Dawn M. Ricks, Philip Edwards, Jonathan R. Schneider, Amy Patel, Jean Srinivasan, Arjun Kallen, Alex Limbago, Brandi Fridkin, Scott CA Natl Healthcare Safety Network Participating NHSN Facilities TI Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010 SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID BLOOD AB OBJECTIVE. To describe antimicrobial resistance patterns for healthcare-associated infections (HAIs) reported to the National Healthcare Safety Network (NHSN) during 2009-2010. METHODS. Central line-associated bloodstream infections, catheter-associated urinary tract infections, ventilator-associated pneumonia, and surgical site infections were included. Pooled mean proportions of isolates interpreted as resistant (or, in some cases, nonsusceptible) to selected antimicrobial agents were calculated by type of HAI and compared to historical data. RESULTS. Overall, 2,039 hospitals reported 1 or more HAIs; 1,749 (86%) were general acute care hospitals, and 1,143 (56%) had fewer than 200 beds. There were 69,475 HAIs and 81,139 pathogens reported. Eight pathogen groups accounted for about 80% of reported pathogens: Staphylococcus aureus (16%), Enterococcus spp. (14%), Escherichia coli (12%), coagulase-negative staphylococci (11%), Candida spp. (9%), Klebsiella pneumoniae (and Klebsiella oxytoca; 8%), Pseudomonas aeruginosa (8%), and Enterobacter spp. (5%). The percentage of resistance was similar to that reported in the previous 2-year period, with a slight decrease in the percentage of S. aureus resistant to oxacillins (MRSA). Nearly 20% of pathogens reported from all HAIs were the following multidrug-resistant phenotypes: MRSA (8.5%); vancomycin-resistant Enterococcus (3%); extended-spectrum cephalosporin-resistant K. pneumoniae and K. oxytoca (2%), E. coli (2%), and Enterobacter spp. (2%); and carbapenem-resistant P. aeruginosa (2%), K. pneumoniae/oxytoca (<1%), E. coli (<1%), and Enterobacter spp. (<1%). Among facilities reporting HAIs with 1 of the above gram-negative bacteria, 20%-40% reported at least 1 with the resistant phenotype. CONCLUSION. While the proportion of resistant isolates did not substantially change from that in the previous 2 years, multidrug-resistant gram-negative phenotypes were reported from a moderate proportion of facilities. Infect Control Hosp Epidemiol 2013;34(1):1-14 C1 [Sievert, Dawn M.; Ricks, Philip; Edwards, Jonathan R.; Schneider, Amy; Patel, Jean; Srinivasan, Arjun; Kallen, Alex; Limbago, Brandi; Fridkin, Scott] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Fridkin, S (reprint author), CDC, MS A-35,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM skf0@cdc.gov FU Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention FX The NHSN surveillance system is supported by the Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention. NR 11 TC 427 Z9 443 U1 14 U2 86 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD JAN PY 2013 VL 34 IS 1 BP 1 EP 14 DI 10.1086/668770 PG 14 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 049YC UT WOS:000312018300001 PM 23221186 ER PT S AU Drennan, J Lanzerotti, MY Varga, M Creighton, SJ Langley, D Cahill, DL AF Drennan, Jessica Lanzerotti, Mary Y. Varga, Maggie Creighton, Sean J. Langley, Derrick Cahill, Diana Lynn GP ASEE TI Developing Best Practices for an Undergraduate STEM Summer Research Program in a Government Institution through a Higher Education Partnership SO 2013 ASEE ANNUAL CONFERENCE SE ASEE Annual Conference & Exposition LA English DT Proceedings Paper CT ASEE Annual Conference CY JUN 23-26, 2013 CL Atlanta, GA SP ASEE AB This paper introduces a novel and unique paradigm to upgrade a long-standing summer research program at a government institution to include components that are now standard at civilian programs, such as National Science Foundation (NSF) Research Experiences for Undergraduates (REU) programs. Critical to the success of this new paradigm is a campuscommunity partnership. This partnership makes it possible for the first time to assess the summer program at the government institution due to government regulations. The AFIT Summer Research Program hosts approximately 50 student contractors each summer; making the program four to five times larger than a typical NSF REU program, and over 10% are female. All students who participate in the AFIT Summer Research Program are required to be U. S. citizens, and are employed under a contractor through the Southwestern Ohio Council for Higher Education (SOCHE). SOCHE has employed nearly 1,000 STEM students over the past 25 years in both summer programs and year-long programs. During this time, a formal assessment tool was not distributed to students to measure the impact of the research experience on student learning because federal regulations [AFI38-501] do not permit Air Force employees at AFIT to legally survey the students since the students work in contractor status (Air Force employees are not legally permitted to survey contractors in any form; neither paper surveys or email surveys are permitted). Due to AFIT policies and procedures surrounding contractors, the AFIT Summer Research Program lacks components of standard comparable NSF-funded REU programs summer research programs at other institutions. These regulations include not being legally permitted to buy refreshments for informal student cohort meetings, not having a dedicated program coordinator, not offering group meetings to discuss resumes, careers, graduate school, or offer a poster conference. While it is typical at other NSF-funded REU programs to have a program coordinator, each student in the AFIT Summer Research Program is directed through his or her own AFIT Faculty Advisor and has a unique experience. Another unique aspect of the AFIT summer program is that all students are required to work the same core hours between 0900 and 1500 each day. The new paradigm that we present in this paper is novel and unique because we were able to figure out a way forward to assess students' experiences in 2012 and use this information to gain support and resources to upgrade future summer student research experiences, starting in 2013. Representatives from SOCHE, AFIT, and NSF-funded ADVANCE program entitled the LEADER Consortium (Launching Equity in the Academy across the Dayton Entrepreneurial Region) met in 2011 and 2012 and came up with this new approach. It was a tremendous effort. We feel the project greatly benefits the students and is a first significant step forward to standardizing the student experiences in the AFIT Summer Research Program and incorporating components that are standard at NSF REU programs. An essential part of this solution is that SOCHE conducts the surveys of the students by email and makes the results available to AFIT and to the LEADER Consortium. SOCHE's assessment tool is a baseline survey conducted when the program was in session (response rate: 54.2%) and a post survey following the program (response rate: 39.6%). Females responded in greater proportion to both surveys: Of respondents to the first survey, 20% were female; of respondents to the second survey, over 36% were female. We are very excited to obtain this solution for assessing the program, which is legal and obeys federal regulations, because SOCHE is the employer and can legally survey the students. Several updates to the program have occurred since the assessment. First, AFIT hired a Civilian Student Coordinator who will oversee all students in 2013 and will implement the recommendations provided by the students in 2012 (for student cohorts and an orientation). Second, AFIT faculty members have offered to organize a student poster conference and student presentations. Third, SOCHE has offered to bring in local experts to give resume feedback and to pay for refreshments for the students (which is legal for SOCHE) at informal gatherings of student cohorts. In summary, we present a unique successful partnership. The campus-community partnership produced student feedback results for the first time. Recommendations based on these results will introduce components of standard STEM programs to the AFIT Summer Research Program, which the AFIT program is lacking. The existence of this partnership is critical to be able to move forward legally to upgrade a long-standing summer research program. C1 [Drennan, Jessica] Ctr Dis Control, Atlanta, GA 30333 USA. [Lanzerotti, Mary Y.] Air Force Inst Technol, Dept Elect & Comp Engn, Comp Engn, Dayton, OH USA. [Varga, Maggie] Southwestern Ohio Council Higher Educ, Program Innovat, Dayton, OH USA. [Creighton, Sean J.] Southwestern Ohio Council Higher Educ, Dayton, OH USA. [Langley, Derrick] Air Force Inst Technol, Elect Engn, Wright Patterson AFB, OH USA. [Cahill, Diana Lynn] Air Force Inst Technol, Wright Patterson AFB, OH USA. RP Drennan, J (reprint author), Ctr Dis Control, Atlanta, GA 30333 USA. NR 12 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC ENGINEERING EDUCATION PI WASHINGTON PA 1818 N STREET, NW SUITE 600, WASHINGTON, DC 20036 USA SN 2153-5965 J9 ASEE ANNU CONF EXPO PY 2013 AR UNSP 6708 PG 16 WC Education & Educational Research; Education, Scientific Disciplines; Engineering, Multidisciplinary SC Education & Educational Research; Engineering GA BE7HA UT WOS:000375255602036 ER PT J AU Auld, SC Click, ES Heilig, C Cain, K Oeltmann, J Bisson, G Mac Kenzie, W AF Auld, S. C. Click, E. S. Heilig, C. Cain, K. Oeltmann, J. Bisson, G. Mac Kenzie, W. TI Negative Tuberculin Skin Test Result Is Associated With An Increased Risk Of Death - United States, 1993-2008 SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Auld, S. C.; Click, E. S.; Heilig, C.; Oeltmann, J.; Mac Kenzie, W.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Cain, K.] US Ctr Dis Control & Prevent, Kisumu, Kenya. [Bisson, G.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. EM via1@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2013 VL 187 MA A2476 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TO UT WOS:000209839101647 ER PT J AU Balk, R Self, WH Woodworth, A Courtney, DM Waterer, GW Grijalva, C Hicks, LA Bramley, AM Jain, S Anderson, EJ Edwards, K Wunderink, RG AF Balk, R. Self, W. H. Woodworth, A. Courtney, D. M. Waterer, G. W. Grijalva, C. Hicks, L. A. Bramley, A. M. Jain, S. Anderson, E. J. Edwards, K. Wunderink, R. G. CA CDC EPIC TI Association Of Pathogens Detected In Community-Acquired Pneumonia (cap) With Serum Procalcitonin (pct) Among Adults: Preliminary Results From The Cdc Etiology Of Pneumonia In The Community (epic) Study SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society CY MAY 17-22, 2013 CL Philadelphia, PA SP Amer Thorac Soc C1 [Balk, R.] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Self, W. H.; Woodworth, A.; Grijalva, C.; Edwards, K.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Courtney, D. M.; Wunderink, R. G.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Waterer, G. W.] Univ Western Australia, Perth, WA, Australia. [Hicks, L. A.; Bramley, A. M.; Jain, S.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Anderson, E. J.] Emory Univ, Sch Med, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2013 VL 187 MA A1153 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TO UT WOS:000209839100135 ER PT J AU Cummings, KJ Stanton, ML Abraham, JL Green, BJ Rittenour, WR Wendland, DM Bachelder, VD Boylstein, RJ Piacitelli, CA Humann, MJ Park, JH Cox-Ganser, JM Kreiss, K AF Cummings, K. J. Stanton, M. L. Abraham, J. L. Green, B. J. Rittenour, W. R. Wendland, D. M. Bachelder, V. D. Boylstein, R. J. Piacitelli, C. A. Humann, M. J. Park, J. -H. Cox-Ganser, J. M. Kreiss, K. TI A Workplace Investigation Of Lymphocytic Bronchiolitis Characterized By Proliferation Of Mucosa-Associated Lymphoid Tissue (malt) SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Cummings, K. J.; Stanton, M. L.; Green, B. J.; Rittenour, W. R.; Boylstein, R. J.; Piacitelli, C. A.; Humann, M. J.; Park, J. -H.; Cox-Ganser, J. M.; Kreiss, K.] NIOSH, Ctr Dis Control & Prevent, Morgantown, WV USA. [Abraham, J. L.] SUNY Upstate Med Univ, Syracuse, NY 13210 USA. [Wendland, D. M.; Bachelder, V. D.] St Lukes Hosp, Duluth, MN USA. EM cvx5@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2013 VL 187 MA A4495 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TH UT WOS:000209838401138 ER PT J AU Doney, B Hnizdo, E Dillon, C Paulose-Ram, R Tilert, T Wolz, M AF Doney, B. Hnizdo, E. Dillon, C. Paulose-Ram, R. Tilert, T. Wolz, M. TI Decline In The Prevalence Of Airflow Limitation In Us Adults Aged 40-79: Nhanes, 1988-1994 And 2007-2010 SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Doney, B.; Hnizdo, E.] NIOSH, Morgantown, WV USA. [Dillon, C.; Paulose-Ram, R.; Tilert, T.] CDC, Natl Ctr Hlth Stat, Bethesda, MD USA. [Wolz, M.] NHLBI, NIH, Bethesda, MD 20892 USA. EM bdoney@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2013 VL 187 MA A3642 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TH UT WOS:000209838400095 ER PT J AU Everett, CK Benator, D Davis, JL Alland, D Heilig, C Persing, DH Tenover, FC Weiner, M Kerrigan, A Zamudio, C Whitworth, WC Goldberg, SV Nahid, P AF Everett, C. K. Benator, D. Davis, J. L. Alland, D. Heilig, C. Persing, D. H. Tenover, F. C. Weiner, M. Kerrigan, A. Zamudio, C. Whitworth, W. C. Goldberg, S. V. Nahid, P. TI Automated Quantitative Pcr Using Xpert (R) Mtb/rif To Monitor Tuberculosis Treatment SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Everett, C. K.; Davis, J. L.; Nahid, P.] UCSF SFGH, San Francisco, CA USA. [Benator, D.] US Dept Vet Affairs, Washington, DC USA. [Alland, D.] Univ Med & Dent New Jersey, Newark, NJ 07103 USA. [Heilig, C.; Goldberg, S. V.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Persing, D. H.; Tenover, F. C.] Cepheid Inc, Sunnyvale, CA USA. [Weiner, M.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Kerrigan, A.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Zamudio, C.] Univ Peruana Cayetano Heredia, Lima, Peru. [Whitworth, W. C.] CDC, Atlanta, GA 30333 USA. EM Charles.Everett@ucsf.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2013 VL 187 MA A3180 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TO UT WOS:000209839102569 ER PT J AU Larson, T Ge, M Antao, VC AF Larson, T. Ge, M. Antao, V. C. TI Factors Associated With The Incidence Of Asbestos-Related Pleural Abnormalities During Nine Years Of Screening In Libby, Montana SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Larson, T.; Ge, M.; Antao, V. C.] Agcy Tox Subst & Dis Registry, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2013 VL 187 MA A3149 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TO UT WOS:000209839102538 ER PT J AU Metcalfe, J Barry, PM Coscolla, M Shaw, T Cilnis, M Oeltmann, JE Posey, J Rose, J Weber, T Koshinsky, H Fofanov, VY Gagneux, S Kato-Maeda, M AF Metcalfe, J. Barry, P. M. Coscolla, M. Shaw, T. Cilnis, M. Oeltmann, J. E. Posey, J. Rose, J. Weber, T. Koshinsky, H. Fofanov, V. Y. Gagneux, S. Kato-Maeda, M. TI Microevolution Of A Successful Multidrug-Resistant Lineage 2 Strain Of M. Tuberculosis Within Hmong Populations In Thailand And California SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Metcalfe, J.; Rose, J.; Kato-Maeda, M.] San Francisco Gen Hosp, San Francisco, CA 94110 USA. [Barry, P. M.; Shaw, T.; Cilnis, M.; Weber, T.] Calif Dept Publ Hlth, Richmond, CA USA. [Coscolla, M.; Gagneux, S.] Swiss Trop & Publ Hlth Inst, TB Res Unit, Basel, Switzerland. [Oeltmann, J. E.; Posey, J.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Koshinsky, H.; Fofanov, V. Y.] Eureka Genom, Hercules, CA USA. EM john.metcalfe@ucsf.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2013 VL 187 MA A6052 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TH UT WOS:000209838403042 ER PT J AU Moro, RN Dorman, S Schluger, NW Stout, J Muzanyi, G Phan, H Feng, PI Heilig, C Bozeman, L Goldberg, SV AF Moro, R. N. Dorman, S. Schluger, N. W. Stout, J. Muzanyi, G. Phan, H. Feng, P. I. Heilig, C. Bozeman, L. Goldberg, S. V. CA TBTC Investigators TI Tolerability And Safety Of Escalating Rifapentine (rpt) Doses During The First 2 Months Of Tuberculosis (tb) Treatment SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Moro, R. N.; Feng, P. I.; Heilig, C.; Bozeman, L.; Goldberg, S. V.] CDC, Atlanta, GA 30333 USA. [Dorman, S.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Schluger, N. W.] Columbia Univ, Med Ctr, New York, NY USA. [Stout, J.] Duke Univ, Sch Med, Durham, NC USA. [Muzanyi, G.] Uganda Case Western Reserve Res Collaborat, Kampala, Uganda. [Phan, H.] Vietnam Natl TB Program Univ Calif San Francisco, Hanoi, Vietnam. EM ise6@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2013 VL 187 MA A6051 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TH UT WOS:000209838403041 ER PT J AU Pagaoa, M Katz, DJ Chen, M Golub, J AF Pagaoa, M. Katz, D. J. Chen, M. Golub, J. TI Time To Diagnosis As A Risk Factor For Transmission Of Tuberculosis Infection SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Pagaoa, M.; Katz, D. J.; Chen, M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Golub, J.] Johns Hopkins Sch Med, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2013 VL 187 MA A1650 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TO UT WOS:000209839100632 ER PT J AU Smith, SB Luqman, AA Self, WH Grace, B Balk, RA Fakhran, S Williams, DJ Bramley, A Jain, S Anderson, E Waterer, GW Edwards, KM Wunderink, RG AF Smith, S. B. Luqman, A. A. Self, W. H. Grace, B. Balk, R. A. Fakhran, S. Williams, D. J. Bramley, A. Jain, S. Anderson, E. Waterer, G. W. Edwards, K. M. Wunderink, R. G. TI Etiology Of Pneumonia In Hemodialysis Patients: Preliminary Results From The Centers For Disease Control And Prevention Etiology Of Pneumonia In The Community (epic) Study SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT International Conference of the American-Thoracic-Society CY MAY 17-22, 2013 CL Philadelphia, PA SP Amer Thorac Soc C1 [Smith, S. B.; Luqman, A. A.; Grace, B.; Wunderink, R. G.] Northwestern Feinberg Sch Med, Chicago, IL USA. [Self, W. H.; Williams, D. J.; Edwards, K. M.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Balk, R. A.] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Fakhran, S.] John H Stroger Jr Hosp Cook Cty, Chicago, IL USA. [Bramley, A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Jain, S.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Anderson, E.] Emory Univ, Sch Med, Atlanta, GA USA. [Waterer, G. W.] Univ Western Australia, Perth, WA, Australia. EM sean@northwestern.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2013 VL 187 MA A1155 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TO UT WOS:000209839100137 ER PT J AU Tilert, T Paulose-Ram, R Dillon, C Hnizdo, E Doney, B AF Tilert, T. Paulose-Ram, R. Dillon, C. Hnizdo, E. Doney, B. TI Estimating The Prevalence Of Chronic Obstructive Pulmonary Disease Using Pre- And Post-Bronchodilator Spirometry Testing: Data From The National Health And Nutrition Examination Survey, 2007-2010 SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Tilert, T.] CDC, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Paulose-Ram, R.; Dillon, C.] Ctr Dis Control & Prevent, Hyattsville, MD USA. [Hnizdo, E.; Doney, B.] NIOSH, CDC, Morgantown, WV USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2013 VL 187 MA A3641 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TH UT WOS:000209838400094 ER PT J AU Yuen, C Chen, M Navin, T AF Yuen, C. Chen, M. Navin, T. TI Predicting Year Of Tuberculosis Elimination Among U.s.-Born Populations By State SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Yuen, C.; Chen, M.; Navin, T.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2013 VL 187 MA A1648 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TO UT WOS:000209839100630 ER PT S AU Gelting, RJ Baloch, M AF Gelting, R. J. Baloch, M. BE Lundqvist, J TI A systems analysis of irrigation water quality in environmental assessments related to foodborne outbreaks SO AT THE CONFLUENCE - SELECTION FROM THE 2012 WORLD WATER WEEK SE Aquatic Procedia LA English DT Proceedings Paper CT Annual World Water Week Conference CY AUG 26-31, 2012 CL Stockholm, SWEDEN SP Stockholm Int Water Inst DE irrigation; foodborne outbreak; systems analysis; environmental assessment; Water Safety Plan ID SPINACH AB Irrigation water quality can affect food safety and health and has been identified as a possible source of pathogens in produce linked to disease outbreaks. Many irrigation water sources are subject to contamination from various sources in surrounding watersheds. A systems-based, watershed scale analysis is therefore necessary to comprehensively identify both sources of contamination and the conditions in the environment that facilitated or created that contamination, termed here 'environmental antecedents'. Three nationwide disease outbreaks linked to produce in the United States (US) are used to illustrate this concept of a watershed scale assessment to investigate potential impacts of irrigation water quality on food safety. (C) 2013 The Authors. Published by Elsevier B.V. C1 [Gelting, R. J.; Baloch, M.] Ctr Dis Control & Prevent, Atlanta, GA USA. EM rug7@cdc.gov NR 13 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2214-241X J9 AQUAT PR PY 2013 VL 1 BP 130 EP 137 DI 10.1016/j.aqpro.2013.07.011 PG 8 WC Environmental Studies SC Environmental Sciences & Ecology GA BB9FK UT WOS:000348253100010 ER PT B AU Cannon, MJ Grosse, SD Fowler, KB AF Cannon, Michael J. Grosse, Scott D. Fowler, Karen B. BE Reddehase, MJ TI The Epidemiology and Public Health Impact of Congenital Cytomegalovirus Infection SO CYTOMEGALOVIRUSES: FROM MOLECULAR PATHOGENESIS TO INTERVENTION, VOL II LA English DT Article; Book Chapter ID SENSORINEURAL HEARING-LOSS; POLYMERASE-CHAIN-REACTION; DRIED BLOOD SPOTS; SEXUALLY-TRANSMITTED-DISEASES; HUMAN-IMMUNODEFICIENCY-VIRUS; TO-MOTHER TRANSMISSION; HEPATITIS-B-VIRUS; DAY-CARE-CENTERS; CHILD DAY-CARE; UNITED-STATES AB Congenital cytomegalovirus (CMV) is one of the most important causes of childhood disability in many countries. The dynamics of congenital CMV are driven by a complex interplay between factors that include the prevalence of CMV infection in the population, the frequency of viral shedding in bodily fluids, the relative importance of different transmission routes, and the incidence of CMV infection among women of reproductive age. Among children infected congenitally, many experience no disease sequelae, while others experience one or more disabilities which can vary in severity and which may be present at birth or may have a delayed onset. From a public health perspective, avenues for addressing congenital CMV include raising awareness, promoting primary prevention through behavioural change, and assessing the utility of prenatal and newborn screening. C1 [Cannon, Michael J.; Grosse, Scott D.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30329 USA. [Fowler, Karen B.] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL USA. RP Cannon, MJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30329 USA. EM mcannon@cdc.gov; sgg4@cdc.gov; kfowler@uab.edu NR 172 TC 3 Z9 3 U1 1 U2 1 PU CAISTER ACADEMIC PRESS PI WYMONDHAM PA 32 HEWITTS LANE, WYMONDHAM NR 18 0JA, ENGLAND BN 978-1-908230-85-0; 978-1-908230-20-1 PY 2013 BP 26 EP 48 PG 23 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA BF6BX UT WOS:000382947900002 ER PT B AU Grosse, SD Ortega-Sanchez, IR Bialek, SR Dollard, SC AF Grosse, Scott D. Ortega-Sanchez, Ismael R. Bialek, Stephanie R. Dollard, Sheila C. BE Reddehase, MJ TI The Economic Impact of Congenital CMV Infection: Methods and Estimates (vol 26, pg 186, 2013) SO CYTOMEGALOVIRUSES: FROM MOLECULAR PATHOGENESIS TO INTERVENTION, VOL II LA English DT Correction; Book Chapter ID COA DEHYDROGENASE-DEFICIENCY; CYTOMEGALOVIRUS-INFECTION; HEARING-LOSS; ADVISORY-COMMITTEE; COST-EFFECTIVENESS; UNITED-STATES; CHILDREN; DISEASE; HEALTH; NETHERLANDS AB Calculation of the economic burden of congenital cytomegalovirus (CMV) is needed to quantify the potential economic impact of preventative interventions. Although no preventative interventions are currently available other than hygiene education and avoidance of exposures by pregnant women, economic assessment may be needed in coming years for a CMV vaccine, prenatal screening followed by pharmacological treatment, or newborn screening and early intervention for hearing loss and other disabilities. Economic estimates of the costs associated with the long-term consequences of congenital CMV infections are important both to demonstrate the potential benefit from the development of preventative interventions and also to assess their expected cost-effectiveness or cost-benefit once they are ready to be implemented. C1 [Grosse, Scott D.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30329 USA. [Ortega-Sanchez, Ismael R.; Bialek, Stephanie R.; Dollard, Sheila C.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Grosse, SD (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30329 USA. EM sgg4@cdc.gov; iao8@cdc.gov; zqg7@cdc.gov; sgd5@cdc.gov NR 34 TC 1 Z9 1 U1 0 U2 0 PU CAISTER ACADEMIC PRESS PI WYMONDHAM PA 32 HEWITTS LANE, WYMONDHAM NR 18 0JA, ENGLAND BN 978-1-908230-85-0; 978-1-908230-20-1 PY 2013 BP 49 EP 54 PG 6 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA BF6BX UT WOS:000382947900003 ER PT B AU Loeb, M Madans, J Weeks, J Miller, K Dahlhamer, J Golden, C AF Loeb, Mitchell Madans, Jennifer Weeks, Julie Miller, Kristen Dahlhamer, James Golden, Cordell BE Barnartt, SN Altman, BM TI DISABILITY AND PARTICIPATION: ASSESSING EMPLOYMENT AND EDUCATION OUTCOMES IN THE NATIONAL HEALTH INTERVIEW SURVEY (2010) SO DISABILITY AND INTERSECTING STATUSES SE Research in Social Science and Disability LA English DT Article; Book Chapter DE Disability; participation; NHIS; ACS; intersectionality ID GENDER AB Purpose - Applying an intersectional approach to the analysis of nationally representative population data collected through the National Health Interview Survey (NHIS), this chapter attempts to address the congruence between functional status (disability) and other relevant socio-demographic background variables (gender, race, self-reported health status, etc.) that may potentially result in disparate access to education and employment. Methodology - Disability is defined and measured using the six American Community Survey (ACS) disability questions. Disability, intersectionality, and equalization of opportunities are assessed in a representative sample of the U.S. adult population as measured on the 2010 NHIS. Data on approximately 32,000 adults age 18 years and over are used to explore, using multivariate techniques, the intersection between disability, age, gender, race/ethnicity, marital status, health insurance, and reported health status, and education and employment outcomes. Findings - The results presented describe a disparity in outcomes of education and employment between disabled and nondisabled adults when controlling for several important background and socio-demographic variables. Exploring the relationships between these variables provides a richer understanding of disability as it exists within the social world. Research implications - In order to further improve our understanding of the population dynamics of disability, disability data must be routinely incorporated into national statistics programs. The ACS questions provide a common approach to the definition and measurement of disability within the Federal Statistical System. C1 [Loeb, Mitchell] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Off Anal & Epidemiol, Hyattsville, MD 20782 USA. [Madans, Jennifer] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Sci, Hyattsville, MD 20782 USA. [Weeks, Julie; Miller, Kristen; Dahlhamer, James; Golden, Cordell] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Loeb, M (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Off Anal & Epidemiol, Hyattsville, MD 20782 USA. NR 22 TC 1 Z9 1 U1 0 U2 0 PU EMERALD GROUP PUBLISHING LTD PI BINGLEY PA HOWARD HOUSE, WAGON LANE, BINGLEY, W YORKSHIRE BD16 1WA, ENGLAND BN 978-1-78350-157-1; 978-1-78350-156-4 J9 RES SOC SCI DISABIL PY 2013 VL 7 BP 171 EP 188 DI 10.1108/S1479-3547(2013)0000007008 PG 18 WC Rehabilitation; Social Sciences, Interdisciplinary SC Rehabilitation; Social Sciences - Other Topics GA BD1TF UT WOS:000358350400006 ER PT S AU Hudspeth, W Reisen, WK Barker, CM Kramer, V Caian, M Craciunescu, V Brown, HE Comrie, AC Zelicoff, A Ward, TG Ragain, RM Simpson, G Stanhope, W Kass-Hout, TA Scharl, A Sonricker, AL Brownstein, JS AF Hudspeth, W. Reisen, W. K. Barker, C. M. Kramer, V. Caian, M. Craciunescu, V. Brown, H. E. Comrie, A. C. Zelicoff, A. Ward, T. G. Ragain, R. M. Simpson, G. Stanhope, W. Kass-Hout, T. A. Scharl, A. Sonricker, A. L. Brownstein, J. S. BE Morain, SA Budge, AM TI Information and decision support systems SO ENVIRONMENTAL TRACKING FOR PUBLIC HEALTH SURVEILLANCE SE International Society for Photogrammetry and Remote Sensing (ISPRS) Book Series LA English DT Article; Book Chapter ID WEST-NILE-VIRUS; LOUIS ENCEPHALITIS-VIRUS; CULEX-TARSALIS DIPTERA; VECTOR COMPETENCE; PUBLIC-HEALTH; EMERGENCY RESPONSE; MOSQUITO DIPTERA; DISEASE OUTBREAK; AVIAN HOST; CALIFORNIA AB This chapter describes various approaches for extending environmental observations into actionable public health decisions. C1 [Hudspeth, W.] Univ New Mexico, Earth Data Anal Ctr, Albuquerque, NM 87131 USA. [Reisen, W. K.; Barker, C. M.] Univ Calif Davis, Sch Vet Med, Davis, CA 95616 USA. [Kramer, V.] Calif Dept Publ Hlth, Vector Borne Dis Sect, Sacramento, CA 95899 USA. [Caian, M.] Natl Meteorol Adm, Bucharest 013686, Romania. [Craciunescu, V.] Natl Meteorol Adm, Remote Sensing & GIS Lab, Bucharest 013686, Romania. [Brown, H. E.; Comrie, A. C.] Univ Arizona, Sch Geog & Dev, Tucson, AZ 85721 USA. [Zelicoff, A.; Ragain, R. M.] St Louis Univ, Sch Publ Hlth, St Louis, MO 63103 USA. [Ward, T. G.] City Lubbock Hlth Dept, Lubbock, TX 79411 USA. [Simpson, G.] New Mexico Dept Hlth, Albuquerque, NM USA. [Stanhope, W.] St Louis Univ, Sch Publ Hlth, Inst Biosecur, St Louis, MO 63104 USA. [Kass-Hout, T. A.] Ctr Dis Control & Prevent, Publ Hlth Surveillance Program Off, Atlanta, GA 30333 USA. [Scharl, A.] MODUL Univ, Vienna, Austria. [Sonricker, A. L.; Brownstein, J. S.] MIT, Boston, MA 02215 USA. [Sonricker, A. L.; Brownstein, J. S.] Childrens Hosp, Boston, MA 02215 USA. RP Hudspeth, W (reprint author), Univ New Mexico, Earth Data Anal Ctr, MSC01-1110, Albuquerque, NM 87131 USA. EM bhudspeth@edac.unm.edu; wkreisen@ucdavis.edu; cmbarker@ucdavis.edu; Vicki.Kramer@cdph.ca.gov; mihaela.caian@gmail.com; vasile.craciunescu@meteoromania.ro; HeidiBrown@email.arizona.edu; comrie@arizona.edu; Zelicoff@slu.edu; Ragain@slu.edu; garyl.simpson@comcast.net; Stanhope@slu.edu; kasshout@gmail.com; arno.scharl@modul.ac.at; amy.sonricker@childrens.harvard.edu; john.brownstein@harvard.edu NR 82 TC 0 Z9 0 U1 0 U2 0 PU A A BALKEMA PUBLISHERS PI LEIDEN PA SCHIPHOLWEG 107C, PO BOX 447, 2316 XC LEIDEN, NETHERLANDS SN 1572-3348 BN 978-0-203-09327-6; 978-0-415-58471-5 J9 ISPRS BOOK SER PY 2013 VL 11 BP 369 EP + PG 74 WC Public, Environmental & Occupational Health; Remote Sensing SC Public, Environmental & Occupational Health; Remote Sensing GA BC2MZ UT WOS:000351090700012 ER PT J AU Cardozo, BL Sivilli, T Crawford, C Scholte, W Petit, P Ghitis, F Ager, A Eriksson, C AF Cardozo, B. Lopes Sivilli, T. Crawford, C. Scholte, W. Petit, P. Ghitis, F. Ager, A. Eriksson, C. TI Psychological trauma and other stressors affecting the mental health of local staff working in the Vanni region in Sri Lanka SO EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY LA English DT Meeting Abstract C1 [Cardozo, B. Lopes; Crawford, C.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Sivilli, T.] Emory Univ, Dept Psychiat, Atlanta, GA 30322 USA. [Scholte, W.; Petit, P.; Ghitis, F.] Antares Fdn, Amsterdam, Netherlands. [Ager, A.] Columbia Univ, New York, NY USA. [Eriksson, C.] Fuller Theol Seminary, Pasadena, CA 91101 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 2000-8066 J9 EUR J PSYCHOTRAUMATO JI Eur. J. Psychotraumatol. PY 2013 VL 4 SU 1 PG 1 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA V44PH UT WOS:000209760400157 ER PT J AU Schenkel, AR Kingry, LC Slayden, RA AF Schenkel, Alan Rowe Kingry, Luke C. Slayden, Richard A. TI The Ly49 gene family. A brief guide to the nomenclature, genetics, and role in intracellular infection SO FRONTIERS IN IMMUNOLOGY LA English DT Review DE Ly49; klra; natural killer lymphocytes; myeloid cells AB Understanding the Ly49 gene family can be challenging in terms of nomenclature and genetic organization. The Ly49 gene family has two major gene nomenclature systems, Ly49 and Killer Cell Lectin-like Receptor subfamily A (klra). Mice from different strains have varying numbers of these genes with strain specific allelic variants, duplications, deletions, and pseudogene sequences. Some members activate NK lymphocytes, invariant NKT (iNKT) lymphocytes and gamma delta T lymphocytes while others inhibit killing activity. One family member, Ly49Q, is expressed only on myeloid cells and is not found on NK, iNKT, or gamma delta T cells. There is growing evidence that these receptors may regulate not just the immune response to viruses, but other intracellular pathogens as well. Thus, this review's primary goal is to provide a guide for researchers first encountering the Ly49 gene family and a foundation for future studies on the role that these gene products play in the immune response, particularly the response to intracellular viral and bacterial pathogens. C1 [Schenkel, Alan Rowe; Kingry, Luke C.; Slayden, Richard A.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA. [Kingry, Luke C.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. RP Schenkel, AR (reprint author), Colorado State Univ, Dept Microbiol Immunol & Pathol, 1682 Campus Delivery, Ft Collins, CO 80523 USA. EM alan.schenkel@colostate.edu RI Slayden, Richard/O-8626-2016; OI Slayden, Richard/0000-0001-6857-7277; Kingry, Luke/0000-0002-5724-2575 FU Rocky Mountain Regional Center of Excellence [U54 AI065357] FX We wish to thank Jamie S. Schenkel and Dr. Andrew P. Makrigiannis for critical reading of this manuscript. This work was supported in part by Rocky Mountain Regional Center of Excellence U54 AI065357. NR 62 TC 6 Z9 7 U1 2 U2 4 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1664-3224 J9 FRONT IMMUNOL JI Front. Immunol. PY 2013 VL 4 AR UNSP 90 DI 10.3389/fimmu.2013.00090 PG 8 WC Immunology SC Immunology GA V38WS UT WOS:000209374100089 PM 23596445 ER PT J AU Gao, JB Gurbaxani, BM Hu, J Heilman, KJ Emanuele, VA Lewis, GF Davila, M Unger, ER Lin, JMS AF Gao, Jianbo Gurbaxani, Brian M. Hu, Jing Heilman, Keri J. Emanuele, Vincent A., II Lewis, Greg F. Davila, Maria Unger, Elizabeth R. Lin, Jin-Mann S. TI Multiscale analysis of heart rate variability in non-stationary environments SO FRONTIERS IN PHYSIOLOGY LA English DT Article DE heart rate variability; fractal; adaptive fractal analysis; chaos; scale-dependent Lyapunov exponent; Trier Social Stress Test; chronic fatigue syndrome ID CHRONIC-FATIGUE-SYNDROME; ACUTE MYOCARDIAL-INFARCTION; TIME-SERIES; BEHAVIOR; SLEEP; INTERVAL; INDEXES; CHAOS AB Heart rate variability (HBV) is highly non-stationary, even if no perturbing influences can be identified during the recording of the data The non-stationarity becomes more profound when HRV data are measured in intrinsically non-stationary environments, such as social stress. In general, HRV data measured in such situations are more difficult to analyze than those measured in constant environments. In this paper, we analyze HRV data measured during a social stress test using two multiscale approaches, the adaptive fractal analysis (AFA) and scale-dependent Lyapunov exponent (SDLE), for the purpose of uncovering differences in HRV between chronic fatigue syndrome (CFS) patients and their matched controls. CFS is a debilitating, heterogeneous illness with no known biomarker. HRV has shown some promise recently as a non-invasive measure of subtle physiological disturbances and trauma that are otherwise difficult to assess. If the HRV in persons with CFS are significantly different from their healthy controls, then certain cardiac irregularities may constitute good candidate biomarkers for CFS. Our multiscale analyses show that there are notable differences in HRV between CFS and their matched controls before a social stress test, but these differences seem to diminish during the test. These analyses illustrate that the two employed multiscale approaches could be useful for the analysis of HRV measured in various environments, both stationary and non stationary. C1 [Gao, Jianbo; Hu, Jing] PMB Intelligence LLC, W Lafayette, IN USA. [Gao, Jianbo] Wright State Univ, Dayton, OH 45435 USA. [Gurbaxani, Brian M.; Emanuele, Vincent A., II; Unger, Elizabeth R.; Lin, Jin-Mann S.] Ctr Dis Control & Prevent, Chron Viral Dis Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. [Heilman, Keri J.; Lewis, Greg F.; Davila, Maria] Univ Illinois, Coll Med, Brain Body Ctr, Chicago, IL USA. [Lewis, Greg F.] Res Triangle Inst, Raleigh, NC USA. RP Gao, JB (reprint author), PMB Intelligence, 882 Pecan Ct, Sunnyvale, CA 94087 USA. EM jbgao.pmb@gmail.com; buw8@cdc.gov; dwe3@cdc.gov OI Unger, Elizabeth/0000-0002-2925-5635 NR 51 TC 4 Z9 4 U1 0 U2 5 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-042X J9 FRONT PHYSIOL JI Front. Physiol. PY 2013 VL 4 AR 119 DI 10.3389/fphys.2013.00119 PG 8 WC Physiology SC Physiology GA AX2LA UT WOS:000346774000117 PM 23755016 ER PT J AU An, DTM Minh, HV Huong, LT Giang, KB Xuan, LTT Hai, PT Nga, PQ Hsia, J AF Dao Thi Minh An Hoang Van Minh Le Thi Huong Kim Bao Giang Le Thi Thanh Xuan Phan Thi Hai Pham Quynh Nga Hsia, Jason TI Knowledge of the health consequences of tobacco smoking: a cross-sectional survey of Vietnamese adults SO GLOBAL HEALTH ACTION LA English DT Article DE knowledge; smoking; health consequences; global adult tobacco survey; Vietnam AB Background: Although substantial efforts have been made to curtail smoking in Vietnam, the 2010 Global Adult Tobacco Survey (GATS) revealed that the proportion of male adults currently smoking remains high at 47.4%. Objectives: To determine the level of, and characteristics associated with, knowledge of the health consequences of smoking among Vietnamese adults. Design: GATS 2010 was designed to survey a nationally representative sample of Vietnamese men and women aged 15 and older drawn from 11,142 households using a two-stage sampling design. Descriptive statistics were calculated and multivariate logistic regression was used to examine associations between postulated exposure factors (age, education, access to information, ethnic group etc.) and knowledge on health risks. Results: General knowledge on the health risks of active smoking (AS) and exposure to second hand smoke (SHS) was good (90% and 83%, respectively). However, knowledge on specific diseases related to tobacco smoking (stroke, heart attack, and lung cancer) appeared to be lower (51.5%). Non-smokers had a significantly higher likelihood of demonstrating better knowledge on health risks related to AS (OR 1.6) and SHS (OR 1.7) than smokers. Adults with secondary education, college education or above also had significantly higher levels knowledge of AS/SHS health risks than those with primary education (AS: ORs 1.6, 1.7, and 1.9, respectively, and SHS: ORs 2.4, 3.9, and 5.7 respectively). Increasing age was positively associated with knowledge of the health consequences of SHS, and access to information was significantly associated with knowledge of AS/SHS health risks (ORs 2.3 and 1.9 respectively). Otherwise, non-Kinh ethnic groups had significantly less knowledge on health risks of AS/SHS than Kinh ethnic groups. Conclusions: It may be necessary to target tobacco prevention programs to specific subgroups including current smokers, adults with low education, non-Kinh ethnics in order to increase their knowledge on health risks of smoking. Comprehensive messages and/or images about specific diseases related to AS/SHS should be conveyed using of different channels and modes specific to local cultures to increase knowledge on smoking health consequences for general population. C1 [Dao Thi Minh An; Hoang Van Minh; Le Thi Huong; Kim Bao Giang; Le Thi Thanh Xuan] Hanoi Med Univ, Dept Epidemiol, Inst Prevent Med & Publ Hlth, Hanoi 100803, Vietnam. [Phan Thi Hai] Vietnam Steering Comm Smoking & Hlth, Hanoi, Vietnam. [Pham Quynh Nga] World Hlth Org Off Viet Nam, Hanoi, Vietnam. [Hsia, Jason] Ctr Dis Control & Prevent, Atlanta, GA USA. RP An, DTM (reprint author), Hanoi Med Univ, Dept Epidemiol, Inst Prevent Med & Publ Hlth, Hanoi 100803, Vietnam. EM daothiminhan@yahoo.com FU Ministry of Health; Ministry of Planning and Investment; World Health Organization FX We also acknowledge and highly appreciate the strong commitment, leadership, and support from Ministry of Health and Ministry of Planning and Investment for completing this survey. Excellent cooperation from the Vietnam Steering Committee on Smoking and Health, the GSO, and Hanoi Medical University has contributed to the success of this project.; Our sincere thanks go to the World Health Organization, from Headquarters to Regional Offices to Country levels, for facilitating GATS implementation, providing technical and management assistance, financial support, and coordinating national and international partners. NR 23 TC 3 Z9 3 U1 0 U2 0 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1654-9880 J9 GLOBAL HEALTH ACTION JI Glob. Health Action PY 2013 VL 6 SU 2 BP 42 EP 50 AR 18707 DI 10.3402/gha.v6i0.18707 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V44HM UT WOS:000209740100008 ER PT J AU Fiebelkorn, AP Rosen, JB Brown, C Zimmerman, CM Renshowitz, H D'Andrea, C Gallagher, KM Harpaz, R Zucker, JR AF Fiebelkorn, Amy Parker Rosen, Jennifer B. Brown, Cedric Zimmerman, Christopher M. Renshowitz, Hyman D'Andrea, Christopher Gallagher, Kathleen M. Harpaz, Rafael Zucker, Jane R. TI Environmental factors potentially associated with mumps transmission in Yeshivas during a mumps outbreak among highly vaccinated students Brooklyn, New York, 2009-2010 SO HUMAN VACCINES & IMMUNOTHERAPEUTICS LA English DT Article DE mumps; mumps transmission; environmental risk factors; high MMR vaccine coverage; mumps outbreak ID UNITED-STATES AB During 2009-2010, a large US mumps outbreak occurred affecting two-dose vaccinated 9th-12th grade Orthodox Jewish boys attending all-male yeshivas (private, traditional Jewish schools). Our objective was to understand mumps transmission dynamics in this well-vaccinated population. We surveyed 9th-12th grade male yeshivas in Brooklyn, NY with reported mumps case-students between 9/1/2009 and 3/30/2010. We assessed vaccination coverage, yeshiva environmental factors (duration of school day, density, mixing, duration of contact), and whether environmental factors were associated with increased mumps attack rates. Ten yeshivas comprising 1769 9th-12th grade students and 264 self-reported mumps cases were included. The average yeshiva attack rate was 14.5% (median: 13.5%, range: 1-31%), despite two-dose measles-mumps-rubella vaccine coverage between 90-100%. School duration was 9-15.5 h/day; students averaged 7 h face-to-face/day with 1-4 study partners. Average daily mean density was 6.6 students per 100 square feet. The number of hours spent face-to-face with a study partner and the number of partners per day showed significant positive associations (p < 0.05) with classroom mumps attack rates in univariate analysis, but these associations did not persist in multivariate analysis. This outbreak was characterized by environmental factors unique to the yeshiva setting (e. g., densely populated environment, prolonged face-to-face contact, mixing among infected students). However, these features were present in all included yeshivas, limiting our ability to discriminate differences. Nonetheless, mumps transmission requires close contact, and these environmental factors may have overwhelmed vaccine-mediated protection increasing the likelihood of vaccine failure among yeshiva students. C1 [Fiebelkorn, Amy Parker; Brown, Cedric; Harpaz, Rafael; Zucker, Jane R.] Ctr Dis Control & Prevent CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Rosen, Jennifer B.; Zimmerman, Christopher M.; Renshowitz, Hyman; Zucker, Jane R.] Bur Immunizat, New York City Dept Hlth & Mental Hyg, New York, NY USA. [D'Andrea, Christopher] New York City Dept Hlth & Mental Hyg, Off Environm Invest, New York, NY USA. [Gallagher, Kathleen M.] CDC, Off Surveillance, Epidemiol & Lab Serv, Atlanta, GA 30333 USA. RP Fiebelkorn, AP (reprint author), Ctr Dis Control & Prevent CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM dez8@cdc.gov NR 23 TC 6 Z9 6 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 2164-5515 EI 2164-554X J9 HUM VACC IMMUNOTHER JI Human Vaccines Immunother. PD JAN PY 2013 VL 9 IS 1 BP 189 EP 194 DI 10.4161/hv.22415 PG 6 WC Biotechnology & Applied Microbiology; Immunology SC Biotechnology & Applied Microbiology; Immunology GA 098VR UT WOS:000315577700033 PM 23442590 ER PT S AU Douglas, TD Kennedy, MJ Quirk, ME Yi, SH Singh, RH AF Douglas, Teresa D. Kennedy, Mary J. Quirk, Meghan E. Yi, Sarah H. Singh, Rani H. BE Zschocke, J Gibson, KM Brown, G Morava, E Peters, V TI Accuracy of Six Anthropometric Skinfold Formulas Versus Air Displacement Plethysmography for Estimating Percent Body Fat in Female Adolescents with Phenylketonuria SO JIMD REPORTS, VOL 10 SE JIMD Reports LA English DT Article; Book Chapter ID BIOELECTRICAL-IMPEDANCE ANALYSIS; X-RAY ABSORPTIOMETRY; AFRICAN-AMERICAN; FREE MASS; PREDICTION EQUATIONS; THICKNESS EQUATIONS; PHYSICAL GROWTH; YOUNG-WOMEN; CHILDREN; DENSITY AB Background: The reliability of studies investigating biological and therapeutic factors that influence body composition in PKU patients depends on accurate anthropometric measurements. Objective: To determine the precision of six anthropometric skinfold equations versus air displacement plethysmography (ADP) for predicting body fat (BF) percentage in female adolescents with PKU. Design: Skinfold and ADP measurements were recorded from a cross section of 59 female patients with PKU, ages 10-19 years. Anthropometric measures were used to calculate percent BF using equations published by Peterson et al., Loftin et al. (TAAG), Slaughter et al., Wilmore and Behnke, Durnin and Womersley, and Jackson et al. Bland-Altman agreement analysis and Lin's concordance correlation coefficient (pc) were used to determine the precision of each equation compared with percent BF determined by ADP. Results: Adolescent females with PKU had a mean BF content of 33% measured by ADP, with an inverse association to birth cohort (r = -0.3, P = 0.016). Based on the Bland-Altman method for evaluating agreement, only Peterson's equation did not differ significantly from ADP percent BF results ( P - 0.23). Peterson's skinfold equation yielded percent BF estimates with the smallest mean difference from ADP and the smallest standard deviation (0.76 +/- 4.8), whereas Slaughter's equation had the largest (-7.7 +/- 7.4). Loftin's TAAG equation had the least mean percent error (2.2%), while Slaughter's equation had the highest (19%). Both TAAG and Peterson's equations had the highest concordance correlation coefficients (pc = 0.8, pc = 0.8), while Slaughter's equation had the lowest (pc = 0.3). Conclusions: Peterson's equation is a precise surrogate for ADP when estimating percent BF in female adolescents with PKU, though Loftin's TAAG equation is also effective. Observed decreases in adiposity correlating with birth cohort could reflect steady improvements in patient nutrition care. C1 [Kennedy, Mary J.; Singh, Rani H.] Emory Univ, Sch Med, Nutr Metab Program, Dept Human Genet,Div Med Genet, 2165 North Decatur Rd, Decatur, GA 30033 USA. [Douglas, Teresa D.; Quirk, Meghan E.; Singh, Rani H.] Emory Univ, Sch Med, Grad Div Biol & Biomed Sci, Nutr & Hlth Sci Program, Decatur, GA 30033 USA. [Yi, Sarah H.] Ctr Dis Control & Prevent CDC, Div Healthcare Qual Promot, Atlanta, GA USA. RP Singh, RH (reprint author), Emory Univ, Sch Med, Nutr Metab Program, Dept Human Genet,Div Med Genet, 2165 North Decatur Rd, Decatur, GA 30033 USA. EM rsingh@emory.edu NR 52 TC 2 Z9 2 U1 1 U2 1 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 2192-8304 BN 978-3-642-37334-3; 978-3-642-37333-6 J9 JIMD REP PY 2013 VL 10 BP 23 EP 31 DI 10.1007/8904_2012_196 D2 10.1007/978-3-642-37334-3 PG 9 WC Endocrinology & Metabolism; Genetics & Heredity SC Endocrinology & Metabolism; Genetics & Heredity GA BE8SB UT WOS:000376974300004 PM 23430796 ER PT J AU Matjasko, JL Vivolo-Kantor, AM AF Matjasko, Jennifer L. Vivolo-Kantor, Alana M. TI The Relationship between a Family-Focused Preventive Intervention, Parenting Practices, and Exposure to Violence during the Transition to Adolescence: Testing a Mediational Model SO JOURNAL OF AGGRESSION MALTREATMENT & TRAUMA LA English DT Article DE at-risk; exposure to violence; families; mediators; parenting; prevention; transition to adolescence AB To prevent youth violence, the GREAT Families program was implemented with a selective sample of 1,196 families of sixth-grade children from low-income schools in 4 cities making the transition to adolescence. To assess intervention effects, we used pre- and posttest data to estimate a structural model to test the hypothesis that random assignment to the intervention would predict changes in parenting practices, which in turn would predict changes in exposure to violence (i.e., a mediational model). We found that participation in GREAT was significantly related to changes in parenting practices and these changes significantly predicted changes in violence exposure. Furthermore, adolescents who reported greater increases in exposure to violence also tended to experience greater decreases in parental monitoring, discipline, and involvement. Implications for future research and prevention efforts are discussed. C1 [Matjasko, Jennifer L.; Vivolo-Kantor, Alana M.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Violence Prevent, Atlanta, GA 30341 USA. RP Matjasko, JL (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, 4770 Buford Highway NE,MS F-64, Atlanta, GA 30341 USA. EM JMatjasko@cdc.gov NR 50 TC 4 Z9 4 U1 1 U2 1 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1092-6771 EI 1545-083X J9 J AGGRESS MALTREAT T JI J. Aggress. Maltreatment Trauma PY 2013 VL 22 IS 1 SI SI BP 45 EP 66 DI 10.1080/10926771.2013.743947 PG 22 WC Psychology, Clinical; Criminology & Penology; Family Studies; Psychiatry SC Psychology; Criminology & Penology; Family Studies; Psychiatry GA V37VK UT WOS:000209303100004 ER PT J AU Eriksson, CB Cardozo, BL Ghitis, F Sabin, M Crawford, CG Zhu, J Rijnen, B Kaiser, R AF Eriksson, Cynthia B. Cardozo, Barbara Lopes Ghitis, Frida Sabin, Miriam Crawford, Carol Gotway Zhu, Julia Rijnen, Bas Kaiser, Reinhard TI Factors Associated With Adverse Mental Health Outcomes in Locally Recruited Aid Workers Assisting Iraqi Refugees in Jordan SO JOURNAL OF AGGRESSION MALTREATMENT & TRAUMA LA English DT Article DE humanitarian aid workers; Jordan; mental health; refugees AB Nongovernmental organizations (NGOs) serve Iraqis living in Jordan as "guests." In 2008, 258 Jordanian humanitarian staff and Iraqi volunteers working for NGOs completed a needs assessment survey. Work characteristics, stressors, and support variables were evaluated regarding their influence on depression, anxiety, post-traumatic stress disorder (PTSD), and burnout through multivariate logistic regressions. There was a significant difference in depression, anxiety, and burnout across nationality. Traumatic exposure increased the risk for anxiety, depression, and PTSD. Working longer in the humanitarian sector was associated with less risk of anxiety and depression, and lower social support was a risk for anxiety. Managers were at higher risk for burnout, and low team cohesion was a risk for burnout. Implications for aid organizations are discussed. C1 [Eriksson, Cynthia B.] Fuller Theol Seminary, Grad Sch Psychol, Pasadena, CA 91101 USA. [Cardozo, Barbara Lopes; Crawford, Carol Gotway; Zhu, Julia] Ctr Dis Control & Prevent, Atlanta, GA USA. [Ghitis, Frida] Int Insights Inc, Atlanta, GA USA. [Sabin, Miriam; Rijnen, Bas] Antares Fdn, Amsterdam, Netherlands. [Kaiser, Reinhard] Ctr Dis Control & Prevent, Ctr Global Hlth, Nairobi, Kenya. RP Eriksson, CB (reprint author), Fuller Theol Seminary, Grad Sch Psychol, 180 North Oakland Ave, Pasadena, CA 91101 USA. EM eriksson@fuller.edu FU Bureau of Populations and Migration of the U.S. State Department; Centers for Disease Control and Prevention (CDC) International Emergency Refugee Health Branch FX The authors wish to acknowledge Tineke van Pietersom of the Antares Foundation for project leadership and Reem Mossa, the local project coordinator and translator, for her invaluable all-around support and translations. Antares received funding from the Bureau of Populations and Migration of the U.S. State Department for this project, and the Centers for Disease Control and Prevention (CDC) International Emergency Refugee Health Branch provided funding for travel and salary of one mental health expert on the team. The protocol and instruments used in this needs assessment were based on previous work by the CDC/Antares Foundation Cooperative agreement research consortium, which consists of the following individuals: Alastair Ager, Columbia University; Carol Gotway Crawford, CDC; Cynthia B. Eriksson, Fuller Theological Seminary, Graduate School of Psychology; David Foy, Pepperdine University; Miranda Olff, University of Amsterdam; Barbara Lopes Cardozo, CDC/International Emergency and Refugee Health Branch; Reinhard Kaiser, Global AIDS Program, CDC Kenya; Willem Scholte, University of Amsterdam; Leslie Snider, War Trauma Foundation; and Miriam Sabin, The Antares Foundation. NR 34 TC 2 Z9 2 U1 2 U2 9 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1092-6771 EI 1545-083X J9 J AGGRESS MALTREAT T JI J. Aggress. Maltreatment Trauma PY 2013 VL 22 IS 6 BP 660 EP 680 DI 10.1080/10926771.2013.803506 PG 21 WC Psychology, Clinical; Criminology & Penology; Family Studies; Psychiatry SC Psychology; Criminology & Penology; Family Studies; Psychiatry GA V37VP UT WOS:000209303600006 ER PT J AU Cummings, KJ Fink, JN Vasudev, M Piacitelli, C Kreiss, K AF Cummings, Kristin J. Fink, Jordan N. Vasudev, Monica Piacitelli, Chris Kreiss, Kathleen TI Vocal Cord Dysfunction Related to Water-Damaged Buildings SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE LA English DT Article DE Vocal cord dysfunction; Asthma; Dampness; Mold AB BACKGROUND: Vocal cord dysfunction (VCD) is the intermittent paradoxical adduction of the vocal cords during respiration, resulting in variable upper airway obstruction. Exposure to damp indoor environments is associated with adverse respiratory health outcomes, including asthma, but its role in the development of VCD is not well described. OBJECTIVE: We describe the spectrum of respiratory illness in occupants of 2 water-damaged office buildings. METHODS: The National Institute for Occupational Safety and Health conducted a health hazard evaluation that included interviews with managers, a maintenance officer, a remediation specialist who had evaluated the 2 buildings, employees, and consulting physicians. In addition, medical records and reports of building evaluations were reviewed. Diagnostic evaluations for VCD had been conducted at the Asthma and Allergy Center of the Medical College of Wisconsin. RESULTS: Two cases of VCD were temporally related to occupancy of water-damaged buildings. The patients experienced cough, chest tightness, dyspnea, wheezing, and hoarseness when in the buildings. Spirometry was normal. Methacholine challenge did not show bronchial hyperreactivity but did elicit symptoms of VCD and inspiratory flow-volume loop truncation. Direct laryngoscopy revealed vocal cord adduction during inspiration. Coworkers developed upper and lower respiratory symptoms; their diagnoses included sinusitis and asthma, consistent with recognized effects of exposure to indoor dampness. Building evaluations provided evidence of water damage and mold growth. CONCLUSION: VCD can occur with exposure to waterdamaged buildings and should be considered in exposed patients with asthma-like symptoms. C1 [Cummings, Kristin J.; Piacitelli, Chris; Kreiss, Kathleen] NIOSH, Div Resp Dis Studies, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Fink, Jordan N.; Vasudev, Monica] Med Coll Wisconsin, Milwaukee, WI 53226 USA. RP Cummings, KJ (reprint author), NIOSH, Ctr Dis Control & Prevent, 1095 Willowdale Rd,MS 2800, Morgantown, WV 26505 USA. EM kcummings@cdc.gov FU National Institute for Occupational Safety and Health, Centers for Diseases Control and Prevention FX Supported by intramural funding from the National Institute for Occupational Safety and Health, Centers for Diseases Control and Prevention. NR 29 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2213-2198 EI 2213-2201 J9 J ALLER CL IMM-PRACT JI J. Allergy Clin. Immunol.-Pract. PD JAN PY 2013 VL 1 IS 1 BP 46 EP 50 DI 10.1016/j.jaip.2012.10.001 PG 5 WC Allergy; Immunology SC Allergy; Immunology GA V38WT UT WOS:000209374200007 PM 24229821 ER PT B AU Gregg, EW AF Gregg, Edward W. BE Rippe, JM TI Epidemiology and Prevention of Type 2 Diabetes SO LIFESTYLE MEDICINE, 2ND EDITION LA English DT Article; Book Chapter ID LIFE-STYLE INTERVENTION; IMPAIRED GLUCOSE-TOLERANCE; SUGAR-SWEETENED BEVERAGES; MIDDLE-AGED WOMEN; BODY-MASS INDEX; UNITED-STATES; FOLLOW-UP; METABOLIC SYNDROME; PUBLIC-HEALTH; WEIGHT-GAIN C1 [Gregg, Edward W.] Ctr Dis Control & Prevent, Epidemiol & Stat Branch, Div Diabet Translat, Atlanta, GA 30329 USA. RP Gregg, EW (reprint author), Ctr Dis Control & Prevent, Epidemiol & Stat Branch, Div Diabet Translat, Atlanta, GA 30329 USA. NR 61 TC 0 Z9 0 U1 0 U2 0 PU CRC PRESS-TAYLOR & FRANCIS GROUP PI BOCA RATON PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA BN 978-1-4398-4544-8; 978-1-4398-4542-4 PY 2013 BP 1281 EP 1288 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA BF6FT UT WOS:000383033900108 ER PT B AU Sleet, DA Ballesteros, MF Baldwin, GT AF Sleet, David A. Ballesteros, Michael F. Baldwin, Grant T. BE Rippe, JM TI Injuries and Lifestyle Medicine SO LIFESTYLE MEDICINE, 2ND EDITION LA English DT Article; Book Chapter ID UNITED-STATES; PREVENTION C1 [Sleet, David A.] Ctr Dis Control & Prevent, Sci, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30329 USA. [Ballesteros, Michael F.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA. [Baldwin, Grant T.] Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. RP Sleet, DA (reprint author), Ctr Dis Control & Prevent, Sci, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30329 USA. NR 36 TC 0 Z9 0 U1 1 U2 1 PU CRC PRESS-TAYLOR & FRANCIS GROUP PI BOCA RATON PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA BN 978-1-4398-4544-8; 978-1-4398-4542-4 PY 2013 BP 1447 EP 1455 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA BF6FT UT WOS:000383033900122 ER PT B AU Ballesteros, MF Gielen, A AF Ballesteros, Michael F. Gielen, Andrea BE Rippe, JM TI Patient Counseling for Unintentional Injury Prevention SO LIFESTYLE MEDICINE, 2ND EDITION LA English DT Article; Book Chapter ID SERVICES-TASK-FORCE; PRIMARY-CARE; RANDOMIZED TRIAL; ADULTS; INTERVENTIONS; GUIDELINES; CHILDREN; PROMOTE; SAFETY C1 [Ballesteros, Michael F.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA 30329 USA. [Gielen, Andrea] Johns Hopkins Ctr Injury Res & Policy, Baltimore, MD USA. RP Ballesteros, MF (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA 30329 USA. NR 36 TC 0 Z9 0 U1 0 U2 0 PU CRC PRESS-TAYLOR & FRANCIS GROUP PI BOCA RATON PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA BN 978-1-4398-4544-8; 978-1-4398-4542-4 PY 2013 BP 1457 EP 1462 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA BF6FT UT WOS:000383033900123 ER PT B AU Dellinger, AM Sleet, DA AF Dellinger, Ann M. Sleet, David A. BE Rippe, JM TI Preventing Traffic Injuries Strategies That Work SO LIFESTYLE MEDICINE, 2ND EDITION LA English DT Article; Book Chapter ID MOTOR-VEHICLE CRASHES; BOOSTER SEAT USE; UNITED-STATES; RESTRAINT USE; INTERVENTIONS; RISK; CHILDREN; INCREASE; SAFETY; EXPERIENCE C1 [Dellinger, Ann M.] Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30329 USA. [Sleet, David A.] Ctr Dis Control & Prevent, Sci, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. RP Dellinger, AM (reprint author), Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30329 USA. NR 90 TC 1 Z9 1 U1 0 U2 0 PU CRC PRESS-TAYLOR & FRANCIS GROUP PI BOCA RATON PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA BN 978-1-4398-4544-8; 978-1-4398-4542-4 PY 2013 BP 1463 EP 1472 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA BF6FT UT WOS:000383033900124 ER PT B AU Mack, KA Liller, KD AF Mack, Karin A. Liller, Karen DeSafey BE Rippe, JM TI Preventing Injuries at Home SO LIFESTYLE MEDICINE, 2ND EDITION LA English DT Article; Book Chapter ID UNITED-STATES; EMERGENCY-DEPARTMENTS; UNINTENTIONAL INJURIES; META-REGRESSION; OLDER ADULTS; CHILDREN; FALLS; CHILDHOOD; RISK; US C1 [Mack, Karin A.] Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30329 USA. [Liller, Karen DeSafey] Univ S Florida, Grad Sch, Tampa, FL USA. [Liller, Karen DeSafey] Univ S Florida, Res & Innovat, Tampa, FL USA. [Liller, Karen DeSafey] Univ S Florida, Coll Publ Hlth, Tampa, FL USA. RP Mack, KA (reprint author), Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30329 USA. NR 89 TC 0 Z9 0 U1 0 U2 0 PU CRC PRESS-TAYLOR & FRANCIS GROUP PI BOCA RATON PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA BN 978-1-4398-4544-8; 978-1-4398-4542-4 PY 2013 BP 1485 EP 1493 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA BF6FT UT WOS:000383033900126 ER PT B AU Stevens, JA Baldwin, GT Ballesteros, MF Noonan, RK Sleet, DA AF Stevens, Judy A. Baldwin, Grant T. Ballesteros, Michael F. Noonan, Rita K. Sleet, David A. BE Rippe, JM TI Falls and Fall Injuries among Older Adults SO LIFESTYLE MEDICINE, 2ND EDITION LA English DT Article; Book Chapter ID RANDOMIZED CONTROLLED-TRIAL; NURSING-HOME RESIDENTS; RISK-FACTORS; HIP FRACTURE; CATARACT-SURGERY; MULTIFACTORIAL INTERVENTION; GENDER-DIFFERENCES; VISUAL IMPAIRMENT; FUNCTIONAL STATUS; PREVENTING FALLS C1 [Stevens, Judy A.; Baldwin, Grant T.] Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30329 USA. [Ballesteros, Michael F.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA. [Noonan, Rita K.] Ctr Dis Control & Prevent, Program Dev & Integrat, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Sleet, David A.] Ctr Dis Control & Prevent, Sci, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. RP Stevens, JA (reprint author), Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30329 USA. NR 108 TC 0 Z9 0 U1 2 U2 2 PU CRC PRESS-TAYLOR & FRANCIS GROUP PI BOCA RATON PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA BN 978-1-4398-4544-8; 978-1-4398-4542-4 PY 2013 BP 1495 EP 1505 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA BF6FT UT WOS:000383033900127 ER PT B AU Coronado, VG McGuire, LC Lionbarger, MR Wald, MM Sarmiento, K Gilchrist, J AF Coronado, Victor G. McGuire, Lisa C. Lionbarger, Michael R. Wald, Marlena M. Sarmiento, Kelly Gilchrist, Julie BE Rippe, JM TI Sports and Recreation-Related Traumatic Brain Injury SO LIFESTYLE MEDICINE, 2ND EDITION LA English DT Article; Book Chapter ID MINOR HEAD-INJURY; SCHOOL FOOTBALL PLAYERS; UNITED-STATES; SOCCER PLAYERS; CLINICAL MANAGEMENT; EXTERNAL CAUSE; YOUNG ATHLETE; CONCUSSION; EPIDEMIOLOGY; COLLEGIATE C1 [Coronado, Victor G.; McGuire, Lisa C.; Lionbarger, Michael R.; Sarmiento, Kelly; Gilchrist, Julie] Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30329 USA. [Wald, Marlena M.] Ctr Dis Control & Prevent, Div Injury Response, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. RP Coronado, VG (reprint author), Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30329 USA. NR 117 TC 1 Z9 1 U1 0 U2 0 PU CRC PRESS-TAYLOR & FRANCIS GROUP PI BOCA RATON PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA BN 978-1-4398-4544-8; 978-1-4398-4542-4 PY 2013 BP 1519 EP 1530 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA BF6FT UT WOS:000383033900129 ER PT B AU Visvesvara, GS Qvarnstrom, Y AF Visvesvara, Govinda S. Qvarnstrom, Yvonne BE Liu, D TI Balamuthia SO MOLECULAR DETECTION OF HUMAN PARASITIC PATHOGENS LA English DT Article; Book Chapter ID GRANULOMATOUS AMEBIC ENCEPHALITIS; FREE-LIVING AMEBAS; MICROVASCULAR ENDOTHELIAL-CELLS; RIBOSOMAL-RNA GENE; CENTRAL-NERVOUS-SYSTEM; MANDRILLARIS MENINGOENCEPHALITIS; LEPTOMYXID-AMEBA; IN-VITRO; OPPORTUNISTIC AMEBAS; SAPPINIA-DIPLOIDEA C1 [Visvesvara, Govinda S.] Ctr Dis Control & Prevent, Dept Hlth & Human Serv, Publ Hlth Serv, Atlanta, GA 30322 USA. [Qvarnstrom, Yvonne] Ctr Dis Control & Prevent, Dept Hlth & Human Serv, Atlanta, GA USA. RP Visvesvara, GS (reprint author), Ctr Dis Control & Prevent, Dept Hlth & Human Serv, Publ Hlth Serv, Atlanta, GA 30322 USA. NR 126 TC 0 Z9 0 U1 0 U2 0 PU CRC PRESS-TAYLOR & FRANCIS GROUP PI BOCA RATON PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA BN 978-1-4398-1243-3; 978-1-4398-1242-6 PY 2013 BP 25 EP 38 PG 14 WC Parasitology SC Parasitology GA BC7QM UT WOS:000355146200004 ER PT B AU Feng, YY Xiao, LH AF Feng, Yaoyu Xiao, Lihua BE Liu, D TI Giardia SO MOLECULAR DETECTION OF HUMAN PARASITIC PATHOGENS LA English DT Article; Book Chapter ID POLYMERASE-CHAIN-REACTION; FRAGMENT LENGTH POLYMORPHISM; INTESTINAL PARASITIC INFECTIONS; GLUTAMATE-DEHYDROGENASE LOCUS; EPITHELIAL BARRIER FUNCTION; DAY-CARE-CENTERS; RIBOSOMAL-RNA; RISK-FACTORS; MOLECULAR EPIDEMIOLOGY; ZOONOTIC TRANSMISSION C1 [Feng, Yaoyu] E China Univ Sci & Technol, Sch Resource & Environm Engn, Shanghai 200237, Peoples R China. [Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne & Waterborne Dis Prevent, Atlanta, GA USA. RP Feng, YY (reprint author), E China Univ Sci & Technol, Sch Resource & Environm Engn, Shanghai 200237, Peoples R China. RI Xiao, Lihua/B-1704-2013 OI Xiao, Lihua/0000-0001-8532-2727 NR 121 TC 0 Z9 0 U1 0 U2 0 PU CRC PRESS-TAYLOR & FRANCIS GROUP PI BOCA RATON PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA BN 978-1-4398-1243-3; 978-1-4398-1242-6 PY 2013 BP 77 EP 90 PG 14 WC Parasitology SC Parasitology GA BC7QM UT WOS:000355146200008 ER PT J AU Ahmed, S Delaney, K Villalba-Diebold, P Aliyu, G Constantine, N Ememabelem, M Vertefeuille, J Blattner, W Nasidi, A Charurat, M AF Ahmed, Saidu Delaney, Kevin Villalba-Diebold, Pacha Aliyu, Gambo Constantine, Niel Ememabelem, Martins Vertefeuille, John Blattner, William Nasidi, Abdulsalami Charurat, Man TI HIV counseling and testing and access-to-care needs of populations most-at-risk for HIV in Nigeria SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV LA English DT Article DE HIV counseling and testing; most-at-risk populations; Nigeria ID FEMALE SEX WORKERS; CONDOM USE; TRANSMISSION; PREVALENCE AB Mobile HIV counseling and testing (mHCT) is an effective tool to access hard-to-reach most-at-risk populations (MARPs), but identifying which populations are not accessing services is often a challenge. We compared correlates of human immunodeficiency virus (HIV) infection and awareness of HIV care services among populations tested through mHCT and at testing facilities in Nigeria. Participants in a cross-sectional study completed a questionnaire and HCT between May 2005 and March 2010. Of 27,586 total participants, 26.7% had been previously tested for HIV; among mHCT clients, 14.7% had previously been tested. HIV prevalence ranged from 6.6% among those tested through a facility to 50.4% among brothel-based sex workers tested by mHCT. Among mHCT participants aged 18-24, women were nine times more likely to be infected than men. Women aged 18-24 were also less likely than their male counterparts to know that there were medicines available to treat HIV (63.2 vs. 68.1%; p=0.03). After controlling for gender, age, and other risk factors, those with current genital ulcer disease were more likely to be HIV-infected (ORmHCT=1.65, 1.31-2.09; ORfacility=1.71, 1.37-2.14), while those previously tested were less likely to be HIV-infected (ORmHCT=0.75, 0.64-0.88; ORfacility=0.27, 0.24-0.31). There is an urgent need to promote strategies to identify those who are HIV-infected within MARPs, particularly young women, and to educate and inform them about availability of HIV testing and care services. mHCT, ideally coupled with sexually transmitted infection management, may help to ensure that MARPs access HIV prevention support, and if infected, access care, and treatment. C1 [Villalba-Diebold, Pacha; Aliyu, Gambo; Constantine, Niel; Blattner, William; Charurat, Man] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA. [Ahmed, Saidu; Aliyu, Gambo; Nasidi, Abdulsalami] Nigerian Fed Minist Hlth, Abuja, Nigeria. [Delaney, Kevin] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Hepatitis STD & TB Prevent, Atlanta, GA USA. [Ememabelem, Martins; Nasidi, Abdulsalami] Fed Capital Terr, Reach Care Fdn, Abuja, Nigeria. [Vertefeuille, John] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Hepatitis STD & TB Prevent, Global AIDS Program, Atlanta, GA USA. RP Charurat, M (reprint author), Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA. EM mcharurat@ihv.umaryland.edu FU FIC NIH HHS [D43 TW001041]; NCHHSTP CDC HHS [U2G PS000651]; PHS HHS [200-2003-01716, 5U2GPS000651] NR 20 TC 7 Z9 7 U1 1 U2 14 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0954-0121 J9 AIDS CARE JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv PY 2013 VL 25 IS 1 BP 85 EP 94 DI 10.1080/09540121.2012.686597 PG 10 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Respiratory System; Social Sciences, Biomedical SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychology; Respiratory System; Biomedical Social Sciences GA 046SB UT WOS:000311783600012 PM 22709242 ER PT J AU Hewett, R VanCuren, A Trocio, L Beaudrault, S Gund, A Luther, M Groom, H AF Hewett, Rafe VanCuren, Anne Trocio, Loralee Beaudrault, Sara Gund, Anona Luther, Mimi Groom, Holly TI Rules and Tools That Improved Vaccines for Children Vaccine-Ordering Practices in Oregon: A 2010 Pilot Project SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE provider behavior; vaccine; Vaccines for Children program; vaccine ordering AB Objective: This project's objective was to enhance efforts to improve vaccine-ordering efficiencies among targeted clinics using publicly purchased vaccines. Design: Using an assessment of ordering behavior developed by the Centers for Disease Control and Prevention, we selected and trained immunization providers and assessed improvements in ordering behavior by comparing ordering patterns before and after the intervention. Setting: A total of 144 Vaccines for Children program providers in Oregon. Participants: We assessed 144 providers trained in the Economic Order Quantity process between January and November 2010. Intervention (if applicable): Providers were invited to participate in regional trainings. Trainings included assignment of ordering frequency and dissemination of tools to support adherence to the recommended ordering frequency. Main Outcome Measure(s): The percent increase in targeted clinics ordering according to recommended order frequency and the resulting decrease in orders placed, as an outcome of training and ordering tools. Results: Only 35% of targeted providers were ordering according to the recommended ordering frequency before the project began. After completing training, utilizing ordering tools and ordering over a 7-month period, 78% of the targeted clinics were ordering according to the recommended frequency, a 120% increase in the number of clinics ordering with the recommended frequency. At baseline, targeted clinics placed 915 total vaccine orders over a 7-month period. After completing training and participating in the Economic Order Quantity process, only 645 orders were placed, a reduction of 30%. Conclusions: The initiative was successful in reducing the number of orders placed by Vaccines for Children providers in Oregon. A previous effort to reduce ordering, without the use of training or tools, did not achieve the same levels of provider compliance, suggesting that the addition of staff and development of tools were helpful in supporting behavior change and improving providers' ability to adhere to assigned order frequencies. Reducing order frequency results in more efficient vaccine ordering patterns and benefits vaccine distributors, Oregon Immunization Program staff, and provider staff. C1 [Hewett, Rafe; VanCuren, Anne; Trocio, Loralee; Beaudrault, Sara; Gund, Anona; Luther, Mimi; Groom, Holly] Oregon Hlth Author, Oregon Immunizat Program, Portland, OR 97232 USA. [Groom, Holly] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Hewett, R (reprint author), Oregon Hlth Author, Oregon Immunizat Program, 800 NE Oregon St,Ste 370, Portland, OR 97232 USA. EM rafe.g.hewett@state.or.us OI Groom, Holly/0000-0003-2866-9788 FU PHS HHS [28054009] NR 11 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD JAN-FEB PY 2013 VL 19 IS 1 BP 9 EP 15 DI 10.1097/PHH.0b013e3182464778 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 047HO UT WOS:000311830300007 PM 23169398 ER PT J AU Luo, HB Sotnikov, S Shah, G Galuska, DA Zhang, XZ AF Luo, Huabin Sotnikov, Sergey Shah, Gulzar Galuska, Deborah A. Zhang, Xinzhi TI Variation in Delivery of the 10 Essential Public Health Services by Local Health Departments for Obesity Control in 2005 and 2008 SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE essential public health services; local health department; obesity control ID UNITED-STATES; CORE FUNCTIONS; US ADULTS; PERFORMANCE; PREVENTION; PREVALENCE; DETERMINANTS; OVERWEIGHT; PROVIDERS; PROGRAMS AB Objectives: To describe and compare the capacity of local health departments (LHDs) to perform 10 essential public health services (EPHS) for obesity control in 2005 and 2008, and explore factors associated with provision of these services. Methods: The data for this study were drawn from the 2005 and 2008 National Profile of Local Health Department surveys, conducted by the National Association of County and City Health Officials. Data were analyzed in SAS version 9.1 (SAS Institute Inc, Cary, North Carolina). Results: The proportion of LHDs that reported that they do not provide any of the EPHS for obesity control decreased from 27.9% in 2005 to 17.0% in 2008. In both 2005 and 2008, the 2 most frequently provided EPHS for obesity control by LHDs were informing, educating, and empowering the people (EPHS 3) and linking people to needed personal health services (EPHS 7). The 2 least frequently provided services were enforcing laws and regulations (EPHS 6) and conducting research (EPHS 10). On average, LHDs provided 3.05 EPHS in 2005 and 3.69 EPHS in 2008. Multiple logistic regression results show that LHDs with larger jurisdiction population, with a local governance, and those that have completed a community health improvement plan were more likely to provide more of the EPHS for obesity (P < .05). Conclusions: The provision of the 10 EPHS for obesity control by LHDs remains low. Local health departments need more assistance and resources to expand performance of EPHS for obesity control. Future studies are needed to evaluate and promote LHD capacity to deliver evidence-based strategies for obesity control in local communities. C1 [Luo, Huabin] Mt Olive Coll, Dept Hlth Care Management, Tillman Sch Business, Mt Olive, NC 28365 USA. [Zhang, Xinzhi] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Galuska, Deborah A.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. [Sotnikov, Sergey] OSTLTS, Atlanta, GA USA. [Shah, Gulzar] Georgia So Univ, Dept Hlth Policy & Management, Statesboro, GA 30460 USA. [Luo, Huabin] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. RP Luo, HB (reprint author), Mt Olive Coll, Dept Hlth Care Management, Tillman Sch Business, 634 Henderson St, Mt Olive, NC 28365 USA. EM hluo@moc.edu FU Intramural CDC HHS [CC999999] NR 36 TC 7 Z9 7 U1 1 U2 16 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD JAN-FEB PY 2013 VL 19 IS 1 BP 53 EP 61 DI 10.1097/PHH.0b013e31824dcd81 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 047HO UT WOS:000311830300013 PM 23169404 ER PT J AU Cantey, PT Chuk, MG Kohl, KS Herrmann, J Weiss, P Graffunder, CM Averhoff, F Kahn, EB Painter, J AF Cantey, Paul T. Chuk, Michelle G. Kohl, Katrin S. Herrmann, Jack Weiss, Paul Graffunder, Corinne M. Averhoff, Francisco Kahn, Emily B. Painter, John TI Public Health Emergency Preparedness: Lessons Learned About Monitoring of Interventions From the National Association of County and City Health Official's Survey of Nonpharmaceutical Interventions for Pandemic H1N1 SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE local health departments; nonpharmaceutical interventions; pandemic H1N1; public health emergency preparedness ID LOCAL HEALTH; INFLUENZA AB Objectives: We assessed local health departments' (LHDs') ability to provide data on nonpharmaceutical interventions (NPIs) for the mitigation of 2009 H1N1 influenza during the pandemic response. Design: Local health departments voluntarily participated weekly in a National Association of County and City Health Officials Web-based survey designed to provide situational awareness to federal partners about NPI recommendations and implementation during the response and to provide insight into the epidemiologic context in which recommendations were made. Setting: Local health departments during the fall 2009 H1N1 pandemic response. Participants: Local health departments that voluntarily participated in the National Association of County and City Health Officials Sentinel Surveillance Network. Main Outcome Measures: Local health departments were asked to report data on recommendations for and the implementation of NPIs from 7 community sectors. Data were also collected on influenza outbreaks; closures, whether recommended by the local health department or not; absenteeism of students in grades K-12; the type(s) of influenza viruses circulating in the jurisdiction; and the health care system capacity. Results: One hundred thirty-nine LHDs participated. Most LHDs issued NPI recommendations to their community over the 10-week survey period with 70% to 97% of LHDs recommending hand hygiene and cough etiquette and 51% to 78% voluntary isolation of ill patients. However, 21% to 48% of LHDs lacked information of closure, absenteeism, or outbreaks in schools, and 28% to 50% lacked information on outpatient clinic capacity. Conclusions: Many LHDs were unable to monitor implementation of NPI (recommended by LHD or not) within their community during the 2009 H1N1 influenza pandemic. This gap makes it difficult to adjust recommendations or messaging during a public health emergency response. Public health preparedness could be improved by strengthening NPI monitoring capacity. C1 [Cantey, Paul T.; Kohl, Katrin S.; Averhoff, Francisco; Kahn, Emily B.; Painter, John] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Graffunder, Corinne M.] Ctr Dis Control & Prevent, Associate Director Policy, Atlanta, GA USA. [Chuk, Michelle G.; Herrmann, Jack] Natl Assoc Cty & City Hlth Officials, Washington, DC USA. [Weiss, Paul] Emory Univ, Dept Biostat, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Cantey, PT (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, 1600 Clifton Rd,MS A-06, Atlanta, GA 30333 USA. EM pcantey@cdc.gov OI Kahn, Emily/0000-0001-7812-7958 FU NCHM CDC HHS [5U38HM000449-04] NR 21 TC 4 Z9 4 U1 0 U2 16 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1078-4659 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD JAN-FEB PY 2013 VL 19 IS 1 BP 70 EP 76 DI 10.1097/PHH.0b013e31824d4666 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 047HO UT WOS:000311830300015 PM 23169406 ER PT J AU Greer, S Williams, I Valderrama, AL Bolton, P Patterson, DG Zhang, ZF AF Greer, Sophia Williams, Ishmael Valderrama, Amy L. Bolton, Patricia Patterson, Davis G. Zhang, Zefeng TI EMS MEDICAL DIRECTION AND PREHOSPITAL PRACTICES FOR ACUTE CARDIOVASCULAR EVENTS SO PREHOSPITAL EMERGENCY CARE LA English DT Article DE emergency medical services; medical director; heart attack; stroke ID SERVICES; ASSOCIATION; OVERSIGHT; SYSTEM; TIME AB Objective. The purpose of this analysis was to determine whether there is an association between type of emergency medical services (EMS) medical direction and local EMS agency practices and characteristics specifically related to emergency response for acute cardiovascular events. Methods. We surveyed 1,292 EMS agencies in nine states. For each cardiovascular prehospital procedure or practice, we compared the proportion of agencies that employed paid (full-or part-time) medical directors with the proportion of agencies that employed volunteer medical directors. We also compared the proportion of EMS agencies who reported direct interaction between emergency medical technicians (EMTs) and their medical director within the previous four weeks with the proportion of agencies who reported no direct interaction. Chi-square tests were used to assess statistical differences in proportion of agencies with a specific procedure by medical director employment status and medical director interaction. We repeated these comparisons using t-tests to evaluate mean differences in call volume. Results. The EMS agencies with prehospital cardiovascular response policies were more likely to report employment of a paid medical director and less likely to report employment of a volunteer medical director. Similarly, agencies with prehospital cardiovascular response practices were more likely to report recent medical director interaction and less likely to report absence of recent medical director interaction. Mean call volumes for chest pain, cardiac arrest, and stroke were higher among agencies having paid medical directors (compared with agencies having volunteer medical directors) and agencies having recent medical director interaction (compared with agencies not having recent medical director interaction). Conclusions. Our study demonstrated that EMS agencies with a paid medical director and agencies with medical director interaction with EMTs in the previous four weeks were more likely to have prehospital cardiovascular procedures in place. Given the strong relationship that both employment status and direct interaction have with the presence of these practices, agencies with limited resources to provide a paid medical director or a medical director that can be actively involved with EMTs should be supported through partnerships and other interventions to ensure that they receive the necessary levels of medical director oversight. C1 [Greer, Sophia; Williams, Ishmael; Valderrama, Amy L.; Zhang, Zefeng] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30341 USA. [Bolton, Patricia] Battelle Mem Inst, Seattle Res Ctr, Seattle, WA USA. [Patterson, Davis G.] Univ Washington, WWAMI Rural Hlth Res Ctr, Seattle, WA 98195 USA. RP Greer, S (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, 4770 Buford Highway NE,MS F-72, Atlanta, GA 30341 USA. EM sgreer@cdc.gov NR 19 TC 3 Z9 3 U1 2 U2 7 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1090-3127 J9 PREHOSP EMERG CARE JI Prehosp. Emerg. Care PD JAN-MAR PY 2013 VL 17 IS 1 BP 38 EP 45 DI 10.3109/10903127.2012.710718 PG 8 WC Emergency Medicine; Public, Environmental & Occupational Health SC Emergency Medicine; Public, Environmental & Occupational Health GA 047KB UT WOS:000311838100006 PM 22913374 ER PT J AU Suchdev, PS Shah, A Jefferds, MED Eleveld, A Patel, M Stein, AD Macdonald, B Ruth, L AF Suchdev, Parminder S. Shah, Ami Jefferds, Maria Elena D. Eleveld, Alie Patel, Minal Stein, Aryeh D. Macdonald, Barbara Ruth, Laird TI Sustainability of market-based community distribution of Sprinkles in western Kenya SO MATERNAL AND CHILD NUTRITION LA English DT Article DE Sprinkles; micronutrient powders; anaemia; sustainability; marketing ID VITAMIN-A-DEFICIENCY; IRON-DEFICIENCY; METAANALYSIS; PROGRAM; ANEMIA; INFLAMMATION; PREVALENCE; FERRITIN; CHILDREN AB To evaluate the sustainability of market-based community distribution of micronutrient powders (Sprinkles (R), Hexagon Nutrition, Mumbai, India.) among pre-school children in Kenya, we conducted in August 2010 a follow-up survey, 18 months after study-related marketing and household monitoring ended. We surveyed 849 children aged 635 months randomly selected from 60 study villages. Nutritional biomarkers were measured by fingerstick; demographic characteristics, Sprinkles purchases and use were assessed through household questionnaires. We compared Sprinkles use, marketing efforts and biomarker levels with the data from surveys conducted in March 2007, March 2008 and March 2009. We used logistic regression to evaluate associations between marketing activities and Sprinkles use in the 2010 survey. At the 2010 follow-up, 21.9% of children used Sprinkles in the previous 7 days, compared with 64.9% in 2008 (P?6 months), and have sought pre-travel advice. Compared to non-expatriates, expatriates returning from Africa had higher proportionate morbidity (PM) for malaria, filariasis, schistosomiasis, and hepatitis E; expatriates from the Asia-Pacific region had higher PM for strongyloidiasis, depression, and anxiety; expatriates returning from Latin America had higher PM for mononucleosis and ingestion-related infections (giardiasis, brucellosis). Expatriates returning from all three regions had higher PM for latent TB, amebiasis, and gastrointestinal infections (other than acute diarrhea) compared to non-expatriates. When the data were stratified by travel reason, business expatriates had higher PM for febrile systemic illness (malaria and dengue) and vaccine-preventable infections (hepatitis A), and volunteer expatriates had higher PM for parasitic infections. Expatriates overall had higher adjusted odds ratios for latent TB and lower odds ratios for acute diarrhea and dermatologic illness. Conclusions: Ill returned expatriates differ from other travelers in travel characteristics and proportionate morbidity for specific diseases, based on the region of exposure and travel reason. They are more likely to present with more serious illness. C1 [Lim, Poh-Lian] Tan Tock Seng Hosp, Inst Infect Dis & Epidemiol, Dept Infect Dis, Singapore, Singapore. [Han, Pauline; Davis, Xiaohong M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Chen, Lin H.] Mt Auburn Hosp, Cambridge, MA USA. [Chen, Lin H.] Harvard Univ, Sch Med, Boston, MA USA. [MacDonald, Susan] Univ Hosp No British Columbia, Prince George, BC, Canada. [Pandey, Prativa] CIWEC Clin Travel Med Ctr, Kathmandu, Nepal. [Hale, DeVon] Univ Utah, Sch Med, Div Infect Dis, Salt Lake City, UT USA. [Schlagenhauf, Patricia] Univ Zurich, Ctr Travel Med, WHO Collaborating Ctr Travellers Hlth, Zurich, Switzerland. [Loutan, Louis] Univ Geneva, Geneva, Switzerland. [Wilder-Smith, Annelies] Heidelberg Univ, Inst Publ Hlth, Heidelberg, Germany. [Freedman, David O.] Univ Alabama Birmingham, Div Infect Dis, Birmingham, AL USA. RP Lim, PL (reprint author), Tan Tock Seng Hosp, Inst Infect Dis & Epidemiol, Dept Infect Dis, Singapore, Singapore. EM pllim@post.harvard.edu RI Wilder-Smith, Annelies/F-8751-2015; OI Wilder-Smith, Annelies/0000-0003-0362-5375; Aoun, Olivier/0000-0001-9554-8439; Gkrania-Klotsas, Effrossyni/0000-0002-0930-8330 FU Xcellerex Inc FX LHC has received research funding from Xcellerex Inc and honoraria from Thompson Media LLC for serving on the editorial board of Travel Medicine Advisor. AWS has received speaker's honoraria from GSK, Sanofi Pasteur and Novartis, and serves on the Novartis Advisory Board for Travel Vaccines. NR 23 TC 18 Z9 18 U1 1 U2 19 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD DEC 31 PY 2012 VL 12 AR 386 DI 10.1186/1471-2334-12-386 PG 10 WC Infectious Diseases SC Infectious Diseases GA 078LA UT WOS:000314099100001 PM 23273048 ER PT J AU Ricks, PM Mavhunga, F Modi, S Indongo, R Zezai, A Lambert, LA DeLuca, N Krashin, JS Nakashima, AK Holtz, TH AF Ricks, Philip M. Mavhunga, Farai Modi, Surbhi Indongo, Rosalia Zezai, Abbas Lambert, Lauren A. DeLuca, Nick Krashin, Jamie S. Nakashima, Allyn K. Holtz, Timothy H. TI Characteristics of multidrug-resistant tuberculosis in Namibia SO BMC INFECTIOUS DISEASES LA English DT Article ID SOUTH-AFRICA; HIV-INFECTION; RISK-FACTORS; COHORT; UGANDA; STRAIN; KENYA AB Background: To describe the epidemiology and possible risk factors for the development of multidrug-resistant tuberculosis (MDR-TB) in Namibia. Methods: Using medical records and patient questionnaires, we conducted a case-control study among patients diagnosed with TB between January 2007 and March 2009. Cases were defined as patients with laboratory-confirmed MDR-TB; controls had laboratory-confirmed drug-susceptible TB or were being treated with WHO Category I or Category II treatment regimens. Results: We enrolled 117 MDR-TB cases and 251 TB controls, of which 100% and 2% were laboratory-confirmed, respectively. Among cases, 97% (113/117) had been treated for TB before the current episode compared with 46% (115/251) of controls (odds ratio [OR] 28.7, 95% confidence interval [CI] 10.3-80.5). Cases were significantly more likely to have been previously hospitalized (OR 1.9, 95% CI 1.1-3.5) and to have had a household member with MDR-TB (OR 5.1, 95% CI 2.1-12.5). These associations remained significant when separately controlled for being currently hospitalized or HIV-infection. Conclusions: MDR-TB was associated with previous treatment for TB, previous hospitalization, and having had a household member with MDR-TB, suggesting that TB control practices have been inadequate. Strengthening basic TB control practices, including expanding laboratory confirmation, directly observed therapy, and infection control, are critical to the prevention of MDR-TB. C1 [Ricks, Philip M.; Modi, Surbhi; Lambert, Lauren A.; Krashin, Jamie S.; Nakashima, Allyn K.; Holtz, Timothy H.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Mavhunga, Farai; Indongo, Rosalia] Minist Hlth & Social Serv, Windhoek, Namibia. [Zezai, Abbas] KNCV TB Fdn, Windhoek, Namibia. [DeLuca, Nick] Ctr Dis Control & Prevent, Windhoek, Namibia. RP Ricks, PM (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM hgp4@cdc.gov OI Krashin, Jamie/0000-0002-7463-6672 NR 39 TC 7 Z9 7 U1 0 U2 21 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD DEC 29 PY 2012 VL 12 AR 385 DI 10.1186/1471-2334-12-385 PG 8 WC Infectious Diseases SC Infectious Diseases GA 078KX UT WOS:000314098800001 PM 23273024 ER PT J AU Jagannathan, P Muhindo, MK Kakuru, A Arinaitwe, E Greenhouse, B Tappero, J Rosenthal, PJ Kaharuza, F Kamya, MR Dorsey, G AF Jagannathan, Prasanna Muhindo, Mary K. Kakuru, Abel Arinaitwe, Emmanuel Greenhouse, Bryan Tappero, Jordan Rosenthal, Philip J. Kaharuza, Frank Kamya, Moses R. Dorsey, Grant TI Increasing incidence of malaria in children despite insecticide-treated bed nets and prompt anti-malarial therapy in Tororo, Uganda SO MALARIA JOURNAL LA English DT Article DE Malaria; Plasmodium falciparum; Immunity; Epidemiology ID PLASMODIUM-FALCIPARUM MALARIA; DIHYDROARTEMISININ-PIPERAQUINE; ARTEMETHER-LUMEFANTRINE; RANDOMIZED-TRIAL; RURAL UGANDA; SCALE-UP; MORBIDITY; MORTALITY; TRANSMISSION; COMBINATION AB Background: The burden of malaria has decreased in parts of Africa following the scaling up of control interventions. However, similar data are limited from high transmission settings. Methods: A cohort of 100 children, aged six weeks to 10 months of age, were enrolled in an area of high malaria transmission intensity and followed through 48 months of age. Children were given a long-lasting insecticide-treated bed net (LLIN) at enrolment and received all care, including monthly blood smears and treatment with artemisinin-based combination therapy (ACT) for uncomplicated malaria, at a dedicated clinic. The incidence of malaria was estimated by passive surveillance and associations between malaria incidence and age, calendar time and season were measured using generalized estimating equations. Results: Reported compliance with LLINs was 98% based on monthly routine evaluations. A total of 1,633 episodes of malaria were observed, with a median incidence of 5.3 per person-year (PPY). There were only six cases of complicated malaria, all single convulsions. Malaria incidence peaked at 6.5 PPY at 23 months of age before declining to 3.5 PPY at 48 months. After adjusting for age and season, the risk of malaria increased by 52% from 2008 to 2011 (RR 1.52, 95% CI 1.10-2.09). Asymptomatic parasitaemia was uncommon (monthly prevalence <10%) and rarely observed prior to 24 months of age. Conclusions: In Tororo, despite provision of LLINs and prompt treatment with ACT, the incidence of malaria is very high and appears to be rising. Additional malaria control interventions in high transmission settings are likely needed. C1 [Jagannathan, Prasanna; Greenhouse, Bryan; Rosenthal, Philip J.; Dorsey, Grant] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94143 USA. [Muhindo, Mary K.; Kakuru, Abel; Arinaitwe, Emmanuel] Infect Dis Res Collaborat, Kampala, Uganda. [Tappero, Jordan] Ctr Dis Control & Prevent, Global AIDS Program, Atlanta, GA USA. [Kaharuza, Frank] Ctr Dis Control & Prevent, Kampala, Uganda. [Kamya, Moses R.] Makerere Univ, Coll Hlth Sci, Dept Med, Kampala, Uganda. RP Jagannathan, P (reprint author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94143 USA. EM jagannathanp@medsfgh.ucsf.edu OI Greenhouse, Bryan/0000-0003-0287-9111 FU Centers for Disease Control and Prevention [U62P024421]; Doris Duke Charitable Foundation; National Institutes of Health [T32 AI60530]; Burroughs Wellcome Fund/American Society of Tropical Medicine and Hygiene FX We are grateful to all the parents and guardians for kindly giving their consent and to the study participants for their cooperation. We thank all the members of the study team for their tireless effort and excellent work. This work was supported by the Centers for Disease Control and Prevention (Cooperative Agreement No U62P024421); Doris Duke Charitable Foundation (GD is a recipient of the Clinical Scientist Development Award and PJR is a Distinguished Clinical Scientist), National Institutes of Health (T32 AI60530 to PJ), and Burroughs Wellcome Fund/American Society of Tropical Medicine and Hygiene (PJ). NR 39 TC 34 Z9 34 U1 4 U2 15 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD DEC 28 PY 2012 VL 11 AR 435 DI 10.1186/1475-2875-11-435 PG 8 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 075GE UT WOS:000313871300002 PM 23273022 ER PT J AU Sato, S Kabeya, H Miura, T Suzuki, K Bai, Y Kosoy, M Sentsui, H Kariwa, H Maruyama, S AF Sato, Shingo Kabeya, Hidenori Miura, Tatsuya Suzuki, Kazuo Bai, Ying Kosoy, Michael Sentsui, Hiroshi Kariwa, Hiroaki Maruyama, Soichi TI Isolation and phylogenetic analysis of Bartonella species from wild carnivores of the suborder Caniformia in Japan SO VETERINARY MICROBIOLOGY LA English DT Article DE Bartonella; Caniformia; Japanese badger; Japanese marten; Wild carnivores ID GENETIC DIVERSITY; WASHOENSIS; SURVEILLANCE; CLARRIDGEIAE; ENDOCARDITIS; PREVALENCE; CALIFORNIA; SQUIRRELS; SEQUENCES; RESERVOIR AB The prevalence of Bartonella species was investigated among wild carnivores of the suborder Caniformia, including 15 Japanese badgers (Meles anakuma), 8 Japanese martens (Martes melampus), 2 Japanese weasels (Mustela itatsi), 1 Siberian weasel (Mustela sibirica), 171 raccoon dogs (Nyctereutes procyonoides), and 977 raccoons (Procyon lotor) in Japan. Bartonella bacteria were isolated from one Japanese badger (6.7%) and from one Japanese marten (12.5%); however, no Bartonella species was found in other representatives of Caniformia. Phylogenetic analysis was based on concatenated sequences of six housekeeping genes (165 rRNA, ftsZ, gltA, groEL, ribC, and rpoB) and sequence of the 165-235 internal transcribed spacer region. The sequence analysis indicated that the isolate derived from the Japanese badger (strain JB-15) can represent a novel Bartonella species and the isolate from the Japanese marten (strain JM-1) was closely related to Bartonella washoensis. This is the first report on isolation of Bartonella from badger and marten. (C) 2012 Elsevier B.V. All rights reserved. C1 [Sato, Shingo; Kabeya, Hidenori; Miura, Tatsuya; Maruyama, Soichi] Nihon Univ, Coll Bioresource Sci, Dept Vet Med, Lab Vet Publ Hlth, Fujisawa, Kanagawa 2520880, Japan. [Suzuki, Kazuo] Hikiiwa Pk Ctr, Wakayama 6460051, Japan. [Bai, Ying; Kosoy, Michael] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. [Sentsui, Hiroshi] Nihon Univ, Coll Bioresource Sci, Dept Vet Med, Lab Vet Epizootiol, Fujisawa, Kanagawa 2520880, Japan. [Kariwa, Hiroaki] Hokkaido Univ, Grad Sch Vet Med, Publ Hlth Lab, Sapporo, Hokkaido 0600818, Japan. RP Maruyama, S (reprint author), Nihon Univ, Coll Bioresource Sci, Dept Vet Med, Lab Vet Publ Hlth, 1866 Kameino, Fujisawa, Kanagawa 2520880, Japan. EM maruyama.soichi@nihon-u.ac.jp FU Ministry of Education, Culture, Sports, Science and Technology, Japan; Ministry of Health, Labour and Welfare, Japan; [23580429] FX This work was supported in part by a Grant-in-Aid for Scientific Research (no. 23580429), and Strategic Research Base Development Program, International Research on Epidemiology of Zoonoses and Training for Young Researchers by Ministry of Education, Culture, Sports, Science and Technology, Japan. It was also supported in part by a Grant-in-Aid from Ministry of Health, Labour and Welfare, Japan. NR 29 TC 11 Z9 11 U1 0 U2 10 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0378-1135 J9 VET MICROBIOL JI Vet. Microbiol. PD DEC 28 PY 2012 VL 161 IS 1-2 BP 130 EP 136 DI 10.1016/j.vetmic.2012.07.012 PG 7 WC Microbiology; Veterinary Sciences SC Microbiology; Veterinary Sciences GA 060GY UT WOS:000312765700016 PM 22841404 ER PT J AU Caidi, H Harcourt, JL Tripp, RA Anderson, LJ Haynes, LM AF Caidi, Hayat Harcourt, Jennifer L. Tripp, Ralph A. Anderson, Larry J. Haynes, Lia M. TI Combination Therapy Using Monoclonal Antibodies against Respiratory Syncytial Virus (RSV) G Glycoprotein Protects from RSV Disease in BALB/c Mice SO PLOS ONE LA English DT Article ID SUBSTANCE-P; F-GLYCOPROTEIN; CX3C MOTIF; INFECTION; BRONCHIOLITIS; INFLAMMATION; NEUTRALIZATION; PATHOGENESIS; VACCINATION; EXPRESSION AB Therapeutic options to control respiratory syncytial virus (RSV) are limited, thus development of new therapeutics is high priority. Previous studies with a monoclonal antibody (mAb) reactive to an epitope proximal to the central conserved region (CCR) of RSV G protein (mAb 131-2G) showed therapeutic efficacy for reducing pulmonary inflammation RSV infection in BALB/c mice. Here, we show a protective effect in RSV-infected mice therapeutically treated with a mAb (130-6D) reactive to an epitope within the CCR of G protein, while treatment with a mAb specific for a carboxyl G protein epitope had no effect. Combined treatment with mAbs 130-6D and 131-2G significantly decreased RSV-associated pulmonary inflammation compared to either antibody alone. The results suggest that anti-RSV G protein mAbs that react at or near the CCR and can block RSV G protein-mediated activities are effective at preventing RSV disease and may be an effective strategy for RSV therapeutic treatment. C1 [Caidi, Hayat; Harcourt, Jennifer L.; Haynes, Lia M.] Ctr Dis Control & Prevent CDC, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Gastroenteritis & Resp Viruses Lab Branch, Atlanta, GA USA. [Tripp, Ralph A.] Univ Georgia, Coll Vet Med, Dept Infect Dis, Athens, GA USA. [Anderson, Larry J.] Emory Childrens Ctr, Div Pediat Infect Dis, Atlanta, GA USA. RP Haynes, LM (reprint author), Ctr Dis Control & Prevent CDC, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Gastroenteritis & Resp Viruses Lab Branch, Atlanta, GA USA. EM loh5@cdc.gov OI Tripp, Ralph/0000-0002-2924-9956 FU National Institutes of Health [5RO1AI06275-03]; Georgia Research Alliance FX This research was supported in part by the National Institutes of Health (5RO1AI06275-03) and through the Georgia Research Alliance to R. T. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 32 TC 8 Z9 8 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 27 PY 2012 VL 7 IS 12 AR e51485 DI 10.1371/journal.pone.0051485 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 061EA UT WOS:000312829100009 PM 23300550 ER PT J AU Bender, TJ Wise, ME Utah, O Moorman, AC Sharapov, U Drobeniuc, J Khudyakov, Y Fricchione, M White-Comstock, MB Thompson, ND Patel, PR AF Bender, Thomas John Wise, Matthew E. Utah, Okey Moorman, Anne C. Sharapov, Umid Drobeniuc, Jan Khudyakov, Yury Fricchione, Marielle White-Comstock, Mary Beth Thompson, Nicola D. Patel, Priti R. TI Outbreak of Hepatitis B Virus Infections Associated with Assisted Monitoring of Blood Glucose in an Assisted Living Facility-Virginia, 2010 SO PLOS ONE LA English DT Article ID VIRAL-HEPATITIS; UNITED-STATES; TRANSMISSION AB Introduction: In January 2010, the Virginia Department of Health received reports of 2 hepatitis B virus (HBV) infections (1 acute, 1 chronic) among residents of a single assisted living facility (ALF). Both infected residents had diabetes and received assisted monitoring of blood glucose (AMBG) at the facility. An investigation was initiated in response. Objective: To determine the extent and mechanism of HBV transmission among ALF residents. Design: Retrospective cohort study. Setting: An ALF that primarily housed residents with neuropsychiatric disorders in 2 adjacent buildings in Virginia. Participants: Residents of the facility as of March 2010. Measurements: HBV serologic testing, relevant medical history, and HBV genome sequences. Risk ratios (RR) and 95% confidence intervals (CIs) were used to identify risk factors for HBV infection. Results: HBV serologic status was determined for 126 (91%) of 139 residents. Among 88 susceptible residents, 14 became acutely infected (attack rate, 16%), and 74 remained uninfected. Acute HBV infection developed among 12 (92%) of 13 residents who received AMBG, compared with 2 (3%) of 75 residents who did not (RR = 35; 95% CI, 8.7, 137). Identified infection control breaches during AMBG included shared use of fingerstick devices for multiple residents. HBV genome sequencing demonstrated 2 building-specific phylogenetic infection clusters, each having 99.8-100% sequence identity. Limitations: Transfer of residents out of the facility prior to our investigation might have contributed to an underestimate of cases. Resident interviews provided insufficient information to fully assess behavioral risk factors for HBV infection. Conclusions: Failure to adhere to safe practices during AMBG resulted in a large HBV outbreak. Protection of a growing and vulnerable ALF population requires improved training of staff and routine facility licensing inspections that scrutinize infection control practices. C1 [Bender, Thomas John; Utah, Okey; White-Comstock, Mary Beth] Virginia Dept Hlth, Richmond, VA USA. [Bender, Thomas John; Wise, Matthew E.] CDC, Epidem Intelligence Serv Program, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Wise, Matthew E.; Thompson, Nicola D.; Patel, Priti R.] CDC, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Moorman, Anne C.; Sharapov, Umid; Drobeniuc, Jan; Khudyakov, Yury] CDC, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Fricchione, Marielle] Drexel Univ, Coll Med, Philadelphia, PA 19104 USA. RP Bender, TJ (reprint author), Virginia Dept Hlth, Richmond, VA USA. EM thomas.john.bender@dm.duke.edu NR 41 TC 5 Z9 6 U1 1 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 26 PY 2012 VL 7 IS 12 AR e50012 DI 10.1371/journal.pone.0050012 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 071TV UT WOS:000313618800005 PM 23300520 ER PT J AU Saydah, S Imperatore, G Geiss, L Gregg, E AF Saydah, Sharon Imperatore, Giuseppina Geiss, Linda Gregg, Edward TI Diabetes Death Rates Among Youths Aged <= 19 Years-United States, 1968-2009 (Reprinted from MMWR vol 43, pg 869-872, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Saydah, Sharon; Imperatore, Giuseppina; Geiss, Linda; Gregg, Edward] CDC, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Saydah, S (reprint author), CDC, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM ssaydah@cdc.gov NR 1 TC 0 Z9 0 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD DEC 26 PY 2012 VL 308 IS 24 BP 2558 EP 2559 DI 10.1001/jama.2012.91503 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 062JR UT WOS:000312916600008 ER PT J AU Clower, J Henretig, F Trella, J Hoffman, R Wheeler, K Maxted, A Weng, C Chen, JH Chang, HG Blog, D Marcus, S Ruck, B Bronstein, A Yip, F Law, R Wolkin, A Lewis, L Schier, JG AF Clower, Jacquelyn Henretig, Fred Trella, Jeanette Hoffman, Robert Wheeler, Katherine Maxted, Angela Weng, Charlene Chen, Jian-Hua Chang, Hwa-Gan Blog, Debra Marcus, Steven Ruck, Bruce Bronstein, Alvin Yip, Fuyuen Law, Royal Wolkin, Amy Lewis, Lauren Schier, Joshua G. TI Notes From the Field: Carbon Monoxide Exposures Reported to Poison Centers and Related to Hurricane Sandy-Northeastern United States, 2012 (Reprinted form MMWR vol 44, pg 905, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Clower, Jacquelyn] Cazador, Herndon, VA USA. [Hoffman, Robert; Wheeler, Katherine] New York City Dept Hyg & Mental Hlth, New York, NY USA. [Maxted, Angela; Weng, Charlene; Chen, Jian-Hua; Chang, Hwa-Gan; Blog, Debra] New York State Dept Hlth, Albany, NY 12237 USA. [Yip, Fuyuen; Law, Royal; Wolkin, Amy; Lewis, Lauren; Schier, Joshua G.] CDC, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. RP Clower, J (reprint author), Cazador, Herndon, VA USA. EM jclower@cdc.gov RI Schier, Joshua/F-9861-2013 NR 1 TC 0 Z9 0 U1 0 U2 6 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD DEC 26 PY 2012 VL 308 IS 24 BP 2560 EP 2560 DI 10.1001/jama.2012.114538 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 062JR UT WOS:000312916600009 ER PT J AU Pan, LP Blanck, HM Sherry, B Dalenius, K Grummer-Strawn, LM AF Pan, Liping Blanck, Heidi M. Sherry, Bettylou Dalenius, Karen Grummer-Strawn, Laurence M. TI Trends in the Prevalence of Extreme Obesity Among US Preschool-Aged Children Living in Low-Income Families, 1998-2010 SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter ID RISK-FACTORS; CHILDHOOD C1 [Pan, Liping; Blanck, Heidi M.; Sherry, Bettylou; Dalenius, Karen; Grummer-Strawn, Laurence M.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30329 USA. RP Pan, LP (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30329 USA. EM lpan@cdc.gov FU Intramural CDC HHS [CC999999] NR 6 TC 60 Z9 61 U1 0 U2 29 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD DEC 26 PY 2012 VL 308 IS 24 BP 2563 EP 2565 DI 10.1001/jama.2012.108099 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 062JR UT WOS:000312916600014 PM 23268509 ER PT J AU Gupta, V Dawood, FS Muangchana, C Lan, PT Xeuatvongsa, A Sovann, L Olveda, R Cutter, J Oo, KY Ratih, TSD Kheong, CC Kapella, BK Kitsutani, P Corwin, A Olsen, SJ AF Gupta, Vinay Dawood, Fatimah S. Muangchana, Charung Lan, Phan Trong Xeuatvongsa, Anonh Sovann, Ly Olveda, Remigio Cutter, Jeffery Oo, Khin Yi Ratih, Theresia Sandra Diah Kheong, Chong Chee Kapella, Bryan K. Kitsutani, Paul Corwin, Andrew Olsen, Sonja J. TI Influenza Vaccination Guidelines and Vaccine Sales in Southeast Asia: 2008-2011 SO PLOS ONE LA English DT Article ID PRODUCTION CAPACITY; IMMUNIZATION; THAILAND AB Background: Southeast Asia is a region with great potential for the emergence of a pandemic influenza virus. Global efforts to improve influenza surveillance in this region have documented the burden and seasonality of influenza viruses and have informed influenza prevention strategies, but little information exists about influenza vaccination guidelines and vaccine sales. Methods: To ascertain the existence of influenza vaccine guidelines and define the scope of vaccine sales, we sent a standard three-page questionnaire to the ten member nations of the Association of Southeast Asian Nations. We also surveyed three multinational manufacturers who supply influenza vaccines in the region. Results: Vaccine sales in the private sector were,1000 per 100,000 population in the 10 countries. Five countries reported purchasing vaccine for use in the public sector. In 2011, Thailand had the highest combined reported rate of vaccine sales (10,333 per 100,000). In the 10 countries combined, the rate of private sector sales during 2010-2011 (after the A(H1N1)2009pdm pandemic) exceeded 2008 pre-pandemic levels. Five countries (Indonesia, Malaysia, Singapore, Thailand and Vietnam) had guidelines for influenza vaccination but only two were consistent with global guidelines. Four recommended vaccination for health care workers, four for elderly persons, three for young children, three for persons with underlying disease, and two for pregnant women. Conclusions: The rate of vaccine sales in Southeast Asia remains low, but there was a positive impact in sales after the A(H1N1) 2009pdm pandemic. Low adherence to global vaccine guidelines suggests that more work is needed in the policy arena. C1 [Gupta, Vinay] Columbia Univ, Coll Phys & Surg, New York, NY USA. [Gupta, Vinay; Olsen, Sonja J.] US CDC Collaborat, Thailand Minist Publ Hlth, Nonthaburi, Thailand. [Dawood, Fatimah S.; Kapella, Bryan K.; Kitsutani, Paul; Corwin, Andrew; Olsen, Sonja J.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Muangchana, Charung] Minist Publ Hlth, Dept Dis Control, Natl Vaccine Comm Off, Nonthaburi, Thailand. [Lan, Phan Trong] Minist Hlth, Gen Dept Prevent Med, Hanoi, Vietnam. [Xeuatvongsa, Anonh] Minist Publ Hlth, Expanded Program Immunizat, Viangchan, Laos. [Sovann, Ly] Minist Publ Hlth, CDC Dept, Phnom Penh, Cambodia. [Olveda, Remigio] Res Inst Trop Med, Dept Hlth, Muntinlupa, Philippines. [Cutter, Jeffery] Minist Hlth, Communicable Dis Div, Singapore, Singapore. [Oo, Khin Yi] Minist Hlth, Natl Hlth Lab, Nay Pyi Taw, Myanmar. [Ratih, Theresia Sandra Diah] Minist Publ Hlth, Expanded Program Immunizat, Jakarta, Indonesia. [Kheong, Chong Chee] Minist Hlth, Dis Control Div, Kuala Lumpur, Malaysia. RP Olsen, SJ (reprint author), US CDC Collaborat, Thailand Minist Publ Hlth, Nonthaburi, Thailand. EM Solsen@cdc.gov FU U.S. Centers for Disease Control and Prevention FX This work was supported by the U.S. Centers for Disease Control and Prevention. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 21 TC 18 Z9 18 U1 2 U2 10 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 21 PY 2012 VL 7 IS 12 AR e52842 DI 10.1371/journal.pone.0052842 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 065OW UT WOS:000313158800100 PM 23285200 ER PT J AU Abu Samra, N Thompson, PN Jori, F Zhang, HW Xiao, LH AF Abu Samra, Nada Thompson, Peter N. Jori, Ferran Zhang, Hongwei Xiao, Lihua TI Enterocytozoon bieneusi at the wildlife/livestock interface of the Kruger National Park, South Africa SO VETERINARY PARASITOLOGY LA English DT Article DE Enterocytozoon bieneusi; Microsporidia; Genotypes; Calve; Kruger National Park; Interface ID VIRUS-INFECTED PATIENTS; EASTERN UNITED-STATES; MOLECULAR CHARACTERIZATION; STOOL SAMPLES; DAIRY CALVES; WILD MAMMALS; MICROSPORIDIA; PREVALENCE; GENOTYPES; IDENTIFICATION AB This study investigates the presence of Enterocytozoon bieneusi in domestic and wild animals living in the wildlife/livestock interface area of the Kruger National Park (KNP) in South Africa. Fifty fecal samples from domestic calves in rural communities and 142 fecal samples from impala (Aepyceros melampus) and buffalo (Syncerus caffer) in the KNP were analysed for Enterocytozoon bieneusi, using a nested PCR targeting the internal transcribed spacer of the rRNA gene. All wildlife samples were negative for E. bieneusi, whereas nine (18%) calf samples were positive. Three cattle specific genotypes (group 2) were identified, belonging to the known genotypes BEB4 and I, and one novel genotype (BEB3-like). One human-pathogenic genotype (D) was detected in one calf. This is the first study on microsporidia performed in a wildlife/livestock interface area of sub-Saharan Africa. Our findings show that at least one genotype of zoonotic importance is circulating in native cattle in the study area and the rest of the identified microsporidia were host-specific genotypes. Larger studies in domestic animals, humans and wildlife are necessary to assess the public health significance of E. bieneusi in that interface area. (C) 2012 Elsevier B.V. All rights reserved. C1 [Abu Samra, Nada; Thompson, Peter N.] Univ Pretoria, Dept Prod Anim Studies, Epidemiol Sect, ZA-0110 Onderstepoort, South Africa. [Jori, Ferran] Univ Pretoria, Dept Zool & Entomol, Mammal Res Inst, UR AGIRs,CIRAD, ZA-0002 Pretoria, South Africa. [Zhang, Hongwei; Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Zhang, Hongwei] Henan Ctr Dis Prevent & Control, Inst Parasite Dis Prevent & Control, Zhengzhou, Peoples R China. RP Abu Samra, N (reprint author), Univ Pretoria, Dept Prod Anim Studies, Epidemiol Sect, Private Bag X04, ZA-0110 Onderstepoort, South Africa. EM nada.nada@gmx.de RI Xiao, Lihua/B-1704-2013; Thompson, Peter/J-2534-2013; OI Xiao, Lihua/0000-0001-8532-2727; Thompson, Peter/0000-0002-2268-9748 FU Faculty of Veterinary Science, University of Pretoria; Centers for Disease Control and Prevention FX This work was supported in part by the Faculty of Veterinary Science, University of Pretoria and the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 34 TC 15 Z9 15 U1 1 U2 12 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-4017 J9 VET PARASITOL JI Vet. Parasitol. PD DEC 21 PY 2012 VL 190 IS 3-4 BP 587 EP 590 DI 10.1016/j.vetpar.2012.06.031 PG 4 WC Parasitology; Veterinary Sciences SC Parasitology; Veterinary Sciences GA 055OD UT WOS:000312425400036 PM 22824060 ER PT J AU Butsashvili, M Kamkamidze, G Topuridze, M Morse, D Triner, W DeHovitz, J Nelson, K McNutt, LA AF Butsashvili, Maia Kamkamidze, George Topuridze, Marina Morse, Dale Triner, Wayne DeHovitz, Jack Nelson, Kenrad McNutt, Louise-Anne TI Associated factors for recommending HBV vaccination to children among Georgian health care workers SO BMC INFECTIOUS DISEASES LA English DT Article DE Hepatitis B; Vaccine; Safety; Health Care Worker; Newborns ID HEPATITIS-B VACCINATION; COVERAGE; VIRUS; IMPLEMENTATION; PROTECTION; INFECTION; EFFICACY; SAFETY AB Background: Most cases of hepatitis B virus (HBV) infection and subsequent liver diseases can be prevented with universal newborn HBV vaccination. The attitudes of health care workers about HBV vaccination and their willingness to recommend vaccine have been shown to impact HBV vaccination coverage and the prevention of vertical transmission of HBV. The purpose of this study was to ascertain the factors associated with health care worker recommendations regarding newborn HBV vaccination. Methods: A cross-sectional study of prevalence and awareness of hepatitis B and hepatitis B vaccine was conducted among randomly selected physicians and nurses employed in seven hospitals in Georgia in 2006 and 2007. Self-administered questionnaires included a module on recommendations for HBV, HCV and HIV. Results: Of the 1328 participants included in this analysis, 36% reported recommending against hepatitis B vaccination for children, including 33% of paediatricians. Among the 70.6% who provided a reason for not recommending HBV vaccine, the most common concern was an adverse vaccine event. Unvaccinated physicians and nurses were more likely to recommend against HBV vaccine (40.4% vs 11.4%, PR 3.54; 95% CI: 2.38, 5.29). Additionally, health care worker age was inversely correlated with recommendations for HBV vaccine with older workers less likely to recommend it. Conclusion: Vaccinating health care workers against HBV may provide a dual benefit by boosting occupational safety as well as strengthening universal coverage programs for newborns. C1 [Butsashvili, Maia; Topuridze, Marina] Natl Ctr Dis Control & Publ Hlth NCDC, GE-0177 Tbilisi, Rep of Georgia. [Kamkamidze, George] Maternal & Child Care Union, Tbilisi, Rep of Georgia. [Morse, Dale] CDC, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. [Triner, Wayne] Albany Med Coll, Dept Emergency Med, Albany, NY 12208 USA. [DeHovitz, Jack] Suny Downstate Med Ctr, Dept Med, Brooklyn, NY 11203 USA. [Nelson, Kenrad] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [McNutt, Louise-Anne] SUNY Albany, Sch Publ Hlth, Rensselaer, NY USA. RP Butsashvili, M (reprint author), Natl Ctr Dis Control & Publ Hlth NCDC, 9 Asatiani St, GE-0177 Tbilisi, Rep of Georgia. EM maiabutsashvili@gmail.com FU Civilian Research and Development Foundation (CRDF) [GEB2-2636-TB-05]; NIH [2D43TW000233, 5D43TW007384]; Fogarty International Center FX This project was supported by Civilian Research and Development Foundation (CRDF) grant # GEB2-2636-TB-05 and NIH Research Grants # 2D43TW000233 and 5D43TW007384 funded by the Fogarty International Center. All authors report no conflicts of interest relevant to this study. NR 29 TC 1 Z9 1 U1 1 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD DEC 20 PY 2012 VL 12 AR 362 DI 10.1186/1471-2334-12-362 PG 6 WC Infectious Diseases SC Infectious Diseases GA 070QQ UT WOS:000313525800002 PM 23256746 ER PT J AU An, Q Hernandez, A Prejean, J German, EJ Thompson, H Hall, HI AF An, Qian Hernandez, Angela Prejean, Joseph German, Emilio J. Thompson, Horace Hall, H. Irene TI Geographic Differences in HIV Infection Among Hispanics or Latinos-46 States and Puerto Rico, 2010 (Reprinted from MMWR, vol 40, pg 805, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [An, Qian; Hernandez, Angela; Prejean, Joseph; German, Emilio J.; Thompson, Horace; Hall, H. Irene] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP An, Q (reprint author), CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM qan@cdc.gov NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD DEC 19 PY 2012 VL 308 IS 23 BP 2450 EP 2452 DI 10.1001/jama.2012.31365 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 055TU UT WOS:000312441400008 ER PT J AU Copeland, G Feldkamp, M Beres, LM Mai, CT Hinton, CF Glidewell, J AF Copeland, Glenn Feldkamp, Marcia Beres, Leslie M. Mai, Cara T. Hinton, Cynthia F. Glidewell, Jill TI Newborn Screening for Critical Congenital Heart Disease: Potential Roles of Birth Defects Surveillance Programs-United States, 2010-2011 (Reprinted from MMWR, vol 42, pg 849, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Mai, Cara T.; Hinton, Cynthia F.; Glidewell, Jill] CDC, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Copeland, Glenn] Michigan Dept Community Hlth, Michigan Birth Defects Registry, Lansing, MI USA. [Feldkamp, Marcia] Univ Utah, Dept Pediat, Utah Birth Defect Network, Salt Lake City, UT 84112 USA. RP Glidewell, J (reprint author), CDC, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. EM mglidewell@cdc.gov NR 8 TC 0 Z9 0 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD DEC 19 PY 2012 VL 308 IS 23 BP 2452 EP 2454 DI 10.1001/jama.2012.64597 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 055TU UT WOS:000312441400009 ER PT J AU Gregg, EW Chen, HY Wagenknecht, LE Clark, JM Delahanty, LM Bantle, J Pownall, HJ Johnson, KC Safford, MM Kitabchi, AE Pi-Sunyer, FX Wing, RR Bertoni, AG AF Gregg, Edward W. Chen, Haiying Wagenknecht, Lynne E. Clark, Jeanne M. Delahanty, Linda M. Bantle, John Pownall, Henry J. Johnson, Karen C. Safford, Monika M. Kitabchi, Abbas E. Pi-Sunyer, F. Xavier Wing, Rena R. Bertoni, Alain G. CA Look AHEAD Res Grp TI Association of an Intensive Lifestyle Intervention With Remission of Type 2 Diabetes SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; BARIATRIC SURGERY; PREVENTION PROGRAM; GLUCOSE-TOLERANCE; MEDICAL THERAPY; OBESE-PATIENTS; WEIGHT-LOSS; MELLITUS; REDUCTION; OUTCOMES AB Context The frequency of remission of type 2 diabetes achievable with lifestyle intervention is unclear. Objective To examine the association of a long-term intensive weight-loss intervention with the frequency of remission from type 2 diabetes to prediabetes or normoglycemia. Design, Setting, and Participants Ancillary observational analysis of a 4-year randomized controlled trial (baseline visit, August 2001-April 2004; last follow-up, April 2008) comparing an intensive lifestyle intervention (ILI) with a diabetes support and education control condition (DSE) among 4503 US adults with body mass index of 25 or higher and type 2 diabetes. Interventions Participants were randomly assigned to receive the ILI, which included weekly group and individual counseling in the first 6 months followed by 3 sessions per month for the second 6 months and twice-monthly contact and regular refresher group series and campaigns in years 2 to 4 (n=2241) or the DSE, which was an offer of 3 group sessions per year on diet, physical activity, and social support (n=2262). Main Outcome Measures Partial or complete remission of diabetes, defined as transition from meeting diabetes criteria to a prediabetes or nondiabetic level of glycemia (fasting plasma glucose <126 mg/dL and hemoglobin A(1c) <6.5% with no antihyperglycemic medication). Results Intensive lifestyle intervention participants lost significantly more weight than DSE participants at year 1 (net difference, -7.9%; 95% CI, -8.3% to -7.6%) and at year 4 (-3.9%; 95% CI, -4.4% to -3.5%) and had greater fitness increases at year 1 (net difference, 15.4%; 95% CI, 13.7%-17.0%) and at year 4 (6.4%; 95% CI, 4.7%-8.1%) (P<.001 for each). The ILI group was significantly more likely to experience any remission (partial or complete), with prevalences of 11.5% (95% CI, 10.1%-12.8%) during the first year and 7.3% (95% CI, 6.2%-8.4%) at year 4, compared with 2.0% for the DSE group at both time points (95% CIs, 1.4%-2.6% at year 1 and 1.5%-2.7% at year 4) (P<.001 for each). Among ILI participants, 9.2% (95% CI, 7.9%-10.4%), 6.4% (95% CI, 5.3%-7.4%), and 3.5% (95% CI, 2.7%-4.3%) had continuous, sustained remission for at least 2, at least 3, and 4 years, respectively, compared with less than 2% of DSE participants (1.7% [95% CI, 1.2%-2.3%] for at least 2 years; 1.3% [95% CI, 0.8%-1.7%] for at least 3 years; and 0.5% [95% CI, 0.2%-0.8%] for 4 years). Conclusions In these exploratory analyses of overweight adults, an intensive lifestyle intervention was associated with a greater likelihood of partial remission of type 2 diabetes compared with diabetes support and education. However, the absolute remission rates were modest. C1 [Gregg, Edward W.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30341 USA. [Chen, Haiying; Wagenknecht, Lynne E.; Bertoni, Alain G.] Wake Forest Sch Med, Winston Salem, NC USA. [Clark, Jeanne M.] Johns Hopkins Med Inst, Baltimore, MD 21205 USA. [Delahanty, Linda M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Bantle, John] Univ Minnesota, Minneapolis, MN USA. [Pownall, Henry J.] Baylor Coll Med, Houston, TX 77030 USA. [Johnson, Karen C.; Kitabchi, Abbas E.] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA. [Safford, Monika M.] Univ Alabama Birmingham, Birmingham, AL USA. [Pi-Sunyer, F. Xavier] Columbia Univ, St Lukes Roosevelt Hosp, New York, NY USA. [Wing, Rena R.] Miriam Hosp, Brown Med Sch, Providence, RI 02906 USA. RP Gregg, EW (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, 4770 Buford Hwy NE,MS K-10, Atlanta, GA 30341 USA. EM edg7@cdc.gov FU US Department of Health and Human Services from the National Institutes of Health (NIH) [DK57136, DK57149, DK56990, DK57177, DK57171, DK57151, DK57182, DK57131, DK57002, DK57078, DK57154, DK57178, DK57219, DK57008, DK57135, DK56992]; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institute of Nursing Research; National Center on Minority Health and Health Disparities; NIH Office of Research on Women's Health; Centers for Disease Control and Prevention; Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases. The Indian Health Service (IHS); Johns Hopkins Medical Institutions Bayview General Clinical Research Center [M01RR02719]; Massachusetts General Hospital Mallinckrodt General Clinical Research Center; Massachusetts Institute of Technology General Clinical Research Center [M01RR01066]; University of Colorado Health Sciences Center General Clinical Research Center [M01RR00051]; Clinical Nutrition Research Unit [P30 DK48520]; University of Tennessee at Memphis General Clinical Research Center [M01RR0021140]; University of Pittsburgh General Clinical Research Center [M01RR000056]; Clinical Translational Research Center; Clinical and Translational Science Award [UL1 RR 024153]; NIH [DK 046204]; VA Puget Sound Health Care System Medical Research Service, Department of Veterans Affairs; Frederic C. Bartter General Clinical Research Center [M01RR01346] FX This study is supported by the US Department of Health and Human Services through the following cooperative agreements from the National Institutes of Health (NIH): DK57136, DK57149, DK56990, DK57177, DK57171, DK57151, DK57182, DK57131, DK57002, DK57078, DK57154, DK57178, DK57219, DK57008, DK57135, and DK56992. The following federal agencies have contributed support: National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institute of Nursing Research; National Center on Minority Health and Health Disparities; NIH Office of Research on Women's Health; and the Centers for Disease Control and Prevention. This research was supported in part by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases. The Indian Health Service (IHS) provided personnel, medical oversight, and use of facilities. Additional support was received from The Johns Hopkins Medical Institutions Bayview General Clinical Research Center (M01RR02719); the Massachusetts General Hospital Mallinckrodt General Clinical Research Center and the Massachusetts Institute of Technology General Clinical Research Center (M01RR01066); the University of Colorado Health Sciences Center General Clinical Research Center (M01RR00051) and Clinical Nutrition Research Unit (P30 DK48520); the University of Tennessee at Memphis General Clinical Research Center (M01RR0021140); the University of Pittsburgh General Clinical Research Center (M01RR000056), the Clinical Translational Research Center funded by Clinical and Translational Science Award UL1 RR 024153 and NIH grant DK 046204; the VA Puget Sound Health Care System Medical Research Service, Department of Veterans Affairs; and the Frederic C. Bartter General Clinical Research Center (M01RR01346). The following organizations have committed to making major contributions to Look AHEAD: FedEx Corp; Health Management Resources; LifeScan Inc, a Johnson and Johnson Company; OPTIFAST of Nestle HealthCare Nutrition Inc; Hoffmann-La Roche Inc; Abbott Nutrition; and Slim-Fast Brand of Unilever North America. NR 32 TC 157 Z9 162 U1 2 U2 59 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD DEC 19 PY 2012 VL 308 IS 23 BP 2489 EP 2496 DI 10.1001/jama.2012.67929 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 055TU UT WOS:000312441400025 PM 23288372 ER PT J AU Powell, SE Hariri, S Steinau, M Bauer, HM Bennett, NM Bloch, KC Niccolai, LM Schafer, S Unger, ER Markowitz, LE AF Powell, Suzanne E. Hariri, Susan Steinau, Martin Bauer, Heidi M. Bennett, Nancy M. Bloch, Karen C. Niccolai, Linda M. Schafer, Sean Unger, Elizabeth R. Markowitz, Lauri E. TI Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions SO VACCINE LA English DT Article DE Human papillomavirus (HPV); Vaccine impact; Cervical intraepithelial neoplasia (CIN) ID UNITED-STATES; QUADRIVALENT VACCINE; DISPARITIES; INFECTION; EFFICACY; DISEASE; WOMEN AB Background: Vaccination against human papillomavirus (HPV) types 16 and 18 is recommended for girls aged 11 or 12 years with catch-up vaccination through age 26 in the U.S. Cervical intraepithelial neoplasia (CIN) grade 2 or 3 and adenocarcinoma in situ (CIN2+) are used to monitor HPV vaccine impact on cervical disease. This report describes vaccination status in women diagnosed with CIN2+ and examines HPV vaccine impact on HPV 16/18-related CIN2+. Methods: As part of a vaccine impact monitoring project (HPV-IMPACT), females 18-31 years with CIN2+ were reported from pathology laboratories in CA, CT, NY, OR, TN from 2008 to 2011. One diagnostic block was selected for HPV DNA typing with Roche Linear Array. Demographic, abnormal Papanicolaou (Pap) test dates and vaccine status information were collected. The abnormal Pap test immediately preceding the CIN2+ diagnosis was defined as the 'trigger Pap'. Results: Among 5083 CIN2+ cases reported to date, 3855 had vaccination history investigated: 1900 had vaccine history documented (vaccinated, with trigger Pap dates, or unvaccinated). Among women who initiated vaccination >24 months before their trigger Pap, there was a significantly lower proportion of CIN2+ lesions due to 16/18 compared to women who were not vaccinated (aPR = .67, 95% CI: .48-.94). Among the 1900 with known vaccination status, 20% initiated vaccination on/after their trigger screening. Women aged 21-23 years were more likely to initiate vaccination on/after the trigger Pap compared to 24-26 year olds (29.0% vs. 19.6%, p = .001), as were non-Hispanic blacks compared to non-Hispanic whites (27.3% vs. 19.0%, p = .001) and publicly compared to privately insured women (38.1% vs. 17.4%, p < .0001). Conclusion: We found a significant reduction in HPV 16/18-related lesions in women with CIN2+ who initiated vaccination at least 24 months prior to their trigger Pap. These preliminary results suggest early impact of the HPV vaccine on vaccine-type disease, but further evaluation is warranted. Published by Elsevier Ltd. C1 [Powell, Suzanne E.; Hariri, Susan; Markowitz, Lauri E.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Steinau, Martin; Unger, Elizabeth R.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Bauer, Heidi M.] Calif Dept Publ Hlth, STD Control Branch, Richmond, CA 94804 USA. [Bennett, Nancy M.] Univ Rochester, Sch Med & Dent, Ctr Community Hlth, Rochester, NY 14607 USA. [Bennett, Nancy M.] Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14607 USA. [Bloch, Karen C.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA. [Bloch, Karen C.] Vanderbilt Univ, Med Ctr, Dept Prevent Med, Nashville, TN 37232 USA. [Niccolai, Linda M.] Yale Univ, Sch Publ Hlth, Div Epidemiol Microbial Dis, New Haven, CT 06520 USA. [Schafer, Sean] Oregon Hlth Author, Ctr Publ Hlth Practice, HIV STD TB Program, Oregon Publ Hlth Div, Portland, OR 97232 USA. RP Powell, SE (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, 1600 Clifton Rd,NE MS-E02, Atlanta, GA 30333 USA. EM gpf7@cdc.gov; shariri@cdc.gov; msteinau@cdc.gov; heidi.bauer@cdph.ca.gov; nancy_bennett@urmc.rochester.edu; karen.bloch@vanderbilt.edu; linda.niccolai@yale.edu; sean.schafer@state.or.us; eunger@cdc.gov; lmarkowitz@cdc.gov OI Unger, Elizabeth/0000-0002-2925-5635 NR 21 TC 42 Z9 43 U1 0 U2 12 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD DEC 17 PY 2012 VL 31 IS 1 BP 109 EP 113 DI 10.1016/j.vaccine.2012.10.092 PG 5 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 067PA UT WOS:000313306400014 PM 23137842 ER PT J AU Soeung, SC Thiep, C Duncan, R Patel, M Hennessey, K AF Soeung, Sann Chan Thiep, Chanthan Duncan, Richard Patel, Minal Hennessey, Karen TI Using data to guide policy: Next steps for preventing perinatal hepatitis B virus transmission in Cambodia SO VACCINE LA English DT Article DE Hepatitis B virus; Vaccination; Perinatal transmission; Birth dose ID IMMUNIZATION; VACCINE AB Background: Cambodia is highly endemic for hepatitis B virus (HBV) infection. Preventing perinatal HBV transmission should be prioritized in health facilities by providing hepatitis B vaccination to all infants within 24 h of birth (timely birth dose coverage). Methods: Teams assessed birth dose policy, practices and coverage in hospitals and health facilities in 10 provinces in Cambodia. Results: Fifty-one sites were assessed. Median (interquartile range) timely birth dose coverage was 66% (48-92%); coverage was 88% (range = 60-96%) in facilities vaccinating on-site and 48% (range = 20-52%) in those referring off-site (p < 0.0001). Overall, 5 (29%) of 16 hospitals that referred vaccination off-site did not tell mothers vaccination should take place within 24 h of birth, and 6 (35%) discharged mothers when no vaccination services were available for infants to receive the birth dose. Conclusions: Newborns can miss a time-sensitive opportunity to be protected against perinatal HBV infection when they are referred for vaccination off-site rather than being vaccinated in the delivery facility. These data support the case to strengthen policies and practices to provide hepatitis B birth dose vaccination in the delivery facility. (c) 2012 Elsevier Ltd. All rights reserved. C1 [Soeung, Sann Chan; Thiep, Chanthan] Minist Hlth, Phnom Penh, Cambodia. [Duncan, Richard] World Hlth Org, Phnom Penh, Cambodia. [Patel, Minal] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hennessey, Karen] World Hlth Org, Western Pacific Reg Off, Manila, Philippines. RP Duncan, R (reprint author), World Hlth Org, Phnom Penh, Cambodia. EM duncanr@wpro.who.int FU Intramural CDC HHS [CC999999] NR 15 TC 3 Z9 3 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD DEC 17 PY 2012 VL 31 IS 1 BP 149 EP 153 DI 10.1016/j.vaccine.2012.10.079 PG 5 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 067PA UT WOS:000313306400020 PM 23127515 ER PT J AU Rowhani-Rahbar, A Klein, NP Dekker, CL Edwards, KM Marchant, CD Vellozzi, C Fireman, B Sejvar, JJ Halsey, NA Baxter, R AF Rowhani-Rahbar, Ali Klein, Nicola P. Dekker, Cornelia L. Edwards, Kathryn M. Marchant, Colin D. Vellozzi, Claudia Fireman, Bruce Sejvar, James J. Halsey, Neal A. Baxter, Roger CA Clinical Immunization Safety Asses TI Biologically plausible and evidence-based risk intervals in immunization safety research SO VACCINE LA English DT Review DE Immunization; Vaccines; Safety; Methods ID ACUTE DISSEMINATED ENCEPHALOMYELITIS; CONTROLLED CASE-SERIES; INACTIVATED INFLUENZA VACCINE; EVENT FOLLOWING IMMUNIZATION; VARICELLA VACCINE; ADVERSE EVENTS; FEBRILE SEIZURES; MULTIPLE-SCLEROSIS; DATA-COLLECTION; CASE-DEFINITION AB In immunization safety research, individuals are considered at risk for the development of certain adverse events following immunization (AEFI) within a specific period of time referred to as the risk interval. These intervals should ideally be determined based on biologic plausibility considering features of the AEFI, presumed or known pathologic mechanism, and the vaccine. Misspecification of the length and timing of these intervals may result in introducing bias in epidemiologic and clinical studies of immunization safety. To date, little work has been done to formally assess and determine biologically plausible and evidence-based risk intervals in immunization safety research. In this report, we present a systematic process to define biologically plausible and evidence-based risk interval estimates for two specific AEFIs, febrile seizures and acute disseminated encephalomyelitis. In addition, we review methodologic issues related to the determination of risk intervals for consideration in future studies of immunization safety. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Rowhani-Rahbar, Ali; Klein, Nicola P.; Fireman, Bruce; Baxter, Roger] Kaiser Permanente, Vaccine Study Ctr, Oakland, CA 94612 USA. [Dekker, Cornelia L.] Stanford Univ, Sch Med, Dept Pediat, Div Pediat Infect Dis, Stanford, CA 94305 USA. [Edwards, Kathryn M.] Vanderbilt Univ, Med Ctr, Dept Pediat, Vanderbilt Vaccine Res Program, Nashville, TN 37232 USA. [Marchant, Colin D.] Boston Univ, Med Ctr, Dept Pediat, Div Pediat Infect Dis, Boston, MA USA. [Vellozzi, Claudia] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Hlth Care Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Sejvar, James J.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Halsey, Neal A.] Johns Hopkins Sch Med, Dept Pediat, Baltimore, MD USA. [Halsey, Neal A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA. RP Rowhani-Rahbar, A (reprint author), Kaiser Permanente, Vaccine Study Ctr, 1 Kaiser Plaza,Floor 16, Oakland, CA 94612 USA. EM ali.x.rowhani-rahbar@kp.org FU Clinical Immunization Safety Assessment Network and Vaccine Safety Datalink; America's Health Insurance Plans Centers for Disease Control and Prevention (CDC) [200-2002-00732]; CDC; GlaxoSmithKline; Merck Co., Inc.; Sanofi Pasteur; Pfizer Inc.; Novartis; MedImmune; National Institutes of Health (NIH); Johns Hopkins University; Berna; Intercel; Protein Sciences FX This study was supported by the Clinical Immunization Safety Assessment Network and Vaccine Safety Datalink through a subcontract with America's Health Insurance Plans under contract 200-2002-00732 from the Centers for Disease Control and Prevention (CDC). Financial disclosure: Dr. Rowhani-Rahbar receives contract funding from the CDC as salary support through the Vaccine Safety Fellowship program. Dr. Klein receives contract funding from the CDC and research support from GlaxoSmithKline, Merck & Co., Inc., Sanofi Pasteur, Pfizer Inc., Novartis, and MedImmune. Dr. Dekker receives contract funding from the National Institutes of Health (NIH) and the CDC, is compensated for serving on the safety monitoring committees for the HIV Vaccine Trials Network and for Pfizer, and serves on the scientific advisory board of PharmaJet. Dr. Edwards receives contract funding from the NIH and the CDC. Dr. Marchant receives contract funding from the CDC, has performed clinical research for GlaxoSmithKline, Sanofi Pasteur, Merck & Co., Inc., Pfizer Inc., MedImmune, and Novartis, has served as a consultant to GlaxoSmithKline, Sanofi Pasteur, MedImmune, and Novartis, and has given lectures sponsored by GlaxoSmithKline and Sanofi Pasteur. Dr. Halsey receives contract funding from the CDC, is compensated for serving on safety monitoring committees for studies of vaccines for Merck & Co., Inc., and Novartis, has received an honorarium for training and support for travel from Sanofi-MSD, has research grants through Johns Hopkins University for studies of vaccines in Guatemala from Berna and Intercel, and has received support for a study of a Merck & Co., Inc. human papillomavirus vaccine in Peru, but receives no support for the effort in Peru. Dr. Baxter receives contract funding from the CDC and research grants from Sanofi Pasteur, MedImmune, Novartis, GlaxoSmithKline, Pfizer Inc., Protein Sciences, and Merck & Co., Inc. Drs. Vellozzi and Sejvar are employees of the CDC. NR 65 TC 19 Z9 19 U1 0 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD DEC 17 PY 2012 VL 31 IS 1 BP 271 EP 277 DI 10.1016/j.vaccine.2012.07.024 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 067PA UT WOS:000313306400038 PM 22835735 ER PT J AU Ayele, W Demissie, G Kassa, W Zemelak, E Afework, A Amare, B Cox, CM Jima, D AF Ayele, Workenesh Demissie, Gelila Kassa, Woubayehu Zemelak, Etsehiwot Afework, Aklog Amare, Berhanu Cox, Chad M. Jima, Daddi TI Challenges of Establishing Routine Influenza Sentinel Surveillance in Ethiopia, 2008-2010 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID SEASONAL INFLUENZA; PNEUMONIA; CHILDREN; ETIOLOGY; INFANTS AB Ethiopia launched influenza surveillance in November 2008. By October 2010, 176 patients evaluated at 5 sentinel health facilities in Addis Ababa met case definitions for influenza-like illness or severe acute respiratory illness (SARI). Most patients (131 [74%]) were children aged 0-4 years. Twelve patients (7%) were positive for influenza virus. Most patients (109 [93%]) were aged < 5 years, of whom only 3 (2.8%) had laboratory-confirmed influenza. Low awareness of influenza by healthcare workers, misperceptions regarding case definitions, and insufficient human resources at sites could have potentially led to many missed cases, resulting in suboptimal surveillance. C1 [Ayele, Workenesh; Demissie, Gelila; Kassa, Woubayehu; Zemelak, Etsehiwot; Afework, Aklog; Jima, Daddi] EHNRI, Natl Influenza Lab, Addis Ababa, Ethiopia. [Amare, Berhanu] CDC, Addis Ababa, Ethiopia. [Cox, Chad M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Ayele, W (reprint author), EHNRI, Natl Influenza Lab, Arbegnoch St 626, Addis Ababa, Ethiopia. EM workenesha@ehnri.gov.et FU CDC under the federal grant "Surveillance and Response to Avian and Pandemic Flu by National Health Authorities Outside the United States" [5U51IP000159-01-5U51IP000159-04, CDC-RFA-IP07-702]; Ethiopian Federal Ministry of Health; Ethiopian Health and Nutrition Research Institute; Addis Ababa Regional Health Bureau; health bureau of Gulele; health bureau of Kolfe-Keranio; health bureau of Akaki-Kality; Yekatit 12 Hospital; Saint Peter's Hospital; Shiromeda Health Center; Kolfe Health Center; Akaki Health Center; CDC Ethiopia; World Health Organization country office FX We thank the healthcare team members involved in the surveillance at each of the health facilities; Dr Brett Archer (National Institute of Communicable Diseases, Johannesburg, South Africa), for his critical reading of the manuscript and editorial revisions; and Dr Stefano Tempia (CDC South Africa), for assistance with the statistical analysis. We also thank the following institutions for their support and respective roles in implementing the surveillance program: the Ethiopian Federal Ministry of Health; the Ethiopian Health and Nutrition Research Institute; the Addis Ababa Regional Health Bureau and the health bureaus of Gulele, Kolfe-Keranio, and Akaki-Kality subcities, where the sentinel health facilities are located; Yekatit 12 Hospital; Saint Peter's Hospital; Shiromeda Health Center; Kolfe Health Center; Akaki Health Center; CDC Ethiopia; and the World Health Organization country office.; This work was supported by the CDC (cooperative agreement 5U51IP000159-01-5U51IP000159-04), under the federal grant "Surveillance and Response to Avian and Pandemic Flu by National Health Authorities Outside the United States" (funding opportunity number CDC-RFA-IP07-702). NR 15 TC 3 Z9 3 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD DEC 15 PY 2012 VL 206 SU 1 BP S41 EP S45 DI 10.1093/infdis/jis531 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 045BA UT WOS:000311667900007 PM 23169970 ER PT J AU Dalhatu, IT Medina-Marino, A Olsen, SJ Hwang, I Gubio, AB Ekanem, EE Coker, EBA Akpan, H Adedeji, AA AF Dalhatu, Ibrahim T. Medina-Marino, Andrew Olsen, Sonja J. Hwang, Inzune Gubio, Aisha Bintu Ekanem, Ekanem E. Coker, E. B. A. Akpan, Henry Adedeji, Adebayo Abel TI Influenza Viruses in Nigeria, 2009-2010: Results From the First 17 Months of a National Influenza Sentinel Surveillance System SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID A H3N2; AFRICA; SEASONALITY; EMERGENCE; EPIDEMIOLOGY; CIRCULATION; DISEASES; BRAZIL; KENYA AB Background. Influenza surveillance data from tropical, sub-Saharan African countries are limited. To better understand the epidemiology of influenza, Nigeria initiated influenza surveillance in 2008. Methods. Outpatients with influenza-like illness (ILI) and inpatients with severe acute respiratory illness (SARI) were enrolled at 4 sentinel facilities. Epidemiologic data were obtained, and respiratory specimens were tested for influenza viruses, using real-time reverse-transcription polymerase chain reaction assays. Results. During April 2009-August 2010, 2841 patients were enrolled. Of 2803 specimens tested, 217 (7.7%) were positive for influenza viruses (167 [8%] were from subjects with ILI, 17 [5%] were from subjects with SARI, and 33 were from subjects with an unclassified condition). During the prepandemic period, subtype H3N2 (A[H3N2]) was the dominant circulating influenza A virus subtype; 2009 pandemic influenza A virus subtype H1N1 (A[H1N1]pdm09) replaced A(H3N2) as the dominant circulating virus during November 2009. Among persons with ILI, A(H1N1)pdm09 was most frequently found in children aged 5-17 years, whereas among subjects with SARI, it was most frequently found in persons aged >= 65 years. The percentage of specimens that tested positive for influenza viruses peaked at 18.9% in February 2010, and the majority were A(H1N1)pdm09. Conclusions. Influenza viruses cause ILI and SARI in Nigeria. Data from additional years are needed to better understand the epidemiology and seasonality of influenza viruses in Nigeria. C1 [Dalhatu, Ibrahim T.; Ekanem, Ekanem E.] Ctr Dis Control & Prevent Nigeria, Abuja, Nigeria. [Gubio, Aisha Bintu] Natl Influenza Reference Lab, Abuja, Nigeria. [Coker, E. B. A.; Akpan, Henry; Adedeji, Adebayo Abel] Fed Minist Hlth, Abuja, Nigeria. [Medina-Marino, Andrew] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA USA. [Olsen, Sonja J.; Hwang, Inzune] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Medina-Marino, Andrew] Illinois Dept Hlth, Chicago, IL USA. RP Dalhatu, IT (reprint author), US Ctr Dis Control & Prevent Nigeria, Plot 252A Herbert Macaulay Way, Abuja, Fed Capital Ter, Nigeria. EM dalhatui@ng.cdc.gov FU Nigerian Federal Ministry of Health; US Department of Health and Human Services; CDC [5U51CI000468] FX This work was funded by the Nigerian Federal Ministry of Health, with the support of the US Department of Health and Human Services and the CDC (cooperative agreement 5U51CI000468). NR 42 TC 8 Z9 8 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD DEC 15 PY 2012 VL 206 SU 1 BP S121 EP S128 DI 10.1093/infdis/jis584 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 045BA UT WOS:000311667900019 PM 23169957 ER PT J AU Katz, MA Schoub, BD Heraud, JM Breiman, RF Njenga, MK Widdowson, MA AF Katz, Mark A. Schoub, Barry D. Heraud, Jean Michel Breiman, Robert F. Njenga, M. Kariuki Widdowson, Marc-Alain TI Influenza in Africa: Uncovering the Epidemiology of a Long-Overlooked Disease SO JOURNAL OF INFECTIOUS DISEASES LA English DT Editorial Material ID PANDEMIC INFLUENZA; MORTALITY; CHILDREN C1 [Katz, Mark A.; Breiman, Robert F.; Njenga, M. Kariuki] Ctr Dis Control & Prevent Kenya, Global Dis Detect Div, Nairobi, Kenya. [Katz, Mark A.] Ctr Dis Control & Prevent Kenya, Influenza Program, Nairobi, Kenya. [Schoub, Barry D.] Natl Hlth Lab Serv, Natl Inst Communicable Dis, Johannesburg, South Africa. [Heraud, Jean Michel] Inst Pasteur Madagascar, Natl Influenza Ctr, Antananarivo, Madagascar. [Widdowson, Marc-Alain] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Katz, MA (reprint author), Ctr Dis Control & Prevent Haiti, Unit 3400,POB 68, DPO, AA 34060 USA. EM katzm@ht.cdc.gov RI HERAUD, Jean-Michel/O-1464-2013; OI HERAUD, Jean-Michel/0000-0003-1107-0859; Widdowson, Marc-Alain/0000-0002-0682-6933 NR 25 TC 22 Z9 22 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD DEC 15 PY 2012 VL 206 SU 1 BP S1 EP S4 DI 10.1093/infdis/jis548 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 045BA UT WOS:000311667900001 PM 23169953 ER PT J AU Kouassi, DP Coulibaly, D Foster, L Kadjo, H N'Zussuouo, T Traore, Y Cherif, D N'gattia, AK Thompson, MG AF Kouassi, Damus P. Coulibaly, Daouda Foster, Lydia Kadjo, Herve N'Zussuouo, Talla Traore, Youssouf Cherif, Djibril N'gattia, Anderson K. Thompson, Mark G. TI Vulnerable Groups Within a Vulnerable Population: Awareness of the A(H1N1)pdm09 Pandemic and Willingness to Be Vaccinated Among Pregnant Women in Ivory Coast SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID SWINE FLU OUTBREAK; PUBLIC PERCEPTIONS; INFLUENZA; RISK; BEHAVIOR; ACCEPT; A/H1N1 AB Background. Because little is known about attitudes toward influenza and influenza vaccine among pregnant women in West Africa, before local distribution of A(H1N1)pdm09 vaccine in Ivory Coast we assessed knowledge of the pandemic and acceptance of the A(H1N1)pdm09 vaccine in a diverse population of pregnant women. Methods. A cross-sectional intercept survey of 411 pregnant women in 4 prenatal care settings was conducted during 15-28 February 2010 in Abidjan, Ivory Coast. Results. The majority (64.5%) of pregnant women said they had heard of the influenza pandemic, and of these, the majority (61.3%) were aware of the A(H1N1)pdm09 vaccine. However, awareness varied significantly by clinical setting, education level, and access to media (P < .001 for all comparisons). After adjustment for other sociodemographic factors, college-educated women were 16.8 (95% confidence interval [CI], 3.3-85.2) times as likely as women without formal education to be aware of the pandemic. After controlling for both education and demographic characteristics, women with televisions were 5 times as likely as women without television to be aware of the pandemic (adjusted odds ratio [aOR], 4.94; 95% CI, 1.34-18.17). Of those aware of the influenza pandemic, 69.8% said they would accept the A(H1N1)pdm09 vaccine while they were pregnant. Although awareness was highest in private prenatal care clinics, compared with public outpatient clinics (90.6% vs 37.5%), acceptance of vaccine was significantly lower in private settings, compared with public outpatient settings (57.3% vs 87.2%; P < .001 for each comparison). Conclusions. Gaps in knowledge about the influenza pandemic and vaccine highlight the challenges of pandemic preparedness in poorer countries, where substantial disparities in education and media access are evident. C1 [Kouassi, Damus P.; Coulibaly, Daouda; Traore, Youssouf; Cherif, Djibril; N'gattia, Anderson K.] Natl Inst Publ Hyg, Abidjan, Cote Ivoire. [Kadjo, Herve] Inst Pasteur, Natl Influenza Ctr, Abidjan, Cote Ivoire. [Kadjo, Herve] Inst Pasteur, Dept Epidem Virus, Resp Virus Unit, Abidjan, Cote Ivoire. [Foster, Lydia; N'Zussuouo, Talla; Thompson, Mark G.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [N'Zussuouo, Talla] US Naval Med Res Unit 3, Cairo, Egypt. [N'Zussuouo, Talla] Univ Ghana, Noguchi Mem Inst Med Res, Legon, Ghana. RP Kouassi, DP (reprint author), Natl Inst Publ Hyg, POB V14, Abidjan, Cote Ivoire. EM paquindamus@yahoo.fr FU CDC [CI07-702, 1U51/1P000154-03]; Ministry of Health of Cote d'Ivoire [1U51/1P000154-03]; US Naval Medical Research Unit FX This work was funded by the CDC through the project "Epidemiology and Laboratory Capacity Building for Surveillance and Response to Avian and Pandemic Influenza in the Republic of Cote d'Ivoire'' (funding opportunity CI07-702). This project was a cooperative agreement (1U51/1P000154-03) between the CDC and the Ministry of Health of Cote d'Ivoire, in collaboration with US Naval Medical Research Unit No. 3. The National Institute of Public Hygiene and the Institute Pasteur of Cote d'Ivoire also contributed to this work. NR 21 TC 3 Z9 3 U1 1 U2 44 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD DEC 15 PY 2012 VL 206 SU 1 BP S114 EP S120 DI 10.1093/infdis/jis532 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 045BA UT WOS:000311667900018 PM 23169956 ER PT J AU Lutwama, JJ Bakamutumaho, B Kayiwa, JT Chiiza, R Namagambo, B Katz, MA Geissler, AL AF Lutwama, Julius J. Bakamutumaho, Barnabas Kayiwa, John T. Chiiza, Richard Namagambo, Barbara Katz, Mark A. Geissler, Aimee L. TI Clinic- and Hospital-Based Sentinel Influenza Surveillance, Uganda 2007-2010 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID SEASONAL INFLUENZA; PNEUMONIA AB Background. To assess the epidemiology and seasonality of influenza in Uganda, we established a sentinel surveillance system for influenza in 5 hospitals and 5 outpatient clinics in 4 geographically distinct regions, using standard case definitions for influenzalike illness (ILI) and severe acute respiratory illness (SARI). Methods. Nasopharyngeal and oropharyngeal specimens were collected from April 2007 through September 2010 from patients with ILI and SARI aged >= 2 months, tested for influenza A and B with real-time reverse-transcription polymerase chain reaction, and subtyped for seasonal A/H1, A/H3, A/H5, and 2009 pandemic influenza A (pH1N1). Results. Among the 2758 patients sampled, 2656 (96%) enrolled with ILI and 101 (4%) with SARI. Specimens from 359 (13.0%) were positive for influenza; 267 (74.4%) were influenza A, and 92 (25.6%) were influenza B. The median age of both patients with ILI and patients with SARI was 4 years (range, 2 months to 67 years); patients aged 5-14 years had the highest influenza-positive percentage (19.6%), and patients aged 0-4 years had the lowest percentage (9.1%). Influenza circulated throughout the year, but the percentage of influenza-positive specimens peaked during June-November, coinciding with the second rainy season. Conclusions. Continued and increased surveillance is needed to better understand the morbidity and mortality of influenza in Uganda. C1 [Lutwama, Julius J.; Bakamutumaho, Barnabas; Kayiwa, John T.; Chiiza, Richard; Namagambo, Barbara] Uganda Virus Res Inst, Natl Influenza Ctr, Entebbe, Uganda. [Katz, Mark A.] Ctr Dis Control Kenya, Nairobi, Kenya. [Geissler, Aimee L.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA USA. RP Geissler, AL (reprint author), Ctr Dis Control & Prevent, 3150 Rampart Rd,T3-5, Ft Collins, CO 80521 USA. EM ihq5@cdc.gov FU US CDC [1U5/IP000157]; Ministry of Health, Uganda; WHO Country and Regional Offices; UVRI; Uganda Ministry of Health FX The surveillance activities were funded by the US CDC, under cooperative agreement 1U5/IP000157. Studies were also supported by the Ministry of Health, Uganda and the WHO Country and Regional Offices. This research was funded by the US CDC, the UVRI, and the Uganda Ministry of Health. The funders had a role in study design, data collection and analysis, decision to publish, and preparation of the manuscript. NR 20 TC 4 Z9 4 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD DEC 15 PY 2012 VL 206 SU 1 BP S87 EP S93 DI 10.1093/infdis/jis578 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 045BA UT WOS:000311667900014 PM 23169978 ER PT J AU Mihigo, R Torrealba, CV Coninx, K Nshimirimana, D Kieny, MP Carrasco, P Hedman, L Widdowson, MA AF Mihigo, Richard Torrealba, Claudia Vivas Coninx, Kanokporn Nshimirimana, Deo Kieny, Marie Paule Carrasco, Peter Hedman, Lisa Widdowson, Marc-Alain TI 2009 Pandemic Influenza A Virus Subtype H1N1 Vaccination in Africa-Successes and Challenges SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID SAFETY; VACCINES AB To provide vaccination against infection due to 2009 pandemic influenza A virus subtype H1N1 (A[H1N1]pdm09) to resource-constrained countries with otherwise very little access to the A(H1N1)pdm09 vaccine, the World Health Organization (WHO) coordinated distribution of donated vaccine to selected countries worldwide, including those in Africa. From February through November 2010, 32.2 million doses were delivered to 34 countries in Africa. Of the 19.2 million doses delivered to countries that reported their vaccination activities to WHO, 12.2 million doses (64%) were administered. Population coverage in these countries varied from 0.4% to 11%, with a median coverage of 4%. All countries targeted pregnant women (median proportion of all vaccine doses administered [mpv], 21% [range, 4%-72%]) and healthcare workers (mpv, 9% [range, 1%-73%]). Fourteen of 19 countries targeted persons with chronic conditions (mpv, 26% [range, 5%-66%]) and 10 of 19 countries vaccinated children (mpv, 54% [range, 17%-75%]). Most vaccine was distributed after peak A(H1N1)pdm09 transmission in the region. The frequency and severity of adverse events were consistent with those recorded after other inactivated influenza vaccines. Pandemic preparedness plans will need to include strategies to ensure more-rapid procedures to identify vaccine supplies and distribute and import vaccines to countries that may bear the brunt of a future pandemic. C1 [Mihigo, Richard; Nshimirimana, Deo] World Hlth Org, Reg Off Africa, Brazzaville, Congo. [Torrealba, Claudia Vivas; Coninx, Kanokporn; Kieny, Marie Paule; Carrasco, Peter; Hedman, Lisa] World Hlth Org, Geneva, Switzerland. [Widdowson, Marc-Alain] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Mihigo, R (reprint author), World Hlth Org, Reg Off Africa, POB 06, Brazzaville, Congo. EM mihigor@who.int OI Widdowson, Marc-Alain/0000-0002-0682-6933 FU WHO FX This work was funded by WHO. NR 15 TC 5 Z9 5 U1 0 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD DEC 15 PY 2012 VL 206 SU 1 BP S22 EP S28 DI 10.1093/infdis/jis535 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 045BA UT WOS:000311667900004 PM 23169967 ER PT J AU Nyatanyi, T Nkunda, R Rukelibuga, J Palekar, R Muhimpundu, MA Kabeja, A Kabanda, A Lowrance, D Tempia, S Koama, JB McAlister, D Mukabayire, O Wane, J Raghunathan, P Katz, M Karema, C AF Nyatanyi, Thierry Nkunda, Richard Rukelibuga, Joseph Palekar, Rakhee Muhimpundu, Marie Aimee Kabeja, Adeline Kabanda, Alice Lowrance, David Tempia, Stefano Koama, Jean Baptiste McAlister, David Mukabayire, Odette Wane, Justin Raghunathan, Pratima Katz, Mark Karema, Corine TI Influenza Sentinel Surveillance in Rwanda, 2008-2010 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID MORTALITY; PNEUMONIA; THAILAND; CHILDREN; VIRUSES; BURDEN AB Background. In 2008, Rwanda established an influenza sentinel surveillance (ISS) system to describe the epidemiology of influenza and monitor for the emergence of novel influenza A viruses. We report surveillance results from August 2008 to July 2010. Methods. We conducted ISS by monitoring patients with influenza-like illness (ILI) and severe acute respiratory infection (SARI) at 6 hospitals. For each case, demographic and clinical data, 1 nasopharyngeal specimen, and 1 oropharyngeal specimen were collected. Specimens were tested by real-time reverse-transcription polymerase chain reaction for influenza A and B viruses at the National Reference Laboratory in Rwanda. Results. A total of 1916 cases (945 ILI and 971 SARI) were identified. Of these, 29.2% (n = 276) of ILI and 10.4% (n = 101) of SARI cases tested positive for influenza. Of the total influenza-positive cases (n = 377), 71.8% (n = 271) were A(H1N1) pdm09, 5.6% (n = 21) influenza A(H1), 7.7% (n = 29) influenza A(H3), 1.6% (n = 6) influenza A (unsubtyped), and 13.3% (n = 50) influenza B. The percentage of positivity for influenza viruses was highest in October-November and February-March, during peaks in rainfall. Conclusions. The implementation of ISS enabled characterization of the epidemiology and seasonality of influenza in Rwanda for the first time. Future efforts should determine the population-based influenza burden to inform interventions such as targeted vaccination. C1 [Rukelibuga, Joseph; Lowrance, David; Koama, Jean Baptiste; McAlister, David; Raghunathan, Pratima] Ctr Dis Control & Prevent CDC Kigali, Kigali, Rwanda. [Palekar, Rakhee] US Ctr Dis Control & Prevent, CDC Influenza Div, Atlanta, GA USA. [Tempia, Stefano] CDC, Johannesburg, South Africa. [Wane, Justin] King Faisal Hosp, Kigali, Rwanda. [Katz, Mark] CDC, Nairobi, Kenya. [Tempia, Stefano] Natl Inst Communicable Dis, Johannesburg, South Africa. [Rukelibuga, Joseph] US Embassy, CDC Rwanda, Kigali, Rwanda. RP Rukelibuga, J (reprint author), US Embassy, CDC Rwanda, 2657 Ave Gendarmerie,BP 28 Kigali 2657, Kigali, Rwanda. EM rukelibugaj@rw.cdc.gov FU Rwandan Ministry of Health; CDC [IP00158] FX The Rwandan ISS system is supported by a cooperative agreement between the Rwandan Ministry of Health and the CDC. This work was supported by the CDC (cooperative agreement number IP00158). Its contents are solely the responsibility of the authors and do not necessarily represent the view of CDC. NR 24 TC 4 Z9 4 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD DEC 15 PY 2012 VL 206 SU 1 BP S74 EP S79 DI 10.1093/infdis/jis574 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 045BA UT WOS:000311667900012 PM 23169976 ER PT J AU Nzussouo, NT Michalove, J Diop, OM Njouom, R Monteiro, MD Adje, HK Manoncourt, S Amankwa, J Koivogui, L Sow, S Elkory, MB Collard, JM Dalhatu, I Niang, MN Lafond, K Moniz, F Coulibaly, D Kronman, KC Oyofo, BA Ampofo, W Tamboura, B Bara, AO Jusot, JF Ekanem, E Sarr, FD Hwang, I Cornelius, C Coker, B Lindstrom, S Davis, R Dueger, E Moen, A Widdowson, MA AF Nzussouo, Ndahwouh Talla Michalove, Jennifer Diop, Ousmane M. Njouom, Richard Monteiro, Maria de Lourdes Adje, Herve Kadjo Manoncourt, Serge Amankwa, Joseph Koivogui, Lamine Sow, Samba Elkory, Mohamed Brahim Collard, Jean-Marc Dalhatu, Ibrahim Niang, Mbayame Ndiaye Lafond, Kathryn Moniz, Filomena Coulibaly, Daouda Kronman, Karl C. Oyofo, Buhari A. Ampofo, William Tamboura, Boubou Bara, Ahmed Ould Jusot, Jean-Francois Ekanem, Ekanem Sarr, Fatoumata Diene Hwang, Inzune Cornelius, Claire Coker, Babajide Lindstrom, Stephen Davis, Richard Dueger, Erica Moen, Ann Widdowson, Marc-Alain TI Delayed 2009 Pandemic Influenza A Virus Subtype H1N1 Circulation in West Africa, May 2009-April 2010 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article AB To understand 2009 pandemic influenza A virus subtype H1N1 (A[H1N1]pdm09) circulation in West Africa, we collected influenza surveillance data from ministries of health and influenza laboratories in 10 countries, including Cameroon, from 4 May 2009 through 3 April 2010. A total of 10 203 respiratory specimens were tested, of which 25% were positive for influenza virus. Until the end of December 2009, only 14% of all detected strains were A(H1N1)pdm09, but the frequency increased to 89% from January through 3 April 2010. Five West African countries did not report their first A(H1N1)pdm09 case until 6 months after the emergence of the pandemic in North America, in April 2009. The time from first detection of A(H1N1)pdm09 in a country to the time of A(H1N1)pdm09 predominance varied from 0 to 37 weeks. Seven countries did not report A(H1N1)pdm09 predominance until 2010. Introduction and transmission of A(H1N1)pdm09 were delayed in this region. C1 [Nzussouo, Ndahwouh Talla] Univ Ghana, US Naval Med Res Unit 3, Noguchi Mem Inst Med Res, Global Dis Detect & Response Program,NAMRU 3, Legon, Accra, Ghana. [Nzussouo, Ndahwouh Talla; Michalove, Jennifer; Lafond, Kathryn; Hwang, Inzune; Lindstrom, Stephen; Davis, Richard; Dueger, Erica; Moen, Ann; Widdowson, Marc-Alain] US Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Diop, Ousmane M.; Niang, Mbayame Ndiaye; Sarr, Fatoumata Diene] Inst Pasteur, Natl Influenza Ctr, Dakar, Senegal. [Njouom, Richard] Ctr Pasteur Cameroon, Natl Influenza Ctr, Yaounde, Cameroon. [Adje, Herve Kadjo] IPCI, Natl Influenza Ctr, Abidjan, Cote Ivoire. [Monteiro, Maria de Lourdes] Minist Hlth, Praia, Cape Verde. [Amankwa, Joseph] Ghana Hlth Serv, Publ Hlth Div, Accra, Ghana. [Koivogui, Lamine] CHU Donka, Lab Virol PFHG, Conakry, Guinea. [Sow, Samba; Tamboura, Boubou] Ctr Dev Vaccins Mali CVD, Ctr Natl Appui Lutte Malad CNAM, Influenza Reference Lab, Bamako, Mali. [Elkory, Mohamed Brahim; Bara, Ahmed Ould] INRSP, Virol Lab, Nouakchott, Mauritania. [Collard, Jean-Marc; Jusot, Jean-Francois] Ctr Rech Med & Sanit CERMES, Influenza Reference Lab, Niamey, Niger. [Moniz, Filomena] Natl Lab Network, Praia, Cape Verde. [Dalhatu, Ibrahim; Ekanem, Ekanem] Ctr Dis Control CDC Nigeria, Abuja, Nigeria. [Coulibaly, Daouda] INHP, Abidjan, Cote Ivoire. [Ampofo, William] NMIMR, Natl Influenza Ctr, Accra, Ghana. [Coker, Babajide] Fed Minist Hlth, Abuja, Nigeria. RP Nzussouo, NT (reprint author), Univ Ghana, US Naval Med Res Unit 3, Noguchi Mem Inst Med Res, Global Dis Detect & Response Program,NAMRU 3, POB LG 581, Legon, Accra, Ghana. EM tallus5@yahoo.fr RI Valle, Ruben/A-7512-2013; OI Widdowson, Marc-Alain/0000-0002-0682-6933 FU CDC; US Naval Medical Research Unit FX This work was supported through a collaborative effort involving all listed institutions. The CDC and the US Naval Medical Research Unit No. 3 funded and/or provided technical assistance to countries such as Ghana, Cote d'Ivoire, Nigeria, Mali, Mauritania, Cameroon, Senegal, and Niger. The Institut Pasteur Dakar, Senegal, provided technical assistance to Cape Verde, Guinea, Mauritania, and Niger. NR 12 TC 14 Z9 14 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD DEC 15 PY 2012 VL 206 SU 1 BP S101 EP S107 DI 10.1093/infdis/jis572 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 045BA UT WOS:000311667900016 PM 23169954 ER PT J AU Radin, JM Katz, MA Tempia, S Nzussouo, NT Davis, R Duque, J Adedeji, A Adjabeng, MJ Ampofo, WK Ayele, W Bakamutumaho, B Barakat, A Cohen, AL Cohen, C Dalhatu, IT Daouda, C Dueger, E Francisco, M Heraud, JM Jima, D Kabanda, A Kadjo, H Kandeel, A Shamamba, SKB Kasolo, F Kronmann, KC Liwewe, MLM Lutwama, JJ Matonya, M Mmbaga, V Mott, JA Muhimpundu, MA Muthoka, P Njuguna, H Randrianasolo, L Refaey, S Sanders, C Talaat, M Theo, A Valente, F Venter, M Woodfill, C Bresee, J Moen, A Widdowson, MA AF Radin, Jennifer Michalove Katz, Mark A. Tempia, Stefano Nzussouo, Ndahwouh Talla Davis, Richard Duque, Jazmin Adedeji, Adebayo Adjabeng, Michael Jeroen Ampofo, William Kwabena Ayele, Workenesh Bakamutumaho, Barnabas Barakat, Amal Cohen, Adam L. Cohen, Cheryl Dalhatu, Ibrahim T. Daouda, Coulibaly Dueger, Erica Francisco, Moises Heraud, Jean-Michel Jima, Daddi Kabanda, Alice Kadjo, Herve Kandeel, Amr Shamamba, Stomy Karhemere Bi Kasolo, Francis Kronmann, Karl C. Liwewe, Mazyanga L. Mazaba Lutwama, Julius Julian Matonya, Miriam Mmbaga, Vida Mott, Joshua A. Muhimpundu, Marie Aimee Muthoka, Phillip Njuguna, Henry Randrianasolo, Laurence Refaey, Samir Sanders, Charlene Talaat, Maha Theo, Andros Valente, Fatima Venter, Marietjie Woodfill, Celia Bresee, Joseph Moen, Ann Widdowson, Marc-Alain TI Influenza Surveillance in 15 Countries in Africa, 2006-2010 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID SUB-SAHARAN AFRICA; A H1N1 VIRUS; SEASONAL INFLUENZA; YOUNG-CHILDREN; BURDEN; IMMUNIZATION; EPIDEMIOLOGY; INFECTION AB Background. In response to the potential threat of an influenza pandemic, several international institutions and governments, in partnership with African countries, invested in the development of epidemiologic and laboratory influenza surveillance capacity in Africa and the African Network of Influenza Surveillance and Epidemiology (ANISE) was formed. Methods. We used a standardized form to collect information on influenza surveillance system characteristics, the number and percent of influenza-positive patients with influenza-like illness (ILI), or severe acute respiratory infection (SARI) and virologic data from countries participating in ANISE. Results. Between 2006 and 2010, the number of ILI and SARI sites in 15 African countries increased from 21 to 127 and from 2 to 98, respectively. Children 0-4 years accounted for 48% of all ILI and SARI cases of which 22% and 10%, respectively, were positive for influenza. Influenza peaks were generally discernible in North and South Africa. Substantial cocirculation of influenza A and B occurred most years. Conclusions. Influenza is a major cause of respiratory illness in Africa, especially in children. Further strengthening influenza surveillance, along with conducting special studies on influenza burden, cost of illness, and role of other respiratory pathogens will help detect novel influenza viruses and inform and develop targeted influenza prevention policy decisions in the region. C1 [Widdowson, Marc-Alain] Ctr Dis Control & Prevent, Int Epidemiol & Res Team, Epidemiol Branch, Influenza Div, Atlanta, GA 30333 USA. [Tempia, Stefano] CTS Global Inc, Los Angeles, CA USA. [Nzussouo, Ndahwouh Talla; Dueger, Erica; Kronmann, Karl C.; Talaat, Maha] US Naval Med Res Unit 3, Cairo, Egypt. [Duque, Jazmin] Battelle Mem Inst, Atlanta, GA USA. [Adjabeng, Michael Jeroen] Ghana Hlth Serv, Dis Surveillance Dept, Rabat, Morocco. [Ampofo, William Kwabena] Univ Ghana, Noguchi Mem Inst Med Res, Rabat, Morocco. [Ayele, Workenesh; Jima, Daddi] Ethiopian Hlth & Nutr Res Inst, Rabat, Morocco. [Barakat, Amal] Minist Sante, Natl Inst Hyg, Rabat, Morocco. [Bakamutumaho, Barnabas; Lutwama, Julius Julian] Uganda Virus Res Inst, Rabat, Morocco. [Heraud, Jean-Michel; Randrianasolo, Laurence] Inst Pasteur Madagascar, Virol Unit, Natl Influenza Ctr, Antananarivo, Madagascar. [Liwewe, Mazyanga L. Mazaba; Theo, Andros] Univ Teaching Hosp, Lusaka, Zambia. [Venter, Marietjie] Univ Pretoria, Dept Med Virol, Zoonosis Unit, ZA-0002 Pretoria, South Africa. [Cohen, Cheryl] Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa. RP Widdowson, MA (reprint author), Ctr Dis Control & Prevent, Int Epidemiol & Res Team, Epidemiol Branch, Influenza Div, 1600 Clifton Rd NE,MS A32, Atlanta, GA 30333 USA. EM zux5@cdc.gov RI Valle, Ruben/A-7512-2013; HERAUD, Jean-Michel/O-1464-2013; Venter, Marietjie/P-9604-2016; OI HERAUD, Jean-Michel/0000-0003-1107-0859; Venter, Marietjie/0000-0003-2696-824X; Duque, Jazmin/0000-0003-3484-276X; Widdowson, Marc-Alain/0000-0002-0682-6933 FU Institute Pasteur; US Centers for Disease Control and Prevention; US Department of Defense FX This work was funded completely or in part by host governments, Institute Pasteur, and cooperative agreements with the US Centers for Disease Control and Prevention and/or the US Department of Defense. NR 34 TC 43 Z9 43 U1 1 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD DEC 15 PY 2012 VL 206 SU 1 BP S14 EP S21 DI 10.1093/infdis/jis606 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 045BA UT WOS:000311667900003 PM 23169960 ER PT J AU Tamfum, JJM Nkwembe, E Shamamba, SKB Bankoshi, F Ilunga, BK Katz, KA Cohen, AL Kabamba, J Wemankoy, EO AF Tamfum, Jean Jacques Muyembe Nkwembe, Edith Shamamba, Stomy Karhemere Bi Bankoshi, Fifi Ilunga, Benoit Kebela Katz, Kenneth A. Cohen, Adam L. Kabamba, Joelle Wemankoy, Emile Okitolonda TI Sentinel Surveillance for Influenza-Like Illness, Severe Acute Respiratory Illness, and Laboratory-Confirmed Influenza in Kinshasa, Democratic Republic of Congo, 2009-2011 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article AB Little is known about influenza in central Africa. We conducted sentinel surveillance for influenza-like illness, severe acute respiratory illness, and laboratory-confirmed influenza at 5 sites in Kinshasa, Democratic Republic of Congo, from January 2009 through April 2011. We obtained samples from 4156 patients, of whom 605 (15%) had specimens containing laboratory-confirmed influenza virus. Apart from the period of pandemic influenza due to influenza A virus subtype H1N1, which occurred during August-December 2009, influenza activity peaked at least once each year from January through March, predominantly among children. These data can guide interventions to reduce the burden of influenza in the Democratic Republic of Congo and central Africa. C1 [Tamfum, Jean Jacques Muyembe; Nkwembe, Edith; Shamamba, Stomy Karhemere Bi; Bankoshi, Fifi] Inst Natl Rech Biomed, Natl Reference Lab Influenza, Kinshasa, Zaire. [Ilunga, Benoit Kebela] Minist Hlth, Dis Control Direct, Kinshasa, Zaire. [Wemankoy, Emile Okitolonda] Kinshasa Sch Publ Hlth, Kinshasa, Zaire. [Kabamba, Joelle] Ctr Dis Control & Prevent, Kinshasa, Zaire. [Cohen, Adam L.] Ctr Dis Control & Prevent S Africa, Pretoria, South Africa. [Katz, Kenneth A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. RP Tamfum, JJM (reprint author), Inst Natl Rech Biomed, Natl Reference Lab Influenza, POB 1192, Kinshasa, Zaire. EM jjmuyembe@yahoo.fr FU CDC [1 U51 CI000464] FX This work was supported by a cooperative agreement with the CDC (grant 1 U51 CI000464). NR 12 TC 6 Z9 6 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD DEC 15 PY 2012 VL 206 SU 1 BP S36 EP S40 DI 10.1093/infdis/jis537 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 045BA UT WOS:000311667900006 ER PT J AU Vos, T Flaxman, AD Naghavi, M Lozano, R Michaud, C Ezzati, M Shibuya, K Salomon, JA Abdalla, S Aboyans, V Abraham, J Ackerman, I Aggarwal, R Ahn, SY Ali, MK Alvarado, M Anderson, HR Anderson, LM Andrews, KG Atkinson, C Baddour, LM Bahalim, AN Barker-Collo, S Barrero, LH Bartels, DH Basanez, MG Baxter, A Bell, ML Benjamin, EJ Bennett, D Bernabe, E Bhalla, K Bhandari, B Bikbov, B Bin Abdulhak, A Birbeck, G Black, JA Blencowe, H Blore, JD Blyth, F Bolliger, I Bonaventure, A Boufous, SA Bourne, R Boussinesq, M Braithwaite, T Brayne, C Bridgett, L Brooker, S Brooks, P Brugha, TS Bryan-Hancock, C Bucello, C Buchbinder, R Buckle, GR Budke, CM Burch, M Burney, P Burstein, R Calabria, B Campbell, B Canter, CE Carabin, H Carapetis, J Carmona, L Cella, C Charlson, F Chen, HL Cheng, ATA Chou, D Chugh, SS Coffeng, LE Colan, SD Colquhoun, S Colson, KE Condon, J Connor, MD Cooper, LT Corriere, M Cortinovis, M de Vaccaro, KC Couser, W Cowie, BC Criqui, MH Cross, M Dabhadkar, KC Dahiya, M Dahodwala, N Damsere-Derry, J Danaei, G Davis, A De Leo, D Degenhardt, L Dellavalle, R Delossantos, A Denenberg, J Derrett, S Des Jarlais, DC Dharmaratne, SD Dherani, M Diaz-Torne, C Dolk, H Dorsey, ER Driscoll, T Duber, H Ebel, B Edmond, K Elbaz, A Ali, SE Erskine, H Erwin, PJ Espindola, P Ewoigbokhan, SE Farzadfar, F Feigin, V Felson, DT Ferrari, A Ferri, CP Fevre, EM Finucane, MM Flaxman, S Flood, L Foreman, K Forouzanfar, MH Fowkes, FGR Franklin, R Fransen, M Freeman, MK Gabbe, BJ Gabriel, SE Gakidou, E Ganatra, HA Garcia, B Gaspari, F Gillum, RF Gmel, G Gosselin, R Grainger, R Groeger, J Guillemin, F Gunnell, D Gupta, R Haagsma, J Hagan, H Halasa, YA Hall, W Haring, D Haro, JM Harrison, JE Havmoeller, R Hay, RJ Higashi, H Hill, C Hoen, B Hoffman, H Hotez, PJ Hoy, D Huang, JJ Ibeanusi, SE Jacobsen, KH James, SL Jarvis, D Jasrasaria, R Jayaraman, S Johns, N Jonas, JB Karthikeyan, G Kassebaum, N Kawakami, N Keren, A Khoo, JP King, CH Knowlton, LM Kobusingye, O Koranteng, A Krishnamurthi, R Lalloo, R Laslett, LL Lathlean, T Leasher, JL Lee, YY Leigh, J Lim, SS Limb, E Lin, JK Lipnick, M Lipshultz, SE Liu, W Loane, M Ohno, SL Lyons, R Ma, JX Mabweijano, J MacIntyre, MF Malekzadeh, R Mallinger, L Manivannan, S Marcenes, W March, L Margolis, DJ Marks, GB Marks, R Matsumori, A Matzopoulos, R Mayosi, BM McAnulty, JH McDermott, MM McGill, N McGrath, J Medina-Mora, ME Meltzer, M Mensah, GA Merriman, TR Meyer, AC Miglioli, V Miller, M Miller, TR Mitchell, PB Mocumbi, AO Moffitt, TE Mokdad, AA Monasta, L Montico, M Moradi-Lakeh, M Moran, A Morawska, L Mori, R Murdoch, ME Mwaniki, MK Naidoo, K Nair, MN Naldi, L Narayan, KMV Nelson, PK Nelson, RG Nevitt, MC Newton, CR Nolte, S Norman, P Norman, R O'Donnell, M O'Hanlon, S Olives, C Omer, SB Ortblad, K Osborne, R Ozgediz, D Page, A Pahari, B Pandian, JD Rivero, AP Patten, SB Pearce, N Padilla, RP Perez-Ruiz, F Perico, N Pesudovs, K Phillips, D Phillips, MR Pierce, K Pion, S Polanczyk, GV Polinder, S Pope, CA Popova, S Porrini, E Pourmalek, F Prince, M Pullan, RL Ramaiah, KD Ranganathan, D Razavi, H Regan, M Rehm, JT Rein, DB Remuzzi, G Richardson, K Rivara, FP Roberts, T Robinson, C De Leon, FR Ronfani, L Room, R Rosenfeld, LC Rushton, L Sacco, RL Saha, S Sampson, U Sanchez-Riera, L Sanman, E Schwebel, DC Scott, JG Segui-Gomez, M Shahraz, S Shepard, DS Shin, H Shivakoti, R Singh, D Singh, GM Singh, JA Singleton, J Sleet, DA Sliwa, K Smith, E Smith, JL Stapelberg, NJC Steer, A Steiner, T Stolk, WA Stovner, LJ Sudfeld, C Syed, S Tamburlini, G Tavakkoli, M Taylor, HR Taylor, JA Taylor, WJ Thomas, B Thomson, WM Thurston, GD Tleyjeh, IM Tonelli, M Towbin, JRA Truelsen, T Tsilimbaris, MK Ubeda, C Undurraga, EA van der Werf, MJ van Os, J Vavilala, MS Venketasubramanian, N Wang, MR Wang, WZ Watt, K Weatherall, DJ Weinstock, MA Weintraub, R Weisskopf, MG Weissman, MM White, RA Whiteford, H Wiersma, ST Wilkinson, JD Williams, HC Williams, SRM Witt, E Wolfe, F Woolf, AD Wulf, S Yeh, PH Zaidi, AKM Zheng, ZJ Zonies, D Lopez, AD Murray, CJL AF Vos, Theo Flaxman, Abraham D. Naghavi, Mohsen Lozano, Rafael Michaud, Catherine Ezzati, Majid Shibuya, Kenji Salomon, Joshua A. Abdalla, Safa Aboyans, Victor Abraham, Jerry Ackerman, Ilana Aggarwal, Rakesh Ahn, Stephanie Y. Ali, Mohammed K. Alvarado, Miriam Anderson, H. Ross Anderson, Laurie M. Andrews, Kathryn G. Atkinson, Charles Baddour, Larry M. Bahalim, Adil N. Barker-Collo, Suzanne Barrero, Lope H. Bartels, David H. Basanez, Maria-Gloria Baxter, Amanda Bell, Michelle L. Benjamin, Emelia J. Bennett, Derrick Bernabe, Eduardo Bhalla, Kavi Bhandari, Bishal Bikbov, Boris Bin Abdulhak, Aref Birbeck, Gretchen Black, James A. Blencowe, Hannah Blore, Jed D. Blyth, Fiona Bolliger, Ian Bonaventure, Audrey Boufous, Soufi Ane Bourne, Rupert Boussinesq, Michel Braithwaite, Tasanee Brayne, Carol Bridgett, Lisa Brooker, Simon Brooks, Peter Brugha, Traolach S. Bryan-Hancock, Claire Bucello, Chiara Buchbinder, Rachelle Buckle, Geoff Rey Budke, Christine M. Burch, Michael Burney, Peter Burstein, Roy Calabria, Bianca Campbell, Benjamin Canter, Charles E. Carabin, Helene Carapetis, Jonathan Carmona, Loreto Cella, Claudia Charlson, Fiona Chen, Honglei Cheng, Andrew Tai-Ann Chou, David Chugh, Sumeet S. Coffeng, Luc E. Colan, Steven D. Colquhoun, Samantha Colson, K. Ellicott Condon, John Connor, Myles D. Cooper, Leslie T. Corriere, Matthew Cortinovis, Monica de Vaccaro, Karen Courville Couser, William Cowie, Benjamin C. Criqui, Michael H. Cross, Marita Dabhadkar, Kaustubh C. Dahiya, Manu Dahodwala, Nabila Damsere-Derry, James Danaei, Goodarz Davis, Adrian De Leo, Diego Degenhardt, Louisa Dellavalle, Robert Delossantos, Allyne Denenberg, Julie Derrett, Sarah Des Jarlais, Don C. Dharmaratne, Samath D. Dherani, Mukesh Diaz-Torne, Cesar Dolk, Helen Dorsey, E. Ray Driscoll, Tim Duber, Herbert Ebel, Beth Edmond, Karen Elbaz, Alexis Ali, Suad Eltahir Erskine, Holly Erwin, Patricia J. Espindola, Patricia Ewoigbokhan, Stalin E. Farzadfar, Farshad Feigin, Valery Felson, David T. Ferrari, Alize Ferri, Cleusa P. Fevre, Eric M. Finucane, Mariel M. Flaxman, Seth Flood, Louise Foreman, Kyle Forouzanfar, Mohammad H. Fowkes, Francis Gerry R. Franklin, Richard Fransen, Marlene Freeman, Michael K. Gabbe, Belinda J. Gabriel, Sherine E. Gakidou, Emmanuela Ganatra, Hammad A. Garcia, Bianca Gaspari, Flavio Gillum, Richard F. Gmel, Gerhard Gosselin, Richard Grainger, Rebecca Groeger, Justina Guillemin, Francis Gunnell, David Gupta, Ramyani Haagsma, Juanita Hagan, Holly Halasa, Yara A. Hall, Wayne Haring, Diana Maria Haro, Josep Harrison, James E. Havmoeller, Rasmus Hay, Roderick J. Higashi, Hideki Hill, Catherine Hoen, Bruno Hoffman, Howard Hotez, Peter J. Hoy, Damian Huang, John J. Ibeanusi, Sydney E. Jacobsen, Kathryn H. James, Spencer L. Jarvis, Deborah Jasrasaria, Rashmi Jayaraman, Sudha Johns, Nicole Jonas, Jost B. Karthikeyan, Ganesan Kassebaum, Nicholas Kawakami, Norito Keren, Andre Khoo, Jon-Paul King, Charles H. Knowlton, Lisa Marie Kobusingye, Olive Koranteng, Adofo Krishnamurthi, Rita Lalloo, Ratilal Laslett, Laura L. Lathlean, Tim Leasher, Janet L. Lee, Yong Yi Leigh, James Lim, Stephen S. Limb, Elizabeth Lin, John Kent Lipnick, Michael Lipshultz, Steven E. Liu, Wei Loane, Maria Ohno, Summer Lockett Lyons, Ronan Ma, Jixiang Mabweijano, Jacqueline MacIntyre, Michael F. Malekzadeh, Reza Mallinger, Leslie Manivannan, Sivabalan Marcenes, Wagner March, Lyn Margolis, David J. Marks, Guy B. Marks, Robin Matsumori, Akira Matzopoulos, Richard Mayosi, Bongani M. McAnulty, John H. McDermott, Mary M. McGill, Neil McGrath, John Elena Medina-Mora, Maria Meltzer, Michele Mensah, George A. Merriman, Tony R. Meyer, Ana-Claire Miglioli, Valeria Miller, Matthew Miller, Ted R. Mitchell, Philip B. Mocumbi, Ana Olga Moffitt, Terrie E. Mokdad, Ali A. Monasta, Lorenzo Montico, Marcella Moradi-Lakeh, Maziar Moran, Andrew Morawska, Lidia Mori, Rintaro Murdoch, Michele E. Mwaniki, Michael K. Naidoo, Kovin Nair, M. Nathan Naldi, Luigi Narayan, K. M. Venkat Nelson, Paul K. Nelson, Robert G. Nevitt, Michael C. Newton, Charles R. Nolte, Sandra Norman, Paul Norman, Rosana O'Donnell, Martin O'Hanlon, Simon Olives, Casey Omer, Saad B. Ortblad, Katrina Osborne, Richard Ozgediz, Doruk Page, Andrew Pahari, Bishnu Pandian, Jeyaraj Durai Rivero, Andrea Panozo Patten, Scott B. Pearce, Neil Perez Padilla, Rogelio Perez-Ruiz, Fernando Perico, Norberto Pesudovs, Konrad Phillips, David Phillips, Michael R. Pierce, Kelsey Pion, Sebastien Polanczyk, Guilherme V. Polinder, Suzanne Pope, C. Arden, III Popova, Svetlana Porrini, Esteban Pourmalek, Farshad Prince, Martin Pullan, Rachel L. Ramaiah, Kapa D. Ranganathan, Dharani Razavi, Homie Regan, Mathilda Rehm, Juergen T. Rein, David B. Remuzzi, Guiseppe Richardson, Kathryn Rivara, Frederick P. Roberts, Thomas Robinson, Carolyn De Leon, Felipe Rodriguez Ronfani, Luca Room, Robin Rosenfeld, Lisa C. Rushton, Lesley Sacco, Ralph L. Saha, Sukanta Sampson, Uchechukwu Sanchez-Riera, Lidia Sanman, Ella Schwebel, David C. Scott, James Graham Segui-Gomez, Maria Shahraz, Saeid Shepard, Donald S. Shin, Hwashin Shivakoti, Rupak Singh, David Singh, Gitanjali M. Singh, Jasvinder A. Singleton, Jessica Sleet, David A. Sliwa, Karen Smith, Emma Smith, Jennifer L. Stapelberg, Nicolas J. C. Steer, Andrew Steiner, Timothy Stolk, Wilma A. Stovner, Lars Jacob Sudfeld, Christopher Syed, Sana Tamburlini, Giorgio Tavakkoli, Mohammad Taylor, Hugh R. Taylor, Jennifer A. Taylor, William J. Thomas, Bernadette Thomson, W. Murray Thurston, George D. Tleyjeh, Imad M. Tonelli, Marcello Towbin, Jeff Rey A. Truelsen, Thomas Tsilimbaris, Miltiadis K. Ubeda, Clotilde Undurraga, Eduardo A. van der Werf, Marieke J. van Os, Jim Vavilala, Monica S. Venketasubramanian, N. Wang, Mengru Wang, Wenzhi Watt, Kerrianne Weatherall, David J. Weinstock, Martin A. Weintraub, Robert Weisskopf, Marc G. Weissman, Myrna M. White, Richard A. Whiteford, Harvey Wiersma, Steven T. Wilkinson, James D. Williams, Hywel C. Williams, Sean R. M. Witt, Emma Wolfe, Frederick Woolf, Anthony D. Wulf, Sarah Yeh, Pon-Hsiu Zaidi, Anita K. M. Zheng, Zhi-Jie Zonies, David Lopez, Alan D. Murray, Christopher J. L. TI Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 SO LANCET LA English DT Article ID NEGLECTED TROPICAL DISEASES; ADJUSTED-LIFE-YEARS; IRON-DEFICIENCY ANEMIA; DEVELOPING-COUNTRIES; ANCHORING VIGNETTES; DEPRESSIVE DISORDER; HEARING IMPAIRMENT; COGNITIVE FUNCTION; MENTAL-DISORDERS; RISK-FACTORS AB Background Non-fatal health outcomes from diseases and injuries are a crucial consideration in the promotion and monitoring of individual and population health. The Global Burden of Disease (GBD) studies done in 1990 and 2000 have been the only studies to quantify non-fatal health outcomes across an exhaustive set of disorders at the global and regional level. Neither effort quantified uncertainty in prevalence or years lived with disability (YLDs). Methods Of the 291 diseases and injuries in the GBD cause list, 289 cause disability. For 1160 sequelae of the 289 diseases and injuries, we undertook a systematic analysis of prevalence, incidence, remission, duration, and excess mortality. Sources included published studies, case notification, population-based cancer registries, other disease registries, antenatal clinic serosurveillance, hospital discharge data, ambulatory care data, household surveys, other surveys, and cohort studies. For most sequelae, we used a Bayesian meta-regression method, DisMod-MR, designed to address key limitations in descriptive epidemiological data, including missing data, inconsistency, and large methodological variation between data sources. For some disorders, we used natural history models, geospatial models, back-calculation models (models calculating incidence from population mortality rates and case fatality), or registration completeness models (models adjusting for incomplete registration with health-system access and other covariates). Disability weights for 220 unique health states were used to capture the severity of health loss. YLDs by cause at age, sex, country, and year levels were adjusted for comorbidity with simulation methods. We included uncertainty estimates at all stages of the analysis. Findings Global prevalence for all ages combined in 2010 across the 1160 sequelae ranged from fewer than one case per 1 million people to 350 000 cases per 1 million people. Prevalence and severity of health loss were weakly correlated (correlation coefficient -0.37). In 2010, there were 777 million YLDs from all causes, up from 583 million in 1990. The main contributors to global YLDs were mental and behavioural disorders, musculoskeletal disorders, and diabetes or endocrine diseases. The leading specific causes of YLDs were much the same in 2010 as they were in 1990: low back pain, major depressive disorder, iron-deficiency anaemia, neck pain, chronic obstructive pulmonary disease, anxiety disorders, migraine, diabetes, and falls. Age-specific prevalence of YLDs increased with age in all regions and has decreased slightly from 1990 to 2010. Regional patterns of the leading causes of YLDs were more similar compared with years of life lost due to premature mortality. Neglected tropical diseases, HIV/AIDS, tuberculosis, malaria, and anaemia were important causes of YLDs in sub-Saharan Africa. Interpretation Rates of YLDs per 100 000 people have remained largely constant over time but rise steadily with age. Population growth and ageing have increased YLD numbers and crude rates over the past two decades. Prevalences of the most common causes of YLDs, such as mental and behavioural disorders and musculoskeletal disorders, have not decreased. Health systems will need to address the needs of the rising numbers of individuals with a range of disorders that largely cause disability but not mortality. Quantification of the burden of non-fatal health outcomes will be crucial to understand how well health systems are responding to these challenges. Effective and affordable strategies to deal with this rising burden are an urgent priority for health systems in most parts of the world. C1 [Baxter, Amanda; Erskine, Holly; Ferrari, Alize; Khoo, Jon-Paul; Saha, Sukanta; Whiteford, Harvey] Univ Queensland, Queensland Ctr Mental Hlth Res, Brisbane, Qld, Australia. [Vos, Theo; Blore, Jed D.; Charlson, Fiona; Higashi, Hideki; Lee, Yong Yi; Norman, Rosana; Page, Andrew; Lopez, Alan D.] Univ Queensland, Sch Populat Hlth, Brisbane, Qld, Australia. [Scott, James Graham] Univ Queensland, Clin Res Ctr, Brisbane, Qld, Australia. [McGrath, John] Univ Queensland, Queensland Brain Inst, Brisbane, Qld, Australia. [Flaxman, Abraham D.; Naghavi, Mohsen; Lozano, Rafael; Ahn, Stephanie Y.; Alvarado, Miriam; Andrews, Kathryn G.; Atkinson, Charles; Bolliger, Ian; Burstein, Roy; Campbell, Benjamin; Chou, David; Colson, K. Ellicott; Delossantos, Allyne; Dharmaratne, Samath D.; Forouzanfar, Mohammad H.; Freeman, Michael K.; Gakidou, Emmanuela; Haring, Diana; James, Spencer L.; Jasrasaria, Rashmi; Johns, Nicole; Lim, Stephen S.; Ohno, Summer Lockett; MacIntyre, Michael F.; Mallinger, Leslie; Mokdad, Ali A.; Nair, M. Nathan; Ortblad, Katrina; Phillips, David; Pierce, Kelsey; Ranganathan, Dharani; Roberts, Thomas; Rosenfeld, Lisa C.; Sanman, Ella; Wang, Mengru; Wulf, Sarah; Murray, Christopher J. L.] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98121 USA. [Anderson, Laurie M.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98121 USA. [Kassebaum, Nicholas] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98121 USA. [Michaud, Catherine] China Med Board, Boston, MA USA. [Ezzati, Majid] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Epidemiol & Biostat, MRC HPA Ctr Environm & Hlth, London, England. [Shibuya, Kenji] Univ Tokyo, Dept Global Hlth Policy, Tokyo, Japan. [Finucane, Mariel M.] Harvard Univ, Dept Biostat, Boston, MA 02115 USA. [Salomon, Joshua A.; Danaei, Goodarz; Lin, John Kent; Miller, Matthew; Singh, Gitanjali M.; Sudfeld, Christopher; Tavakkoli, Mohammad; Weisskopf, Marc G.; White, Richard A.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Liu, Wei] Harvard Univ, Dept Epidemiol, Boston, MA 02115 USA. [Knowlton, Lisa Marie] Harvard Univ, Harvard Humanitarian Initiat, Boston, MA 02115 USA. [Colan, Steven D.] Harvard Univ, Boston Childrens Hosp, Boston, MA 02115 USA. [Jayaraman, Sudha] Harvard Univ, Brigham & Womens Hosp, Boston, MA 02115 USA. [Bartels, David H.; Bhalla, Kavi] Harvard Univ, Harvard Med Sch, Boston, MA 02115 USA. [Aboyans, Victor] Dupuytren Univ Hosp, Dept Cardiol, Limoges, France. [Abraham, Jerry] Univ Texas San Antonio, San Antonio, TX USA. [Steer, Andrew] Univ Melbourne, Ctr Int Child Hlth, Melbourne, Vic, Australia. [Weintraub, Robert] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia. [Degenhardt, Louisa] Univ Melbourne, Ctr Hlth Policy Programs & Econ, Melbourne, Vic, Australia. [Room, Robin] Univ Melbourne, Sch Populat Hlth, Melbourne, Vic, Australia. [Aggarwal, Rakesh] Sanjay Gandhi Postgrad Inst Med Sci, Lucknow, Uttar Pradesh, India. [Omer, Saad B.] Emory Univ, Sch Publ Hlth, Atlanta, GA USA. [Omer, Saad B.] Emory Univ, Sch Med, Atlanta, GA USA. [Anderson, H. Ross; Gupta, Ramyani; Limb, Elizabeth] St Georges Univ London, London, England. [Baddour, Larry M.; Erwin, Patricia J.; Gabriel, Sherine E.] Mayo Clin, Rochester, MN USA. [Barker-Collo, Suzanne] Univ Auckland, Auckland 1, New Zealand. [Barrero, Lope H.] Pontificia Univ Javeriana, Sch Engn, Dept Ind Engn, Bogota, Colombia. [Bell, Michelle L.; Huang, John J.; Ozgediz, Doruk] Yale Univ, New Haven, CT USA. [Felson, David T.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Bennett, Derrick] Univ Oxford, Clin Trial Serv Unit, Oxford, England. [Bennett, Derrick] Univ Oxford, Epidemiol Studies Unit, Oxford, England. [Bernabe, Eduardo] Kings Coll London, Inst Dent, London WC2R 2LS, England. [Hay, Roderick J.] Kings Coll London, Hosp NHS Trust, London WC2R 2LS, England. [Prince, Martin] Kings Coll London, Inst Psychiat, London WC2R 2LS, England. [Dahiya, Manu] Queen Mary Univ London, Inst Dent, London, England. [Bikbov, Boris] Moscow State Univ Med & Dent, Res Inst Transplantol & Artificial Organs, Moscow, Russia. [Bin Abdulhak, Aref; Tleyjeh, Imad M.] King Fahad Med City, Riyadh, Saudi Arabia. [Birbeck, Gretchen] Michigan State Univ, E Lansing, MI 48824 USA. [Black, James A.] MRC, Epidemiol Unit, Cambridge, England. [Blencowe, Hannah; Brooker, Simon; Edmond, Karen; Pearce, Neil; Pullan, Rachel L.; Smith, Jennifer L.] London Sch Hyg & Trop Med, London WC1, England. [Smith, Emma] Univ Sydney, No Clin Sch, Dept Rheumatol, Sydney, NSW 2006, Australia. [Fransen, Marlene] Univ Sydney, Fac Hlth Sci, Sydney, NSW 2006, Australia. [March, Lyn; Sanchez-Riera, Lidia] Univ Sydney, Inst Bone & Joint Res, Sydney, NSW 2006, Australia. [Driscoll, Tim; Leigh, James] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW 2006, Australia. [Bonaventure, Audrey; Elbaz, Alexis] INSERM, Paris, France. [Calabria, Bianca; Degenhardt, Louisa; Nelson, Paul K.; Singleton, Jessica] Univ New S Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW, Australia. [Bucello, Chiara; Mitchell, Philip B.] Univ New S Wales, Sydney, NSW, Australia. [Bourne, Rupert] Anglia Ruskin Univ, Vis & Eye Res Unit, Cambridge, England. [Braithwaite, Tasanee] Moorfields Eye Hosp, London, England. [Brayne, Carol; Richardson, Kathryn] Univ Cambridge, Cambridge, England. [Brugha, Traolach S.] Univ Leicester, Leicester, Leics, England. [Bryan-Hancock, Claire; Flood, Louise; Harrison, James E.; Lathlean, Tim; Pesudovs, Konrad] Flinders Univ S Australia, Adelaide, SA 5001, Australia. [Buchbinder, Rachelle] Cabrini Inst, Malvern, Vic, Australia. [Gabbe, Belinda J.] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia. [Buckle, Geoff Rey; Manivannan, Sivabalan] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Budke, Christine M.] Texas A&M Univ, College Stn, TX USA. [Burch, Michael] Great Ormond St Hosp Sick Children, London WC1N 3JH, England. [Canter, Charles E.] Washington Univ, St Louis, MO USA. [Carabin, Helene] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. [Carapetis, Jonathan] Univ Western Australia, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Perth, WA 6009, Australia. [Carmona, Loreto] Univ Camilo Jose Cela, Villanueva De La Canada, Spain. [Cella, Claudia; Cortinovis, Monica; Gaspari, Flavio; Miglioli, Valeria; Perico, Norberto; Remuzzi, Guiseppe] Mario Negri Inst Pharmacol Res, I-24100 Bergamo, Italy. [Chen, Honglei] NIEHS, Res Triangle Pk, NC 27709 USA. [Cheng, Andrew Tai-Ann] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan. [Havmoeller, Rasmus] Cedars Sinai Med Ctr, Inst Heart, Los Angeles, CA 90048 USA. [Polinder, Suzanne] Univ Med Ctr Rotterdam, Dept Publ Hlth, Erasmus MC, Rotterdam, Netherlands. [Colquhoun, Samantha; Condon, John] Menzies Sch Hlth Res, Darwin, NT, Australia. [Connor, Myles D.] Natl Hlth Serv, Edinburgh, Midlothian, Scotland. [Connor, Myles D.; Fowkes, Francis Gerry R.] Univ Edinburgh, Edinburgh, Midlothian, Scotland. [Connor, Myles D.] Univ Witwatersrand, Johannesburg, South Africa. [Cooper, Leslie T.] Loyola Univ, Sch Med, Chicago, IL 60611 USA. [Corriere, Matthew] Wake Forest Univ, Sch Publ Hlth Sci, Winston Salem, NC 27109 USA. [de Vaccaro, Karen Courville] Hosp Dr Gustavo N Collado, Puerto Chitre, Panama. [Cowie, Benjamin C.] Victorian Infect Dis Reference Lab, Melbourne, Vic, Australia. [Criqui, Michael H.; Denenberg, Julie] Univ Calif San Diego, San Diego, CA 92103 USA. [Dahodwala, Nabila; Margolis, David J.] Univ Penn, Philadelphia, PA 19104 USA. [Damsere-Derry, James] Bldg & Rd Res Inst, Kumasi, Ghana. [Davis, Adrian] MRC Hearing & Commun Grp, Manchester, Lancs, England. [Lalloo, Ratilal] Griffith Univ, Sch Dent & Oral Hlth, Brisbane, Qld 4111, Australia. [Lalloo, Ratilal] Griffith Univ, Populat & Social Hlth Res Program, Brisbane, Qld 4111, Australia. [Dellavalle, Robert] Denver VA Med Ctr, Denver, CO USA. [Derrett, Sarah; Grainger, Rebecca; Merriman, Tony R.; Taylor, William J.; Thomson, W. Murray] Univ Otago, Dunedin, New Zealand. [Des Jarlais, Don C.] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA. [Dharmaratne, Samath D.] Univ Peradeniya, Peradeniya, Sri Lanka. [Dherani, Mukesh] Univ Liverpool, Liverpool L69 3BX, Merseyside, England. [Diaz-Torne, Cesar] Hosp Santa Creu & Sant Pau, Barcelona, Spain. [Dolk, Helen; Loane, Maria] Univ Ulster, Ulster, Ireland. [Ali, Suad Eltahir] Fed Minist Hlth, Khartoum, Sudan. [Espindola, Patricia] Hosp Maciel, Montevideo, Uruguay. [Ewoigbokhan, Stalin E.] Emerald Publ Hlth Consulting Serv Ltd, Abuja, Nigeria. [Malekzadeh, Reza] Univ Tehran Med Sci, Digest Dis Res Ctr, Tehran, Iran. [Feigin, Valery] Auckland Tech Univ, Natl Inst Stroke & Appl Neurosci, Auckland, New Zealand. [Polanczyk, Guilherme V.] Univ Fed Sao Paulo, Sch Med, Sao Paulo, Brazil. [Flaxman, Seth] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA. [Franklin, Richard] Royal Life Saving Soc, Sydney, NSW, Australia. [Franklin, Richard; Watt, Kerrianne] James Cook Univ, Townsville, Qld 4811, Australia. [Gillum, Richard F.] Howard Univ, Coll Med, Washington, DC USA. [Gmel, Gerhard] Addict Info Switzerland, Lausanne, Switzerland. [Nevitt, Michael C.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Groeger, Justina] Suny Downstate Med Ctr, Coll Med, Brooklyn, NY 11203 USA. [Sleet, David A.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Guillemin, Francis] Univ Lorraine, Nancy, France. [Gunnell, David] Univ Bristol, Bristol, Avon, England. [Hagan, Holly; Thurston, George D.] NYU, New York, NY USA. [Halasa, Yara A.; Shahraz, Saeid; Shepard, Donald S.; Undurraga, Eduardo A.] Brandeis Univ, Waltham, MA USA. [Maria Haro, Josep] Univ Barcelona, CIBERSAM, St Bio De Llobregat, Spain. [Havmoeller, Rasmus] Karolinska Univ Hosp, Stockholm, Sweden. [Hill, Catherine] Queen Elizabeth Hosp, Adelaide, SA, Australia. [Hoen, Bruno] Univ Franche Comte, F-25030 Besancon, France. [Hoen, Bruno] Ctr Hosp Reg Univ Besancon, Besancon, France. [Hoffman, Howard] NIDCD, NIH, Bethesda, MD USA. [Hotez, Peter J.] Baylor Coll Med, Natl Sch Trop Med, Waco, TX USA. [Ibeanusi, Sydney E.] Univ Port Harcourt, Port Harcourt, Nigeria. [Jacobsen, Kathryn H.] George Mason Univ, Fairfax, VA 22030 USA. [Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Heidelberg, Germany. [Karthikeyan, Ganesan] All India Inst Med Sci, New Delhi, India. [Keren, Andre] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Cardiol, IL-91010 Jerusalem, Israel. [King, Charles H.] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Kobusingye, Olive] Makerere Univ, Sch Publ Hlth, Kampala, Uganda. [Kobusingye, Olive] Univ S Africa, Johannesburg, South Africa. [Koranteng, Adofo] Kwame Nkrumah Univ Sci & Technol, Kumasi, Ghana. [Laslett, Laura L.] Univ Tasmania, Hobart, Tas 7001, Australia. [Leasher, Janet L.] Nova SE Univ, Ft Lauderdale, FL 33314 USA. [Lipshultz, Steven E.; Sacco, Ralph L.; Wilkinson, James D.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA. [Lyons, Ronan] Swansea Univ, Swansea, W Glam, Wales. [Ma, Jixiang] China Ctr Dis Control, Natl Ctr Noncommunicable Dis Control & Prevent, Beijing, Peoples R China. [Mabweijano, Jacqueline] Mulago Hosp, Kampala, Uganda. [Matsumori, Akira] Asian Pacific Soc Cardiol, Kyoto, Japan. [Matzopoulos, Richard] MRC, Tygerberg, South Africa. [Sliwa, Karen] Univ Cape Town, Hatter Inst, ZA-7925 Cape Town, South Africa. [Mensah, George A.] Univ Cape Town, Dept Med, ZA-7925 Cape Town, South Africa. [McAnulty, John H.] Legacy Hlth Syst, Portland, OR USA. [McDermott, Mary M.] Northwestern Univ, Feinberg Sch Med, Evanston, IL USA. [Elena Medina-Mora, Maria] Natl Inst Psychiat Ramon de la Fuente, Mexico City, DF, Mexico. [Meltzer, Michele] Thomas Jefferson Univ, Philadelphia, PA 19107 USA. [Miller, Ted R.] Pacific Inst Res & Evaluat, Calverton, MD USA. [Mocumbi, Ana Olga] Natl Inst Hlth, Maputo, Mozambique. [Mocumbi, Ana Olga] Univ Eduardo Mondlane, Maputo, Mozambique. [Moffitt, Terrie E.] Duke Univ, Durham, NC USA. [Monasta, Lorenzo; Montico, Marcella; Ronfani, Luca; Tamburlini, Giorgio] IRCCS Burlo Garofolo, Inst Maternal & Child Hlth, Trieste, Italy. [Weissman, Myrna M.] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA. [Morawska, Lidia] Queensland Univ Technol, Brisbane, Qld 4001, Australia. [Mori, Rintaro] Natl Ctr Child Hlth & Dev, Tokyo, Japan. [Murdoch, Michele E.] Watford Dist Gen Hosp, Watford, England. [Mwaniki, Michael K.] Kemri Wellcome Trust, Kilifi, Kenya. [Naidoo, Kovin] Univ KwaZulu Natal, AVRI, Durban, South Africa. [Naldi, Luigi] Ctr Studi GISED, Bergamo, Italy. [Nolte, Sandra] Charite, D-13353 Berlin, Germany. [O'Donnell, Martin] Natl Univ Ireland Galway, HRB Clin Res Facil, Galway, Ireland. [Osborne, Richard] Deakin Univ, Melbourne, Vic, Australia. [Pahari, Bishnu] BP Koirala Inst Hlth Sci, Dharan, Nepal. [Pandian, Jeyaraj Durai] Betty Cowan Res & Innovat Ctr, Ludhiana, Punjab, India. [Rivero, Andrea Panozo] Hosp Joan 23, La Paz, Bolivia. [Patten, Scott B.] Univ Calgary, Calgary, AB, Canada. [Perez Padilla, Rogelio] Inst Nacl Enfermedades Resp, Mexico City, DF, Mexico. [Perez-Ruiz, Fernando] Hosp Univ Cruces, Baracaldo, Spain. [Phillips, Michael R.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Mental Hlth Ctr, Shanghai 200030, Peoples R China. [Zheng, Zhi-Jie] Shanghai Jiao Tong Univ, Sch Publ Hlth, Shanghai 200030, Peoples R China. [Pope, C. Arden, III] Brigham Young Univ, Provo, UT 84602 USA. [Popova, Svetlana; Rehm, Juergen T.] Ctr Addict & Mental Hlth, Toronto, ON, Canada. [Porrini, Esteban] Hosp Univ Canarias, Tenerif, Spain. [Pourmalek, Farshad] Univ British Columbia, Fac Med, Sch Populat & Publ Hlth, Vancouver, BC, Canada. [Ramaiah, Kapa D.] Vector Control Res Ctr, Pondicherry, India. [Razavi, Homie] Ctr Dis Anal, Louisville, CO USA. [Regan, Mathilda] Univ Calif Berkeley, Berkeley, CA 94720 USA. [Rein, David B.] Univ Chicago, NORC, Chicago, IL 60637 USA. [De Leon, Felipe Rodriguez] Complejo Hosp Caja Seguro Social, Panama City, Panama. [Room, Robin] Turning Point Alcohol & Drug Ctr, Ctr Alcohol Policy Res, Fitzroy, SA, Australia. [Sampson, Uchechukwu] Vanderbilt Univ, Nashville, TN USA. [Schwebel, David C.; Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL USA. [Segui-Gomez, Maria] Minist Interior, Madrid, Spain. [Shin, Hwashin] Hlth Canada, Ottawa, ON K1A 0L2, Canada. [Singh, David] Queens Med Ctr, Honolulu, HI USA. [Stovner, Lars Jacob] Norwegian Univ Sci & Technol, Dept Neurosci, N-7034 Trondheim, Norway. [Syed, Sana; Zaidi, Anita K. M.] Agwa Khan Univ, Karachi, Pakistan. [Taylor, Jennifer A.] Drexel Univ, Sch Publ Hlth, Philadelphia, PA 19104 USA. [Tonelli, Marcello] Univ Alberta, Alberta Kidney Dis Network, Edmonton, AB, Canada. [Towbin, Jeff Rey A.] Cincinnati Childrens Hosp, Cincinnati, OH USA. [Truelsen, Thomas] Copenhagen Univ Hosp, Dept Neurol, Herlev, Denmark. [Tsilimbaris, Miltiadis K.] Univ Crete, Sch Med, Iraklion, Greece. [Ubeda, Clotilde] ANLIS, Inst Nacl Epidemiol, Malbran, Argentina. [van der Werf, Marieke J.] KNCV TB Fdn, The Hague, Netherlands. [van Os, Jim] Maastricht Univ Med Ctr, Maastricht, Netherlands. [Venketasubramanian, N.] Natl Univ Singapore, Singapore 117548, Singapore. [Wang, Wenzhi] Capital Med Univ, Beijing Neurosurg Inst, Beijing, Peoples R China. [Weinstock, Martin A.] Brown Univ, Providence, RI 02912 USA. [Weintraub, Robert] Royal Childrens Hosp, Melbourne, Vic, Australia. [Weintraub, Robert] Murdoch Childrens Res Inst, Melbourne, Vic, Australia. [Williams, Hywel C.] Univ Nottingham, Nottingham NG7 2RD, England. [Williams, Sean R. M.] Univ Western Sydney, Campbelltown, NSW, Australia. [Wolfe, Frederick] Arthrit Res, Wichita, KS USA. [Woolf, Anthony D.] Royal Cornwall Hosp, Truro, England. [Yeh, Pon-Hsiu] London Sch Econ, London WC2A 2AE, England. [Zonies, David] Landstuhl Reg Med Ctr, Landstuhl, Germany. [Nelson, Robert G.] NIDDK, NIH, Bethesda, MD USA. RP Murray, CJL (reprint author), Univ Washington, Inst Hlth Metr & Evaluat, 2301 5th Ave,Suite 600, Seattle, WA 98121 USA. EM cjlm@uw.edu RI Higashi, Hideki/D-3797-2011; Undurraga, Eduardo/I-3739-2014; Bolliger, Ian/C-4207-2016; Boussinesq, Michel/J-7256-2016; Jacobsen, Kathryn/B-5857-2008; Naldi, Luigi/K-6343-2016; Lalloo, Ratilal/O-5624-2014; Scott, James/D-5900-2012; Salomon, Joshua/D-3898-2009; Franklin, Richard/H-1731-2012; Dellavalle, Robert/L-2020-2013; Baxter, Amanda/E-5449-2011; Research ID, CTBCC /O-3564-2014; Prince, Martin/A-9170-2010; Charlson, Fiona/F-5290-2011; Harrison, James/B-8958-2009; Whiteford, Harvey/A-4840-2009; Ferri, Cleusa/B-2922-2010; Tonelli, Marcello/B-3028-2009; Haro, Josep Maria/D-1423-2011; Carabin, Helene/B-7600-2016; Patten, Scott/B-4434-2011; Monasta, Lorenzo/B-1388-2012; Stovner, Lars/D-5025-2014; Moffitt, Terrie/D-5295-2011; Ebel, Beth/F-4544-2014; Lopez, Alan/F-1487-2010; Laslett, Laura/G-3973-2011; Narayan, K.M. Venkat /J-9819-2012; Hall, Wayne/A-3283-2008; Ronfani, Luca/B-6668-2013; Nolte, Sandra/B-7498-2008; Bikbov, Boris/I-4594-2013; Lee, Yong Yi/C-1373-2015; Degenhardt, Louisa/D-4515-2012; Norman, Paul/C-5485-2013; Lathlean, Tim/K-3653-2013; Saha, Sukanta/K-3774-2012; Carmona, Loreto/A-2748-2014; McGrath, John/G-5493-2010; Montico, Marcella/B-5290-2013; Black, James/A-5917-2010; Erskine, Holly/K-5244-2012; NORMAN, ROSANA/F-2774-2010; Buchbinder, Rachelle/G-2952-2011; Polanczyk, Guilherme/C-2345-2012; Jarvis, Deborah/E-6494-2011 OI Merriman, Tony/0000-0003-0844-8726; Chen, Honglei/0000-0003-3446-7779; Perez-Ruiz, Fernando/0000-0002-5268-1894; King, Charles/0000-0001-8349-9270; Osborne, Richard/0000-0002-9081-2699; Pesudovs, Konrad/0000-0002-6322-9369; Mayosi, Bongani/0000-0001-6641-8950; Gabbe, Belinda/0000-0001-7096-7688; Bernabe, Eduardo/0000-0002-1858-3713; Cella, Claudia/0000-0002-9210-0775; Taylor, Hugh/0000-0002-9437-784X; Erskine, Holly/0000-0003-3119-9211; Aboyans, Victor/0000-0002-0322-9818; Weissman, Myrna/0000-0003-3490-3075; Mitchell, Philip/0000-0002-7954-5235; Razavi, Homie/0000-0002-2658-6930; Pourmalek, Farshad/0000-0002-2134-0771; Miller, Ted/0000-0002-0958-2639; Cesar, Diaz-Torne/0000-0001-6275-7699; Fevre, Eric/0000-0001-8931-4986; Higashi, Hideki/0000-0002-5534-0905; Phillips, David/0000-0003-2569-1015; Johns, Nicole/0000-0003-4513-4582; Moradi-Lakeh, Maziar/0000-0001-7381-5305; Benjamin, Emelia/0000-0003-4076-2336; Newton, Charles/0000-0002-6999-5507; Leasher, Janet/0000-0002-8779-5162; Aggarwal, Rakesh/0000-0001-9689-494X; Mock, Charles/0000-0002-0564-568X; Loane, Maria/0000-0002-1206-3637; Undurraga, Eduardo/0000-0002-4425-1253; Cowie, Benjamin/0000-0002-7087-5895; O'Donnell, Martin/0000-0002-7347-7761; O'donnell, Colm/0000-0002-8004-450X; Malekzadeh, Reza/0000-0003-1043-3814; singh, jasvinder/0000-0003-3485-0006; Mensah, George/0000-0002-0387-5326; Bolliger, Ian/0000-0001-8055-297X; Boussinesq, Michel/0000-0001-6312-0681; Jacobsen, Kathryn/0000-0002-4198-6246; Naldi, Luigi/0000-0002-3160-2835; Lalloo, Ratilal/0000-0001-5822-1269; Scott, James/0000-0002-0744-0688; Salomon, Joshua/0000-0003-3929-5515; Franklin, Richard/0000-0003-1864-4552; Dellavalle, Robert/0000-0001-8132-088X; Hotez, Peter/0000-0001-8770-1042; Ebel, Beth/0000-0001-9310-8325; Baxter, Amanda/0000-0001-8198-9022; Prince, Martin/0000-0003-1379-7146; Charlson, Fiona/0000-0003-2876-5040; Harrison, James/0000-0001-9893-8491; Whiteford, Harvey/0000-0003-4667-6623; Ferri, Cleusa/0000-0002-1815-7685; Haro, Josep Maria/0000-0002-3984-277X; Patten, Scott/0000-0001-9871-4041; Monasta, Lorenzo/0000-0001-7774-548X; Moffitt, Terrie/0000-0002-8589-6760; Lopez, Alan/0000-0001-5818-6512; Laslett, Laura/0000-0002-4336-0095; Narayan, K.M. Venkat /0000-0001-8621-5405; Hall, Wayne/0000-0003-1984-0096; Ronfani, Luca/0000-0001-5710-3914; Nolte, Sandra/0000-0001-6185-9423; Bikbov, Boris/0000-0002-1925-7506; Lee, Yong Yi/0000-0003-2359-6823; Degenhardt, Louisa/0000-0002-8513-2218; Norman, Paul/0000-0003-3406-0506; Carmona, Loreto/0000-0002-4401-2551; McGrath, John/0000-0002-4792-6068; Montico, Marcella/0000-0003-0377-8232; Black, James/0000-0002-2200-3179; NORMAN, ROSANA/0000-0002-9742-1957; Polanczyk, Guilherme/0000-0003-2311-3289; FU Berlin Heart Honoraria; Lundbeck; Medtronic; Prana Biotechnology; Safework Australia; Assurance-Maladie (CNAMTS) InVS; Inserm; CHU de Nancy; CHU de Nice; Conseil Regional de Lorraine; Societe Francaise de Negma-Lerads; Pfizer; Pierre Fabre Medicaments; Sanofi-Aventis France; Spanish Health Ministry; Hospital de Cruces Rheumatology Association; Novartis; National Council for Scientific and Technological Development (CNPq, Brazil); European Chemical Industry Council (CEFIC); CONCAWE (Conservation of Clean Air and Water Europe); Takeda; Savient; Ardea; Regeneron; Allergan; URL pharmaceuticals; 36 companies; National Institutes of Arthritis, Musculoskeletal and Skin Diseases (NIAMS); National Institute on Aging (NIA); National Cancer Institute (NCI); Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs); Moscow State University of Medicine and Dentistry, Moscow, Russia; Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow, Russia; International Society of Nephrology; Wellcome Trust [098045, 085308]; Department of Health London for the National Health Service Information Centre; University of Leicester; Australian National Health and Medical Research Council (NHMRC); Monash University; Cabrini Health; BUPA Foundation; NIH, the National Institute of Environmental Health Sciences; Africa Programme for Onchocerciasis Control (WHO/APOC); NIH [K23 AG034236]; Parkinson Council; Australian NHMRC; US Department of Veterans Affairs; Health Research Council of New Zealand; University of Otago; National Institute for Stroke and Applied Neurosciences; Swedish Research Council [2011-1071]; Bill and Melinda Gates Foundation; Australian National Health and Medical Research Council; World Health Organization; World Mental Health Japan (WMH-J); Grant for Research on Psychiatric and Neurological Diseases and Mental Health from the Japan Ministry of Health, Labour, and Welfare [H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013]; Australian Government; National Health and Medical Research Council of Australia; Arthritis Foundation of Australia; Tasmanian Community Fund; Masonic Centenary Medical Research Foundation; Royal Hobart Hospital Research Foundation; University of Tasmania; Tehran University of Medical Sciences; South African Medical Research Council Burden of Disease Research Unit; University of Cape Town School of Public Health and Family Medicine; Brien Holden Vision Institute; National Drug and Alcohol Research Centre (UNSW, Australia); Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases; Biostatistics, Epidemiologic and Bioinformatic Training in Environmental Health Training Grant [ES015459]; Burke Global Health Fellowship; Harold Amos Medical Faculty Development Award of the Robert Wood Johnson Foundation; Vanderbilt Clinical and Translational Scholars Award; European Center for Injury Prevention, Universidad de Navarra; National Institute of Environmental Health Sciences [ES00260]; Wellcome Trust UK; Medical Research Council UK; Anthony Cerami and Ann Dunne Research Trust; AUT University FX C E Canter has worked as an Optum Health consultant, Blue Cross Blue Shield consultant, and received Berlin Heart Honoraria and travel fees. E R Dorsey has received payments for consulting services from Lundbeck and Medtronic and research support from Lundbeck and Prana Biotechnology. T Driscoll was supported in part by funding from the National Occupational Health and Safety Commission (now Safework Australia). M Ezzati chaired a session and gave a talk at the World Cardiology Congress (WCC), with travel cost reimbursed by the World Heart Federation. At the WCC, he also gave a talk at a session organised by PepsiCo with no financial or other remuneration. F Guillemin did a study on osteoarthritis epidemiology in an institution that received grants from public sources: Assurance-Maladie (CNAMTS) InVS, Inserm, CHU de Nancy, CHU de Nice, Conseil Regional de Lorraine, Societe Francaise de Negma-Lerads, Pfizer, Pierre Fabre Medicaments, Sanofi-Aventis France. H J Hoffman is a US Federal Government employee of the National Institutes of Health (NIH). P J Hotez reports holding several positions: Dean, National School of Tropical Medicine, Baylor College of Medicine; Director, Sabin Vaccine Institute Texas Children's Hospital Center for Vaccine Development; and President, Sabin Vaccine Institute. He also is an inventor on several patents: 5,527,937 "Hookworm Anticoagulant"; 5,753,787 "Nucleic Acids for Ancylostoma Secreted Proteins"; 7,303,752 B2 "Hookworm vaccine"; 12/492,734 "Human Hookworm Vaccine"; 61/077,256 "Multivalent Anthelminthic Vaccine"; and PCT-20100701/0.20.5.18 "Malaria Transmission blocking vaccine". G A Mensah is a former employee of PepsiCo. F Perez-Ruiz was an advisor for Ardea, Menarini, Novartis, Metabolex; was a member of the Speaker's Bureau for Menarini, Novartis; an advisor for educational issues for Savient; led investigation grants for the Spanish Health Ministry, Hospital de Cruces Rheumatology Association; and was principal investigator in clinical trials for Ardea. G V Polanczyk has served as a speaker or consultant to Eli-Lily, Novartis, Janssen-Cilag, and Shire Pharmaceuticals, developed educational material for Janssen-Cilag, and received an independent investigator grant from Novartis and from the National Council for Scientific and Technological Development (CNPq, Brazil). L Rushton received honorarium for board membership of the European Centre for Ecotoxicology and Toxicology of Chemicals and received research grants to Imperial College London (as PI) from the European Chemical Industry Council (CEFIC) and CONCAWE (Conservation of Clean Air and Water Europe). J A Singh has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals, and Novartis. J A Singh is a member of the executive of OMERACT, an organisation that develops outcome measures in rheumatology and receives arms-length funding from 36 companies; a member of the American College of Rheumatology's Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. J A Singh is supported by research grants from the National Institutes of Arthritis, Musculoskeletal and Skin Diseases (NIAMS), National Institute on Aging (NIA), National Cancer Institute (NCI) and the Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs) and is also supported by the resources and the use of facilities at the VA Medical Center at Birmingham, Alabama, USA.; We would like to thank the countless individuals who have contributed to the Global Burden of Disease Study 2010 in various capacities. We would also like to specifically acknowledge the important contribution to this work from multiple staff members of the World Health Organization. We also wish to express our gratitude to the following organizations that hosted consultations during the final stages of the analytic process, providing valuable feedback about the results and the data to improve the study's findings overall: Pan American Health Organization; Eastern Mediterranean Regional Office of WHO; UNAIDS; Ministry of Health, Brazil; China Centers for Disease Control; and the University of Zambia. We would like to thank Lori M Newman, Jordis Ott, Poul Erik Petersen, Shekhar Saxena, and Gretchen A Stevens for their collaboration and input into the analyses and estimates. Finally, we would like to acknowledge the extensive support from all staff members at the Institute for Health Metrics and Evaluation and specifically thank: James Bullard, Andrew Ernst, and Serkan Yalcin for their tireless support of the computational infrastructure required to produce the results; Linda A Ettinger for her expert administrative support in order to facilitate communication and coordination amongst the authors; Peter Speyer, Abigail McLain, Katherine Leach-Kemon, and Eden Stork for their persistent and valuable work to gain access to and catalog as much data as possible to inform the estimates; Erin C Mullany for her systematic efforts in organizing drafts of papers, formatting correspondence with expert groups, and preparing the final manuscript; Brad Bell for his review, critiques, and insights about the DisMod-MR software which helped to improve its performance and results; and Jiaji Du for his work developing the user interface for the DisMod-MR software so that multiple expert groups could use it and easily assess the results. The following individuals would like to acknowledge various forms of institutional support. J P Abraham, B Bartels, and P Yeh recognize the support of the World Bank Global Road Safety Facility and Department of Global Health & Population, Harvard School of Public Health, and the World Health Organization Violence and Injury Prevention. B Bikbov acknowledges support from the Moscow State University of Medicine and Dentistry, Moscow, Russia; Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow, Russia; International Society of Nephrology. R Bourne acknowledges the Vision & Eye Research Unit, Postgraduate Medical Institute, Anglia Ruskin University, Cambridge, UK. S Brooker is supported by a Wellcome Trust Senior Fellowship in Basic Biomedical Science (098045). T S Brugha received funding from the Department of Health London, for the National Health Service Information Centre, by the University of Leicester. R Buchbinder is partially funded by an Australian National Health and Medical Research Council (NHMRC) Practitioner Fellowship, Monash University and Cabrini Health. P Burney and D Jarvis acknowledge that the Chronic Respiratory Disease Group received support from the BUPA Foundation, who had no role in study design, data collection and analysis, interpretation of data, decision to publish, or preparation of the manuscript. C Cella, M Cortinovis, F Gaspari, V Miglioli, and N Perico on behalf of the entire Genitourinary Expert Group acknowledge the International Society of Nephrology (ISN).; H Chen acknowledges that his participation in this study was in part supported by the intramural research program of the NIH, the National Institute of Environmental Health Sciences. L E Coffeng and W A Stolk received financial support from the Africa Programme for Onchocerciasis Control (WHO/APOC) for their work on onchocerciasis. B C Cowie received institutional support from the Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia. M Cross and L March acknowledge the University of Sydney (USYD); Institute of Bone and Joint Research, University of Sydney, Department of Rheumatology, Royal North Shore Hospital, St Leonards NSW 2065 Australia. N Dahodwala was supported by NIH grant K23 AG034236 and the Parkinson Council while working on this project. L Degenhardt is supported by an Australian NHMRC Senior Research Fellowship and funding to support her work for illicit drug dependence was provided by the Australian National Drug and Alcohol Research Centre of the University of New South Wales, Australia. R Dellavalle was supported by the US Department of Veterans Affairs while contributing to this study. S Derrett acknowledges the Health Research Council of New Zealand and the University of Otago for their support. V Feigin and R Krishnamurthi were supported by the National Institute for Stroke and Applied Neurosciences, AUT University. E Fevre acknowledges the Wellcome Trust for grant 085308. W Hall was supported by an NHMRC Australia Fellowship. R Havmoeller was supported by a grant from the Swedish Research Council (#2011-1071). D Hoy was supported by the Bill and Melinda Gates Foundation and the Australian National Health and Medical Research Council. K H Jacobsen was supported by the World Health Organization for her work on hepatitis A. N Kawakami notes that the collection of data ultimately used in this study was supported by the following grants: The World Mental Health Japan (WMH-J) is supported by the Grant for Research on Psychiatric and Neurological Diseases and Mental Health (H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013) from the Japan Ministry of Health, Labour, and Welfare. He would like to thank staff members, field coordinators, and interviewers of the WMH Japan 2002-2004 Survey. L L Laslett is supported by an Australian Government Australian Postgraduate Award. She also notes that the TasOAC study, the results of which were used in this research, was supported by the National Health and Medical Research Council of Australia; Arthritis Foundation of Australia; Tasmanian Community Fund; Masonic Centenary Medical Research Foundation, Royal Hobart Hospital Research Foundation, and University of Tasmania Institutional Research Grants Scheme. R Malekzadeh funding from research grant of Tehran University of Medical Sciences to do the related studies. R Matzopoulos acknowledges the two institutions that support his research work: South African Medical Research Council Burden of Disease Research Unit; and the University of Cape Town School of Public Health and Family Medicine. T Merriman acknowledges the Health Research Council of New Zealand. K Naidoo was supported by the Brien Holden Vision Institute. P Nelson was supported by the National Drug and Alcohol Research Centre (UNSW, Australia). R G Nelson acknowledges his research was supported in part by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases. C Olives was funded in part by the Biostatistics, Epidemiologic and Bioinformatic Training in Environmental Health Training Grant (ES015459).; D Ozgediz acknowledges the staff and collaborators at the Mulago Hospital and Makerere University in Kampala, Uganda. K Pesudovs received institutional support from Flinders University. R Room's position at the University of Melbourne and Turning Point Alcohol and Drug Centre is funded by the Foundation for Alcohol Research and Education and the Victorian Department of Health. J A Salomon received support from the Burke Global Health Fellowship while working on this study. U Sampson received funding support from the Harold Amos Medical Faculty Development Award of the Robert Wood Johnson Foundation and the Vanderbilt Clinical and Translational Scholars Award. L Sanchez-Riera acknowledges the Spanish Society of Rheumatology (Sociedad Espanola de Reumatologia). M Segui-Gomez's participation was partly supported by funds from the European Center for Injury Prevention, Universidad de Navarra. E Smith acknowledges the Department of Health and Ageing, Commonwealth Government of Australia, Institute of Bone and Joint Research (IBJR), University of Sydney (USYD). G D Thurston was supported in part by Center grant ES00260 from the National Institute of Environmental Health Sciences. D J Weatherall was supported by the Wellcome Trust UK, the Medical Research Council UK and the Anthony Cerami and Ann Dunne Research Trust. NR 109 TC 1603 Z9 1678 U1 114 U2 579 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 EI 1474-547X J9 LANCET JI Lancet PD DEC 15 PY 2012 VL 380 IS 9859 BP 2163 EP 2196 PG 34 WC Medicine, General & Internal SC General & Internal Medicine GA 055AL UT WOS:000312387000015 PM 23245607 ER PT J AU Murray, CJL Vos, T Lozano, R Naghavi, M Flaxman, AD Michaud, C Ezzati, M Shibuya, K Salomon, JA Abdalla, S Aboyans, V Abraham, J Ackerman, I Aggarwal, R Ahn, SY Ali, MK Alvarado, M Anderson, HR Anderson, LM Andrews, KG Atkinson, C Baddour, LM Bahalim, AN Barker-Collo, S Barrero, LH Bartels, DH Basanez, MG Baxter, A Bell, ML Benjamin, EJ Bennett, D Bernabe, E Bhalla, K Bhandari, B Bikbov, B Bin Abdulhak, A Birbeck, G Black, JA Blencowe, H Blore, JD Blyth, F Bolliger, I Bonaventure, A Boufous, SA Bourne, R Boussinesq, M Braithwaite, T Brayne, C Bridgett, L Brooker, S Brooks, P Brugha, TS Bryan-Hancock, C Bucello, C Buchbinder, R Buckle, G Budke, CM Burch, M Burney, P Burstein, R Calabria, B Campbell, B Canter, CE Carabin, H Carapetis, J Carmona, L Cella, C Charlson, F Chen, HL Cheng, ATA Chou, D Chugh, SS Coffeng, LE Colan, SD Colquhoun, S Colson, KE Condon, J Connor, MD Cooper, LT Corriere, M Cortinovis, M De Vaccaro, KC Couser, W Cowie, BC Criqui, MH Cross, M Dabhadkar, KC Dahiya, M Dahodwala, N Damsere-Derry, J Danaei, G Davis, A De Leo, D Degenhardt, L Dellavalle, R Delossantos, A Denenberg, J Derrett, S Des Jarlais, DC Dharmaratne, SD Dherani, M Diaz-Torne, C Dolk, H Dorsey, ER Driscoll, T Duber, H Ebel, B Edmond, K Elbaz, A Ali, SE Erskine, H Erwin, PJ Espindola, P Ewoigbokhan, SE Farzadfar, F Feigin, V Felson, DT Ferrari, A Ferri, CP Fevre, EM Finucane, MM Flaxman, S Flood, L Foreman, K Forouzanfar, MH Fowkes, FGR Fransen, M Freeman, MK Gabbe, BJ Gabriel, SE Gakidou, E Ganatra, HA Garcia, B Gaspari, F Gillum, RF Gmel, G Gonzalez-Medina, D Gosselin, R Grainger, R Grant, B Groeger, J Guillemin, F Gunnell, D Gupta, R Haagsma, J Hagan, H Halasa, YA Hall, W Haring, D Haro, JM Harrison, JE Havmoeller, R Hay, RJ Higashi, H Hill, C Hoen, B Hoffman, H Hotez, PJ Hoy, D Huang, JJ Ibeanusi, SE Jacobsen, KH James, SL Jarvis, D Jasrasaria, R Jayaraman, S Johns, N Jonas, JB Karthikeyan, G Kassebaum, N Kawakami, N Keren, A Khoo, JP King, CH Knowlton, LM Kobusingye, O Koranteng, A Krishnamurthi, R Laden, F Lalloo, R Laslett, LL Lathlean, T Leasher, JL Lee, YY Leigh, J Levinson, D Lim, SS Limb, E Lin, JK Lipnick, M Lipshultz, SE Liu, W Loane, M Ohno, SL Lyons, R Mabweijano, J MacIntyre, MF Malekzadeh, R Mallinger, L Manivannan, S Marcenes, W March, L Margolis, DJ Marks, GB Marks, R Matsumori, A Matzopoulos, R Mayosi, BM McAnulty, JH McDermott, MM McGill, N McGrath, J Medina-Mora, ME Meltzer, M Mensah, GA Merriman, TR Meyer, AC Miglioli, V Miller, M Miller, TR Mitchell, PB Mock, C Mocumbi, AO Moffitt, TE Mokdad, AA Monasta, L Montico, M Moradi-Lakeh, M Moran, A Morawska, L Mori, R Murdoch, ME Mwaniki, MK Naidoo, K Nair, MN Naldi, L Narayan, KMV Nelson, PK Nelson, RG Nevitt, MC Newton, CR Nolte, S Norman, P Norman, R O'Donnell, M O'Hanlon, S Olives, C Omer, SB Ortblad, K Osborne, R Ozgediz, D Page, A Pahari, B Pandian, JD Rivero, AP Patten, SB Pearce, N Padilla, RP Perez-Ruiz, F Perico, N Pesudovs, K Phillips, D Phillips, MR Pierce, K Pion, S Polanczyk, GV Polinder, S Pope, CA Popova, S Porrini, E Pourmalek, F Prince, M Pullan, RL Ramaiah, KD Ranganathan, D Razavi, H Regan, M Rehm, JT Rein, DB Remuzzi, G Richardson, K Rivara, FP Roberts, T Robinson, C De Leon, FR Ronfani, L Room, R Rosenfeld, LC Rushton, L Sacco, RL Saha, S Sampson, U Sanchez-Riera, L Sanman, E Schwebel, DC Scott, JG Segui-Gomez, M Shahraz, S Shepard, DS Shin, H Shivakoti, R Singh, D Singh, GM Singh, JA Singleton, J Sleet, DA Sliwa, K Smith, E Smith, JL Stapelberg, NJC Steer, A Steiner, T Stolk, WA Stovner, LJ Sudfeld, C Syed, S Tamburlini, G Tavakkoli, M Taylor, HR Taylor, JA Taylor, WJ Thomas, B Thomson, WM Thurston, GD Tleyjeh, IM Tonelli, M Towbin, JRA Truelsen, T Tsilimbaris, MK Ubeda, C Undurraga, EA van der Werf, MJ van Os, J Vavilala, MS Venketasubramanian, N Wang, MR Wang, WZ Watt, K Weatherall, DJ Weinstock, MA Weintraub, R Weisskopf, MG Weissman, MM White, RA Whiteford, H Wiebe, N Wiersma, ST Wilkinson, JD Williams, HC Williams, SRM Witt, E Wolfe, F Woolf, AD Wulf, S Yeh, PH Zaidi, AKM Zheng, ZJ Zonies, D Lopez, AD AF Murray, Christopher J. L. Vos, Theo Lozano, Rafael Naghavi, Mohsen Flaxman, Abraham D. Michaud, Catherine Ezzati, Majid Shibuya, Kenji Salomon, Joshua A. Abdalla, Safa Aboyans, Victor Abraham, Jerry Ackerman, Ilana Aggarwal, Rakesh Ahn, Stephanie Y. Ali, Mohammed K. Alvarado, Miriam Anderson, H. Ross Anderson, Laurie M. Andrews, Kathryn G. Atkinson, Charles Baddour, Larry M. Bahalim, Adil N. Barker-Collo, Suzanne Barrero, Lope H. Bartels, David H. Basanez, Maria-Gloria Baxter, Amanda Bell, Michelle L. Benjamin, Emelia J. Bennett, Derrick Bernabe, Eduardo Bhalla, Kavi Bhandari, Bishal Bikbov, Boris Bin Abdulhak, Aref Birbeck, Gretchen Black, James A. Blencowe, Hannah Blore, Jed D. Blyth, Fiona Bolliger, Ian Bonaventure, Audrey Boufous, Soufi Ane Bourne, Rupert Boussinesq, Michel Braithwaite, Tasanee Brayne, Carol Bridgett, Lisa Brooker, Simon Brooks, Peter Brugha, Traolach S. Bryan-Hancock, Claire Bucello, Chiara Buchbinder, Rachelle Buckle, Geoffrey Budke, Christine M. Burch, Michael Burney, Peter Burstein, Roy Calabria, Bianca Campbell, Benjamin Canter, Charles E. Carabin, Helene Carapetis, Jonathan Carmona, Loreto Cella, Claudia Charlson, Fiona Chen, Honglei Cheng, Andrew Tai-Ann Chou, David Chugh, Sumeet S. Coffeng, Luc E. Colan, Steven D. Colquhoun, Samantha Colson, K. Ellicott Condon, John Connor, Myles D. Cooper, Leslie T. Corriere, Matthew Cortinovis, Monica De Vaccaro, Karen Courville Couser, William Cowie, Benjamin C. Criqui, Michael H. Cross, Marita Dabhadkar, Kaustubh C. Dahiya, Manu Dahodwala, Nabila Damsere-Derry, James Danaei, Goodarz Davis, Adrian De Leo, Diego Degenhardt, Louisa Dellavalle, Robert Delossantos, Allyne Denenberg, Julie Derrett, Sarah Des Jarlais, Don C. Dharmaratne, Samath D. Dherani, Mukesh Diaz-Torne, Cesar Dolk, Helen Dorsey, E. Ray Driscoll, Tim Duber, Herbert Ebel, Beth Edmond, Karen Elbaz, Alexis Ali, Suad Eltahir Erskine, Holly Erwin, Patricia J. Espindola, Patricia Ewoigbokhan, Stalin E. Farzadfar, Farshad Feigin, Valery Felson, David T. Ferrari, Alize Ferri, Cleusa P. Fevre, Eric M. Finucane, Mariel M. Flaxman, Seth Flood, Louise Foreman, Kyle Forouzanfar, Mohammad H. Fowkes, Francis Gerry R. Fransen, Marlene Freeman, Michael K. Gabbe, Belinda J. Gabriel, Sherine E. Gakidou, Emmanuela Ganatra, Hammad A. Garcia, Bianca Gaspari, Flavio Gillum, Richard F. Gmel, Gerhard Gonzalez-Medina, Diego Gosselin, Richard Grainger, Rebecca Grant, Bridget Groeger, Justina Guillemin, Francis Gunnell, David Gupta, Ramyani Haagsma, Juanita Hagan, Holly Halasa, Yara A. Hall, Wayne Haring, Diana Maria Haro, Josep Harrison, James E. Havmoeller, Rasmus Hay, Roderick J. Higashi, Hideki Hill, Catherine Hoen, Bruno Hoffman, Howard Hotez, Peter J. Hoy, Damian Huang, John J. Ibeanusi, Sydney E. Jacobsen, Kathryn H. James, Spencer L. Jarvis, Deborah Jasrasaria, Rashmi Jayaraman, Sudha Johns, Nicole Jonas, Jost B. Karthikeyan, Ganesan Kassebaum, Nicholas Kawakami, Norito Keren, Andre Khoo, Jon-Paul King, Charles H. Knowlton, Lisa Marie Kobusingye, Olive Koranteng, Adofo Krishnamurthi, Rita Laden, Francine Lalloo, Ratilal Laslett, Laura L. Lathlean, Tim Leasher, Janet L. Lee, Yong Yi Leigh, James Levinson, Daphna Lim, Stephen S. Limb, Elizabeth Lin, John Kent Lipnick, Michael Lipshultz, Steven E. Liu, Wei Loane, Maria Ohno, Summer Lockett Lyons, Ronan Mabweijano, Jacqueline MacIntyre, Michael F. Malekzadeh, Reza Mallinger, Leslie Manivannan, Sivabalan Marcenes, Wagner March, Lyn Margolis, David J. Marks, Guy B. Marks, Robin Matsumori, Akira Matzopoulos, Richard Mayosi, Bongani M. McAnulty, John H. McDermott, Mary M. McGill, Neil McGrath, John Elena Medina-Mora, Maria Meltzer, Michele Mensah, George A. Merriman, Tony R. Meyer, Ana-Claire Miglioli, Valeria Miller, Matthew Miller, Ted R. Mitchell, Philip B. Mock, Charles Mocumbi, Ana Olga Moffitt, Terrie E. Mokdad, Ali A. Monasta, Lorenzo Montico, Marcella Moradi-Lakeh, Maziar Moran, Andrew Morawska, Lidia Mori, Rintaro Murdoch, Michele E. Mwaniki, Michael K. Naidoo, Kovin Nair, M. Nathan Naldi, Luigi Narayan, K. M. Venkat Nelson, Paul K. Nelson, Robert G. Nevitt, Michael C. Newton, Charles R. Nolte, Sandra Norman, Paul Norman, Rosana O'Donnell, Martin O'Hanlon, Simon Olives, Casey Omer, Saad B. Ortblad, Katrina Osborne, Richard Ozgediz, Doruk Page, Andrew Pahari, Bishnu Pandian, Jeyaraj Durai Panozo Rivero, Andrea Patten, Scott B. Pearce, Neil Perez Padilla, Rogelio Perez-Ruiz, Fernando Perico, Norberto Pesudovs, Konrad Phillips, David Phillips, Michael R. Pierce, Kelsey Pion, Sebastien Polanczyk, Guilherme V. Polinder, Suzanne Pope, C. Arden, III Popova, Svetlana Porrini, Esteban Pourmalek, Farshad Prince, Martin Pullan, Rachel L. Ramaiah, Kapa D. Ranganathan, Dharani Razavi, Homie Regan, Mathilda Rehm, Juergen T. Rein, David B. Remuzzi, Guiseppe Richardson, Kathryn Rivara, Frederick P. Roberts, Thomas Robinson, Carolyn Rodriguez De Leon, Felipe Ronfani, Luca Room, Robin Rosenfeld, Lisa C. Rushton, Lesley Sacco, Ralph L. Saha, Sukanta Sampson, Uchechukwu Sanchez-Riera, Lidia Sanman, Ella Schwebel, David C. Scott, James Graham Segui-Gomez, Maria Shahraz, Saeid Shepard, Donald S. Shin, Hwashin Shivakoti, Rupak Singh, David Singh, Gitanjali M. Singh, Jasvinder A. Singleton, Jessica Sleet, David A. Sliwa, Karen Smith, Emma Smith, Jennifer L. Stapelberg, Nicolas J. C. Steer, Andrew Steiner, Timothy Stolk, Wilma A. Stovner, Lars Jacob Sudfeld, Christopher Syed, Sana Tamburlini, Giorgio Tavakkoli, Mohammad Taylor, Hugh R. Taylor, Jennifer A. Taylor, William J. Thomas, Bernadette Thomson, W. Murray Thurston, George D. Tleyjeh, Imad M. Tonelli, Marcello Towbin, Jeff Rey A. Truelsen, Thomas Tsilimbaris, Miltiadis K. Ubeda, Clotilde Undurraga, Eduardo A. van der Werf, Marieke J. van Os, Jim Vavilala, Monica S. Venketasubramanian, N. Wang, Mengru Wang, Wenzhi Watt, Kerrianne Weatherall, David J. Weinstock, Martin A. Weintraub, Robert Weisskopf, Marc G. Weissman, Myrna M. White, Richard A. Whiteford, Harvey Wiebe, Natasha Wiersma, Steven T. Wilkinson, James D. Williams, Hywel C. Williams, Sean R. M. Witt, Emma Wolfe, Frederick Woolf, Anthony D. Wulf, Sarah Yeh, Pon-Hsiu Zaidi, Anita K. M. Zheng, Zhi-Jie Zonies, David Lopez, Alan D. TI Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 SO LANCET LA English DT Article ID PUBLIC-HEALTH UTILITY; RISK-FACTORS; ECONOMIC COST; MORTALITY; POPULATION; AUSTRALIA; COUNTRIES; DEATH; LOST; METAANALYSIS AB Background Measuring disease and injury burden in populations requires a composite metric that captures both premature mortality and the prevalence and severity of ill-health. The 1990 Global Burden of Disease study proposed disability-adjusted life years (DALYs) to measure disease burden. No comprehensive update of disease burden worldwide incorporating a systematic reassessment of disease and injury-specific epidemiology has been done since the 1990 study. We aimed to calculate disease burden worldwide and for 21 regions for 1990, 2005, and 2010 with methods to enable meaningful comparisons over time. Methods We calculated DALYs as the sum of years of life lost (YLLs) and years lived with disability (YLDs). DALYs were calculated for 291 causes, 20 age groups, both sexes, and for 187 countries, and aggregated to regional and global estimates of disease burden for three points in time with strictly comparable definitions and methods. YLLs were calculated from age-sex-country-time-specific estimates of mortality by cause, with death by standardised lost life expectancy at each age. YLDs were calculated as prevalence of 1160 disabling sequelae, by age, sex, and cause, and weighted by new disability weights for each health state. Neither YLLs nor YLDs were age-weighted or discounted. Uncertainty around cause-specific DALYs was calculated incorporating uncertainty in levels of all-cause mortality, cause-specific mortality, prevalence, and disability weights. Findings Global DALYs remained stable from 1990 (2.503 billion) to 2010 (2.490 billion). Crude DALYs per 1000 decreased by 23% (472 per 1000 to 361 per 1000). An important shift has occurred in DALY composition with the contribution of deaths and disability among children (younger than 5 years of age) declining from 41% of global DALYs in 1990 to 25% in 2010. YLLs typically account for about half of disease burden in more developed regions (high-income Asia Pacific, western Europe, high-income North America, and Australasia), rising to over 80% of DALYs in sub-Saharan Africa. In 1990, 47% of DALYs worldwide were from communicable, maternal, neonatal, and nutritional disorders, 43% from non-communicable diseases, and 10% from injuries. By 2010, this had shifted to 35%, 54%, and 11%, respectively. Ischaemic heart disease was the leading cause of DALYs worldwide in 2010 (up from fourth rank in 1990, increasing by 29%), followed by lower respiratory infections (top rank in 1990; 44% decline in DALYs), stroke (fifth in 1990; 19% increase), diarrhoeal diseases (second in 1990; 51% decrease), and HIV/AIDS (33rd in 1990; 351% increase). Major depressive disorder increased from 15th to 11th rank (37% increase) and road injury from 12th to 10th rank (34% increase). Substantial heterogeneity exists in rankings of leading causes of disease burden among regions. Interpretation Global disease burden has continued to shift away from communicable to non-communicable diseases and from premature death to years lived with disability. In sub-Saharan Africa, however, many communicable, maternal, neonatal, and nutritional disorders remain the dominant causes of disease burden. The rising burden from mental and behavioural disorders, musculoskeletal disorders, and diabetes will impose new challenges on health systems. Regional heterogeneity highlights the importance of understanding local burden of disease and setting goals and targets for the post-2015 agenda taking such patterns into account. Because of improved definitions, methods, and data, these results for 1990 and 2010 supersede all previously published Global Burden of Disease results. C1 [Baxter, Amanda; Erskine, Holly; Ferrari, Alize; Khoo, Jon-Paul; Saha, Sukanta; Whiteford, Harvey] Univ Queensland, Queensland Ctr Mental Hlth Res, Brisbane, Qld, Australia. [Vos, Theo; Blore, Jed D.; Charlson, Fiona; Higashi, Hideki; Lee, Yong Yi; Norman, Rosana; Page, Andrew; Lopez, Alan D.] Univ Queensland, Sch Populat Hlth, Brisbane, Qld, Australia. [Scott, James Graham] Univ Queensland, Clin Res Ctr, Brisbane, Qld, Australia. [McGrath, John] Univ Queensland, Queensland Brain Inst, Brisbane, Qld, Australia. [Murray, Christopher J. L.; Lozano, Rafael; Naghavi, Mohsen; Flaxman, Abraham D.; Ahn, Stephanie Y.; Alvarado, Miriam; Andrews, Kathryn G.; Atkinson, Charles; Bolliger, Ian; Burstein, Roy; Campbell, Benjamin; Chou, David; Colson, K. Ellicott; Delossantos, Allyne; Dharmaratne, Samath D.; Forouzanfar, Mohammad H.; Freeman, Michael K.; Gakidou, Emmanuela; Gonzalez-Medina, Diego; Haring, Diana; James, Spencer L.; Jasrasaria, Rashmi; Johns, Nicole; Lim, Stephen S.; Ohno, Summer Lockett; MacIntyre, Michael F.; Mallinger, Leslie; Mokdad, Ali A.; Nair, M. Nathan; Ortblad, Katrina; Phillips, David; Pierce, Kelsey; Ranganathan, Dharani; Roberts, Thomas; Rosenfeld, Lisa C.; Sanman, Ella; Wang, Mengru; Wulf, Sarah] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98121 USA. [Anderson, Laurie M.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98121 USA. [Kassebaum, Nicholas] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98121 USA. [Michaud, Catherine] China Med Board, Boston, MA USA. [Ezzati, Majid] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Epidemiol & Biostat, MRC HPA Ctr Environm & Hlth, London, England. [Shibuya, Kenji] Univ Tokyo, Dept Global Hlth Policy, Tokyo, Japan. [Finucane, Mariel M.] Harvard Univ, Dept Biostat, Boston, MA 02115 USA. [Salomon, Joshua A.; Danaei, Goodarz; Laden, Francine; Lin, John Kent; Miller, Matthew; Singh, Gitanjali M.; Sudfeld, Christopher; Tavakkoli, Mohammad; Weisskopf, Marc G.; White, Richard A.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Liu, Wei] Harvard Univ, Dept Epidemiol, Boston, MA 02115 USA. [Knowlton, Lisa Marie] Harvard Univ, Harvard Humanitarian Initiat, Boston, MA 02115 USA. [Colan, Steven D.] Harvard Univ, Boston Childrens Hosp, Boston, MA 02115 USA. [Jayaraman, Sudha] Harvard Univ, Brigham & Womens Hosp, Boston, MA 02115 USA. [Bartels, David H.; Bhalla, Kavi] Harvard Univ, Harvard Med Sch, Boston, MA 02115 USA. [Aboyans, Victor] Dupuytren Univ Hosp, Dept Cardiol, Limoges, France. [Abraham, Jerry] Univ Texas San Antonio, San Antonio, TX USA. [Steer, Andrew] Univ Melbourne, Ctr Int Child Hlth, Melbourne, Vic, Australia. [Weintraub, Robert] Univ Melbourne, Dept Pediat, Melbourne, Vic, Australia. [Degenhardt, Louisa] Univ Melbourne, Ctr Hlth Policy Programs & Econ, Melbourne, Vic, Australia. [Room, Robin] Univ Melbourne, Sch Populat Hlth, Melbourne, Vic, Australia. [Aggarwal, Rakesh] Sanjay Gandhi Postgrad Inst Med Sci, Lucknow, Uttar Pradesh, India. [Omer, Saad B.] Emory Univ, Sch Publ Hlth, Atlanta, GA USA. [Omer, Saad B.] Emory Univ, Sch Med, Atlanta, GA USA. [Anderson, H. Ross; Gupta, Ramyani; Limb, Elizabeth] St Georges Univ London, London, England. [Baddour, Larry M.; Erwin, Patricia J.; Gabriel, Sherine E.] Mayo Clin, Rochester, MN USA. [Barker-Collo, Suzanne] Univ Auckland, Auckland 1, New Zealand. [Barrero, Lope H.] Pontificia Univ Javeriana, Sch Engn, Dept Ind Engn, Bogota, Colombia. [Bell, Michelle L.; Huang, John J.; Ozgediz, Doruk] Yale Univ, New Haven, CT USA. [Felson, David T.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Bennett, Derrick] Univ Oxford, Clin Trial Serv Unit, Oxford, England. [Bennett, Derrick] Univ Oxford, Epidemiol Studies Unit, Oxford, England. [Bernabe, Eduardo] Kings Coll London, Inst Dent, London WC2R 2LS, England. [Hay, Roderick J.] Kings Coll London, Hosp NHS Trust, London WC2R 2LS, England. [Prince, Martin] Kings Coll London, Inst Psychiat, London WC2R 2LS, England. [Dahiya, Manu] Queen Mary Univ London, Inst Dent, London, England. [Bikbov, Boris] Moscow State Univ Med & Dent, Res Inst Transplantol & Artificial Organs, Moscow, Russia. [Bin Abdulhak, Aref; Tleyjeh, Imad M.] King Fahad Med City, Riyadh, Saudi Arabia. [Birbeck, Gretchen] Michigan State Univ, E Lansing, MI 48824 USA. [Black, James A.] MRC, Epidemiol Unit, Cambridge, England. [Blencowe, Hannah; Brooker, Simon; Edmond, Karen; Pearce, Neil; Pullan, Rachel L.; Smith, Jennifer L.] London Sch Hyg & Trop Med, London WC1, England. [Smith, Emma] Univ Sydney, No Clin Sch, Dept Rheumatol, Sydney, NSW 2006, Australia. [Fransen, Marlene] Univ Sydney, Fac Hlth Sci, Sydney, NSW 2006, Australia. [March, Lyn; Sanchez-Riera, Lidia] Univ Sydney, Inst Bone & Joint Res, Sydney, NSW 2006, Australia. [Driscoll, Tim; Leigh, James] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW 2006, Australia. [Bonaventure, Audrey; Elbaz, Alexis] INSERM, Paris, France. [Calabria, Bianca; Degenhardt, Louisa; Nelson, Paul K.; Singleton, Jessica] Univ New S Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW, Australia. [Bucello, Chiara; Mitchell, Philip B.] Univ New S Wales, Sydney, NSW, Australia. [Bourne, Rupert] Anglia Ruskin Univ, Vis & Eye Res Unit, Cambridge, England. [Braithwaite, Tasanee] Moorfields Eye Hosp, London, England. [Brayne, Carol; Richardson, Kathryn] Univ Cambridge, Cambridge, England. [Brugha, Traolach S.] Univ Leicester, Leicester, Leics, England. [Bryan-Hancock, Claire; Flood, Louise; Harrison, James E.; Lathlean, Tim; Pesudovs, Konrad] Flinders Univ S Australia, Adelaide, SA 5001, Australia. [Buchbinder, Rachelle] Cabrini Inst, Malvern, Vic, Australia. [Gabbe, Belinda J.] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia. [Buckle, Geoffrey; Manivannan, Sivabalan] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Budke, Christine M.] Texas A&M Univ, College Stn, TX USA. [Burch, Michael] Great Ormond St Hosp Sick Children, London WC1N 3JH, England. [Canter, Charles E.] Washington Univ, St Louis, MO USA. [Carabin, Helene] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. [Carapetis, Jonathan] Univ Western Australia, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Perth, WA 6009, Australia. [Carmona, Loreto] Univ Camilo Jose Cela, Villanueva De La Canada, Spain. [Cella, Claudia; Cortinovis, Monica; Gaspari, Flavio; Miglioli, Valeria; Perico, Norberto; Remuzzi, Guiseppe] Mario Negri Inst Pharmacol Res, I-24100 Bergamo, Italy. [Chen, Honglei] NIEHS, Res Triangle Pk, NC 27709 USA. [Cheng, Andrew Tai-Ann] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan. [Havmoeller, Rasmus] Cedars Sinai Med Ctr, Inst Heart, Los Angeles, CA 90048 USA. [Polinder, Suzanne] Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands. [Colquhoun, Samantha; Condon, John] Menzies Sch Hlth Res, Darwin, NT, Australia. [Connor, Myles D.] Natl Hlth Serv, Edinburgh, Midlothian, Scotland. [Connor, Myles D.; Fevre, Eric M.; Fowkes, Francis Gerry R.] Univ Edinburgh, Edinburgh, Midlothian, Scotland. [Connor, Myles D.] Univ Witwatersrand, Johannesburg, South Africa. [Cooper, Leslie T.] Loyola Univ, Sch Med, Chicago, IL 60611 USA. [Corriere, Matthew] Wake Forest Univ, Sch Publ Hlth Sci, Winston Salem, NC 27109 USA. [De Vaccaro, Karen Courville] Hosp Dr Gustavo N Collado, Puerto Chitre, Panama. [Cowie, Benjamin C.] Victorian Infect Dis Reference Lab, Melbourne, Vic, Australia. [Criqui, Michael H.; Denenberg, Julie] Univ Calif San Diego, San Diego, CA 92103 USA. [Dahodwala, Nabila; Margolis, David J.] Univ Penn, Philadelphia, PA 19104 USA. [Damsere-Derry, James] Bldg & Rd Res Inst, Kumasi, Ghana. [Davis, Adrian] MRC Hearing & Commun Grp, Manchester, Lancs, England. [Lalloo, Ratilal] Griffith Univ, Sch Dent & Oral Hlth, Brisbane, Qld 4111, Australia. [Lalloo, Ratilal] Griffith Univ, Populat & Social Hlth Res Program, Brisbane, Qld 4111, Australia. [Dellavalle, Robert] Denver VA Med Ctr, Denver, VA USA. [Derrett, Sarah; Grainger, Rebecca; Merriman, Tony R.; Taylor, William J.; Thomson, W. Murray] Univ Otago, Dunedin, New Zealand. [Des Jarlais, Don C.] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA. [Dharmaratne, Samath D.] Univ Peradeniya, Peradeniya, Sri Lanka. [Dherani, Mukesh] Univ Liverpool, Liverpool L69 3BX, Merseyside, England. [Diaz-Torne, Cesar] Hosp Santa Creu & Sant Pau, Barcelona, Spain. [Dolk, Helen; Loane, Maria] Univ Ulster, Ulster, Ireland. [Ali, Suad Eltahir] Fed Minist Hlth, Khartoum, Sudan. [Espindola, Patricia] Hosp Maciel, Montevideo, Uruguay. [Ewoigbokhan, Stalin E.] Emerald Publ Hlth Consulting Serv Ltd, Abuja, Nigeria. [Malekzadeh, Reza] Univ Tehran Med Sci, Digest Dis Res Ctr, Tehran, Iran. [Feigin, Valery] Auckland Tech Univ, Natl Inst Stroke & Appl Neurosci, Auckland, New Zealand. [Polanczyk, Guilherme V.] Univ Fed Sao Paulo, Sch Med, Sao Paulo, Brazil. [Flaxman, Seth] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA. [Watt, Kerrianne] James Cook Univ, Townsville, Qld 4811, Australia. [Gillum, Richard F.] Howard Univ, Coll Med, Washington, DC USA. [Gmel, Gerhard] Addict Info Switzerland, Lausanne, Switzerland. [Nevitt, Michael C.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Groeger, Justina] Suny Downstate Med Ctr, Coll Med, Brooklyn, NY 11203 USA. [Sleet, David A.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Guillemin, Francis] Univ Lorraine, Nancy, France. [Gunnell, David] Univ Bristol, Bristol, Avon, England. [Hagan, Holly; Thurston, George D.] NYU, New York, NY USA. [Halasa, Yara A.; Shahraz, Saeid; Shepard, Donald S.; Undurraga, Eduardo A.] Brandeis Univ, Waltham, MA USA. [Maria Haro, Josep] Univ Barcelona, CIBERSAM, St Boi De Llobregat, Spain. [Havmoeller, Rasmus] Karolinska Univ Hosp, Stockholm, Sweden. [Hill, Catherine] Queen Elizabeth Hosp, Adelaide, SA, Australia. [Hoen, Bruno] Univ Franche Comte, F-25030 Besancon, France. [Hoen, Bruno] Ctr Hosp Reg Univ Besancon, Besancon, France. [Hoffman, Howard] NIDCD, NIH, Bethesda, MD USA. [Nelson, Robert G.] NIDDK, NIH, Bethesda, MD USA. [Hotez, Peter J.] Baylor Coll Med, Natl Sch Trop Med, Waco, TX USA. [Ibeanusi, Sydney E.] Univ Port Harcourt, Port Harcourt, Nigeria. [Jacobsen, Kathryn H.] George Mason Univ, Fairfax, VA 22030 USA. [Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Heidelberg, Germany. [Karthikeyan, Ganesan] All India Inst Med Sci, New Delhi, India. [Keren, Andre] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Cardiol, IL-91010 Jerusalem, Israel. [King, Charles H.] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Kobusingye, Olive] Makerere Univ, Sch Publ Hlth, Kampala, Uganda. [Kobusingye, Olive] Univ S Africa, Johannesburg, South Africa. [Koranteng, Adofo] Kwame Nkrumah Univ Sci & Technol, Kumasi, Ghana. [Laslett, Laura L.] Univ Tasmania, Hobart, Tas 7001, Australia. [Leasher, Janet L.] Nova SE Univ, Ft Lauderdale, FL 33314 USA. [Levinson, Daphna] Minist Hlth, Jerusalem, Israel. [Lipshultz, Steven E.; Sacco, Ralph L.; Wilkinson, James D.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA. [Lyons, Ronan] Swansea Univ, Swansea, W Glam, Wales. [Mabweijano, Jacqueline] Mulago Hosp, Kampala, Uganda. [Matsumori, Akira] Asian Pacific Soc Cardiol, Kyoto, Japan. [Matzopoulos, Richard] MRC, Tygerberg, South Africa. [Sliwa, Karen] Univ Cape Town, Hatter Inst, ZA-7925 Cape Town, South Africa. [Mensah, George A.] Univ Cape Town, Dept Med, ZA-7925 Cape Town, South Africa. [McAnulty, John H.] Legacy Hlth Syst, Portland, OR USA. [McDermott, Mary M.] Northwestern Univ, Feinberg Sch Med, Evanston, IL USA. [Elena Medina-Mora, Maria] Natl Inst Psychiat Ramon de la Fuente, Mexico City, DF, Mexico. [Meltzer, Michele] Thomas Jefferson Univ, Philadelphia, PA 19107 USA. [Miller, Ted R.] Pacific Inst Res & Evaluat, Calverton, MD USA. [Mocumbi, Ana Olga] Natl Inst Hlth, Maputo, Mozambique. [Mocumbi, Ana Olga] Univ Eduardo Mondlane, Maputo, Mozambique. [Moffitt, Terrie E.] Duke Univ, Durham, NC USA. [Monasta, Lorenzo; Montico, Marcella; Ronfani, Luca; Tamburlini, Giorgio] IRCCS Burlo Garofolo, Inst Maternal & Child Hlth, Trieste, Italy. [Weissman, Myrna M.] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA. [Morawska, Lidia] Queensland Univ Technol, Brisbane, Qld 4001, Australia. [Mori, Rintaro] Natl Ctr Child Hlth & Dev, Tokyo, Japan. [Murdoch, Michele E.] Watford Dist Gen Hosp, Watford, England. [Mwaniki, Michael K.] Kemri Wellcome Trust, Kilifi, Kenya. [Naidoo, Kovin] Univ KwaZulu Natal, AVRI, Durban, South Africa. [Naldi, Luigi] Ctr Studi GISED, Bergamo, Italy. [Nolte, Sandra] Charite, D-13353 Berlin, Germany. [O'Donnell, Martin] Natl Univ Ireland Galway, HRB Clin Res Facil, Galway, Ireland. [Osborne, Richard] Deakin Univ, Melbourne, Vic, Australia. [Pahari, Bishnu] BP Koirala Inst Hlth Sci, Dharan, Nepal. [Pandian, Jeyaraj Durai] Betty Cowan Res & Innovat Ctr, Ludhiana, Punjab, India. [Panozo Rivero, Andrea] Hosp Joan 23, La Paz, Bolivia. [Patten, Scott B.] Univ Calgary, Calgary, AB, Canada. [Perez Padilla, Rogelio] Inst Nacl Enfermedades Resp, Mexico City, DF, Mexico. [Perez-Ruiz, Fernando] Hosp Univ Cruces, Baracaldo, Spain. [Phillips, Michael R.] Shanghai Jiao Tong Univ, Shanghai Mental Hlth Ctr, Sch Med, Shanghai 200030, Peoples R China. [Zheng, Zhi-Jie] Shanghai Jiao Tong Univ, Sch Publ Hlth, Shanghai 200030, Peoples R China. [Pope, C. Arden, III] Brigham Young Univ, Provo, UT 84602 USA. [Popova, Svetlana; Rehm, Juergen T.] Ctr Addict & Mental Hlth, Toronto, ON, Canada. [Porrini, Esteban] Hosp Univ Canarias, Tenerif, Spain. [Pourmalek, Farshad] Univ British Columbia, Fac Med, Sch Populat & Publ Hlth, Vancouver, BC, Canada. [Ramaiah, Kapa D.] Vector Control Res Ctr, Pondicherry, India. [Razavi, Homie] Ctr Dis Anal, Louisville, CO USA. [Regan, Mathilda] Univ Calif Berkeley, Berkeley, CA 94720 USA. [Rein, David B.] Univ Chicago, NORC, Chicago, IL 60637 USA. [Rodriguez De Leon, Felipe] Complejo Hosp Caja Seguro Social, Panama City, Panama. [Room, Robin] Turning Point Alcohol & Drug Ctr, Ctr Alcohol Policy Res, Fitzroy, SA, Australia. [Sampson, Uchechukwu] Vanderbilt Univ, Nashville, TN USA. [Schwebel, David C.; Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham, AL USA. [Segui-Gomez, Maria] Minist Interior, Madrid, Spain. [Shin, Hwashin] Hlth Canada, Ottawa, ON K1A 0L2, Canada. [Singh, David] Queens Med Ctr, Honolulu, HI USA. [Stovner, Lars Jacob] Norwegian Univ Sci & Technol, Dept Neurosci, N-7034 Trondheim, Norway. [Syed, Sana; Zaidi, Anita K. M.] Aga Khan Univ, Karachi, Pakistan. [Taylor, Jennifer A.] Drexel Univ, Sch Publ Hlth, Philadelphia, PA 19104 USA. [Tonelli, Marcello] Univ Alberta, Alberta Kidney Dis Network, Edmonton, AB, Canada. [Towbin, Jeff Rey A.] Cincinnati Childrens Hosp, Cincinnati, OH USA. [Truelsen, Thomas] Copenhagen Univ Hosp, Dept Neurol, Herlev, Denmark. [Tsilimbaris, Miltiadis K.] Univ Crete, Sch Med, Iraklion, Greece. [Ubeda, Clotilde] ANLIS, Inst Nacl Epidemiol, Malbran, Argentina. [van der Werf, Marieke J.] KNCV TB Fdn, The Hague, Netherlands. [van Os, Jim] Maastricht Univ, Med Ctr, Maastricht, Netherlands. [Venketasubramanian, N.] Natl Univ Singapore, Singapore 117548, Singapore. [Wang, Wenzhi] Capital Med Univ, Beijing Neurosurg Inst, Beijing, Peoples R China. [Weinstock, Martin A.] Brown Univ, Providence, RI 02912 USA. [Weintraub, Robert] Royal Childrens Hosp, Melbourne, Vic, Australia. [Weintraub, Robert] Murdoch Childrens Res Inst, Melbourne, Vic, Australia. [Williams, Hywel C.] Univ Nottingham, Nottingham NG7 2RD, England. [Williams, Sean R. M.] Hollywood Orthopaed Grp, Perth, WA, Australia. [Wolfe, Frederick] Arthrit Res, Wichita, KS USA. [Woolf, Anthony D.] Royal Cornwall Hosp, Truro, England. [Yeh, Pon-Hsiu] London Sch Econ, London WC2A 2AE, England. [Zonies, David] Landstuhl Reg Med Ctr, Landstuhl, Germany. RP Murray, CJL (reprint author), Univ Washington, Inst Hlth Metr & Evaluat, 2301 5th Ave,Suite 600, Seattle, WA 98121 USA. EM cjlm@uw.edu RI Saha, Sukanta/K-3774-2012; Carmona, Loreto/A-2748-2014; McGrath, John/G-5493-2010; Montico, Marcella/B-5290-2013; Black, James/A-5917-2010; Erskine, Holly/K-5244-2012; NORMAN, ROSANA/F-2774-2010; Buchbinder, Rachelle/G-2952-2011; Polanczyk, Guilherme/C-2345-2012; Jarvis, Deborah/E-6494-2011; Degenhardt, Louisa/D-4515-2012; Norman, Paul/C-5485-2013; Lathlean, Tim/K-3653-2013; Stovner, Lars/D-5025-2014; Moffitt, Terrie/D-5295-2011; Lopez, Alan/F-1487-2010; Laslett, Laura/G-3973-2011; Nolte, Sandra/B-7498-2008; Narayan, K.M. Venkat /J-9819-2012; Hall, Wayne/A-3283-2008; Ronfani, Luca/B-6668-2013; Bikbov, Boris/I-4594-2013; Lee, Yong Yi/C-1373-2015; Baxter, Amanda/E-5449-2011; Undurraga, Eduardo/I-3739-2014; Higashi, Hideki/D-3797-2011; Boussinesq, Michel/J-7256-2016; Jacobsen, Kathryn/B-5857-2008; Naldi, Luigi/K-6343-2016; Lalloo, Ratilal/O-5624-2014; Scott, James/D-5900-2012; Salomon, Joshua/D-3898-2009; Dellavalle, Robert/L-2020-2013; Research ID, CTBCC /O-3564-2014; Prince, Martin/A-9170-2010; Charlson, Fiona/F-5290-2011; Harrison, James/B-8958-2009; Whiteford, Harvey/A-4840-2009; Ferri, Cleusa/B-2922-2010; Tonelli, Marcello/B-3028-2009; Haro, Josep Maria/D-1423-2011; Carabin, Helene/B-7600-2016; Patten, Scott/B-4434-2011; Monasta, Lorenzo/B-1388-2012; Bolliger, Ian/C-4207-2016 OI Carmona, Loreto/0000-0002-4401-2551; McGrath, John/0000-0002-4792-6068; Montico, Marcella/0000-0003-0377-8232; Black, James/0000-0002-2200-3179; NORMAN, ROSANA/0000-0002-9742-1957; Polanczyk, Guilherme/0000-0003-2311-3289; Degenhardt, Louisa/0000-0002-8513-2218; Norman, Paul/0000-0003-3406-0506; Moffitt, Terrie/0000-0002-8589-6760; Lopez, Alan/0000-0001-5818-6512; Laslett, Laura/0000-0002-4336-0095; Nolte, Sandra/0000-0001-6185-9423; Narayan, K.M. Venkat /0000-0001-8621-5405; Hall, Wayne/0000-0003-1984-0096; Ronfani, Luca/0000-0001-5710-3914; Bikbov, Boris/0000-0002-1925-7506; Lee, Yong Yi/0000-0003-2359-6823; Baxter, Amanda/0000-0001-8198-9022; Loane, Maria/0000-0002-1206-3637; Undurraga, Eduardo/0000-0002-4425-1253; O'Donnell, Martin/0000-0002-7347-7761; O'donnell, Colm/0000-0002-8004-450X; Malekzadeh, Reza/0000-0003-1043-3814; Moradi-Lakeh, Maziar/0000-0001-7381-5305; Aggarwal, Rakesh/0000-0001-9689-494X; Mensah, George/0000-0002-0387-5326; Higashi, Hideki/0000-0002-5534-0905; Benjamin, Emelia/0000-0003-4076-2336; Newton, Charles/0000-0002-6999-5507; Weissman, Myrna/0000-0003-3490-3075; Mitchell, Philip/0000-0002-7954-5235; Pourmalek, Farshad/0000-0002-2134-0771; Miller, Ted/0000-0002-0958-2639; Mayosi, Bongani/0000-0001-6641-8950; Gabbe, Belinda/0000-0001-7096-7688; Bernabe, Eduardo/0000-0002-1858-3713; Cella, Claudia/0000-0002-9210-0775; Taylor, Hugh/0000-0002-9437-784X; Merriman, Tony/0000-0003-0844-8726; Chen, Honglei/0000-0003-3446-7779; Perez-Ruiz, Fernando/0000-0002-5268-1894; Osborne, Richard/0000-0002-9081-2699; Cowie, Benjamin/0000-0002-7087-5895; Boussinesq, Michel/0000-0001-6312-0681; Jacobsen, Kathryn/0000-0002-4198-6246; Naldi, Luigi/0000-0002-3160-2835; Lalloo, Ratilal/0000-0001-5822-1269; Scott, James/0000-0002-0744-0688; Salomon, Joshua/0000-0003-3929-5515; Dellavalle, Robert/0000-0001-8132-088X; Hotez, Peter/0000-0001-8770-1042; Ebel, Beth/0000-0001-9310-8325; Mock, Charles/0000-0002-0564-568X; Prince, Martin/0000-0003-1379-7146; Charlson, Fiona/0000-0003-2876-5040; Harrison, James/0000-0001-9893-8491; Whiteford, Harvey/0000-0003-4667-6623; Ferri, Cleusa/0000-0002-1815-7685; Haro, Josep Maria/0000-0002-3984-277X; Patten, Scott/0000-0001-9871-4041; Monasta, Lorenzo/0000-0001-7774-548X; Bolliger, Ian/0000-0001-8055-297X FU Berlin Heart Honoraria; Lundbeck; Medtronic; Prana Biotechnology; Safework Australia; Assurance-Maladie (CNAMTS) InVS; Inserm; CHU de Nancy; CHU de Nice; Conseil Regional de Lorraine; Societe Francaise de Negma-Lerads; Pfizer; Pierre Fabre Medicaments; Sanofi-Afentis France; Spanish Health Ministry; Hospital de Cruces Rheumatology Association; Novartis; National Council for Scientific and Technological Development (CNPq, Brazil); Takeda; Savient; Ardea; Regeneron; Allergan; URL pharmaceuticals; 36 companies; National Institutes of Arthritis, Musculoskeletal and Skin Diseases (NIAMS); National Institutes of Aging (NIA); National Cancer Institute (NCI); Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs); Wellcome Trust [098045, 085308]; Department of Health London for the National Health Service Information Centre; University of Leicester; Australian National Health and Medical Research Council (NHMRC); Monash University; Cabrini Health; BUPA Foundation; NIH; National Institute of Environmental Health Sciences; Africa Programme for Onchocerciasis Control (WHO/APOC); Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia; NIH [K23 AG034236]; Parkinson Council; Australian NHMRC; US Department of Veterans Affairs; Health Research Council of New Zealand; University of Otago; National Institute for Stroke and Applied Neurosciences; AUT University; NHMRC; Swedish Research Council [2011-1071]; Bill and Melinda Gates Foundation; Australian National Health and Medical Research Council; World Health Organization; World Mental Health Japan (WMH-J); Japan Ministry of Health, Labour, and Welfare [H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013]; Australian Government; National Health and Medical Research Council of Australia; Arthritis Foundation of Australia; Tasmanian Community Fund; Masonic Centenary Medical Research Foundation; Royal Hobart Hospital Research Foundation; University of Tasmania; Tehran University of Medical Sciences; South African Medical Research Council Burden of Disease Research Unit; University of Cape Town School of Public Health and Family Medicine; Brien Holden Vision Institute; National Drug and Alcohol Research Centre (UNSW, Australia); Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases; Biostatistics, Epidemiologic and Bioinformatic Training in Environmental Health Training Grant [ES015459]; Foundation for Alcohol Research and Education; Victorian Department of Health; Burke Global Health Fellowship; Harold Amos Medical Faculty Development Award of the Robert Wood Johnson Foundation; Vanderbilt Clinical and Translational Scholars Award; Spanish Society of Rheumatology (Sociedad Espanola de Reumatologia); European Center for Injury Prevention, Universidad de Navarra; Department of Health and Ageing; Commonwealth Government of Australia; Institute of Bone and Joint Research (IBJR); University of Sydney (USYD); National Institute of Environmental Health Sciences [ES00260]; Wellcome Trust UK; Medical Research Council UK; Anthony Cerami and Ann Dunne Research Trust FX C E Canter has worked as an Optum Health consultant, Blue Cross Blue Shield consultant, and received Berlin Heart Honoraria and travel fees. E R Dorsey has received payments for consulting services from Lundbeck and Medtronic and research support from Lundbeck and Prana Biotechnology. T Driscoll was supported in part by funding from the National Occupational Health and Safety Commission (now Safework Australia). M Ezzati chaired a session and gave a talk at the World Cardiology Congress (WCC), with travel cost reimbursed by the World Heart Federation. At the WCC, he also gave a talk at a session organised by PepsiCo with no financial or other remuneration. F Guillemin conducted a study on osteoarthritis epidemiology in an institution that received grants from public sources: Assurance-Maladie (CNAMTS) InVS, Inserm, CHU de Nancy, CHU de Nice, Conseil Regional de Lorraine, Societe Francaise de Negma-Lerads, Pfizer, Pierre Fabre Medicaments, Sanofi-Afentis France. H J Hoffman is a US Federal Government employee of the National Institutes of Health (NIH). P J Hotez reports holding several positions: Dean, National School of Tropical Medicine, Baylor College of Medicine; Director, Sabin Vaccine Institute Texas Children's Hospital Center for Vaccine Development; and President, Sabin Vaccine Institute. He also is an inventor on several patents: 5,527,937 "Hookworm Anticoagulant"; 5,753,787 "Nucleic Acids for Ancylostoma Secreted Proteins"; 7,303,752 B2 "Hookworm vaccine"; 12/492,734 "Human Hookworm Vaccine"; 61/077,256 "Multivalent Anthelminthic Vaccine"; and PCT-20100701/0.20.5.18 "Malaria Transmission blocking vaccine". G Mensah is a former employee of PepsiCo. F Perez-Ruiz was an advisor for Ardea, Menarini, Novartis, Metabolex; was a member of the Speaker's Bureau for Menarini, Novartis; an advisor for educational issues for Savient; led investigation grants for the Spanish Health Ministry, Hospital de Cruces Rheumatology Association; and was principal investigator in clinical trials for Ardea. G V Polanczyk has served as a speaker and/or consultant to Eli-Lily, Novartis, Janssen-Cilag, and Shire Pharmaceuticals, developed educational material for Janssen-Cilag, and received an independent investigator grant from Novartis and from the National Council for Scientific and Technological Development (CNPq, Brazil). L Rushton received honorarium for board membership of the European Centre for Ecotoxicology and Toxicology of Chemicals and received research grants to Imperial College London (as PI) from the European Chemical Industry Council (CEFIC) and CONCAWE (Conservation of Clean Air and Water Europe). J A Singh has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals and Novartis. J A Singh is a member of the executive of OMERACT, an organisation that develops outcome measures in rheumatology and receives arms-length funding from 36 companies; a member of the American College of Rheumatology's Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. J A Singh is supported by research grants from the National Institutes of Arthritis, Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Aging (NIA), National Cancer Institute (NCI), and the Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs) and is also supported by the resources and the use of facilities at the VA Medical Center at Birmingham, AL, USA.; We would like to thank the countless individuals who have contributed to the Global Burden of Disease 2010 study in various capacities. We would like to specifically acknowledge the important contribution to this work from multiple staff members of the World Health Organization. We also wish to express our gratitude to the following organisations that hosted consultations during the final stages of the analytic process, providing valuable feedback about the results and the data to improve the study's findings overall: Pan American Health Organization; Eastern Mediterranean Regional Office of WHO; UNAIDS; Ministry of Health, Brazil; China Centers for Disease Control; and the University of Zambia. We would like to thank Lori M Newman, Jordis Ott, Poul Erik Petersen, Shekhar Saxena, and Gretchen A Stevens for their collaboration and input into the analyses and estimates. Finally, we would like to acknowledge the extensive support from all staff members at the Institute for Health Metrics and Evaluation and specifically thank: James Bullard, Andrew Ernst, and Serkan Yalcin for their tireless support of the computational infrastructure required to produce the results; Linda A Ettinger for her expert administrative support in order to facilitate communication and coordination amongst the authors; Peter Speyer, Abigail McLain, Katherine Leach-Kemon, and Eden Stork for their persistent and valuable work to gain access to and catalog as much data as possible to inform the estimates; and Erin C Mullany for her systematic efforts in organising drafts of papers, formatting correspondence with expert groups, and preparing the final manuscript. The following individuals would like to acknowledge various forms of institutional support. J P Abraham, B Bartels, and P Yeh recognise the support of the World Bank Global Road Safety Facility and Department of Global Health & Population, Harvard School of Public Health, and the World Health Organization Violence and Injury Prevention. B Bikbov acknowledges support from the Moscow State University of Medicine and Dentistry, Moscow, Russia; Academician V I Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow, Russia; International Society of Nephrology. R Bourne acknowledges the Vision & Eye Research Unit, Postgraduate Medical Institute, Anglia Ruskin University, Cambridge, UK. S Brooker is supported by a Wellcome Trust Senior Fellowship in Basic Biomedical Science (098045). T S Brugha received funding from the Department of Health London, for the National Health Service Information Centre, by the University of Leicester. R Buchbinder is partially funded by an Australian National Health and Medical Research Council (NHMRC) Practitioner Fellowship, Monash University, and Cabrini Health. P Burney and D Jarvis acknowledge the Chronic Respiratory Disease group received funding from the BUPA Foundation. They had no role in study design, data collection and analysis, interpretation of data, decision to publish, or preparation of the manuscript. C Cella, M Cortinovis, F Gaspari, V Miglioli, and N Perico, on behalf of the entire Genitourinary Expert Group, acknowledge the International Society of Nephrology (ISN). H Chen acknowledges that his participation in this study was in part supported by the intramural research program of the NIH, the National Institute of Environmental Health Sciences. L E Coffeng, and W A Stolk received financial support from the Africa Programme for Onchocerciasis Control (WHO/APOC) for their work on onchocerciasis.; B C Cowie received institutional support from the Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia. M Cross and L March acknowledge the University of Sydney (USYD); Institute of Bone and Joint Research, University of Sydney, Department of Rheumatology, Royal North Shore Hospital, St Leonards NSW 2065 Australia. N Dahodwala was supported by NIH grant K23 AG034236 and the Parkinson Council while working on this project. L Degenhardt is supported by an Australian NHMRC Senior Research Fellowship and funding to support her work for illicit drug dependence was provided by the Australian National Drug and Alcohol Research Centre of the University of New South Wales, Australia. R Dellavalle was supported by the US Department of Veterans Affairs while contributing to this study. S Derrett acknowledges the Health Research Council of New Zealand and the University of Otago for their support. V Feigin and R Krishnamurthi were supported by the National Institute for Stroke and Applied Neurosciences, AUT University. E Fevre acknowledges the Wellcome Trust for grant 085308. W Hall was supported by an NHMRC Australia Fellowship. R Havmoeller was supported by a grant from the Swedish Research Council (#2011-1071). D Hoy was supported by the Bill and Melinda Gates Foundation and the Australian National Health and Medical Research Council. K H Jacobsen was supported by the World Health Organization for her work on hepatitis A. N Kawakami notes that the collection of data ultimately used in this study was supported by the following grants: The World Mental Health Japan (WMH-J) is supported by the Grant for Research on Psychiatric and Neurological Diseases and Mental Health (H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013) from the Japan Ministry of Health, Labour, and Welfare. He would like to thank staff members, field coordinators, and interviewers of the WMH Japan 2002-2004 Survey. L L Laslett is supported by an Australian Government Australian Postgraduate Award. She also notes that the TasOAC study, the results of which were used in this research, was supported by the National Health and Medical Research Council of Australia; Arthritis Foundation of Australia; Tasmanian Community Fund; Masonic Centenary Medical Research Foundation, Royal Hobart Hospital Research Foundation, and University of Tasmania Institutional Research Grants Scheme. R Malekzadeh received funding from a research grant of Tehran University of Medical Sciences to do the related studies. R Matzopoulos acknowledges the two institutions that support his research work: South African Medical Research Council Burden of Disease Research Unit; and the University of Cape Town School of Public Health and Family Medicine. T Merriman acknowledges the Health Research Council of New Zealand. K Naidoo was supported by the Brien Holden Vision Institute. P Nelson was supported by the National Drug and Alcohol Research Centre (UNSW, Australia). R G Nelson acknowledges his research was supported in part by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases. C Olives was funded in part by the Biostatistics, Epidemiologic and Bioinformatic Training in Environmental Health Training Grant (ES015459). D Ozgediz acknowledges the staff and collaborators at the Mulago Hospital and Makerere University in Kampala, Uganda. K Pesudovs received institutional support from Flinders University.; R Room's position at the University of Melbourne and Turning Point Alcohol and Drug Centre is funded by the Foundation for Alcohol Research and Education and the Victorian Department of Health. J A Salomon received support from the Burke Global Health Fellowship while working on this study. U Sampson received funding support from the Harold Amos Medical Faculty Development Award of the Robert Wood Johnson Foundation and the Vanderbilt Clinical and Translational Scholars Award. L Sanchez-Riera acknowledges the Spanish Society of Rheumatology (Sociedad Espanola de Reumatologia). M Segui-Gomez's participation was partly supported by funds from the European Center for Injury Prevention, Universidad de Navarra. E Smith acknowledges the Department of Health and Ageing, Commonwealth Government of Australia, Institute of Bone and Joint Research (IBJR), University of Sydney (USYD). G D Thurston was supported in part by Center grant ES00260 from the National Institute of Environmental Health Sciences. D J Weatherall was supported by the Wellcome Trust UK, the Medical Research Council UK and the Anthony Cerami and Ann Dunne Research Trust. NR 112 TC 2073 Z9 2153 U1 88 U2 712 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 EI 1474-547X J9 LANCET JI Lancet PD DEC 15 PY 2012 VL 380 IS 9859 BP 2197 EP 2223 PG 27 WC Medicine, General & Internal SC General & Internal Medicine GA 055AL UT WOS:000312387000016 PM 23245608 ER PT J AU Lim, SS Vos, T Flaxman, AD Danaei, G Shibuya, K Adair-Rohani, H Amann, M Anderson, HR Andrews, KG Aryee, M Atkinson, C Bacchus, LJ Bahalim, AN Balakrishnan, K Balmes, J Barker-Collo, S Baxter, A Bell, ML Blore, JD Blyth, F Bonner, C Borges, G Bourne, R Boussinesq, M Brauer, M Brooks, P Bruce, NG Brunekreef, B Bryan-Hancock, C Bucello, C Buchbinder, R Bull, F Burnett, RT Byers, TE Calabria, B Carapetis, J Carnahan, E Chafe, Z Charlson, F Chen, HL Chen, JS Cheng, ATA Child, JC Cohen, A Colson, KE Cowie, BC Darby, S Darling, S Davis, A Degenhardt, L Dentener, F Des Jarlais, DC Devries, K Dherani, M Ding, EL Dorsey, ER Driscoll, T Edmond, K Ali, SE Engell, RE Erwin, PJ Fahimi, S Falder, G Farzadfar, F Ferrari, A Finucane, MM Flaxman, S Fowkes, FGR Freedman, G Freeman, MK Gakidou, E Ghosh, S Giovannucci, E Gmel, G Graham, K Grainger, R Grant, B Gunnell, D Gutierrez, HR Hall, W Hoek, HW Hogan, A Hosgood, HD Hoy, D Hu, H Hubbell, BJ Hutchings, SJ Ibeanusi, SE Jacklyn, GL Jasrasaria, R Jonas, JB Kan, HD Kanis, JA Kassebaum, N Kawakami, N Khang, YH Khatibzadeh, S Khoo, JP Kok, C Laden, F Lalloo, R Lan, Q Lathlean, T Leasher, JL Leigh, J Li, Y Lin, JK Lipshultz, SE London, S Lozano, R Lu, Y Mak, J Malekzadeh, R Mallinger, L Marcenes, W March, L Marks, R Martin, R McGale, P McGrath, J Mehta, S Mensah, GA Merriman, TR Micha, R Michaud, C Mishra, V Hanafiah, KM Mokdad, AA Morawska, L Mozaffarian, D Murphy, T Naghavi, M Neal, B Nelson, PK Nolla, JM Norman, R Olives, C Omer, SB Orchard, J Osborne, R Ostro, B Page, A Pandey, KD Parry, CDH Passmore, E Patra, J Pearce, N Pelizzari, PM Petzold, M Phillips, MR Pope, D Pope, CA Powles, J Rao, M Razavi, H Rehfuess, EA Rehm, JT Ritz, B Rivara, FP Roberts, T Robinson, C Rodriguez-Portales, JA Romieu, I Room, R Rosenfeld, LC Roy, A Rushton, L Salomon, JA Sampson, U Sanchez-Riera, L Sanman, E Sapkota, A Seedat, S Shi, PL Shield, K Shivakoti, R Singh, GM Sleet, DA Smith, E Smith, KR Stapelberg, NJC Steenland, K Stockl, H Stovner, LJ Straif, K Straney, L Thurston, GD Tran, JH Van Dingenen, R van Donkelaar, A Veerman, JL Vijayakumar, L Weintraub, R Weissman, MM White, RA Whiteford, H Wiersma, ST Wilkinson, JD Williams, HC Williams, W Wilson, N Woolf, AD Yip, P Zielinski, JM Lopez, AD Murray, CJL Ezzati, M AF Lim, Stephen S. Vos, Theo Flaxman, Abraham D. Danaei, Goodarz Shibuya, Kenji Adair-Rohani, Heather Amann, Markus Anderson, H. Ross Andrews, Kathryn G. Aryee, Martin Atkinson, Charles Bacchus, Loraine J. Bahalim, Adil N. Balakrishnan, Kalpana Balmes, John Barker-Collo, Suzanne Baxter, Amanda Bell, Michelle L. Blore, Jed D. Blyth, Fiona Bonner, Carissa Borges, Guilherme Bourne, Rupert Boussinesq, Michel Brauer, Michael Brooks, Peter Bruce, Nigel G. Brunekreef, Bert Bryan-Hancock, Claire Bucello, Chiara Buchbinder, Rachelle Bull, Fiona Burnett, Richard T. Byers, Tim E. Calabria, Bianca Carapetis, Jonathan Carnahan, Emily Chafe, Zoe Charlson, Fiona Chen, Honglei Chen, Jian Shen Cheng, Andrew Tai-Ann Child, Jennifer Christine Cohen, Aaron Colson, K. Ellicott Cowie, Benjamin C. Darby, Sarah Darling, Susan Davis, Adrian Degenhardt, Louisa Dentener, Frank Des Jarlais, Don C. Devries, Karen Dherani, Mukesh Ding, Eric L. Dorsey, E. Ray Driscoll, Tim Edmond, Karen Ali, Suad Eltahir Engell, Rebecca E. Erwin, Patricia J. Fahimi, Saman Falder, Gail Farzadfar, Farshad Ferrari, Alize Finucane, Mariel M. Flaxman, Seth Fowkes, Francis Gerry R. Freedman, Greg Freeman, Michael K. Gakidou, Emmanuela Ghosh, Santu Giovannucci, Edward Gmel, Gerhard Graham, Kathryn Grainger, Rebecca Grant, Bridget Gunnell, David Gutierrez, Hialy R. Hall, Wayne Hoek, Hans W. Hogan, Anthony Hosgood, H. Dean, III Hoy, Damian Hu, Howard Hubbell, Bryan J. Hutchings, Sally J. Ibeanusi, Sydney E. Jacklyn, Gemma L. Jasrasaria, Rashmi Jonas, Jost B. Kan, Haidong Kanis, John A. Kassebaum, Nicholas Kawakami, Norito Khang, Young-Ho Khatibzadeh, Shahab Khoo, Jon-Paul Kok, Cindy Laden, Francine Lalloo, Ratilal Lan, Qing Lathlean, Tim Leasher, Janet L. Leigh, James Li, Yang Lin, John Kent Lipshultz, Steven E. London, Stephanie Lozano, Rafael Lu, Yuan Mak, Joelle Malekzadeh, Reza Mallinger, Leslie Marcenes, Wagner March, Lyn Marks, Robin Martin, Randall McGale, Paul McGrath, John Mehta, Sumi Mensah, George A. Merriman, Tony R. Micha, Renata Michaud, Catherine Mishra, Vinod Hanafiah, Khayriyyah Mohd Mokdad, Ali A. Morawska, Lidia Mozaffarian, Dariush Murphy, Tasha Naghavi, Mohsen Neal, Bruce Nelson, Paul K. Miquel Nolla, Joan Norman, Rosana Olives, Casey Omer, Saad B. Orchard, Jessica Osborne, Richard Ostro, Bart Page, Andrew Pandey, Kiran D. Parry, Charles D. H. Passmore, Erin Patra, Jayadeep Pearce, Neil Pelizzari, Pamela M. Petzold, Max Phillips, Michael R. Pope, Dan Pope, C. Arden, III Powles, John Rao, Mayuree Razavi, Homie Rehfuess, Eva A. Rehm, Juergen T. Ritz, Beate Rivara, Frederick P. Roberts, Thomas Robinson, Carolyn Rodriguez-Portales, Jose A. Romieu, Isabelle Room, Robin Rosenfeld, Lisa C. Roy, Ananya Rushton, Lesley Salomon, Joshua A. Sampson, Uchechukwu Sanchez-Riera, Lidia Sanman, Ella Sapkota, Amir Seedat, Soraya Shi, Peilin Shield, Kevin Shivakoti, Rupak Singh, Gitanjali M. Sleet, David A. Smith, Emma Smith, Kirk R. Stapelberg, Nicolas J. C. Steenland, Kyle Stoeckl, Heidi Stovner, Lars Jacob Straif, Kurt Straney, Lahn Thurston, George D. Tran, Jimmy H. Van Dingenen, Rita van Donkelaar, Aaron Veerman, J. Lennert Vijayakumar, Lakshmi Weintraub, Robert Weissman, Myrna M. White, Richard A. Whiteford, Harvey Wiersma, Steven T. Wilkinson, James D. Williams, Hywel C. Williams, Warwick Wilson, Nicholas Woolf, Anthony D. Yip, Paul Zielinski, Jan M. Lopez, Alan D. Murray, Christopher J. L. Ezzati, Majid TI A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 SO LANCET LA English DT Article ID CORONARY-HEART-DISEASE; LUNG-CANCER RISK; FINE PARTICULATE MATTER; ASIA-PACIFIC REGION; LONG-TERM EXPOSURE; BODY-MASS INDEX; RANDOMIZED CONTROLLED-TRIAL; CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; AIR-POLLUTION AB Background Quantification of the disease burden caused by different risks informs prevention by providing an account of health loss different to that provided by a disease-by-disease analysis. No complete revision of global disease burden caused by risk factors has been done since a comparative risk assessment in 2000, and no previous analysis has assessed changes in burden attributable to risk factors over time. Methods We estimated deaths and disability-adjusted life years (DALYs; sum of years lived with disability [YLD] and years of life lost [YLL]) attributable to the independent effects of 67 risk factors and clusters of risk factors for 21 regions in 1990 and 2010. We estimated exposure distributions for each year, region, sex, and age group, and relative risks per unit of exposure by systematically reviewing and synthesising published and unpublished data. We used these estimates, together with estimates of cause-specific deaths and DALYs from the Global Burden of Disease Study 2010, to calculate the burden attributable to each risk factor exposure compared with the theoretical-minimum-risk exposure. We incorporated uncertainty in disease burden, relative risks, and exposures into our estimates of attributable burden. Findings In 2010, the three leading risk factors for global disease burden were high blood pressure (7.0% [95% uncertainty interval 6.2-7.7] of global DALYs), tobacco smoking including second-hand smoke (6.3% [5.5-7.0]), and alcohol use (5.5% [5.0-5.9]). In 1990, the leading risks were childhood underweight (7.9% [6.8-9.4]), household air pollution from solid fuels (HAP; 7.0% [5.6-8.3]), and tobacco smoking including second-hand smoke (6.1% [5.4-6.8]). Dietary risk factors and physical inactivity collectively accounted for 10.0% (95% UI 9.2-10.8) of global DALYs in 2010, with the most prominent dietary risks being diets low in fruits and those high in sodium. Several risks that primarily affect childhood communicable diseases, including unimproved water and sanitation and childhood micronutrient deficiencies, fell in rank between 1990 and 2010, with unimproved water and sanitation accounting for 0.9% (0.4-1.6) of global DALYs in 2010. However, in most of sub-Saharan Africa childhood underweight, HAP, and non-exclusive and discontinued breastfeeding were the leading risks in 2010, while HAP was the leading risk in south Asia. The leading risk factor in Eastern Europe, most of Latin America, and southern sub-Saharan Africa in 2010 was alcohol use; in most of Asia, North Africa and Middle East, and central Europe it was high blood pressure. Despite declines, tobacco smoking including second-hand smoke remained the leading risk in high-income north America and western Europe. High body-mass index has increased globally and it is the leading risk in Australasia and southern Latin America, and also ranks high in other high-income regions, North Africa and Middle East, and Oceania. Interpretation Worldwide, the contribution of different risk factors to disease burden has changed substantially, with a shift away from risks for communicable diseases in children towards those for non-communicable diseases in adults. These changes are related to the ageing population, decreased mortality among children younger than 5 years, changes in cause-of-death composition, and changes in risk factor exposures. New evidence has led to changes in the magnitude of key risks including unimproved water and sanitation, vitamin A and zinc deficiencies, and ambient particulate matter pollution. The extent to which the epidemiological shift has occurred and what the leading risks currently are varies greatly across regions. In much of sub-Saharan Africa, the leading risks are still those associated with poverty and those that affect children. C1 [Lim, Stephen S.; Flaxman, Abraham D.; Andrews, Kathryn G.; Atkinson, Charles; Carnahan, Emily; Colson, K. Ellicott; Engell, Rebecca E.; Freedman, Greg; Freeman, Michael K.; Gakidou, Emmanuela; Jasrasaria, Rashmi; Lozano, Rafael; Mallinger, Leslie; Mokdad, Ali A.; Murphy, Tasha; Naghavi, Mohsen; Roberts, Thomas; Rosenfeld, Lisa C.; Sanman, Ella; Straney, Lahn; Murray, Christopher J. L.] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98121 USA. [Kassebaum, Nicholas] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98121 USA. [Baxter, Amanda; Ferrari, Alize; Khoo, Jon-Paul; Whiteford, Harvey] Univ Queensland, Queensland Ctr Mental Hlth Res, Brisbane, Qld, Australia. [Vos, Theo; Blore, Jed D.; Charlson, Fiona; Norman, Rosana; Page, Andrew; Lopez, Alan D.] Univ Queensland, Sch Populat Hlth, Brisbane, Qld, Australia. [McGrath, John] Univ Queensland, Inst Brain, Brisbane, Qld, Australia. [Finucane, Mariel M.] Harvard Univ, Dept Biostat, Boston, MA 02115 USA. [Khatibzadeh, Shahab] Harvard Univ, Dept Epidemiol, Boston, MA 02115 USA. [Danaei, Goodarz; Ding, Eric L.; Giovannucci, Edward; Laden, Francine; Lin, John Kent; Micha, Renata; Mozaffarian, Dariush; Rao, Mayuree; Salomon, Joshua A.; Singh, Gitanjali M.; White, Richard A.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Mozaffarian, Dariush] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Shibuya, Kenji] Univ Tokyo, Dept Global Hlth Policy, Tokyo, Japan. [Balmes, John] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. [Amann, Markus] Int Inst Appl Syst Anal, A-2361 Laxenburg, Austria. [Anderson, H. Ross] Univ London, London, England. [Hanafiah, Khayriyyah Mohd] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Aryee, Martin] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Bacchus, Loraine J.; Child, Jennifer Christine; Devries, Karen; Edmond, Karen; Falder, Gail; Mak, Joelle; Pearce, Neil; Stoeckl, Heidi] London Sch Hyg & Trop Med, London WC1, England. [Balakrishnan, Kalpana; Ghosh, Santu] Sri Ramachandra Univ, Chennai, Tamil Nadu, India. [Barker-Collo, Suzanne] Univ Auckland, Auckland 1, New Zealand. [Bell, Michelle L.] Yale Univ, New Haven, CT USA. [Leigh, James] Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia. [Smith, Emma] Univ Sydney, No Clin Sch, Dept Rheumatol, Sydney, NSW 2006, Australia. [Chen, Jian Shen; March, Lyn; Sanchez-Riera, Lidia; Wilson, Nicholas] Univ Sydney, Inst Bone & Joint Res, Sydney, NSW 2006, Australia. [Borges, Guilherme] Natl Inst Psychiat, Mexico City, DF, Mexico. [Borges, Guilherme] Univ Nacl Autonoma Mexico, Mexico City 04510, DF, Mexico. [Bourne, Rupert] Anglia Ruskin Univ, Vis & Eye Res Unit, Cambridge, England. [Brauer, Michael] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Weintraub, Robert] Univ Melbourne, Dept Pediat, Melbourne, Vic, Australia. [Degenhardt, Louisa] Univ Melbourne, Ctr Hlth Policy Programs & Econ, Melbourne, Vic, Australia. [Room, Robin] Univ Melbourne, Sch Populat Hlth, Melbourne, Vic, Australia. [Bruce, Nigel G.; Dherani, Mukesh; Pope, Dan] Univ Liverpool, Liverpool L69 3BX, Merseyside, England. [Brunekreef, Bert] Univ Utrecht, Insititute Risk Assessment Sci, Utrecht, Netherlands. [Bryan-Hancock, Claire; Lathlean, Tim] Flinders Univ S Australia, Adelaide, SA 5001, Australia. [Calabria, Bianca; Degenhardt, Louisa; Nelson, Paul K.] Univ New S Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW, Australia. [Buchbinder, Rachelle] Cabrini Inst, Malvern, Vic, Australia. [Buchbinder, Rachelle; Hoy, Damian] Monash Univ, Melbourne, Vic 3004, Australia. [Carapetis, Jonathan] Univ Western Australia, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Perth, WA 6009, Australia. [Burnett, Richard T.; Zielinski, Jan M.] Hlth Canada, Ottawa, ON K1A 0L2, Canada. [Byers, Tim E.] Colorado Sch Publ Hlth, Aurora, CO USA. [Chen, Honglei; London, Stephanie] NIEHS, Res Triangle Pk, NC 27709 USA. [Cheng, Andrew Tai-Ann] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan. [Cohen, Aaron] Hlth Effects Inst, Boston, MA USA. [Cowie, Benjamin C.] Victorian Infect Dis Reference Lab, Melbourne, Vic, Australia. [McGale, Paul] Univ Oxford, Clin Trial Serv Unit, Oxford, England. [Davis, Adrian] MRC Hearing & Commun Grp, Manchester, Lancs, England. [Dentener, Frank; Van Dingenen, Rita] Commiss European Communities, Joint Res Ctr, B-1049 Brussels, Belgium. [Des Jarlais, Don C.] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA. [Ali, Suad Eltahir] Fed Minist Hlth, Khartoum, Sudan. [Erwin, Patricia J.] Mayo Clin, Rochester, MN USA. [Powles, John] Univ Cambridge, Inst Publ Hlth, Cambridge, England. [Fahimi, Saman] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England. [Malekzadeh, Reza] Univ Tehran Med Sci, Digest Dis Res Ctr, Tehran, Iran. [Flaxman, Seth] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA. [Fowkes, Francis Gerry R.] Univ Edinburgh, Edinburgh, Midlothian, Scotland. [Gmel, Gerhard] Addict Info Switzerland, Lausanne, Switzerland. [Graham, Kathryn; Rehm, Juergen T.; Shield, Kevin] Ctr Addict & Mental Hlth, Toronto, ON, Canada. [Grainger, Rebecca; Merriman, Tony R.] Univ Otago, Dunedin, New Zealand. [Lan, Qing] NCI, Occupat & Environm Epidemiol Branch, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA. [Gunnell, David] Univ Bristol, Bristol, Avon, England. [Weissman, Myrna M.] Columbia Univ, Coll Phys & Surg, New York, NY USA. [Gutierrez, Hialy R.; Weissman, Myrna M.] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA. [Hoek, Hans W.] Parnassia Psychiat Inst, The Hague, Netherlands. [Hogan, Anthony] Australian Natl Univ, Canberra, ACT, Australia. [Hosgood, H. Dean, III] Yeshiva Univ, Albert Einstein Coll Med, New York, NY 10033 USA. [Hu, Howard] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada. [Hubbell, Bryan J.] US EPA, Washington, DC 20460 USA. [Hutchings, Sally J.; Rushton, Lesley; Ezzati, Majid] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Epidemiol & Biostat, MRC HPA Ctr Environm & Hlth, London, England. [Ibeanusi, Sydney E.] Univ Port Harcourt, Port Harcourt, Nigeria. [Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Heidelberg, Germany. [Kan, Haidong] Fudan Univ, Shanghai 200433, Peoples R China. [Kanis, John A.] Univ Sheffield, Sheffield, S Yorkshire, England. [Khang, Young-Ho] Univ Ulsan, Coll Med, Dept Prevent Med, Seoul, South Korea. [Kok, Cindy] Spinal Cord Injury Network, Glebe, New Zealand. [Lalloo, Ratilal] Griffith Univ, Sch Dent & Oral Hlth, Brisbane, Qld 4111, Australia. [Lalloo, Ratilal] Griffith Univ, Populat & Social Hlth Res Program, Brisbane, Qld 4111, Australia. [Leasher, Janet L.] Nova SE Univ, Ft Lauderdale, FL 33314 USA. [Li, Yang] George Inst Global Hlth, Crit Care & Trauma Div, Sydney, NSW, Australia. [Lipshultz, Steven E.; Wilkinson, James D.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA. [Marcenes, Wagner] Queen Mary Univ London, London, England. [Martin, Randall; van Donkelaar, Aaron] Dalhousie Univ, Halifax, NS, Canada. [Mehta, Sumi] Global Alliance Clean Cookstoves, Washington, DC USA. [Mensah, George A.] Univ Cape Town, Dept Med, ZA-7925 Cape Town, South Africa. [Micha, Renata] Agr Univ Athens, Athens, Greece. [Michaud, Catherine] China Med Board, Boston, MA USA. [Mishra, Vinod] United Nations Populat Div, New York, NY USA. [Morawska, Lidia] Queensland Univ Technol, Brisbane, Qld 4001, Australia. [Miquel Nolla, Joan] Hosp Univ Bellvitge, Inst Invest Biomed Bellvitge, Dept Rheumatol, Barcelona, Spain. [Omer, Saad B.; Steenland, Kyle] Emory Univ, Sch Publ Hlth, Atlanta, GA USA. [Omer, Saad B.] Emory Univ, Sch Med, Atlanta, GA USA. [Osborne, Richard] Deakin Univ, Melbourne, Vic, Australia. [Ostro, Bart] Calif Environm Protect Agcy, Sacramento, CA USA. [Pandey, Kiran D.] World Bank, Washington, DC 20433 USA. [Parry, Charles D. H.] S African MRC, Cape Town, South Africa. [Patra, Jayadeep] St Michaels Hosp, Toronto, ON M5B 1W8, Canada. [Pelizzari, Pamela M.] Ctr Medicare & Medicaid Serv, Baltimore, MD USA. [Petzold, Max] Univ Gothenburg, Sahlgrenska Acad, Ctr Appl Biostat, Gothenburg, Sweden. [Phillips, Michael R.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Mental Hlth Ctr, Shanghai 200030, Peoples R China. [Pope, C. Arden, III] Brigham Young Univ, Provo, UT 84602 USA. [Razavi, Homie] Ctr Dis Anal, Louisville, CO USA. [Rehfuess, Eva A.] Univ Munich, Munich, Germany. [Ritz, Beate] Univ Calif Los Angeles, Los Angeles, CA USA. [Robinson, Carolyn] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Rodriguez-Portales, Jose A.] Pontificia Univ Catolica Chile, Santiago, Chile. [Romieu, Isabelle; Straif, Kurt] Int Agcy Res Canc, F-69372 Lyon, France. [Room, Robin] Turning Point Alcohol & Drug Ctr, Ctr Alcohol Policy Res, Fitzroy, SA, Australia. [Roy, Ananya] Univ Med & Dent New Jersey, Newark, NJ 07103 USA. [Sampson, Uchechukwu] Vanderbilt Univ, Nashville, TN USA. [Sapkota, Amir] Univ Maryland, Sch Publ Hlth, Baltimore, MD 21201 USA. [Seedat, Soraya] Univ Stellenbosch, ZA-7600 Stellenbosch, South Africa. [Sleet, David A.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Baltimore, MD USA. [Stovner, Lars Jacob] Norwegian Univ Sci & Technol, Dept Neurosci, N-7034 Trondheim, Norway. [Thurston, George D.] NYU, New York, NY USA. [Vijayakumar, Lakshmi] Voluntary Hlth Serv, Chennai, Tamil Nadu, India. [Weintraub, Robert] Royal Childrens Hosp, Melbourne, Vic, Australia. [Weintraub, Robert] Murdoch Childrens Res Inst, Melbourne, Vic, Australia. [Williams, Hywel C.] Univ Nottingham, Nottingham NG7 2RD, England. [Williams, Warwick] Natl Acoust Labs, Sydney, NSW, Australia. [Woolf, Anthony D.] Royal Cornwall Hosp, Truro, England. [Yip, Paul] Univ Hong Kong, Ctr Suicide Res & Prevent, Hong Kong, Hong Kong, Peoples R China. RP Lim, SS (reprint author), Univ Washington, Inst Hlth Metr & Evaluat, 2301 5th Ave,Suite 600, Seattle, WA 98121 USA. EM stevelim@uw.edu RI Balakrishnan, Kalpana/B-6653-2015; Lopez, Alan/F-1487-2010; Hall, Wayne/A-3283-2008; Stockwell, Tim/B-6662-2012; Baxter, Amanda/E-5449-2011; Ritz, Beate/E-3043-2015; Charlson, Fiona/F-5290-2011; Whiteford, Harvey/A-4840-2009; Boussinesq, Michel/J-7256-2016; Bacchus, Loraine/J-9996-2016; Lalloo, Ratilal/O-5624-2014; Salomon, Joshua/D-3898-2009; Pope, Daniel/C-3054-2014; Sapkota, Amir/A-5968-2011; McGrath, John/G-5493-2010; Stovner, Lars/D-5025-2014; Orchard, Jessica/E-2078-2013; NORMAN, ROSANA/F-2774-2010; Buchbinder, Rachelle/G-2952-2011; Degenhardt, Louisa/D-4515-2012; Bull, Fiona/G-4148-2012; Veerman, Lennert/A-9973-2011; Lathlean, Tim/K-3653-2013; Parry, Charles/A-2906-2009; Martin, Randall/C-1205-2014; OI Jacklyn, Gemma/0000-0002-4814-3241; Devries, Karen/0000-0001-8935-2181; Weissman, Myrna/0000-0003-3490-3075; Hoek, Hans/0000-0001-6353-5465; Borges, Guilherme/0000-0002-3269-0507; London, Stephanie/0000-0003-4911-5290; Khang, Young-Ho/0000-0002-9585-8266; brunekreef, bert/0000-0001-9908-0060; Powles, John/0000-0002-0766-7989; Stockl, Heidi/0000-0002-0907-8483; Hu, Howard/0000-0002-3676-2707; Balakrishnan, Kalpana/0000-0002-5905-1801; Cowie, Benjamin/0000-0002-7087-5895; O'donnell, Colm/0000-0002-8004-450X; Malekzadeh, Reza/0000-0003-1043-3814; Mensah, George/0000-0002-0387-5326; Lopez, Alan/0000-0001-5818-6512; Hall, Wayne/0000-0003-1984-0096; Baxter, Amanda/0000-0001-8198-9022; Charlson, Fiona/0000-0003-2876-5040; Whiteford, Harvey/0000-0003-4667-6623; Boussinesq, Michel/0000-0001-6312-0681; Bacchus, Loraine/0000-0002-9966-8208; Lalloo, Ratilal/0000-0001-5822-1269; Salomon, Joshua/0000-0003-3929-5515; Ghosh, Santu/0000-0003-1358-3471; McGrath, John/0000-0002-4792-6068; Orchard, Jessica/0000-0002-5702-7277; NORMAN, ROSANA/0000-0002-9742-1957; Degenhardt, Louisa/0000-0002-8513-2218; Veerman, Lennert/0000-0002-3206-8232; Parry, Charles/0000-0001-9787-2785; Martin, Randall/0000-0003-2632-8402; Brauer, Michael/0000-0002-9103-9343; Merriman, Tony/0000-0003-0844-8726; Chen, Honglei/0000-0003-3446-7779; Osborne, Richard/0000-0002-9081-2699 FU Lundbeck; Prana Biotechnology; Abbott; Amgen; AstraZeneca; George Clinical; GlaxoSmithKline; Novartis; PepsiCo; Pfizer; Pharmacy Guild of Australia; Roche; Sanofi-Aventis; Seervier; Tanabe; Australian Food and Grocery Council; Bupa Australia; Johnson and Johnson; Merck Schering-Plough; Servier; United Healthcare Group; Imperial College London (as PI) from the European Chemical Industry Council; CONCAWE; USEPA; Shell Foundation; Fight for Sight; Australian National Health and Medical Research Council; Monash University; Cabrini Health; Health Effects Institute; William and Flora Hewlett Foundation; Cancer Research UK; Safework Australia; Johns Hopkins Vaccine Initiative Scholarship; WHO; Parnassia Psychiatric Institute, The Hague, Netherlands; Department of Psychiatry, University Medical Center Groningen, University of Groningen, Netherlands; World Mental Health Japan; Grant for Research on Psychiatric and Neurological Diseases and Mental Health from the Japan Ministry of Health, Labour, and Welfare [H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013]; Intramural Research Program of the NIH (National Cancer Institute); Division of Intramural Research, National Institute of Environmental Health Sciences, USA; Australian Research Council Future Fellowship; National Health and Medical Research Council of Australia Senior Research Fellowship; Munich Centre of Health Sciences; Foundation for Alcohol Research and Education; Victorian Department of Health; Burke Global Health Fellowship; Harold Amos Medical Faculty Development Award of the Robert Wood Johnson Foundation; Vanderbilt Clinical and Translational Scholars Award; Spanish Society of Rheumatology; South African Research Chairs Initiative; National Research Foundation; National Institute of Environmental Health Sciences [ES00260]; UK Medical Research Council (MRC); National Institute for Health Research Comprehensive Biomedical research Centre at Imperial College Healthcare NHS Trust; Nutrition Impact Model Study (NIMS); Bill & Melinda Gates Foundation; Spanish Rheumatology Association; Institute of Bone and Joint Research; University of Sydney FX A Davis is employed by the NHS on works for the UK Dept of Health as lead adviser on audiology. E R Dorsey has been a consultant for Medtronic and Lundbeck and has received grant support from Lundbeck and Prana Biotechnology. M Ezzati chaired a session and gave a talk at the World Cardiology Congress (WCC), with travel cost reimbursed by the World Heart Federation. At the WCC, he also gave a talk at a session organised by Pepsico with no financial remuneration. G A Mensah is a former employee of PepsiCo. D Mozaffarian has received: ad hoc travel reimbursement and/or honoraria for one-time specific presentations on diet and cardiometabolic diseases from Nutrition Impact (9/10), the International Life Sciences Institute (12/10), Bunge (11/11), Pollock Institute (3/12), and Quaker Oats (4/12; modest); and Unilever's North America Scientific Advisory Board (modest). B Neal is the Chair of the Australian Division of World Action on Salt and Health. He has consulted to Roche and Takeda. He has received lecture fees, travel fees, or reimbursements from Abbott, Amgen, AstraZeneca, George Clinical, GlaxoSmithKline, Novartis, PepsiCo, Pfizer, Pharmacy Guild of Australia, Roche, Sanofi-Aventis, Seervier, and Tanabe. He holds research support from the Australian Food and Grocery Council, Bupa Australia, Johnson and Johnson, Merck Schering-Plough, Roche, Servier, and United Healthcare Group. He is not employed by a commercial entity and has no equity ownership or stock options, patents or royalties, or any other financial or non-financial support that might be viewed as a conflict of interest. L Rushton received honorarium for board membership of the European Centre for Ecotoxicology and Toxicology of Chemicals and research grants to Imperial College London (as PI) from the European Chemical Industry Council and CONCAWE.; We thank the countless individuals who have contributed to the Global Burden of Disease Study 2010 in various capacities. We specifically acknowledge the important contribution to this work from multiple staff members of the World Health Organization. We also thank the following organisations that hosted consultations during the final stages of the analytical process, providing valuable feedback about the results and the data to improve the study's findings overall: Pan American Health Organization; Eastern Mediterranean Regional Office of WHO; UNAIDS; Ministry of Health, Brazil; China Centers for Disease Control; and the University of Zambia. We thank Regina Guthold, Jordis Ott, Annette Pruss-Ustun, and Gretchen A Stevens for their collaboration and input into the analyses and estimates. Finally, we acknowledge the extensive support from all staff members at the Institute for Health Metrics and Evaluation and specifically thank: James Bullard, Andrew Ernst, and Serkan Yalcin for their tireless support of the computational infrastructure required to produce the results; Linda A Ettinger for her expert administrative support to facilitate communication and coordination amongst the authors; Peter Speyer, Abigail McLain, Katherine Leach-Kemon, and Eden Stork for their persistent and valuable work to gain access to and catalogue as much data as possible to inform the estimates; and Erin C Mullany for her systematic efforts in organising drafts of papers, formatting correspondence with expert groups, and preparing the final manuscript. J Balmes, Z Chafe, and K R Smith acknowledge that their aspects of the research were also supported by USEPA and the Shell Foundation, neither of which had any role in design, data collection, analysis, interpretation, or decisions related to publication. R Bourne acknowledges Institutional Support: Vision & Eye Research Unit, Postgraduate Medical Institute, Anglia Ruskin University, Cambridge, UK. Funding support: Fight for Sight (Dr Hans and Mrs Gertrude Hirsch award). R Buchbinder was partially supported by an Australian National Health and Medical Research Council Practitioner Fellowship, Monash University, and Cabrini Health. A J Cohen received support from the Health Effects Institute and The William and Flora Hewlett Foundation. S Darby was supported by Cancer Research UK. L Degenhardt was supported by an Australian National Health and Medical Research Council Senior Research Fellowship. T Driscoll was supported in part by funding from the National Occupational Health and Safety Commission (now Safework Australia). K M Hanafiah's work for the GBD hepatitis C prevalence study was funded partly by Johns Hopkins Vaccine Initiative Scholarship and partly by WHO. H W Hoek acknowledges the support of: the Parnassia Psychiatric Institute, The Hague, Netherlands; the Department of Psychiatry, University Medical Center Groningen, University of Groningen, Netherlands; and the Department of Epidemiology, Columbia University, New York, USA. D Hoy was supported by the Bill & Melinda Gates Foundation and the Australian National Health and Medical Research Council. N Kawakami notes that data used in the study was collected through support from the following grants: The World Mental Health Japan is supported by the Grant for Research on Psychiatric and Neurological Diseases and Mental Health (H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013) from the Japan Ministry of Health, Labour, and Welfare. He thanks staff members, filed coordinators, and interviewers of the WMH Japan 2002-2004 Survey.; Q Lan was supported in part by the Intramural Research Program of the NIH (National Cancer Institute). S London is supported by the Division of Intramural Research, National Institute of Environmental Health Sciences, USA. T R Merriman acknowledges the Health Research Council of New Zealand. B Neal was supported in his contribution to this work by an Australian Research Council Future Fellowship and a National Health and Medical Research Council of Australia Senior Research Fellowship. C Olives was supported in his contribution to this work by an Australian Research Council Future Fellowship and a National Health and Medical Research Council of Australia Senior Research Fellowship. E A Rehfuess acknowledges financial support from the Munich Centre of Health Sciences. R Room's position at the University of Melbourne and Turning Point Alcohol and Drug Centre is funded by the Foundation for Alcohol Research and Education and the Victorian Department of Health. J A Salomon received support from the Burke Global Health Fellowship while working on this study. U Sampson was supported in part by: The Harold Amos Medical Faculty Development Award of the Robert Wood Johnson Foundation; The Vanderbilt Clinical and Translational Scholars Award. L Sanchez-Riera acknowledges the Spanish Society of Rheumatology for their funds. S Seedat is supported by the South African Research Chairs Initiative, hosted by the Department of Science and Technology and the National Research Foundation. G D Thurston was supported in part by grant ES00260 from the National Institute of Environmental Health Sciences. J M Zielinski acknowledges institutional support from: Health Canada, University of Ottawa, and WHO (International Radon Project). M Ezzati's research is supported by a Strategic Award from the UK Medical Research Council (MRC) and by the National Institute for Health Research Comprehensive Biomedical research Centre at Imperial College Healthcare NHS Trust. Work on micronutrient deficiencies was supported by the Nutrition Impact Model Study (NIMS) funded by the Bill & Melinda Gates Foundation. The GBD Osteoporosis Expert Group was supported by the Spanish Rheumatology Association, Institute of Bone and Joint Research, University of Sydney. The GBD Osteoporosis Expert Group also acknowledges the contributions made by Professor Philip Sambrook who passed away in April, 2012. NR 192 TC 2676 Z9 2777 U1 203 U2 1287 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 EI 1474-547X J9 LANCET JI Lancet PD DEC 15 PY 2012 VL 380 IS 9859 BP 2224 EP 2260 PG 37 WC Medicine, General & Internal SC General & Internal Medicine GA 055AL UT WOS:000312387000017 PM 23245609 ER PT J AU Ershova, JV Kurbatova, EV Moonan, PK Cegielski, JP AF Ershova, Julia V. Kurbatova, Ekaterina V. Moonan, Patrick K. Cegielski, J. Peter TI Acquired Resistance to Second-Line Drugs Among Persons With Tuberculosis in the United States SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID MULTIDRUG-RESISTANT; MYCOBACTERIUM-TUBERCULOSIS; TREATMENT OUTCOMES; SURVEILLANCE; MANAGEMENT; LATVIA AB Background. Acquired resistance to second-line drugs (SLDs) is a problem in treating patients with drug-resistant tuberculosis worldwide. The objectives of this study were to identify risk factors for acquired resistance (AR) to injectable SLDs (INJ SLDs) and fluoroquinolones in the US National tuberculosis Surveillance System, 1993-2008. Methods. We selected cases for which the initial and final drug susceptibility test (DST) results had been reported. We defined AR as resistance at the final DST but susceptibility to the same drug at the initial DST. We analyzed AR using 2-way frequency tables and multivariable logistic regression. Results. The baseline prevalence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis was 12.6% (1864/14 770) and 0.38% (56/14 770), respectively. Of 2274 individuals without initial resistance to INJ SLDs, 49 (2.2%) acquired resistance. Of 1141 initially susceptible to fluoroquinolones, 32 (2.8%) acquired resistance. The AR to INJ SLDs was associated with age group 25-44 years (adjusted odds ratio [aOR], 2.7; 95% confidence interval [CI], 1.2-6.3), positive HIV (human immunodeficiency virus) status (aOR, 2.5; 95% CI, 1.3-4.7), MDR at treatment initiation (aOR, 5.5; 95% CI, 2.9-10.5), and treatment with any SLD (aOR, 2.4; 95% CI, 1.2-4.7). The AR to fluoroquinolones was associated with MDR tuberculosis at treatment initiation (aOR, 6.5; 95% CI, 2.9-14.6). Conclusions. Among patients with initial and final DST reported, the risk factors for AR to INJ SLDs included age, positive HIV status, MDR tuberculosis and initial treatment with any SLD, while the only predictor for AR to fluoroquinolones was MDR tuberculosis at treatment initiation. Providers should consider monitoring SLD DST for MDR tuberculosis patients in the indicated subgroups. C1 [Ershova, Julia V.; Kurbatova, Ekaterina V.; Moonan, Patrick K.; Cegielski, J. Peter] US Ctr Dis Control & Prevent, Atlanta, GA USA. RP Ershova, JV (reprint author), CDC, Int Res & Programs Branch, Div TB Eliminat, Mailstop E-10,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM jershova@cdc.gov RI Moonan, Patrick/F-4307-2014; OI Moonan, Patrick/0000-0002-3550-2065 FU Intramural CDC HHS [CC999999] NR 24 TC 12 Z9 12 U1 0 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD DEC 15 PY 2012 VL 55 IS 12 BP 1600 EP 1607 DI 10.1093/cid/cis748 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 044SF UT WOS:000311643000002 PM 22942206 ER PT J AU Hariri, S Unger, ER Powell, SE Bauer, HM Bennett, NM Bloch, KC Niccolai, LM Schafer, S Steinau, M Markowitz, LE AF Hariri, Susan Unger, Elizabeth R. Powell, Suzanne E. Bauer, Heidi M. Bennett, Nancy M. Bloch, Karen C. Niccolai, Linda M. Schafer, Sean Steinau, Martin Markowitz, Lauri E. CA HPV-IMPACT Working Grp TI Human Papillomavirus Genotypes in High-Grade Cervical Lesions in the United States SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID HPV VACCINE; CANCER; RISK; WOMEN; PERSISTENCE; NEOPLASIA; INFECTION; PRECANCER; COHORT AB Background. Two vaccines protect against human papillomaviruses (HPV) 16 and 18, which cause 70% of cervical cancer and 50% of cervical intraepithelial neoplasia 2/3 and adenocarcinoma in situ (CIN2+). Monitoring HPV types in CIN2+ may be used to assess HPV vaccine impact. Methods. As part of a multisite vaccine impact monitoring project (HPV-IMPACT), biopsy specimens used to diagnose CIN2+ were obtained for HPV DNA typing for women aged 18-39 years. Results. Among 4,121 CIN2+ cases reported during 2008-2009 in 18- to 39-year-old women 3058 (74.2%) were tested; 96% were HPV DNA positive. HPV 16 was most common (49.1%), followed by HPV 31 (10.4%) and HPV 52 (9.7%). HPV 18 prevalence was 5.5% overall. Proportion of CIN2+ cases associated with HPV 16/18 was highest (56.3%) in 25- to 29-year-old women. HPV 16/18-associated lesions were less common in non-Hispanic blacks (41.9%) and Hispanics (46.3%) compared with non-Hispanic whites (59.1%) (P<.0001); the difference remained significant when adjusted for covariates. Compared to non-Hispanic whites, HPV 35 and 58 were significantly more common in non-Hispanic blacks (14.5% vs 4.2%; 12.3% vs 3.4%) and HPV 45 was higher in Hispanics (3.7% vs 1.5%). Conclusions. Age and racial/ethnic differences in HPV type distribution may have implications for vaccine impact and should be considered in monitoring trends. C1 [Hariri, Susan; Powell, Suzanne E.; Markowitz, Lauri E.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Unger, Elizabeth R.; Steinau, Martin] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Bauer, Heidi M.] Calif Dept Publ Hlth, STD Control Branch, Richmond, CA USA. [Bennett, Nancy M.] Univ Rochester, Sch Med & Dent, Dept Med, New York, NY USA. [Bennett, Nancy M.] Univ Rochester, Sch Med & Dent, Ctr Community Hlth, New York, NY USA. [Bloch, Karen C.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA. [Bloch, Karen C.] Vanderbilt Univ, Med Ctr, Dept Prevent Med, Nashville, TN USA. [Niccolai, Linda M.] Yale Univ, Sch Publ Hlth, Div Epidemiol Microbial Dis, New Haven, CT USA. [Schafer, Sean] Oregon Dept Human Serv, Div STD, HIV STD TB Program, Portland, OR USA. RP Hariri, S (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, 1600 Clifton Rd,MS E-02, Atlanta, GA 30333 USA. EM shariri@cdc.gov OI Unger, Elizabeth/0000-0002-2925-5635 FU CDC FX This work was supported by CDC. NR 28 TC 26 Z9 27 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD DEC 15 PY 2012 VL 206 IS 12 BP 1878 EP 1886 DI 10.1093/infdis/jis627 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 045AW UT WOS:000311667400011 PM 23045628 ER PT J AU Mugavero, MJ Westfall, AO Zinski, A Davila, J Drainoni, ML Gardner, LI Keruly, JC Malitz, F Marks, G Metsch, L Wilson, TE Giordano, TP AF Mugavero, Michael J. Westfall, Andrew O. Zinski, Anne Davila, Jessica Drainoni, Mari-Lynn Gardner, Lytt I. Keruly, Jeanne C. Malitz, Faye Marks, Gary Metsch, Lisa Wilson, Tracey E. Giordano, Thomas P. CA Retention Care RIC Study Grp TI Measuring Retention in HIV Care: The Elusive Gold Standard SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE retention in care; adherence; engagement in care; viral load ID ANTIRETROVIRAL THERAPY; INFECTED PERSONS; VIRAL LOAD; PREVENTION; ENGAGEMENT; TRANSMISSION; ASSOCIATION; GUIDELINES; MORTALITY; ADHERENCE AB Background: Measuring retention in HIV primary care is complex, as care includes multiple visits scheduled at varying intervals over time. We evaluated 6 commonly used retention measures in predicting viral load (VL) suppression and the correlation among measures. Methods: Clinic-wide patient-level data from 6 academic HIV clinics were used for 12 months preceding implementation of the Centers for Disease Control and Prevention/Health Resources and Services Administration (CDC/HRSA) retention in care intervention. Six retention measures were calculated for each patient based on scheduled primary HIV provider visits: count and dichotomous missed visits, visit adherence, 6-month gap, 4-month visit constancy, and the HRSA HIV/AIDS Bureau (HRSA HAB) retention measure. Spearman correlation coefficients and separate unadjusted logistic regression models compared retention measures with one another and with 12-month VL suppression, respectively. The discriminatory capacity of each measure was assessed with the c-statistic. Results: Among 10,053 patients, 8235 (82%) had 12-month VL measures, with 6304 (77%) achieving suppression (VL < 400 copies/mL). All 6 retention measures were significantly associated (P < 0.0001) with VL suppression (odds ratio; 95% CI, c-statistic): missed visit count (0.73; 0.71 to 0.75, 0.67), missed visit dichotomous (3.2; 2.8 to 3.6, 0.62), visit adherence (3.9; 3.5 to 4.3,0.69), gap (3.0; 2.6 to 3.3, 0.61), visit constancy (2.8; 2.5 to 3.0, 0.63), and HRSA HAB (3.8; 3.3 to 4.4, 0.59). Measures incorporating "no-show" visits were highly correlated (Spearman coefficient = 0.83-0.85), as were measures based solely on kept visits (Spearman coefficient = 0.72-0.77). Correlation coefficients were lower across these 2 groups of measures (range = 0.16-0.57). Conclusions: Six retention measures displayed a wide range of correlation with one another, yet each measure had significant association and modest discrimination for VL suppression. These data suggest there is no clear gold standard and that selection of a retention measure may be tailored to context. C1 [Mugavero, Michael J.; Westfall, Andrew O.; Zinski, Anne] Univ Alabama Birmingham, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA. [Davila, Jessica; Giordano, Thomas P.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Davila, Jessica; Giordano, Thomas P.] Michael E DeBakey VA Med Ctr, Hlth Serv Res & Dev Ctr Excellence, Houston, TX USA. [Drainoni, Mari-Lynn] Boston Univ, Infect Dis Sect, Med Ctr, Boston, MA USA. [Drainoni, Mari-Lynn] Boston Univ, Sch Publ Hlth, Med Ctr, Dept Hlth Policy & Management, Boston, MA USA. [Gardner, Lytt I.; Marks, Gary] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Keruly, Jeanne C.] Johns Hopkins Univ, Div Infect Dis, Dept Med, Baltimore, MD USA. [Malitz, Faye] HIV AIDS Bur, Div Sci & Policy, US Hlth Resources & Serv Adm, Rockville, MD USA. [Metsch, Lisa] Univ Miami, Div Hlth Serv Res & Policy, Dept Epidemiol, Sch Publ Hlth, Coral Gables, FL 33124 USA. [Wilson, Tracey E.] Suny Downstate Med Ctr, Dept Community Hlth Sci, Sch Publ Hlth, New York, NY USA. [Giordano, Thomas P.] Baylor Coll Med, Dept Med, Infect Dis Sect, Houston, TX 77030 USA. RP Mugavero, MJ (reprint author), 1530 3rd Ave S,BBRB 206H, Birmingham, AL 35294 USA. EM mmugavero@uab.edu OI Westfall, Andrew/0000-0002-0468-4695 FU Centers for Disease Control and Prevention (CDC); Health Resources and Services Administration through CDC [200-2007-23685, 200-2007-23690, 200-2007-23689, 200-2007-23687, 200-2007-23684, 200-2007-23692]; National Institute of Mental Health [5K23MH082641-05]; Bristol-Myers Squibb; Gilead Sciences; Merck Foundation; Pfizer, Inc,; Tibotec Therapeutics; Definicare, LLC FX Supported by the Centers for Disease Control and Prevention (CDC) and the Health Resources and Services Administration through CDC contracts 200-2007-23685, 200-2007-23690, 200-2007-23689, 200-2007-23687, 200-2007-23684, 200-2007-23692. M. J. Mugavero was also supported by National Institute of Mental Health Grant 5K23MH082641-05.; MJM has received consulting fees (advisory board) from Bristol-Myers Squibb, Gilead Sciences and Merck Foundation, and grant support from Bristol-Myers Squibb, Pfizer, Inc, Tibotec Therapeutics, and Definicare, LLC. NR 26 TC 73 Z9 73 U1 4 U2 25 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD DEC 15 PY 2012 VL 61 IS 5 BP 574 EP 580 DI 10.1097/QAI.0b013e318273762f PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 046UQ UT WOS:000311790300012 PM 23011397 ER PT J AU Haaland, RE Chaowanachan, T Evans-Strickfaden, T van de Wijgert, JH Kilmarx, PH McLean, CA Hart, CE AF Haaland, Richard E. Chaowanachan, Thanyanan Evans-Strickfaden, Tammy van de Wijgert, Janneke H. Kilmarx, Peter H. McLean, Catherine A. Hart, Clyde E. TI Carrageenan-Based Gel Retains Limited Anti-HIV-1 Activity 8-24 Hours After Vaginal Application by HIV-Infected Thai Women Enrolled in a Phase I Safety Trial SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Letter ID DOUBLE-BLIND; PREVENTION; MICROBICIDES; CARRAGUARD C1 [Haaland, Richard E.; Chaowanachan, Thanyanan; Evans-Strickfaden, Tammy; Hart, Clyde E.] US Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Branch Lab, Atlanta, GA 30333 USA. [van de Wijgert, Janneke H.] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands. [van de Wijgert, Janneke H.] Amsterdam Inst Global Hlth & Dev, Amsterdam, Netherlands. [Kilmarx, Peter H.; McLean, Catherine A.] US Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Haaland, RE (reprint author), US Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Branch Lab, Atlanta, GA 30333 USA. OI Kilmarx, Peter/0000-0001-6464-3345 NR 13 TC 1 Z9 1 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD DEC 15 PY 2012 VL 61 IS 5 BP E71 EP E73 DI 10.1097/QAI.0b013e318271c8f9 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 046UQ UT WOS:000311790300003 PM 23183152 ER PT J AU Kurth, AE Mayer, K Beauchamp, G McKinstry, L Farrior, J Buchacz, K Donnell, D Branson, B El-Sadr, W AF Kurth, Ann E. Mayer, Kenneth Beauchamp, Geetha McKinstry, Laura Farrior, Jennifer Buchacz, Kate Donnell, Deborah Branson, Bernard El-Sadr, Wafaa CA HTPN 065 TLC-Plus Study Team TI Clinician Practices and Attitudes Regarding Early Antiretroviral Therapy in the United States SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE HIV prevention; early antiretroviral therapy; test and treat; clinician survey ID HIV-1 TRANSMISSION; VIRAL LOAD; PREVENTION; COHORT; METAANALYSIS; INITIATION; INFECTION; EPIDEMIC; TREAT AB Background: Use of antiretroviral therapy (ART) to prevent HIV transmission has received substantial attention after a recent trial demonstrating efficacy of ART to reduce HIV transmission in HIV-discordant couples. Objective: To assess practices and attitudes of HIV clinicians regarding early initiation of ART for treatment and prevention of HIV at sites participating in the HIV Prevention Trials Network 065 study. Design: Cross-sectional internet-based survey. Methods: ART-prescribing clinicians (n = 165 physicians, nurse practitioners, physician assistants) at 38 HIV care sites in Bronx, NY, and Washington, DC, completed a brief anonymous Internet survey, before any participation in the HIV Prevention Trials Network 065 study. Analyses included associations between clinician characteristics and willingness to prescribe ART for prevention. Results: Almost all respondents (95%), of whom 59% were female, 66% white, and 77% HIV specialists, "strongly agreed/agreed" that early ART can decrease HIV transmission. Fifty-six percent currently recommend ART initiation for HIV-infected patients with CD4+ count <500 cells per cubic millimeter, and 14% indicated that they initiate ART irrespective of CD4+ count. Most (75%) indicated that they would consider initiating ART earlier than otherwise indicated for patients in HIV-discordant sexual partnerships, and 40% would do so if a patient was having unprotected sex with a partner of unknown HIV status. There were no significant differences by age, gender, or clinician type in likelihood of initiating ART for reasons including HIV transmission prevention to sexual partners. Conclusions: This sample of US clinicians indicated support for early ART initiation to prevent HIV transmission, especially for situations where such transmission would be more likely to occur. C1 [Kurth, Ann E.] NYU, New York, NY 10003 USA. [Mayer, Kenneth] Harvard Univ, Beth Israel Deaconess Hosp, Boston, MA 02115 USA. [Beauchamp, Geetha; McKinstry, Laura; Donnell, Deborah] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Farrior, Jennifer] FHI 360, Durham, NC USA. [Buchacz, Kate; Branson, Bernard] Ctr Dis Control & Prevent, Atlanta, GA USA. [El-Sadr, Wafaa] Columbia Univ, Harlem Hosp, ICAP, New York, NY USA. RP Kurth, AE (reprint author), NYU, 726 Broadway,Room 1017, New York, NY 10003 USA. EM akurth@nyu.edu RI Kurth, Ann/A-1615-2013; OI Donnell, Deborah/0000-0002-0587-7480 FU NIAID; NIMH [UM1 AI068619, UM1 AI068617]; National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC FX HIV Prevention Trials Network 065 is sponsored by: NIAID and NIMH (Cooperative Agreements #UM1 AI068619; #UM1 AI068617); National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC. NR 26 TC 13 Z9 13 U1 0 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD DEC 15 PY 2012 VL 61 IS 5 BP E65 EP E69 DI 10.1097/QAI.0b013e31826a184c PG 5 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 046UQ UT WOS:000311790300001 PM 23183150 ER PT J AU Kotloff, KL Blackwelder, WC Nasrin, D Nataro, JP Farag, TH van Eijk, A Adegbola, RA Alonso, PL Breiman, RF Faruque, ASG Saha, D Sow, SO Sur, D Zaidi, AKM Biswas, K Panchalingam, S Clemens, JD Cohen, D Glass, RI Mintz, ED Sommerfelt, H Levine, MM AF Kotloff, Karen L. Blackwelder, William C. Nasrin, Dilruba Nataro, James P. Farag, Tamer H. van Eijk, Annemieke Adegbola, Richard A. Alonso, Pedro L. Breiman, Robert F. Faruque, Abu Syed Golam Saha, Debasish Sow, Samba O. Sur, Dipika Zaidi, Anita K. M. Biswas, Kousick Panchalingam, Sandra Clemens, John D. Cohen, Dani Glass, Roger I. Mintz, Eric D. Sommerfelt, Halvor Levine, Myron M. TI The Global Enteric Multicenter Study (GEMS) of Diarrheal Disease in Infants and Young Children in Developing Countries: Epidemiologic and Clinical Methods of the Case/Control Study SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID SUB-SAHARAN AFRICA; ROTAVIRUS DIARRHEA; RURAL BANGLADESH; EPISODES; VACCINE; DEATHS; POPULATION; INFECTIONS; MORTALITY; COMMUNITY AB Background. Diarrhea is a leading cause of illness and death among children aged <5 years in developing countries. This paper describes the clinical and epidemiological methods used to conduct the Global Enteric Multicenter Study (GEMS), a 3-year, prospective, age-stratified, case/control study to estimate the population-based burden, microbiologic etiology, and adverse clinical consequences of acute moderate-to-severe diarrhea (MSD) among a censused population of children aged 0-59 months seeking care at health centers in sub-Saharan Africa and South Asia. Methods. GEMS was conducted at 7 field sites, each serving a population whose demography and healthcare utilization practices for childhood diarrhea were documented. We aimed to enroll 220 MSD cases per year from selected health centers serving each site in each of 3 age strata (0-11, 12-23, and 24-59 months), along with 1-3 matched community controls. Cases and controls supplied clinical, epidemiologic, and anthropometric data at enrollment and again approximately 60 days later, and provided enrollment stool specimens for identification and characterization of potential diarrheal pathogens. Verbal autopsy was performed if a child died. Analytic strategies will calculate the fraction of MSD attributable to each pathogen and the incidence, financial costs, nutritional consequences, and case fatality overall and by pathogen. Conclusions. When completed, GEMS will provide estimates of the incidence, etiology, and outcomes of MSD among infants and young children in sub-Saharan Africa and South Asia. This information can guide development and implementation of public health interventions to diminish morbidity and mortality from diarrheal diseases. C1 [Kotloff, Karen L.; Nataro, James P.; Levine, Myron M.] Univ Maryland, Sch Med, Ctr Vaccine Dev, Dept Pediat, Baltimore, MD 21201 USA. [Kotloff, Karen L.; Blackwelder, William C.; Nasrin, Dilruba; Nataro, James P.; Farag, Tamer H.; Panchalingam, Sandra; Levine, Myron M.] Univ Maryland, Sch Med, Ctr Vaccine Dev, Dept Med, Baltimore, MD 21201 USA. [van Eijk, Annemieke] Univ Liverpool, Liverpool Sch Trop Med, Child & Reprod Hlth Grp, Liverpool L69 3BX, Merseyside, England. [Adegbola, Richard A.; Saha, Debasish] Med Res Council United Kingdom Unit, Fajara, Gambia. [Alonso, Pedro L.] Univ Barcelona, Hosp Clin, Ctr Recerca Salut Int Barcelona, E-08007 Barcelona, Spain. [Breiman, Robert F.] US Ctr Dis Control & Prevent, Kenya Off, Global Dis Detect Div, Nairobi, Kenya. [Faruque, Abu Syed Golam] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh. [Sow, Samba O.] Ctr Dev Vaccins, Bamako, Mali. [Sur, Dipika] Natl Inst Cholera & Enter Dis, Kolkata, India. [Zaidi, Anita K. M.] Aga Khan Univ, Dept Paediat & Child Hlth, Karachi, Pakistan. [Biswas, Kousick] Cooperat Studies Program Coordinating Ctr, Dept Vet Affairs, Perry Point, MD USA. [Clemens, John D.] Int Vaccine Inst, Seoul, South Korea. [Cohen, Dani] Tel Aviv Univ, Sackler Fac Med, Sch Publ Hlth, Dept Epidemiol & Prevent Med, Ramat Aviv, Israel. [Glass, Roger I.] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA. [Mintz, Eric D.] US Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. [Sommerfelt, Halvor] Univ Bergen, Ctr Int Hlth, Oslo, Norway. [Sommerfelt, Halvor] Norwegian Inst Publ Hlth, Div Infect Dis Control, Oslo, Norway. RP Kotloff, KL (reprint author), Univ Maryland, Sch Med, Ctr Vaccine Dev, Dept Pediat, 685 W Baltimore St,HSF 480, Baltimore, MD 21201 USA. EM kkotloff@medicine.umaryland.edu RI kotloff, karen/E-7768-2012 OI kotloff, karen/0000-0003-1808-6431 FU Bill & Melinda Gates Foundation [38874] FX This work was supported by the Bill & Melinda Gates Foundation (grant number 38874). NR 43 TC 68 Z9 68 U1 2 U2 15 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD DEC 15 PY 2012 VL 55 SU 4 BP S232 EP S245 DI 10.1093/cid/cis753 PG 14 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 044QP UT WOS:000311637600003 PM 23169936 ER PT J AU Panchalingam, S Antonio, M Hossain, A Mandomando, I Ochieng, B Oundo, J Ramamurthy, T Tamboura, B Zaidi, AKM Petri, W Houpt, E Murray, P Prado, V Vidal, R Steele, D Strockbine, N Sansonetti, P Glass, RI Robins-Browne, RM Tauschek, M Svennerholm, AM Kotloff, K Levine, MM Nataro, JP AF Panchalingam, Sandra Antonio, Martin Hossain, Anowar Mandomando, Inacio Ochieng, Ben Oundo, Joseph Ramamurthy, T. Tamboura, Boubou Zaidi, Anita K. M. Petri, William Houpt, Eric Murray, Patrick Prado, Valeria Vidal, Roberto Steele, Duncan Strockbine, Nancy Sansonetti, Philippe Glass, Roger I. Robins-Browne, Roy M. Tauschek, Marija Svennerholm, Ann-Marie Kotloff, Karen Levine, Myron M. Nataro, James P. TI Diagnostic Microbiologic Methods in the GEMS-1 Case/Control Study SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID DIARRHEAGENIC ESCHERICHIA-COLI; FECAL SPECIMENS; PCR; CHILDREN; ANTIGEN; SAMPLES AB To understand the etiology of moderate-to-severe diarrhea among children in high mortality areas of sub-Saharan Africa and South Asia, we performed a comprehensive case/control study of children aged < 5 years at 7 sites. Each site employed an identical case/control study design and each utilized a uniform comprehensive set of microbiological assays to identify the likely bacterial, viral and protozoal etiologies. The selected assays effected a balanced consideration of cost, robustness and performance, and all assays were performed at the study sites. Identification of bacterial pathogens employed streamlined conventional bacteriologic biochemical and serological algorithms. Diarrheagenic Escherichia coli were identified by application of a multiplex polymerase chain reaction assay for enterotoxigenic, enteroaggregative, and enteropathogenic E. coli. Rotavirus, adenovirus, Entamoeba histolytica, Giardia enterica, and Cryptosporidium species were detected by commercially available enzyme immunoassays on stool samples. Samples positive for adenovirus were further evaluated for adenovirus serotypes 40 and 41. We developed a novel multiplex assay to detect norovirus (types 1 and 2), astrovirus, and sapovirus. The portfolio of diagnostic assays used in the GEMS study can be broadly applied in developing countries seeking robust cost-effective methods for enteric pathogen detection. C1 [Nataro, James P.] Univ Virginia, Sch Med, Dept Pediat, Charlottesville, VA 22908 USA. [Panchalingam, Sandra; Kotloff, Karen; Levine, Myron M.; Nataro, James P.] Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA. [Antonio, Martin] MRC, Fajara, Gambia. [Hossain, Anowar] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh. [Mandomando, Inacio] Ctr Invest Saude, Manhica, Maputo, Mozambique. [Ochieng, Ben; Oundo, Joseph] Kenya Med Res Inst CDC, Kisumu, Kenya. [Ramamurthy, T.] Natl Inst Cholera & Enter Dis, Kolkata, India. [Tamboura, Boubou] Ctr Vaccine Dev Mali, Bamako, Mali. [Zaidi, Anita K. M.] Aga Khan Univ, Karachi, Pakistan. [Petri, William; Houpt, Eric] Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22908 USA. [Murray, Patrick; Strockbine, Nancy; Glass, Roger I.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Prado, Valeria; Vidal, Roberto] Univ Chile, Santiago, Chile. [Steele, Duncan] World Hlth Org, Geneva, Switzerland. [Sansonetti, Philippe] Inst Pasteur, Paris, France. [Robins-Browne, Roy M.; Tauschek, Marija] Univ Melbourne, Melbourne, Vic 3010, Australia. [Svennerholm, Ann-Marie] Univ Gothenburg, Gothenburg, Sweden. RP Nataro, JP (reprint author), Univ Virginia, Sch Med, Dept Pediat, 3601 W Clin,Hosp Dr, Charlottesville, VA 22908 USA. EM jpn2r@virginia.edu RI kotloff, karen/E-7768-2012; OI kotloff, karen/0000-0003-1808-6431; Robins-Browne, Roy/0000-0001-9179-7884 FU Bill & Melinda Gates Foundation [38874] FX This work was supported by the Bill & Melinda Gates Foundation (grant number 38874). NR 18 TC 53 Z9 53 U1 1 U2 15 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD DEC 15 PY 2012 VL 55 SU 4 BP S294 EP S302 DI 10.1093/cid/cis754 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 044QP UT WOS:000311637600008 PM 23169941 ER PT J AU Silver, B Nagel, MA Mahalingam, R Cohrs, R Schmid, DS Gilden, D AF Silver, Brian Nagel, Maria A. Mahalingam, Ravi Cohrs, Randall Schmid, D. Scott Gilden, Don TI Varicella zoster virus vasculopathy: A treatable form of rapidly progressive multi-infarct dementia after 2 years' duration SO JOURNAL OF THE NEUROLOGICAL SCIENCES LA English DT Article DE VZV vasculopathy; Ischemic optic neuropathy; Multi-infarct dementia ID FEATURES AB We describe an extraordinarily protracted case of varicella zoster virus (VZV) multifocal vasculopathy in a man who presented initially with ischemic optic neuropathy and then suffered 4 episodes of stroke manifesting as multi-infarct dementia over a 2-year period. Brain magnetic resonance imaging (MRI) and angiography (MRA) revealed cortical and subcortical infarctions as well as vasculitic occlusion and stenosis. The patient was treated with corticosteroids and later with cyclophosphamide. More than 2 years after the onset of neurological disease, two cerebrospinal fluid (CSF) examinations revealed the presence of anti-VZV IgG antibody with reduced serum-to-CSF ratios of anti-VZV IgG compared with ratios for total IgG and albumin, indicative of intrathecal synthesis of anti-VZV IgG. After definitive diagnosis, immunosuppressive drugs were discontinued and he was treated with intravenous acyclovir; both mental status and gait improved and no further episodes of neurological dysfunction ensued. The favorable outcome in this patient indicates that VZV vasculopathy can be treated successfully even after 26 months. VZV must be considered as a possible cause of neurological disease in any patient with idiopathic multifocal vasculopathy. (C) 2012 Elsevier B.V. All rights reserved. C1 [Silver, Brian] Brown Univ, Warren Alpert Med Sch, Dept Neurol, Providence, RI 02912 USA. [Nagel, Maria A.; Mahalingam, Ravi; Cohrs, Randall; Gilden, Don] Univ Colorado, Sch Med, Dept Neurol, Aurora, CO USA. [Schmid, D. Scott] Ctr Dis Control & Prevent, Atlanta, GA USA. [Gilden, Don] Univ Colorado, Sch Med, Dept Microbiol, Aurora, CO USA. RP Gilden, D (reprint author), 12700 E 19th Ave,Mail Stop B182, Aurora, CO 80045 USA. EM don.gilden@ucdenver.edu FU National Institutes of Health [AG006127, AG032958] FX This work was supported in part by Public Health Service grants AG006127 and AG032958 from the National Institutes of Health. NR 7 TC 11 Z9 12 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0022-510X J9 J NEUROL SCI JI J. Neurol. Sci. PD DEC 15 PY 2012 VL 323 IS 1-2 BP 245 EP 247 DI 10.1016/j.jns.2012.07.059 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 037UT UT WOS:000311132700043 PM 22935406 ER PT J AU Ford, ES Wheaton, AG Mannino, DM Presley-Cantrell, L Li, CY Croft, JB AF Ford, Earl S. Wheaton, Anne G. Mannino, David M. Presley-Cantrell, Letitia Li, Chaoyang Croft, Janet B. TI Elevated cardiovascular risk among adults with obstructive and restrictive airway functioning in the United States: a cross-sectional study of the National Health and Nutrition Examination Survey from 2007-2010 SO RESPIRATORY RESEARCH LA English DT Article DE Chronic obstructive pulmonary disease; Cardiovascular diseases; Risk factors; Spirometry ID SMOKING-CESSATION INTERVENTIONS; PULMONARY-DISEASE PATIENTS; LUNG-FUNCTION IMPAIRMENT; C-REACTIVE PROTEIN; METABOLIC SYNDROME; SYSTEMIC INFLAMMATION; INHALED ANTICHOLINERGICS; ENDOTHELIAL DYSFUNCTION; GENERAL-POPULATION; POTENTIAL ROLE AB Background: Reasons for the excess risk for cardiovascular disease among people with chronic obstructive pulmonary disease remain unclear. Our objective was to examine the cardiovascular risk profile for adults with obstructive and restrictive impairments of lung functioning in a representative sample of adults from the United States. Methods: We used data from adults aged 20-79 years who participated in the National Health and Nutrition Examination Survey from 2007 to 2010 and had a pulmonary function test. The severity of obstructive impairment was defined by adapting the Global Initiative for Chronic Obstructive Lung Disease criteria. Results: Among 7249 participants, 80.9% had a normal pulmonary function test, 5.7% had a restrictive impairment, 7.9% had mild obstructive impairment, and 5.5% had moderate or severe/very severe obstructive impairment. Participants with obstructive impairment had high rates of smoking and increased serum concentrations of cotinine. Compared to participants with normal pulmonary functioning, participants with at least moderate obstructive impairment had elevated concentrations of C-reactive protein but lower concentrations of total cholesterol and non-high-density lipoprotein cholesterol. Among participants aged 50-74 years, participants with at least a moderate obstructive impairment or a restrictive impairment had an elevated predicted 10-year risk for cardiovascular disease. Conclusions: The high rates of smoking among adults with impaired pulmonary functioning, particularly those with obstructive impairment, point to a need for aggressive efforts to promote smoking cessation in these adults. In addition, adults with restrictive impairment may require increased attention to and fine-tuning of their cardiovascular risk profile. C1 [Ford, Earl S.; Wheaton, Anne G.; Presley-Cantrell, Letitia; Croft, Janet B.] Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Mannino, David M.] Univ Kentucky, Coll Publ Hlth, Dept Prevent Med & Environm Hlth, Lexington, KY USA. [Li, Chaoyang] Ctr Dis Control & Prevent, Div Behav Surveillance, Publ Hlth Surveillance Program Off, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30341 USA. RP Ford, ES (reprint author), Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. EM eford@cdc.gov OI Mannino, David/0000-0003-3646-7828 NR 70 TC 13 Z9 14 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1465-993X EI 1465-9921 J9 RESP RES JI Respir. Res. PD DEC 13 PY 2012 VL 13 AR 115 DI 10.1186/1465-9921-13-115 PG 12 WC Respiratory System SC Respiratory System GA 076LI UT WOS:000313957600001 PM 23237325 ER PT J AU Singh, PP Lucchi, NW Blackstock, A Udhayakumar, V Singh, N AF Singh, Puspendra P. Lucchi, Naomi W. Blackstock, Anna Udhayakumar, Venkatachalam Singh, Neeru TI Intervillous Macrophage Migration Inhibitory Factor Is Associated with Adverse Birth Outcomes in a Study Population in Central India SO PLOS ONE LA English DT Article ID PLASMODIUM-FALCIPARUM MALARIA; RAPID DIAGNOSTIC-TEST; PLACENTAL MALARIA; INFECTED ERYTHROCYTES; PREGNANCY OUTCOMES; UP-REGULATION; FACTOR MIF; BLOOD; EXPRESSION; CYTOKINES AB Macrophage migration inhibitory factor (MIF) is a pluripotent factor produced by a variety of cells. It plays an important biological role in the regulation of pregnancy and has been shown to influence malaria pathogenesis. In this study, the levels of MIF in the peripheral, cord and placental intervillous blood (IVB) plasma collected from women residing in a malaria endemic region of Central India was determined and its association with malaria in pregnancy and birth outcomes was investigated. MIF levels were significantly different in IVB, peripheral, and cord plasma, with IVB plasma having the highest MIF levels and peripheral plasma having the lowest. Placental malaria positive women had significantly higher IVB plasma MIF levels than placental malaria negative women, but this relationship was not seen in peripheral or cord plasma MIF levels. In addition, the odds of stillbirth and low birth weight deliveries for the uppermost placental MIF quartile (irrespective of placental malaria status) was significantly higher than that of the lowest placental MIF quartile, supporting the hypothesis that elevated concentrations of placental MIF may be associated with an increased risk of adverse birth outcome. Citation: Singh PP, Lucchi NW, Blackstock A, Udhayakumar V, Singh N (2012) Intervillous Macrophage Migration Inhibitory Factor Is Associated with Adverse Birth Outcomes in a Study Population in Central India. PLoS ONE 7(12): e51678. doi:10.1371/journal.pone.0051678 C1 [Singh, Puspendra P.; Singh, Neeru] Reg Med Res Ctr Tribals, Jabalpur, Madhya Pradesh, India. [Singh, Puspendra P.; Singh, Neeru] Natl Inst Malaria Res Field Unit, Jabalpur, Madhya Pradesh, India. [Lucchi, Naomi W.; Blackstock, Anna; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. [Blackstock, Anna] Atlanta Res & Educ Fdn, VA Med Ctr, Decatur, GA USA. RP Singh, N (reprint author), Reg Med Res Ctr Tribals, Jabalpur, Madhya Pradesh, India. EM neeru.singh@gmail.com FU Indian Council of Medical Research (ICMR), Ministry of Health and Family Welfare, Govt. of India, New Delhi FX The study was funded by Indian Council of Medical Research (ICMR), Ministry of Health and Family Welfare, Govt. of India, New Delhi. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 44 TC 3 Z9 3 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 13 PY 2012 VL 7 IS 12 AR e51678 DI 10.1371/journal.pone.0051678 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 055AH UT WOS:000312386600035 PM 23272137 ER PT J AU Kainer, M Wiese, AD Benedict, K Braden, C Brandt, M Harris, J Park, BJ Guh, A Jernigan, J Schaefer, M Weber, JT Wise, M Smith, RM Nguyen, D AF Kainer, Marion Wiese, Andrew D. Benedict, Kaitlin Braden, Chris Brandt, Mary Harris, Julie Park, Benjamin J. Guh, Alice Jernigan, John Schaefer, Melissa Weber, J. Todd Wise, Matt Smith, Rachel M. Nguyen, Duc TI Multistate Outbreak of Fungal Infection Associated with Injection of Methylprednisolone Acetate Solution from a Single Compounding Pharmacy-United States, 2012 (Reprinted from MMWR, vol 41, pg 839, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Smith, Rachel M.; Nguyen, Duc] CDC, Atlanta, GA 30333 USA. RP Smith, RM (reprint author), CDC, Atlanta, GA 30333 USA. EM vih9@cdc.gov NR 1 TC 0 Z9 0 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD DEC 12 PY 2012 VL 308 IS 22 BP 2328 EP 2331 DI 10.1001/jama.2012.64944 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 051MW UT WOS:000312132400012 ER PT J AU DiOrio, M Fowler, B Page, SL Thomas, R Sohner, K Bowman, A Slemons, R Davis, WG Garten, R Lindstrom, S Jhung, M Uyeki, TM Quinn, C AF DiOrio, Mary Fowler, Brian Page, Shannon L. Thomas, Richard Sohner, Kevin Bowman, Andrew Slemons, Richard Davis, William G. Garten, Rebecca Lindstrom, Stephen Jhung, Michael Uyeki, Timothy M. Quinn, Celia TI Influenza A (H3N2) Variant Virus-Related Hospitalizations-Ohio, 2012 (Reprinted from MMWR, vol 38, pg 764, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Quinn, Celia] CDC, Atlanta, GA 30333 USA. [DiOrio, Mary; Fowler, Brian; Page, Shannon L.; Thomas, Richard; Sohner, Kevin] Ohio Dept Hlth, Columbus, OH 43266 USA. [Bowman, Andrew; Slemons, Richard] Ohio State Univ, Dept Vet Prevent Med, Columbus, OH 43210 USA. RP Quinn, C (reprint author), CDC, Atlanta, GA 30333 USA. EM fyq6@cdc.gov RI Bowman, Andrew/B-4321-2012 OI Bowman, Andrew/0000-0002-0738-8453 NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD DEC 12 PY 2012 VL 308 IS 22 BP 2331 EP 2333 DI 10.1001/jama.2012.14341 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 051MW UT WOS:000312132400013 ER PT J AU Ko, F Vitale, S Chou, CF Cotch, MF Saaddine, J Friedman, DS AF Ko, Fang Vitale, Susan Chou, Chiu-Fang Cotch, Mary Frances Saaddine, Jinan Friedman, David S. TI Prevalence of Nonrefractive Visual Impairment in US Adults and Associated Risk Factors, 1999-2002 and 2005-2008 SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID TYPE-2 DIABETES-MELLITUS; UNITED-STATES; TEMPORAL TRENDS; RETINOPATHY; CHILDREN; ADOLESCENTS; PERSPECTIVE; HEALTH AB Context Over the past decade, chronic illnesses with ophthalmic sequelae such as diabetes and diabetic retinopathy have increased. Objectives To estimate prevalence of nonrefractive visual impairment and to describe its relationship with demographic and systemic risk factors including diagnosed diabetes. Design, Setting, and Participants The National Health and Nutrition Examination Survey (NHANES) examined a representative sample of the US noninstitutionalized population. In 1999-2002 and 2005-2008, 9471 and 10 480 participants aged 20 years or older received questionnaires, laboratory tests, and physical examinations. Visual acuity of less than 20/40 aided by autorefractor was classified as nonrefractive visual impairment. Main Outcome Measure Nonrefractive visual impairment. Results Weighted prevalence of nonrefractive visual impairment increased 21% among US adults aged 20 years and older from 1.4% in 1999-2002 to 1.7% in 2005-2008 (P=.03); and increased 40% among non-Hispanic whites aged 20-39 years from 0.5% to 0.7% (P=.008). In multivariable analyses, statistically significant risk factors for nonrefractive visual impairment in 1999-2002 included age (per year odds ratio [OR], 1.07; 95% CI, 1.05-1.09), poverty (OR, 2.18; 95% CI, 1.31-3.64), lack of insurance (OR, 1.85; 95% CI, 1.16-2.95), and diabetes with 10 or more years since diagnosis (OR, 1.93; 95% CI, 1.15-3.25). In 2005-2008, risk factors included age (OR, 1.05; 95% CI, 1.04-1.07), poverty (OR, 2.23; 95% CI, 1.55-3.22), education less than high school (OR, 2.11; 95% CI, 1.54-2.90), and diabetes with 10 or more years since diagnosis (OR, 2.67; 95% CI, 1.64-4.37). Prevalence of diabetes with 10 or more years since diagnosis increased 22% overall from 2.8% to 3.6% (P=.02); and 133% among non-Hispanic whites aged 20-39 years from 0.3% to 0.7% (P<.001). Conclusion Prevalence of nonrefractive visual impairment was significantly higher in 2005-2008 than in 1999-2002 and may be attributable, in part, to higher prevalence of diabetes, an associated risk factor that increased in prevalence during this time period. JAMA. 2012;308(22):2361-2368 www.jama.com C1 [Ko, Fang; Friedman, David S.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Dana Ctr Prevent Ophthalmol, Baltimore, MD 21205 USA. [Friedman, David S.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Vitale, Susan; Cotch, Mary Frances] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA. [Chou, Chiu-Fang; Saaddine, Jinan] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Friedman, DS (reprint author), Wilmer 120,600 N Wolfe St, Baltimore, MD 21287 USA. EM david.friedman@jhu.edu OI Cotch, Mary Frances/0000-0002-2046-4350 FU National Eye Institute (ARVO); Pepose; David Friedman Research Grant Award; Centers for Disease Control and Prevention (CDC) [1U58DP002653-01]; National Center for Health Statistics (NCHS); CDC; National Institutes of Health (NIH) [Z01EY000402] FX All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Friedman reports having consulted for Alcon, Bausch and Lomb, Merck, Pfizer, Allergan, Nidek, and QLT. Dr Ko reports receipt of support for travel to meetings for the study or other purposes from the National Eye Institute (ARVO travel grant), a Pepose travel grant, and a David Friedman Research Grant Award for provision of writing assistance, medicines, equipment, or administratrive support. The remaining authors report no disclosures.; This study was supported by the Centers for Disease Control and Prevention (CDC) grant 1U58DP002653-01 and the David Friedman Research Grant Award. The National Health and Nutrition Examination Survey (NHANES) is sponsored by the National Center for Health Statistics (NCHS), CDC. Funding for the vision component was provided by the National Eye Institute (NEI), National Institutes of Health (NIH), Intramural Research Program grant Z01EY000402. NR 37 TC 29 Z9 30 U1 0 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD DEC 12 PY 2012 VL 308 IS 22 BP 2361 EP 2368 DI 10.1001/jama.2012.85685 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 051MW UT WOS:000312132400026 PM 23232894 ER PT J AU Klevens, J Kee, R AF Klevens, Joanne Kee, Romina TI Partner Violence Screening and Women's Quality of Life Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 [Klevens, Joanne] Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30333 USA. [Kee, Romina] John H Stroger Jr Hosp Cook Cty, Collaborat Res Unit, Chicago, IL USA. RP Klevens, J (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30333 USA. EM jklevens@cdc.gov NR 4 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD DEC 12 PY 2012 VL 308 IS 22 BP 2335 EP 2335 DI 10.1001/jama.2012.14876 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 051MW UT WOS:000312132400016 ER PT J AU Castellanos, ME Bardaji, A Menegon, M Mayor, A Desai, M Severini, C Menendez, C Padilla, N AF Eugenia Castellanos, Maria Bardaji, Azucena Menegon, Michela Mayor, Alfredo Desai, Meghna Severini, Carlo Menendez, Clara Padilla, Norma TI Plasmodium vivax congenital malaria in an area of very low endemicity in Guatemala: implications for clinical and epidemiological surveillance in a malaria elimination context SO MALARIA JOURNAL LA English DT Article DE Plasmodium vivax; Congenital; Malaria; Guatemala ID UMBILICAL-CORD-BLOOD; FALCIPARUM; COLOMBIA; RISK; INFECTIONS; NIGERIA; KENYA; URABA AB This is a report of the first Plasmodium vivax congenital malaria case in Guatemala and the first case in Latin America with genotypical, histological and clinical characterization. The findings show that maternal P. vivax infection still occurs in areas that are in the pathway towards malaria elimination, and can be associated with detrimental health effects for the neonate. It also highlights the need in very low transmission areas of not only maintaining, but increasing awareness of the problem and developing surveillance strategies, based on population risk, to detect the infection especially in this vulnerable group of the population. C1 [Eugenia Castellanos, Maria; Padilla, Norma] Univ Valle Guatemala, Ctr Estudios Salud, Guatemala City, Guatemala. [Bardaji, Azucena; Mayor, Alfredo; Menendez, Clara] Univ Barcelona, Barcelona Ctr Int Hlth Res, CRESIB, Hosp Clin, E-08036 Barcelona, Spain. [Menegon, Michela; Severini, Carlo] Ist Super Sanita, I-00161 Rome, Italy. [Desai, Meghna] Ctr Dis Control & Prevent CDC, Ctr Global Hlth, Div Parasit Dis & Malaria, Atlanta, GA 30341 USA. RP Bardaji, A (reprint author), Univ Barcelona, Barcelona Ctr Int Hlth Res, CRESIB, Hosp Clin, Rosello 132,5-1, E-08036 Barcelona, Spain. EM abardaji@clinic.ub.es RI SEVERINI, CARLO/C-4977-2016 FU European Union [PREGVAX 201588]; Malaria in Pregnancy Consortium (MiPc) through a grant from the Bill & Melinda Gates Foundation [46099]; Centro de Estudios en Salud of Universidad del Valle de Guatemala FX The research leading to these results has received funding from the European Union Sev